det||study-2/NN||this-1/DT	root||ROOT-0/null||study-2/NN	vmod||study-2/NN||using-3/VBG	amod||research-5/NN||participatory-4/JJ	dobj||using-3/VBG||research-5/NN	nsubj||abusing-42/VBG||research-5/NN	nn||methods-11/NNS||action-7/NN	appos||methods-11/NNS||pra-9/NN	dobj||using-3/VBG||methods-11/NNS	conj_and||research-5/NN||methods-11/NNS	nsubj||abusing-42/VBG||methods-11/NNS	vmod||research-5/NN||sought-12/VBN	aux||understand-14/VB||to-13/TO	ccomp||sought-12/VBN||understand-14/VB	dobj||understand-14/VB||factors-15/NNS	advmod||understand-14/VB||related-16/VBN	prep_to||related-16/VBN||alcoholabuse-18/NN	prep_to||related-16/VBN||non-adherence-20/NN	conj_and||alcoholabuse-18/NN||non-adherence-20/NN	aux||formulate-23/VB||to-22/TO	ccomp||sought-12/VBN||formulate-23/VB	conj_and||understand-14/VB||formulate-23/VB	amod||interventions-25/NNS||appropriate-24/JJ	dobj||formulate-23/VB||interventions-25/NNS	det||sample-28/NN||a-27/DT	prep_in||formulate-23/VB||sample-28/NN	prep_of||sample-28/NN||people-30/NNS	vmod||people-30/NNS||living-31/VBG	prep_with||living-31/VBG||hiv-33/NN	prep_with||living-31/VBG||aids-35/NNS	conj_and||hiv-33/NN||aids-35/NNS	appos||research-5/NN||plwha-37/NNP	aux||abusing-42/VBG||were-40/VBD	advmod||abusing-42/VBG||also-41/RB	rcmod||research-5/NN||abusing-42/VBG	dobj||abusing-42/VBG||alcohol-43/NN	prep_at||using-3/VBG||kariobangi-46/NNS	prep_in||kariobangi-46/NNS||nairobi-48/NNS	appos||nairobi-48/NNS||kenya-50/NN	aids-35||hiv-33||no||this study using participatory research and action (pra) methods sought to understand factors related to alcoholabuse and non-adherence and to formulate appropriate interventions in a sample of people living with hiv and aids (plwha) who were also abusing alcohol, at kariobangi in nairobi, kenya.
nsubjpass||identified-3/VBN||viruses-1/NNS	auxpass||identified-3/VBN||were-2/VBD	root||ROOT-0/null||identified-3/VBN	num||%-6/NN||94.7-5/CD	prep_in||identified-3/VBN||%-6/NN	nn||rsv-11/NN||rt-8/NN	nn||rsv-11/NN||amplification-9/NN	nn||rsv-11/NN||reaction-10/NN	agent||identified-3/VBN||rsv-11/NN	advmod||rsv-11/NN||only-12/RB	num||%-15/NN||45.8-14/CD	appos||rsv-11/NN||%-15/NN	agent||identified-3/VBN||rv-18/NN	conj_and||rsv-11/NN||rv-18/NN	advmod||rv-18/NN||only-19/RB	num||%-22/NN||7.2-21/CD	appos||rv-18/NN||%-22/NN	agent||identified-3/VBN||hmpv-25/NN	conj_and||rsv-11/NN||hmpv-25/NN	advmod||hmpv-25/NN||only-26/RB	num||%-29/NN||3.8-28/CD	appos||hmpv-25/NN||%-29/NN	amod||rsv/rv-33/NNS||dual-32/JJ	agent||identified-3/VBN||rsv/rv-33/NNS	conj_and||rsv-11/NN||rsv/rv-33/NNS	num||%-36/NN||14.3-35/CD	appos||rsv/rv-33/NNS||%-36/NN	amod||virus-41/NN||other-40/JJ	agent||identified-3/VBN||virus-41/NN	conj_and||rsv-11/NN||virus-41/NN	advmod||virus-41/NN||only-42/RB	num||%-45/NN||2-44/CD	appos||virus-41/NN||%-45/NN	agent||identified-3/VBN||coinfections-48/NNS	conj_or||rsv-11/NN||coinfections-48/NNS	num||%-51/NN||9-50/CD	appos||coinfections-48/NNS||%-51/NN	virus-41||viruses-1||no||viruses were identified in 94.7% by rt amplification reaction rsv only (45.8%), rv only (7.2%), hmpv only (3.8%), dual rsv/rv (14.3%), and other virus only (2%) or coinfections (9%).
nsubj||investigated-2/VBD||we-1/PRP	root||ROOT-0/null||investigated-2/VBD	mark||change-16/VB||whether-3/IN	num||minutes-5/NNS||60-4/CD	nsubj||change-16/VB||minutes-5/NNS	prep_of||minutes-5/NNS||ischemia-7/NN	vmod||ischemia-7/NN||followed-8/VBN	num||minutes-11/NNS||30-10/CD	agent||followed-8/VBN||minutes-11/NNS	prep_of||minutes-11/NNS||reperfusion-13/NN	aux||change-16/VB||do-14/VBP	neg||change-16/VB||not-15/RB	ccomp||investigated-2/VBD||change-16/VB	det||relaxation-18/NN||the-17/DT	dobj||change-16/VB||relaxation-18/NN	amod||arteries-21/NNS||visceral-20/JJ	prep_of||relaxation-18/NN||arteries-21/NNS	det||plasma-24/NN||the-23/DT	dobj||change-16/VB||plasma-24/NN	conj_nor||relaxation-18/NN||plasma-24/NN	amod||levels-27/NNS||renal-26/JJ	conj_nor||relaxation-18/NN||levels-27/NNS	conj_and||plasma-24/NN||levels-27/NNS	prep_of||levels-27/NNS||malondialdehyde-29/NN	appos||malondialdehyde-29/NN||mda-31/NN	amod||nitrate-36/NN||nitrite-34/JJ	nn||nitrate-36/NN||plus-35/NN	prep_of||levels-27/NNS||nitrate-36/NN	conj_and||malondialdehyde-29/NN||nitrate-36/NN	appos||malondialdehyde-29/NN||nox-38/NN	nitrite-34||ischemia-7||no_rel||we investigated whether 60 minutes of ischemia followed by 30 minutes of reperfusion do not change the relaxation of visceral arteries nor the plasma and renal levels of malondialdehyde (mda) and nitrite plus nitrate (nox).
nsubjpass||collected-16/VBN||data-1/NNS	det||incidence-4/NN||the-3/DT	prep_on||data-1/NNS||incidence-4/NN	nn||infection-7/NN||vzv-6/NN	prep_of||incidence-4/NN||infection-7/NN	appos||infection-7/NN||chickenpox-9/NN	poss||period-14/NN||their-12/PRP$	amod||period-14/NN||undergraduate-13/JJ	prep_during||infection-7/NN||period-14/NN	auxpass||collected-16/VBN||was-15/VBD	root||ROOT-0/null||collected-16/VBN	xcomp||collected-16/VBN||using-17/VBG	det||questionnaire-21/NN||a-18/DT	amod||questionnaire-21/NN||self-administered-19/JJ	amod||questionnaire-21/NN||structured-20/JJ	dobj||using-17/VBG||questionnaire-21/NN	chickenpox-9||vzv-6||no||data on the incidence of vzv infection (chickenpox) during their undergraduate period was collected using a self-administered structured questionnaire.
amod||apnea-3/NN||obstructive-1/JJ	nn||apnea-3/NN||sleep-2/NN	nsubj||common-5/JJ||apnea-3/NN	cop||common-5/JJ||is-4/VBZ	root||ROOT-0/null||common-5/JJ	prep_in||common-5/JJ||patients-7/NNS	prep_with||patients-7/NNS||type2diabetes-9/CD	poss||association-13/NN||its-12/PRP$	nsubjpass||examined-20/VBN||association-13/NN	prep_with||association-13/NN||insulin-15/NN	prep_with||association-13/NN||insulinresistance-17/NN	conj_and||insulin-15/NN||insulinresistance-17/NN	aux||examined-20/VBN||has-18/VBZ	auxpass||examined-20/VBN||been-19/VBN	conj_and||common-5/JJ||examined-20/VBN	amod||studies-23/NNS||cross-sectional-22/JJ	prep_in||examined-20/VBN||studies-23/NNS	insulin-15||type2diabetes-9||no_rel||obstructive sleep apnea is common in patients with type2diabetes, and its association with insulin and insulinresistance has been examined in cross-sectional studies.
amod||enzyme-2/NN||insulin-degrading-1/JJ	nsubj||ubiquitously-8/NN||enzyme-2/NN	appos||enzyme-2/NN||ide-4/NN	cop||ubiquitously-8/NN||is-6/VBZ	det||ubiquitously-8/NN||a-7/DT	root||ROOT-0/null||ubiquitously-8/NN	nsubj||degrades-12/VBZ||ubiquitously-8/NN	vmod||ubiquitously-8/NN||expressed-9/VBN	acomp||expressed-9/VBN||zinc-metalloprotease-10/JJ	rcmod||ubiquitously-8/NN||degrades-12/VBZ	amod||substrates-17/NNS||several-13/JJ	amod||substrates-17/NNS||pathophysiologically-14/JJ	amod||substrates-17/NNS||significant-15/JJ	nn||substrates-17/NNS||extracellular-16/NN	dobj||degrades-12/VBZ||substrates-17/NNS	prep_including||substrates-17/NNS||insulin-20/NN	det||²-25/NN||the-22/DT	amod||²-25/NN||amyloid-23/JJ	nn||²-25/NN||î-24/NN	prep_including||substrates-17/NNS||²-25/NN	conj_and||insulin-20/NN||²-25/NN	dep||²-25/NN||protein-27/NN	nn||²-30/NNP||aî-29/NNP	appos||protein-27/NN||²-30/NNP	csubj||suggests-36/VBZ||accumulating-34/VBG	dobj||accumulating-34/VBG||evidence-35/NN	conj_and||ubiquitously-8/NN||suggests-36/VBZ	nsubj||degrades-12/VBZ||suggests-36/VBZ	mark||operative-42/VBN||that-37/IN	nn||dysfunction-39/NN||ide-38/NN	nsubjpass||operative-42/VBN||dysfunction-39/NN	aux||operative-42/VBN||may-40/MD	auxpass||operative-42/VBN||be-41/VB	ccomp||suggests-36/VBZ||operative-42/VBN	det||disease-48/NN||both-44/DT	amod||disease-48/NN||type2diabetesmellitus-45/JJ	conj_and||type2diabetesmellitus-45/JJ||alzheimer-47/JJ	amod||disease-48/NN||alzheimer-47/JJ	prep_in||operative-42/VBN||disease-48/NN	appos||disease-48/NN||ad-50/NN	type2diabetesmellitus-45||insulin-20||yes||insulin-degrading enzyme (ide) is a ubiquitously expressed zinc-metalloprotease that degrades several pathophysiologically significant extracellular substrates, including insulin and the amyloid î²-protein (aî²), and accumulating evidence suggests that ide dysfunction may be operative in both type2diabetesmellitus and alzheimer disease (ad).
nsubj||impacts-3/VBZ||hiv/aids-1/NNS	advmod||impacts-3/VBZ||negatively-2/RB	root||ROOT-0/null||impacts-3/VBZ	nn||alleviation-5/NN||poverty-4/NN	dobj||impacts-3/VBZ||alleviation-5/NN	nsubj||hinder-12/VB||alleviation-5/NN	nn||security-8/NN||food-7/NN	dobj||impacts-3/VBZ||security-8/NN	conj_and||alleviation-5/NN||security-8/NN	nsubj||hinder-12/VB||security-8/NN	advmod||hinder-12/VB||reciprocally-11/RB	rcmod||alleviation-5/NN||hinder-12/VB	det||scale-15/NN||the-13/DT	amod||scale-15/NN||rapid-14/JJ	dobj||hinder-12/VB||scale-15/NN	prt||hinder-12/VB||up-16/RP	dobj||impacts-3/VBZ||effectiveness-18/NN	conj_and||alleviation-5/NN||effectiveness-18/NN	nsubj||hinder-12/VB||effectiveness-18/NN	nn||programs-22/NNS||hiv-20/NN	nn||programs-22/NNS||care-21/NN	prep_of||effectiveness-18/NN||programs-22/NNS	aids--1||hiv-20||no||hiv/aids negatively impacts poverty alleviation and food security, which reciprocally hinder the rapid scale up and effectiveness of hiv care programs.
det||objective-3/NN||the-1/DT	amod||objective-3/NN||primary-2/JJ	nsubj||was-8/VBD||objective-3/NN	nsubj||investigate-10/VB||objective-3/NN	det||research-7/NN||the-5/DT	amod||research-7/NN||present-6/JJ	prep_of||objective-3/NN||research-7/NN	root||ROOT-0/null||was-8/VBD	aux||investigate-10/VB||to-9/TO	xcomp||was-8/VBD||investigate-10/VB	amod||effects-12/NNS||behavioral-11/JJ	dobj||investigate-10/VB||effects-12/NNS	det||range-15/NN||a-14/DT	prep_of||effects-12/NNS||range-15/NN	prep_of||range-15/NN||doses-17/NNS	amod||l-amphetamine-20/NN||chronic-19/JJ	prep_of||doses-17/NNS||l-amphetamine-20/NN	amod||symptoms-23/NNS||adhd-like-22/JJ	prep_on||investigate-10/VB||symptoms-23/NNS	det||shr-26/NN||the-25/DT	prep_in||symptoms-23/NNS||shr-26/NN	adhd--1||amphetamine--1||yes||the primary objective of the present research was to investigate behavioral effects of a range of doses of chronic l-amphetamine on adhd-like symptoms in the shr.
det||number-2/NN||the-1/DT	nsubj||similar-26/JJ||number-2/NN	prep_of||number-2/NN||patients-4/NNS	vmod||patients-4/NNS||experiencing-5/VBG	nn||vomiting-7/NN||breakthrough-6/NN	dobj||experiencing-5/VBG||vomiting-7/NN	amod||$-10/$||0â-9/JJ	prep_at||experiencing-5/VBG||$-10/$	num||$-10/$||30-12/CD	amod||$-15/$||31â-14/JJ	prep_at||experiencing-5/VBG||$-15/$	conj_and||$-10/$||$-15/$	num||$-15/$||60-17/CD	prep_at||experiencing-5/VBG||61â-20/NNS	conj_and||$-10/$||61â-20/NNS	num||minutes-24/NNS||$-21/$	num||$-21/$||120-23/CD	dep||61â-20/NNS||minutes-24/NNS	cop||similar-26/JJ||was-25/VBD	root||ROOT-0/null||similar-26/JJ	prep_between||similar-26/JJ||groups-28/NNS	det||periods-32/NNS||these-30/DT	nn||periods-32/NNS||time-31/NN	prep_for||groups-28/NNS||periods-32/NNS	advmod||experienced-40/VBD||however-34/RB	amod||patients-37/NNS||more-36/JJR	nsubj||experienced-40/VBD||patients-37/NNS	vmod||patients-37/NNS||receiving-38/VBG	dobj||receiving-38/VBG||ondansetron-39/NN	parataxis||similar-26/JJ||experienced-40/VBD	nn||-lrb--43/NN||vomiting-41/NN	amod||-lrb--43/NN||overall-42/JJ	dobj||experienced-40/VBD||-lrb--43/NN	number||-lsb--45/NN||7-44/CD	amod||-lrb--43/NN||-lsb--45/NN	number||-rsb--48/NN||22-46/CD	dep||-rsb--48/NN||%-47/NN	amod||-lrb--43/NN||-rsb--48/NN	prep||experienced-40/VBD||vs.-49/CC	number||-lsb--51/NN||2-50/CD	amod||patients-55/NNS||-lsb--51/NN	num||%-53/NN||3.2-52/CD	dep||-lsb--51/NN||%-53/NN	amod||patients-55/NNS||-rsb--54/JJ	pobj||vs.-49/CC||patients-55/NNS	vmod||patients-55/NNS||p-57/VBN	dep||-rrb--61/NN||=-58/SYM	neg||-rrb--61/NN||not-59/RB	amod||-rrb--61/NN||significant-60/JJ	ccomp||p-57/VBN||-rrb--61/NN	vomiting-41||ondansetron-39||yes||the number of patients experiencing breakthrough vomiting at 0â $ `` 30 , 31â $ `` 60 , and 61â $ `` 120 minutes was similar between groups for these time periods ; however , more patients receiving ondansetron experienced vomiting overall -lrb- 7 -lsb- 22 % -rsb- vs. 2 -lsb- 3.2 % -rsb- patients , p = not significant -rrb- .
det||study-2/NN||the-1/DT	nsubj||included-3/VBD||study-2/NN	root||ROOT-0/null||included-3/VBD	num||children-6/NNS||2227-4/CD	nn||children-6/NNS||ghanaian-5/NN	dobj||included-3/VBD||children-6/NNS	nsubjpass||given-16/VBN||children-6/NNS	dep||children-6/NNS||3â-8/VBN	num||months-12/NNS||$-9/$	num||$-9/$||59-11/CD	tmod||3â-8/VBN||months-12/NNS	auxpass||given-16/VBN||were-15/VBD	rcmod||children-6/NNS||given-16/VBN	amod||bimonthly-21/NNS||sulphadoxine-pyrimethamine-17/JJ	discourse||bimonthly-21/NNS||sp-19/UH	dobj||given-16/VBN||bimonthly-21/NNS	dobj||given-16/VBN||artesunate-23/NN	dobj||given-16/VBN||amodiaquine-25/NN	conj_plus||artesunate-23/NN||amodiaquine-25/NN	mark||aq-29/VBP||as-27/IN	nsubj||aq-29/VBP||+-28/PRP	dep||amodiaquine-25/NN||aq-29/VBP	dep||amodiaquine-25/NN||monthly-31/JJ	dep||amodiaquine-25/NN||bimonthly-33/JJ	conj_or||monthly-31/JJ||bimonthly-33/JJ	dobj||given-16/VBN||placebo-36/NN	conj_or||artesunate-23/NN||placebo-36/NN	advmod||spanning-41/VBG||monthly-37/JJ	num||months-40/NNS||six-39/CD	prep_for||monthly-37/JJ||months-40/NNS	vmod||placebo-36/NN||spanning-41/VBG	det||season-45/NN||the-42/DT	nn||season-45/NN||malaria-43/NN	nn||season-45/NN||transmission-44/NN	dobj||spanning-41/VBG||season-45/NN	malaria-43||pyrimethamine--1||yes||the study included 2227 ghanaian children (3â59 months) who were given sulphadoxine-pyrimethamine (sp) bimonthly, artesunate plus amodiaquine (as+aq) monthly or bimonthly, or placebo monthly for six months spanning the malaria transmission season.
det||profile-3/NN||the-1/DT	nn||profile-3/NN||search-2/NN	nsubj||consisted-4/VBD||profile-3/NN	root||ROOT-0/null||consisted-4/VBD	prep_of||consisted-4/VBD||terms-6/NNS	vmod||terms-6/NNS||referring-7/VBG	amod||deficiency-12/NN||vitamind-9/JJ	conj_or||vitamind-9/JJ||vitamind-11/JJ	amod||deficiency-12/NN||vitamind-11/JJ	prep_to||referring-7/VBG||deficiency-12/NN	amod||studies-17/NNS||prevalence-14/JJ	conj_or||prevalence-14/JJ||cross-sectional-16/JJ	amod||studies-17/NNS||cross-sectional-16/JJ	prep_to||referring-7/VBG||studies-17/NNS	conj_and||deficiency-12/NN||studies-17/NNS	prep_to||referring-7/VBG||countries-20/NNS	conj_and||deficiency-12/NN||countries-20/NNS	conj_and||deficiency-12/NN||ethnicity-22/NN	conj_or||countries-20/NNS||ethnicity-22/NN	cross--1||vitamind-11||no_rel||the search profile consisted of terms referring to vitamind or vitamind deficiency, prevalence or cross-sectional studies, and countries or ethnicity.
nsubj||unknown-24/JJ||effectiveness-1/NN	prep_of||effectiveness-1/NN||cotrimoxazole-3/NN	appos||effectiveness-1/NN||ctx-5/NN	prepc_compared_with||effectiveness-1/NN||with-8/IN	amod||intermittent-preventive-therapy-13/NN||sulfadoxine-pyrimethamine-9/JJ	appos||intermittent-preventive-therapy-13/NN||sp-11/NN	pobj||effectiveness-1/NN||intermittent-preventive-therapy-13/NN	appos||intermittent-preventive-therapy-13/NN||iptp-15/NN	prep_for||intermittent-preventive-therapy-13/NN||malaria-18/NN	amod||women-22/NNS||hiv-infected-20/JJ	amod||women-22/NNS||pregnant-21/JJ	prep_in||malaria-18/NN||women-22/NNS	cop||unknown-24/JJ||is-23/VBZ	root||ROOT-0/null||unknown-24/JJ	malaria-18||pyrimethamine--1||yes||effectiveness of cotrimoxazole (ctx) compared with sulfadoxine-pyrimethamine (sp) intermittent-preventive-therapy (iptp) for malaria in hiv-infected pregnant women is unknown.
amod||damage-3/NN||chronic-1/JJ	amod||damage-3/NN||hepatic-2/JJ	nsubj||leads-4/VBZ||damage-3/NN	root||ROOT-0/null||leads-4/VBZ	nn||fibrosis-7/NN||liver-6/NN	prep_to||leads-4/VBZ||fibrosis-7/NN	nsubjpass||characterized-11/VBN||fibrosis-7/NN	auxpass||characterized-11/VBN||is-10/VBZ	rcmod||fibrosis-7/NN||characterized-11/VBN	det||accumulation-14/NN||the-13/DT	agent||characterized-11/VBN||accumulation-14/NN	amod||matrix-18/NN||collagen-rich-16/JJ	nn||matrix-18/NN||extracellular-17/NN	prep_of||accumulation-14/NN||matrix-18/NN	collagen--1||fibrosis-7||no_rel||chronic hepatic damage leads to liver fibrosis, which is characterized by the accumulation of collagen-rich extracellular matrix.
det||data-2/NNS||these-1/DT	nsubj||established-4/VBN||data-2/NNS	aux||established-4/VBN||have-3/VBP	root||ROOT-0/null||established-4/VBN	mark||prion-9/VBN||that-5/IN	amod||prions-7/NNS||kuru-6/JJ	nsubj||prion-9/VBN||prions-7/NNS	aux||prion-9/VBN||have-8/VBP	ccomp||established-4/VBN||prion-9/VBN	nn||properties-11/NNS||strain-10/NN	nsubj||equivalent-12/JJ||properties-11/NNS	xcomp||prion-9/VBN||equivalent-12/JJ	prep_to||equivalent-12/JJ||those-14/DT	amod||prions-29/NNS||classical-16/JJ	dep||prions-29/NNS||sporadic-18/JJ	conj_and||sporadic-18/JJ||iatrogenic-20/JJ	dep||prions-29/NNS||iatrogenic-20/JJ	amod||prions-29/NNS||cjd-22/JJ	nn||prions-29/NNS||prions-23/NNS	conj_but||prions-23/NNS||distinct-25/JJ	nn||prions-29/NNS||distinct-25/JJ	amod||cjd-28/NN||variant-27/JJ	prep_from||distinct-25/JJ||cjd-28/NN	prep_of||those-14/DT||prions-29/NNS	prions-29||kuru-6||no_rel||these data have established that kuru prions have prion strain properties equivalent to those of classical (sporadic and iatrogenic) cjd prions but distinct from variant cjd prions.
nn||subcutaneous-2/NNS||immuneglobulin-1/NN	nsubj||high-concentration-8/NN||subcutaneous-2/NNS	number||%-4/NN||20-3/CD	amod||subcutaneous-2/NNS||%-4/NN	cop||high-concentration-8/NN||is-5/VBZ	det||high-concentration-8/NN||a-6/DT	amod||high-concentration-8/NN||new-7/JJ	root||ROOT-0/null||high-concentration-8/NN	number||g/l-11/CD||200-10/CD	dep||high-concentration-8/NN||g/l-11/CD	nsubj||indicated-26/VBD||solution-13/NN	advmod||purified-16/JJ||highly-15/RB	amod||igg-18/NN||purified-16/JJ	amod||igg-18/NN||human-17/JJ	prep_of||solution-13/NN||igg-18/NN	nn||¥-22/NNP||â-20/NNP	nn||¥-22/NNP||-21/NNP	dep||igg-18/NN||¥-22/NNP	num||%-24/NN||98-23/CD	dep||¥-22/NNP||%-24/NN	rcmod||high-concentration-8/NN||indicated-26/VBD	det||eu-29/NN||the-28/DT	prep_in||indicated-26/VBD||eu-29/NN	det||us-32/PRP||the-31/DT	prep_in||indicated-26/VBD||us-32/PRP	conj_and||eu-29/NN||us-32/PRP	nn||therapy-36/NN||antibody-34/NN	nn||therapy-36/NN||replacement-35/NN	prep_for||indicated-26/VBD||therapy-36/NN	prep_in||therapy-36/NN||patients-38/NNS	prep_in||therapy-36/NN||patients-38/NNS	conj_and||patients-38/NNS||patients-38/NNS	amod||immunodeficiency-41/NN||primary-40/JJ	prep_with||patients-38/NNS||immunodeficiency-41/NN	nn||deficiency-44/NN||antibody-43/NN	prep_with||immunodeficiency-41/NN||deficiency-44/NN	det||eu-49/NN||the-48/DT	prep_in||patients-38/NNS||eu-49/NN	nn||therapy-52/NN||replacement-51/NN	prep_for||eu-49/NN||therapy-52/NN	amod||immunodeficiency-55/NN||humoral-54/JJ	prep_in||therapy-52/NN||immunodeficiency-55/NN	amod||immunodeficiency-55/NN||secondary-56/JJ	prep_to||indicated-26/VBD||myeloma-58/NN	prep_to||indicated-26/VBD||chroniclymphocyticleukaemia-60/NN	conj_or||myeloma-58/NN||chroniclymphocyticleukaemia-60/NN	immunodeficiency-55||immuneglobulin-1||yes||immuneglobulin subcutaneous 20% is a new high-concentration (200 g/l) solution of highly purified human igg (â¥98%) indicated in the eu and the us for antibody replacement therapy in patients with primary immunodeficiency with antibody deficiency, and in the eu for replacement therapy in humoral immunodeficiency secondary to myeloma or chroniclymphocyticleukaemia.
amod||diagnosed-10/NN||anonymized-2/JJ	amod||diagnosed-10/NN||linkage-3/JJ	det||survey-6/NN||the-5/DT	prep_with||linkage-3/JJ||survey-6/NN	amod||hivinfections-9/NNS||prevalent-8/JJ	prep_of||survey-6/NN||hivinfections-9/NNS	prep_through||categorized-35/VBN||diagnosed-10/NN	nn||scotland-14/NN||health-12/NN	nn||scotland-14/NN||protection-13/NN	conj_and||diagnosed-10/NN||scotland-14/NN	prep_through||categorized-35/VBN||scotland-14/NN	amod||databases-17/NNS||national-16/JJ	appos||diagnosed-10/NN||databases-17/NNS	det||patients-21/NNS||all-19/DT	nn||patients-21/NNS||hiv-20/NN	prep_of||databases-17/NNS||patients-21/NNS	prep_in||patients-21/NNS||care-23/NN	det||uk-26/NN||the-25/DT	prep_in||care-23/NN||uk-26/NN	advmod||uk-26/NN||up-27/RB	prep_to||up-27/RB||december-29/NNP	num||december-29/NNP||2006-30/CD	amod||patients-33/NNS||loss-to-follow-up-32/JJ	nsubjpass||categorized-35/VBN||patients-33/NNS	auxpass||categorized-35/VBN||were-34/VBD	root||ROOT-0/null||categorized-35/VBN	prep_as||categorized-35/VBN||transfers-37/NNS	advmod||received-40/VBN||subsequently-39/RB	dep||transfers-37/NNS||received-40/VBN	dobj||received-40/VBN||care-41/NN	det||clinic-46/NN||another-43/DT	nn||clinic-46/NN||uk-44/NN	nn||clinic-46/NN||hiv-45/NN	prep_at||received-40/VBN||clinic-46/NN	prep_as||categorized-35/VBN||uklfu-49/VBG	conj_or||transfers-37/NNS||uklfu-49/VBG	neg||record-52/NN||no-51/DT	dep||uklfu-49/VBG||record-52/NN	amod||attendance-55/NN||subsequent-54/JJ	prep_of||record-52/NN||attendance-55/NN	det||clinic-59/NN||any-57/DT	nn||clinic-59/NN||hiv-58/NN	prep_at||attendance-55/NN||clinic-59/NN	det||uk-62/NN||the-61/DT	prep_in||clinic-59/NN||uk-62/NN	hivinfections-9||hiv-58||no||through anonymized linkage with the survey of prevalent hivinfections diagnosed and health protection scotland, national databases of all hiv patients in care in the uk up to december 2006, loss-to-follow-up patients were categorized as transfers (subsequently received care at another uk hiv clinic) or uklfu (no record of subsequent attendance at any hiv clinic in the uk).
amod||studies-3/NNS||basic-1/JJ	nn||studies-3/NNS||science-2/NN	nsubj||provided-20/VBD||studies-3/NNS	det||conference-8/NN||the-5/DT	amod||conference-8/NN||5th-6/JJ	nn||conference-8/NN||ias-7/NN	prep_at||studies-3/NNS||conference-8/NN	nn||pathogenesis-11/NNS||hiv-10/NN	prep_on||conference-8/NN||pathogenesis-11/NNS	prep_on||conference-8/NN||treatment-13/NN	conj_and||pathogenesis-11/NNS||treatment-13/NN	prep_on||conference-8/NN||prevention-15/NN	conj_and||pathogenesis-11/NNS||prevention-15/NN	appos||studies-3/NNS||ias-17/NN	num||ias-17/NN||2009-18/CD	root||ROOT-0/null||provided-20/VBD	amod||information-23/NN||important-21/JJ	amod||information-23/NN||new-22/JJ	dobj||provided-20/VBD||information-23/NN	nsubj||has-25/VBZ||information-23/NN	rcmod||information-23/NN||has-25/VBZ	dobj||has-25/VBZ||implications-26/NNS	neg||only-28/JJ||not-27/RB	preconj||has-25/VBZ||only-28/JJ	prep_for||has-25/VBZ||treatment-30/NN	advmod||understanding-36/VBG||better-35/RBR	prep_for||has-25/VBZ||understanding-36/VBG	conj_and||treatment-30/NN||understanding-36/VBG	det||dynamics-39/NNS||the-37/DT	amod||dynamics-39/NNS||complex-38/JJ	dobj||understanding-36/VBG||dynamics-39/NNS	prep_of||dynamics-39/NNS||hivinfection-41/NN	advmod||understanding-36/VBG||epidemiology-43/RB	det||impact-47/NN||the-46/DT	dobj||provided-20/VBD||impact-47/NN	conj_and||information-23/NN||impact-47/NN	nsubj||has-25/VBZ||impact-47/NN	prep_of||impact-47/NN||biology-49/NN	prep_of||impact-47/NN||genetics-51/NNS	conj_and||biology-49/NN||genetics-51/NNS	prep_on||provided-20/VBD||vulnerability-53/NN	prep_to||provided-20/VBD||hivinfection-55/NN	nn||progression-58/NN||disease-57/NN	prep_to||provided-20/VBD||progression-58/NN	conj_and||hivinfection-55/NN||progression-58/NN	det||risk-61/NN||the-60/DT	prep_to||provided-20/VBD||risk-61/NN	conj_and||hivinfection-55/NN||risk-61/NN	amod||transmission-64/NN||vertical-63/JJ	prep_of||risk-61/NN||transmission-64/NN	hivinfection-55||hiv-10||no||basic science studies at the 5th ias conference on hiv pathogenesis, treatment and prevention (ias 2009) provided important new information that has implications not only for treatment, but also for better understanding the complex dynamics of hivinfection, epidemiology, and the impact of biology and genetics on vulnerability to hivinfection, disease progression and the risk of vertical transmission.
advmod||one-6/CD||worldwide-1/RB	amod||type1diabetes-4/NNS||insulin-dependent-3/JJ	nsubj||one-6/CD||type1diabetes-4/NNS	cop||one-6/CD||is-5/VBZ	root||ROOT-0/null||one-6/CD	det||most-9/JJS||the-8/DT	prep_of||one-6/CD||most-9/JJS	advmod||diagnosed-11/VBN||frequently-10/RB	vmod||most-9/JJS||diagnosed-11/VBN	amod||disorders-14/NNS||long-term-12/JJ	nn||disorders-14/NNS||endocrine-13/NN	dobj||diagnosed-11/VBN||disorders-14/NNS	vmod||disorders-14/NNS||found-15/VBN	prep_in||found-15/VBN||children-17/NNS	det||incidences-20/NNS||the-19/DT	nsubj||increasing-26/VBG||incidences-20/NNS	det||diseased-23/JJ||this-22/DT	prep_of||incidences-20/NNS||diseased-23/JJ	aux||increasing-26/VBG||is-24/VBZ	advmod||increasing-26/VBG||still-25/RB	conj_and||one-6/CD||increasing-26/VBG	type1diabetes-4||insulin--1||yes||worldwide, insulin-dependent type1diabetes is one of the most frequently diagnosed long-term endocrine disorders found in children and the incidences of this diseased is still increasing.
nsubjpass||spread-3/VBN||vzv-1/NN	nsubj||cause-7/VB||vzv-1/NN	auxpass||spread-3/VBN||is-2/VBZ	root||ROOT-0/null||spread-3/VBN	agent||spread-3/VBN||aerosol-5/NN	aux||cause-7/VB||to-6/TO	xcomp||spread-3/VBN||cause-7/VB	dobj||cause-7/VB||chickenpox-8/NN	nsubj||infection-21/NN||chickenpox-8/NN	amod||countries-14/NNS||temperate-13/JJ	prep_in||infection-21/NN||countries-14/NNS	cop||infection-21/NN||is-16/VBZ	det||infection-21/NN||a-17/DT	advmod||benign-19/JJ||relatively-18/RB	amod||infection-21/NN||benign-19/JJ	nn||infection-21/NN||childhood-20/NN	rcmod||chickenpox-8/NN||infection-21/NN	advmod||tends-28/VBZ||yet-23/RB	amod||countries-26/NNS||tropical-25/JJ	prep_in||tends-28/VBZ||countries-26/NNS	nsubj||tends-28/VBZ||it-27/PRP	nsubj||occur-30/VB||it-27/PRP	parataxis||spread-3/VBN||tends-28/VBZ	aux||occur-30/VB||to-29/TO	xcomp||tends-28/VBZ||occur-30/VB	advmod||age-33/NN||later-32/RB	prep_at||occur-30/VB||age-33/NN	det||trend-36/NN||a-35/DT	appos||age-33/NN||trend-36/NN	vmod||trend-36/NN||associated-37/VBN	advmod||increased-40/JJ||markedly-39/RB	amod||severity-41/NN||increased-40/JJ	prep_with||associated-37/VBN||severity-41/NN	prep_including||severity-41/NN||complications-43/NNS	prep_including||severity-41/NN||hospitalization-45/NN	conj_and||complications-43/NNS||hospitalization-45/NN	amod||burden-49/NN||overall-48/JJ	prep_including||severity-41/NN||burden-49/NN	conj_and||complications-43/NNS||burden-49/NN	prep_of||burden-49/NN||care-51/NN	chickenpox-8||vzv-1||yes||vzv is spread by aerosol to cause chickenpox, which, in temperate countries, is a relatively benign childhood infection; yet in tropical countries it tends to occur at later age, a trend associated with markedly increased severity including complications, hospitalization, and overall burden of care.
amod||diuretics-4/NNS||hydrochlorothiazide-1/JJ	conj_and||hydrochlorothiazide-1/JJ||thiazide-like-3/JJ	amod||diuretics-4/NNS||thiazide-like-3/JJ	nsubjpass||considered-6/VBN||diuretics-4/NNS	auxpass||considered-6/VBN||are-5/VBP	root||ROOT-0/null||considered-6/VBN	amod||drugs-8/NNS||first-line-7/JJ	dobj||considered-6/VBN||drugs-8/NNS	amod||therapy-11/NN||initial-10/JJ	prep_for||drugs-8/NNS||therapy-11/NN	amod||arterialhypertension-14/NN||uncomplicated-13/JJ	prep_in||considered-6/VBN||arterialhypertension-14/NN	arterialhypertension-14||hydrochlorothiazide-1||yes||hydrochlorothiazide and thiazide-like diuretics are considered first-line drugs for initial therapy in uncomplicated arterialhypertension.
det||population-2/NN||the-1/DT	nsubj||comprised-3/VBN||population-2/NN	nsubj||receiving-13/VBG||population-2/NN	root||ROOT-0/null||comprised-3/VBN	dobj||comprised-3/VBN||patients-4/NNS	det||diagnosis-8/NN||a-6/DT	amod||diagnosis-8/NN||first-7/JJ	prep_with||comprised-3/VBN||diagnosis-8/NN	amod||depressivedisorder-11/NN||major-10/JJ	prep_of||diagnosis-8/NN||depressivedisorder-11/NN	conj_and||comprised-3/VBN||receiving-13/VBG	det||one-18/NN||the-15/DT	amod||one-18/NN||first-16/JJ	nn||one-18/NN||time-17/NN	prep_for||receiving-13/VBG||one-18/NN	det||escitalopram-23/NN||the-20/DT	amod||escitalopram-23/NN||following-21/JJ	nn||escitalopram-23/NN||ssris-22/NNS	prep_of||one-18/NN||escitalopram-23/NN	appos||escitalopram-23/NN||sertraline-25/NN	appos||escitalopram-23/NN||paroxetine-27/NN	conj_and||sertraline-25/NN||paroxetine-27/NN	appos||escitalopram-23/NN||citalopram-30/NN	conj_and||sertraline-25/NN||citalopram-30/NN	depressivedisorder-11||citalopram-30||yes||the population comprised patients with a first diagnosis of major depressivedisorder and receiving for the first time one of the following ssris escitalopram, sertraline, paroxetine, and citalopram.
det||outcome-3/NN||the-1/DT	amod||outcome-3/NN||primary-2/JJ	nsubj||percentage-6/NN||outcome-3/NN	cop||percentage-6/NN||was-4/VBD	det||percentage-6/NN||the-5/DT	root||ROOT-0/null||percentage-6/NN	prep_of||percentage-6/NN||patients-8/NNS	prep_with||patients-8/NNS||vomiting-10/NN	amod||31â-17/NNS||0â-12/JJ	amod||31â-17/NNS||$-13/$	num||$-13/$||30-15/CD	prep_at||vomiting-10/NN||31â-17/NNS	dep||vomiting-10/NN||$-18/$	num||$-18/$||60-20/CD	dep||vomiting-10/NN||61â-23/NNS	conj_and||$-18/$||61â-23/NNS	num||minutes-27/NNS||$-24/$	num||$-24/$||120-26/CD	dep||61â-23/NNS||minutes-27/NNS	det||administration-30/NN||the-29/DT	prep_after||percentage-6/NN||administration-30/NN	prep_of||administration-30/NN||ondansetron-32/NN	prep_of||administration-30/NN||prochlorperazine-34/NN	conj_or||ondansetron-32/NN||prochlorperazine-34/NN	vomiting-10||ondansetron-32||yes||the primary outcome was the percentage of patients with vomiting at 0â30, 31â60, and 61â120 minutes after the administration of ondansetron or prochlorperazine.
prep_in||correlated-8/VBN||addition-2/NN	amod||concentration-5/NN||formate-4/JJ	nsubjpass||correlated-8/VBN||concentration-5/NN	nsubjpass||correlated-38/VBN||concentration-5/NN	auxpass||correlated-8/VBN||was-6/VBD	advmod||correlated-8/VBN||negatively-7/RB	root||ROOT-0/null||correlated-8/VBN	amod||pc20-11/NNS||methacholine-10/JJ	prep_with||correlated-8/VBN||pc20-11/NNS	num||0.39-21/NNS||râ-13/CD	amod||0.39-21/NNS||$-14/$	number||=-16/CD||-15/CD	num||$-14/$||=-16/CD	amod||0.39-21/NNS||â-17/JJ	amod||0.39-21/NNS||$-18/$	dep||$-18/$||â-19/JJ	nsubj||asthmatics-32/VBZ||0.39-21/NNS	nn||â-27/NN||pâ-23/NN	amod||â-27/NN||$-24/$	dep||$-24/$||-25/JJ	nn||â-27/NN||=-26/NNP	appos||0.39-21/NNS||â-27/NN	dep||â-27/NN||$-28/$	num||$-28/$||0-29/CD	num||$-28/$||.002-30/CD	dep||pc20-11/NNS||asthmatics-32/VBZ	advmod||asthmatics-32/VBZ||only-33/RB	advmod||correlated-38/VBN||positively-37/RB	conj_and||correlated-8/VBN||correlated-38/VBN	det||nitrite-43/NN||the-40/DT	amod||nitrite-43/NN||no-derived-41/JJ	nn||nitrite-43/NN||ion-42/NN	prep_with||correlated-38/VBN||nitrite-43/NN	dep||nitrite-43/NN||râ-45/VBN	dobj||râ-45/VBN||$-46/$	number||=-48/CD||-47/CD	num||$-46/$||=-48/CD	dep||râ-45/VBN||â-49/VB	dobj||â-49/VB||$-50/$	number||.46-52/CD||0-51/CD	num||$-50/$||.46-52/CD	appos||$-50/$||p-54/NN	number||0.0001-56/CD||<-55/CD	dep||p-54/NN||0.0001-56/CD	amod||ige-64/NN||total-62/JJ	nn||ige-64/NN||serum-63/NN	prep_with||correlated-38/VBN||ige-64/NN	conj_and||nitrite-43/NN||ige-64/NN	dep||ige-64/NN||râ-66/VBN	num||â-70/NN||$-67/$	number||=-69/CD||-68/CD	num||$-67/$||=-69/CD	dobj||râ-66/VBN||â-70/NN	nsubj||asthmatics-84/VBZ||$-71/$	num||$-71/$||0-72/CD	num||$-71/$||.28-73/CD	nn||â-79/NN||pâ-75/NN	amod||â-79/NN||$-76/$	dep||$-76/$||-77/JJ	nn||â-79/NN||=-78/NNP	appos||$-71/$||â-79/NN	dep||â-79/NN||$-80/$	num||$-80/$||0-81/CD	num||$-80/$||.016-82/CD	rcmod||â-70/NN||asthmatics-84/VBZ	advmod||asthmatics-84/VBZ||only-85/RB	ion-42||asthmatics-84||no_rel||in addition, formate concentration was negatively correlated with methacholine pc20 (râ=ââ0.39, pâ=â0.002, asthmatics only), and positively correlated with the no-derived ion nitrite (râ=â0.46, p<0.0001) as well as with total serum ige (râ=â0.28, pâ=â0.016, asthmatics only).
nsubjpass||assigned-20/VBN||outpatients-2/NNS	advmod||assigned-20/VBN||with-3/RB	nsubj||maintained-7/VBN||schizophrenia-4/NN	nsubjpass||assigned-20/VBN||schizophrenia-4/NN	aux||maintained-7/VBN||had-6/VBD	rcmod||schizophrenia-4/NN||maintained-7/VBN	dobj||maintained-7/VBN||stability-8/NN	amod||olanzapine-12/NN||open-label-10/JJ	amod||olanzapine-12/NN||oral-11/JJ	prep_on||maintained-7/VBN||olanzapine-12/NN	number||8-16/CD||4-14/CD	dep||8-16/CD||to-15/TO	num||weeks-17/NNS||8-16/CD	prep_for||olanzapine-12/NN||weeks-17/NNS	auxpass||assigned-20/VBN||were-18/VBD	advmod||assigned-20/VBN||randomly-19/RB	root||ROOT-0/null||assigned-20/VBN	prep_to||assigned-20/VBN||low-24/NN	num||weeks-30/NNS||150-28/CD	amod||weeks-30/NNS||mg/2-29/JJ	dep||low-24/NN||weeks-30/NNS	dep||weeks-30/NNS||n-32/NN	dep||140-34/CD||=-33/SYM	rcmod||n-32/NN||140-34/CD	dep||low-24/NN||medium-39/NN	num||weeks-45/NNS||405-43/CD	amod||weeks-45/NNS||mg/4-44/JJ	dep||medium-39/NN||weeks-45/NNS	nn||318-49/NNP||n-47/NNP	nn||318-49/NNP||=-48/NNP	dep||weeks-45/NNS||318-49/NNP	advmod||medium-39/NN||or-52/CC	nsubj||lai-70/VBP||high-55/NN	num||weeks-61/NNS||300-59/CD	amod||weeks-61/NNS||mg/2-60/JJ	dep||high-55/NN||weeks-61/NNS	dep||weeks-61/NNS||n-63/NN	dep||141-65/CD||=-64/SYM	rcmod||n-63/NN||141-65/CD	advmod||high-55/NN||dosages-67/RB	prep_of||high-55/NN||olanzapine-69/JJ	ccomp||assigned-20/VBN||lai-70/VBP	num||weeks-73/NNS||24-72/CD	prep_for||lai-70/VBP||weeks-73/NNS	schizophrenia-4||olanzapine-69||yes||" outpatients with schizophrenia who had maintained stability on open-label oral olanzapine for 4 to 8 weeks were randomly assigned to ""low"" (150 mg/2 weeks; n = 140), ""medium"" (405 mg/4 weeks; n = 318), or ""high"" (300 mg/2 weeks; n = 141) dosages of olanzapine lai for 24 weeks."
det||aliskiren-3/NN||the-2/DT	prep_in||received-23/VBD||aliskiren-3/NN	det||evaluation-6/NN||the-5/DT	prep_in||aliskiren-3/NN||evaluation-6/NN	prep_of||evaluation-6/NN||proteinuria-8/NN	nn||study-14/NN||diabetes-10/NNP	appos||study-14/NN||avoid-12/NNP	prep_in||proteinuria-8/NN||study-14/NN	num||patients-18/NNS||599-16/CD	amod||patients-18/NNS||hypertensive-17/JJ	nsubj||received-23/VBD||patients-18/NNS	prep_with||patients-18/NNS||type2diabetes-20/NN	prep_with||patients-18/NNS||nephropathy-22/NN	conj_and||type2diabetes-20/NN||nephropathy-22/NN	root||ROOT-0/null||received-23/VBD	num||months-25/NNS||6-24/CD	dobj||received-23/VBD||months-25/NNS	prep_of||months-25/NNS||aliskiren-27/NN	num||mg-30/NN||150-29/CD	dep||months-25/NNS||mg-30/NN	advmod||titrated-32/VBN||daily-31/RB	vmod||mg-30/NN||titrated-32/VBN	number||mg-35/CD||300-34/CD	prep_to||titrated-32/VBN||mg-35/CD	advmod||titrated-32/VBN||daily-36/RB	num||months-39/NNS||3-38/CD	prep_after||titrated-32/VBN||months-39/NNS	nn||therapy-51/NN||placebo-42/NN	dep||therapy-51/NN||added-43/VBN	num||losartan-47/NN||100-45/CD	nn||losartan-47/NN||mg-46/NN	prep_to||added-43/VBN||losartan-47/NN	amod||antihypertensive-50/JJ||optimal-49/JJ	conj_and||added-43/VBN||antihypertensive-50/JJ	dep||therapy-51/NN||antihypertensive-50/JJ	dobj||received-23/VBD||therapy-51/NN	conj_or||months-25/NNS||therapy-51/NN	nephropathy-22||antihypertensive-50||no_rel||in the aliskiren in the evaluation of proteinuria in diabetes (avoid) study, 599 hypertensive patients with type2diabetes and nephropathy received 6 months of aliskiren (150 mg daily titrated to 300 mg daily after 3 months) or placebo added to 100 mg losartan and optimal antihypertensive therapy.
expl||were-2/VBD||there-1/EX	root||ROOT-0/null||were-2/VBD	amod||decreases-4/NNS||significant-3/JJ	nsubj||were-2/VBD||decreases-4/NNS	prep_in||decreases-4/NNS||survival-6/NN	nn||output-9/NN||urine-8/NN	prep_in||decreases-4/NNS||output-9/NN	conj_and||survival-6/NN||output-9/NN	amod||output-12/NN||cardiac-11/JJ	prep_in||decreases-4/NNS||output-12/NN	conj_and||survival-6/NN||output-12/NN	nn||delivery-15/NN||oxygen-14/NN	conj_and||survival-6/NN||delivery-15/NN	conj_and||output-12/NN||delivery-15/NN	amod||min-18/NN||60â-17/JJ	prep_at||output-12/NN||min-18/NN	amod||consumption-21/NN||o2-20/JJ	prep_in||decreases-4/NNS||consumption-21/NN	conj_and||survival-6/NN||consumption-21/NN	amod||min-24/NN||120â-23/JJ	prep_at||consumption-21/NN||min-24/NN	det||group-28/NN||the-26/DT	nn||group-28/NN||pneumonia-27/NN	prep_in||min-24/NN||group-28/NN	prepc_compared_to||group-28/NN||to-30/TO	det||group-35/NN||the-31/DT	amod||group-35/NN||nonâ-32/JJ	amod||group-35/NN||$-33/$	number||$-33/$||pneumonia-34/CD	pobj||group-28/NN||group-35/NN	pneumonia-34||o2-20||yes||there were significant decreases in survival, urine output, cardiac output and oxygen delivery at 60â min and o2 consumption at 120â min in the pneumonia group compared to the nonâ?pneumonia group.
nn||criteria-2/NNS||inclusion-1/NN	nsubj||>-8/NNS||criteria-2/NNS	det||cohort-5/NN||the-4/DT	prep_in||criteria-2/NNS||cohort-5/NN	aux||>-8/NNS||were-6/VBD	nn||>-8/NNS||age-7/NN	root||ROOT-0/null||>-8/NNS	num||years-10/NNS||18-9/CD	dobj||>-8/NNS||years-10/NNS	amod||infection-13/NN||hiv-1-12/JJ	dobj||>-8/NNS||infection-13/NN	conj_or||years-10/NNS||infection-13/NN	amod||infection-20/NN||chronichepatitisc-15/JJ	nn||infection-20/NN||virus-16/NN	nn||infection-20/NN||hcv-18/NN	dobj||>-8/NNS||infection-20/NN	conj_or||years-10/NNS||infection-20/NN	amod||response-23/NN||sustained-22/JJ	dobj||>-8/NNS||response-23/NN	conj_or||years-10/NNS||response-23/NN	aux||hcv-25/VB||to-24/TO	vmod||>-8/NNS||hcv-25/VB	dobj||hcv-25/VB||treatment-26/NN	chronichepatitisc-15||hcv-25||no||inclusion criteria in the cohort were age > 18 years, hiv-1 infection, chronichepatitisc virus (hcv) infection or sustained response to hcv treatment.
aux||begin-2/VB||to-1/TO	advcl||utilized-23/VBD||begin-2/VB	aux||understand-4/VB||to-3/TO	xcomp||begin-2/VB||understand-4/VB	det||contributions-6/NNS||the-5/DT	dobj||understand-4/VB||contributions-6/NNS	amod||obesity-9/NN||maternal-8/JJ	prep_of||contributions-6/NNS||obesity-9/NN	prep_of||contributions-6/NNS||over-nutrition-11/NN	conj_and||obesity-9/NN||over-nutrition-11/NN	amod||development-14/NN||human-13/JJ	prep_to||understand-4/VB||development-14/NN	det||origins-18/NNS||the-16/DT	amod||origins-18/NNS||early-17/JJ	prep_to||understand-4/VB||origins-18/NNS	conj_and||development-14/NN||origins-18/NNS	prep_of||origins-18/NNS||obesity-20/NN	nsubj||utilized-23/VBD||we-22/PRP	root||ROOT-0/null||utilized-23/VBD	det||model-27/NN||a-24/DT	amod||model-27/NN||non-human-25/JJ	nn||model-27/NN||primate-26/NN	dobj||utilized-23/VBD||model-27/NN	aux||investigate-29/VB||to-28/TO	vmod||utilized-23/VBD||investigate-29/VB	det||effects-31/NNS||the-30/DT	dobj||investigate-29/VB||effects-31/NNS	amod||feeding-35/NN||maternal-33/JJ	amod||feeding-35/NN||high-fat-34/JJ	prep_of||effects-31/NNS||feeding-35/NN	vmod||utilized-23/VBD||obesity-37/VB	conj_and||investigate-29/VB||obesity-37/VB	nn||milk-40/NN||breast-39/NN	prep_on||obesity-37/VB||milk-40/NN	prep_on||obesity-37/VB||maternal-42/NN	conj_and||milk-40/NN||maternal-42/NN	amod||composition-47/NN||fetal-44/JJ	nn||composition-47/NN||plasma-45/NN	nn||composition-47/NN||fattyacid-46/NN	prep_on||obesity-37/VB||composition-47/NN	conj_and||milk-40/NN||composition-47/NN	amod||development-51/NN||fetal-49/JJ	amod||development-51/NN||hepatic-50/JJ	conj_and||milk-40/NN||development-51/NN	conj_and||composition-47/NN||development-51/NN	obesity-37||fattyacid-46||no_rel||to begin to understand the contributions of maternal obesity and over-nutrition to human development and the early origins of obesity, we utilized a non-human primate model to investigate the effects of maternal high-fat feeding and obesity on breast milk, maternal and fetal plasma fattyacid composition and fetal hepatic development.
nsubj||show-3/VBP||we-1/PRP	advmod||show-3/VBP||here-2/RB	root||ROOT-0/null||show-3/VBP	mark||higher-25/JJR||that-4/IN	det||frequency-7/NN||the-5/DT	amod||frequency-7/NN||average-6/JJ	nsubj||higher-25/JJR||frequency-7/NN	amod||cells-14/NNS||total-9/JJ	conj_and||total-9/JJ||cd8-11/JJ	amod||cells-14/NNS||cd8-11/JJ	amod||cells-14/NNS||+-12/JJ	nn||cells-14/NNS||nkt-13/NN	prep_of||frequency-7/NN||cells-14/NNS	prep_in||cells-14/NNS||pbmcs-16/NNS	num||subjects-22/NNS||128-18/CD	amod||latent-20/JJ||healthy-19/JJ	amod||subjects-22/NNS||latent-20/JJ	amod||subjects-22/NNS||ebv-infected-21/JJ	prep_from||pbmcs-16/NNS||subjects-22/NNS	cop||higher-25/JJR||is-23/VBZ	advmod||higher-25/JJR||significantly-24/RB	ccomp||show-3/VBP||higher-25/JJR	prep||higher-25/JJR||than-26/IN	pcomp||than-26/IN||in-27/IN	num||patients-32/NNS||17-28/CD	amod||patients-32/NNS||acute-29/JJ	nn||patients-32/NNS||ebv-30/NN	nn||patients-32/NNS||infectiousmononucleosis-31/NN	pobj||in-27/IN||patients-32/NNS	num||patients-37/NNS||16-34/CD	amod||patients-37/NNS||ebv-associated-35/JJ	nn||patients-37/NNS||hodgkinlymphoma-36/NN	pobj||in-27/IN||patients-37/NNS	conj_and||patients-32/NNS||patients-37/NNS	num||subjects-44/NNS||16-40/CD	amod||subjects-44/NNS||ebv-negative-41/JJ	amod||subjects-44/NNS||normal-42/JJ	nn||subjects-44/NNS||control-43/NN	pobj||in-27/IN||subjects-44/NNS	conj_and||patients-32/NNS||subjects-44/NNS	infectiousmononucleosis-31||ebv-30||no||we here show that the average frequency of total and cd8+ nkt cells in pbmcs from 128 healthy latent ebv-infected subjects is significantly higher than in 17 acute ebv infectiousmononucleosis patients, 16 ebv-associated hodgkinlymphoma patients, and 16 ebv-negative normal control subjects.
nsubj||pathogens-9/NNS||bacillusanthracis-1/NNS	conj_and||bacillusanthracis-1/NNS||francisellatularensis-3/NNS	nsubj||pathogens-9/NNS||francisellatularensis-3/NNS	conj_and||bacillusanthracis-1/NNS||yersiniapestis-6/NNS	nsubj||pathogens-9/NNS||yersiniapestis-6/NNS	cop||pathogens-9/NNS||are-7/VBP	amod||pathogens-9/NNS||bacterial-8/JJ	root||ROOT-0/null||pathogens-9/NNS	nsubj||cause-12/VB||pathogens-9/NNS	nsubjpass||listed-27/VBN||pathogens-9/NNS	aux||cause-12/VB||can-11/MD	rcmod||pathogens-9/NNS||cause-12/VB	dobj||cause-12/VB||anthrax-13/NN	amod||disease-18/NN||lethal-15/JJ	amod||disease-18/NN||acute-16/JJ	amod||disease-18/NN||pneumonic-17/JJ	dobj||cause-12/VB||disease-18/NN	conj_and||anthrax-13/NN||disease-18/NN	dobj||cause-12/VB||bubonicplague-21/NN	conj_and||anthrax-13/NN||bubonicplague-21/NN	advmod||cause-12/VB||respectively-23/RB	auxpass||listed-27/VBN||are-26/VBP	rcmod||pathogens-9/NNS||listed-27/VBN	conj_and||cause-12/VB||listed-27/VBN	amod||category-30/NN||niaid-29/JJ	prep_as||listed-27/VBN||category-30/NN	det||pathogens-33/NNS||a-31/DT	nn||pathogens-33/NNS||priority-32/NN	dobj||listed-27/VBN||pathogens-33/NNS	amod||use-36/NN||possible-35/JJ	prep_for||pathogens-33/NNS||use-36/NN	amod||weapons-39/NNS||biological-38/JJ	prep_as||use-36/NN||weapons-39/NNS	bubonicplague-21||yersiniapestis-6||no||bacillusanthracis , francisellatularensis , and yersiniapestis are bacterial pathogens that can cause anthrax, lethal acute pneumonic disease, and bubonicplague, respectively, and are listed as niaid category a priority pathogens for possible use as biological weapons.
amod||alterations-2/NNS||genomic-1/JJ	nsubj||add-4/VB||alterations-2/NNS	nsubj||indicate-8/VB||alterations-2/NNS	aux||add-4/VB||may-3/MD	root||ROOT-0/null||add-4/VB	amod||information-6/NN||prognostic-5/JJ	dobj||add-4/VB||information-6/NN	conj_and||add-4/VB||indicate-8/VB	amod||aggressiveness-10/NN||biological-9/JJ	dobj||indicate-8/VB||aggressiveness-10/NN	advmod||indicate-8/VB||thereby-11/RB	xcomp||indicate-8/VB||emphasizing-12/VBG	det||need-14/NN||the-13/DT	dobj||emphasizing-12/VBG||need-14/NN	amod||profiling-17/NN||genome-wide-16/JJ	prep_for||emphasizing-12/VBG||profiling-17/NN	amod||cancers-20/NNS||oral-19/JJ	prep_of||profiling-17/NN||cancers-20/NNS	add-4||cancers-20||no_rel||genomic alterations may add prognostic information and indicate biological aggressiveness thereby emphasizing the need for genome-wide profiling of oral cancers.
ccomp||insulinresistance-22/VBP||the-2/NN	dep||appears-9/VBZ||freet4.tsh-5/VBG	nsubj||appears-9/VBZ||product-8/NN	nsubj||predictor-15/NN||product-8/NN	rcmod||the-2/NN||appears-9/VBZ	aux||predictor-15/NN||to-10/TO	cop||predictor-15/NN||be-11/VB	det||predictor-15/NN||an-12/DT	advmod||stronger-14/JJR||even-13/RB	amod||predictor-15/NN||stronger-14/JJR	xcomp||appears-9/VBZ||predictor-15/NN	dep||the-2/NN||of-16/IN	pobj||of-16/IN||dap-17/NN	nsubj||insulinresistance-22/VBP||independently-19/NNP	prep_of||independently-19/NNP||homa-21/NN	root||ROOT-0/null||insulinresistance-22/VBP	dobj||insulinresistance-22/VBP||index-23/NN	dobj||insulinresistance-22/VBP||obesity-25/NN	conj_and||index-23/NN||obesity-25/NN	insulinresistance-22||tsh--1||no_rel||" the ""freet4.tsh"" product appears to be an even stronger predictor of dap, independently of homa insulinresistance index and obesity."
nn||ig-2/NN||conclusion-1/NN	nsubj||have-7/VBP||ig-2/NN	nn||regimes-6/NNS||id-4/NN	nn||regimes-6/NNS||basal-bolus-5/NNS	conj_and||ig-2/NN||regimes-6/NNS	nsubj||have-7/VBP||regimes-6/NNS	ccomp||represent-22/VB||have-7/VBP	amod||safety-9/NN||comparative-8/JJ	dobj||have-7/VBP||safety-9/NN	dobj||have-7/VBP||efficacy-11/NN	conj_and||safety-9/NN||efficacy-11/NN	prepc_based_on||have-7/VBP||on-14/IN	det||study-17/NN||the-15/DT	nn||study-17/NN||hollander-16/NN	pobj||have-7/VBP||study-17/NN	nsubj||represent-22/VB||ig-19/NN	advmod||represent-22/VB||however-20/RB	aux||represent-22/VB||may-21/MD	root||ROOT-0/null||represent-22/VB	det||option-28/NN||a-23/DT	advmod||more-25/JJR||significantly-24/RB	amod||option-28/NN||more-25/JJR	nn||option-28/NN||cost-26/NN	nn||option-28/NN||saving-27/NN	dobj||represent-22/VB||option-28/NN	amod||patients-31/NNS||t2d-30/JJ	prep_for||option-28/NN||patients-31/NNS	advmod||requiring-34/VBG||germany-33/RB	prepc_in||represent-22/VB||requiring-34/VBG	amod||therapy-38/NN||basal-bolus-35/JJ	nn||therapy-38/NN||insulin-36/NN	nn||therapy-38/NN||analogue-37/NN	dobj||requiring-34/VBG||therapy-38/NN	amod||savings-43/NNS||potential-40/JJ	amod||savings-43/NNS||annual-41/JJ	nn||savings-43/NNS||cost-42/NN	prep_with||therapy-38/NN||savings-43/NNS	nn||684/patient-48/NNPS||â-45/NNP	nn||684/patient-48/NNPS||-46/NNP	nn||684/patient-48/NNPS||¬-47/NNP	prep_of||savings-43/NNS||684/patient-48/NNPS	prepc_compared_to||requiring-34/VBG||to-50/TO	pobj||requiring-34/VBG||id-51/NN	t2d-30||insulin-36||yes||conclusion ig and id basal-bolus regimes have comparative safety and efficacy, based on the hollander study, ig however may represent a significantly more cost saving option for t2d patients in germany requiring basal-bolus insulin analogue therapy with potential annual cost savings of â¬ 684/patient compared to id.
nn||hbp-2/NN||baseline-1/NN	nsubj||â-18/NN||hbp-2/NN	nn||s.d.-6/NNP||meanâ-4/NNP	nn||s.d.-6/NNP||±-5/NNP	appos||hbp-2/NN||s.d.-6/NNP	det||morning-10/NN||the-9/DT	prep_in||hbp-2/NN||morning-10/NN	det||measurement-14/NN||the-12/DT	amod||measurement-14/NN||first-13/JJ	appos||morning-10/NN||measurement-14/NN	cop||â-18/NN||was-16/VBD	num||â-18/NN||151.6-17/CD	root||ROOT-0/null||â-18/NN	number||16.4-20/CD||±-19/CD	dep||â-18/NN||16.4-20/CD	punct||â-38/NNS||/-21/:	number||â-23/CD||87.1-22/CD	num||â-26/NNS||â-23/CD	nn||â-26/NNS||±-24/NNP	num||â-26/NNS||11.8-25/CD	nsubj||â-38/NNS||â-26/NNS	num||â-26/NNS||$-27/$	number||mmâ-29/CD||-28/CD	num||$-27/$||mmâ-29/CD	amod||â-26/NNS||$-30/$	number||hg-32/CD||-31/CD	num||$-30/$||hg-32/CD	advmod||bedtime-35/JJ||at-34/IN	amod||â-26/NNS||bedtime-35/JJ	conj_and||$-30/$||bedtime-35/JJ	cop||â-38/NNS||was-36/VBD	num||â-38/NNS||144.3-37/CD	dep||â-18/NN||â-38/NNS	number||16.8-40/CD||±-39/CD	num||â-38/NNS||16.8-40/CD	punct||â-38/NNS||/-41/:	number||â-43/CD||82.8-42/CD	num||â-46/NN||â-43/CD	nn||â-46/NN||±-44/NNP	num||â-46/NN||11.9-45/CD	dep||â-18/NN||â-46/NN	dep||â-18/NN||$-47/$	num||$-47/$||-48/CD	vmod||$-47/$||mmâ-49/VBN	dobj||mmâ-49/VBN||$-50/$	number||hg-52/CD||-51/CD	num||$-50/$||hg-52/CD	mark||â-58/NN||whereas-54/IN	nsubj||â-58/NN||cbp-55/NN	cop||â-58/NN||was-56/VBD	num||â-58/NN||153.6-57/CD	dep||â-18/NN||â-58/NN	num||19.0-60/CD||±-59/CD	dep||â-58/NN||19.0-60/CD	punct||19.0-60/CD||/-61/:	number||â-63/CD||87.1-62/CD	num||â-66/NN||â-63/CD	nn||â-66/NN||±-64/NNP	num||â-66/NN||13.4-65/CD	nsubj||mmâ-69/VBP||â-66/NN	amod||â-66/NN||$-67/$	dep||$-67/$||-68/JJ	dep||19.0-60/CD||mmâ-69/VBP	dobj||mmâ-69/VBP||$-70/$	number||hg-72/CD||-71/CD	num||$-70/$||hg-72/CD	hg-72||hbp-2||no_rel||baseline hbp (meanâ±s.d.) in the morning (the first measurement) was 151.6â±16.4/87.1â±11.8âmmâhg and at bedtime was 144.3â±16.8/82.8â±11.9âmmâhg, whereas cbp was 153.6â±19.0/87.1â±13.4âmmâhg.
amod||mice-2/NNS||nod/scid-1/JJ	nsubjpass||grafted-22/VBN||mice-2/NNS	vmod||mice-2/NNS||undergoing-3/VBG	det||protocol-6/NN||an-4/DT	amod||protocol-6/NN||immunomodulatory-5/JJ	dobj||undergoing-3/VBG||protocol-6/NN	nsubj||includes-8/VBZ||protocol-6/NN	rcmod||protocol-6/NN||includes-8/VBZ	amod||liposomes-11/NNS||clodronate-loaded-10/JJ	appos||mice-2/NNS||liposomes-11/NNS	amod||macrophages-14/NNS||deplete-13/JJ	prep_to||liposomes-11/NNS||macrophages-14/NNS	det||antibody-19/NN||an-16/DT	amod||antibody-19/NN||anti-polymorphonuclear-17/JJ	nn||antibody-19/NN||leukocytes-18/NNS	prep_to||liposomes-11/NNS||antibody-19/NN	conj_and||macrophages-14/NNS||antibody-19/NN	auxpass||grafted-22/VBN||were-21/VBD	root||ROOT-0/null||grafted-22/VBN	amod||cells-27/NNS||human-24/JJ	amod||cells-27/NNS||red-25/JJ	nn||cells-27/NNS||blood-26/NN	prep_with||grafted-22/VBN||cells-27/NNS	nn||falciparum-30/NN||p.-29/NN	prep_with||grafted-22/VBN||falciparum-30/NN	conj_and||cells-27/NNS||falciparum-30/NN	antibody-19||scid--1||no_rel||nod/scid mice undergoing an immunomodulatory protocol that includes , clodronate-loaded liposomes to deplete macrophages and an anti-polymorphonuclear leukocytes antibody , were grafted with human red blood cells and p. falciparum .
det||three-2/CD||the-1/DT	nsubjpass||intensified-4/VBN||three-2/CD	auxpass||intensified-4/VBN||are-3/VBP	root||ROOT-0/null||intensified-4/VBN	nn||screening-6/NN||tb-5/NN	dobj||intensified-4/VBN||screening-6/NN	appos||screening-6/NN||icf-8/NN	prep_among||intensified-4/VBN||people-11/NNS	vmod||people-11/NNS||living-12/VBG	prep_with||living-12/VBG||hiv-14/NN	det||provision-17/NN||the-16/DT	appos||hiv-14/NN||provision-17/NN	amod||therapy-21/NN||isoniazid-19/JJ	nn||therapy-21/NN||preventive-20/NN	prep_of||provision-17/NN||therapy-21/NN	appos||therapy-21/NN||ipt-23/NN	nn||control-28/NN||tb-26/NN	nn||control-28/NN||infection-27/NN	prep_of||provision-17/NN||control-28/NN	conj_and||therapy-21/NN||control-28/NN	appos||therapy-21/NN||ic-30/NN	tb-26||isoniazid-19||yes||the three are intensified tb screening (icf) among people living with hiv, the provision of isoniazid preventive therapy (ipt) and tb infection control(ic).
prep_from||had-12/VBD||january-2/NNP	num||january-2/NNP||2004-3/CD	prep_to||had-12/VBD||june-5/NNP	num||june-5/NNP||2005-6/CD	num||patients-9/NNS||254-8/CD	nsubj||had-12/VBD||patients-9/NNS	nsubj||received-25/VBD||patients-9/NNS	prep_with||patients-9/NNS||stemi-11/NNS	root||ROOT-0/null||had-12/VBD	amod||reversal-14/NN||immediate-13/JJ	dobj||had-12/VBD||reversal-14/NN	prep_of||reversal-14/NN||anticoagulation-16/NN	amod||administration-19/NN||protamine-18/JJ	prep_by||had-12/VBD||administration-19/NN	amod||stenting-23/NN||infarct-21/JJ	nn||stenting-23/NN||artery-22/NN	prep_after||administration-19/NN||stenting-23/NN	conj_and||had-12/VBD||received-25/VBD	amod||therapy-27/NN||abciximab-26/JJ	dobj||received-25/VBD||therapy-27/NN	nn||infusion-30/NN||heparin-29/NN	prep_without||received-25/VBD||infusion-30/NN	appos||infusion-30/NN||group-32/NN	num||group-32/NN||1-33/CD	heparin-29||infarct-21||no_rel||from january 2004 to june 2005, 254 patients with stemi had immediate reversal of anticoagulation by protamine administration after infarct artery stenting and received abciximab therapy without heparin infusion (group 1).
det||effects-3/NNS||the-1/DT	amod||effects-3/NNS||anti-inflammatory-2/JJ	nsubj||are-12/VBP||effects-3/NNS	nsubj||are-12/VBP||effects-3/NNS	vmod||effects-3/NNS||combined-5/VBN	amod||induction-8/NN||direct-7/JJ	prep_with||combined-5/VBN||induction-8/NN	prep_of||induction-8/NN||il-10-10/CD	root||ROOT-0/null||are-12/VBP	conj_and||are-12/VBP||are-12/VBP	prep_of||are-12/VBP||interest-14/NN	prep_with||interest-14/NN||respect-16/NN	amod||treatment-19/NN||possible-18/JJ	prep_to||are-12/VBP||treatment-19/NN	prep_of||treatment-19/NN||inflammatoryboweldiseases-21/NNS	prep_in||are-12/VBP||support-26/NN	det||system-31/NN||a-28/DT	amod||system-31/NN||healthy-29/JJ	amod||system-31/NN||immune-30/JJ	prep_of||support-26/NN||system-31/NN	anti-inflammatory-2||inflammatoryboweldiseases-21||no_rel||the anti-inflammatory effects, combined with direct induction of il-10, are of interest with respect to possible treatment of inflammatoryboweldiseases as well as in support of a healthy immune system.
nsubjpass||found-3/VBN||it-1/PRP	auxpass||found-3/VBN||was-2/VBD	root||ROOT-0/null||found-3/VBN	mark||crosslinked-8/VBN||that-4/IN	nsubjpass||crosslinked-8/VBN||lignin-5/NN	auxpass||crosslinked-8/VBN||was-6/VBD	advmod||crosslinked-8/VBN||chemically-7/RB	ccomp||found-3/VBN||crosslinked-8/VBN	prep||crosslinked-8/VBN||not-9/RB	advmod||not-9/RB||just-10/RB	advmod||trapped-12/JJ||physically-11/RB	amod||foams-17/NNS||trapped-12/JJ	det||polyurethane-16/NN||the-14/DT	amod||polyurethane-16/NN||rigid-15/JJ	prep_in||trapped-12/JJ||polyurethane-16/NN	pobj||not-9/RB||foams-17/NNS	rigid-15||chemically-7||no_rel||it was found that lignin was chemically crosslinked not just physically trapped in the rigid polyurethane foams.
det||aim-2/NN||the-1/DT	nsubj||was-6/VBD||aim-2/NN	nsubj||assess-8/VB||aim-2/NN	nsubj||dexamethasone-19/VBP||aim-2/NN	det||study-5/NN||this-4/DT	prep_of||aim-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||assess-8/VB||to-7/TO	xcomp||was-6/VBD||assess-8/VB	det||efficacy-10/NN||the-9/DT	dobj||assess-8/VB||efficacy-10/NN	det||dose-15/NN||a-12/DT	amod||dose-15/NN||single-13/JJ	amod||dose-15/NN||prophylactic-14/JJ	prep_of||efficacy-10/NN||dose-15/NN	prep_of||dose-15/NN||amoxicillin-17/NNP	xcomp||was-6/VBD||dexamethasone-19/VBP	conj_and/or||assess-8/VB||dexamethasone-19/VBP	prepc_in||dexamethasone-19/VBP||preventing-21/VBG	dobj||preventing-21/VBG||postoperativecomplications-22/NNS	appos||postoperativecomplications-22/NNS||pc-24/NN	det||removal-29/NN||a-27/DT	amod||removal-29/NN||surgical-28/JJ	prep_after||preventing-21/VBG||removal-29/NN	det||molar-35/NN||a-31/DT	amod||molar-35/NN||single-32/JJ	amod||molar-35/NN||mandibular-33/JJ	amod||molar-35/NN||third-34/JJ	prep_of||removal-29/NN||molar-35/NN	appos||molar-35/NN||m3-37/NNP	postoperativecomplications-22||dexamethasone-19||no_rel||the aim of this study was to assess the efficacy of a single prophylactic dose of amoxicillin and/or dexamethasone in preventing postoperativecomplications (pc) after a surgical removal of a single mandibular third molar (m3).
poss||results-2/NNS||our-1/PRP$	nsubj||indicate-3/VBP||results-2/NNS	root||ROOT-0/null||indicate-3/VBP	mark||apoptosis-8/VBZ||that-4/IN	det||block-7/NN||the-5/DT	nn||block-7/NN||bacteria-6/NNS	nsubj||apoptosis-8/VBZ||block-7/NN	ccomp||indicate-3/VBP||apoptosis-8/VBZ	amod||checkpoints-11/NNS||multiple-10/JJ	prep_at||apoptosis-8/VBZ||checkpoints-11/NNS	det||pathways-14/NNS||both-13/DT	prep_along||checkpoints-11/NNS||pathways-14/NNS	advmod||block-32/VB||so-15/RB	mark||block-32/VB||that-16/IN	advmod||fails-21/VBZ||even-17/RB	mark||fails-21/VBZ||if-18/IN	det||cell-20/NN||a-19/DT	nsubj||fails-21/VBZ||cell-20/NN	nsubj||prevent-23/VB||cell-20/NN	advcl||block-32/VB||fails-21/VBZ	aux||prevent-23/VB||to-22/TO	xcomp||fails-21/VBZ||prevent-23/VB	dobj||prevent-23/VB||apoptosis-24/NNS	det||step-28/NN||an-26/DT	amod||step-28/NN||early-27/JJ	prep_at||prevent-23/VB||step-28/NN	nsubj||block-32/VB||shigella-30/NN	aux||block-32/VB||will-31/MD	advcl||apoptosis-8/VBZ||block-32/VB	dobj||block-32/VB||apoptosis-33/NNS	det||level-36/NN||the-35/DT	prep_at||block-32/VB||level-36/NN	prep_of||level-36/NN||caspase-3-38/CD	shigella-30||bacteria-6||no||our results indicate that the bacteria block apoptosis at multiple checkpoints along both pathways so that even if a cell fails to prevent apoptosis at an early step, shigella will block apoptosis at the level of caspase-3.
dep||help-60/VB||the-2/NN	dep||the-2/NN||gloom-5/NN	amod||results-11/NNS||disappointing-9/JJ	nn||results-11/NNS||research-10/NN	prep_over||help-60/VB||results-11/NNS	prep_on||help-60/VB||vaccine-13/NN	nsubj||threatens-19/VBZ||development-14/NN	nsubj||overshadow-21/VB||development-14/NN	conj_and||development-14/NN||virucides-16/NNS	nsubj||threatens-19/VBZ||virucides-16/NNS	nsubj||overshadow-21/VB||virucides-16/NNS	rcmod||vaccine-13/NN||threatens-19/VBZ	aux||overshadow-21/VB||to-20/TO	xcomp||threatens-19/VBZ||overshadow-21/VB	advmod||positive-23/JJ||more-22/RBR	acomp||overshadow-21/VB||positive-23/JJ	amod||vaccine-13/NN||hiv/aids-related-26/JJ	dep||hiv/aids-related-26/JJ||news-27/NN	prep_such_as||news-27/NN||findings-31/NNS	det||circumcision-34/NN||that-32/DT	amod||circumcision-34/NN||male-33/JJ	nsubj||reduce-36/VB||circumcision-34/NN	aux||reduce-36/VB||might-35/MD	parataxis||help-60/VB||reduce-36/VB	det||likelihood-38/NN||the-37/DT	dobj||reduce-36/VB||likelihood-38/NN	nn||transmission-41/NN||hiv-40/NN	prep_of||likelihood-38/NN||transmission-41/NN	nsubj||giving-44/VBG||that-43/WDT	dobj||reduce-36/VB||giving-44/VBG	conj_and||likelihood-38/NN||giving-44/VBG	amod||drugs-46/NNS||antiretroviral-45/JJ	dobj||giving-44/VBG||drugs-46/NNS	prep||reduce-36/VB||to-47/TO	nsubj||help-60/VB||high-risk-50/JJ	amod||people-54/NNS||hiv-negative-53/JJ	nsubj||help-60/VB||people-54/NNS	amod||prophylaxis-57/NNS||pre-exposure-56/JJ	appos||people-54/NNS||prophylaxis-57/NNS	aux||help-60/VB||could-59/MD	root||ROOT-0/null||help-60/VB	xcomp||help-60/VB||protect-61/VB	dobj||protect-61/VB||them-62/PRP	prep_from||protect-61/VB||infection-64/NN	aids--1||hiv-40||no||" the ""gloom"" over disappointing research results on vaccine development and virucides ""threatens to overshadow more positive"" hiv/aids-related news, such as findings that male circumcision might reduce the likelihood of hiv transmission and that giving antiretroviral drugs to ""high-risk"" hiv-negative people (pre-exposure prophylaxis) could help protect them from infection."
det||causes-3/NNS||the-1/DT	amod||causes-3/NNS||molecular-2/JJ	nsubj||responsible-27/JJ||causes-3/NNS	nsubj||contribute-36/VBP||causes-3/NNS	prep_of||causes-3/NNS||insulinresistance-5/NN	vmod||responsible-27/JJ||i.e.-7/VBG	amod||insulin-9/NN||impaired-8/VBN	dobj||i.e.-7/VBG||insulin-9/NN	vmod||insulin-9/NN||signalling-10/VBG	det||pathway-15/NN||the-12/DT	amod||pathway-15/NN||phosphoinositol-3-13/JJ	nn||pathway-15/NN||kinase-14/NN	prep_through||signalling-10/VBG||pathway-15/NN	amod||signalling-18/NN||intact-17/JJ	prep_with||pathway-15/NN||signalling-18/NN	det||kinase-23/NN||the-20/DT	amod||kinase-23/NN||mitogen-activated-21/JJ	nn||kinase-23/NN||protein-22/NN	prep_through||signalling-10/VBG||kinase-23/NN	advmod||signalling-10/VBG||pathway-24/RB	cop||responsible-27/JJ||are-26/VBP	root||ROOT-0/null||responsible-27/JJ	det||impairment-30/NN||the-29/DT	prep_for||responsible-27/JJ||impairment-30/NN	amod||metabolism-34/NN||insulin-stimulated-32/JJ	nn||metabolism-34/NN||glucose-33/NN	prep_in||impairment-30/NN||metabolism-34/NN	conj_and||responsible-27/JJ||contribute-36/VBP	det||rate-40/NN||the-38/DT	amod||rate-40/NN||accelerated-39/VBN	prep_to||contribute-36/VBP||rate-40/NN	prep_of||rate-40/NN||cvd-42/NN	amod||patients-45/NNS||type2diabetes-44/JJ	prep_in||cvd-42/NN||patients-45/NNS	type2diabetes-44||insulin-9||yes||the molecular causes of insulinresistance , i.e. impaired insulin signalling through the phosphoinositol-3 kinase pathway with intact signalling through the mitogen-activated protein kinase pathway , are responsible for the impairment in insulin-stimulated glucose metabolism and contribute to the accelerated rate of cvd in type2diabetes patients .
nsubj||used-2/VBD||we-1/PRP	root||ROOT-0/null||used-2/VBD	num||data-6/NNS||2005-3/CD	amod||data-6/NNS||hiv/aids-4/JJ	amod||data-6/NNS||behavioral-5/JJ	dobj||used-2/VBD||data-6/NNS	num||groups-10/NNS||ten-8/CD	nn||groups-10/NNS||target-9/NN	prep_from||used-2/VBD||groups-10/NNS	aids--1||hiv--1||no||we used 2005 hiv/aids behavioral data from ten target groups.
amod||msm-6/NN||high-2/JJ	nn||msm-6/NN||risk-3/NN	nn||msm-6/NN||hiv-4/NN	amod||msm-6/NN||uninfected-5/JJ	nsubj||report-8/VBP||msm-6/NN	prep_in||associated-21/VBN||msm-6/NN	rcmod||msm-6/NN||report-8/VBP	amod||intercourse-11/NN||unprotected-9/JJ	amod||intercourse-11/NN||anal-10/JJ	dobj||report-8/VBP||intercourse-11/NN	preconj||partners-17/NNS||both-13/DT	nn||partners-17/NNS||seroconcordant-14/NN	conj_and||seroconcordant-14/NN||serodiscordant-16/NN	nn||partners-17/NNS||serodiscordant-16/NN	prep_with||report-8/VBP||partners-17/NNS	nsubjpass||associated-21/VBN||serosorting-19/NN	auxpass||associated-21/VBN||was-20/VBD	root||ROOT-0/null||associated-21/VBN	det||risk-26/NN||a-23/DT	amod||risk-26/NN||modest-24/JJ	amod||risk-26/NN||decreased-25/VBN	prep_with||associated-21/VBN||risk-26/NN	prep_of||risk-26/NN||hivinfection-28/NN	hivinfection-28||hiv-4||no||in high risk hiv uninfected msm who report unprotected anal intercourse with both seroconcordant and serodiscordant partners, serosorting was associated with a modest decreased risk of hivinfection.
amod||risks-4/NNS||gastrointestinal-3/JJ	prep_because_of||propose-30/VBP||risks-4/NNS	nn||complications-8/NNS||ulcer-7/NN	prep_including||risks-4/NNS||complications-8/NNS	amod||risks-12/NNS||cardiovascular-11/JJ	conj_and||risks-4/NNS||risks-12/NNS	prep_because_of||propose-30/VBP||risks-12/NNS	nn||events-18/NNS||hypertension-15/NN	conj_and||hypertension-15/NN||thrombotic-17/JJ	nn||events-18/NNS||thrombotic-17/JJ	prep_including||risks-12/NNS||events-18/NNS	vmod||events-18/NNS||associated-19/VBN	amod||anti-inflammatorydrugs-22/NNS||nonsteroidal-21/JJ	prep_with||associated-19/VBN||anti-inflammatorydrugs-22/NNS	num||nsaids-24/NNS||-LSB--23/CD	npadvmod||-RSB--25/JJ||nsaids-24/NNS	amod||anti-inflammatorydrugs-22/NNS||-RSB--25/JJ	det||guidelines-29/NNS||these-28/DT	nsubj||propose-30/VBP||guidelines-29/NNS	root||ROOT-0/null||propose-30/VBP	dobj||propose-30/VBP||acetaminophen-31/NN	det||anti-inflammatoryagents-36/NNS||the-33/DT	amod||anti-inflammatoryagents-36/NNS||first-34/JJ	nn||anti-inflammatoryagents-36/NNS||choice-35/NN	prep_as||propose-30/VBP||anti-inflammatoryagents-36/NNS	ulcer-7||acetaminophen-31||no_rel||because of gastrointestinal risks (including ulcer complications) and cardiovascular risks (including hypertension and thrombotic events associated with nonsteroidal anti-inflammatorydrugs [nsaids]), these guidelines propose acetaminophen as the first choice anti-inflammatoryagents.
poss||study-3/NN||our-1/PRP$	amod||study-3/NN||previous-2/JJ	nsubj||reported-4/VBD||study-3/NN	root||ROOT-0/null||reported-4/VBD	mark||contain-21/VBP||that-5/IN	preconj||gb-8/NN||both-6/DT	amod||gb-8/NN||glycoproteins-7/JJ	nsubj||contain-21/VBP||gb-8/NN	conj_and||gb-8/NN||gh-10/NN	nsubj||contain-21/VBP||gh-10/NN	det||marek-14/NN||the-12/DT	amod||marek-14/NN||herpesvirus-13/JJ	prep_of||gb-8/NN||marek-14/NN	amod||virus-17/NN||sdisease-16/JJ	dep||marek-14/NN||virus-17/NN	appos||marek-14/NN||mdv-19/NN	ccomp||reported-4/VBD||contain-21/VBP	num||domains-26/NNS||eleven-22/CD	amod||domains-26/NNS||potential-23/JJ	amod||domains-26/NNS||heptad-24/JJ	nn||domains-26/NNS||repeat-25/NN	dobj||contain-21/VBP||domains-26/NNS	marek'sdisease--1||herpesvirus-13||no||our previous study reported that both glycoproteins gb and gh of the herpesvirus marek'sdisease virus (mdv) contain eleven potential heptad repeat domains.
det||aim-2/NN||the-1/DT	nsubj||was-3/VBD||aim-2/NN	nsubj||determine-5/VB||aim-2/NN	root||ROOT-0/null||was-3/VBD	aux||determine-5/VB||to-4/TO	xcomp||was-3/VBD||determine-5/VB	dobj||associated-9/VBN||which-6/WDT	nsubjpass||associated-9/VBN||factors-7/NNS	auxpass||associated-9/VBN||are-8/VBP	ccomp||determine-5/VB||associated-9/VBN	prep_with||associated-9/VBN||improvements-11/NNS	det||level-14/NN||the-13/DT	prep_in||improvements-11/NNS||level-14/NN	prep_of||level-14/NN||health-16/NN	amod||patients-21/NNS||male-18/JJ	conj_and||male-18/JJ||female-20/JJ	amod||patients-21/NNS||female-20/JJ	prep_of||health-16/NN||patients-21/NNS	prep_with||associated-9/VBN||hiv/aids-23/NNS	prep_in||hiv/aids-23/NNS||andalusia-25/NN	prep_in||associated-9/VBN||terms-28/NNS	amod||years-32/NNS||disability-adjusted-30/JJ	nn||years-32/NNS||life-31/NN	prep_of||terms-28/NNS||years-32/NNS	aids--1||hiv--1||no||the aim was to determine which factors are associated with improvements in the level of health of male and female patients with hiv/aids in andalusia, in terms of disability-adjusted life years.
amod||examination-2/NN||slit-lamp-1/JJ	nsubj||show-5/VB||examination-2/NN	aux||show-5/VB||did-3/VBD	neg||show-5/VB||not-4/RB	root||ROOT-0/null||show-5/VB	det||difference-8/NN||any-6/DT	amod||difference-8/NN||significant-7/JJ	dobj||show-5/VB||difference-8/NN	det||degree-11/NN||the-10/DT	prep_between||difference-8/NN||degree-11/NN	prep_of||degree-11/NN||edema-13/NN	amod||infiltration-16/NN||cellular-15/JJ	prep_between||difference-8/NN||infiltration-16/NN	conj_or||degree-11/NN||infiltration-16/NN	det||corneas-19/NNS||the-18/DT	prep_between||infiltration-16/NN||corneas-19/NNS	nn||rabbits-24/NNS||control-21/NN	conj_and||control-21/NN||enalapril-treated-23/JJ	nn||rabbits-24/NNS||enalapril-treated-23/JJ	prep_of||corneas-19/NNS||rabbits-24/NNS	edema-13||enalapril--1||yes||slit-lamp examination did not show any significant difference between the degree of edema or cellular infiltration between the corneas of control and enalapril-treated rabbits.
amod||participants-3/NNS||twenty-one-1/JJ	amod||participants-3/NNS||stabilized-2/JJ	nsubjpass||randomized-13/VBN||participants-3/NNS	nsubj||adjunctive-15/VB||participants-3/NNS	dep||participants-3/NNS||diagnosed-4/VBN	prep_with||diagnosed-4/VBN||schizophrenia-6/NN	dep||participants-3/NNS||undergoing-8/VBG	conj_and||diagnosed-4/VBN||undergoing-8/VBG	dobj||undergoing-8/VBG||treatment-9/NN	prep_with||undergoing-8/VBG||risperidone-11/NN	auxpass||randomized-13/VBN||were-12/VBD	root||ROOT-0/null||randomized-13/VBN	aux||adjunctive-15/VB||to-14/TO	xcomp||randomized-13/VBN||adjunctive-15/VB	dobj||adjunctive-15/VB||treatment-16/NN	prep_with||adjunctive-15/VB||mirtazapine-18/NN	num||mg/day-21/NN||15-20/CD	dep||mirtazapine-18/NN||mg/day-21/NN	det||weeks-26/NNS||the-23/DT	amod||weeks-26/NNS||first-24/JJ	num||weeks-26/NNS||two-25/CD	prep_for||mg/day-21/NN||weeks-26/NNS	num||mg/day-29/NN||30-28/CD	dep||mg/day-21/NN||mg/day-29/NN	det||weeks-34/NNS||the-31/DT	amod||weeks-34/NNS||next-32/JJ	num||weeks-34/NNS||six-33/CD	prep_for||mg/day-29/NN||weeks-34/NNS	prep_with||adjunctive-15/VB||placebo-37/NN	conj_or||mirtazapine-18/NN||placebo-37/NN	schizophrenia-6||risperidone-11||yes||twenty-one stabilized participants diagnosed with schizophrenia and undergoing treatment with risperidone were randomized to adjunctive treatment with mirtazapine (15 mg/day for the first two weeks, 30 mg/day for the next six weeks) or placebo.
nn||concentrations-2/NNS||serum-1/NN	nsubjpass||measured-50/VBN||concentrations-2/NNS	amod||cytokines-5/NNS||proinflammatory-4/JJ	prep_of||concentrations-2/NNS||cytokines-5/NNS	amod||interleukin-6-8/JJ||interleukin-1alpha-6/JJ	amod||cytokines-5/NNS||interleukin-6-8/JJ	nn||necrosis-11/NNS||tumor-10/NN	prep_of||concentrations-2/NNS||necrosis-11/NNS	conj_and||cytokines-5/NNS||necrosis-11/NNS	amod||colonystimulatingfactor-15/NN||factor-alpha-12/JJ	amod||colonystimulatingfactor-15/NN||granulocyte-macrophage-14/JJ	dep||necrosis-11/NNS||colonystimulatingfactor-15/NN	dep||colonystimulatingfactor-15/NN||gm-csf-17/JJ	det||markers-22/NNS||some-20/DT	amod||markers-22/NNS||biochemical-21/JJ	prep_of||concentrations-2/NNS||markers-22/NNS	conj_and||cytokines-5/NNS||markers-22/NNS	prep_of||markers-22/NNS||osteoporosis-24/NN	nn||alkaline-31/NN||osteocalcin-26/NN	conj_and||osteocalcin-26/NN||total-28/NN	nn||alkaline-31/NN||total-28/NN	conj_and||osteocalcin-26/NN||bone-30/NN	nn||alkaline-31/NN||bone-30/NN	dep||concentrations-2/NNS||alkaline-31/NN	amod||telopeptides-41/NNS||phosphatase-32/JJ	amod||telopeptides-41/NNS||procollagen-34/JJ	nn||telopeptides-41/NNS||type-35/NN	amod||telopeptides-41/NNS||i-36/JJ	amod||telopeptides-41/NNS||carboxyterminal-37/JJ	amod||telopeptides-41/NNS||propeptide-38/JJ	amod||telopeptides-41/NNS||carboxyterminal-40/JJ	dep||alkaline-31/NN||telopeptides-41/NNS	nn||collagen-45/NN||type-43/FW	nn||collagen-45/NN||i-44/FW	prep_of||telopeptides-41/NNS||collagen-45/NN	dep||collagen-45/NN||ctx-47/NN	auxpass||measured-50/VBN||were-49/VBD	root||ROOT-0/null||measured-50/VBN	colonystimulatingfactor-15||osteoporosis-24||no_rel||serum concentrations of proinflammatory cytokines interleukin-1alpha, interleukin-6, tumor necrosis factor-alpha, granulocyte-macrophage colonystimulatingfactor (gm-csf) and some biochemical markers of osteoporosis (osteocalcin, total and bone alkaline phosphatase, procollagen type i carboxyterminal propeptide, carboxyterminal telopeptides of type i collagen--ctx) were measured.
det||vaccine-5/NN||the-1/DT	amod||vaccine-5/NN||only-2/JJ	advmod||available-4/JJ||currently-3/RB	amod||vaccine-5/NN||available-4/JJ	nsubj||calmette-guerin-14/NN||vaccine-5/NN	prep_against||vaccine-5/NN||tuberculosis-7/NNP	appos||vaccine-5/NN||tb-9/NN	cop||calmette-guerin-14/NN||is-11/VBZ	amod||bacille-13/JJ||mycobacteriumbovis-12/JJ	amod||calmette-guerin-14/NN||bacille-13/JJ	root||ROOT-0/null||calmette-guerin-14/NN	nsubj||inconsistent-21/JJ||calmette-guerin-14/NN	nsubj||protect-24/VB||calmette-guerin-14/NN	appos||calmette-guerin-14/NN||bcg-16/NN	aux||inconsistent-21/JJ||has-20/VBZ	rcmod||calmette-guerin-14/NN||inconsistent-21/JJ	advmod||inconsistent-21/JJ||efficacy-22/RB	aux||protect-24/VB||to-23/TO	xcomp||inconsistent-21/JJ||protect-24/VB	det||disease-27/NN||the-26/DT	prep_against||protect-24/VB||disease-27/NN	prep_in||inconsistent-21/JJ||adults-29/NNS	tuberculosis-7||bcg-16||yes||the only currently available vaccine against tuberculosis (tb) is mycobacteriumbovis bacille calmette-guerin (bcg), which has inconsistent efficacy to protect against the disease in adults.
nsubj||hold-49/VBP||comparison-1/NN	det||sequence-8/NN||the-3/DT	amod||sequence-8/NN||fcov-4/JJ	amod||sequence-8/NN||c1je-5/JJ	amod||sequence-8/NN||genomic-6/JJ	nn||sequence-8/NN||rna-7/NN	prep_of||comparison-1/NN||sequence-8/NN	mark||have-26/VBP||sequence-8/NN	prep_with||sequence-8/NN||that-10/DT	det||virus-17/NN||the-12/DT	nn||virus-17/NN||laboratory-13/NN	nn||virus-17/NN||strain-14/NN	amod||virus-17/NN||fcov-15/JJ	nn||virus-17/NN||fip-16/NN	prep_of||that-10/DT||virus-17/NN	appos||virus-17/NN||fipv-19/NNP	nsubj||showed-22/VBD||79-1146-21/CD	rcmod||sequence-8/NN||showed-22/VBD	det||viruses-25/NNS||both-24/DT	nsubj||have-26/VBP||viruses-25/NNS	ccomp||showed-22/VBD||have-26/VBP	det||organisation-30/NN||a-27/DT	amod||organisation-30/NN||similar-28/JJ	nn||organisation-30/NN||genome-29/NN	dobj||have-26/VBP||organisation-30/NN	prep_of||comparison-1/NN||predictions-32/NNS	conj_and||sequence-8/NN||predictions-32/NNS	mark||have-26/VBP||predictions-32/NNS	vmod||predictions-32/NNS||made-33/VBN	det||frames-38/NNS||the-35/DT	amod||frames-38/NNS||open-36/JJ	nn||frames-38/NNS||reading-37/NN	prep_for||made-33/VBN||frames-38/NNS	prep_for||made-33/VBN||cis-40/NN	conj_and||frames-38/NNS||cis-40/NN	amod||elements-43/NNS||acting-42/VBG	prep_of||comparison-1/NN||elements-43/NNS	conj_and||sequence-8/NN||elements-43/NNS	mark||have-26/VBP||elements-43/NNS	det||genome-48/NN||the-45/DT	nn||genome-48/NN||fipv-46/NNP	num||genome-48/NN||79-1146-47/CD	prep_of||elements-43/NNS||genome-48/NN	root||ROOT-0/null||hold-49/VBP	acomp||hold-49/VBP||true-50/JJ	amod||c1je-53/NNS||fcov-52/JJ	prep_for||hold-49/VBP||c1je-53/NNS	fip-16||fipv-46||no||comparison of the fcov c1je genomic rna sequence with that of the laboratory strain fcov fip virus (fipv) 79-1146 showed that both viruses have a similar genome organisation and predictions made for the open reading frames and cis -acting elements of the fipv 79-1146 genome hold true for fcov c1je.
prep_in||shown-7/VBN||addition-2/NN	amod||studies-5/NNS||epidemiologic-4/JJ	nsubj||shown-7/VBN||studies-5/NNS	aux||shown-7/VBN||have-6/VBP	root||ROOT-0/null||shown-7/VBN	mark||resulted-18/VBD||that-8/IN	det||use-10/NN||the-9/DT	nsubj||resulted-18/VBD||use-10/NN	amod||agents-13/NNS||no-donating-12/JJ	prep_of||use-10/NN||agents-13/NNS	prep_with||agents-13/NNS||nsaids-15/NNS	prep_with||agents-13/NNS||aspirin-17/NN	conj_or||nsaids-15/NNS||aspirin-17/NN	ccomp||shown-7/VBN||resulted-18/VBD	amod||risk-21/NN||reduced-20/VBN	prep_in||resulted-18/VBD||risk-21/NN	prep_for||risk-21/NN||gastrointestinalbleeding-23/NN	nsaids-15||gastrointestinalbleeding-23||no_rel||in addition, epidemiologic studies have shown that the use of no-donating agents with nsaids or aspirin resulted in reduced risk for gastrointestinalbleeding.
det||best-3/JJS||the-2/DT	prep_to||report-13/NN||best-3/JJS	poss||knowledge-6/NN||our-5/PRP$	prep_of||best-3/JJS||knowledge-6/NN	nsubj||report-13/NN||this-8/DT	cop||report-13/NN||is-9/VBZ	det||report-13/NN||the-10/DT	amod||report-13/NN||first-11/JJ	nn||report-13/NN||case-12/NN	root||ROOT-0/null||report-13/NN	det||treatment-17/NN||the-15/DT	amod||treatment-17/NN||successful-16/JJ	prep_of||report-13/NN||treatment-17/NN	amod||metastasis-20/NNS||peritoneal-19/JJ	prep_of||treatment-17/NN||metastasis-20/NNS	amod||adenocarcinoma-24/NN||small-22/JJ	nn||adenocarcinoma-24/NN||bowel-23/NN	prep_from||metastasis-20/NNS||adenocarcinoma-24/NN	amod||surgery-27/NN||cytoreductive-26/JJ	prep_by||adenocarcinoma-24/NN||surgery-27/NN	nn||chemotherapy-30/NN||combination-29/NN	prep_by||adenocarcinoma-24/NN||chemotherapy-30/NN	conj_and||surgery-27/NN||chemotherapy-30/NN	amod||acid/fluorouracil/oxaliplatin-33/NN||folinic-32/JJ	dep||surgery-27/NN||acid/fluorouracil/oxaliplatin-33/NN	amod||acid/fluorouracil/irinotecan-36/NN||folinic-35/JJ	dep||surgery-27/NN||acid/fluorouracil/irinotecan-36/NN	conj_and||acid/fluorouracil/oxaliplatin-33/NN||acid/fluorouracil/irinotecan-36/NN	amod||k-39/NN||polysaccharide-38/JJ	prep_with||acid/fluorouracil/oxaliplatin-33/NN||k-39/NN	metastasis-20||irinotecan--1||yes||to the best of our knowledge, this is the first case report of the successful treatment of peritoneal metastasis from small bowel adenocarcinoma by cytoreductive surgery and combination chemotherapy (folinic acid/fluorouracil/oxaliplatin and folinic acid/fluorouracil/irinotecan with polysaccharide k).
poss||sample-2/NN||our-1/PRP$	nsubjpass||taken-4/VBN||sample-2/NN	auxpass||taken-4/VBN||was-3/VBD	root||ROOT-0/null||taken-4/VBN	prep_from||taken-4/VBN||women-6/NNS	nsubj||participated-10/VBN||women-6/NNS	aux||participated-10/VBN||had-8/VBD	advmod||participated-10/VBN||recently-9/RB	rcmod||women-6/NNS||participated-10/VBN	det||trial-15/NN||a-12/DT	amod||trial-15/NN||randomized-13/JJ	amod||trial-15/NN||controlled-14/JJ	prep_in||participated-10/VBN||trial-15/NN	vmod||trial-15/NN||investigating-16/VBG	det||effects-18/NNS||the-17/DT	dobj||investigating-16/VBG||effects-18/NNS	prep_of||effects-18/NNS||acupuncture-20/NN	prep_on||investigating-16/VBG||hotflashes-22/NNS	det||effect-26/NN||a-24/DT	nn||effect-26/NN||side-25/NN	appos||hotflashes-22/NNS||effect-26/NN	amod||treatment-29/NN||estrogen-antagonist-28/JJ	prep_of||effect-26/NN||treatment-29/NN	hotflashes-22||estrogen--1||yes||our sample was taken from women who had recently participated in a randomized controlled trial investigating the effects of acupuncture on hotflashes, a side effect of estrogen-antagonist treatment.
det||calcineurininhibitors-3/NNS||the-1/DT	amod||calcineurininhibitors-3/NNS||topical-2/JJ	nsubjpass||used-11/VBN||calcineurininhibitors-3/NNS	nsubj||treat-13/VB||calcineurininhibitors-3/NNS	nsubj||inhibit-20/VB||calcineurininhibitors-3/NNS	appos||calcineurininhibitors-3/NNS||tacrolimus-5/NNS	appos||calcineurininhibitors-3/NNS||pimecrolimus-7/NNS	conj_and||tacrolimus-5/NNS||pimecrolimus-7/NNS	aux||used-11/VBN||have-9/VBP	auxpass||used-11/VBN||been-10/VBN	root||ROOT-0/null||used-11/VBN	aux||treat-13/VB||to-12/TO	xcomp||used-11/VBN||treat-13/VB	amod||cutaneous-15/JJ||resistant-14/JJ	amod||lupus-16/NNS||cutaneous-15/JJ	dobj||treat-13/VB||lupus-16/NNS	prep_since||treat-13/VB||2002-18/CD	xcomp||used-11/VBN||inhibit-20/VB	conj_and||treat-13/VB||inhibit-20/VB	det||proliferation-22/NN||the-21/DT	dobj||inhibit-20/VB||proliferation-22/NN	dobj||inhibit-20/VB||activation-24/NN	conj_and||proliferation-22/NN||activation-24/NN	prep_of||proliferation-22/NN||t-cells-26/NNS	conj_and||treat-13/VB||suppress-28/VB	conj_and||inhibit-20/VB||suppress-28/VB	amod||cutaneousinflammation-30/NN||immune-mediated-29/JJ	dobj||suppress-28/VB||cutaneousinflammation-30/NN	calcineurininhibitors-3||lupus-16||no_rel||the topical calcineurininhibitors, tacrolimus and pimecrolimus, have been used to treat resistant cutaneous lupus since 2002 and inhibit the proliferation and activation of t-cells and suppress immune-mediated cutaneousinflammation.
det||world-2/NN||the-1/DT	nsubj||overcome-5/VBN||world-2/NN	aux||overcome-5/VBN||has-3/VBZ	advmod||overcome-5/VBN||recently-4/RB	root||ROOT-0/null||overcome-5/VBN	det||pandemic-9/NN||the-6/DT	amod||pandemic-9/NN||first-7/JJ	nn||pandemic-9/NN||influenza-8/NN	dobj||overcome-5/VBN||pandemic-9/NN	det||century-13/NN||the-11/DT	amod||century-13/NN||21st-12/JJ	prep_of||pandemic-9/NN||century-13/NN	vmod||century-13/NN||caused-14/VBN	det||virus-19/NN||a-16/DT	amod||virus-19/NN||novel-17/JJ	amod||virus-19/NN||h1n1-18/JJ	agent||caused-14/VBN||virus-19/NN	appos||virus-19/NN||ph1n1-21/NNP	nsubj||reassortant-27/NN||which-23/WDT	cop||reassortant-27/NN||is-24/VBZ	det||reassortant-27/NN||a-25/DT	amod||reassortant-27/NN||triple-26/JJ	ccomp||virus-19/NN||reassortant-27/NN	vmod||reassortant-27/NN||comprising-28/VBG	nsubj||derived-30/VBN||genes-29/NNS	nsubj||different-42/JJ||genes-29/NNS	ccomp||comprising-28/VBG||derived-30/VBN	prep_from||derived-30/VBN||avian-32/NN	prep_from||derived-30/VBN||human-34/JJ	conj_and||avian-32/NN||human-34/JJ	amod||influenzaviruses-38/NNS||swine-37/JJ	prep_from||derived-30/VBN||influenzaviruses-38/NNS	conj_and||avian-32/NN||influenzaviruses-38/NNS	advmod||different-42/JJ||antigenically-40/RB	advmod||different-42/JJ||quite-41/RB	ccomp||comprising-28/VBG||different-42/JJ	conj_and||derived-30/VBN||different-42/JJ	amod||strains-46/NNS||seasonal-44/JJ	amod||strains-46/NNS||h1n1-45/JJ	prep_from||different-42/JJ||strains-46/NNS	influenza-8||influenzaviruses-38||no||the world has recently overcome the first influenza pandemic of the 21st century caused by a novel h1n1 virus (ph1n1) which is a triple reassortant comprising genes derived from avian, human, and swine influenzaviruses and antigenically quite different from seasonal h1n1 strains.
det||prevalence-3/NN||a-1/DT	amod||prevalence-3/NN||high-2/JJ	nsubj||poses-18/VBZ||prevalence-3/NN	prep_of||prevalence-3/NN||hepatitisbvirus-5/NNS	appos||hepatitisbvirus-5/NNS||hbv-7/NN	amod||virus-11/NN||hepatitisc-10/JJ	prep_of||prevalence-3/NN||virus-11/NN	conj_and||hepatitisbvirus-5/NNS||virus-11/NN	appos||hepatitisbvirus-5/NNS||hcv-13/NN	nn||donors-17/NNS||blood-16/NN	prep_in||prevalence-3/NN||donors-17/NNS	root||ROOT-0/null||poses-18/VBZ	det||risk-21/NN||an-19/DT	amod||risk-21/NN||increased-20/VBN	dobj||poses-18/VBZ||risk-21/NN	nn||transmission-25/NN||window-23/NN	nn||transmission-25/NN||period-24/NN	prep_of||risk-21/NN||transmission-25/NN	nn||transfusion-28/NN||blood-27/NN	prep_through||transmission-25/NN||transfusion-28/NN	hbv-7||hepatitisbvirus-5||no||a high prevalence of hepatitisbvirus (hbv) and hepatitisc virus (hcv) in blood donors poses an increased risk of window period transmission through blood transfusion.
nsubj||reviewed-3/VBN||we-1/PRP	advmod||reviewed-3/VBN||retrospectively-2/RB	root||ROOT-0/null||reviewed-3/VBN	poss||data-5/NNS||our-4/PRP$	dobj||reviewed-3/VBN||data-5/NNS	prep_of||data-5/NNS||patients-7/NNS	amod||genotype-10/NN||chronichepatitisc-9/JJ	prep_with||reviewed-3/VBN||genotype-10/NN	num||genotype-10/NN||1-11/CD	vmod||genotype-10/NN||treated-12/VBN	amod||±-16/NNP||pegylated-14/JJ	nn||±-16/NNP||interferon-î-15/NNS	prep_with||treated-12/VBN||±-16/NNP	prep_with||treated-12/VBN||ribavirin-18/NNP	conj_and||±-16/NNP||ribavirin-18/NNP	chronichepatitisc-9||interferon--1||yes||we retrospectively reviewed our data of patients with chronichepatitisc genotype 1 treated with pegylated interferon-î± and ribavirin.
nsubj||carried-2/VBD||we-1/PRP	nsubj||examined-14/VBD||we-1/PRP	root||ROOT-0/null||carried-2/VBD	prt||carried-2/VBD||out-3/RP	nn||monotherapy-5/NN||candesartan-4/NN	dobj||carried-2/VBD||monotherapy-5/NN	prep_in||carried-2/VBD||patients-7/NNS	amod||moderate-11/JJ||mild-9/JJ	dep||moderate-11/JJ||to-10/TO	amod||hypertension-12/NN||moderate-11/JJ	prep_with||carried-2/VBD||hypertension-12/NN	conj_and||carried-2/VBD||examined-14/VBD	det||changes-17/NNS||the-15/DT	amod||changes-17/NNS||longitudinal-16/JJ	dobj||examined-14/VBD||changes-17/NNS	nn||profile-21/NN||plasma-19/NN	nn||profile-21/NN||lipid-20/NN	prep_in||examined-14/VBD||profile-21/NN	hypertension-12||candesartan-4||yes||we carried out candesartan monotherapy in patients with mild to moderate hypertension and examined the longitudinal changes in plasma lipid profile.
nn||virus-3/NN||hepatitis-1/NN	nn||virus-3/NN||delta-2/NN	nsubjpass||known-15/VBN||virus-3/NN	nsubj||induce-17/VB||virus-3/NN	appos||virus-3/NN||hdv-5/NN	amod||co-infection-12/NN||hepatitisbvirus-8/JJ	appos||co-infection-12/NN||hbv-10/NN	conj_and||virus-3/NN||co-infection-12/NN	nsubjpass||known-15/VBN||co-infection-12/NN	nsubj||induce-17/VB||co-infection-12/NN	auxpass||known-15/VBN||is-13/VBZ	advmod||known-15/VBN||well-14/RB	root||ROOT-0/null||known-15/VBN	aux||induce-17/VB||to-16/TO	xcomp||known-15/VBN||induce-17/VB	det||spectrum-19/NN||a-18/DT	dobj||induce-17/VB||spectrum-19/NN	nsubj||advance-27/VBP||spectrum-19/NN	amod||liverdiseases-24/NNS||acute-21/JJ	conj_and||acute-21/JJ||chronic-23/JJ	amod||liverdiseases-24/NNS||chronic-23/JJ	prep_of||spectrum-19/NN||liverdiseases-24/NNS	advmod||advance-27/VBP||further-26/RB	rcmod||spectrum-19/NN||advance-27/VBP	prep_to||advance-27/VBP||cirrhosis-29/NNS	amod||hepatitis-32/NN||fulminant-31/JJ	appos||cirrhosis-29/NNS||hepatitis-32/NN	nn||carcinoma-35/NN||hepatocellular-34/NN	appos||cirrhosis-29/NNS||carcinoma-35/NN	conj_and||hepatitis-32/NN||carcinoma-35/NN	appos||hepatitis-32/NN||hcc-37/NN	hbv-10||hepatitisbvirus-8||no||hepatitis delta virus (hdv) and hepatitisbvirus (hbv) co-infection is well known to induce a spectrum of acute and chronic liverdiseases which further advance to cirrhosis, fulminant hepatitis and hepatocellular carcinoma (hcc).
nsubj||disease-9/NN||severeacuterespiratorysyndrome-1/NN	appos||severeacuterespiratorysyndrome-1/NN||sars-3/NNS	cop||disease-9/NN||is-5/VBZ	det||disease-9/NN||an-6/DT	amod||disease-9/NN||emerging-7/VBG	amod||disease-9/NN||infectious-8/JJ	root||ROOT-0/null||disease-9/NN	vmod||disease-9/NN||caused-10/VBN	det||coronavirussars-cov-14/NN||the-12/DT	nn||coronavirussars-cov-14/NN||novel-13/NN	agent||caused-10/VBN||coronavirussars-cov-14/NN	severeacuterespiratorysyndrome-1||sars-cov--1||no||severeacuterespiratorysyndrome (sars) is an emerging infectious disease caused by the novel coronavirussars-cov.
mark||reduces-19/VBZ||although-1/IN	det||minimization-3/NN||the-2/DT	nsubj||reduces-19/VBZ||minimization-3/NN	det||volume-8/NN||the-5/DT	amod||volume-8/NN||applied-6/JJ	amod||volume-8/NN||tidal-7/JJ	prep_of||minimization-3/NN||volume-8/NN	appos||volume-8/NN||vt-10/NN	amod||ventilation-15/NN||high-frequency-13/JJ	nn||ventilation-15/NN||oscillatory-14/NN	prep_during||volume-8/NN||ventilation-15/NN	appos||ventilation-15/NN||hfov-17/NNP	advcl||result-30/VB||reduces-19/VBZ	det||risk-21/NN||the-20/DT	dobj||reduces-19/VBZ||risk-21/NN	nn||stress-25/NN||alveolar-23/NN	nn||stress-25/NN||shear-24/NN	prep_of||risk-21/NN||stress-25/NN	nsubj||result-30/VB||it-27/PRP	aux||result-30/VB||can-28/MD	advmod||result-30/VB||also-29/RB	root||ROOT-0/null||result-30/VB	amod||co2-elimination-33/NN||insufficient-32/JJ	prep_in||result-30/VB||co2-elimination-33/NN	amod||respiratoryacidosis-36/NNS||severe-35/JJ	prep_with||result-30/VB||respiratoryacidosis-36/NNS	respiratoryacidosis-36||co2--1||no||although the minimization of the applied tidal volume (vt) during high-frequency oscillatory ventilation (hfov) reduces the risk of alveolar shear stress, it can also result in insufficient co2-elimination with severe respiratoryacidosis.
det||model-7/NN||a-1/DT	amod||primate-3/JJ||non-human-2/JJ	amod||model-7/NN||primate-3/JJ	appos||model-7/NN||nhp-5/NN	nsubjpass||employed-11/VBN||model-7/NN	nsubj||study-13/VB||model-7/NN	prep_of||model-7/NN||glutensensitivity-9/NN	auxpass||employed-11/VBN||was-10/VBD	root||ROOT-0/null||employed-11/VBN	aux||study-13/VB||to-12/TO	xcomp||employed-11/VBN||study-13/VB	det||perturbations-16/NNS||the-14/DT	nn||perturbations-16/NNS||gene-15/NN	dobj||study-13/VB||perturbations-16/NNS	vmod||perturbations-16/NNS||associated-17/VBN	amod||changes-21/NNS||dietary-19/JJ	nn||changes-21/NNS||gluten-20/NN	prep_with||associated-17/VBN||changes-21/NNS	amod||tissues-25/NNS||small-23/JJ	amod||tissues-25/NNS||intestinal-24/JJ	prep_in||changes-21/NNS||tissues-25/NNS	amod||macaques-29/NNS||gluten-sensitive-27/JJ	nn||macaques-29/NNS||rhesus-28/NNS	prep_from||associated-17/VBN||macaques-29/NNS	nn||mulatta-32/NN||macaca-31/NN	appos||macaques-29/NNS||mulatta-32/NN	glutensensitivity-9||gluten-20||no||a non-human primate (nhp) model of glutensensitivity was employed to study the gene perturbations associated with dietary gluten changes in small intestinal tissues from gluten-sensitive rhesus macaques ( macaca mulatta ).
nn||myers-2/NNS||dr.-1/NN	poss||laboratory-4/NN||myers-2/NNS	nsubj||revealed-5/VBD||laboratory-4/NN	root||ROOT-0/null||revealed-5/VBD	det||specificity-7/NN||the-6/DT	dobj||revealed-5/VBD||specificity-7/NN	nn||signals-10/NNS||leptin-9/NN	prep_of||specificity-7/NN||signals-10/NNS	amod||control-13/NN||metabolic-12/JJ	prep_in||revealed-5/VBD||control-13/NN	det||role-17/NN||the-16/DT	prep_including||revealed-5/VBD||role-17/NN	amod||signaling-20/NNS||leptin-stat3-19/JJ	prep_for||role-17/NN||signaling-20/NNS	det||regulation-23/NN||the-22/DT	prep_in||signaling-20/NNS||regulation-23/NN	nn||balance-26/NN||energy-25/NN	prep_of||regulation-23/NN||balance-26/NN	nn||homeostasis-29/NNS||glucose-28/NN	prep_of||regulation-23/NN||homeostasis-29/NNS	conj_and||balance-26/NN||homeostasis-29/NNS	dr--1||glucose-28||no_rel||dr. myers ' laboratory revealed the specificity of leptin signals in metabolic control , including the role for leptin-stat3 signaling in the regulation of energy balance and glucose homeostasis .
nn||analysis-3/NN||glycan-1/NN	nn||analysis-3/NN||microarray-2/NN	nsubj||reassortantâ-11/VBD||analysis-3/NN	det||â-8/NN||a-5/DT	amod||â-8/NN||high-6/JJ	nn||â-8/NN||infectivity-7/NN	prep_with||analysis-3/NN||â-8/NN	amod||â-8/NN||$-9/$	dep||$-9/$||triple-10/JJ	root||ROOT-0/null||reassortantâ-11/VBD	nsubj||spread-24/VBN||$-12/$	nsubj||showed-51/VBD||$-12/$	num||$-12/$||virus-13/CD	amod||/-17/NN||a/swine/mn-16/JJ	dep||$-12/$||/-17/NN	num||/-17/NN||593/99-18/CD	appos||$-12/$||h3n2-20/NNP	rcmod||$-12/$||spread-24/VBN	advmod||spread-24/VBN||widely-25/RB	det||population-31/NN||the-27/DT	nn||population-31/NN||north-28/NN	nn||population-31/NN||american-29/NN	nn||population-31/NN||swine-30/NNS	prep_throughout||spread-24/VBN||population-31/NN	det||virus-37/NN||a-33/DT	dep||human-36/JJ||lower-34/JJR	advmod||human-36/JJ||infectivity-35/RB	amod||virus-37/NN||human-36/JJ	conj_and||$-12/$||virus-37/NN	nsubj||spread-24/VBN||virus-37/NN	nsubj||showed-51/VBD||virus-37/NN	vmod||virus-37/NN||isolated-38/VBN	det||pig-42/NN||a-40/DT	amod||pig-42/NN||single-41/JJ	prep_from||isolated-38/VBN||pig-42/NN	dep||virus-37/NN||a/swine/ont-44/VB	number||00130/97-46/CD||/-45/CD	dobj||a/swine/ont-44/VB||00130/97-46/CD	appos||00130/97-46/CD||h3n2-48/NNP	ccomp||reassortantâ-11/VBD||showed-51/VBD	mark||viruses-54/VBZ||that-52/IN	nsubj||viruses-54/VBZ||both-53/DT	ccomp||showed-51/VBD||viruses-54/VBZ	acomp||viruses-54/VBZ||bound-55/VBN	advmod||bound-55/VBN||exclusively-56/RB	prep_to||bound-55/VBN||glycans-58/NNS	vmod||glycans-58/NNS||containing-59/VBG	nn||±-61/NNP||neuacî-60/NNP	dobj||containing-59/VBG||±-61/NNP	vmod||±-61/NNP||2â-62/VBG	dobj||2â-62/VBG||$-63/$	npadvmod||polylactosamine-72/JJ||6-65/CD	prep_with||6-65/CD||strong-68/JJ	amod||6-65/CD||binding-69/JJ	dep||sialylated-71/CD||to-70/TO	num||6-65/CD||sialylated-71/CD	amod||n-75/NNS||polylactosamine-72/JJ	conj_and||polylactosamine-72/JJ||sialylated-74/JJ	amod||n-75/NNS||sialylated-74/JJ	npadvmod||--76/RB||n-75/NNS	num||$-63/$||glycans-77/CD	virus-37||mn--1||no_rel||glycan microarray analysis with a high infectivity âtriple reassortantâ? virus ((a/swine/mn/593/99 (h3n2)) that spread widely throughout the north american swine population and a lower infectivity human virus isolated from a single pig (a/swine/ont/00130/97 (h3n2)) showed that both viruses bound exclusively to glycans containing neuacî±2â6, with strong binding to sialylated polylactosamine and sialylated n -glycans.
nsubj||constructed-3/VBN||we-1/PRP	aux||constructed-3/VBN||have-2/VBP	dep||take-52/VB||constructed-3/VBN	det||model-5/NN||a-4/DT	dobj||constructed-3/VBN||model-5/NN	prep_of||model-5/NN||hivinfection-7/NN	mark||types-13/VBZ||that-8/IN	nsubj||types-13/VBZ||differentiates-9/NNS	nsubj||used-17/VBN||differentiates-9/NNS	det||hla-12/NN||these-11/DT	prep_between||differentiates-9/NNS||hla-12/NN	ccomp||constructed-3/VBN||types-13/VBZ	aux||used-17/VBN||have-16/VBP	ccomp||constructed-3/VBN||used-17/VBN	conj_and||types-13/VBZ||used-17/VBN	amod||estimates-19/NNS||reported-18/VBN	dobj||used-17/VBN||estimates-19/NNS	det||number-22/NN||the-21/DT	prep_of||estimates-19/NNS||number-22/NN	prep_of||number-22/NN||people-24/NNS	vmod||people-24/NNS||infected-25/VBN	prep_with||infected-25/VBN||hiv-27/NN	det||rates-31/NNS||the-29/DT	amod||rates-31/NNS||different-30/JJ	prep_with||infected-25/VBN||rates-31/NNS	conj_and||hiv-27/NN||rates-31/NNS	prep_of||rates-31/NNS||progression-33/NN	aux||acquiredimmunodeficiencysyndrome-35/VB||to-34/TO	xcomp||infected-25/VBN||acquiredimmunodeficiencysyndrome-35/VB	dobj||acquiredimmunodeficiencysyndrome-35/VB||aids-37/NNS	nsubj||provide-40/VB||aids-37/NNS	aux||provide-40/VB||to-39/TO	xcomp||acquiredimmunodeficiencysyndrome-35/VB||provide-40/VB	det||estimate-44/NN||a-41/DT	dep||bound-43/VBN||lower-42/JJR	amod||estimate-44/NN||bound-43/VBN	dobj||provide-40/VB||estimate-44/NN	det||length-47/NN||the-46/DT	prep_on||provide-40/VB||length-47/NN	prep_of||length-47/NN||time-49/NN	nsubj||take-52/VB||it-50/PRP	nsubj||impose-56/VB||it-50/PRP	aux||take-52/VB||would-51/MD	root||ROOT-0/null||take-52/VB	prep_for||take-52/VB||hiv-54/NN	aux||impose-56/VB||to-55/TO	xcomp||take-52/VB||impose-56/VB	amod||change-59/NN||major-57/JJ	amod||change-59/NN||genetic-58/JJ	dobj||impose-56/VB||change-59/NN	prep_in||impose-56/VB||humans-61/NNS	hivinfection-7||hiv-54||no||we have constructed a model of hivinfection that differentiates between these hla types, and have used reported estimates of the number of people infected with hiv and the different rates of progression to acquiredimmunodeficiencysyndrome (aids) to provide a lower bound estimate on the length of time it would take for hiv to impose major genetic change in humans.
nn||treatment-3/NN||gancyclovir-2/NN	prep_following||went-11/VBD||treatment-3/NN	amod||viremia-7/NN||subsequent-5/JJ	nn||viremia-7/NN||cytomegalovirus-6/NNS	prep_of||treatment-3/NN||viremia-7/NN	det||patient-10/NN||the-9/DT	nsubj||went-11/VBD||patient-10/NN	nsubj||receive-14/VB||patient-10/NN	root||ROOT-0/null||went-11/VBD	prt||went-11/VBD||on-12/RP	aux||receive-14/VB||to-13/TO	xcomp||went-11/VBD||receive-14/VB	det||course-16/NN||a-15/DT	dobj||receive-14/VB||course-16/NN	prep_of||course-16/NN||epoch-18/NN	advmod||mg/m2/day-52/NN||etoposide-20/RB	num||mg/m2/day-22/NNS||50-21/CD	pobj||etoposide-20/RB||mg/m2/day-22/NNS	prep_on||etoposide-20/RB||days-24/NNS	amod||mg/m2/day-52/NN||1â-25/JJ	amod||mg/m2/day-52/NN||$-26/$	num||$-26/$||4-28/CD	amod||mg/m2/day-52/NN||vincristine-30/JJ	num||mg/m2/day-32/NNS||0.4-31/CD	dep||vincristine-30/JJ||mg/m2/day-32/NNS	prep_on||mg/m2/day-32/NNS||days-34/NNS	amod||mg/m2/day-52/NN||1â-35/JJ	amod||mg/m2/day-52/NN||$-36/$	num||$-36/$||4-38/CD	amod||mg/m2/day-52/NN||doxorubicin-40/JJ	num||mg/m2/day-42/NNS||10-41/CD	dep||doxorubicin-40/JJ||mg/m2/day-42/NNS	prep_on||mg/m2/day-42/NNS||days-44/NNS	amod||mg/m2/day-52/NN||1â-45/JJ	amod||mg/m2/day-52/NN||$-46/$	num||$-46/$||4-48/CD	amod||mg/m2/day-52/NN||cyclophosphamide-50/JJ	number||cyclophosphamide-50/JJ||750-51/CD	dep||epoch-18/NN||mg/m2/day-52/NN	prep_on||mg/m2/day-52/NN||day-54/NN	num||day-54/NN||6-55/CD	advmod||1â-63/JJ||prednisolone-58/RB	num||mg/m2/day-60/NNS||60-59/CD	pobj||prednisolone-58/RB||mg/m2/day-60/NNS	prep_on||prednisolone-58/RB||days-62/NNS	prep_on||mg/m2/day-52/NN||1â-63/JJ	conj_and||day-54/NN||1â-63/JJ	dep||1â-63/JJ||$-64/$	num||$-64/$||6-66/CD	etoposide-20||cytomegalovirus-6||no_rel||following gancyclovir treatment of subsequent cytomegalovirus viremia, the patient went on to receive a course of epoch (etoposide 50 mg/m2/day on days 1â4, vincristine 0.4 mg/m2/day on days 1â4, doxorubicin 10 mg/m2/day on days 1â4, cyclophosphamide 750 mg/m2/day on day 6, and prednisolone 60 mg/m2/day on days 1â6).
nn||depletion-2/NN||iron-1/NN	nsubjpass||evaluated-15/VBN||depletion-2/NN	appos||depletion-2/NN||lack-4/NN	nn||stores-7/NNS||iron-6/NN	prep_of||lack-4/NN||stores-7/NNS	advmod||evaluated-15/VBN||irondeficiency-9/RB	nsubjpass||evaluated-15/VBN||irondeficiencyanemia-11/NN	conj_and||irondeficiencyanemia-11/NN||anemia-13/NN	nsubjpass||evaluated-15/VBN||anemia-13/NN	auxpass||evaluated-15/VBN||were-14/VBD	root||ROOT-0/null||evaluated-15/VBN	prep_among||evaluated-15/VBN||them-17/PRP	irondeficiencyanemia-11||iron-6||yes||iron depletion, lack of iron stores, irondeficiency, irondeficiencyanemia and anemia were evaluated among them.
nsubj||herpesvirus-11/NNS||marek-1/NN	amod||virus-4/NN||sdisease-3/JJ	dep||marek-1/NN||virus-4/NN	appos||marek-1/NN||mdv-6/NN	cop||herpesvirus-11/NNS||is-8/VBZ	det||herpesvirus-11/NNS||an-9/DT	amod||herpesvirus-11/NNS||oncogenic-10/JJ	root||ROOT-0/null||herpesvirus-11/NNS	nsubj||causes-14/VBZ||herpesvirus-11/NNS	rcmod||herpesvirus-11/NNS||causes-14/VBZ	amod||lymphoma-16/NN||malignant-15/JJ	dobj||causes-14/VBZ||lymphoma-16/NN	prep_in||lymphoma-16/NN||chickens-18/NNS	marek'sdisease--1||herpesvirus-11||no||marek'sdisease virus (mdv) is an oncogenic herpesvirus, which causes malignant lymphoma in chickens.
nsubjpass||induced-3/VBN||diarrhoea-1/NN	auxpass||induced-3/VBN||was-2/VBD	root||ROOT-0/null||induced-3/VBN	amod||administration-6/NN||oral-5/JJ	agent||induced-3/VBN||administration-6/NN	num||castoroil-10/NN||0.5-8/CD	nn||castoroil-10/NN||ml-9/NN	prep_of||administration-6/NN||castoroil-10/NN	det||mouse-13/NN||each-12/DT	prep_to||induced-3/VBN||mouse-13/NN	num||h-16/NN||1-15/CD	appos||mouse-13/NN||h-16/NN	det||treatments-20/NNS||the-18/DT	amod||treatments-20/NNS||above-19/JJ	prep_after||induced-3/VBN||treatments-20/NNS	castoroil-10||diarrhoea-1||no_rel||diarrhoea was induced by oral administration of 0.5 ml castoroil to each mouse, 1 h after the above treatments.
nsubj||shown-4/VBN||we-1/PRP	aux||shown-4/VBN||have-2/VBP	advmod||shown-4/VBN||recently-3/RB	root||ROOT-0/null||shown-4/VBN	mark||induces-13/VBZ||that-5/IN	det||meal-12/NN||a-6/DT	amod||meal-12/NN||high-fat-7/JJ	nn||meal-12/NN||high-carbohydrate-8/NN	dep||meal-12/NN||hfhc-10/JJ	nsubj||induces-13/VBZ||meal-12/NN	ccomp||shown-4/VBN||induces-13/VBZ	det||increase-15/NN||an-14/DT	dobj||induces-13/VBZ||increase-15/NN	nn||concentrations-18/NNS||plasma-17/NN	prep_in||increase-15/NN||concentrations-18/NNS	prep_of||concentrations-18/NNS||endotoxin-20/NN	amod||-RSB--25/NNP||lipopolysaccharide-22/JJ	nn||-RSB--25/NNP||-LSB--23/NNP	nn||-RSB--25/NNP||lps-24/NN	appos||endotoxin-20/NN||-RSB--25/NNP	det||expression-29/NN||the-28/DT	prep_in||increase-15/NN||expression-29/NN	conj_and||concentrations-18/NNS||expression-29/NN	amod||receptor-4-32/NN||toll-like-31/JJ	prep_of||expression-29/NN||receptor-4-32/NN	dep||receptor-4-32/NN||tlr-4-34/JJ	dobj||induces-13/VBZ||suppresser-37/NN	conj_and||increase-15/NN||suppresser-37/NN	amod||socs3-42/NNS||cytokine-39/JJ	amod||socs3-42/NNS||signaling-3-40/JJ	prep_of||suppresser-37/NN||socs3-42/NNS	nn||cells-46/NNS||mononuclear-45/NN	prep_in||socs3-42/NNS||cells-46/NNS	appos||cells-46/NNS||mncs-48/NNS	prep_in||cells-46/NNS||addition-51/NN	amod||stress-54/NN||oxidative-53/JJ	prep_to||induces-13/VBZ||stress-54/NN	amod||inflammation-57/NN||cellular-56/JJ	prep_to||induces-13/VBZ||inflammation-57/NN	conj_and||stress-54/NN||inflammation-57/NN	carbohydrate--1||inflammation-57||no_rel||we have recently shown that a high-fat high-carbohydrate (hfhc) meal induces an increase in plasma concentrations of endotoxin (lipopolysaccharide [lps]) and the expression of toll-like receptor-4 (tlr-4) and suppresser of cytokine signaling-3 (socs3) in mononuclear cells (mncs) in addition to oxidative stress and cellular inflammation.
det||genetics-2/NNS||the-1/DT	nsubj||variable-17/JJ||genetics-2/NNS	nn||infection-5/NN||hcv-4/NN	prep_of||genetics-2/NNS||infection-5/NN	prep_in||infection-5/NN||humans-7/NNS	det||course-11/NN||the-9/DT	nn||course-11/NN||disease-10/NN	prep_of||genetics-2/NNS||course-11/NN	conj_and||infection-5/NN||course-11/NN	prep_of||course-11/NN||chronichepatitisc-13/NN	cop||variable-17/JJ||are-14/VBP	dep||variable-17/JJ||both-15/DT	advmod||variable-17/JJ||remarkably-16/RB	root||ROOT-0/null||variable-17/JJ	chronichepatitisc-13||hcv-4||no||the genetics of hcv infection in humans and the disease course of chronichepatitisc are both remarkably variable.
aux||understand-3/VB||to-1/TO	advmod||understand-3/VB||better-2/RBR	advcl||conducted-28/VBN||understand-3/VB	det||need-5/NN||the-4/DT	dobj||understand-3/VB||need-5/NN	amod||therapy-10/NN||paediatric-7/JJ	amod||therapy-10/NN||second-line-8/JJ	amod||therapy-10/NN||antiretroviral-9/JJ	prep_for||need-5/NN||therapy-10/NN	appos||therapy-10/NN||art-12/NN	det||survey-18/NN||an-15/DT	nn||survey-18/NN||art-16/NN	nn||survey-18/NN||management-17/NN	nsubjpass||conducted-28/VBN||survey-18/NN	det||analysis-22/NN||a-20/DT	amod||analysis-22/NN||cross-sectional-21/JJ	conj_and||survey-18/NN||analysis-22/NN	nsubjpass||conducted-28/VBN||analysis-22/NN	amod||use-26/NN||second-line-24/JJ	nn||use-26/NN||art-25/NN	prep_of||analysis-22/NN||use-26/NN	auxpass||conducted-28/VBN||were-27/VBD	root||ROOT-0/null||conducted-28/VBN	det||asia-32/NN||the-30/DT	nn||asia-32/NN||treat-31/NN	prep_in||conducted-28/VBN||asia-32/NN	amod||database-36/NN||paediatric-33/JJ	nn||database-36/NN||hiv-34/NN	nn||database-36/NN||observational-35/NN	xcomp||conducted-28/VBN||database-36/NN	det||africa-41/NN||the-38/DT	amod||africa-41/NN||iedea-39/JJ	amod||africa-41/NN||southern-40/JJ	xcomp||conducted-28/VBN||africa-41/NN	conj_and||database-36/NN||africa-41/NN	amod||databases-45/NNS||international-43/JJ	amod||databases-45/NNS||epidemiologic-44/JJ	dep||database-36/NN||databases-45/NNS	aux||evaluate-47/VB||to-46/TO	vmod||databases-45/NNS||evaluate-47/VB	dobj||evaluate-47/VB||aids-48/NNS	amod||cohorts-51/NNS||regional-50/JJ	dep||database-36/NN||cohorts-51/NNS	aids-48||hiv-34||no||to better understand the need for paediatric second-line antiretroviral therapy (art), an art management survey and a cross-sectional analysis of second-line art use were conducted in the treat asia paediatric hiv observational database and the iedea southern africa (international epidemiologic databases to evaluate aids) regional cohorts.
advmod||ppi-12/NN||currently-1/RB	det||treatment-5/NN||the-3/DT	nn||treatment-5/NN||mainstream-4/NN	nsubj||ppi-12/NN||treatment-5/NN	prep_for||treatment-5/NN||gerd-7/NN	prep_in||gerd-7/NN||children-9/NNS	cop||ppi-12/NN||is-10/VBZ	det||ppi-12/NN||a-11/DT	root||ROOT-0/null||ppi-12/NN	gerd-7||ppi-12||no_rel||currently, the mainstream treatment for gerd in children is a ppi.
nn||propofol-2/NN||microemulsion-1/NN	nsubjpass||developed-4/VBN||propofol-2/NN	nsubj||avoid-6/VB||propofol-2/NN	auxpass||developed-4/VBN||was-3/VBD	root||ROOT-0/null||developed-4/VBN	aux||avoid-6/VB||to-5/TO	xcomp||developed-4/VBN||avoid-6/VB	det||effects-9/NNS||these-7/DT	nn||effects-9/NNS||side-8/NN	dobj||avoid-6/VB||effects-9/NNS	nsubj||is-18/VBZ||incidence-11/NN	conj_and||incidence-11/NN||severity-13/NN	nsubj||is-18/VBZ||severity-13/NN	prep_of||incidence-11/NN||pain-15/NN	prep_on||pain-15/NN||injection-17/NN	conj_but||developed-4/VBN||is-18/VBZ	dep||than-20/IN||higher-19/JJR	advmod||is-18/VBZ||than-20/IN	nn||propofol-24/NN||lipid-22/NN	nn||propofol-24/NN||emulsion-23/NN	prep_with||is-18/VBZ||propofol-24/NN	pain-15||propofol-24||yes||microemulsion propofol was developed to avoid these side effects but incidence and severity of pain on injection is higher than with lipid emulsion propofol.
advmod||help-17/VB||therefore-1/RB	poss||findings-4/NNS||our-3/PRP$	nsubj||help-17/VB||findings-4/NNS	amod||sites-7/NNS||functional-6/JJ	prep_of||findings-4/NNS||sites-7/NNS	nsubj||help-17/VB||substrates-9/NNS	conj_and||substrates-9/NNS||inhibitors-11/NNS	nsubj||help-17/VB||inhibitors-11/NNS	det||enzymes-15/NNS||these-13/DT	nn||enzymes-15/NNS||nudix-14/NN	prep_for||substrates-9/NNS||enzymes-15/NNS	aux||help-17/VB||may-16/MD	root||ROOT-0/null||help-17/VB	prep_in||help-17/VB||structure-19/NN	prep||help-17/VB||based-20/VBN	pobj||based-20/VBN||drug-21/NN	vmod||drug-21/NN||designing-22/VBG	amod||pneumonia-25/NN||streprococcus-24/JJ	prep_against||designing-22/VBG||pneumonia-25/NN	nn||faecalis-28/NNS||enterococcus-27/NN	prep_against||designing-22/VBG||faecalis-28/NNS	conj_and||pneumonia-25/NN||faecalis-28/NNS	enzymes-15||pneumonia-25||no_rel||therefore, our findings of functional sites, substrates and inhibitors for these nudix enzymes may help in structure based drug designing against streprococcus pneumonia and enterococcus faecalis
amod||components-3/NNS||individual-2/JJ	prep_among||observed-15/VBN||components-3/NNS	prep_of||components-3/NNS||mets-5/NNS	nsubjpass||observed-15/VBN||differences-7/NNS	prep_between||differences-7/NNS||women-9/NNS	prep_with||women-9/NNS||ra-11/NN	prep_with||women-9/NNS||controls-13/NNS	conj_and||ra-11/NN||controls-13/NNS	auxpass||observed-15/VBN||were-14/VBD	root||ROOT-0/null||observed-15/VBN	prep_for||observed-15/VBN||hypertension-17/NN	appos||hypertension-17/NN||p-19/NNP	number||0.001-21/CD||<-20/CD	num||p-19/NNP||0.001-21/CD	amod||high-25/JJ||low-24/JJ	amod||levels-31/NNS||high-25/JJ	nn||levels-31/NNS||density-26/NN	nn||levels-31/NNS||lipoprotein-cholesterol-27/NN	dep||levels-31/NNS||hdl-c-29/JJ	prep_for||observed-15/VBN||levels-31/NNS	conj_and||hypertension-17/NN||levels-31/NNS	appos||levels-31/NNS||p-33/NNP	number||0.001-35/CD||<-34/CD	num||p-33/NNP||0.001-35/CD	amod||obesity-40/NN||abdominal-39/JJ	prep_for||observed-15/VBN||obesity-40/NN	conj_and||hypertension-17/NN||obesity-40/NN	dep||hypertension-17/NN||p-42/VBN	dep||0.019-44/CD||=-43/SYM	ccomp||p-42/VBN||0.019-44/CD	cholesterol--1||hypertension-17||no_rel||among individual components of mets, differences between women with ra and controls were observed for hypertension ( p < 0.001), low high density lipoprotein-cholesterol (hdl-c) levels ( p < 0.001), and abdominal obesity ( p = 0.019).
amod||concentrations-3/NNS||increased-1/VBN	nn||concentrations-3/NNS||hepcidin-2/NN	nsubj||lead-4/VBP||concentrations-3/NNS	nsubj||iron-6/VB||concentrations-3/NNS	root||ROOT-0/null||lead-4/VBP	aux||iron-6/VB||to-5/TO	xcomp||lead-4/VBP||iron-6/VB	dobj||iron-6/VB||sequestration-7/NN	prep_in||sequestration-7/NN||macrophages-9/NNS	vmod||sequestration-7/NN||contributing-11/VBG	det||pathogenesis-14/NNS||the-13/DT	prep_to||contributing-11/VBG||pathogenesis-14/NNS	prep_of||pathogenesis-14/NNS||anaemia-16/NN	amod||disease-19/NN||chronic-18/JJ	prep_of||anaemia-16/NN||disease-19/NN	mark||observed-24/VBN||whereas-20/IN	amod||hepcidin-22/NN||decreased-21/VBN	nsubjpass||observed-24/VBN||hepcidin-22/NN	auxpass||observed-24/VBN||is-23/VBZ	advcl||contributing-11/VBG||observed-24/VBN	amod||ironoverloaddiseases-29/NNS||irondeficiency-26/JJ	conj_and||irondeficiency-26/JJ||primary-28/JJ	amod||ironoverloaddiseases-29/NNS||primary-28/JJ	prep_in||observed-24/VBN||ironoverloaddiseases-29/NNS	prep_such_as||ironoverloaddiseases-29/NNS||hereditaryhemochromatosis-32/NNS	irondeficiency-26||iron-6||yes||increased hepcidin concentrations lead to iron sequestration in macrophages, contributing to the pathogenesis of anaemia of chronic disease whereas decreased hepcidin is observed in irondeficiency and primary ironoverloaddiseases such as hereditaryhemochromatosis.
det||report-4/NN||an-1/DT	amod||report-4/NN||interventional-2/JJ	nn||report-4/NN||case-3/NN	root||ROOT-0/null||report-4/NN	det||male-8/NN||a-6/DT	amod||male-8/NN||70-year-old-7/JJ	prep_of||report-4/NN||male-8/NN	nsubj||developed-10/VBD||male-8/NN	rcmod||male-8/NN||developed-10/VBD	amod||myopia-14/NN||bilateral-11/JJ	dobj||developed-10/VBD||acute-13/JJ	amod||myopia-14/NN||acute-13/JJ	conj_and||myopia-14/NN||acute-13/JJ	dobj||developed-10/VBD||myopia-14/NN	dobj||developed-10/VBD||angleclosureglaucoma-16/NN	conj_and||myopia-14/NN||angleclosureglaucoma-16/NN	prepc_after||developed-10/VBD||ingesting-18/VBG	amod||tablets-20/NNS||methazolamide-19/JJ	dobj||ingesting-18/VBG||tablets-20/NNS	det||treatment-23/NN||the-22/DT	prep_for||ingesting-18/VBG||treatment-23/NN	amod||glaucoma-27/NN||normal-25/JJ	nn||glaucoma-27/NN||tension-26/NN	prep_of||treatment-23/NN||glaucoma-27/NN	angleclosureglaucoma-16||methazolamide-19||yes||an interventional case report of a 70-year-old male who developed bilateral, acute myopia and angleclosureglaucoma after ingesting methazolamide tablets for the treatment of normal tension glaucoma.
advmod||isolated-4/VBD||therefore-1/RB	nsubj||isolated-4/VBD||we-3/PRP	nsubj||found-14/VBD||we-3/PRP	root||ROOT-0/null||isolated-4/VBD	dobj||isolated-4/VBD||macrophages-5/NNS	det||phase-9/NN||the-7/DT	amod||phase-9/NN||resolving-8/JJ	prep_from||isolated-4/VBD||phase-9/NN	amod||inflammation-12/NN||acute-11/JJ	prep_of||phase-9/NN||inflammation-12/NN	conj_and||isolated-4/VBD||found-14/VBD	mark||possess-29/VBP||that-15/IN	prepc_compared_with||possess-29/VBP||with-17/IN	amod||cells-22/NNS||classically-18/JJ	amod||cells-22/NNS||activated-19/VBN	nn||cells-22/NNS||proinflammatory-20/NN	amod||cells-22/NNS||m1-21/JJ	pobj||possess-29/VBP||cells-22/NNS	amod||macrophages-25/NNS||resolution-phase-24/JJ	nsubj||possess-29/VBP||macrophages-25/NNS	nsubj||express-34/VB||macrophages-25/NNS	appos||macrophages-25/NNS||rms-27/NN	ccomp||found-14/VBD||possess-29/VBP	amod||properties-32/NNS||weaker-30/JJR	amod||properties-32/NNS||bactericidal-31/JJ	dobj||possess-29/VBP||properties-32/NNS	ccomp||found-14/VBD||express-34/VB	conj_and||possess-29/VBP||express-34/VB	det||phenotype-38/NN||an-35/DT	amod||phenotype-38/NN||alternatively-36/JJ	amod||phenotype-38/NN||activated-37/VBN	dobj||express-34/VB||phenotype-38/NN	cc||express-34/VB||but-39/CC	amod||markers-42/NNS||elevated-41/JJ	prep_with||express-34/VB||markers-42/NNS	amod||cells-45/NNS||m1-44/JJ	prep_of||markers-42/NNS||cells-45/NNS	amod||cyclooxygenase-48/NN||inducible-47/JJ	prep_including||cells-45/NNS||cyclooxygenase-48/NN	number||2-51/CD||cox-50/CD	dep||cyclooxygenase-48/NN||2-51/CD	amod||synthase-55/NN||nitricoxide-54/JJ	prep_including||cells-45/NNS||synthase-55/NN	conj_and||cyclooxygenase-48/NN||synthase-55/NN	appos||cyclooxygenase-48/NN||inos-57/NNS	nitricoxide-54||inflammation-12||no_rel||therefore, we isolated macrophages from the resolving phase of acute inflammation and found that compared with classically activated proinflammatory m1 cells, resolution-phase macrophages (rms) possess weaker bactericidal properties and express an alternatively activated phenotype but with elevated markers of m1 cells including inducible cyclooxygenase (cox 2) and nitricoxide synthase (inos).
amod||biopsies-2/NNS||conjunctival-1/JJ	nsubjpass||obtained-4/VBN||biopsies-2/NNS	auxpass||obtained-4/VBN||were-3/VBD	root||ROOT-0/null||obtained-4/VBN	det||fornix-8/NN||the-6/DT	amod||fornix-8/NN||inferior-7/JJ	prep_from||obtained-4/VBN||fornix-8/NN	amod||surgery-12/NN||routine-10/JJ	nn||surgery-12/NN||cataract-11/NN	prep_during||fornix-8/NN||surgery-12/NN	num||patients-15/NNS||20-14/CD	prep_from||obtained-4/VBN||patients-15/NNS	amod||open-angleglaucoma-18/NN||primary-17/JJ	prep_with||patients-15/NNS||open-angleglaucoma-18/NN	nsubj||received-22/VBN||open-angleglaucoma-18/NN	aux||received-22/VBN||had-21/VBD	rcmod||open-angleglaucoma-18/NN||received-22/VBN	det||monotherapy-24/NN||a-23/DT	dobj||received-22/VBN||monotherapy-24/NN	dobj||received-22/VBN||monotherapy-24/NN	conj_and||monotherapy-24/NN||monotherapy-24/NN	preconj||monotherapy-24/NN||either-25/CC	prep_with||monotherapy-24/NN||timolol-27/NN	prep_with||monotherapy-24/NN||latanoprost-29/NN	conj_or||timolol-27/NN||latanoprost-29/NN	prep_from||monotherapy-24/NN||10-33/CD	amod||patients-35/NNS||non-glaucomatous-34/JJ	dep||monotherapy-24/NN||patients-35/NNS	open-angleglaucoma-18||latanoprost-29||yes||conjunctival biopsies were obtained from the inferior fornix during routine cataract surgery from 20 patients with primary open-angleglaucoma, who had received a monotherapy either with timolol or latanoprost, and from 10 non-glaucomatous patients.
det||agent-3/NN||a-1/DT	amod||agent-3/NN||third-2/JJ	nsubjpass||shown-10/VBN||agent-3/NN	nsubj||enhance-12/VB||agent-3/NN	nsubjpass||approved-31/VBN||agent-3/NN	appos||agent-3/NN||cetuximab-5/NN	auxpass||shown-10/VBN||was-8/VBD	advmod||shown-10/VBN||recently-9/RB	rcmod||agent-3/NN||shown-10/VBN	aux||enhance-12/VB||to-11/TO	xcomp||shown-10/VBN||enhance-12/VB	dobj||enhance-12/VB||survival-13/NN	advmod||used-15/VBN||when-14/WRB	advcl||enhance-12/VB||used-15/VBN	prep_with||used-15/VBN||cisplatin-17/NN	prep_with||used-15/VBN||vinorelbine-19/NN	conj_and||cisplatin-17/NN||vinorelbine-19/NN	amod||therapy-23/NN||first-21/JJ	nn||therapy-23/NN||line-22/NN	prep_as||used-15/VBN||therapy-23/NN	amod||nsclc-26/NN||advanced-25/JJ	prep_for||used-15/VBN||nsclc-26/NN	aux||approved-31/VBN||will-28/MD	advmod||approved-31/VBN||likely-29/RB	auxpass||approved-31/VBN||be-30/VB	root||ROOT-0/null||approved-31/VBN	amod||agencies-34/NNS||regulatory-33/JJ	agent||approved-31/VBN||agencies-34/NNS	nsclc-26||vinorelbine-19||yes||a third agent, cetuximab, which was recently shown to enhance survival when used with cisplatin and vinorelbine as first line therapy for advanced nsclc, will likely be approved by regulatory agencies.
det||combination-2/NN||the-1/DT	nsubj||effective-8/JJ||combination-2/NN	prep_of||combination-2/NN||remifentanil-4/NN	prep_of||combination-2/NN||lidocaine-6/NN	conj_and||remifentanil-4/NN||lidocaine-6/NN	cop||effective-8/JJ||is-7/VBZ	root||ROOT-0/null||effective-8/JJ	prepc_in||effective-8/JJ||alleviating-10/VBG	dobj||alleviating-10/VBG||pain-11/NN	vmod||pain-11/NN||associated-12/VBN	det||injection-17/NN||a-14/DT	amod||injection-17/NN||microemulsion-15/JJ	amod||injection-17/NN||propofol-16/JJ	prep_with||associated-12/VBN||injection-17/NN	prepc_compared_with||associated-12/VBN||with-19/IN	advmod||lidocaine-21/NN||just-20/RB	pobj||associated-12/VBN||lidocaine-21/NN	pain-11||propofol-16||yes||the combination of remifentanil and lidocaine is effective in alleviating pain associated with a microemulsion propofol injection compared with just lidocaine.
amod||administration-6/NN||objective-1/JJ	nn||administration-6/NN||â-2/NN	nn||administration-6/NN||$-3/NN	nn||administration-6/NN||bedtime-5/NN	nsubj||prevents-17/VBZ||administration-6/NN	nsubj||causes-21/VBZ||administration-6/NN	num||mg-9/NN||5.0-8/CD	prep_of||administration-6/NN||mg-9/NN	det||terbutaline-16/NN||the-11/DT	nn||terbutaline-16/NN||î-12/NN	punct||terbutaline-16/NN||²-13/``	amod||terbutaline-16/NN||2-adrenergic-14/JJ	nn||terbutaline-16/NN||agonist-15/NN	prep_of||mg-9/NN||terbutaline-16/NN	root||ROOT-0/null||prevents-17/VBZ	amod||hypoglycemia-19/NN||nocturnal-18/JJ	dobj||prevents-17/VBZ||hypoglycemia-19/NN	conj_but||prevents-17/VBZ||causes-21/VBZ	nn||hyperglycemia-23/NN||morning-22/NN	dobj||causes-21/VBZ||hyperglycemia-23/NN	prep_in||causes-21/VBZ||type1diabetes-25/CD	terbutaline-16||hypoglycemia-19||no_rel||objective âbedtime administration of 5.0 mg of the î²2-adrenergic agonist terbutaline prevents nocturnal hypoglycemia but causes morning hyperglycemia in type1diabetes.
nsubj||examined-2/VBD||we-1/PRP	root||ROOT-0/null||examined-2/VBD	det||ability-4/NN||the-3/DT	dobj||examined-2/VBD||ability-4/NN	amod||antagonists-7/NNS||h4r-6/JJ	prep_of||ability-4/NN||antagonists-7/NNS	aux||modify-10/VB||to-8/TO	advmod||modify-10/VB||therapeutically-9/RB	vmod||examined-2/VBD||modify-10/VB	det||effects-12/NNS||the-11/DT	dobj||modify-10/VB||effects-12/NNS	amod||production-16/NN||th2-14/JJ	nn||production-16/NN||cytokine-15/NN	prep_of||effects-12/NNS||production-16/NN	amod||hyperplasia-21/NN||goblet-19/JJ	nn||hyperplasia-21/NN||cell-20/NN	prep_such_as||production-16/NN||hyperplasia-21/NN	appos||hyperplasia-21/NN||gch-23/NN	nn||deposition-28/NN||collagen-27/NN	prep_such_as||production-16/NN||deposition-28/NN	conj_and||hyperplasia-21/NN||deposition-28/NN	det||model-32/NN||a-30/DT	amod||model-32/NN||sub-chronic-31/JJ	prep_in||deposition-28/NN||model-32/NN	prep_of||model-32/NN||asthma-34/NN	asthma-34||collagen-27||no_rel||we examined the ability of h4r antagonists to therapeutically modify the effects of th2 cytokine production such as goblet cell hyperplasia (gch), and collagen deposition in a sub-chronic model of asthma.
advmod||importantly-2/RB||most-1/RBS	advmod||have-9/VB||importantly-2/RB	amod||cddp-6/NN||ad-ing4-4/JJ	nn||cddp-6/NN||plus-5/NN	nsubj||have-9/VB||cddp-6/NN	aux||have-9/VB||did-7/VBD	neg||have-9/VB||not-8/RB	root||ROOT-0/null||have-9/VB	amod||toxicities-11/NNS||overlapping-10/VBG	dobj||have-9/VB||toxicities-11/NNS	amod||cells-17/NNS||hl-7702-13/JJ	amod||cells-17/NNS||normal-14/JJ	amod||cells-17/NNS||human-15/JJ	nn||cells-17/NNS||liver-16/NN	prep_in||toxicities-11/NNS||cells-17/NNS	amod||tissues-21/NNS||normal-19/JJ	nn||tissues-21/NNS||liver-20/NN	prep_in||toxicities-11/NNS||tissues-21/NNS	conj_and||cells-17/NNS||tissues-21/NNS	prep_of||toxicities-11/NNS||mice-23/NNS	hl--1||cddp-6||yes||most importantly, ad-ing4 plus cddp did not have overlapping toxicities in hl-7702 normal human liver cells and normal liver tissues of mice.
det||data-2/NNS||these-1/DT	nsubj||demonstrate-3/VBP||data-2/NNS	root||ROOT-0/null||demonstrate-3/VBP	mark||expressed-8/VBN||that-4/IN	nn||proteins-6/NNS||socs-5/NNS	nsubjpass||expressed-8/VBN||proteins-6/NNS	auxpass||expressed-8/VBN||are-7/VBP	ccomp||demonstrate-3/VBP||expressed-8/VBN	amod||lines-13/NNS||human-10/JJ	nn||lines-13/NNS||melanoma-11/NN	nn||lines-13/NNS||cell-12/NN	prep_in||expressed-8/VBN||lines-13/NNS	poss||modulation-16/NN||their-15/PRP$	nsubj||influence-18/VB||modulation-16/NN	aux||influence-18/VB||can-17/MD	conj_and||demonstrate-3/VBP||influence-18/VB	det||responsiveness-20/NNS||the-19/DT	dobj||influence-18/VB||responsiveness-20/NNS	nn||cells-23/NNS||melanoma-22/NN	prep_of||responsiveness-20/NNS||cells-23/NNS	nn||±-26/NNP||ifn-î-25/NNP	prep_to||influence-18/VB||±-26/NNP	nn||³-29/NNP||ifn-î-28/NNP	prep_to||influence-18/VB||³-29/NNP	conj_and||±-26/NNP||³-29/NNP	ifn--1||melanoma-22||no_rel||these data demonstrate that socs proteins are expressed in human melanoma cell lines and their modulation can influence the responsiveness of melanoma cells to ifn-î± and ifn-î³.
mark||mediators-10/NNS||because-1/IN	nn||interferons-4/NNS||type-2/FW	nn||interferons-4/NNS||i-3/FW	nsubj||mediators-10/NNS||interferons-4/NNS	appos||interferons-4/NNS||ifns-6/NNS	cop||mediators-10/NNS||are-8/VBP	amod||mediators-10/NNS||crucial-9/JJ	advcl||investigated-18/VBD||mediators-10/NNS	nn||defense-13/NN||host-12/NN	prep_of||mediators-10/NNS||defense-13/NN	prep_against||defense-13/NN||viruses-15/NNS	nsubj||investigated-18/VBD||we-17/PRP	root||ROOT-0/null||investigated-18/VBD	det||effect-20/NN||the-19/DT	dobj||investigated-18/VBD||effect-20/NN	prep_of||effect-20/NN||ebvinfection-22/NN	det||pathway-27/NN||the-24/DT	amod||pathway-27/NN||ifnî-25/JJ	amod||pathway-27/NN||±-26/JJ	prep_on||investigated-18/VBD||pathway-27/NN	amod||monocytes-31/NNS||primary-29/JJ	amod||monocytes-31/NNS||human-30/JJ	prep_in||pathway-27/NN||monocytes-31/NNS	interferons-4||ebvinfection-22||no_rel||because type i interferons (ifns) are crucial mediators of host defense against viruses, we investigated the effect of ebvinfection on the ifnî± pathway in primary human monocytes.
det||aim-2/NN||the-1/DT	nsubj||was-6/VBD||aim-2/NN	nsubj||evaluate-8/VB||aim-2/NN	det||study-5/NN||this-4/DT	prep_of||aim-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||evaluate-8/VB||to-7/TO	xcomp||was-6/VBD||evaluate-8/VB	det||effectiveness-10/NN||the-9/DT	dobj||evaluate-8/VB||effectiveness-10/NN	prep_of||effectiveness-10/NN||monotherapy-12/NN	amod||therapy-17/NN||interferonalpha-2b-14/JJ	conj_and||interferonalpha-2b-14/JJ||combination-16/NN	amod||therapy-17/NN||combination-16/NN	prep_with||evaluate-8/VB||therapy-17/NN	prep_with||therapy-17/NN||interferonalpha-2b-19/NNP	prep_with||therapy-17/NN||ribavirin-21/NNP	conj_plus||interferonalpha-2b-19/NNP||ribavirin-21/NNP	prep_on||evaluate-8/VB||chronichepatitiscinfection-23/NN	amod||patients-26/NNS||thalassaemic-25/JJ	prep_in||chronichepatitiscinfection-23/NN||patients-26/NNS	chronichepatitiscinfection-23||ribavirin-21||yes||the aim of this study was to evaluate the effectiveness of monotherapy with interferonalpha-2b and combination therapy with interferonalpha-2b plus ribavirin on chronichepatitiscinfection in thalassaemic patients.
det||questionnaire-2/NN||the-1/DT	nsubj||consisted-3/VBD||questionnaire-2/NN	nsubj||questions-21/VBZ||questionnaire-2/NN	nsubj||assess-23/VB||questionnaire-2/NN	root||ROOT-0/null||consisted-3/VBD	num||questions-6/NNS||24-5/CD	prep_of||consisted-3/VBD||questions-6/NNS	prep_regarding||questions-6/NNS||awareness-8/NN	det||modes-11/NNS||the-10/DT	prep_of||awareness-8/NN||modes-11/NNS	prep_of||modes-11/NNS||transmission-13/NN	prep_of||transmission-13/NN||hiv/aids-15/NNS	num||questions-18/NNS||nine-17/CD	appos||hiv/aids-15/NNS||questions-18/NNS	conj_and||consisted-3/VBD||questions-21/VBZ	aux||assess-23/VB||to-22/TO	xcomp||questions-21/VBZ||assess-23/VB	det||attitude-25/NN||the-24/DT	dobj||assess-23/VB||attitude-25/NN	prep_toward||assess-23/VB||people-27/NNS	vmod||people-27/NNS||living-28/VBG	prep_with||living-28/VBG||hiv/aids-30/NNS	appos||hiv/aids-30/NNS||plwha-32/NNP	num||questions-36/NNS||15-35/CD	appos||hiv/aids-30/NNS||questions-36/NNS	aids--1||hiv--1||no||the questionnaire consisted of 24 questions regarding awareness of the modes of transmission of hiv/aids (nine questions) and questions to assess the attitude toward people living with hiv/aids (plwha) (15 questions).
aux||address-2/VB||to-1/TO	root||ROOT-0/null||address-2/VB	det||problems-5/NNS||the-3/DT	amod||problems-5/NNS||long-term-4/JJ	dobj||address-2/VB||problems-5/NNS	nn||wear-9/NN||bearing-7/NN	nn||wear-9/NN||surface-8/NN	prep_of||problems-5/NNS||wear-9/NN	prep_of||problems-5/NNS||osteolysis-11/NNS	conj_and||wear-9/NN||osteolysis-11/NNS	vmod||osteolysis-11/NNS||associated-12/VBN	amod||metal-polyethylene-15/NN||conventional-14/JJ	prep_with||associated-12/VBN||metal-polyethylene-15/NN	dep||metal-polyethylene-15/NN||m-pe-17/JJ	amod||arthroplasty-21/NN||total-19/JJ	nn||arthroplasty-21/NN||hip-20/NN	dep||metal-polyethylene-15/NN||arthroplasty-21/NN	appos||metal-polyethylene-15/NN||tha-23/NN	appos||metal-polyethylene-15/NN||metal-metal-26/NN	appos||metal-metal-26/NN||m-m-28/NNP	amod||bearings-36/NNS||ceramic-ceramic-32/JJ	appos||bearings-36/NNS||c-c-34/NNP	nsubjpass||introduced-39/VBN||bearings-36/NNS	aux||introduced-39/VBN||have-37/VBP	auxpass||introduced-39/VBN||been-38/VBN	conj_and||address-2/VB||introduced-39/VBN	osteolysis-11||metal--1||no_rel||to address the long-term problems of bearing surface wear and osteolysis associated with conventional metal-polyethylene (m-pe) total hip arthroplasty (tha), metal-metal (m-m), and ceramic-ceramic (c-c) bearings have been introduced.
det||subclinical-3/NN||a-1/DT	amod||subclinical-3/NN||higher-2/JJR	nsubjpass||associated-6/VBN||subclinical-3/NN	advmod||associated-6/VBN||vitaminadeficiency-4/RB	auxpass||associated-6/VBN||was-5/VBD	root||ROOT-0/null||associated-6/VBN	neg||receiving-9/VBG||not-8/RB	prepc_with||associated-6/VBN||receiving-9/VBG	nn||supplement-11/NN||vitamina-10/NN	dobj||receiving-9/VBG||supplement-11/NN	det||year-14/NN||the-13/DT	prep_over||receiving-9/VBG||year-14/NN	aux||ill-18/JJ||having-16/VBG	cop||ill-18/JJ||been-17/VBN	vmod||receiving-9/VBG||ill-18/JJ	det||weeks-22/NNS||the-20/DT	num||weeks-22/NNS||two-21/CD	prep_during||ill-18/JJ||weeks-22/NNS	xcomp||ill-18/JJ||preceding-23/VBG	det||survey-25/NN||the-24/DT	nsubj||belonging-32/VBG||survey-25/NN	amod||vaccination-30/NN||no-27/DT	conj_or||no-27/DT||incomplete-29/JJ	amod||vaccination-30/NN||incomplete-29/JJ	appos||survey-25/NN||vaccination-30/NN	vmod||preceding-23/VBG||belonging-32/VBG	det||mother-35/NN||a-34/DT	prep_to||belonging-32/VBG||mother-35/NN	amod||parity-38/NN||high-37/JJ	prep_with||ill-18/JJ||parity-38/NN	amod||levels-42/NNS||low-41/JJ	nsubjpass||associated-56/VBN||levels-42/NNS	nsubj||being-50/VBG||awareness-44/NN	prep_of||awareness-44/NN||vitamina-46/NNP	advmod||vitamina-46/NNP||moreover-48/RB	prepc_of||levels-42/NNS||being-50/VBG	nn||household-53/NN||muslim-52/NN	prep_from||being-50/VBG||household-53/NN	auxpass||associated-56/VBN||was-54/VBD	advmod||associated-56/VBN||strongly-55/RB	conj_and||associated-6/VBN||associated-56/VBN	amod||levels-59/NNS||higher-58/JJR	prep_with||associated-56/VBN||levels-59/NNS	amod||vitaminadeficiency-62/NN||subclinical-61/JJ	prep_of||levels-59/NNS||vitaminadeficiency-62/NN	vitaminadeficiency-62||vitamina-46||yes||a higher subclinical vitaminadeficiency was associated with not receiving vitamina supplement over the year , having been ill during the two weeks preceding the survey , no or incomplete vaccination , belonging to a mother with high parity , and low levels of awareness of vitamina. moreover , being from muslim household was strongly associated with higher levels of subclinical vitaminadeficiency .
det||aim-2/NN||the-1/DT	nsubj||was-6/VBD||aim-2/NN	nsubj||evaluate-8/VB||aim-2/NN	nsubj||compare-10/VB||aim-2/NN	det||study-5/NN||this-4/DT	prep_of||aim-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||evaluate-8/VB||to-7/TO	xcomp||was-6/VBD||evaluate-8/VB	xcomp||was-6/VBD||compare-10/VB	conj_and||evaluate-8/VB||compare-10/VB	det||effects-12/NNS||the-11/DT	dobj||evaluate-8/VB||effects-12/NNS	det||combination-18/NN||a-14/DT	amod||combination-18/NN||long-term-15/JJ	amod||combination-18/NN||fixed-dose-17/JJ	prep_of||effects-12/NNS||combination-18/NN	prep_of||combination-18/NN||sitagliptin-20/NN	prep_of||combination-18/NN||metformin-22/NN	conj_and||sitagliptin-20/NN||metformin-22/NN	prep_as||evaluate-8/VB||add-on-24/JJ	prep_to||add-on-24/JJ||insulin-26/NN	nn||index-30/NN||body-28/NN	nn||index-30/NN||mass-29/NN	prep_on||insulin-26/NN||index-30/NN	amod||glucose-34/NN||fasting-32/JJ	nn||glucose-34/NN||plasma-33/NN	prep_on||insulin-26/NN||glucose-34/NN	conj_and||index-30/NN||glucose-34/NN	prep_on||insulin-26/NN||fructosamine-36/NN	conj_and||index-30/NN||fructosamine-36/NN	prep_on||insulin-26/NN||hba1c-38/NNS	conj_and||index-30/NN||hba1c-38/NNS	prep_on||insulin-26/NN||lipids-40/NNS	conj_and||index-30/NN||lipids-40/NNS	amod||dose-44/NN||daily-43/JJ	prep_on||insulin-26/NN||dose-44/NN	conj_and||index-30/NN||dose-44/NN	prep_of||dose-44/NN||insulin-46/NN	det||type2diabetes-52/NNS||both-48/DT	amod||type2diabetes-52/NNS||type1diabetes-49/JJ	conj_and||type1diabetes-49/JJ||insulin-treated-51/JJ	amod||type2diabetes-52/NNS||insulin-treated-51/JJ	prep_in||insulin-46/NN||type2diabetes-52/NNS	type2diabetes-52||metformin-22||yes||the aim of this study was to evaluate and compare the effects of a long-term, fixed-dose combination of sitagliptin and metformin as add-on to insulin on body mass index, fasting plasma glucose, fructosamine, hba1c, lipids, and daily dose of insulin in both type1diabetes and insulin-treated type2diabetes.
amod||culture-2/NN||viral-1/JJ	nsubj||standard-6/NN||culture-2/NN	cop||standard-6/NN||is-3/VBZ	det||standard-6/NN||the-4/DT	amod||standard-6/NN||gold-5/JJ	root||ROOT-0/null||standard-6/NN	det||diagnosis-9/NN||the-8/DT	prep_for||standard-6/NN||diagnosis-9/NN	prep_of||diagnosis-9/NN||chikungunyafever-11/NN	gold-5||chikungunyafever-11||no_rel||viral culture is the gold standard for the diagnosis of chikungunyafever.
nsubj||found-2/VBD||we-1/PRP	root||ROOT-0/null||found-2/VBD	mark||suggesting-25/VBG||that-3/IN	amod||cells-5/NNS||phototrophic-4/JJ	nsubj||suggesting-25/VBG||cells-5/NNS	cop||suggesting-25/VBG||are-6/VBP	advmod||impacted-8/JJ||less-7/RBR	acomp||suggesting-25/VBG||impacted-8/JJ	prep_by||impacted-8/JJ||irondeficiency-10/NN	det||correlates-13/NNS||this-12/DT	prep_by||impacted-8/JJ||correlates-13/NNS	conj_and||irondeficiency-10/NN||correlates-13/NNS	poss||content-18/NN||their-15/PRP$	amod||content-18/NN||higher-16/JJR	nn||content-18/NN||iron-17/NN	prep_with||suggesting-25/VBG||content-18/NN	det||basis-23/NN||a-20/DT	amod||basis-23/NN||per-21/IN	nn||basis-23/NN||cell-22/NN	prep_on||content-18/NN||basis-23/NN	ccomp||found-2/VBD||suggesting-25/VBG	det||capacity/ability-28/NN||a-26/DT	amod||capacity/ability-28/NN||greater-27/JJR	dobj||suggesting-25/VBG||capacity/ability-28/NN	nn||assimilation-31/NN||iron-30/NN	prep_for||suggesting-25/VBG||assimilation-31/NN	det||state-35/NN||this-33/DT	amod||state-35/NN||metabolic-34/JJ	prep_in||assimilation-31/NN||state-35/NN	irondeficiency-10||iron-30||yes||we found that phototrophic cells are less impacted by irondeficiency and this correlates with their higher iron content on a per cell basis, suggesting a greater capacity/ability for iron assimilation in this metabolic state.
prepc_according_to||-lrb--9/VBD||to-2/TO	nn||diffusion-4/NN||disc-3/NN	pobj||-lrb--9/VBD||diffusion-4/NN	nn||s.aureus-8/NNS||methicillin-6/NN	nn||s.aureus-8/NNS||resistance-7/NN	nsubj||-lrb--9/VBD||s.aureus-8/NNS	root||ROOT-0/null||-lrb--9/VBD	nn||-rrb--11/NNP||mrsa-10/NNP	nsubj||%-14/NN||-rrb--11/NNP	cop||%-14/NN||was-12/VBD	num||%-14/NN||75-13/CD	ccomp||-lrb--9/VBD||%-14/NN	amod||aurous-19/NNS||vancomycin-16/JJ	nn||aurous-19/NNS||resistance-17/NN	nn||aurous-19/NNS||s.-18/NN	nsubj||-lrb--20/VBD||aurous-19/NNS	nsubj||based-27/VBN||aurous-19/NNS	conj_and||-lrb--9/VBD||-lrb--20/VBD	nn||-rrb--22/NNP||vrsa-21/NNP	nsubj||%-25/NN||-rrb--22/NNP	cop||%-25/NN||was-23/VBD	num||%-25/NN||0-24/CD	ccomp||-lrb--20/VBD||%-25/NN	conj_and||-lrb--9/VBD||based-27/VBN	conj_and||-lrb--20/VBD||based-27/VBN	prep_on||based-27/VBN||mic-29/NN	nsubj||%-34/NN||mrsa-31/NN	cop||%-34/NN||was-32/VBD	num||%-34/NN||68.5-33/CD	dep||-lrb--9/VBD||%-34/NN	nsubj||%-39/NN||vrsa-36/NN	cop||%-39/NN||was-37/VBD	num||%-39/NN||0-38/CD	conj_and||-lrb--9/VBD||%-39/NN	mrsa-31||s.aureus-8||no||according to disc diffusion , methicillin resistance s.aureus -lrb- mrsa -rrb- was 75 % and vancomycin resistance s. aurous -lrb- vrsa -rrb- was 0 % and based on mic , mrsa was 68.5 % and vrsa was 0 % .
amod||antagonists-2/NNS||trpv1-1/JJ	nsubj||attenuated-6/VBD||antagonists-2/NNS	nn||scavengers-5/NNS||formaldehyde-4/NN	conj_and||antagonists-2/NNS||scavengers-5/NNS	nsubj||attenuated-6/VBD||scavengers-5/NNS	root||ROOT-0/null||attenuated-6/VBD	nn||responses-10/NNS||bone-7/NN	nn||responses-10/NNS||cancer-8/NN	nn||responses-10/NNS||pain-9/NN	dobj||attenuated-6/VBD||responses-10/NNS	cancer-8||formaldehyde-4||no_rel||trpv1 antagonists and formaldehyde scavengers attenuated bone cancer pain responses.
prep_in||studied-15/VBN||total-2/NN	num||subjects-5/NNS||2,011-4/CD	nsubjpass||studied-15/VBN||subjects-5/NNS	dep||subjects-5/NNS||aged-7/VBN	dobj||aged-7/VBN||30â-8/NNS	num||years-12/NNS||$-9/$	num||$-9/$||70-11/CD	dep||30â-8/NNS||years-12/NNS	auxpass||studied-15/VBN||were-14/VBD	root||ROOT-0/null||studied-15/VBN	num||patients-19/NNS||1,247-18/CD	prep_including||studied-15/VBN||patients-19/NNS	amod||type2diabetes-22/NNS||recent-onset-21/JJ	prep_with||patients-19/NNS||type2diabetes-22/NNS	amod||autoantibodies-26/NNS||glutamicacid-24/VBN	nn||autoantibodies-26/NNS||decarboxylase-25/NN	prep_without||type2diabetes-22/NNS||autoantibodies-26/NNS	dep||autoantibodies-26/NNS||gadas-28/NNS	number||nonâ-32/CD||117-31/CD	num||patients-36/NNS||nonâ-32/CD	amod||patients-36/NNS||$-33/$	dep||$-33/$||insulin-requiring-35/NN	appos||autoantibodies-26/NNS||patients-36/NNS	prep_with||patients-36/NNS||gadas-38/NNS	nsubj||received-42/VBN||gadas-38/NNS	aux||received-42/VBN||had-40/VBD	neg||received-42/VBN||not-41/RB	rcmod||gadas-38/NNS||received-42/VBN	nn||therapy-44/NN||insulin-43/NN	dobj||received-42/VBN||therapy-44/NN	quantmod||6-48/CD||at-46/IN	mwe||at-46/IN||least-47/JJS	pobj||at-46/IN||least-47/JJS	num||months-49/NNS||6-48/CD	prep_for||therapy-44/NN||months-49/NNS	prep_after||received-42/VBN||diagnosis-51/NN	dep||patients-36/NNS||designated-53/VBN	nn||diabetes-56/NN||latent-54/NN	amod||diabetes-56/NN||autoimmune-55/JJ	dobj||designated-53/VBN||diabetes-56/NN	prep_of||diabetes-56/NN||adults-58/NNS	vmod||adults-58/NNS||-LSB--59/VBN	prep||-LSB--59/VBN||lada-60/NN	dep||lada-60/NN||-RSB--61/NN	num||type-65/NN||288-64/CD	prep_with||patients-19/NNS||type-65/NN	conj_and||type2diabetes-22/NNS||type-65/NN	num||patients-68/NNS||1-66/CD	amod||patients-68/NNS||diabetic-67/JJ	dep||type-65/NN||patients-68/NNS	num||subjects-73/NNS||359-71/CD	amod||subjects-73/NNS||normal-72/JJ	prep_with||patients-19/NNS||subjects-73/NNS	conj_and||type2diabetes-22/NNS||subjects-73/NNS	type2diabetes-22||insulin-43||yes||in total, 2,011 subjects (aged 30â70 years) were studied, including 1,247 patients with recent-onset type2diabetes without glutamicacid decarboxylase autoantibodies (gadas), 117 nonâinsulin-requiring patients with gadas who had not received insulin therapy for at least 6 months after diagnosis (designated latent autoimmune diabetes of adults [lada]), 288 type 1 diabetic patients, and 359 normal subjects.
poss||pharmacokinetics-4/NNS||their-2/PRP$	amod||pharmacokinetics-4/NNS||long-acting-3/JJ	prep_despite||associated-14/VBN||pharmacokinetics-4/NNS	det||use-7/NN||the-6/DT	nsubjpass||associated-14/VBN||use-7/NN	prep_of||use-7/NN||insulinglargine-9/NN	prep_of||use-7/NN||detemir-11/NN	conj_or||insulinglargine-9/NN||detemir-11/NN	auxpass||associated-14/VBN||is-12/VBZ	neg||associated-14/VBN||not-13/RB	root||ROOT-0/null||associated-14/VBN	det||incidence-18/NN||a-16/DT	amod||incidence-18/NN||lower-17/JJR	prep_with||associated-14/VBN||incidence-18/NN	prep_of||incidence-18/NN||dka-20/NN	prepc_compared_with||associated-14/VBN||with-22/IN	pobj||associated-14/VBN||nphinsulin-23/NN	nphinsulin-23||dka-20||no_rel||despite their long-acting pharmacokinetics, the use of insulinglargine or detemir is not associated with a lower incidence of dka compared with nphinsulin.
mark||have-3/VBP||although-1/IN	nsubj||have-3/VBP||nsaids-2/NNS	advcl||associated-20/VBN||have-3/VBP	det||place-6/NN||a-4/DT	amod||place-6/NN||well-established-5/JJ	dobj||have-3/VBP||place-6/NN	amod||indications-9/NNS||certain-8/JJ	prep_for||place-6/NN||indications-9/NNS	det||management-12/NN||the-11/DT	prep_in||indications-9/NNS||management-12/NN	prep_of||management-12/NN||oa-14/NN	prep_of||management-12/NN||ra-16/NN	conj_and||oa-14/NN||ra-16/NN	nsubjpass||associated-20/VBN||they-18/PRP	auxpass||associated-20/VBN||are-19/VBP	root||ROOT-0/null||associated-20/VBN	amod||gastrointestinal-23/JJ||significant-22/JJ	amod||toxicity-27/NNS||gastrointestinal-23/JJ	appos||toxicity-27/NNS||gi-25/NN	prep_with||associated-20/VBN||toxicity-27/NNS	nsaids-2||oa-14||no_rel||although nsaids have a well-established place for certain indications in the management of oa and ra, they are associated with significant gastrointestinal (gi) toxicity.
nsubj||replicate-6/VB||bovineherpesvirustype1-1/NNS	nsubj||cause-11/VB||bovineherpesvirustype1-1/NNS	dep||bovineherpesvirustype1-1/NNS||bohv-1-3/JJ	aux||replicate-6/VB||may-5/MD	root||ROOT-0/null||replicate-6/VB	det||sites-9/NNS||both-8/DT	prep_at||replicate-6/VB||sites-9/NNS	conj_and||replicate-6/VB||cause-11/VB	num||entities-15/NNS||two-12/CD	amod||entities-15/NNS||major-13/JJ	amod||entities-15/NNS||clinical-14/JJ	dobj||cause-11/VB||entities-15/NNS	vmod||entities-15/NNS||designated-16/VBN	prep_as||designated-16/VBN||infectiousbovinerhinotracheitis-18/NNS	appos||infectiousbovinerhinotracheitis-18/NNS||ibr-20/NN	amod||vulvovaginitis/balanoposthitis-25/NNS||infectious-23/JJ	nn||vulvovaginitis/balanoposthitis-25/NNS||pustular-24/NN	prep_as||designated-16/VBN||vulvovaginitis/balanoposthitis-25/NNS	conj_and||infectiousbovinerhinotracheitis-18/NNS||vulvovaginitis/balanoposthitis-25/NNS	appos||infectiousbovinerhinotracheitis-18/NNS||ipv/ipb-27/NN	prep_in||designated-16/VBN||cattle-30/NNS	infectiousbovinerhinotracheitis-18||bovineherpesvirustype1-1||no||bovineherpesvirustype1 (bohv-1) may replicate at both sites and cause two major clinical entities designated as infectiousbovinerhinotracheitis (ibr) and infectious pustular vulvovaginitis/balanoposthitis (ipv/ipb) in cattle.
amod||aminotransferase-2/NN||alanine-1/JJ	nsubj||dna-18/VBP||aminotransferase-2/NN	appos||aminotransferase-2/NN||alt-4/NN	amod||aminotransferase-8/NN||aspartate-7/JJ	conj_and||aminotransferase-2/NN||aminotransferase-8/NN	nsubj||dna-18/VBP||aminotransferase-8/NN	appos||aminotransferase-8/NN||ast-10/NN	conj_and||aminotransferase-2/NN||hepatitisbvirus-14/NNS	nsubj||dna-18/VBP||hepatitisbvirus-14/NNS	appos||aminotransferase-2/NN||hbv-16/NN	root||ROOT-0/null||dna-18/VBP	mark||â-24/NN||before-19/IN	det||treatment-21/NN||the-20/DT	nsubj||â-24/NN||treatment-21/NN	cop||â-24/NN||were-22/VBD	num||â-24/NN||184-23/CD	advcl||dna-18/VBP||â-24/NN	number||188-26/CD||±-25/CD	num||iu/l-27/NN||188-26/CD	dep||â-24/NN||iu/l-27/NN	number||â-30/CD||150-29/CD	num||iu/l-33/NN||â-30/CD	nn||iu/l-33/NN||±-31/NNP	num||iu/l-33/NN||138-32/CD	dep||â-24/NN||iu/l-33/NN	conj_and||iu/l-27/NN||iu/l-33/NN	number||â-37/CD||7.1-36/CD	num||copies/ml-41/NN||â-37/CD	nn||copies/ml-41/NN||±-38/NNP	num||copies/ml-41/NN||1.2-39/CD	nn||copies/ml-41/NN||log-40/NN	dep||â-24/NN||copies/ml-41/NN	conj_and||iu/l-27/NN||copies/ml-41/NN	advmod||â-24/NN||respectively-43/RB	hbv-16||hepatitisbvirus-14||no||alanine aminotransferase (alt), aspartate aminotransferase (ast), and hepatitisbvirus (hbv) dna before the treatment were 184 â± 188 iu/l, 150 â± 138 iu/l, and 7.1 â± 1.2 log copies/ml, respectively.
nsubj||warts-9/NNS||condylomaacuminata-1/NN	cop||warts-9/NNS||are-2/VBP	amod||warts-9/NNS||soft-3/JJ	amod||warts-9/NNS||skin-5/JJ	amod||warts-9/NNS||colored-6/JJ	amod||warts-9/NNS||fleshy-8/JJ	root||ROOT-0/null||warts-9/NNS	nsubjpass||caused-12/VBN||warts-9/NNS	auxpass||caused-12/VBN||are-11/VBP	rcmod||warts-9/NNS||caused-12/VBN	det||humanpapillomavirus-15/NNS||the-14/DT	agent||caused-12/VBN||humanpapillomavirus-15/NNS	appos||humanpapillomavirus-15/NNS||hpv-17/NN	condylomaacuminata-1||humanpapillomavirus-15||no||condylomaacuminata are soft, skin colored, fleshy warts that are caused by the humanpapillomavirus (hpv).
amod||aim-3/NN||objective-1/JJ	det||aim-3/NN||the-2/DT	nsubj||was-7/VBD||aim-3/NN	nsubj||present-9/VB||aim-3/NN	det||study-6/NN||this-5/DT	prep_of||aim-3/NN||study-6/NN	root||ROOT-0/null||was-7/VBD	aux||present-9/VB||to-8/TO	xcomp||was-7/VBD||present-9/VB	det||results-11/NNS||the-10/DT	dobj||present-9/VB||results-11/NNS	det||analysis-15/NN||a-13/DT	amod||analysis-15/NN||prespecified-14/JJ	prep_of||results-11/NNS||analysis-15/NN	amod||endpoints-19/NNS||key-17/JJ	amod||endpoints-19/NNS||secondary-18/JJ	prep_of||analysis-15/NN||endpoints-19/NNS	det||study-27/NN||a-21/DT	amod||study-27/NN||12-week-22/JJ	amod||study-27/NN||open-label-24/JJ	amod||study-27/NN||single-arm-26/JJ	prep_from||present-9/VB||study-27/NN	vmod||study-27/NN||evaluating-28/VBG	det||efficacy-30/NN||the-29/DT	dobj||evaluating-28/VBG||efficacy-30/NN	dobj||evaluating-28/VBG||safety-32/NN	conj_and||efficacy-30/NN||safety-32/NN	amod||hydrochlorothiazide-36/NN||olmesartanmedoxomil-34/JJ	nn||hydrochlorothiazide-36/NN||plus-35/NN	prep_of||efficacy-30/NN||hydrochlorothiazide-36/NN	appos||hydrochlorothiazide-36/NN||hctz-38/NNP	prep_in||evaluating-28/VBG||patients-41/NNS	prep_with||patients-41/NNS||hypertension-43/NN	prep_with||patients-41/NNS||type2diabetes-45/NNS	conj_and||hypertension-43/NN||type2diabetes-45/NNS	hypertension-43||hydrochlorothiazide-36||yes||objective the aim of this study was to present the results of a prespecified analysis of key secondary endpoints from a 12-week, open-label, single-arm study evaluating the efficacy and safety of olmesartanmedoxomil plus hydrochlorothiazide (hctz) in patients with hypertension and type2diabetes.
advmod||report-15/VBP||here-1/RB	det||coexistence-6/NN||a-4/DT	amod||coexistence-6/NN||unique-5/JJ	prep_as||report-15/VBP||coexistence-6/NN	det||entities-12/NNS||these-8/DT	num||entities-12/NNS||two-9/CD	amod||entities-12/NNS||seperated-10/JJ	amod||entities-12/NNS||clinical-11/JJ	prep_of||coexistence-6/NN||entities-12/NNS	nsubj||report-15/VBP||we-14/PRP	root||ROOT-0/null||report-15/VBP	det||woman-18/NN||a-16/DT	amod||woman-18/NN||30-yr-old-17/JJ	dobj||report-15/VBP||woman-18/NN	vmod||woman-18/NN||presenting-19/VBG	amod||spasm-22/NN||carpal-21/JJ	prep_with||presenting-19/VBG||spasm-22/NN	vmod||spasm-22/NN||related-23/VBN	amod||preparation-43/NN||hypocalcemia-25/JJ	amod||calcium-28/NN||ionized-27/JJ	dep||preparation-43/NN||calcium-28/NN	num||mm/l-31/NN||1.90-30/CD	prep_of||calcium-28/NN||mm/l-31/NN	amod||preparation-43/NN||due-33/JJ	aux||acute-35/VB||to-34/TO	xcomp||due-33/JJ||acute-35/VB	amod||poisoning-37/NN||phosphate-36/JJ	dobj||acute-35/VB||poisoning-37/NN	amod||bowel-42/NN||oral-39/JJ	nn||bowel-42/NN||sodium-40/NN	nn||bowel-42/NN||phosphate-41/NN	prep_after||acute-35/VB||bowel-42/NN	prep_to||related-23/VBN||preparation-43/NN	nsubj||resolved-46/VBN||preparation-43/NN	rcmod||preparation-43/NN||resolved-46/VBN	advmod||resolved-46/VBN||rapidly-47/RB	amod||intravenously-50/NN||calciumgluconate-49/JJ	prep_after||resolved-46/VBN||intravenously-50/NN	spasm-22||calciumgluconate-49||no_rel||here, as a unique coexistence of these two seperated clinical entities, we report a 30-yr-old woman presenting with carpal spasm related to hypocalcemia (ionized calcium of 1.90 mm/l) due to acute phosphate poisoning after oral sodium phosphate bowel preparation, which resolved rapidly after calciumgluconate intravenously.
nsubj||agents-13/NNS||dengueviruses-1/NNS	amod||members-4/NNS||mosquito-borne-3/JJ	appos||dengueviruses-1/NNS||members-4/NNS	det||family-8/NN||the-6/DT	amod||family-8/NN||flaviviridae-7/JJ	prep_of||members-4/NNS||family-8/NN	cop||agents-13/NNS||are-10/VBP	det||agents-13/NNS||the-11/DT	amod||agents-13/NNS||causative-12/JJ	root||ROOT-0/null||agents-13/NNS	prep_of||agents-13/NNS||denguefever-15/NN	poss||complications-19/NNS||its-17/PRP$	amod||complications-19/NNS||associated-18/VBN	conj_and||agents-13/NNS||complications-19/NNS	amod||fever-23/NN||dengue-21/JJ	amod||fever-23/NN||haemorrhagic-22/JJ	conj_and||agents-13/NNS||fever-23/NN	conj_and||complications-19/NNS||fever-23/NN	conj_and||agents-13/NNS||dengueshocksyndrome-25/NN	conj_and||complications-19/NNS||dengueshocksyndrome-25/NN	dengueshocksyndrome-25||dengueviruses-1||no||dengueviruses, mosquito-borne members of the flaviviridae family, are the causative agents of denguefever and its associated complications, dengue haemorrhagic fever and dengueshocksyndrome.
nsubj||immunosuppressiveagent-19/NN||rapamycin-1/NN	appos||rapamycin-1/NN||rapa-3/NNP	det||inhibitor-7/NN||an-6/DT	appos||rapamycin-1/NN||inhibitor-7/NN	amod||target-10/NN||mammalian-9/JJ	prep_of||inhibitor-7/NN||target-10/NN	prep_of||target-10/NN||rapamycin-12/NN	appos||rapamycin-12/NN||mtor-14/NN	cop||immunosuppressiveagent-19/NN||is-17/VBZ	det||immunosuppressiveagent-19/NN||an-18/DT	root||ROOT-0/null||immunosuppressiveagent-19/NN	nsubj||has-21/VBZ||immunosuppressiveagent-19/NN	rcmod||immunosuppressiveagent-19/NN||has-21/VBZ	amod||effects-23/NNS||anti-proliferative-22/JJ	dobj||has-21/VBZ||effects-23/NNS	det||tumors-26/NNS||some-25/DT	prep_on||effects-23/NNS||tumors-26/NNS	immunosuppressiveagent-19||tumors-26||no_rel||rapamycin (rapa), an inhibitor of mammalian target of rapamycin (mtor), is an immunosuppressiveagent that has anti-proliferative effects on some tumors.
det||model-7/NN||a-1/DT	amod||primate-3/JJ||non-human-2/JJ	amod||model-7/NN||primate-3/JJ	appos||model-7/NN||nhp-5/NN	nsubjpass||employed-11/VBN||model-7/NN	nsubj||study-13/VB||model-7/NN	prep_of||model-7/NN||glutensensitivity-9/NN	auxpass||employed-11/VBN||was-10/VBD	root||ROOT-0/null||employed-11/VBN	aux||study-13/VB||to-12/TO	xcomp||employed-11/VBN||study-13/VB	det||perturbations-16/NNS||the-14/DT	nn||perturbations-16/NNS||gene-15/NN	dobj||study-13/VB||perturbations-16/NNS	vmod||perturbations-16/NNS||associated-17/VBN	amod||changes-21/NNS||dietary-19/JJ	nn||changes-21/NNS||gluten-20/NN	prep_with||associated-17/VBN||changes-21/NNS	amod||tissues-25/NNS||small-23/JJ	amod||tissues-25/NNS||intestinal-24/JJ	prep_in||changes-21/NNS||tissues-25/NNS	amod||macaques-29/NNS||gluten-sensitive-27/JJ	nn||macaques-29/NNS||rhesus-28/NNS	prep_from||associated-17/VBN||macaques-29/NNS	nn||mulatta-32/NN||macaca-31/NN	appos||macaques-29/NNS||mulatta-32/NN	glutensensitivity-9||gluten-20||no||a non-human primate (nhp) model of glutensensitivity was employed to study the gene perturbations associated with dietary gluten changes in small intestinal tissues from gluten-sensitive rhesus macaques ( macaca mulatta ).
nn||nleinpurpura-3/NNP||henoch-schã-1/NNP	nn||nleinpurpura-3/NNP||¶-2/NNP	nsubj||syndrome-10/NN||nleinpurpura-3/NNP	cop||syndrome-10/NN||is-4/VBZ	det||syndrome-10/NN||a-5/DT	amod||syndrome-10/NN||common-6/JJ	amod||syndrome-10/NN||immunoglobulin-7/JJ	amod||syndrome-10/NN||a-mediated-8/JJ	amod||syndrome-10/NN||vasculitic-9/JJ	root||ROOT-0/null||syndrome-10/NN	prep_in||syndrome-10/NN||children-12/NNS	vmod||children-12/NNS||characterized-14/VBN	amod||rash-17/NN||purpuric-16/JJ	agent||characterized-14/VBN||rash-17/NN	agent||characterized-14/VBN||arthritis-19/NN	conj_and||rash-17/NN||arthritis-19/NN	agent||characterized-14/VBN||abdominalpain-21/NN	conj_and||rash-17/NN||abdominalpain-21/NN	abdominalpain-21||immunoglobulin-7||no_rel||henoch-schã¶nleinpurpura is a common immunoglobulin a-mediated vasculitic syndrome in children, characterized by purpuric rash, arthritis and abdominalpain.
aux||investigate-2/VB||to-1/TO	advcl||studied-22/VBD||investigate-2/VB	mark||factor-14/NN||whether-3/IN	amod||density-7/NN||increased-4/VBN	amod||density-7/NN||lymphatic-5/JJ	nn||density-7/NN||vessel-6/NN	nsubj||factor-14/NN||density-7/NN	appos||density-7/NN||lvd-9/NN	cop||factor-14/NN||is-11/VBZ	det||factor-14/NN||a-12/DT	amod||factor-14/NN||prognostic-13/JJ	ccomp||investigate-2/VB||factor-14/NN	amod||metastasis-17/NNS||nodal-16/JJ	prep_for||factor-14/NN||metastasis-17/NNS	prep_for||factor-14/NN||survival-19/NN	conj_and||metastasis-17/NNS||survival-19/NN	nsubj||studied-22/VBD||we-21/PRP	root||ROOT-0/null||studied-22/VBD	amod||lvd-24/NN||peritumoral-23/JJ	dobj||studied-22/VBD||lvd-24/NN	dep||lvd-24/NN||p-lvd-26/JJ	amod||lvd-30/NN||intratumoral-29/JJ	dobj||studied-22/VBD||lvd-30/NN	conj_and||lvd-24/NN||lvd-30/NN	dep||lvd-30/NN||i-lvd-32/JJ	prep_in||lvd-24/NN||samples-35/NNS	num||patients-38/NNS||102-37/CD	prep_from||samples-35/NNS||patients-38/NNS	amod||carcinoma-41/NN||endometrial-40/JJ	prep_with||patients-38/NNS||carcinoma-41/NN	amod||tissues-45/NNS||endometrial-43/JJ	nn||tissues-45/NNS||carcinoma-44/NN	nsubjpass||analyzed-47/VBN||tissues-45/NNS	auxpass||analyzed-47/VBN||were-46/VBD	dobj||studied-22/VBD||analyzed-47/VBN	conj_and||lvd-24/NN||analyzed-47/VBN	amod||vessels-50/NNS||lymphatic-49/JJ	prep_for||analyzed-47/VBN||vessels-50/NNS	amod||staining-53/NN||immunohistochemical-52/JJ	agent||analyzed-47/VBN||staining-53/NN	det||antibody-56/NN||an-55/DT	prep_with||analyzed-47/VBN||antibody-56/NN	prep_against||antibody-56/NN||lyve-1-58/CD	i---1||carcinoma-44||no_rel||to investigate whether increased lymphatic vessel density (lvd) is a prognostic factor for nodal metastasis and survival, we studied peritumoral lvd (p-lvd) and intratumoral lvd (i-lvd) in samples from 102 patients with endometrial carcinoma; endometrial carcinoma tissues were analyzed for lymphatic vessels by immunohistochemical staining with an antibody against lyve-1.
det||total-2/NN||a-1/DT	nsubjpass||enrolled-29/VBN||total-2/NN	num||patients-5/NNS||130-4/CD	prep_of||total-2/NN||patients-5/NNS	vmod||patients-5/NNS||aged-6/VBN	mwe||than-8/IN||less-7/JJR	quantmod||16-9/CD||than-8/IN	num||years-10/NNS||16-9/CD	dobj||aged-6/VBN||years-10/NNS	dep||years-10/NNS||range-12/NN	num||months-14/NNS||6-13/CD	dep||range-12/NN||months-14/NNS	num||years-17/NNS||16-16/CD	prep_to||months-14/NNS||years-17/NNS	amod||epilepsy-21/NN||refractory-20/JJ	prep_with||aged-6/VBN||epilepsy-21/NN	nsubj||initiated-24/VBN||epilepsy-21/NN	aux||initiated-24/VBN||had-23/VBD	rcmod||epilepsy-21/NN||initiated-24/VBN	dobj||initiated-24/VBN||treatment-25/NN	prep_with||initiated-24/VBN||lacosamide-27/NN	auxpass||enrolled-29/VBN||were-28/VBD	root||ROOT-0/null||enrolled-29/VBN	num||units-33/NNS||18-31/CD	amod||units-33/NNS||neuropediatric-32/JJ	prep_at||enrolled-29/VBN||units-33/NNS	prep_in||units-33/NNS||hospitals-35/NNS	prep_across||hospitals-35/NNS||spain-37/NN	epilepsy-21||lacosamide-27||yes||a total of 130 patients aged less than 16 years (range 6 months to 16 years) with refractory epilepsy who had initiated treatment with lacosamide were enrolled at 18 neuropediatric units in hospitals across spain.
mark||reached-11/VBN||after-1/IN	det||concentration-6/NN||the-2/DT	nn||concentration-6/NN||target-3/NN	nn||concentration-6/NN||effect-4/NN	nn||concentration-6/NN||site-5/NN	nsubjpass||reached-11/VBN||concentration-6/NN	prep_of||concentration-6/NN||remifentanil-8/NN	aux||reached-11/VBN||had-9/VBD	auxpass||reached-11/VBN||been-10/VBN	advcl||controlled-15/VBD||reached-11/VBN	det||target-14/NN||the-13/DT	nsubj||controlled-15/VBD||target-14/NN	root||ROOT-0/null||controlled-15/VBD	nsubjpass||started-20/VBN||infusion-16/NN	prep_of||infusion-16/NN||propofol-18/NN	auxpass||started-20/VBN||was-19/VBD	dep||controlled-15/VBD||started-20/VBN	amod||pain-23/NN||propofol-induced-22/JJ	nsubjpass||recorded-25/VBN||pain-23/NN	auxpass||recorded-25/VBN||was-24/VBD	dep||controlled-15/VBD||recorded-25/VBN	conj_and||started-20/VBN||recorded-25/VBN	pain-23||remifentanil-8||yes||after the target effect site concentration of remifentanil had been reached, the target controlled infusion of propofol was started and propofol-induced pain was recorded.
amod||acid-2/NN||arachidonic-1/JJ	nsubj||stimulated-8/VBN||acid-2/NN	poss||metabolites-5/NNS||its-4/PRP$	conj_and||acid-2/NN||metabolites-5/NNS	nsubj||stimulated-8/VBN||metabolites-5/NNS	aux||stimulated-8/VBN||have-6/VBP	advmod||stimulated-8/VBN||recently-7/RB	root||ROOT-0/null||stimulated-8/VBN	amod||interest-10/NN||great-9/JJ	dobj||stimulated-8/VBN||interest-10/NN	nn||biology-13/NN||cancer-12/NN	prep_in||stimulated-8/VBN||biology-13/NN	prep_unlike||received-30/VBN||prostaglandins-18/NNS	conj_and||prostaglandins-18/NNS||leukotrienes-20/NNS	prep_unlike||received-30/VBN||leukotrienes-20/NNS	det||link-22/NN||the-21/DT	nsubj||received-30/VBN||link-22/NN	amod||metabolites-26/NNS||cytochome-24/JJ	amod||metabolites-26/NNS||p450-25/JJ	prep_between||link-22/NN||metabolites-26/NNS	prep_between||link-22/NN||cancer-28/NN	conj_and||metabolites-26/NNS||cancer-28/NN	aux||received-30/VBN||has-29/VBZ	conj_but||stimulated-8/VBN||received-30/VBN	amod||attention-32/NN||little-31/JJ	dobj||received-30/VBN||attention-32/NN	cancer-28||prostaglandins-18||no_rel||arachidonic acid and its metabolites have recently stimulated great interest in cancer biology; but, unlike prostaglandins and leukotrienes the link between cytochome p450 metabolites and cancer has received little attention.
mark||skin-9/NN||although-1/IN	det||majority-3/NN||the-2/DT	nsubj||skin-9/NN||majority-3/NN	amod||infections-6/NNS||ca-mrsa-5/JJ	prep_of||majority-3/NN||infections-6/NNS	cop||skin-9/NN||are-7/VBP	amod||skin-9/NN||mild-8/JJ	advcl||reported-18/VBN||skin-9/NN	conj_and||skin-9/NN||softtissueinfections-11/NNS	advcl||reported-18/VBN||softtissueinfections-11/NNS	amod||life-threatening-14/JJ||severe-13/JJ	amod||cases-15/NNS||life-threatening-14/JJ	nsubjpass||reported-18/VBN||cases-15/NNS	aux||reported-18/VBN||have-16/VBP	auxpass||reported-18/VBN||been-17/VBN	root||ROOT-0/null||reported-18/VBN	ca--1||softtissueinfections-11||no_rel||although the majority of ca-mrsa infections are mild skin and softtissueinfections, severe life-threatening cases have been reported.
amod||plasma-2/NN||higher-1/JJR	nsubjpass||associated-11/VBN||plasma-2/NN	amod||fattyacids-5/NNS||n-3-3/JJ	amod||fattyacids-5/NNS||polyunsaturated-4/JJ	dep||plasma-2/NN||fattyacids-5/NNS	appos||plasma-2/NN||pufa-7/NNP	aux||associated-11/VBN||have-9/VBP	auxpass||associated-11/VBN||been-10/VBN	root||ROOT-0/null||associated-11/VBN	det||risk-15/NN||a-13/DT	amod||risk-15/NN||lower-14/JJR	prep_with||associated-11/VBN||risk-15/NN	nn||cognitivedecline-19/NN||age-17/NN	amod||cognitivedecline-19/NN||related-18/VBN	prep_of||risk-15/NN||cognitivedecline-19/NN	aux||affect-24/VB||to-22/TO	advmod||affect-24/VB||beneficially-23/RB	prep_of||risk-15/NN||affect-24/VB	conj_and||cognitivedecline-19/NN||affect-24/VB	vmod||cognitivedecline-19/NN||affect-24/VB	amod||factors-27/NNS||cardiometabolic-25/JJ	nn||factors-27/NNS||risk-26/NN	dobj||affect-24/VB||factors-27/NNS	cognitivedecline-19||fattyacids-5||no_rel||higher plasma n-3 polyunsaturated fattyacids (pufa) have been associated with a lower risk of age related cognitivedecline, and to beneficially affect cardiometabolic risk factors.
nsubjpass||caused-3/VBN||alcoholicliverdisease-1/NN	auxpass||caused-3/VBN||is-2/VBZ	root||ROOT-0/null||caused-3/VBN	amod||exposure-8/NN||acute-5/JJ	conj_and||acute-5/JJ||chronic-7/JJ	amod||exposure-8/NN||chronic-7/JJ	agent||caused-3/VBN||exposure-8/NN	prep_to||caused-3/VBN||ethanol-10/NN	nsubj||promotes-12/VBZ||ethanol-10/NN	rcmod||ethanol-10/NN||promotes-12/VBZ	amod||stress-14/NN||oxidative-13/JJ	dobj||promotes-12/VBZ||stress-14/NN	amod||response-17/NN||inflammatory-16/JJ	dobj||promotes-12/VBZ||response-17/NN	conj_and||stress-14/NN||response-17/NN	alcoholicliverdisease-1||ethanol-10||no||alcoholicliverdisease is caused by acute and chronic exposure to ethanol which promotes oxidative stress and inflammatory response.
det||trial-4/NN||a-2/DT	amod||trial-4/NN||clinical-3/JJ	prep_in||-rrb--38/VBZ||trial-4/NN	nn||doxycycline-10/NNP||chloroquine-6/NNP	conj_vs.||chloroquine-6/NNP||chloroquine-8/NNP	nn||doxycycline-10/NNP||chloroquine-8/NNP	amod||doxycycline-10/NNP||plus-9/IN	prep_of||trial-4/NN||doxycycline-10/NNP	prep_of||trial-4/NN||doxycycline-12/NNP	conj_vs.||doxycycline-10/NNP||doxycycline-12/NNP	advmod||n-26/VBN||alone-13/RB	nn||vivax-16/NN||plasmodium-15/NN	nn||n-18/NN||vivax-16/NN	amod||n-18/NN||-lrb--17/JJ	prep_against||alone-13/RB||n-18/NN	dep||-rrb--21/JJ||=-19/SYM	number||-rrb--21/JJ||64-20/CD	dep||n-18/NN||-rrb--21/JJ	amod||-lrb--25/NNS||plasmodium-23/JJ	nn||-lrb--25/NNS||falciparum-24/NN	dep||n-18/NN||-lrb--25/NNS	conj_or||-rrb--21/JJ||-lrb--25/NNS	vmod||doxycycline-10/NNP||n-26/VBN	dep||malaria-30/NN||=-27/SYM	num||malaria-30/NN||98-28/CD	amod||malaria-30/NN||-rrb--29/JJ	ccomp||n-26/VBN||malaria-30/NN	det||wcc-37/NN||the-32/DT	amod||wcc-37/NN||total-33/JJ	amod||wcc-37/NN||white-34/JJ	nn||wcc-37/NN||cell-35/NN	nn||wcc-37/NN||-lrb--36/NN	nsubj||-rrb--38/VBZ||wcc-37/NN	nsubj||platelet-40/VBD||wcc-37/NN	root||ROOT-0/null||-rrb--38/VBZ	conj_and||-rrb--38/VBZ||platelet-40/VBD	amod||counts-44/NNS||-lrb--41/JJ	nn||counts-44/NNS||plt-42/NN	nn||counts-44/NNS||-rrb--43/NN	nsubj||measured-46/JJ||counts-44/NNS	cop||measured-46/JJ||were-45/VBD	ccomp||platelet-40/VBD||measured-46/JJ	prep_on||measured-46/JJ||days-48/NNS	dep||measured-46/JJ||0-49/CD	num||0-49/CD||3-51/CD	num||0-49/CD||7-53/CD	dep||measured-46/JJ||28-55/CD	conj_and||0-49/CD||28-55/CD	num||papuans-59/NNS||57-57/CD	amod||papuans-59/NNS||indigenous-58/JJ	prep_in||measured-46/JJ||papuans-59/NNS	prep_with||papuans-59/NNS||life-61/NN	amod||exposure-64/NN||long-62/JJ	nn||exposure-64/NN||malaria-63/NN	dobj||-rrb--38/VBZ||exposure-64/NN	num||immigrants-69/NNS||105-66/CD	nn||immigrants-69/NNS||non-67/NN	nn||immigrants-69/NNS||papuan-68/NN	dobj||-rrb--38/VBZ||immigrants-69/NNS	conj_and||exposure-64/NN||immigrants-69/NNS	amod||parts-72/NNS||other-71/JJ	prep_from||-rrb--38/VBZ||parts-72/NNS	prep_of||parts-72/NNS||indonesia-74/NN	amod||exposure-78/NN||limited-76/VBN	nn||exposure-78/NN||malaria-77/NN	prep_with||-rrb--38/VBZ||exposure-78/NN	malaria-77||doxycycline-12||yes||in a clinical trial of chloroquine vs. chloroquine plus doxycycline vs. doxycycline alone against plasmodium vivax -lrb- n = 64 -rrb- or plasmodium falciparum -lrb- n = 98 -rrb- malaria , the total white cell -lrb- wcc -rrb- and platelet -lrb- plt -rrb- counts were measured on days 0 , 3 , 7 and 28 in 57 indigenous papuans with life long malaria exposure and 105 non papuan immigrants from other parts of indonesia with limited malaria exposure .
amod||hypertension-2/NN||aldosterone-salt-1/JJ	nsubjpass||prevented-4/VBN||hypertension-2/NN	auxpass||prevented-4/VBN||was-3/VBD	root||ROOT-0/null||prevented-4/VBN	advmod||prevented-4/VBN||completely-5/RB	agent||prevented-4/VBN||spironolactone-7/NN	advmod||prevented-4/VBN||modestly-9/RB	agent||prevented-4/VBN||losartan-11/NN	conj_and||spironolactone-7/NN||losartan-11/NN	conj_and||spironolactone-7/NN||apocynin-13/NN	conj_and||losartan-11/NN||apocynin-13/NN	hypertension-2||losartan-11||yes||aldosterone-salt hypertension was prevented completely by spironolactone and modestly by losartan and apocynin.
expl||was-2/VBD||there-1/EX	root||ROOT-0/null||was-2/VBD	advmod||significant-4/JJ||statistically-3/RB	amod||association-5/NN||significant-4/JJ	nsubj||was-2/VBD||association-5/NN	prep_of||association-5/NN||hypomagnesemia-7/NN	amod||asthma-12/NN||tachypnoea-9/JJ	amod||asthma-12/NN||severe-11/JJ	prep_with||was-2/VBD||asthma-12/NN	appos||asthma-12/NN||use-14/NN	amod||²-18/NNS||long-acting-16/JJ	nn||²-18/NNS||î-17/NN	prep_of||use-14/NN||²-18/NNS	nn||²-48/NNS||agonist-20/NN	amod||corticosteroids-23/NNS||inhaled-22/JJ	appos||agonist-20/NN||corticosteroids-23/NNS	appos||agonist-20/NN||theophylline-25/NN	appos||agonist-20/NN||use-27/NN	nn||medications-33/NNS||â-29/NNP	nn||medications-33/NNS||-30/NNP	nn||medications-33/NNS||¥-31/NNP	num||medications-33/NNS||3-32/CD	prep_of||use-27/NN||medications-33/NNS	amod||exacerbations-38/NNS||previous-35/JJ	conj_and||previous-35/JJ||future-37/JJ	amod||exacerbations-38/NNS||future-37/JJ	appos||agonist-20/NN||exacerbations-38/NNS	neg||with-41/IN||not-40/RB	conj_but||agonist-20/NN||with-41/IN	nn||²-48/NNS||with-41/IN	pobj||with-41/IN||tachycardia-42/NN	pobj||with-41/IN||use-44/NN	conj_or||tachycardia-42/NN||use-44/NN	amod||î-47/NN||short-acting-46/JJ	prep_of||tachycardia-42/NN||î-47/NN	dep||use-14/NN||²-48/NNS	dep||²-48/NNS||2-49/CD	dep||use-14/NN||agonist-51/NN	dep||use-14/NN||montelukast-53/NN	conj_or||agonist-51/NN||montelukast-53/NN	asthma-12||montelukast-53||yes||there was statistically significant association of hypomagnesemia with tachypnoea, severe asthma, use of long-acting î²-agonist, inhaled corticosteroids, theophylline, use of â¥ 3 medications, previous and future exacerbations but not with tachycardia or use of short-acting î²2 -agonist or montelukast.
advmod||investigated-25/VBN||sulphadoxine-pyrimethamine-1/RB	dep||investigated-25/VBN||sp-3/VB	det||treatment-8/NN||a-5/DT	advmod||used-7/VBN||widely-6/RB	amod||treatment-8/NN||used-7/VBN	nsubjpass||investigated-25/VBN||treatment-8/NN	amod||malaria-11/NN||uncomplicated-10/JJ	prep_for||treatment-8/NN||malaria-11/NN	prep_for||treatment-8/NN||recommended-13/VBN	conj_and||malaria-11/NN||recommended-13/VBN	amod||treatment-17/NN||intermittent-15/JJ	nn||treatment-17/NN||preventive-16/NN	prep_for||recommended-13/VBN||treatment-17/NN	prep_of||recommended-13/VBN||malaria-19/NN	prep_in||recommended-13/VBN||pregnancy-21/NN	aux||investigated-25/VBN||is-23/VBZ	auxpass||investigated-25/VBN||being-24/VBG	root||ROOT-0/null||investigated-25/VBN	amod||treatment-29/NN||intermittent-27/JJ	nn||treatment-29/NN||preventive-28/NN	prep_for||investigated-25/VBN||treatment-29/NN	prep_of||treatment-29/NN||malaria-31/NN	prep_in||malaria-31/NN||infants-33/NNS	appos||infants-33/NNS||ipti-35/NNP	malaria-31||pyrimethamine--1||no||sulphadoxine-pyrimethamine (sp) a widely used treatment for uncomplicated malaria and recommended for intermittent preventive treatment of malaria in pregnancy, is being investigated for intermittent preventive treatment of malaria in infants (ipti).
det||study-5/NN||this-1/DT	amod||study-5/NN||double-blind-2/JJ	amod||study-5/NN||placebo-controlled-3/JJ	amod||study-5/NN||paralleled-4/JJ	nsubj||randomized-6/VBD||study-5/NN	root||ROOT-0/null||randomized-6/VBD	num||patients-8/NNS||302-7/CD	dobj||randomized-6/VBD||patients-8/NNS	prep_with||randomized-6/VBD||type2diabetes-10/NNS	amod||a1c-13/NNS||mean-12/JJ	dep||type2diabetes-10/NNS||a1c-13/NNS	num||%-15/NN||8.3-14/CD	dep||a1c-13/NNS||%-15/NN	nn||monotherapy-19/NN||metformin-18/NN	prep_on||randomized-6/VBD||monotherapy-19/NN	parataxis||randomized-6/VBD||mean-21/VB	dobj||mean-21/VB||1.5-22/CD	advmod||mean-21/VB||g/day-23/RB	aux||receive-26/VB||to-25/TO	vmod||randomized-6/VBD||receive-26/VB	dobj||receive-26/VB||one-27/CD	num||doses-31/NNS||five-29/CD	amod||doses-31/NNS||incb13739-30/JJ	prep_of||one-27/CD||doses-31/NNS	prep_of||one-27/CD||placebo-33/NN	conj_or||doses-31/NNS||placebo-33/NN	advmod||daily-35/JJ||once-34/RB	advmod||receive-26/VB||daily-35/JJ	num||weeks-38/NNS||12-37/CD	prep_for||daily-35/JJ||weeks-38/NNS	type2diabetes-10||metformin-18||yes||this double-blind placebo-controlled paralleled study randomized 302 patients with type2diabetes (mean a1c 8.3%) on metformin monotherapy (mean 1.5 g/day) to receive one of five incb13739 doses or placebo once daily for 12 weeks.
nsubj||endocrinedisease-6/NN||endogenous-1/NNS	vmod||endogenous-1/NNS||cushing-2/VBG	dobj||cushing-2/VBG||syndrome-3/NN	cop||endocrinedisease-6/NN||is-4/VBZ	det||endocrinedisease-6/NN||an-5/DT	root||ROOT-0/null||endocrinedisease-6/NN	vmod||endocrinedisease-6/NN||caused-7/VBN	amod||secretion-10/NN||excessive-9/JJ	agent||caused-7/VBN||secretion-10/NN	nn||hormone-13/NN||adrenocorticotropin-12/NN	prep_of||secretion-10/NN||hormone-13/NN	quantmod||80-16/CD||approximately-15/RB	num||%-17/NN||80-16/CD	prep_in||caused-7/VBN||%-17/NN	prep_of||%-17/NN||cases-19/NNS	advmod||caused-7/VBN||usually-21/RB	det||adenoma-26/NN||a-23/DT	advmod||corticotroph-25/JJ||pituitary-24/RB	amod||adenoma-26/NN||corticotroph-25/JJ	agent||caused-7/VBN||adenoma-26/NN	amod||-RSB--31/NNP||cushingdisease-28/JJ	nn||-RSB--31/NNP||-LSB--29/NNP	nn||-RSB--31/NNP||cd-30/NN	appos||adenoma-26/NN||-RSB--31/NNP	cd-30||endocrinedisease-6||no_rel||endogenous cushing syndrome is an endocrinedisease caused by excessive secretion of adrenocorticotropin hormone in approximately 80% of cases, usually by a pituitary corticotroph adenoma (cushingdisease [cd]).
det||lack-2/NN||the-1/DT	nsubj||highlights-15/VBZ||lack-2/NN	det||association-5/NN||an-4/DT	prep_of||lack-2/NN||association-5/NN	cop||amplicor-8/NN||being-7/VBG	prepc_between||association-5/NN||amplicor-8/NN	amod||amplicor-8/NN||positive-9/JJ	amod||amplicor-8/NN||tf-11/JJ	conj_and||positive-9/JJ||tf-11/JJ	det||gambia-14/NN||the-13/DT	prep_in||amplicor-8/NN||gambia-14/NN	root||ROOT-0/null||highlights-15/VBZ	det||correlation-18/NN||the-16/DT	amod||correlation-18/NN||poor-17/JJ	dobj||highlights-15/VBZ||correlation-18/NN	det||presence-21/NN||the-20/DT	prep_between||correlation-18/NN||presence-21/NN	amod||signs-25/NNS||trachoma-23/JJ	amod||signs-25/NNS||clinical-24/JJ	prep_of||presence-21/NN||signs-25/NNS	prep_between||correlation-18/NN||evidence-27/NN	conj_and||presence-21/NN||evidence-27/NN	amod||infection-30/NN||c.trachomatis-29/JJ	prep_of||evidence-27/NN||infection-30/NN	det||setting-33/NN||this-32/DT	prep_in||infection-30/NN||setting-33/NN	trachoma-23||c.trachomatis-29||no||the lack of an association between being amplicor positive and tf in the gambia highlights the poor correlation between the presence of trachoma clinical signs and evidence of c.trachomatis infection in this setting .
det||epidemic-7/NN||the-1/DT	amod||epidemic-7/NN||global-2/JJ	nn||epidemic-7/NN||humanimmunodeficiencyvirusinfection/acquiredimmuno-deficiencysyndrome-3/NN	appos||epidemic-7/NN||hiv/aids-5/NNS	nsubj||one-9/CD||epidemic-7/NN	cop||one-9/CD||is-8/VBZ	root||ROOT-0/null||one-9/CD	det||threats-13/NNS||the-11/DT	amod||threats-13/NNS||biggest-12/JJS	prep_of||one-9/CD||threats-13/NNS	amod||life-16/NN||human-15/JJ	prep_to||threats-13/NNS||life-16/NN	acquiredimmuno-deficiencysyndrome--1||hiv--1||no||the global humanimmunodeficiencyvirusinfection/acquiredimmuno-deficiencysyndrome (hiv/aids) epidemic is one of the biggest threats to human life.
nsubjpass||administered-25/VBN||questionnaires-1/NNS	aux||ascertain-3/VB||to-2/TO	vmod||questionnaires-1/NNS||ascertain-3/VB	det||presence-5/NN||the-4/DT	dobj||ascertain-3/VB||presence-5/NN	amod||conditions-8/NNS||atopy-associated-7/JJ	prep_of||presence-5/NN||conditions-8/NNS	nn||fever-12/NN||hay-11/NN	prep_such_as||conditions-8/NNS||fever-12/NN	prep_such_as||conditions-8/NNS||atopicdermatitis-14/NNS	conj_and||fever-12/NN||atopicdermatitis-14/NNS	prep_such_as||conditions-8/NNS||asthma-16/NN	conj_and||fever-12/NN||asthma-16/NN	amod||rhinitis-19/NNS||allergic-18/JJ	prep_such_as||conditions-8/NNS||rhinitis-19/NNS	conj_and||fever-12/NN||rhinitis-19/NNS	amod||conjunctivitis-23/NNS||allergic-22/JJ	prep_such_as||conditions-8/NNS||conjunctivitis-23/NNS	conj_and||fever-12/NN||conjunctivitis-23/NNS	auxpass||administered-25/VBN||were-24/VBD	root||ROOT-0/null||administered-25/VBN	det||parents-28/NNS||the-27/DT	prep_to||administered-25/VBN||parents-28/NNS	num||pupils-31/NNS||128-30/CD	prep_of||parents-28/NNS||pupils-31/NNS	det||3rd-34/NNS||the-33/DT	prep_in||pupils-31/NNS||3rd-34/NNS	amod||grades-37/NNS||6th-36/JJ	prep_to||administered-25/VBN||grades-37/NNS	amod||school-40/NN||elementary-39/JJ	prep_of||grades-37/NNS||school-40/NN	atopicdermatitis-14||atopy--1||no||questionnaires to ascertain the presence of atopy-associated conditions such as hay fever, atopicdermatitis, asthma, allergic rhinitis, and allergic conjunctivitis were administered to the parents of 128 pupils in the 3rd to 6th grades of elementary school.
prepc_according_to||+-11/VBD||to-2/TO	det||sensitivity-5/NN||the-3/DT	amod||sensitivity-5/NN||different-4/JJ	pobj||+-11/VBD||sensitivity-5/NN	poss||bone-8/NN||their-7/PRP$	prep_of||sensitivity-5/NN||bone-8/NN	nn||cd34-10/NNS||marrow-9/NN	nsubj||+-11/VBD||cd34-10/NNS	root||ROOT-0/null||+-11/VBD	dobj||+-11/VBD||cells-12/NNS	dep||vitro-15/NN||in-14/IN	amod||treatment-16/NN||vitro-15/NN	prep_to||+-11/VBD||treatment-16/NN	nn||patients-26/NNS||etoposide-18/NN	conj_or||etoposide-18/NN||mafosfamide-20/NN	nn||patients-26/NNS||mafosfamide-20/NN	dep||patients-26/NNS||acutemyeloidleukaemia-22/NN	nn||patients-26/NNS||aml-24/NN	prep_with||+-11/VBD||patients-26/NNS	amod||remission-30/NN||apparent-28/JJ	amod||remission-30/NN||complete-29/JJ	prep_in||+-11/VBD||remission-30/NN	appos||remission-30/NN||cr-32/NN	amod||induction-36/NN||chemotherapy-35/JJ	nsubjpass||classified-39/VBN||induction-36/NN	aux||classified-39/VBN||may-37/MD	auxpass||classified-39/VBN||be-38/VB	prepc_after||remission-30/NN||classified-39/VBN	num||groups-42/NNS||three-41/CD	prep_into||classified-39/VBN||groups-42/NNS	appos||groups-42/NNS||i-44/NNP	advmod||responsive-47/JJ||normally-46/RB	amod||groups-42/NNS||responsive-47/JJ	appos||chemoresistant-52/NNS||ii-50/NN	dep||groups-42/NNS||chemoresistant-52/NNS	appos||remission-30/NN||iii-55/NN	advmod||chemosensitive-58/JJ||highly-57/RB	amod||remission-30/NN||chemosensitive-58/JJ	acutemyeloidleukaemia-22||etoposide-18||yes||according to the different sensitivity of their bone marrow cd34+ cells to in vitro treatment with etoposide or mafosfamide, acutemyeloidleukaemia (aml) patients in apparent complete remission (cr) after chemotherapy induction may be classified into three groups (i) normally responsive; (ii) chemoresistant; (iii) highly chemosensitive.
nsubjpass||identified-3/VBN||subjects-1/NNS	auxpass||identified-3/VBN||were-2/VBD	root||ROOT-0/null||identified-3/VBN	amod||tolerance-7/NN||normal-5/JJ	nn||tolerance-7/NN||glucose-6/NN	prep_as||identified-3/VBN||tolerance-7/NN	discourse||tolerance-7/NN||ngt-9/UH	prep_as||identified-3/VBN||impairedglucosetolerance-12/NN	conj_or||tolerance-7/NN||impairedglucosetolerance-12/NN	discourse||impairedglucosetolerance-12/NN||igt-14/UH	det||diabetes-22/NN||cfâ-18/DT	npadvmod||related-21/JJ||$-19/$	amod||diabetes-22/NN||related-21/JJ	prep_as||identified-3/VBN||diabetes-22/NN	conj_or||tolerance-7/NN||diabetes-22/NN	amod||hyperglycemia-25/NN||fasting-24/VBG	prep_without||identified-3/VBN||hyperglycemia-25/NN	dep||hyperglycemia-25/NN||cfrd-27/VBN	dep||cfrd-27/VBN||fhâ-28/NNP	hyperglycemia-25||glucose-6||no||subjects were identified as normal glucose tolerance (ngt), impairedglucosetolerance (igt), or cfârelated diabetes without fasting hyperglycemia (cfrd fhâ).
nn||pressure-2/NN||blood-1/NN	nsubjpass||compared-63/VBN||pressure-2/NN	appos||pressure-2/NN||bp-4/NN	amod||glucose-9/NN||random-7/JJ	nn||glucose-9/NN||plasma-8/NN	conj_or||pressure-2/NN||glucose-9/NN	nsubjpass||compared-63/VBN||glucose-9/NN	dep||glucose-9/NN||p-glucose-11/JJ	conj_or||pressure-2/NN||anthropometrics-14/NNS	conj_and||glucose-9/NN||anthropometrics-14/NNS	conj_or||pressure-2/NN||prevalence-19/NN	conj_and||glucose-9/NN||prevalence-19/NN	prep_of||prevalence-19/NN||hypertension-21/NN	nn||>-24/NNS||bp-23/NN	dep||glucose-9/NN||>-24/NNS	num||mmhg-26/NN||140/90-25/CD	dep||>-24/NNS||mmhg-26/NN	conj_or||pressure-2/NN||impairedglucosetolerance-29/NN	nsubjpass||compared-63/VBN||impairedglucosetolerance-29/NN	dep||impairedglucosetolerance-29/NN||igt-31/NN	amod||â-35/NN||p-glucose-33/JJ	amod||â-35/NN||7.8-34/JJ	dep||igt-31/NN||â-35/NN	dep||â-35/NN||$-36/$	amod||mmol/l-39/NNS||11.0-38/JJ	npadvmod||11.1-50/RB||mmol/l-39/NNS	amod||¥-49/NNP||dm-44/JJ	amod||¥-49/NNP||p-glucose-46/JJ	nn||¥-49/NNP||â-47/NNP	nn||¥-49/NNP||-48/NNP	prep_diabetes||mmol/l-39/NNS||¥-49/NNP	dep||mmol/l-51/CD||11.1-50/RB	num||$-36/$||mmol/l-51/CD	conj_or||pressure-2/NN||overweight-55/NN	nsubjpass||compared-63/VBN||overweight-55/NN	dep||pressure-2/NN||bmi-57/VBN	xcomp||bmi-57/VBN||>-58/VBG	num||kg/m2-60/NNS||25-59/CD	dobj||>-58/VBG||kg/m2-60/NNS	auxpass||compared-63/VBN||were-62/VBD	root||ROOT-0/null||compared-63/VBN	det||groups-67/NNS||the-65/DT	num||groups-67/NNS||three-66/CD	prep_between||compared-63/VBN||groups-67/NNS	impairedglucosetolerance-29||glucose-9||no_rel||blood pressure (bp), random plasma glucose (p-glucose) and anthropometrics, as well as prevalence of hypertension (bp>140/90 mmhg), impairedglucosetolerance (igt; p-glucose 7.8â11.0 mmol/l), diabetes (dm; p-glucose â¥11.1 mmol/l), or overweight (bmi>25 kg/m2) were compared between the three groups.
nsubj||quantified-2/VBN||we-1/PRP	root||ROOT-0/null||quantified-2/VBN	det||hbz-4/NN||the-3/DT	dobj||quantified-2/VBN||hbz-4/NN	nn||levels-9/NNS||tax-6/NN	nn||levels-9/NNS||mrna-7/NN	nn||levels-9/NNS||expression-8/NN	dobj||quantified-2/VBN||levels-9/NNS	conj_and||hbz-4/NN||levels-9/NNS	amod||blood-12/NN||peripheral-11/JJ	prep_in||quantified-2/VBN||blood-12/NN	number||/-16/NN||56-14/CD	dep||/-16/NN||htlv-1-associatedmyelopathy-15/JJ	amod||patients-21/NNS||/-16/NN	nn||patients-21/NNS||tropicalspasticparaparesis-17/NN	appos||patients-21/NNS||ham/tsp-19/NN	prep_from||quantified-2/VBN||patients-21/NNS	number||atl-24/CD||10-23/CD	num||patients-25/NNS||atl-24/CD	prep_from||quantified-2/VBN||patients-25/NNS	conj_and||patients-21/NNS||patients-25/NNS	num||carriers-30/NNS||38-27/CD	amod||carriers-30/NNS||healthy-28/JJ	amod||carriers-30/NNS||asymptomatic-29/JJ	prep_from||quantified-2/VBN||carriers-30/NNS	conj_and||patients-21/NNS||carriers-30/NNS	appos||carriers-30/NNS||hcs-32/NN	num||controls-38/NNS||20-35/CD	amod||controls-38/NNS||normal-36/JJ	amod||controls-38/NNS||uninfected-37/JJ	prep_from||quantified-2/VBN||controls-38/NNS	conj_and||patients-21/NNS||controls-38/NNS	amod||lines-46/NNS||human-43/JJ	amod||lines-46/NNS||leukemic-44/JJ	amod||lines-46/NNS||t-cell-45/JJ	prep_from||quantified-2/VBN||lines-46/NNS	conj_and||patients-21/NNS||lines-46/NNS	amod||lines-50/NNS||htlv-1-infected-48/JJ	amod||lines-50/NNS||t-cell-49/JJ	conj_and||patients-21/NNS||lines-50/NNS	conj_and||lines-46/NNS||lines-50/NNS	det||data-54/NNS||the-53/DT	nsubjpass||correlated-56/VBN||data-54/NNS	auxpass||correlated-56/VBN||were-55/VBD	conj_and||quantified-2/VBN||correlated-56/VBN	amod||parameters-59/NNS||clinical-58/JJ	prep_with||correlated-56/VBN||parameters-59/NNS	tropicalspasticparaparesis-17||htlv-1--1||no||we quantified the hbz and tax mrna expression levels in peripheral blood from 56 htlv-1-associatedmyelopathy/tropicalspasticparaparesis (ham/tsp) patients, 10 atl patients, 38 healthy asymptomatic carriers (hcs) and 20 normal uninfected controls, as well as human leukemic t-cell lines and htlv-1-infected t-cell lines, and the data were correlated with clinical parameters.
det||study-2/NN||this-1/DT	nsubj||gives-3/VBZ||study-2/NN	root||ROOT-0/null||gives-3/VBZ	iobj||gives-3/VBZ||us-4/PRP	det||knowledge-9/NN||an-5/DT	amod||knowledge-9/NN||overview-6/JJ	prep_about||overview-6/JJ||hiv/aids-8/NNS	dobj||gives-3/VBZ||knowledge-9/NN	prep_in||knowledge-9/NN||detention-11/NN	nn||province-14/NN||hunan-13/NN	prep_in||detention-11/NN||province-14/NN	det||sites-19/NNS||all-17/DT	nn||sites-19/NNS||detention-18/NN	nsubj||provided-23/VBD||sites-19/NNS	det||study-22/NN||the-21/DT	prep_in||sites-19/NNS||study-22/NN	conj_and||gives-3/VBZ||provided-23/VBD	amod||services-26/NNS||hiv/aids-24/JJ	nn||services-26/NNS||intervention-25/NN	dobj||provided-23/VBD||services-26/NNS	prep_among||provided-23/VBD||detainees-28/NNS	nsubj||focused-30/VBN||detainees-28/NNS	rcmod||detainees-28/NNS||focused-30/VBN	amod||attitude-35/NN||hiv/aids-32/JJ	nn||attitude-35/NN||knowledge-33/NN	prep_on||focused-30/VBN||attitude-35/NN	nn||behaviors-39/NNS||health-38/NN	prep_on||focused-30/VBN||behaviors-39/NNS	conj_and||attitude-35/NN||behaviors-39/NNS	aids--1||hiv--1||no||this study gives us an overview about hiv/aids knowledge in detention in hunan province, and all detention sites in the study provided hiv/aids intervention services among detainees that focused on hiv/aids knowledge, attitude, and health behaviors.
amod||objectives-2/NNS||secondary-1/JJ	nsubj||effectiveness-5/NN||objectives-2/NNS	cop||effectiveness-5/NN||were-3/VBD	det||effectiveness-5/NN||the-4/DT	root||ROOT-0/null||effectiveness-5/NN	prep_of||effectiveness-5/NN||ondansetron-7/NN	prep_of||effectiveness-5/NN||prochlorperazine-9/NN	conj_and||ondansetron-7/NN||prochlorperazine-9/NN	aux||treat-11/VB||to-10/TO	vmod||effectiveness-5/NN||treat-11/VB	dobj||treat-11/VB||nausea-12/NN	poss||tolerability-15/NN||their-14/PRP$	dobj||treat-11/VB||tolerability-15/NN	conj_and||nausea-12/NN||tolerability-15/NN	nausea-12||prochlorperazine-9||yes||secondary objectives were the effectiveness of ondansetron and prochlorperazine to treat nausea and their tolerability.
det||emergence-4/NN||the-3/DT	prep_because_of||recommended-23/VBN||emergence-4/NN	amod||resistance-7/NN||chloroquine-6/JJ	prep_of||emergence-4/NN||resistance-7/NN	prep_in||resistance-7/NN||mali-9/NNS	nsubjpass||recommended-23/VBN||artemether-lumefantrine-11/NN	nsubj||available-35/JJ||artemether-lumefantrine-11/NN	appos||artemether-lumefantrine-11/NN||al-13/NNP	conj_or||artemether-lumefantrine-11/NN||artesunate-amodiaquine-16/NN	nsubjpass||recommended-23/VBN||artesunate-amodiaquine-16/NN	quantmod||aq-20/CD||as-18/RB	number||aq-20/CD||+-19/CD	dep||artesunate-amodiaquine-16/NN||aq-20/CD	auxpass||recommended-23/VBN||are-22/VBP	root||ROOT-0/null||recommended-23/VBN	amod||therapy-26/NN||first-line-25/JJ	prep_as||recommended-23/VBN||therapy-26/NN	amod||malaria-29/NN||uncomplicated-28/JJ	prep_for||therapy-26/NN||malaria-29/NN	aux||available-35/JJ||have-32/VBP	neg||available-35/JJ||not-33/RB	cop||available-35/JJ||been-34/VBN	conj_but||recommended-23/VBN||available-35/JJ	prep_in||available-35/JJ||mali-37/NNS	prep||available-35/JJ||until-38/IN	pobj||until-38/IN||recently-39/RB	amod||costs-43/NNS||high-42/JJ	prep_because_of||recently-39/RB||costs-43/NNS	malaria-29||chloroquine-6||yes||because of the emergence of chloroquine resistance in mali, artemether-lumefantrine (al) or artesunate-amodiaquine (as+aq) are recommended as first-line therapy for uncomplicated malaria, but have not been available in mali until recently because of high costs.
dep||positive-16/JJ||c-2/NN	amod||cytology-5/NN||asc-h-4/JJ	nsubj||positive-16/JJ||cytology-5/NN	appos||cytology-5/NN||21-7/CD	dep||cytology-5/NN||14-9/CD	num||%-12/NN||67-11/CD	appos||cytology-5/NN||%-12/NN	cop||positive-16/JJ||were-14/VBD	advmod||positive-16/JJ||p16-15/RB	root||ROOT-0/null||positive-16/JJ	num||biopsies-19/NNS||6-18/CD	nsubj||showed-25/VBD||biopsies-19/NNS	amod||biopsies-19/NNS||available-20/JJ	advmod||showed-25/VBD||â-21/RB	pobj||â-21/RB||$-22/$	num||$-22/$||5-24/CD	ccomp||positive-16/JJ||showed-25/VBD	nn||3/carcinoma-27/NNS||cin-26/NN	nsubj||ca-31/MD||3/carcinoma-27/NNS	amod||/-30/NNS||situ-29/JJ	prep_in||3/carcinoma-27/NNS||/-30/NNS	ccomp||showed-25/VBD||ca-31/MD	nsubj||showed-34/VBD||1-33/CD	conj_and||positive-16/JJ||showed-34/VBD	number||1-36/CD||cin-35/CD	dobj||showed-34/VBD||1-36/CD	prep_with||showed-34/VBD||possibility-38/NN	prep_of||possibility-38/NN||under-sampling-40/NN	carcinoma--1||ca-31||no_rel||(c) asc-h cytology (21) 14 (67%) were p16 positive (6 biopsies available â 5 showed cin 3/carcinoma in situ /ca and 1 showed cin 1 with possibility of under-sampling.
amod||duration-4/NN||short-2/JJ	nn||duration-4/NN||disease-3/NN	prep_despite||increased-28/VBN||duration-4/NN	amod||treatment-8/NN||intensive-6/JJ	nn||treatment-8/NN||insulin-7/NN	conj_and||duration-4/NN||treatment-8/NN	prep_despite||increased-28/VBN||treatment-8/NN	amod||control-12/NN||fair-10/JJ	amod||control-12/NN||glycemic-11/JJ	conj_and||duration-4/NN||control-12/NN	prep_despite||increased-28/VBN||control-12/NN	neg||signs-16/NNS||no-15/DT	conj_and||duration-4/NN||signs-16/NNS	prep_despite||increased-28/VBN||signs-16/NNS	nn||complications-19/NNS||microvascular-18/NN	prep_of||signs-16/NNS||complications-19/NNS	nsubj||increased-28/VBN||children-21/NNS	conj_and||children-21/NNS||adolescents-23/NNS	nsubj||increased-28/VBN||adolescents-23/NNS	prep_with||children-21/NNS||type1diabetes-25/CD	aux||increased-28/VBN||had-26/VBD	advmod||increased-28/VBN||slightly-27/RB	root||ROOT-0/null||increased-28/VBN	dobj||increased-28/VBN||cimt-29/NN	prepc_compared_with||increased-28/VBN||with-31/IN	amod||subjects-34/NNS||healthy-32/JJ	nn||subjects-34/NNS||control-33/NN	pobj||increased-28/VBN||subjects-34/NNS	det||differences-38/NNS||the-37/DT	nsubj||prominent-41/JJ||differences-38/NNS	cop||prominent-41/JJ||were-39/VBD	advmod||prominent-41/JJ||more-40/RBR	conj_and||increased-28/VBN||prominent-41/JJ	prep_in||prominent-41/JJ||boys-43/NNS	type1diabetes-25||insulin-7||yes||despite short disease duration, intensive insulin treatment, fair glycemic control, and no signs of microvascular complications, children and adolescents with type1diabetes had slightly increased cimt compared with healthy control subjects, and the differences were more prominent in boys.
aux||assess-2/VB||to-1/TO	root||ROOT-0/null||assess-2/VB	det||efficacy-4/NN||the-3/DT	dobj||assess-2/VB||efficacy-4/NN	dobj||assess-2/VB||tolerability-6/NN	conj_and||efficacy-4/NN||tolerability-6/NN	det||association-9/NN||the-8/DT	prep_of||efficacy-4/NN||association-9/NN	dep||association-9/NN||sibutramine-10/NN	dep||sibutramine-10/NN||10â-12/NNS	dep||10â-12/NNS||$-13/$	amod||orlistat-21/NNS||20â-15/JJ	dep||20â-15/JJ||$-16/$	num||$-16/$||-17/CD	dep||$-16/$||mg/day-18/NN	nn||orlistat-21/NNS||and-20/NNP	npadvmod||treatment-34/JJR||orlistat-21/NNS	dep||orlistat-21/NNS||120â-23/NNS	num||times-28/NNS||$-24/$	number||mg-26/CD||-25/CD	num||$-24/$||mg-26/CD	num||times-28/NNS||2-3-27/CD	dep||120â-23/NNS||times-28/NNS	det||day-30/NN||a-29/DT	dep||times-28/NNS||day-30/NN	prep_in||orlistat-21/NNS||the-33/DT	amod||obesity-36/NNS||treatment-34/JJR	prep||treatment-34/JJR||of-35/IN	npadvmod||in-37/IN||obesity-36/NNS	dep||trial-41/CD||in-37/IN	dep||in-37/IN||a-38/NNP	prep_six-month||in-37/IN||open-40/JJ	num||$-13/$||trial-41/CD	obesity-36||orlistat-21||yes||to assess the efficacy and tolerability of the association sibutramine (10â20âmg/day) and orlistat (120âmg 2-3 times a day) in the treatment of obesity in a six-month open trial.
nsubj||including-4/VBG||indexes-1/NNS	prep_of||indexes-1/NNS||inflammation-3/NN	root||ROOT-0/null||including-4/VBG	amod||factor-îºb-6/NN||nuclear-5/JJ	nsubj||binding-10/JJ||factor-îºb-6/NN	appos||factor-îºb-6/NN||nf-îºb-8/NNP	xcomp||including-4/VBG||binding-10/JJ	det||expression-14/NN||the-13/DT	nsubj||increased-38/VBN||expression-14/NN	prep_of||expression-14/NN||socs3-16/CD	nsubj||necrosis-19/VBZ||tumor-18/NN	parataxis||increased-38/VBN||necrosis-19/VBZ	nn||±-21/NNP||factor-î-20/NNP	dobj||necrosis-19/VBZ||±-21/NNP	nn||±-24/NNP||tnf-î-23/NNP	appos||±-21/NNP||±-24/NNP	dobj||necrosis-19/VBZ||interleukin-28/NN	conj_and||±-21/NNP||interleukin-28/NN	appos||interleukin-28/NN||il-30/NN	num||²-34/NNS||-1-32/CD	nn||²-34/NNS||î-33/NN	dep||±-21/NNP||²-34/NNS	prep_in||²-34/NNS||mncs-36/NNS	conj_and||including-4/VBG||increased-38/VBN	advmod||increased-38/VBN||significantly-39/RB	nn||intake-44/NN||glucose-41/NN	conj_and||glucose-41/NN||cream-43/NN	nn||intake-44/NN||cream-43/NN	prep_after||increased-38/VBN||intake-44/NN	amod||expression-48/NN||tlr-4-47/JJ	nsubj||increased-53/VBD||expression-48/NN	nn||concentrations-52/NNS||plasma-50/NN	nn||concentrations-52/NNS||lps-51/NN	conj_and||expression-48/NN||concentrations-52/NNS	nsubj||increased-53/VBD||concentrations-52/NNS	conj_but||including-4/VBG||increased-53/VBD	advmod||increased-53/VBD||only-54/RB	nn||intake-57/NN||cream-56/NN	prep_after||increased-53/VBD||intake-57/NN	tumor-18||glucose-41||no_rel||indexes of inflammation including nuclear factor-îºb (nf-îºb) binding, and the expression of socs3, tumor necrosis factor-î± (tnf-î±), and interleukin (il)-1î² in mncs, increased significantly after glucose and cream intake, but tlr-4 expression and plasma lps concentrations increased only after cream intake.
nn||policies-3/NNS||results-1/NNS	nn||policies-3/NNS||national-level-2/NN	nsubj||had-6/VBN||policies-3/NNS	nsubj||response-16/NN||policies-3/NNS	aux||had-6/VBN||have-5/VBP	rcmod||policies-3/NNS||had-6/VBN	det||impact-9/NN||a-7/DT	amod||impact-9/NN||major-8/JJ	dobj||had-6/VBN||impact-9/NN	prepc_on||had-6/VBN||chinaâ-11/VBG	dobj||chinaâ-11/VBG||$-12/$	num||$-12/$||-13/CD	cop||response-16/NN||s-14/VBZ	amod||response-16/NN||hiv/aids-15/JJ	dep||include-17/VBP||response-16/NN	root||ROOT-0/null||include-17/VBP	amod||frees-21/NNS||â-18/JJ	amod||frees-21/NNS||$-19/$	dep||$-19/$||four-20/JJ	dobj||include-17/VBP||frees-21/NNS	num||careâ-24/NNS||one-23/CD	dobj||include-17/VBP||careâ-24/NNS	conj_and||frees-21/NNS||careâ-24/NNS	nsubj||include-17/VBP||$-25/$	num||$-25/$||-26/CD	amod||plans-30/NNS||5-year-28/JJ	nn||plans-30/NNS||action-29/NN	nsubj||include-17/VBP||plans-30/NNS	conj_and||$-25/$||plans-30/NNS	amod||regulation-34/NN||hiv/aids-33/JJ	nsubj||include-17/VBP||regulation-34/NN	conj_and||$-25/$||regulation-34/NN	aids--1||hiv--1||no||results national-level policies that have had a major impact on chinaâs hiv/aids response include âfour frees and one careâ; 5-year action plans; and hiv/aids regulation.
mark||indicated-2/VBD||while-1/IN	advcl||extends-20/VBZ||indicated-2/VBD	prep_for||indicated-2/VBD||schizophrenia-4/NN	amod||mania-7/NN||acute-6/JJ	prep_for||indicated-2/VBD||mania-7/NN	conj_and||schizophrenia-4/NN||mania-7/NN	amod||base-14/NN||ziprasidoneâ-9/JJ	amod||base-14/NN||$-10/$	dep||$-10/$||-11/JJ	nn||base-14/NN||s-12/NN	nn||base-14/NN||evidence-13/NN	nsubj||extends-20/VBZ||base-14/NN	conj_and||base-14/NN||use-16/NN	nsubj||extends-20/VBZ||use-16/NN	amod||practice-19/NN||clinical-18/JJ	prep_in||base-14/NN||practice-19/NN	root||ROOT-0/null||extends-20/VBZ	det||approvals-24/NNS||these-22/DT	amod||approvals-24/NNS||regulatory-23/JJ	prep_beyond||extends-20/VBZ||approvals-24/NNS	base-14||schizophrenia-4||no_rel||while indicated for schizophrenia and acute mania, ziprasidoneâs evidence base and use in clinical practice extends beyond these regulatory approvals.
det||emergence-4/NN||the-3/DT	prep_because_of||recommended-23/VBN||emergence-4/NN	amod||resistance-7/NN||chloroquine-6/JJ	prep_of||emergence-4/NN||resistance-7/NN	prep_in||resistance-7/NN||mali-9/NNS	nsubjpass||recommended-23/VBN||artemether-lumefantrine-11/NN	nsubj||available-35/JJ||artemether-lumefantrine-11/NN	appos||artemether-lumefantrine-11/NN||al-13/NNP	conj_or||artemether-lumefantrine-11/NN||artesunate-amodiaquine-16/NN	nsubjpass||recommended-23/VBN||artesunate-amodiaquine-16/NN	quantmod||aq-20/CD||as-18/RB	number||aq-20/CD||+-19/CD	dep||artesunate-amodiaquine-16/NN||aq-20/CD	auxpass||recommended-23/VBN||are-22/VBP	root||ROOT-0/null||recommended-23/VBN	amod||therapy-26/NN||first-line-25/JJ	prep_as||recommended-23/VBN||therapy-26/NN	amod||malaria-29/NN||uncomplicated-28/JJ	prep_for||therapy-26/NN||malaria-29/NN	aux||available-35/JJ||have-32/VBP	neg||available-35/JJ||not-33/RB	cop||available-35/JJ||been-34/VBN	conj_but||recommended-23/VBN||available-35/JJ	prep_in||available-35/JJ||mali-37/NNS	prep||available-35/JJ||until-38/IN	pobj||until-38/IN||recently-39/RB	amod||costs-43/NNS||high-42/JJ	prep_because_of||recently-39/RB||costs-43/NNS	malaria-29||lumefantrine--1||yes||because of the emergence of chloroquine resistance in mali, artemether-lumefantrine (al) or artesunate-amodiaquine (as+aq) are recommended as first-line therapy for uncomplicated malaria, but have not been available in mali until recently because of high costs.
det||aim-2/NN||the-1/DT	nsubj||was-7/VBD||aim-2/NN	nsubj||investigate-12/VB||aim-2/NN	det||study-6/NN||the-4/DT	amod||study-6/NN||present-5/JJ	prep_of||aim-2/NN||study-6/NN	root||ROOT-0/null||was-7/VBD	advmod||was-7/VBD||therefore-9/RB	aux||investigate-12/VB||to-11/TO	xcomp||was-7/VBD||investigate-12/VB	det||effects-14/NNS||the-13/DT	dobj||investigate-12/VB||effects-14/NNS	det||therapy-18/NN||a-16/DT	amod||therapy-18/NN||first-line-17/JJ	prep_of||effects-14/NNS||therapy-18/NN	preconj||phenylephrine-21/NN||either-20/DT	prep_with||investigate-12/VB||phenylephrine-21/NN	prep_with||investigate-12/VB||norepinephrine-23/NN	conj_or||phenylephrine-21/NN||norepinephrine-23/NN	amod||hemodynamics-28/NNS||systemic-25/JJ	conj_and||systemic-25/JJ||regional-27/JJ	amod||hemodynamics-28/NNS||regional-27/JJ	prep_on||phenylephrine-21/NN||hemodynamics-28/NNS	prep_in||investigate-12/VB||patients-30/NNS	prep_with||patients-30/NNS||septicshock-32/NN	septicshock-32||phenylephrine-21||yes||the aim of the present study was, therefore, to investigate the effects of a first-line therapy with either phenylephrine or norepinephrine on systemic and regional hemodynamics in patients with septicshock.
nsubjpass||associated-4/VBN||fatigue-1/NN	auxpass||associated-4/VBN||was-2/VBD	neg||associated-4/VBN||not-3/RB	root||ROOT-0/null||associated-4/VBN	prep_with||associated-4/VBN||symptoms-6/NNS	prep_of||symptoms-6/NNS||depression-8/NN	nn||quality-11/NN||sleep-10/NN	prep_of||symptoms-6/NNS||quality-11/NN	conj_or||depression-8/NN||quality-11/NN	prep_of||symptoms-6/NNS||gender-13/NN	conj_or||depression-8/NN||gender-13/NN	amod||use-17/NN||supplemental-15/JJ	nn||use-17/NN||oxygen-16/NN	prep_of||symptoms-6/NNS||use-17/NN	conj_or||depression-8/NN||use-17/NN	nn||status-20/NN||smoking-19/NN	prep_of||symptoms-6/NNS||status-20/NN	conj_or||depression-8/NN||status-20/NN	amod||scores-27/NNS||medical-23/JJ	nn||scores-27/NNS||research-24/NN	nn||scores-27/NNS||council-25/NN	nn||scores-27/NNS||dyspnea-26/NN	prep_of||symptoms-6/NNS||scores-27/NNS	conj_or||depression-8/NN||scores-27/NNS	oxygen-16||fatigue-1||no_rel||fatigue was not associated with symptoms of depression, sleep quality, gender, supplemental oxygen use, smoking status, or medical research council dyspnea scores.
poss||data-2/NNS||our-1/PRP$	nsubj||suggest-3/VBP||data-2/NNS	root||ROOT-0/null||suggest-3/VBP	mark||endogenous-9/VBZ||that-4/IN	nn||tissues-6/NNS||cancer-5/NN	nsubj||endogenous-9/VBZ||tissues-6/NNS	advmod||secrete-8/JJ||directly-7/RB	amod||tissues-6/NNS||secrete-8/JJ	ccomp||suggest-3/VBP||endogenous-9/VBZ	dobj||endogenous-9/VBZ||formaldehyde-10/NN	det||formaldehyde-14/NN||this-13/DT	nsubj||induces-18/VBZ||formaldehyde-14/NN	amod||concentration-17/NN||low-16/JJ	prep_at||formaldehyde-14/NN||concentration-17/NN	conj_and||suggest-3/VBP||induces-18/VBZ	amod||pain-22/NN||metastatic-19/JJ	nn||pain-22/NN||bone-20/NN	nn||pain-22/NN||cancer-21/NN	dobj||induces-18/VBZ||pain-22/NN	amod||activation-25/NN||trpv1-24/JJ	prep_through||induces-18/VBZ||activation-25/NN	advmod||induces-18/VBZ||especially-26/RB	nn||environment-30/NN||tumor-28/NN	amod||environment-30/NN||acidic-29/JJ	prep_under||induces-18/VBZ||environment-30/NN	pain-22||formaldehyde-14||no_rel||our data suggest that cancer tissues directly secrete endogenous formaldehyde, and this formaldehyde at low concentration induces metastatic bone cancer pain through trpv1 activation especially under tumor acidic environment.
det||rat-6/NN||the-1/DT	amod||rat-6/NN||goto-kakizaki-2/JJ	nn||rat-6/NN||gk-4/NN	nsubj||model-17/NN||rat-6/NN	cop||model-17/NN||is-7/VBZ	det||model-17/NN||a-8/DT	amod||type2diabetes-12/NNS||well-studied-9/JJ	amod||type2diabetes-12/NNS||non-obese-10/JJ	amod||type2diabetes-12/NNS||spontaneous-11/JJ	nn||model-17/NN||type2diabetes-12/NNS	appos||type2diabetes-12/NNS||t2d-14/NNP	nn||model-17/NN||animal-16/NN	root||ROOT-0/null||model-17/NN	vmod||model-17/NN||characterized-18/VBN	amod||secretion-23/NN||impaired-20/VBN	amod||secretion-23/NN||glucose-stimulated-21/JJ	nn||secretion-23/NN||insulin-22/NN	agent||characterized-18/VBN||secretion-23/NN	appos||secretion-23/NN||gsis-25/NNS	det||cells-31/NNS||the-28/DT	amod||cells-31/NNS||pancreatic-29/JJ	amod||cells-31/NNS||beta-30/JJ	prep_in||secretion-23/NN||cells-31/NNS	t2d-14||insulin-22||yes||the goto-kakizaki (gk) rat is a well-studied non-obese spontaneous type2diabetes (t2d) animal model characterized by impaired glucose-stimulated insulin secretion (gsis) in the pancreatic beta cells.
det||structures-3/NNS||the-1/DT	amod||structures-3/NNS||three-dimensional-2/JJ	nsubj||determined-8/VBD||structures-3/NNS	amod||gpgs-6/NNS||m.tuberculosis-5/JJ	prep_of||structures-3/NNS||gpgs-6/NNS	advmod||determined-8/VBD||now-7/RB	root||ROOT-0/null||determined-8/VBD	xcomp||determined-8/VBD||provide-9/VB	amod||data-11/NNS||such-10/JJ	dobj||provide-9/VB||data-11/NNS	det||family-16/NN||a-13/DT	amod||enzyme-15/JJ||novel-14/JJ	amod||family-16/NN||enzyme-15/JJ	prep_for||provide-9/VB||family-16/NN	nsubj||lay-44/VBD||family-16/NN	advmod||establishing-19/VBG||clearly-18/RB	vmod||family-16/NN||establishing-19/VBG	det||determinants-22/NNS||the-20/DT	amod||determinants-22/NNS||molecular-21/JJ	dobj||establishing-19/VBG||determinants-22/NNS	amod||recognition-25/NN||substrate-24/JJ	prep_for||establishing-19/VBG||recognition-25/NN	prep_for||establishing-19/VBG||catalysis-27/NNS	conj_and||recognition-25/NN||catalysis-27/NNS	mark||providing-30/VBG||while-29/IN	advcl||establishing-19/VBG||providing-30/VBG	det||scaffold-33/NN||an-31/DT	amod||scaffold-33/NN||experimental-32/JJ	dobj||providing-30/VBG||scaffold-33/NN	det||design-38/NN||the-35/DT	amod||design-38/NN||structure-based-36/JJ	amod||design-38/NN||rational-37/JJ	prep_for||providing-30/VBG||design-38/NN	amod||inhibitors-41/NNS||specific-40/JJ	prep_of||design-38/NN||inhibitors-41/NNS	rcmod||family-16/NN||lay-44/VBD	det||foundation-46/NN||the-45/DT	dobj||lay-44/VBD||foundation-46/NN	det||development-49/NN||the-48/DT	prep_for||lay-44/VBD||development-49/NN	amod||therapies-53/NNS||novel-51/JJ	amod||therapies-53/NNS||anti-tuberculosis-52/JJ	prep_of||development-49/NN||therapies-53/NNS	tuberculosis--1||m.tuberculosis-5||no||the three-dimensional structures of m.tuberculosis gpgs now determined provide such data for a novel enzyme family , clearly establishing the molecular determinants for substrate recognition and catalysis , while providing an experimental scaffold for the structure-based rational design of specific inhibitors , which lay the foundation for the development of novel anti-tuberculosis therapies .
poss||model-2/NN||our-1/PRP$	nsubj||predicts-3/VBZ||model-2/NN	root||ROOT-0/null||predicts-3/VBZ	mark||increases-13/VBZ||that-4/IN	mark||increases-13/VBZ||as-5/IN	det||prevalence-8/NN||the-6/DT	nn||prevalence-8/NN||tb-7/NN	nsubj||increases-13/VBZ||prevalence-8/NN	det||population-12/NN||the-10/DT	nn||population-12/NN||suspect-11/NN	prep_in||prevalence-8/NN||population-12/NN	advcl||predicts-3/VBZ||increases-13/VBZ	ccomp||predicts-3/VBZ||increases-13/VBZ	expl||is-15/VBZ||there-14/EX	ccomp||increases-13/VBZ||is-15/VBZ	det||increase-18/NN||an-16/DT	amod||increase-18/NN||exponential-17/JJ	nsubj||is-15/VBZ||increase-18/NN	det||risk-21/NN||the-20/DT	prep_in||increase-18/NN||risk-21/NN	amod||events-25/NNS||mtb-23/JJ	amod||events-25/NNS||cross-contamination-24/JJ	prep_of||risk-21/NN||events-25/NNS	vmod||events-25/NNS||expected-26/VBN	advmod||negative-29/JJ||otherwise-28/RB	amod||samples-30/NNS||negative-29/JJ	prep_in||expected-26/VBN||samples-30/NNS	dep||expected-26/VBN||even-32/RB	amod||performance-36/NN||equivalent-34/JJ	amod||performance-36/NN||technical-35/JJ	prep_with||expected-26/VBN||performance-36/NN	det||laboratories-39/NNS||the-38/DT	prep_of||performance-36/NN||laboratories-39/NNS	tb-7||mtb-23||no||our model predicts that as the tb prevalence in the suspect population increases there is an exponential increase in the risk of mtb cross-contamination events expected in otherwise negative samples, even with equivalent technical performance of the laboratories.
det||article-2/NN||this-1/DT	nsubj||reviews-5/VBZ||article-2/NN	nsubj||focuses-16/VBZ||article-2/NN	nsubj||proposes-25/VBZ||article-2/NN	nsubj||hypothesized-30/VBN||article-2/NN	advmod||reviews-5/VBZ||first-3/JJ	dep||first-3/JJ||briefly-4/NN	root||ROOT-0/null||reviews-5/VBZ	det||prevalence-7/NN||the-6/DT	dobj||reviews-5/VBZ||prevalence-7/NN	amod||factors-10/NNS||associated-9/VBN	dobj||reviews-5/VBZ||factors-10/NNS	conj_and||prevalence-7/NN||factors-10/NNS	amod||ptsd-13/NN||accident-related-12/JJ	prep_of||factors-10/NNS||ptsd-13/NN	advmod||focuses-16/VBZ||then-15/RB	conj_and||reviews-5/VBZ||focuses-16/VBZ	det||model-20/NN||a-18/DT	amod||model-20/NN||conceptual-19/JJ	prep_on||focuses-16/VBZ||model-20/NN	nn||memory-23/NN||fear-22/NN	prep_of||model-20/NN||memory-23/NN	conj_and||reviews-5/VBZ||proposes-25/VBZ	det||new-27/JJ||a-26/DT	dobj||proposes-25/VBZ||new-27/JJ	advmod||hypothesized-30/VBN||rationally-29/RB	conj_and||reviews-5/VBZ||hypothesized-30/VBN	amod||intervention-33/NN||translational-31/JJ	nn||intervention-33/NN||preventive-32/NN	dobj||hypothesized-30/VBN||intervention-33/NN	prep_for||intervention-33/NN||ptsd-35/NN	prepc_through||hypothesized-30/VBN||promoting-37/VBG	amod||neurogenesis-39/NNS||hippocampal-38/JJ	dobj||promoting-37/VBG||neurogenesis-39/NNS	amod||supplementation-42/NN||omega-3fattyacid-41/JJ	prep_by||promoting-37/VBG||supplementation-42/NN	omega-3fattyacid-41||ptsd-35||no_rel||this article first briefly reviews the prevalence and associated factors of accident-related ptsd, then focuses on a conceptual model of fear memory and proposes a new, rationally hypothesized translational preventive intervention for ptsd through promoting hippocampal neurogenesis by omega-3fattyacid supplementation.
amod||drugs-3/NNS||other-1/JJ	amod||drugs-3/NNS||anti-tuberculous-2/JJ	nsubjpass||added-16/VBN||drugs-3/NNS	amod||ethambutol-7/JJ||pyrazinamide-5/JJ	dep||drugs-3/NNS||ethambutol-7/JJ	det||steroid-11/NN||a-10/DT	conj_and||drugs-3/NNS||steroid-11/NN	nsubjpass||added-16/VBN||steroid-11/NN	appos||steroid-11/NN||dexamethasone-13/NN	auxpass||added-16/VBN||were-15/VBD	root||ROOT-0/null||added-16/VBN	tuberculous--1||pyrazinamide-5||yes||other anti-tuberculous drugs (pyrazinamide, ethambutol) and a steroid (dexamethasone) were added.
mark||proven-7/VBN||while-1/IN	preconj||itraconazole-3/NN||both-2/DT	nsubj||proven-7/VBN||itraconazole-3/NN	nsubj||effective-10/JJ||itraconazole-3/NN	conj_and||itraconazole-3/NN||terbinafine-5/NN	nsubj||proven-7/VBN||terbinafine-5/NN	nsubj||effective-10/JJ||terbinafine-5/NN	aux||proven-7/VBN||have-6/VBP	advcl||known-17/VBN||proven-7/VBN	aux||effective-10/JJ||to-8/TO	cop||effective-10/JJ||be-9/VB	xcomp||proven-7/VBN||effective-10/JJ	prep_against||effective-10/JJ||onychomycosis-12/NNS	advmod||little-15/JJ||very-14/RB	nsubjpass||known-17/VBN||little-15/JJ	auxpass||known-17/VBN||is-16/VBZ	root||ROOT-0/null||known-17/VBN	poss||efficacy-21/NN||their-19/PRP$	amod||efficacy-21/NN||comparative-20/JJ	prep_about||known-17/VBN||efficacy-21/NN	prepc_in||known-17/VBN||achieving-23/VBG	amod||cure-27/NN||mycological-24/JJ	conj_and||mycological-24/JJ||clinical-26/JJ	amod||cure-27/NN||clinical-26/JJ	dobj||achieving-23/VBG||cure-27/NN	onychomycosis-12||itraconazole-3||yes||while both itraconazole and terbinafine have proven to be effective against onychomycosis, very little is known about their comparative efficacy in achieving mycological and clinical cure.
nsubjpass||compared-6/VBN||progress-1/NN	amod||injury-4/NN||renal-3/JJ	prep_of||progress-1/NN||injury-4/NN	auxpass||compared-6/VBN||was-5/VBD	root||ROOT-0/null||compared-6/VBN	amod||mice-11/NNS||nephropathy-resistant-8/JJ	amod||mice-11/NNS||wild-type-9/JJ	amod||mice-11/NNS||c57bl/6-10/JJ	prep_with||compared-6/VBN||mice-11/NNS	vmod||mice-11/NNS||given-12/VBN	dobj||given-12/VBN||stz-13/NN	stz-13||nephropathy--1||no_rel||progress of renal injury was compared with nephropathy-resistant wild-type c57bl/6 mice given stz.
aux||minimize-2/VB||to-1/TO	root||ROOT-0/null||minimize-2/VB	dobj||minimize-2/VB||hypoglycemia-3/NN	prep_in||minimize-2/VB||subjects-5/NNS	prep_with||subjects-5/NNS||type1diabetes-7/CD	amod||delivery-11/NN||automated-9/VBN	nn||delivery-11/NN||glucagon-10/NN	prep_by||minimize-2/VB||delivery-11/NN	det||system-17/NN||a-13/DT	amod||system-17/NN||closed-loop-14/JJ	nn||system-17/NN||insulin-15/NN	nn||system-17/NN||delivery-16/NN	prep_in||delivery-11/NN||system-17/NN	hypoglycemia-3||glucagon-10||yes||to minimize hypoglycemia in subjects with type1diabetes by automated glucagon delivery in a closed-loop insulin delivery system.
det||results-3/NNS||the-1/DT	nn||results-3/NNS||trial-2/NN	nsubj||provide-5/VB||results-3/NNS	aux||provide-5/VB||would-4/MD	root||ROOT-0/null||provide-5/VB	dobj||provide-5/VB||evidence-6/NN	det||efficacy-9/NN||the-8/DT	prep_on||provide-5/VB||efficacy-9/NN	prep_of||efficacy-9/NN||domperidone-11/NN	nsubjpass||used-16/VBN||domperidone-11/NN	auxpass||used-16/VBN||is-14/VBZ	advmod||used-16/VBN||largely-15/RB	rcmod||domperidone-11/NN||used-16/VBN	amod||practice-19/NN||clinical-18/JJ	prep_in||used-16/VBN||practice-19/NN	det||lack-22/NN||the-21/DT	prep_despite||used-16/VBN||lack-22/NN	amod||evaluation-25/NN||proper-24/JJ	prep_of||lack-22/NN||evaluation-25/NN	det||profile-30/NN||a-27/DT	amod||profile-30/NN||controversial-28/JJ	nn||profile-30/NN||safety-29/NN	prep_of||lack-22/NN||profile-30/NN	conj_and||evaluation-25/NN||profile-30/NN	dep||used-16/VBN||as-32/RB	prepc_compared_to||used-16/VBN||to-34/TO	prep_despite||used-16/VBN||ondansetron-35/NN	nsubjpass||authorized-41/VBN||which-37/WDT	auxpass||authorized-41/VBN||is-38/VBZ	neg||authorized-41/VBN||not-39/RB	advmod||authorized-41/VBN||yet-40/RB	dep||used-16/VBN||authorized-41/VBN	prep_in||authorized-41/VBN||italy-43/NN	prep_despite||authorized-41/VBN||evidence-45/NN	xcomp||authorized-41/VBN||supporting-46/VBG	poss||efficacy-48/NN||its-47/PRP$	dobj||supporting-46/VBG||efficacy-48/NN	prepc_in||supporting-46/VBG||treating-50/VBG	dobj||treating-50/VBG||vomiting-51/NN	ondansetron-35||vomiting-51||no_rel||the trial results would provide evidence on the efficacy of domperidone, which is largely used in clinical practice despite the lack of proper evaluation and a controversial safety profile, as compared to ondansetron, which is not yet authorized in italy despite evidence supporting its efficacy in treating vomiting.
det||treatment-3/NN||the-1/DT	amod||treatment-3/NN||lidocaine-2/JJ	nsubj||decreased-7/VBD||treatment-3/NN	vmod||treatment-3/NN||resulted-4/VBN	prep||resulted-4/VBN||in-5/IN	pcomp||in-5/IN||significantly-6/RB	root||ROOT-0/null||decreased-7/VBD	nn||activity-9/NN||brain-8/NN	dobj||decreased-7/VBD||activity-9/NN	det||groups-13/NNS||both-11/DT	amod||groups-13/NNS||patient-12/JJ	prep_in||decreased-7/VBD||groups-13/NNS	amod||regions-17/NNS||distinct-15/JJ	nn||regions-17/NNS||brain-16/NN	prep_with||decreased-7/VBD||regions-17/NNS	vmod||regions-17/NNS||responding-18/VBG	det||group-21/NN||each-20/DT	prep_in||responding-18/VBG||group-21/NN	nsubjpass||correlated-29/VBN||sub-regions-24/NNS	det||areas-27/NNS||these-26/DT	prep_within||sub-regions-24/NNS||areas-27/NNS	auxpass||correlated-29/VBN||were-28/VBD	conj_and||decreased-7/VBD||correlated-29/VBN	nn||ratings-32/NNS||pain-31/NN	prep_with||correlated-29/VBN||ratings-32/NNS	advmod||correlated-29/VBN||specifically-33/RB	det||group-36/NN||each-35/DT	prep_for||correlated-29/VBN||group-36/NN	amod||cortex-40/NN||medial-38/JJ	amod||cortex-40/NN||prefrontal-39/JJ	dep||group-36/NN||cortex-40/NN	prep_in||cortex-40/NN||cbp-42/NN	prep_in||cortex-40/NN||thalamus-44/NNS	conj_and||cbp-42/NN||thalamus-44/NNS	prep_in||cortex-40/NN||oa-46/NN	oa-46||lidocaine-2||no_rel||the lidocaine treatment resulted in significantly decreased brain activity in both patient groups with distinct brain regions responding in each group, and sub-regions within these areas were correlated with pain ratings specifically for each group (medial prefrontal cortex in cbp and thalamus in oa).
aux||compare-2/VB||to-1/TO	root||ROOT-0/null||compare-2/VB	det||levels-6/NNS||the-3/DT	nn||levels-6/NNS||blood-4/NN	nn||levels-6/NNS||lactate-5/NN	dobj||compare-2/VB||levels-6/NNS	prep_between||levels-6/NNS||patients-8/NNS	prep_with||compare-2/VB||psychoticdisorder-10/NN	vmod||psychoticdisorder-10/NN||receiving-11/VBG	advmod||receiving-11/VBG||first-12/RB	nsubj||receiving-16/VBG||those-15/DT	conj_and||compare-2/VB||receiving-16/VBG	amod||antipsychotics-18/NNS||second-generation-17/JJ	dobj||receiving-16/VBG||antipsychotics-18/NNS	antipsychotics-18||psychoticdisorder-10||no_rel||to compare the blood lactate levels between patients with psychoticdisorder receiving first- and those receiving second-generation antipsychotics.
det||paper-2/NN||this-1/DT	nsubj||explores-3/VBZ||paper-2/NN	root||ROOT-0/null||explores-3/VBZ	det||association-6/NN||the-4/DT	amod||association-6/NN||possible-5/JJ	dobj||explores-3/VBZ||association-6/NN	prep_between||association-6/NN||antibiotics-8/NNS	vmod||antibiotics-8/NNS||prescribed-9/VBN	prep_in||prescribed-9/VBN||infancy-11/NN	prep_in||prescribed-9/VBN||allergicdisorders-13/NNS	conj_and||infancy-11/NN||allergicdisorders-13/NNS	advmod||eczema-16/NN||mainly-15/RB	appos||infancy-11/NN||eczema-16/NN	appos||infancy-11/NN||asthma-18/NN	conj_and||eczema-16/NN||asthma-18/NN	prep_in||prescribed-9/VBN||childhood-21/NN	asthma-18||antibiotics-8||no_rel||this paper explores the possible association between antibiotics prescribed in infancy and allergicdisorders, mainly eczema and asthma, in childhood.
det||study-3/NN||this-2/DT	prep_in||investigated-6/VBD||study-3/NN	nsubj||investigated-6/VBD||we-5/PRP	root||ROOT-0/null||investigated-6/VBD	det||effect-8/NN||the-7/DT	dobj||investigated-6/VBD||effect-8/NN	det||mixture-12/NN||a-10/DT	amod||mixture-12/NN||lidocaine-11/JJ	prep_of||effect-8/NN||mixture-12/NN	prep_on||investigated-6/VBD||pain-14/NN	dep||pain-14/NN||induced-15/VBN	amod||injection-19/NN||microemulsion-17/JJ	amod||injection-19/NN||propofol-18/JJ	prep_by||induced-15/VBN||injection-19/NN	dep||pain-14/NN||sought-22/VBN	conj_and||induced-15/VBN||sought-22/VBN	aux||determine-24/VB||to-23/TO	xcomp||sought-22/VBN||determine-24/VB	det||dose-27/NN||the-25/DT	amod||dose-27/NN||optimal-26/JJ	dobj||determine-24/VB||dose-27/NN	nsubj||reduce-32/VB||dose-27/NN	prep_of||dose-27/NN||lidocaine-29/NN	aux||reduce-32/VB||could-31/MD	rcmod||dose-27/NN||reduce-32/VB	dobj||reduce-32/VB||pain-33/NN	prepc_on||reduce-32/VB||injecting-35/VBG	det||mixture-38/NN||a-36/DT	amod||mixture-38/NN||propofol-lidocaine-37/JJ	dobj||injecting-35/VBG||mixture-38/NN	pain-33||propofol-18||yes||in this study, we investigated the effect of a lidocaine mixture on pain induced by microemulsion propofol injection, and sought to determine the optimal dose of lidocaine that could reduce pain on injecting a propofol-lidocaine mixture.
det||study-2/NN||this-1/DT	nsubj||gives-3/VBZ||study-2/NN	root||ROOT-0/null||gives-3/VBZ	iobj||gives-3/VBZ||us-4/PRP	det||knowledge-9/NN||an-5/DT	amod||knowledge-9/NN||overview-6/JJ	prep_about||overview-6/JJ||hiv/aids-8/NNS	dobj||gives-3/VBZ||knowledge-9/NN	prep_in||knowledge-9/NN||detention-11/NN	nn||province-14/NN||hunan-13/NN	prep_in||detention-11/NN||province-14/NN	det||sites-19/NNS||all-17/DT	nn||sites-19/NNS||detention-18/NN	nsubj||provided-23/VBD||sites-19/NNS	det||study-22/NN||the-21/DT	prep_in||sites-19/NNS||study-22/NN	conj_and||gives-3/VBZ||provided-23/VBD	amod||services-26/NNS||hiv/aids-24/JJ	nn||services-26/NNS||intervention-25/NN	dobj||provided-23/VBD||services-26/NNS	prep_among||provided-23/VBD||detainees-28/NNS	nsubj||focused-30/VBN||detainees-28/NNS	rcmod||detainees-28/NNS||focused-30/VBN	amod||attitude-35/NN||hiv/aids-32/JJ	nn||attitude-35/NN||knowledge-33/NN	prep_on||focused-30/VBN||attitude-35/NN	nn||behaviors-39/NNS||health-38/NN	prep_on||focused-30/VBN||behaviors-39/NNS	conj_and||attitude-35/NN||behaviors-39/NNS	aids--1||hiv--1||no||this study gives us an overview about hiv/aids knowledge in detention in hunan province, and all detention sites in the study provided hiv/aids intervention services among detainees that focused on hiv/aids knowledge, attitude, and health behaviors.
nn||odns-2/NNS||sup-1/NN	nsubj||had-3/VBD||odns-2/NNS	root||ROOT-0/null||had-3/VBD	det||effect-7/NN||a-4/DT	amod||effect-7/NN||significant-5/JJ	amod||effect-7/NN||synergistic-6/JJ	dobj||had-3/VBD||effect-7/NN	prep_with||effect-7/NN||5-fluorouracil-9/NN	prep_with||effect-7/NN||vinorelbine-11/NN	conj_and||5-fluorouracil-9/NN||vinorelbine-11/NN	prep_with||effect-7/NN||gemcitabine-13/NN	conj_and||5-fluorouracil-9/NN||gemcitabine-13/NN	prep_with||effect-7/NN||paclitaxel-15/NN	conj_and||5-fluorouracil-9/NN||paclitaxel-15/NN	prep_with||effect-7/NN||irinotecan-17/NN	conj_and||5-fluorouracil-9/NN||irinotecan-17/NN	det||index-23/NN||a-20/DT	amod||index-23/NN||mean-21/JJ	nn||index-23/NN||combination-22/NN	prep_with||had-3/VBD||index-23/NN	prep_of||index-23/NN||0.43-25/CD	dep||$-27/$||â-26/RB	dep||0.43-25/CD||$-27/$	npadvmod||indicates-33/RB||0.78-29/NNP	dep||0.78-29/NNP||<-31/RB	prep||<-31/RB||1.0-32/IN	dep||synergism-34/CD||indicates-33/RB	num||$-27/$||synergism-34/CD	det||line-41/NN||the-37/DT	amod||line-41/NN||a549-38/JJ	amod||line-41/NN||nsclc-39/JJ	nn||line-41/NN||cell-40/NN	prep_in||0.43-25/CD||line-41/NN	nsclc-39||vinorelbine-11||yes||sup odns had a significant synergistic effect with 5-fluorouracil, vinorelbine, gemcitabine, paclitaxel and irinotecan, with a mean combination index of 0.43â0.78 (<1.0 indicates synergism) in the a549 nsclc cell line.
nsubj||point-2/VBP||we-1/PRP	root||ROOT-0/null||point-2/VBP	prt||point-2/VBP||out-3/RP	neg||only-5/JJ||not-4/RB	preconj||association-7/NN||only-5/JJ	det||association-7/NN||the-6/DT	dobj||point-2/VBP||association-7/NN	det||abscess-11/NNS||an-9/DT	amod||abscess-11/NNS||epidural-10/JJ	prep_of||association-7/NN||abscess-11/NNS	amod||jointinfection-14/NN||facet-13/JJ	prep_with||abscess-11/NNS||jointinfection-14/NN	det||indication-20/NN||the-18/DT	amod||indication-20/NN||possible-19/JJ	dobj||point-2/VBP||indication-20/NN	conj_and||association-7/NN||indication-20/NN	amod||cement-23/NN||antibiotic-bone-22/JJ	prep_of||indication-20/NN||cement-23/NN	rcmod||indication-20/NN||beads-24/VBZ	det||treatment-27/NN||the-26/DT	prep_in||beads-24/VBZ||treatment-27/NN	amod||abscesses-30/NNS||epidural-29/JJ	prep_of||treatment-27/NN||abscesses-30/NNS	jointinfection-14||antibiotic--1||no_rel||we point out not only the association of an epidural abscess with facet jointinfection, but also the possible indication of antibiotic-bone cement beads in the treatment of epidural abscesses.
nsubjpass||excluded-6/VBN||patients-1/NNS	amod||tuberculosis-4/NNP||rifampicin-resistant-3/JJ	prep_with||patients-1/NNS||tuberculosis-4/NNP	auxpass||excluded-6/VBN||were-5/VBD	root||ROOT-0/null||excluded-6/VBN	tuberculosis-4||rifampicin--1||yes||patients with rifampicin-resistant tuberculosis were excluded.
nsubj||extracted-2/VBD||we-1/PRP	nsubj||compared-4/VBD||we-1/PRP	root||ROOT-0/null||extracted-2/VBD	conj_and||extracted-2/VBD||compared-4/VBD	det||markers-9/NN||the-5/DT	amod||markers-9/NN||following-6/VBG	amod||markers-9/NN||parameters-7/JJ	nn||markers-9/NN||biochemical-8/NN	dobj||extracted-2/VBD||markers-9/NN	nn||markers-12/NNS||hbv-11/NN	dobj||extracted-2/VBD||markers-12/NNS	conj_and||markers-9/NN||markers-12/NNS	nn||antigen-15/NN||surface-14/NN	dep||markers-12/NNS||antigen-15/NN	amod||antibody-18/NN||core-17/JJ	dep||antigen-15/NN||antibody-18/NN	nn||antibody-21/NN||surface-20/NN	dep||antigen-15/NN||antibody-21/NN	conj_and||antibody-18/NN||antibody-21/NN	nn||antibody-25/NN||hcv-24/NN	dobj||extracted-2/VBD||antibody-25/NN	conj_and||markers-9/NN||antibody-25/NN	amod||studies-28/NNS||radiological-27/JJ	dobj||extracted-2/VBD||studies-28/NNS	conj_and||markers-9/NN||studies-28/NNS	dobj||extracted-2/VBD||length-31/NN	conj_and||markers-9/NN||length-31/NN	prep_of||length-31/NN||stay-33/NN	appos||stay-33/NN||los-35/NN	antibody-25||hbv-11||no_rel||we extracted and compared the following parameters biochemical markers, hbv markers (surface antigen, core antibody and surface antibody), hcv antibody, radiological studies, and length of stay (los).
amod||studies-2/NNS||mechanistic-1/JJ	nsubj||showed-3/VBD||studies-2/NNS	dep||mediated-17/VBD||showed-3/VBD	mark||formed-6/VBD||that-4/IN	nsubj||formed-6/VBD||conjugates-5/NNS	ccomp||showed-3/VBD||formed-6/VBD	det||porphyrin-13/NN||the-8/DT	amod||porphyrin-13/NN||mono-9/JJ	conj_and||mono-9/JJ||tri-cationic-12/JJ	amod||porphyrin-13/NN||tri-cationic-12/JJ	prep_from||formed-6/VBD||porphyrin-13/NN	amod||antibody-16/NN||anti-cd104-15/JJ	prep_from||formed-6/VBD||antibody-16/NN	conj_and||porphyrin-13/NN||antibody-16/NN	root||ROOT-0/null||mediated-17/VBD	nn||irradiation-20/NN||apoptosis-18/NNS	amod||irradiation-20/NN||following-19/VBG	dobj||mediated-17/VBD||irradiation-20/NN	amod||light-24/NN||non-thermal-22/JJ	amod||light-24/NN||red-23/JJ	prep_with||mediated-17/VBD||light-24/NN	number||â-27/CD||630-26/CD	num||±-28/NNS||â-27/CD	prep_of||light-24/NN||±-28/NNS	num||wavelength-31/NN||15-29/CD	nn||wavelength-31/NN||nm-30/NN	nsubj||mediated-17/VBD||wavelength-31/NN	mono-9||antibody-16||no_rel||mechanistic studies showed that conjugates formed from the mono- and tri-cationic porphyrin and anti-cd104 antibody mediated apoptosis following irradiation with non-thermal red light of 630 â± 15 nm wavelength.
det||outbreak-4/NN||a-1/DT	num||outbreak-4/NN||2007-2/CD	nn||outbreak-4/NN||hemorrhagicfever-3/NN	nsubj||demonstrated-7/VBD||outbreak-4/NN	prep_in||outbreak-4/NN||uganda-6/NN	root||ROOT-0/null||demonstrated-7/VBD	det||existence-9/NN||the-8/DT	dobj||demonstrated-7/VBD||existence-9/NN	det||species-14/NNS||a-11/DT	amod||species-14/NNS||new-12/JJ	num||species-14/NNS||ebov-13/CD	prep_of||existence-9/NN||species-14/NNS	appos||existence-9/NN||bundibugyo-16/NN	nsubj||differed-22/VBN||bundibugyo-16/NN	appos||bundibugyo-16/NN||bebov-18/NNP	rcmod||bundibugyo-16/NN||differed-22/VBN	prep_from||differed-22/VBN||viruses-24/NNS	vmod||viruses-24/NNS||covered-25/VBN	amod||candidates-29/NNS||current-27/JJ	nn||candidates-29/NNS||vaccine-28/NN	agent||covered-25/VBN||candidates-29/NNS	quantmod||43-33/CD||up-31/IN	dep||43-33/CD||to-32/TO	num||%-34/NN||43-33/CD	agent||covered-25/VBN||%-34/NN	amod||sequence-37/NN||genome-36/JJ	prep_in||%-34/NN||sequence-37/NN	hemorrhagicfever-3||viruses-24||no||a 2007 hemorrhagicfever outbreak in uganda demonstrated the existence of a new ebov species, bundibugyo (bebov), that differed from viruses covered by current vaccine candidates by up to 43% in genome sequence.
advmod||model-3/VBD||here-1/RB	nsubj||model-3/VBD||we-2/PRP	root||ROOT-0/null||model-3/VBD	det||performance-5/NN||the-4/DT	dobj||model-3/VBD||performance-5/NN	amod||systems-10/NNS||mtb-7/JJ	amod||systems-10/NNS||liquid-8/JJ	nn||systems-10/NNS||culture-9/NN	prep_of||performance-5/NN||systems-10/NNS	amod||settings-20/NNS||high-12/JJ	conj_and||high-12/JJ||low-14/JJ	amod||settings-20/NNS||low-14/JJ	amod||settings-20/NNS||tuberculosis-15/JJ	appos||settings-20/NNS||tb-17/NN	nn||settings-20/NNS||prevalence-19/NN	prep_in||model-3/VBD||settings-20/NNS	vmod||settings-20/NNS||using-21/VBG	amod||data-24/NNS||detailed-22/JJ	amod||data-24/NNS||published-23/VBN	dobj||using-21/VBG||data-24/NNS	vmod||using-21/VBG||concentrating-25/VBG	det||frequency-29/NN||the-27/DT	amod||frequency-29/NN||likely-28/JJ	prep_on||concentrating-25/VBG||frequency-29/NN	amod||events-32/NNS||cross-contamination-31/JJ	prep_of||frequency-29/NN||events-32/NNS	tuberculosis-15||mtb-7||no||here we model the performance of mtb liquid culture systems in high and low tuberculosis (tb) prevalence settings using detailed published data concentrating on the likely frequency of cross-contamination events.
nn||identification-2/NN||species-1/NN	nsubj||seems-13/VBZ||identification-2/NN	nsubj||important-16/JJ||identification-2/NN	prep_of||identification-2/NN||isolates-4/NNP	vmod||isolates-4/NNP||belonging-5/VBG	det||-rrb--12/NNS||the-7/DT	amod||complex-9/JJ||mycobacteriumtuberculosis-8/JJ	amod||-rrb--12/NNS||complex-9/JJ	amod||-rrb--12/NNS||-lrb--10/JJ	nn||-rrb--12/NNS||mtc-11/NN	prep_to||belonging-5/VBG||-rrb--12/NNS	root||ROOT-0/null||seems-13/VBZ	aux||important-16/JJ||to-14/TO	cop||important-16/JJ||be-15/VB	xcomp||seems-13/VBZ||important-16/JJ	det||treatment-20/NN||the-18/DT	amod||treatment-20/NN||appropriate-19/JJ	prep_for||important-16/JJ||treatment-20/NN	prep_of||treatment-20/NN||patients-22/NNS	mark||resistant-29/JJ||since-24/IN	nn||bovis-26/NNS||m.-25/NN	nsubj||resistant-29/JJ||bovis-26/NNS	cop||resistant-29/JJ||is-27/VBZ	advmod||resistant-29/JJ||naturally-28/RB	advcl||important-16/JJ||resistant-29/JJ	det||drug-38/NN||a-31/DT	amod||drug-38/NN||first-32/JJ	nn||drug-38/NN||line-33/NN	amod||drug-38/NN||anti-tuberculosis-34/JJ	nn||drug-38/NN||-lrb--35/NNP	nn||drug-38/NN||tb-36/NN	nn||drug-38/NN||-rrb--37/NN	prep_to||resistant-29/JJ||drug-38/NN	appos||drug-38/NN||pyrazinamide-40/NN	mark||susceptible-50/JJ||while-42/IN	nsubj||susceptible-50/JJ||most-43/JJS	det||members-48/NNS||the-45/DT	amod||members-48/NNS||other-46/JJ	nn||members-48/NNS||mtc-47/NN	prep_of||most-43/JJS||members-48/NNS	cop||susceptible-50/JJ||are-49/VBP	advcl||resistant-29/JJ||susceptible-50/JJ	det||agent-54/NN||this-52/DT	amod||agent-54/NN||antimicrobial-53/JJ	prep_to||susceptible-50/JJ||agent-54/NN	tuberculosis--1||pyrazinamide-40||yes||species identification of isolates belonging to the mycobacteriumtuberculosis complex -lrb- mtc -rrb- seems to be important for the appropriate treatment of patients , since m. bovis is naturally resistant to a first line anti-tuberculosis -lrb- tb -rrb- drug , pyrazinamide , while most of the other mtc members are susceptible to this antimicrobial agent .
det||implementation-3/NN||the-2/DT	prep_in||suggested-14/VBD||implementation-3/NN	prep_of||implementation-3/NN||panel-5/NN	amod||networks-10/NNS||chinese-7/JJ	amod||networks-10/NNS||human-8/JJ	nn||networks-10/NNS||avianinfluenza-9/NN	prep_on||panel-5/NN||networks-10/NNS	det||results-13/NNS||the-12/DT	nsubj||suggested-14/VBD||results-13/NNS	root||ROOT-0/null||suggested-14/VBD	mark||were-17/VBD||that-15/IN	expl||were-17/VBD||there-16/EX	ccomp||suggested-14/VBD||were-17/VBD	det||number-21/NN||a-18/DT	advmod||low-20/JJ||relatively-19/RB	amod||number-21/NN||low-20/JJ	nsubj||were-17/VBD||number-21/NN	prep_of||number-21/NN||discrepancies-23/NNS	preconj||concise-26/JJ||both-25/DT	amod||works-33/NNS||concise-26/JJ	advmod||concise-26/JJ||reproducibility-28/RB	conj_and||concise-26/JJ||reproducibility-28/RB	amod||works-33/NNS||reproducibility-28/RB	conj_and||concise-26/JJ||in-29/IN	amod||works-33/NNS||in-29/IN	amod||avianinfluenzavirus-31/NNS||chinese-30/JJ	prep_in||concise-26/JJ||avianinfluenzavirus-31/NNS	amod||works-33/NNS||net-32/JJ	prep_for||discrepancies-23/NNS||works-33/NNS	avianinfluenza-9||avianinfluenzavirus-31||no||in the implementation of panel on chinese human avianinfluenza networks, the results suggested that there were a relatively low number of discrepancies for both concise and reproducibility in chinese avianinfluenzavirus net works.
num||protocols-2/NNS||six-1/CD	nsubj||included-3/VBD||protocols-2/NNS	root||ROOT-0/null||included-3/VBD	amod||guidelines-7/NNS||cervical-4/JJ	nn||guidelines-7/NNS||cancer-5/NN	nn||guidelines-7/NNS||screening-6/NN	dobj||included-3/VBD||guidelines-7/NNS	amod||suppositories-11/NNS||green-9/JJ	nn||suppositories-11/NNS||tea-10/NN	dobj||included-3/VBD||suppositories-11/NNS	conj_and||guidelines-7/NNS||suppositories-11/NNS	amod||folicacid-15/NN||oral-14/JJ	dobj||included-3/VBD||folicacid-15/NN	conj_and||guidelines-7/NNS||folicacid-15/NN	cancer-5||folicacid-15||no_rel||six protocols included cervical cancer screening guidelines, green tea suppositories, and oral folicacid.
poss||recommendations-2/NNS||their-1/PRP$	nsubj||included-3/VBD||recommendations-2/NNS	root||ROOT-0/null||included-3/VBD	dep||make-12/VB||1-5/LS	det||country-10/NN||every-7/DT	amod||country-10/NN||dengue-8/JJ	amod||country-10/NN||endemic-9/JJ	nsubj||make-12/VB||country-10/NN	aux||make-12/VB||should-11/MD	dep||included-3/VBD||make-12/VB	dobj||make-12/VB||reporting-13/NN	amod||cases-16/NNS||dengue-15/JJ	prep_of||reporting-13/NN||cases-16/NNS	det||government-19/NN||the-18/DT	prep_to||make-12/VB||government-19/NN	amod||government-19/NN||mandatory-20/JJ	dep||developed-30/VBN||2-23/LS	amod||systems-27/NNS||electronic-25/JJ	nn||systems-27/NNS||reporting-26/NN	nsubjpass||developed-30/VBN||systems-27/NNS	nsubjpass||used-32/VBN||systems-27/NNS	aux||developed-30/VBN||should-28/MD	auxpass||developed-30/VBN||be-29/VB	parataxis||make-12/VB||developed-30/VBN	parataxis||make-12/VB||used-32/VBN	conj_and||developed-30/VBN||used-32/VBN	nsubj||include-43/VB||3-35/NNP	amod||data-41/NNS||minimum-38/JJ	nn||data-41/NNS||dengue-39/NN	nn||data-41/NNS||surveillance-40/NN	prep_at||3-35/NNP||data-41/NNS	aux||include-43/VB||should-42/MD	conj_and||included-3/VBD||include-43/VB	dobj||include-43/VB||incidence-44/NN	nn||rates-47/NNS||hospitalization-46/NN	appos||incidence-44/NN||rates-47/NNS	appos||rates-47/NNS||deaths-49/NNS	nn||group-52/NN||age-51/NN	prep_by||include-43/VB||group-52/NN	dep||completed-61/VBN||4-55/LS	amod||studies-58/NNS||additional-57/JJ	nsubjpass||completed-61/VBN||studies-58/NNS	nsubj||check-63/VB||studies-58/NNS	aux||completed-61/VBN||should-59/MD	auxpass||completed-61/VBN||be-60/VB	conj_and||included-3/VBD||completed-61/VBN	aux||check-63/VB||to-62/TO	xcomp||completed-61/VBN||check-63/VB	det||sensitivity-65/NN||the-64/DT	dobj||check-63/VB||sensitivity-65/NN	det||system-68/NN||the-67/DT	prep_of||sensitivity-65/NN||system-68/NN	dep||share-75/VB||5-71/CD	nsubj||share-75/VB||laboratories-73/NNS	aux||share-75/VB||should-74/MD	conj_and||included-3/VBD||share-75/VB	dobj||share-75/VB||expertise-76/NN	dobj||share-75/VB||data-78/NNS	conj_and||expertise-76/NN||data-78/NNS	appos||tests-83/NNS||6-81/CD	dep||expertise-76/NN||tests-83/NNS	nsubj||identify-85/VBP||tests-83/NNS	rcmod||tests-83/NNS||identify-85/VBP	nsubjpass||used-89/VBN||denguevirus-86/NNS	aux||used-89/VBN||should-87/MD	auxpass||used-89/VBN||be-88/VB	ccomp||identify-85/VBP||used-89/VBN	prep_in||used-89/VBN||patients-91/NNS	prep_with||patients-91/NNS||fever-93/NN	num||days-96/NNS||four-95/CD	prep_for||fever-93/NN||days-96/NNS	cc||less-98/JJR||or-97/CC	num||days-96/NNS||less-98/JJR	nn||tests-101/NNS||antibody-100/NN	nsubjpass||used-104/VBN||tests-101/NNS	nsubj||diagnose-109/VB||tests-101/NNS	aux||used-104/VBN||should-102/MD	auxpass||used-104/VBN||be-103/VB	conj_and||included-3/VBD||used-104/VBN	prep_after||used-104/VBN||day-106/NN	num||day-106/NN||4-107/CD	aux||diagnose-109/VB||to-108/TO	xcomp||used-104/VBN||diagnose-109/VB	dobj||diagnose-109/VB||dengue-110/NN	appos||detection-117/NN||7-114/CD	amod||detection-117/NN||early-116/JJ	nsubj||goals-125/NNS||detection-117/NN	conj_and||detection-117/NN||prediction-119/NN	nsubj||goals-125/NNS||prediction-119/NN	amod||outbreaks-122/NNS||dengue-121/JJ	prep_of||prediction-119/NN||outbreaks-122/NNS	aux||goals-125/NNS||should-123/MD	cop||goals-125/NNS||be-124/VB	conj_and||included-3/VBD||goals-125/NNS	amod||systems-129/NNS||national-127/JJ	nn||systems-129/NNS||surveillance-128/NN	prep_for||goals-125/NNS||systems-129/NNS	dengue-121||denguevirus-86||no||their recommendations included (1) every dengue endemic country should make reporting of dengue cases to the government mandatory; (2) electronic reporting systems should be developed and used; (3) at minimum dengue surveillance data should include incidence, hospitalization rates, deaths by age group; (4) additional studies should be completed to check the sensitivity of the system; (5) laboratories should share expertise and data; (6) tests that identify denguevirus should be used in patients with fever for four days or less and antibody tests should be used after day 4 to diagnose dengue; and (7) early detection and prediction of dengue outbreaks should be goals for national surveillance systems.
amod||trials-3/NNS||recent-1/JJ	amod||trials-3/NNS||randomized-2/JJ	nsubj||indicate-4/VBP||trials-3/NNS	nsubjpass||considered-40/VBN||trials-3/NNS	root||ROOT-0/null||indicate-4/VBP	mark||has-20/VBZ||that-5/IN	det||strategy-8/NN||a-6/DT	amod||strategy-8/NN||rate-control-7/JJ	nsubj||has-20/VBZ||strategy-8/NN	prepc_along_with||has-20/VBZ||with-11/IN	nn||treatment-13/NN||anticoagulation-12/NN	pobj||has-20/VBZ||treatment-13/NN	prep_with||treatment-13/NN||warfarin-15/NN	advmod||appropriate-18/JJ||when-17/WRB	advcl||has-20/VBZ||appropriate-18/JJ	ccomp||indicate-4/VBP||has-20/VBZ	det||outcome-23/NN||a-21/DT	amod||outcome-23/NN||similar-22/JJ	dobj||has-20/VBZ||outcome-23/NN	prep_in||outcome-23/NN||terms-25/NNS	prep_of||terms-25/NNS||mortality-27/NN	prep_of||terms-25/NNS||morbidity-29/NN	conj_and||mortality-27/NN||morbidity-29/NN	nn||control-32/NN||rhythm-31/NN	prep_as||has-20/VBZ||control-32/NN	aux||considered-40/VBN||could-35/MD	advmod||considered-40/VBN||therefore-37/RB	auxpass||considered-40/VBN||be-39/VB	conj_and||indicate-4/VBP||considered-40/VBN	det||strategy-45/NN||the-42/DT	amod||strategy-45/NN||primary-43/JJ	nn||strategy-45/NN||management-44/NN	prep_as||considered-40/VBN||strategy-45/NN	prep_for||strategy-45/NN||atrialfibrillation-47/NN	prep_in||considered-40/VBN||patients-49/NNS	nn||failure-52/NN||heart-51/NN	prep_with||patients-49/NNS||failure-52/NN	atrialfibrillation-47||warfarin-15||yes||recent randomized trials indicate that a rate-control strategy, along with anticoagulation treatment with warfarin, when appropriate, has a similar outcome in terms of mortality and morbidity as rhythm control, and could, therefore, be considered as the primary management strategy for atrialfibrillation in patients with heart failure.
det||effects-3/NNS||the-1/DT	amod||effects-3/NNS||inhibitory-2/JJ	nsubj||similar-9/JJ||effects-3/NNS	det||antibodies-7/NNS||these-5/DT	num||antibodies-7/NNS||five-6/CD	prep_of||effects-3/NNS||antibodies-7/NNS	cop||similar-9/JJ||were-8/VBD	root||ROOT-0/null||similar-9/JJ	det||specific-19/NN||those-11/DT	amod||specific-19/NN||observed-12/JJ	det||antibody-18/NN||a-14/DT	advmod||described-16/JJ||previously-15/RB	amod||antibody-18/NN||described-16/JJ	nn||antibody-18/NN||neutralizing-17/NN	prep_with||observed-12/JJ||antibody-18/NN	prep_to||similar-9/JJ||specific-19/NN	det||loop-24/NN||the-21/DT	amod||loop-24/NN||140s-22/JJ	amod||loop-24/NN||antigenic-23/JJ	prep_for||specific-19/NN||loop-24/NN	ccomp||similar-9/JJ||present-25/VB	prep_within||present-25/VB||ha1-27/CD	ccomp||similar-9/JJ||highlight-29/VB	conj_and||present-25/VB||highlight-29/VB	det||possibility-32/NN||the-30/DT	amod||possibility-32/NN||exciting-31/JJ	dobj||highlight-29/VB||possibility-32/NN	mark||efficacious-38/NNS||that-33/IN	det||antibodies-35/NNS||these-34/DT	nsubj||efficacious-38/NNS||antibodies-35/NNS	aux||efficacious-38/NNS||may-36/MD	cop||efficacious-38/NNS||be-37/VB	ccomp||similar-9/JJ||efficacious-38/NNS	amod||strains-42/NNS||multiple-40/JJ	amod||strains-42/NNS||h5n1-41/JJ	prep_against||efficacious-38/NNS||strains-42/NNS	h5n1-41||antibody-18||no_rel||the inhibitory effects of these five antibodies were similar to those observed with a previously described neutralizing antibody specific for the 140s antigenic loop present within ha1 and highlight the exciting possibility that these antibodies may be efficacious against multiple h5n1 strains.
prep||excluded-20/VBN||given-1/VBN	det||insulin-4/NN||the-2/DT	amod||insulin-4/NN||low-3/JJ	pobj||given-1/VBN||insulin-4/NN	nn||levels-7/NNS||glucose-6/NN	pobj||given-1/VBN||levels-7/NNS	conj_and||insulin-4/NN||levels-7/NNS	amod||fasting-10/NN||prolonged-9/JJ	prep_after||insulin-4/NN||fasting-10/NN	nn||action-15/NN||hyperglycemia-12/NN	conj_and||hyperglycemia-12/NN||insulin-14/NN	nn||action-15/NN||insulin-14/NN	nsubjpass||excluded-20/VBN||action-15/NN	nsubj||intramuscular-31/VBP||action-15/NN	nn||se-17/FW||per-16/FW	advmod||excluded-20/VBN||se-17/FW	aux||excluded-20/VBN||can-18/MD	auxpass||excluded-20/VBN||be-19/VB	root||ROOT-0/null||excluded-20/VBN	amod||mechanisms-23/NNS||underlying-22/VBG	prep_as||excluded-20/VBN||mechanisms-23/NNS	vmod||mechanisms-23/NNS||pointing-25/VBG	amod||ffa-29/NN||elevated-27/JJ	nn||ffa-29/NN||plasma-28/NN	prep_toward||pointing-25/VBG||ffa-29/NN	conj_and/or||excluded-20/VBN||intramuscular-31/VBP	amod||accumulation-33/NN||fat-32/JJ	dobj||intramuscular-31/VBP||accumulation-33/NN	amod||causes-36/NNS||possible-35/JJ	prep_as||intramuscular-31/VBP||causes-36/NNS	det||reduction-40/NN||the-38/DT	amod||reduction-40/NN||observed-39/JJ	prep_for||causes-36/NNS||reduction-40/NN	amod||capacity-43/NN||mitochondrial-42/JJ	prep_in||reduction-40/NN||capacity-43/NN	hyperglycemia-12||insulin-14||yes||given the low insulin and glucose levels after prolonged fasting, hyperglycemia and insulin action per se can be excluded as underlying mechanisms, pointing toward elevated plasma ffa and/or intramuscular fat accumulation as possible causes for the observed reduction in mitochondrial capacity.
amod||models-3/NNS||logistic-1/JJ	nn||models-3/NNS||regression-2/NN	nsubjpass||fitted-5/VBN||models-3/NNS	nsubj||assess-7/VB||models-3/NNS	auxpass||fitted-5/VBN||were-4/VBD	root||ROOT-0/null||fitted-5/VBN	aux||assess-7/VB||to-6/TO	xcomp||fitted-5/VBN||assess-7/VB	det||association-9/NN||the-8/DT	dobj||assess-7/VB||association-9/NN	amod||geometric-12/JJ||stavudine-11/JJ	amod||ratio-14/NN||geometric-12/JJ	amod||ratio-14/NN||mean-13/JJ	prep_between||association-9/NN||ratio-14/NN	number||1-16/CD||>-15/CD	num||ratio-14/NN||1-16/CD	amod||glucose-20/NN||impaired-18/VBN	amod||glucose-20/NN||fasting-19/JJ	dobj||assess-7/VB||glucose-20/NN	conj_and||association-9/NN||glucose-20/NN	appos||glucose-20/NN||impairedglucosetolerance-22/NN	appos||glucose-20/NN||hyperlactataemia-24/NN	conj_and||impairedglucosetolerance-22/NN||hyperlactataemia-24/NN	appos||glucose-20/NN||hypertriglyceridaemia-26/NN	conj_and||impairedglucosetolerance-22/NN||hypertriglyceridaemia-26/NN	appos||glucose-20/NN||lipoatrophy-29/NN	conj_and||impairedglucosetolerance-22/NN||lipoatrophy-29/NN	stavudine-11||impairedglucosetolerance-22||no_rel||logistic regression models were fitted to assess the association between stavudine geometric mean ratio > 1 and impaired fasting glucose, impairedglucosetolerance, hyperlactataemia, hypertriglyceridaemia, and lipoatrophy.
expl||was-2/VBD||there-1/EX	root||ROOT-0/null||was-2/VBD	det||incidence-6/NN||a-3/DT	advmod||lower-5/JJR||significantly-4/RB	amod||incidence-6/NN||lower-5/JJR	nsubj||was-2/VBD||incidence-6/NN	prep_of||incidence-6/NN||microemulsion-8/NN	amod||pain-11/NN||propofol-9/JJ	nn||pain-11/NN||injection-10/NN	npadvmod||than-26/IN||pain-11/NN	dep||pain-11/NN||severity-13/$	num||severity-13/$||2-14/CD	dep||pain-11/NN||more-16/JJR	conj_or||severity-13/$||more-16/JJR	det||group-21/NN||the-19/DT	nn||group-21/NN||combination-20/NN	prep_in||severity-13/$||group-21/NN	num||%-24/NN||12.5-23/CD	appos||pain-11/NN||%-24/NN	advmod||was-2/VBD||than-26/IN	det||groups-32/NNS||the-28/DT	amod||groups-32/NNS||remifentanil-29/JJ	conj_and||remifentanil-29/JJ||lidocaine-31/JJ	amod||groups-32/NNS||lidocaine-31/JJ	prep_in||than-26/IN||groups-32/NNS	num||%-35/NN||90-34/CD	nsubj||p-42/VBP||%-35/NN	num||%-38/NN||65-37/CD	conj_and||%-35/NN||%-38/NN	nsubj||p-42/VBP||%-38/NN	advmod||%-38/NN||respectively-40/RB	dep||groups-32/NNS||p-42/VBP	num||0.05-44/CD||<-43/CD	dobj||p-42/VBP||0.05-44/CD	pain-11||propofol-9||yes||there was a significantly lower incidence of microemulsion propofol injection pain (severity 2 or more) in the combination group (12.5%) than in the remifentanil and lidocaine groups (90% and 65%, respectively, p < 0.05).
amod||options-2/NNS||several-1/JJ	nsubjpass||licensed-10/VBN||options-2/NNS	det||treatment-5/NN||the-4/DT	prep_for||options-2/NNS||treatment-5/NN	prep_of||treatment-5/NN||hepatitisb-7/NN	aux||licensed-10/VBN||have-8/VBP	auxpass||licensed-10/VBN||been-9/VBN	root||ROOT-0/null||licensed-10/VBN	det||interferon-15/NN||the-12/DT	amod||interferon-15/NN||last-13/JJ	nn||interferon-15/NN||years-14/NNS	prep_in||licensed-10/VBN||interferon-15/NN	amod||interferon-18/NN||pegylated-17/JJ	prep_in||licensed-10/VBN||interferon-18/NN	conj_and||interferon-15/NN||interferon-18/NN	prep_in||licensed-10/VBN||lamivudine-20/NN	conj_and||interferon-15/NN||lamivudine-20/NN	prep_in||licensed-10/VBN||adefovir-22/NN	conj_and||interferon-15/NN||adefovir-22/NN	prep_in||licensed-10/VBN||entecavir-24/NN	conj_and||interferon-15/NN||entecavir-24/NN	prep_in||licensed-10/VBN||telbivudine-27/NN	conj_and||interferon-15/NN||telbivudine-27/NN	hepatitisb-7||telbivudine-27||yes||several options for the treatment of hepatitisb have been licensed in the last years interferon, pegylated interferon, lamivudine, adefovir, entecavir, and telbivudine.
det||decrease-2/NN||a-1/DT	nsubjpass||associated-17/VBN||decrease-2/NN	amod||anaerobes-6/NNS||total-4/JJ	nn||anaerobes-6/NNS||obligate-5/NN	prep_in||decrease-2/NN||anaerobes-6/NNS	det||increase-9/NN||an-8/DT	conj_and||decrease-2/NN||increase-9/NN	nsubjpass||associated-17/VBN||increase-9/NN	amod||bacteria-12/NNS||pathogenic-11/JJ	prep_in||increase-9/NN||bacteria-12/NNS	det||gut-15/NN||the-14/DT	prep_in||bacteria-12/NNS||gut-15/NN	auxpass||associated-17/VBN||are-16/VBP	root||ROOT-0/null||associated-17/VBN	amod||complications-20/NNS||septic-19/JJ	prep_with||associated-17/VBN||complications-20/NNS	prep_with||associated-17/VBN||mortality-22/NN	conj_and||complications-20/NNS||mortality-22/NN	prep_in||associated-17/VBN||patients-24/NNS	prep_with||patients-24/NNS||sirs-26/NNS	sirs-26||bacteria-12||no||a decrease in total obligate anaerobes and an increase in pathogenic bacteria in the gut are associated with septic complications and mortality in patients with sirs.
num||forms-2/NNS||two-1/CD	nsubj||c/d-8/VBP||forms-2/NNS	prep_of||forms-2/NNS||hepatitisbvirus-4/NNS	appos||hepatitisbvirus-4/NNS||hbv-6/NN	root||ROOT-0/null||c/d-8/VBP	nsubjpass||identified-12/VBN||recombinant-9/JJ	aux||identified-12/VBN||have-10/VBP	auxpass||identified-12/VBN||been-11/VBN	ccomp||c/d-8/VBP||identified-12/VBN	amod||china-15/NN||western-14/JJ	prep_in||identified-12/VBN||china-15/NN	nsubjpass||known-20/VBN||little-18/RB	auxpass||known-20/VBN||is-19/VBZ	conj_but||c/d-8/VBP||known-20/VBN	poss||geographical-23/NN||their-22/PRP$	prep_about||known-20/VBN||geographical-23/NN	amod||distributions-26/NNS||ethnic-25/JJ	prep_about||known-20/VBN||distributions-26/NNS	conj_and||geographical-23/NN||distributions-26/NNS	prep_about||known-20/VBN||particularly-29/RB	advmod||geographical-23/NN||particularly-29/RB	conj_and||geographical-23/NN||particularly-29/RB	det||significance-32/NN||the-30/DT	amod||significance-32/NN||clinical-31/JJ	dep||geographical-23/NN||significance-32/NN	amod||mutations-35/NNS||specific-34/JJ	dep||geographical-23/NN||mutations-35/NNS	conj_and||significance-32/NN||mutations-35/NNS	det||region-39/NN||the-37/DT	amod||region-39/NN||pre-core-38/JJ	prep_in||known-20/VBN||region-39/NN	hbv-6||hepatitisbvirus-4||no||two forms of hepatitisbvirus (hbv) c/d recombinant have been identified in western china, but little is known about their geographical and ethnic distributions, and particularly the clinical significance and specific mutations in the pre-core region.
amod||cells-2/NNS||epithelial-1/JJ	nsubjpass||grown-29/VBN||cells-2/NNS	nsubjpass||treated-36/VBN||cells-2/NNS	amod||brushings-5/NNS||bronchial-4/JJ	prep_from||cells-2/NNS||brushings-5/NNS	prep_of||brushings-5/NNS||normal-7/JJ	dep||normal-7/JJ||n-9/VBN	dep||8-11/CD||=-10/SYM	ccomp||n-9/VBN||8-11/CD	prep_of||brushings-5/NNS||asthma-14/NN	conj_and||normal-7/JJ||asthma-14/NN	dep||asthma-14/NN||n-16/VBN	dep||8-18/CD||=-17/SYM	ccomp||n-16/VBN||8-18/CD	amod||subjects-27/NNS||copd-21/JJ	dep||copd-21/JJ||n-23/VBN	dep||8-25/CD||=-24/SYM	ccomp||n-23/VBN||8-25/CD	prep_of||brushings-5/NNS||subjects-27/NNS	conj_and||normal-7/JJ||subjects-27/NNS	auxpass||grown-29/VBN||were-28/VBD	root||ROOT-0/null||grown-29/VBN	amod||cultures-33/NNS||air-liquid-31/JJ	nn||cultures-33/NNS||interface-32/NN	prep_in||grown-29/VBN||cultures-33/NNS	conj_and||grown-29/VBN||treated-36/VBN	nn||smoke-39/NN||cigarette-38/NN	prep_with||treated-36/VBN||smoke-39/NN	ccomp||treated-36/VBN||extract-40/VB	appos||th2-45/NN||cse-42/NN	amod||th2-45/NN||and/or-44/JJ	dobj||extract-40/VB||th2-45/NN	amod||il-13-47/JJ||cytokine-46/JJ	amod||th2-45/NN||il-13-47/JJ	conj_and||grown-29/VBN||followed-49/VBN	conj_and||treated-36/VBN||followed-49/VBN	nn||infection-52/NN||mp-51/NN	prep_by||followed-49/VBN||infection-52/NN	prep_by||followed-49/VBN||treatment-54/NN	conj_and||infection-52/NN||treatment-54/NN	nn||albuterol-59/NN||î-56/NN	nn||albuterol-59/NN||²-57/NNP	amod||albuterol-59/NN||2-agonists-58/JJ	prep_with||followed-49/VBN||albuterol-59/NN	conj_and||grown-29/VBN||formoterol-61/JJ	conj_and||treated-36/VBN||formoterol-61/JJ	quantmod||seven-65/CD||up-63/IN	dep||seven-65/CD||to-64/TO	num||days-66/NNS||seven-65/CD	prep_for||formoterol-61/JJ||days-66/NNS	asthma-14||albuterol-59||yes||epithelial cells from bronchial brushings of normal (n = 8), asthma (n = 8) and copd (n = 8) subjects were grown in air-liquid interface cultures, and treated with cigarette smoke extract (cse) and/or th2 cytokine il-13, followed by mp infection and treatment with î²2-agonists albuterol and formoterol for up to seven days.
det||frequency-3/NN||the-1/DT	nn||frequency-3/NN||hypoglycemia-2/NN	nsubjpass||associated-6/VBN||frequency-3/NN	auxpass||associated-6/VBN||was-4/VBD	neg||associated-6/VBN||not-5/RB	root||ROOT-0/null||associated-6/VBN	prep_with||associated-6/VBN||age-8/NN	nn||modality-12/NN||insulin-11/NN	prep_with||associated-6/VBN||modality-12/NN	conj_or||age-8/NN||modality-12/NN	dep||modality-12/NN||pump-14/NN	amod||injections-18/NNS||multiple-16/JJ	amod||injections-18/NNS||daily-17/JJ	dep||modality-12/NN||injections-18/NNS	conj_versus||pump-14/NN||injections-18/NNS	insulin-11||hypoglycemia-2||no_rel||the hypoglycemia frequency was not associated with age or with insulin modality (pump versus multiple daily injections).
nsubj||used-2/VBD||we-1/PRP	root||ROOT-0/null||used-2/VBD	amod||francisco-4/NN||san-3/JJ	poss||system-8/NN||francisco-4/NN	amod||system-8/NN||hiv/aids-6/JJ	nn||system-8/NN||surveillance-7/NN	dobj||used-2/VBD||system-8/NN	aux||examine-10/VB||to-9/TO	vmod||used-2/VBD||examine-10/VB	det||trends-12/NNS||the-11/DT	dobj||examine-10/VB||trends-12/NNS	prep_in||examine-10/VB||cvl-14/NN	aids--1||hiv--1||no||we used san francisco's hiv/aids surveillance system to examine the trends in cvl.
amod||animals-5/NNS||stz-treated-4/JJ	prep_with_respect_to||characterized-14/VBN||animals-5/NNS	nsubjpass||characterized-14/VBN||mice-7/NNS	vmod||mice-7/NNS||co-injected-8/VBN	nn||trail-12/NN||stz-10/NN	nn||trail-12/NN||+-11/NN	prep_with||co-injected-8/VBN||trail-12/NN	auxpass||characterized-14/VBN||were-13/VBD	root||ROOT-0/null||characterized-14/VBN	dep||levels-19/NNS||1-16/LS	amod||levels-19/NNS||lower-18/JJR	agent||characterized-14/VBN||levels-19/NNS	prep_of||levels-19/NNS||hyperglycemia-21/NN	dep||levels-26/NNS||2-23/LS	amod||levels-26/NNS||higher-25/JJR	agent||characterized-14/VBN||levels-26/NNS	conj_and||levels-19/NNS||levels-26/NNS	nn||weight-29/NN||body-28/NN	prep_of||levels-26/NNS||weight-29/NN	prep_of||levels-26/NNS||insulinemia-31/NN	conj_and||weight-29/NN||insulinemia-31/NN	dep||preservation-37/NN||3-33/LS	det||preservation-37/NN||a-35/DT	amod||preservation-37/NN||partial-36/JJ	agent||characterized-14/VBN||preservation-37/NN	conj_and||levels-19/NNS||preservation-37/NN	amod||islets-40/NNS||pancreatic-39/JJ	prep_of||preservation-37/NN||islets-40/NNS	amod||morphology-43/NN||normal-42/JJ	prep_with||islets-40/NNS||morphology-43/NN	dep||expression-50/NN||4-46/LS	det||expression-50/NN||a-48/DT	amod||expression-50/NN||lower-49/JJR	agent||characterized-14/VBN||expression-50/NN	conj_and||levels-19/NNS||expression-50/NN	det||systemic-53/NN||both-52/DT	prep_of||expression-50/NN||systemic-53/NN	amod||±-56/NNS||tnf-î-55/JJ	appos||systemic-53/NN||±-56/NNS	appos||systemic-53/NN||opg-58/NN	conj_and||±-56/NNS||opg-58/NN	amod||markers-73/NNS||pancreatic-61/JJ	nn||molecule-66/NN||vascular-63/NN	nn||molecule-66/NN||cell-64/NN	nn||molecule-66/NN||adhesion-65/NN	dep||pancreatic-61/JJ||molecule-66/NN	nn||-1-70/NNP||-LSB--67/NNP	nn||-1-70/NNP||vcam-68/NNP	nn||-1-70/NNP||-RSB--69/NNP	dep||molecule-66/NN||-1-70/NNP	amod||markers-73/NNS||inflammatory-72/JJ	prep_of||expression-50/NN||markers-73/NNS	conj_and||systemic-53/NN||markers-73/NNS	stz-10||hyperglycemia-21||no_rel||with respect to stz-treated animals, mice co-injected with stz+trail were characterized by 1 ) lower levels of hyperglycemia, 2 ) higher levels of body weight and insulinemia, 3 ) a partial preservation of pancreatic islets with normal morphology, and 4 ) a lower expression of both systemic (tnf-î± and opg) and pancreatic (vascular cell adhesion molecule [vcam]-1) inflammatory markers.
aux||evaluate-2/VB||to-1/TO	root||ROOT-0/null||evaluate-2/VB	det||cost-effectiveness-4/NNS||the-3/DT	dobj||evaluate-2/VB||cost-effectiveness-4/NNS	prep_of||cost-effectiveness-4/NNS||aripiprazole-6/NN	prep_of||cost-effectiveness-4/NNS||olanzapine-8/NN	conj_and||aripiprazole-6/NN||olanzapine-8/NN	prep_in||evaluate-2/VB||patients-10/NNS	prep_with||patients-10/NNS||schizophrenia-12/NN	schizophrenia-12||aripiprazole-6||yes||to evaluate the cost-effectiveness of aripiprazole and olanzapine in patients with schizophrenia.
prep_in||similar-24/JJ||patients-2/NNS	advmod||resectable-5/JJ||initially-4/RB	amod||tumors-6/NNS||resectable-5/JJ	prep_with||patients-2/NNS||tumors-6/NNS	det||$-13/NN||â-8/DT	amod||$-13/NN||$-9/$	dep||$-9/$||resectable-10/JJ	dep||$-9/$||tumor-11/NN	amod||$-13/NN||patientsâ-12/JJ	appos||tumors-6/NNS||$-13/NN	nn||frequencies-17/NNS||resection-16/NN	nsubj||similar-24/JJ||frequencies-17/NNS	conj_and||frequencies-17/NNS||survival-19/NN	nsubj||similar-24/JJ||survival-19/NN	amod||therapy-22/NN||neoadjuvant-21/JJ	prep_after||frequencies-17/NNS||therapy-22/NN	cop||similar-24/JJ||are-23/VBP	root||ROOT-0/null||similar-24/JJ	prep_to||similar-24/JJ||those-26/DT	prep_of||those-26/DT||patients-28/NNS	advmod||tumors-32/NNS||primarily-30/RB	amod||tumors-32/NNS||resected-31/VBN	prep_with||patients-28/NNS||tumors-32/NNS	amod||therapy-35/NN||adjuvant-34/JJ	prep_with||patients-28/NNS||therapy-35/NN	conj_and||tumors-32/NNS||therapy-35/NN	tumors-32||adjuvant-34||no_rel||in patients with initially resectable tumors (âresectable tumor patientsâ?), resection frequencies and survival after neoadjuvant therapy are similar to those of patients with primarily resected tumors and adjuvant therapy.
advmod||demonstrate-3/VBP||here-1/RB	nsubj||demonstrate-3/VBP||we-2/PRP	root||ROOT-0/null||demonstrate-3/VBP	mark||infected-7/VBD||that-4/IN	amod||influenzavirus-6/NNS||h5n1-5/JJ	nsubj||infected-7/VBD||influenzavirus-6/NNS	ccomp||demonstrate-3/VBP||infected-7/VBD	nsubj||increased-10/VBN||mice-8/NNS	aux||increased-10/VBN||had-9/VBD	ccomp||infected-7/VBD||increased-10/VBN	dobj||increased-10/VBN||levels-11/NNS	amod||byproducts-17/NNS||c5a-13/JJ	conj_and||c5a-13/JJ||c3-15/JJ	amod||byproducts-17/NNS||c3-15/JJ	nn||byproducts-17/NNS||activation-16/NN	prep_of||levels-11/NNS||byproducts-17/NNS	prep||increased-10/VBN||as-18/IN	prepc_compared_to||increased-10/VBN||to-20/TO	pobj||increased-10/VBN||mice-21/NNS	vmod||mice-21/NNS||infected-22/VBN	preconj||seasonal-25/JJ||either-24/DT	prep_with||infected-22/VBN||seasonal-25/JJ	amod||influenzaviruses-30/NNS||pandemic-27/JJ	num||influenzaviruses-30/NNS||2009-28/CD	amod||influenzaviruses-30/NNS||h1n1-29/JJ	prep_with||infected-22/VBN||influenzaviruses-30/NNS	conj_or||seasonal-25/JJ||influenzaviruses-30/NNS	h5n1-5||influenzaviruses-30||no||here we demonstrate that h5n1 influenzavirus infected mice had increased levels of c5a and c3 activation byproducts as compared to mice infected with either seasonal or pandemic 2009 h1n1 influenzaviruses.
nsubj||aimed-2/VBD||we-1/PRP	nsubj||determine-4/VB||we-1/PRP	root||ROOT-0/null||aimed-2/VBD	aux||determine-4/VB||to-3/TO	xcomp||aimed-2/VBD||determine-4/VB	det||accuracy-6/NN||the-5/DT	dobj||determine-4/VB||accuracy-6/NN	poss||microarray-9/NN||our-8/PRP$	prep_of||accuracy-6/NN||microarray-9/NN	amod||dna-13/NN||anal-11/JJ	nn||dna-13/NN||cancer-12/NN	prep_in||microarray-9/NN||dna-13/NN	nn||genotypes-16/NNS||hpv-15/NN	prep_for||dna-13/NN||genotypes-16/NNS	prepc_compared_to||determine-4/VB||to-18/TO	det||dna-20/NN||the-19/DT	pobj||determine-4/VB||dna-20/NN	vmod||dna-20/NN||sequencing-21/VBG	amod||standard-23/NN||gold-22/JJ	dobj||sequencing-21/VBG||standard-23/NN	cancer-12||gold-22||no_rel||we aimed to determine the accuracy of our microarray in anal cancer dna for hpv genotypes compared to the dna sequencing gold standard.
num||assays-4/NNS||two-1/CD	amod||assays-4/NNS||real-time-2/JJ	nn||assays-4/NNS||pcr-3/NN	nsubjpass||carried-13/VBN||assays-4/NNS	nsubj||investigate-16/VB||assays-4/NNS	vmod||assays-4/NNS||followed-5/VBN	amod||pcr-8/NN||nested-7/JJ	agent||followed-5/VBN||pcr-8/NN	nn||analysis-11/NN||sequence-10/NN	agent||followed-5/VBN||analysis-11/NN	conj_and||pcr-8/NN||analysis-11/NN	auxpass||carried-13/VBN||were-12/VBD	root||ROOT-0/null||carried-13/VBN	prt||carried-13/VBN||out-14/RP	aux||investigate-16/VB||to-15/TO	xcomp||carried-13/VBN||investigate-16/VB	det||prevalence-18/NN||the-17/DT	dobj||investigate-16/VB||prevalence-18/NN	nn||phagocytophilum-21/NN||a.-20/NN	prep_of||prevalence-18/NN||phagocytophilum-21/NN	nn||rickettsiae-24/NN||spottedfever-23/NN	prep_of||prevalence-18/NN||rickettsiae-24/NN	conj_and||phagocytophilum-21/NN||rickettsiae-24/NN	prep_in||phagocytophilum-21/NN||ticks-26/NNS	num||areas-29/NNS||seven-28/CD	prep_from||investigate-16/VB||areas-29/NNS	prep_in||areas-29/NNS||sweden-31/NN	spottedfever-23||rickettsiae-24||no||two real-time pcr assays followed by nested pcr and sequence analysis were carried out to investigate the prevalence of a. phagocytophilum and spottedfever rickettsiae in ticks from seven areas in sweden .
prep_in||detected-21/VBN||june-2/NNP	num||june-2/NNP||2005-3/CD	det||outbreak-6/NN||an-5/DT	nsubjpass||detected-21/VBN||outbreak-6/NN	nn||-rrb--19/NN||denguevirus-8/NNS	nn||-rrb--19/NN||-lrb--9/NNP	nn||-rrb--19/NN||denv-10/NNP	nn||-rrb--19/NN||-rrb--11/NNP	amod||-rrb--19/NN||serotype-2-12/JJ	prep_with||serotype-2-12/JJ||cases-14/NNS	nn||-lrb--17/NNS||denguehemorrhagicfever-16/NN	prep_of||cases-14/NNS||-lrb--17/NNS	nn||-rrb--19/NN||dhf-18/NN	prep_of||outbreak-6/NN||-rrb--19/NN	auxpass||detected-21/VBN||was-20/VBD	root||ROOT-0/null||detected-21/VBN	nn||croix-24/NN||st.-23/NN	prep_in||detected-21/VBN||croix-24/NN	dep||islands-28/NNS||us-26/PRP	amod||islands-28/NNS||virgin-27/JJ	parataxis||detected-21/VBN||islands-28/NNS	denguehemorrhagicfever-16||denguevirus-8||no||in june 2005 , an outbreak of denguevirus -lrb- denv -rrb- serotype-2 with cases of denguehemorrhagicfever -lrb- dhf -rrb- was detected in st. croix , us virgin islands .
det||use-3/NN||the-1/DT	amod||use-3/NN||combined-2/VBN	nsubjpass||associated-23/VBN||use-3/NN	prep_of||use-3/NN||propofol-5/NN	prep_of||use-3/NN||remifentanil-7/NN	conj_and||propofol-5/NN||remifentanil-7/NN	det||infusion-11/NN||a-9/DT	amod||infusion-11/NN||continuous-10/JJ	prep_as||use-3/NN||infusion-11/NN	prep_as||use-3/NN||infusion-11/NN	conj_and||infusion-11/NN||infusion-11/NN	prep_before||infusion-11/NN||performance-13/NN	det||block-16/NN||the-15/DT	prep_of||performance-13/NN||block-16/NN	amod||surgery-21/NN||lengthy-19/JJ	amod||surgery-21/NN||vitreo-retinal-20/JJ	prep_during||infusion-11/NN||surgery-21/NN	auxpass||associated-23/VBN||was-22/VBD	root||ROOT-0/null||associated-23/VBN	det||incidence-27/NN||a-25/DT	amod||incidence-27/NN||lower-26/JJR	prep_with||associated-23/VBN||incidence-27/NN	amod||discomfort-30/NN||patient-29/JJ	prep_of||incidence-27/NN||discomfort-30/NN	nn||pain-33/NN||breakthrough-32/NN	prep_of||incidence-27/NN||pain-33/NN	conj_and||discomfort-30/NN||pain-33/NN	amod||movement-37/NN||patient-36/JJ	prep_of||incidence-27/NN||movement-37/NN	conj_and||discomfort-30/NN||movement-37/NN	amod||degree-41/NN||high-40/JJ	prep_along_with||incidence-27/NN||degree-41/NN	prepc_of||degree-41/NN||surgeonsâ-43/VBG	nn||stability-49/NN||$-44/$	number||satisfaction-46/CD||-45/CD	num||$-44/$||satisfaction-46/CD	conj_and||$-44/$||hemodynamic-48/JJ	nn||stability-49/NN||hemodynamic-48/JJ	dobj||surgeonsâ-43/VBG||stability-49/NN	pain-33||propofol-5||yes||the combined use of propofol and remifentanil as a continuous infusion before performance of the block and during lengthy vitreo-retinal surgery was associated with a lower incidence of patient discomfort, breakthrough pain, and patient movement along with high degree of surgeonsâ satisfaction and hemodynamic stability.
vmod||predicted-43/VBD||using-1/VBG	det||horizon-4/NN||a-2/DT	nn||horizon-4/NN||prediction-3/NN	dobj||using-1/VBG||horizon-4/NN	num||min-7/NN||35-6/CD	prep_of||horizon-4/NN||min-7/NN	det||threshold-11/NN||a-9/DT	nn||threshold-11/NN||glucose-10/NN	dobj||using-1/VBG||threshold-11/NN	conj_and||horizon-4/NN||threshold-11/NN	num||mg/dl-14/NN||80-13/CD	prep_of||threshold-11/NN||mg/dl-14/NN	det||threshold-19/NN||a-17/DT	amod||threshold-19/NN||voting-18/VBG	dobj||using-1/VBG||threshold-19/NN	conj_and||horizon-4/NN||threshold-19/NN	prep_of||threshold-19/NN||three-21/CD	num||algorithms-24/NNS||five-23/CD	prep_of||three-21/CD||algorithms-24/NNS	aux||predict-26/VB||to-25/TO	vmod||three-21/CD||predict-26/VB	dobj||predict-26/VB||hypoglycemia-27/NN	dep||threshold-19/NN||defined-29/VBN	det||readings-35/NNS||a-31/DT	amod||readings-35/NNS||freestyle-32/JJ	nn||readings-35/NNS||plasma-33/NN	nn||readings-35/NNS||glucose-34/NN	prep_as||defined-29/VBN||readings-35/NNS	vmod||readings-35/NNS||<-36/VBG	num||mg/dl-38/NN||60-37/CD	dobj||<-36/VBG||mg/dl-38/NN	det||hpa-42/NN||the-41/DT	nsubj||predicted-43/VBD||hpa-42/NN	root||ROOT-0/null||predicted-43/VBD	num||%-45/NN||91-44/CD	dobj||predicted-43/VBD||%-45/NN	det||events-49/NNS||the-47/DT	amod||events-49/NNS||hypoglycemic-48/JJ	prep_of||%-45/NN||events-49/NNS	hypoglycemia-27||glucose-34||yes||using a prediction horizon of 35 min, a glucose threshold of 80 mg/dl, and a voting threshold of three of five algorithms to predict hypoglycemia (defined as a freestyle plasma glucose readings <60 mg/dl), the hpa predicted 91% of the hypoglycemic events.
poss||results-2/NNS||our-1/PRP$	nsubj||indicate-3/VBP||results-2/NNS	root||ROOT-0/null||indicate-3/VBP	mark||share-8/VB||that-4/IN	nsubj||share-8/VB||lrua-5/NN	conj_and||lrua-5/NN||lrub-7/NN	nsubj||share-8/VB||lrub-7/NN	ccomp||indicate-3/VBP||share-8/VB	amod||epitopes-10/NNS||immuno-relevant-9/JJ	dobj||share-8/VB||epitopes-10/NNS	nn||proteins-13/NNS||eye-12/NN	prep_with||share-8/VB||proteins-13/NNS	vmod||share-8/VB||suggesting-15/VBG	mark||contribute-24/VB||that-16/IN	amod||interactions-19/NNS||cross-reactive-17/JJ	nn||interactions-19/NNS||antibody-18/NN	nsubj||contribute-24/VB||interactions-19/NNS	nn||antigens-22/NNS||eye-21/NN	prep_with||interactions-19/NNS||antigens-22/NNS	aux||contribute-24/VB||may-23/MD	ccomp||suggesting-15/VBG||contribute-24/VB	prep_to||contribute-24/VB||immunopathogenesis-26/NNS	prep_of||immunopathogenesis-26/NNS||leptospira-28/NN	dep||share-8/VB||associated-30/JJ	amod||uveitis-32/NNS||recurrent-31/JJ	dobj||associated-30/JJ||uveitis-32/NNS	cross--1||antibody-18||no_rel||our results indicate that lrua and lrub share immuno-relevant epitopes with eye proteins, suggesting that cross-reactive antibody interactions with eye antigens may contribute to immunopathogenesis of leptospira -associated recurrent uveitis.
det||aim-2/NN||the-1/DT	nsubj||was-6/VBD||aim-2/NN	nsubj||evaluate-8/VB||aim-2/NN	det||study-5/NN||this-4/DT	prep_of||aim-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||evaluate-8/VB||to-7/TO	xcomp||was-6/VBD||evaluate-8/VB	det||response-10/NN||the-9/DT	dobj||evaluate-8/VB||response-10/NN	prep_to||evaluate-8/VB||initiation-12/NN	amod||detemir-16/NN||once-daily-14/JJ	nn||detemir-16/NN||insulin-15/NN	prep_of||initiation-12/NN||detemir-16/NN	prep_in||evaluate-8/VB||patients-18/NNS	vmod||patients-18/NNS||aged-19/VBN	nn||-21/NNS||â-20/NN	dobj||aged-19/VBN||-21/NNS	xcomp||aged-19/VBN||¥-22/VBG	amod||years-24/NNS||75â-23/JJ	tmod||¥-22/VBG||years-24/NNS	amod||t2dm-28/NNS||type2diabetesmellitus-26/JJ	prep_with||¥-22/VBG||t2dm-28/NNS	vmod||t2dm-28/NNS||treated-30/VBN	num||drugs-37/NNS||one-32/CD	conj_or||one-32/CD||more-34/JJR	num||drugs-37/NNS||more-34/JJR	amod||drugs-37/NNS||oral-35/JJ	amod||drugs-37/NNS||antidiabetic-36/JJ	prep_with||treated-30/VBN||drugs-37/NNS	appos||drugs-37/NNS||oads-39/NNS	type2diabetesmellitus-26||insulin-15||yes||the aim of this study was to evaluate the response to initiation of once-daily insulin detemir in patients aged â¥75â years with type2diabetesmellitus (t2dm) treated with one or more oral antidiabetic drugs (oads).
nsubjpass||injected-4/VBN||animals-1/NNS	nsubj||showed-20/VBD||animals-1/NNS	auxpass||injected-4/VBN||were-3/VBD	rcmod||animals-1/NNS||injected-4/VBN	det||dose-8/NN||a-6/DT	amod||dose-8/NN||low-7/JJ	prep_with||injected-4/VBN||dose-8/NN	num||î-11/NN||10-10/CD	dep||dose-8/NN||î-11/NN	num||g-13/NN||1/4-12/CD	dep||î-11/NN||g-13/NN	nn||transposon-18/NN||statin-16/NN	nn||transposon-18/NN||ae-17/NN	prep_of||dose-8/NN||transposon-18/NN	vmod||transposon-18/NN||plasmid-19/VBN	root||ROOT-0/null||showed-20/VBD	det||decrease-23/NN||a-21/DT	amod||decrease-23/NN||significant-22/JJ	dobj||showed-20/VBD||decrease-23/NN	nn||formation-26/NN||tumor-25/NN	prep_in||showed-20/VBD||formation-26/NN	advmod||plasmid-33/VBD||only-27/RB	advmod||plasmid-33/VBD||when-28/WRB	nsubj||plasmid-33/VBD||co-injected-29/JJ	nn||transposase-encoding-32/NN||sb-31/NN	prep_with||co-injected-29/JJ||transposase-encoding-32/NN	advcl||showed-20/VBD||plasmid-33/VBD	mark||affect-62/VB||while-35/IN	prep_for||affect-62/VB||animals-37/NNS	vmod||animals-37/NNS||injected-38/VBN	det||dose-42/NN||a-40/DT	amod||dose-42/NN||higher-41/JJR	prep_with||injected-38/VBN||dose-42/NN	num||î-45/NN||25-44/CD	dep||dose-42/NN||î-45/NN	num||g-47/NN||1/4-46/CD	dep||î-45/NN||g-47/NN	amod||transposon-52/NN||statin-50/JJ	nn||transposon-52/NN||ae-51/NN	prep_of||dose-42/NN||transposon-52/NN	nsubj||affect-62/VB||co-injection-54/NN	amod||plasmid-58/NN||sb-56/JJ	amod||plasmid-58/NN||transposase-encoding-57/JJ	prep_of||co-injection-54/NN||plasmid-58/NN	aux||affect-62/VB||did-59/VBD	neg||affect-62/VB||not-60/RB	advmod||affect-62/VB||significantly-61/RB	dep||plasmid-33/VBD||affect-62/VB	nn||load-64/NN||tumor-63/NN	dobj||affect-62/VB||load-64/NN	tumor-63||sb-56||no_rel||animals that were injected with a low dose (10 î¼g) of statin ae transposon plasmid showed a significant decrease in tumor formation only when co-injected with sb transposase-encoding plasmid, while for animals injected with a higher dose (25 î¼g) of statin ae transposon, co-injection of sb transposase-encoding plasmid did not significantly affect tumor load.
vmod||shown-12/VBN||using-1/VBG	nn||preparations-5/NNS||bloc-3/NN	nn||preparations-5/NNS||medullary-4/NN	prep_en||using-1/VBG||preparations-5/NNS	amod||mice-8/NNS||neonatal-7/JJ	prep_from||using-1/VBG||mice-8/NNS	nsubj||shown-12/VBN||we-10/PRP	aux||shown-12/VBN||have-11/VBP	root||ROOT-0/null||shown-12/VBN	det||time-16/NN||the-14/DT	amod||time-16/NN||first-15/JJ	prep_for||shown-12/VBN||time-16/NN	mark||abolished-24/VBN||that-17/IN	det||response-20/NN||the-18/DT	amod||response-20/NN||respiratory-19/JJ	nsubjpass||abolished-24/VBN||response-20/NN	prep_to||response-20/NN||acidosis-22/NNS	auxpass||abolished-24/VBN||is-23/VBZ	dep||time-16/NN||abolished-24/VBN	prep_after||abolished-24/VBN||pre-treatment-26/NN	det||fluoxetine-31/NN||the-28/DT	amod||fluoxetine-31/NN||serotonin-transporter-29/JJ	nn||fluoxetine-31/NN||blocker-30/NN	prep_with||abolished-24/VBN||fluoxetine-31/NN	dep||âµm-37/NN||25â-33/NNS	dep||âµm-37/NN||$-34/$	num||$-34/$||50-36/CD	dep||time-16/NN||âµm-37/NN	number||min-40/NN||20-39/CD	dep||âµm-37/NN||min-40/NN	det||antidepressant-46/NN||a-43/DT	advmod||used-45/VBN||commonly-44/RB	amod||antidepressant-46/NN||used-45/VBN	appos||time-16/NN||antidepressant-46/NN	antidepressant-46||acidosis-22||no_rel||using en bloc medullary preparations from neonatal mice, we have shown for the first time that the respiratory response to acidosis is abolished after pre-treatment with the serotonin-transporter blocker fluoxetine (25â50 âµm, 20 min), a commonly used antidepressant.
det||emergence-3/NN||the-1/DT	amod||emergence-3/NN||recent-2/JJ	nsubj||raised-16/VBD||emergence-3/NN	nsubj||resembles-36/VBZ||emergence-3/NN	det||coronavirus-8/NNS||a-5/DT	amod||coronavirus-8/NNS||novel-6/JJ	amod||coronavirus-8/NNS||human-7/JJ	prep_of||emergence-3/NN||coronavirus-8/NNS	dep||emergence-3/NN||hcov-emc-10/JJ	det||middle-14/NN||the-13/DT	prep_in||emergence-3/NN||middle-14/NN	advmod||raised-16/VBD||east-15/RB	root||ROOT-0/null||raised-16/VBD	amod||concerns-18/NNS||considerable-17/JJ	dobj||raised-16/VBD||concerns-18/NNS	mark||associated-23/VBN||as-20/IN	nsubjpass||associated-23/VBN||it-21/PRP	auxpass||associated-23/VBN||is-22/VBZ	advcl||raised-16/VBD||associated-23/VBN	amod||pneumonia-27/NN||severe-25/JJ	amod||pneumonia-27/NN||acute-26/JJ	prep_with||associated-23/VBN||pneumonia-27/NN	prep_with||associated-23/VBN||renalfailure-29/NN	conj_and||pneumonia-27/NN||renalfailure-29/NN	amod||outcome-33/NN||fatal-32/JJ	prep_with||associated-23/VBN||outcome-33/NN	conj_and||pneumonia-27/NN||outcome-33/NN	advmod||resembles-36/VBZ||thus-35/RB	conj_and||raised-16/VBD||resembles-36/VBZ	det||presentation-39/NN||the-37/DT	amod||presentation-39/NN||clinical-38/JJ	xcomp||resembles-36/VBZ||presentation-39/NN	amod||sars-43/NNS||severeacuterespiratorysyndrome-41/JJ	prep_of||presentation-39/NN||sars-43/NNS	vmod||sars-43/NNS||observed-45/VBN	prep_in||observed-45/VBN||2002-47/CD	prep_in||observed-45/VBN||2003-49/CD	conj_and||2002-47/CD||2003-49/CD	severeacuterespiratorysyndrome-41||coronavirus-8||no||the recent emergence of a novel human coronavirus (hcov-emc) in the middle east raised considerable concerns, as it is associated with severe acute pneumonia, renalfailure, and fatal outcome and thus resembles the clinical presentation of severeacuterespiratorysyndrome (sars) observed in 2002 and 2003.
nn||scores-2/NNS||nausea-1/NN	nsubj||severe-12/JJ||scores-2/NNS	nsubj||similar-14/JJ||scores-2/NNS	prep_at||scores-2/NNS||baseline-4/NN	conj_and||scores-2/NNS||0â-6/NNS	nsubj||severe-12/JJ||0â-6/NNS	num||minutes-10/NNS||$-7/$	num||$-7/$||30-9/CD	dep||0â-6/NNS||minutes-10/NNS	cop||severe-12/JJ||were-11/VBD	root||ROOT-0/null||severe-12/JJ	conj_and||severe-12/JJ||similar-14/JJ	prep_between||severe-12/JJ||groups-16/NNS	advmod||had-35/VBD||however-18/RB	amod||$-22/$||31â-21/JJ	prep_at||had-35/VBD||$-22/$	num||$-22/$||60-24/CD	conj_and||$-22/$||61â-26/NNS	prep_at||had-35/VBD||61â-26/NNS	num||minutes-30/NNS||$-27/$	num||$-27/$||120-29/CD	dep||61â-26/NNS||minutes-30/NNS	nsubj||had-35/VBD||patients-32/NNS	vmod||patients-32/NNS||receiving-33/VBG	dobj||receiving-33/VBG||prochlorperazine-34/NN	parataxis||severe-12/JJ||had-35/VBD	amod||control-37/NN||better-36/JJR	dobj||had-35/VBD||control-37/NN	nn||=-47/FW||nausea-39/FW	nn||=-47/FW||-lrb--40/FW	nn||=-47/FW||24.9-41/FW	nn||=-47/FW||vs.-42/FW	nn||=-47/FW||43.7-43/FW	nn||=-47/FW||mm-44/FW	dep||=-47/FW||p-46/FW	prep_of||control-37/NN||=-47/FW	dep||=-47/FW||0.03-48/CD	nn||=-56/FW||16.8-50/FW	nn||=-56/FW||vs.-51/FW	nn||=-56/FW||34.3-52/FW	nn||=-56/FW||mm-53/FW	dep||=-56/FW||p-55/FW	dep||=-47/FW||=-56/FW	num||-rrb--58/NNS||0.05-57/CD	dep||=-56/FW||-rrb--58/NNS	nausea-39||prochlorperazine-34||yes||nausea scores at baseline and 0â $ `` 30 minutes were severe and similar between groups ; however , at 31â $ `` 60 and 61â $ `` 120 minutes , patients receiving prochlorperazine had better control of nausea -lrb- 24.9 vs. 43.7 mm , p = 0.03 ; 16.8 vs. 34.3 mm , p = 0.05 -rrb- .
nsubj||belong-15/VBP||endostatin-1/NN	conj_and||endostatin-1/NN||anastellin-3/NN	nsubj||belong-15/VBP||anastellin-3/NN	appos||endostatin-1/NN||fragments-5/NNS	nn||xviii-9/NNS||collagen-7/NN	nn||xviii-9/NNS||type-8/NN	prep_of||fragments-5/NNS||xviii-9/NNS	appos||endostatin-1/NN||fibronectin-11/NN	conj_and||fragments-5/NNS||fibronectin-11/NN	advmod||fibronectin-11/NN||respectively-13/RB	root||ROOT-0/null||belong-15/VBP	det||family-18/NN||a-17/DT	prep_to||belong-15/VBP||family-18/NN	amod||inhibitors-21/NNS||endogenous-20/JJ	prep_of||family-18/NN||inhibitors-21/NNS	prep_of||inhibitors-21/NNS||angiogenesis-23/NNS	nsubj||inhibit-25/VBP||angiogenesis-23/NNS	rcmod||angiogenesis-23/NNS||inhibit-25/VBP	nn||growth-27/NN||tumor-26/NN	dobj||inhibit-25/VBP||growth-27/NN	dobj||inhibit-25/VBP||metastasis-29/NNS	conj_and||growth-27/NN||metastasis-29/NNS	det||number-32/NN||a-31/DT	prep_in||growth-27/NN||number-32/NN	nn||models-35/NNS||mouse-34/NN	prep_of||number-32/NN||models-35/NNS	amod||cancer-38/NN||human-37/JJ	prep_of||models-35/NNS||cancer-38/NN	collagen-7||metastasis-29||no_rel||endostatin and anastellin, fragments of collagen type xviii and fibronectin, respectively, belong to a family of endogenous inhibitors of angiogenesis which inhibit tumor growth and metastasis in a number of mouse models of human cancer.
nsubj||has-2/VBZ||mtb-1/NN	root||ROOT-0/null||has-2/VBZ	amod||glycolipids-6/NNS||several-3/JJ	nn||glycolipids-6/NNS||cell-4/NN	nn||glycolipids-6/NNS||wall-5/NN	dobj||has-2/VBZ||glycolipids-6/NNS	amod||models-36/NNS||common-8/JJ	prep_with||common-8/JJ||ms-10/NN	nsubj||play-13/VBP||ms-10/NN	rcmod||ms-10/NN||play-13/VBP	det||role-16/NN||an-14/DT	amod||role-16/NN||important-15/JJ	dobj||play-13/VBP||role-16/NN	det||pathogenesis-19/NNS||the-18/DT	prep_in||role-16/NN||pathogenesis-19/NNS	prep_of||pathogenesis-19/NNS||tuberculosis-21/NNP	det||induction-24/NN||the-23/DT	prep_in||role-16/NN||induction-24/NN	conj_and||pathogenesis-19/NNS||induction-24/NN	det||response-29/NN||a-26/DT	amod||response-29/NN||protective-27/JJ	amod||response-29/NN||immune-28/JJ	prep_of||induction-24/NN||response-29/NN	nn||infection-32/NN||mtb-31/NN	prep_against||response-29/NN||infection-32/NN	det||animal-35/NN||some-34/DT	prep_in||infection-32/NN||animal-35/NN	prep_in||glycolipids-6/NNS||models-36/NNS	tuberculosis-21||mtb-31||no||mtb has several cell wall glycolipids in common with ms, which play an important role in the pathogenesis of tuberculosis and the induction of a protective immune response against mtb infection in some animal models.
nsubj||appear-4/VBP||prochlorperazine-1/NN	nsubj||effective-8/JJ||prochlorperazine-1/NN	conj_and||prochlorperazine-1/NN||ondansetron-3/NN	nsubj||appear-4/VBP||ondansetron-3/NN	nsubj||effective-8/JJ||ondansetron-3/NN	root||ROOT-0/null||appear-4/VBP	aux||effective-8/JJ||to-5/TO	cop||effective-8/JJ||be-6/VB	advmod||effective-8/JJ||equally-7/RB	xcomp||appear-4/VBP||effective-8/JJ	prepc_at||effective-8/JJ||treating-10/VBG	dobj||treating-10/VBG||vomiting-11/NN	det||department-15/NN||the-13/DT	nn||department-15/NN||emergency-14/NN	prep_in||treating-10/VBG||department-15/NN	vomiting-11||prochlorperazine-1||yes||prochlorperazine and ondansetron appear to be equally effective at treating vomiting in the emergency department.
amod||diagnosis-2/NN||timely-1/JJ	nsubj||important-7/JJ||diagnosis-2/NN	nsubj||prevent-9/VB||diagnosis-2/NN	amod||hivinfection-5/NN||primary-4/JJ	prep_of||diagnosis-2/NN||hivinfection-5/NN	cop||important-7/JJ||is-6/VBZ	root||ROOT-0/null||important-7/JJ	aux||prevent-9/VB||to-8/TO	xcomp||important-7/JJ||prevent-9/VB	amod||transmission-11/NN||further-10/JJ	dobj||prevent-9/VB||transmission-11/NN	prep_of||transmission-11/NN||hiv-13/NN	hivinfection-5||hiv-13||no||timely diagnosis of primary hivinfection is important to prevent further transmission of hiv.
vmod||demonstrate-9/VBP||using-1/VBG	amod||models-3/NNS||macrophage-2/JJ	dobj||using-1/VBG||models-3/NNS	amod||ironoverloaddisease-6/NN||human-5/JJ	prep_of||models-3/NNS||ironoverloaddisease-6/NN	nsubj||demonstrate-9/VBP||we-8/PRP	root||ROOT-0/null||demonstrate-9/VBP	mark||altered-14/VBD||that-10/IN	nn||senses-13/NNS||c.-11/NN	nn||senses-13/NNS||glabrata-12/NN	nsubj||altered-14/VBD||senses-13/NNS	ccomp||demonstrate-9/VBP||altered-14/VBD	nn||levels-16/NNS||iron-15/NN	dobj||altered-14/VBD||levels-16/NNS	det||compartment-20/NN||the-18/DT	amod||compartment-20/NN||phagosomal-19/JJ	prep_within||altered-14/VBD||compartment-20/NN	ironoverloaddisease-6||iron-15||no||using macrophage models of human ironoverloaddisease , we demonstrate that c. glabrata senses altered iron levels within the phagosomal compartment .
amod||formulations-3/NNS||fixed-dose-1/JJ	nn||formulations-3/NNS||combination-2/NN	nsubjpass||approved-15/VBN||formulations-3/NNS	prep_of||formulations-3/NNS||olmesartanmedoxomil-5/NN	det||arb-8/NN||an-7/DT	prep_of||formulations-3/NNS||arb-8/NN	conj_and||olmesartanmedoxomil-5/NN||arb-8/NN	det||amlodipine-13/NN||the-11/DT	nn||amlodipine-13/NN||ccb-12/NN	prep_of||formulations-3/NNS||amlodipine-13/NN	conj_and||olmesartanmedoxomil-5/NN||amlodipine-13/NN	auxpass||approved-15/VBN||are-14/VBP	root||ROOT-0/null||approved-15/VBN	amod||countries-19/NNS||several-17/JJ	nn||countries-19/NNS||european-18/NN	prep_in||approved-15/VBN||countries-19/NNS	prep_for||countries-19/NNS||patients-21/NNS	amod||hypertension-24/NN||essential-23/JJ	prep_with||patients-21/NNS||hypertension-24/NN	hypertension-24||amlodipine-13||yes||fixed-dose combination formulations of olmesartanmedoxomil, an arb, and the ccb amlodipine are approved in several european countries for patients with essential hypertension.
mark||higher-6/JJR||although-1/IN	amod||prevalence-3/NN||hbsag-2/VBG	nsubj||higher-6/JJR||prevalence-3/NN	cop||higher-6/JJR||is-4/VBZ	advmod||higher-6/JJR||much-5/RB	advcl||high-29/JJ||higher-6/JJR	prep_among||higher-6/JJR||subjects-8/NNS	nsubj||hivpositive-11/JJ||subjects-8/NNS	cop||hivpositive-11/JJ||are-10/VBP	rcmod||subjects-8/NNS||hivpositive-11/JJ	num||%-14/NN||14.0-13/CD	dep||subjects-8/NNS||%-14/NN	num||%-17/NN||4.3-16/CD	dep||subjects-8/NNS||%-17/NN	conj_versus||%-14/NN||%-17/NN	det||prevalence-21/NN||the-20/DT	nsubj||high-29/JJ||prevalence-21/NN	nsubj||warrant-32/VB||prevalence-21/NN	prepc_of||prevalence-21/NN||hbsag-23/VBG	amod||subjects-27/NNS||hiv-25/JJ	amod||subjects-27/NNS||negative-26/JJ	prep_in||hbsag-23/VBG||subjects-27/NNS	cop||high-29/JJ||is-28/VBZ	root||ROOT-0/null||high-29/JJ	advmod||high-29/JJ||enough-30/RB	aux||warrant-32/VB||to-31/TO	xcomp||high-29/JJ||warrant-32/VB	det||recommendation-34/NN||a-33/DT	dobj||warrant-32/VB||recommendation-34/NN	aux||screen-36/VB||to-35/TO	vmod||recommendation-34/NN||screen-36/VB	det||clients-38/NNS||all-37/DT	dobj||screen-36/VB||clients-38/NNS	nn||centers-41/NNS||vct-40/NN	prep_at||screen-36/VB||centers-41/NNS	nn||status-45/NN||hiv-44/NN	prep_irrespective_of||screen-36/VB||status-45/NN	hbsag-23||hivpositive-11||no_rel||although hbsag prevalence is much higher among subjects who are hivpositive (14.0% versus 4.3%), the prevalence of hbsag in hiv negative subjects is high enough to warrant a recommendation to screen all clients at vct centers irrespective of hiv status.
nn||design-2/NN||research-1/NN	nsubjpass||compared-47/VBN||design-2/NN	nsubj||detect-49/VB||design-2/NN	conj_and||design-2/NN||methods-4/NNS	nsubjpass||compared-47/VBN||methods-4/NNS	nsubj||detect-49/VB||methods-4/NNS	nn||$-7/NNP||resultsâ-6/NNP	conj_and||design-2/NN||$-7/NNP	nsubjpass||compared-47/VBN||$-7/NNP	nsubj||detect-49/VB||$-7/NNP	conj_and||design-2/NN||measures-9/NNS	nsubjpass||compared-47/VBN||measures-9/NNS	nsubj||detect-49/VB||measures-9/NNS	amod||risk-12/NN||cardiovascular-11/JJ	prep_of||measures-9/NNS||risk-12/NN	nn||composition-15/NN||body-14/NN	conj_and||design-2/NN||composition-15/NN	nsubjpass||compared-47/VBN||composition-15/NN	nsubj||detect-49/VB||composition-15/NN	nn||hormones-19/NNS||serum-18/NN	conj_and||design-2/NN||hormones-19/NNS	nsubjpass||compared-47/VBN||hormones-19/NNS	nsubj||detect-49/VB||hormones-19/NNS	det||examinations-23/NNS||the-21/DT	amod||examinations-23/NNS||baseline-22/JJ	prep_from||hormones-19/NNS||examinations-23/NNS	det||study-28/NN||the-25/DT	amod||study-28/NN||insulinresistance-26/JJ	nn||study-28/NN||atherosclerosis-27/NNS	prep_of||examinations-23/NNS||study-28/NN	num||women-32/NNS||524-30/CD	amod||women-32/NNS||nondiabetic-31/JJ	prep_on||study-28/NN||women-32/NNS	amod||women-36/NNS||258-34/JJ	amod||women-36/NNS||diabetic-35/JJ	prep_on||study-28/NN||women-36/NNS	conj_and||women-32/NNS||women-36/NNS	num||men-40/NNS||421-38/CD	amod||men-40/NNS||nondiabetic-39/JJ	prep_on||study-28/NN||men-40/NNS	conj_and||women-32/NNS||men-40/NNS	num||men-45/NNS||220-43/CD	amod||men-45/NNS||diabetic-44/JJ	prep_on||study-28/NN||men-45/NNS	conj_and||women-32/NNS||men-45/NNS	auxpass||compared-47/VBN||were-46/VBD	root||ROOT-0/null||compared-47/VBN	aux||detect-49/VB||to-48/TO	xcomp||compared-47/VBN||detect-49/VB	amod||differences-52/NNS||greater-50/JJR	amod||differences-52/NNS||adverse-51/JJ	dobj||detect-49/VB||differences-52/NNS	prep_in||detect-49/VB||women-54/NNS	prep||detect-49/VB||than-55/IN	pcomp||than-55/IN||in-56/IN	pobj||in-56/IN||men-57/NNS	hormones-19||atherosclerosis-27||no_rel||research design and methods and resultsâ measures of cardiovascular risk, body composition, and serum hormones from the baseline examinations of the insulinresistance atherosclerosis study on 524 nondiabetic women, 258 diabetic women, 421 nondiabetic men, and 220 diabetic men were compared to detect greater adverse differences in women than in men.
nsubjpass||involved-13/VBN||dnak/hsp70-1/NNS	poss||dnaj-5/NN||its-3/PRP$	amod||dnaj-5/NN||co-chaperone-4/JJ	conj_and||dnak/hsp70-1/NNS||dnaj-5/NN	nsubjpass||involved-13/VBN||dnaj-5/NN	det||grpe-11/NN||the-7/DT	amod||grpe-11/NN||nucleotide-8/JJ	nn||grpe-11/NN||exchange-9/NN	nn||grpe-11/NN||factor-10/NN	conj_and||dnak/hsp70-1/NNS||grpe-11/NN	nsubjpass||involved-13/VBN||grpe-11/NN	auxpass||involved-13/VBN||are-12/VBP	root||ROOT-0/null||involved-13/VBN	prep_among||involved-13/VBN||others-16/NNS	nn||shocks-20/NNS||heat-19/NN	prep_in||involved-13/VBN||shocks-20/NNS	amod||responses-25/NNS||heavymetal-22/JJ	amod||responses-25/NNS||cellular-23/JJ	nn||responses-25/NNS||stress-24/NN	prep_in||involved-13/VBN||responses-25/NNS	conj_and||shocks-20/NNS||responses-25/NNS	shocks-20||heavymetal-22||no_rel||dnak/hsp70, its co-chaperone dnaj and the nucleotide exchange factor grpe are involved, among others, in heat shocks and heavymetal cellular stress responses.
det||effect-2/NN||the-1/DT	nsubjpass||assessed-12/VBN||effect-2/NN	amod||hyperglycaemia-5/NN||acute-4/JJ	prep_on||effect-2/NN||hyperglycaemia-5/NN	nn||message-9/NN||liver-7/NN	nn||message-9/NN||enzyme-8/NN	prep_on||effect-2/NN||message-9/NN	conj_and||hyperglycaemia-5/NN||message-9/NN	auxpass||assessed-12/VBN||were-10/VBD	advmod||assessed-12/VBN||also-11/RB	root||ROOT-0/null||assessed-12/VBN	enzyme-8||hyperglycaemia-5||no_rel||the effect on acute hyperglycaemia and liver enzyme message were also assessed.
nsubjpass||recommended-19/VBN||screening-1/NN	nn||antigen-5/NN||hbv-3/NN	nn||antigen-5/NN||surface-4/NN	prep_for||screening-1/NN||antigen-5/NN	appos||antigen-5/NN||hbsag-7/NN	prep_before||antigen-5/NN||initiation-10/NN	nn||therapy-14/NN||combination-12/NN	amod||therapy-14/NN||antiretroviral-13/JJ	prep_of||initiation-10/NN||therapy-14/NN	appos||therapy-14/NN||cart-16/NN	auxpass||recommended-19/VBN||is-18/VBZ	root||ROOT-0/null||recommended-19/VBN	hbv-3||hbsag-7||yes||screening for hbv surface antigen (hbsag) before initiation of combination antiretroviral therapy (cart) is recommended.
aux||investigate-2/VB||to-1/TO	dep||hla-3/VBP||investigate-2/VB	root||ROOT-0/null||hla-3/VBP	amod||patients-7/NNS||b27-4/JJ	amod||patients-7/NNS||positive-5/JJ	nn||patients-7/NNS||jia-6/NN	dobj||hla-3/VBP||patients-7/NNS	amod||characteristics-9/NNS||clinical-8/JJ	nsubj||hla-3/VBP||characteristics-9/NNS	vmod||characteristics-9/NNS||determined-11/VBN	amod||types-15/NNS||hla-12/JJ	amod||types-15/NNS||b27-13/JJ	nn||types-15/NNS||allele-14/NN	dobj||determined-11/VBN||types-15/NNS	poss||connection-18/NN||their-17/PRP$	dobj||determined-11/VBN||connection-18/NN	conj_and||types-15/NNS||connection-18/NN	amod||treatment-21/NN||antirheumatic-20/JJ	prep_with||determined-11/VBN||treatment-21/NN	amod||groups-25/NNS||homogenous-23/JJ	nn||groups-25/NNS||patient-24/NN	prep_in||determined-11/VBN||groups-25/NNS	antirheumatic-20||jia-6||no_rel||to investigate hla b27 positive jia patients clinical characteristics, determined hla b27 allele types and their connection with antirheumatic treatment in homogenous patient groups.
nsubjpass||expressed-17/VBN||genes-1/NNS	vmod||genes-1/NNS||encoding-2/VBG	det||pilus-5/NNS||the-3/DT	amod||pilus-5/NNS||toxin-coregulated-4/JJ	dobj||encoding-2/VBG||pilus-5/NNS	appos||pilus-5/NNS||tcp-7/NN	nn||toxin-11/NN||cholera-10/NN	dobj||encoding-2/VBG||toxin-11/NN	conj_and||pilus-5/NNS||toxin-11/NN	appos||toxin-11/NN||ct-13/NN	auxpass||expressed-17/VBN||were-15/VBD	advmod||expressed-17/VBN||powerfully-16/RB	root||ROOT-0/null||expressed-17/VBN	advmod||expressed-17/VBN||early-18/RB	det||process-22/NN||the-20/DT	amod||process-22/NN||infectious-21/JJ	prep_in||expressed-17/VBN||process-22/NN	prep_in||process-22/NN||bacteria-24/NNS	advmod||bacteria-24/NNS||adjacent-25/JJ	amod||surfaces-28/NNS||epithelial-27/JJ	prep_to||adjacent-25/JJ||surfaces-28/NNS	cholera-10||bacteria-24||no||genes encoding the toxin-coregulated pilus (tcp) and cholera toxin (ct) were powerfully expressed early in the infectious process in bacteria adjacent to epithelial surfaces.
nsubj||tested-2/VBD||we-1/PRP	root||ROOT-0/null||tested-2/VBD	num||inhibitors-7/NNS||two-3/CD	amod||inhibitors-7/NNS||c-met-4/JJ	amod||inhibitors-7/NNS||small-5/JJ	nn||inhibitors-7/NNS||molecule-6/NN	dobj||tested-2/VBD||inhibitors-7/NNS	amod||inhibitors-7/NNS||pha-665752-9/JJ	amod||inhibitors-7/NNS||pf-2341066-11/JJ	conj_and||pha-665752-9/JJ||pf-2341066-11/JJ	amod||activity-15/NN||anti-proliferative-14/JJ	prep_for||tested-2/VBD||activity-15/NN	nn||assay-18/NN||mts-17/NN	prep_by||tested-2/VBD||assay-18/NN	nn||assay-22/NN||cell-20/NN	nn||assay-22/NN||proliferation-21/NN	prep_by||tested-2/VBD||assay-22/NN	conj_and||assay-18/NN||assay-22/NN	amod||lines-28/NNS||human-24/JJ	nn||lines-28/NNS||prostate-25/NN	nn||lines-28/NNS||cancer-26/NN	nn||lines-28/NNS||cell-27/NN	prep_on||assay-18/NN||lines-28/NNS	amod||levels-31/NNS||different-30/JJ	prep_with||lines-28/NNS||levels-31/NNS	nn||sensitivity-34/NN||androgen-33/NN	prep_of||levels-31/NNS||sensitivity-34/NN	androgen-33||cancer-26||no_rel||we tested two c-met small molecule inhibitors, pha-665752 and pf-2341066, for anti-proliferative activity by mts assay and cell proliferation assay on human prostate cancer cell lines with different levels of androgen sensitivity.
num||weeks-3/NNS||12-2/CD	prep_at||%-14/NN||weeks-3/NNS	det||proportions-6/NNS||the-5/DT	nsubj||%-14/NN||proportions-6/NNS	prep_of||proportions-6/NNS||subjects-8/NNS	nsubj||had-10/VBD||subjects-8/NNS	rcmod||subjects-8/NNS||had-10/VBD	dobj||had-10/VBD||hypocalcemia-11/NN	cop||%-14/NN||were-12/VBD	num||%-14/NN||5.4-13/CD	root||ROOT-0/null||%-14/NN	num||%-17/NN||19.5-16/CD	conj_and||%-14/NN||%-17/NN	det||calciumacetate-20/NN||the-19/DT	prep_for||%-14/NN||calciumacetate-20/NN	det||groups-24/NNS||the-22/DT	nn||groups-24/NNS||placebo-23/NN	prep_for||%-14/NN||groups-24/NNS	conj_and||calciumacetate-20/NN||groups-24/NNS	advmod||%-14/NN||respectively-26/RB	mark||%-37/NN||while-28/IN	det||proportions-30/NNS||the-29/DT	nsubj||%-37/NN||proportions-30/NNS	prep_of||proportions-30/NNS||those-32/DT	prep_with||those-32/DT||hypercalcemia-34/NN	cop||%-37/NN||were-35/VBD	num||%-37/NN||13.5-36/CD	advcl||%-14/NN||%-37/NN	num||%-40/NN||0-39/CD	advcl||%-14/NN||%-40/NN	conj_and||%-37/NN||%-40/NN	advmod||%-37/NN||respectively-42/RB	hypercalcemia-34||calciumacetate-20||no||at 12 weeks, the proportions of subjects who had hypocalcemia were 5.4% and 19.5% for the calciumacetate and the placebo groups, respectively, while the proportions of those with hypercalcemia were 13.5% and 0%, respectively.
nsubj||allopurinol-10/NN||options-1/NNS	prep_for||options-1/NNS||treatment-3/NN	amod||gout-6/NN||chronic-5/JJ	prep_of||treatment-3/NN||gout-6/NN	prep_until||gout-6/NN||2008-8/CD	cop||allopurinol-10/NN||were-9/VBD	root||ROOT-0/null||allopurinol-10/NN	det||inhibitor-15/NN||a-12/DT	amod||inhibitor-15/NN||xanthine-13/JJ	nn||inhibitor-15/NN||oxidase-14/NN	conj_and||allopurinol-10/NN||inhibitor-15/NN	det||group-19/NN||the-18/DT	conj_and||allopurinol-10/NN||group-19/NN	prep_of||group-19/NN||drugs-21/NNS	vmod||drugs-21/NNS||known-22/VBN	prep_as||known-22/VBN||uricosurics-24/NNS	nsubj||stimulate-26/VB||uricosurics-24/NNS	rcmod||uricosurics-24/NNS||stimulate-26/VB	det||excretion-29/NN||the-27/DT	amod||excretion-29/NN||renal-28/JJ	dobj||stimulate-26/VB||excretion-29/NN	amod||acid-32/NN||uric-31/JJ	prep_of||excretion-29/NN||acid-32/NN	gout-6||allopurinol-10||yes||options for treatment of chronic gout until 2008 were allopurinol, a xanthine oxidase inhibitor, and the group of drugs known as uricosurics that stimulate the renal excretion of uric acid.
root||ROOT-0/null||similar-1/JJ	amod||bacteria-6/NNS||many-3/JJ	amod||bacteria-6/NNS||other-4/JJ	nn||bacteria-6/NNS||intracellular-5/NN	prep_to||similar-1/JJ||bacteria-6/NNS	mark||depends-29/VBZ||that-7/IN	nsubj||depends-29/VBZ||replicate-8/NNP	det||cytosol-11/NN||the-10/DT	prep_within||replicate-8/NNP||cytosol-11/NN	prep_such_as||cytosol-11/NN||listeria-15/NN	prep_such_as||cytosol-11/NN||shigella-17/NN	conj_and||listeria-15/NN||shigella-17/NN	prep_such_as||cytosol-11/NN||burkholderia-19/NN	conj_and||listeria-15/NN||burkholderia-19/NN	prep_such_as||cytosol-11/NN||rickettsia-22/NN	conj_and||listeria-15/NN||rickettsia-22/NN	det||virulence-25/NN||the-24/DT	appos||listeria-15/NN||virulence-25/NN	nn||tularensis-28/NNS||f.-27/NN	prep_of||virulence-25/NN||tularensis-28/NNS	dep||similar-1/JJ||depends-29/VBZ	poss||ability-32/NN||its-31/PRP$	prep_on||depends-29/VBZ||ability-32/NN	aux||modulate-34/VB||to-33/TO	dep||ability-32/NN||modulate-34/VB	dobj||modulate-34/VB||biogenesis-35/NNS	poss||phagosome-38/NN||its-37/PRP$	prep_of||biogenesis-35/NNS||phagosome-38/NN	aux||escape-41/VB||to-40/TO	dep||ability-32/NN||escape-41/VB	conj_and||modulate-34/VB||escape-41/VB	det||cytosol-46/NN||the-43/DT	nn||cytosol-46/NN||host-44/NN	nn||cytosol-46/NN||cell-45/NN	prep_into||escape-41/VB||cytosol-46/NN	advmod||proliferates-49/VBZ||where-47/WRB	nsubj||proliferates-49/VBZ||it-48/PRP	advcl||escape-41/VB||proliferates-49/VBZ	shigella-17||bacteria-6||no||similar to many other intracellular bacteria that replicate within the cytosol , such as listeria , shigella , burkholderia , and rickettsia , the virulence of f. tularensis depends on its ability to modulate biogenesis of its phagosome and to escape into the host cell cytosol where it proliferates .
det||majority-2/NN||the-1/DT	nsubjpass||infected-14/VBN||majority-2/NN	prep_of||majority-2/NN||decedents-4/NNS	nsubj||remained-6/VBD||decedents-4/NNS	rcmod||decedents-4/NNS||remained-6/VBD	xcomp||remained-6/VBD||culture-7/NN	amod||culture-7/NN||positive-8/JJ	prepc_despite||positive-8/JJ||receiving-10/VBG	nn||treatment-12/NN||tuberculosis-11/NNP	dobj||receiving-10/VBG||treatment-12/NN	auxpass||infected-14/VBN||were-13/VBD	root||ROOT-0/null||infected-14/VBN	amod||m.tuberculosis-17/NNS||pan-susceptible-16/JJ	prep_with||infected-14/VBN||m.tuberculosis-17/NNS	xcomp||infected-14/VBN||suggesting-19/VBG	mark||made-26/VBN||that-20/IN	det||diagnosis-22/NN||the-21/DT	nsubjpass||made-26/VBN||diagnosis-22/NN	nsubj||alter-30/VB||diagnosis-22/NN	prep_of||diagnosis-22/NN||tuberculosis-24/NNP	auxpass||made-26/VBN||was-25/VBD	ccomp||suggesting-19/VBG||made-26/VBN	advmod||late-28/RB||too-27/RB	advmod||made-26/VBN||late-28/RB	aux||alter-30/VB||to-29/TO	xcomp||made-26/VBN||alter-30/VB	det||course-33/NN||the-31/DT	amod||course-33/NN||fatal-32/JJ	dobj||alter-30/VB||course-33/NN	det||infection-36/NN||the-35/DT	prep_of||course-33/NN||infection-36/NN	tuberculosis-24||m.tuberculosis-17||no||the majority of decedents who remained culture positive despite receiving tuberculosis treatment were infected with pan-susceptible m.tuberculosis , suggesting that the diagnosis of tuberculosis was made too late to alter the fatal course of the infection .
det||infection-2/NN||the-1/DT	nsubjpass||analyzed-17/VBN||infection-2/NN	nn||explants-5/NNS||prostate-4/NN	prep_of||infection-2/NN||explants-5/NNS	prep_following||explants-5/NNS||exposures-7/NNS	amod||strains-15/NNS||hiv-1-9/JJ	dep||hiv-1-9/JJ||r5-10/CD	num||r5-10/CD||r5x4-12/CD	dep||hiv-1-9/JJ||x4-14/CD	conj_and||r5-10/CD||x4-14/CD	prep_with||exposures-7/NNS||strains-15/NNS	auxpass||analyzed-17/VBN||was-16/VBD	root||ROOT-0/null||analyzed-17/VBN	det||measure-20/NN||the-19/DT	prep_through||analyzed-17/VBN||measure-20/NN	nn||activity-23/NN||rt-22/NN	prep_of||measure-20/NN||activity-23/NN	nn||supernatants-26/NNS||culture-25/NN	prep_in||activity-23/NN||supernatants-26/NNS	det||quantification-29/NN||the-28/DT	prep_of||measure-20/NN||quantification-29/NN	conj_and||activity-23/NN||quantification-29/NN	prep_of||quantification-29/NN||hivdna-31/NN	det||explants-34/NNS||the-33/DT	prep_in||hivdna-31/NN||explants-34/NNS	det||detection-37/NN||the-36/DT	prep_of||measure-20/NN||detection-37/NN	conj_and||activity-23/NN||detection-37/NN	nn||cells-42/NNS||hiv-39/NN	nn||cells-42/NNS||rna-40/NN	nn||cells-42/NNS||+-41/NN	prep_of||detection-37/NN||cells-42/NNS	prep_in||analyzed-17/VBN||situ-44/NN	hivdna-31||hiv-39||no||the infection of prostate explants following exposures with hiv-1 r5, r5x4 and x4 strains was analyzed through the measure of rt activity in culture supernatants, the quantification of hivdna in the explants and the detection of hiv rna+ cells in situ .
advmod||diagnosed-3/JJ||newly-2/RB	amod||patients-4/NNS||diagnosed-3/JJ	prep_in||documented-31/VBN||patients-4/NNS	prep_with||patients-4/NNS||hodgkinlymphoma-6/NN	dep||documented-31/VBN||hl-8/VB	det||effect-11/NN||the-10/DT	nsubjpass||documented-31/VBN||effect-11/NN	prep_of||effect-11/NN||doxorubicin-13/NN	prep_of||effect-11/NN||bleomycin-15/NN	conj_and||doxorubicin-13/NN||bleomycin-15/NN	prep_of||effect-11/NN||vinblastine-17/NN	conj_and||doxorubicin-13/NN||vinblastine-17/NN	prep_of||effect-11/NN||dacarbazine-19/NN	conj_and||doxorubicin-13/NN||dacarbazine-19/NN	dep||doxorubicin-13/NN||abvd-21/VBN	amod||neutropenia-25/NN||related-24/VBN	dep||doxorubicin-13/NN||neutropenia-25/NN	amod||delivery-28/NN||chemotherapy-27/JJ	prep_on||neutropenia-25/NN||delivery-28/NN	auxpass||documented-31/VBN||is-29/VBZ	advmod||documented-31/VBN||poorly-30/RB	root||ROOT-0/null||documented-31/VBN	hodgkinlymphoma-6||vinblastine-17||yes||in newly diagnosed patients with hodgkinlymphoma (hl) the effect of doxorubicin, bleomycin, vinblastine and dacarbazine (abvd)-related neutropenia on chemotherapy delivery is poorly documented.
nsubj||induces-19/VBZ||bortezomib-1/NN	det||inhibitor-5/NN||a-3/DT	amod||inhibitor-5/NN||proteasome-4/JJ	appos||bortezomib-1/NN||inhibitor-5/NN	vmod||inhibitor-5/NN||approved-6/VBN	det||treatment-9/NN||the-8/DT	prep_for||approved-6/VBN||treatment-9/NN	prep_of||treatment-9/NN||multiplemyeloma-11/NN	det||neoplasm-16/NN||a-13/DT	nn||neoplasm-16/NN||plasma-14/NN	nn||neoplasm-16/NN||cell-15/NN	dep||inhibitor-5/NN||neoplasm-16/NN	root||ROOT-0/null||induces-19/VBZ	nn||apoptosis-22/NNS||plasma-20/NN	nn||apoptosis-22/NNS||cell-21/NN	dobj||induces-19/VBZ||apoptosis-22/NNS	multiplemyeloma-11||bortezomib-1||yes||bortezomib, a proteasome inhibitor approved for the treatment of multiplemyeloma (a plasma cell neoplasm), induces plasma cell apoptosis.
amod||loci-2/NNS||genetic-1/JJ	nsubj||demonstrate-11/VBP||loci-2/NNS	vmod||loci-2/NNS||identified-3/VBN	poss||effect-6/NN||their-5/PRP$	prep_through||identified-3/VBN||effect-6/NN	amod||hyperinsulinemia-10/NN||hyperglycemia-8/JJ	amod||hyperinsulinemia-10/NN||and/or-9/JJ	prep_on||effect-6/NN||hyperinsulinemia-10/NN	root||ROOT-0/null||demonstrate-11/VBP	amod||heterogeneity-13/NN||considerable-12/JJ	dobj||demonstrate-11/VBP||heterogeneity-13/NN	prep_in||demonstrate-11/VBP||associations-15/NNS	prep_with||associations-15/NNS||measures-17/NNS	nn||processing-20/NN||insulin-19/NN	prep_of||measures-17/NNS||processing-20/NN	prep_of||measures-17/NNS||secretion-22/NN	conj_and||processing-20/NN||secretion-22/NN	prep_of||measures-17/NNS||sensitivity-25/NN	conj_and||processing-20/NN||sensitivity-25/NN	hyperglycemia-8||insulin-19||yes||genetic loci identified through their effect on hyperglycemia and/or hyperinsulinemia demonstrate considerable heterogeneity in associations with measures of insulin processing, secretion, and sensitivity.
advmod||successful-7/JJ||overall-1/RB	det||curriculum-5/NN||the-3/DT	amod||curriculum-5/NN||j2j-4/JJ	nsubj||successful-7/JJ||curriculum-5/NN	cop||successful-7/JJ||is-6/VBZ	root||ROOT-0/null||successful-7/JJ	prepc_in||successful-7/JJ||providing-9/VBG	iobj||providing-9/VBG||journalists-10/NNS	det||understanding-14/NN||a-12/DT	amod||understanding-14/NN||clear-13/JJ	prep_with||journalists-10/NNS||understanding-14/NN	det||hiv/aids-18/NNS||the-16/DT	amod||hiv/aids-18/NNS||current-17/JJ	prep_of||understanding-14/NN||hiv/aids-18/NNS	amod||objectives-21/NNS||medical-19/JJ	nn||objectives-21/NNS||research-20/NN	dobj||providing-9/VBG||objectives-21/NNS	dobj||providing-9/VBG||issues-23/NNS	conj_and||objectives-21/NNS||issues-23/NNS	amod||journalists-26/NNS||most-25/JJS	prep_with||objectives-21/NNS||journalists-26/NNS	vmod||journalists-26/NNS||reporting-27/VBG	det||ability-30/NN||an-28/DT	amod||ability-30/NN||increased-29/VBN	dobj||reporting-27/VBG||ability-30/NN	aux||investigate-33/VB||to-31/TO	advmod||investigate-33/VB||better-32/RBR	vmod||reporting-27/VBG||investigate-33/VB	vmod||reporting-27/VBG||disseminate-35/VB	conj_and||investigate-33/VB||disseminate-35/VB	amod||information-37/NN||accurate-36/JJ	dobj||investigate-33/VB||information-37/NN	det||subject-40/NN||this-39/DT	prep_on||information-37/NN||subject-40/NN	aids--1||hiv--1||no||overall, the j2j curriculum is successful in providing journalists with a clear understanding of the current hiv/aids medical research objectives and issues with most journalists reporting an increased ability to better investigate and disseminate accurate information on this subject.
prep||used-18/VBN||given-1/VBN	det||safety-3/NN||the-2/DT	pobj||given-1/VBN||safety-3/NN	pobj||given-1/VBN||effectiveness-5/NN	conj_and||safety-3/NN||effectiveness-5/NN	amod||costs-9/NNS||low-8/JJ	pobj||given-1/VBN||costs-9/NNS	conj_and||safety-3/NN||costs-9/NNS	prep_of||costs-9/NNS||albendazole-11/NN	det||drug-14/NN||this-13/DT	nsubjpass||used-18/VBN||drug-14/NN	aux||used-18/VBN||could-15/MD	auxpass||used-18/VBN||be-16/VB	advmod||used-18/VBN||potentially-17/RB	root||ROOT-0/null||used-18/VBN	mark||and/or-22/VBZ||as-19/IN	det||alternative-21/NN||an-20/DT	nsubj||and/or-22/VBZ||alternative-21/NN	advcl||used-18/VBN||and/or-22/VBZ	det||replacement-24/NN||a-23/DT	dobj||and/or-22/VBZ||replacement-24/NN	det||protocols-30/NNS||the-26/DT	amod||protocols-30/NNS||existing-27/VBG	amod||protocols-30/NNS||metronidazole-28/JJ	nn||protocols-30/NNS||therapy-29/NN	prep_for||replacement-24/NN||protocols-30/NNS	det||treatment-33/NN||the-32/DT	prep_in||protocols-30/NNS||treatment-33/NN	prep_of||treatment-33/NN||giardiasis-35/NNS	prep_in||giardiasis-35/NNS||humans-37/NNS	giardiasis-35||albendazole-11||yes||given the safety, effectiveness, and low costs of albendazole, this drug could be potentially used as an alternative and/or a replacement for the existing metronidazole therapy protocols in the treatment of giardiasis in humans.
prep_in||negligible-40/JJ||conclusion-2/NN	prep_in||negligible-40/JJ||patients-5/NNS	prep_with||patients-5/NNS||myocardialinfarction-7/NN	det||contribution-11/NN||the-9/DT	amod||contribution-11/NN||individual-10/JJ	nsubj||negligible-40/JJ||contribution-11/NN	amod||requirements-15/NNS||warfarin-13/JJ	nn||requirements-15/NNS||dose-14/NN	prep_to||contribution-11/NN||requirements-15/NNS	prep||requirements-15/NNS||from-16/IN	nn||*-18/NNP||vkorc1-17/NNP	pobj||from-16/IN||*-18/NNP	num||*-18/NNP||3-19/CD	num||*-18/NNP||vkorc1-21/CD	dep||4-23/CD||*-22/SYM	dep||*-18/NNP||4-23/CD	amod||polymorphisms-38/NNS||cyp4f2-26/JJ	num||câ-29/NN||1347-28/CD	dep||polymorphisms-38/NNS||câ-29/NN	dep||â-33/NN||$-30/$	num||â-33/NN||-31/CD	amod||â-33/NN||>-32/JJ	dep||câ-29/NN||â-33/NN	dep||â-33/NN||$-34/$	number||t-36/CD||-35/CD	num||$-34/$||t-36/CD	prep||requirements-15/NNS||polymorphisms-38/NNS	conj_and||from-16/IN||polymorphisms-38/NNS	pobj||from-16/IN||polymorphisms-38/NNS	cop||negligible-40/JJ||was-39/VBD	root||ROOT-0/null||negligible-40/JJ	myocardialinfarction-7||warfarin-13||yes||in conclusion, in patients with myocardialinfarction, the individual contribution to warfarin dose requirements from vkorc1*3, vkorc1*4, and cyp4f2 (1347 câ>ât) polymorphisms was negligible.
nsubj||anticoagulant-7/NN||warfarin-1/NN	cop||anticoagulant-7/NN||is-2/VBZ	det||anticoagulant-7/NN||a-3/DT	advmod||prescribed-5/JJ||commonly-4/RB	amod||anticoagulant-7/NN||prescribed-5/JJ	amod||anticoagulant-7/NN||oral-6/JJ	root||ROOT-0/null||anticoagulant-7/NN	prep_in||anticoagulant-7/NN||patients-9/NNS	amod||thromboembolism-16/NN||prosthetic-11/JJ	nn||thromboembolism-16/NN||valve-12/NN	nn||thromboembolism-16/NN||disease-13/NN	prep_with||patients-9/NNS||venous-15/NNS	conj_and||thromboembolism-16/NN||venous-15/NNS	prep_with||patients-9/NNS||thromboembolism-16/NN	prep_with||patients-9/NNS||stroke-18/NN	conj_and||thromboembolism-16/NN||stroke-18/NN	thromboembolism-16||warfarin-1||yes||warfarin is a commonly prescribed oral anticoagulant in patients with prosthetic valve disease, venous thromboembolism and stroke.
amod||basic-2/JJ||htlv-1-1/JJ	amod||gene-9/NN||basic-2/JJ	amod||gene-9/NN||leucine-3/JJ	nn||gene-9/NN||zipper-4/NN	nn||gene-9/NN||factor-5/NN	appos||gene-9/NN||hbz-7/NN	nsubj||has-10/VBZ||gene-9/NN	root||ROOT-0/null||has-10/VBZ	det||role-13/NN||a-11/DT	amod||role-13/NN||critical-12/JJ	dobj||has-10/VBZ||role-13/NN	amod||infectivity-16/NN||htlv-1-15/JJ	prep_in||role-13/NN||infectivity-16/NN	det||development-19/NN||the-18/DT	dobj||has-10/VBZ||development-19/NN	conj_and||role-13/NN||development-19/NN	prep_of||development-19/NN||atl-21/NN	prep_of||development-19/NN||ham/tsp-23/NN	conj_and||atl-21/NN||ham/tsp-23/NN	ham--1||htlv-1-15||no||htlv-1 basic leucine zipper factor (hbz) gene has a critical role in htlv-1 infectivity and the development of atl and ham/tsp.
det||analysis-2/NN||this-1/DT	nsubj||illustrates-14/VBZ||analysis-2/NN	nn||patterns-5/NNS||workforce-4/NN	prep_of||analysis-2/NN||patterns-5/NNS	num||facilities-8/NNS||30-7/CD	prep_across||patterns-5/NNS||facilities-8/NNS	num||districts-11/NNS||three-10/CD	prep_in||facilities-8/NNS||districts-11/NNS	prep_of||districts-11/NNS||zambia-13/NN	root||ROOT-0/null||illustrates-14/VBZ	mark||been-25/VBN||that-15/IN	det||achievements-18/NNS||the-16/DT	amod||achievements-18/NNS||remarkable-17/JJ	nsubj||been-25/VBN||achievements-18/NNS	amod||delivery-23/NN||scaling-up-20/JJ	nn||delivery-23/NN||hiv/aids-21/NN	nn||delivery-23/NN||service-22/NN	prep_in||achievements-18/NNS||delivery-23/NN	aux||been-25/VBN||has-24/VBZ	ccomp||illustrates-14/VBZ||been-25/VBN	det||back-28/NN||the-27/DT	prep_on||been-25/VBN||back-28/NN	amod||levels-33/NNS||sustained-30/JJ	amod||levels-33/NNS||non-hiv-31/JJ	nn||levels-33/NNS||workload-32/NN	prep_of||back-28/NN||levels-33/NNS	amod||workload-37/NN||increasing-35/VBG	nn||workload-37/NN||hiv-36/NN	prep_of||back-28/NN||workload-37/NN	conj_and||levels-33/NNS||workload-37/NN	amod||numbers-42/NNS||stagnant-39/JJ	nn||numbers-42/NNS||health-40/NN	nn||numbers-42/NNS||worker-41/NN	prep_of||back-28/NN||numbers-42/NNS	conj_and||levels-33/NNS||numbers-42/NNS	aids--1||hiv-36||no||this analysis of workforce patterns across 30 facilities in three districts of zambia illustrates that the remarkable achievements in scaling-up hiv/aids service delivery has been on the back of sustained non-hiv workload levels, increasing hiv workload and stagnant health worker numbers.
nsubj||drugs-6/NNS||naltrexone-1/NN	conj_and||naltrexone-1/NN||acamprosate-3/NN	nsubj||drugs-6/NNS||acamprosate-3/NN	cop||drugs-6/NNS||are-4/VBP	det||drugs-6/NNS||the-5/DT	root||ROOT-0/null||drugs-6/NNS	amod||choice-9/NN||first-8/JJ	prep_of||drugs-6/NNS||choice-9/NN	aux||treat-11/VB||to-10/TO	vmod||drugs-6/NNS||treat-11/VB	dobj||treat-11/VB||chronicalcoholism-12/NN	chronicalcoholism-12||naltrexone-1||yes||naltrexone and acamprosate are the drugs of first choice to treat chronicalcoholism.
poss||results-2/NNS||our-1/PRP$	nsubj||suggest-3/VBP||results-2/NNS	root||ROOT-0/null||suggest-3/VBP	mark||associated-20/VBN||that-4/IN	amod||inflammation-6/NN||colonic-5/JJ	nsubjpass||associated-20/VBN||inflammation-6/NN	amod||mice-12/NNS||il10-8/JJ	dep||mice-12/NNS||/-10/NNP	prep_in||inflammation-6/NN||mice-12/NNS	vmod||inflammation-6/NN||inoculated-13/VBN	prep_with||inoculated-13/VBN||solutions-15/NNS	vmod||solutions-15/NNS||containing-16/VBG	amod||strains-18/NNS||enterococcus-17/JJ	dobj||containing-16/VBG||strains-18/NNS	auxpass||associated-20/VBN||is-19/VBZ	ccomp||suggest-3/VBP||associated-20/VBN	nn||changes-24/NNS||gene-22/NN	nn||changes-24/NNS||expression-23/NN	prep_with||associated-20/VBN||changes-24/NNS	amod||changes-24/NNS||similar-25/JJ	prep_to||similar-25/JJ||those-27/DT	amod||ibd-30/NN||human-29/JJ	prep_of||those-27/DT||ibd-30/NN	advmod||cd-33/VBN||specifically-32/RB	vmod||changes-24/NNS||cd-33/VBN	mark||model-49/NN||that-36/IN	det||inoculum-42/NN||the-38/DT	amod||inoculum-42/NN||efâ-39/JJ	amod||inoculum-42/NN||·-40/JJ	nn||inoculum-42/NN||cif-41/NN	prep_with||model-49/NN||inoculum-42/NN	prep_in||inoculum-42/NN||particular-44/NN	nsubj||model-49/NN||this-45/DT	cop||model-49/NN||is-46/VBZ	det||model-49/NN||an-47/DT	amod||model-49/NN||appropriate-48/JJ	ccomp||suggest-3/VBP||model-49/NN	conj_and||associated-20/VBN||model-49/NN	aux||investigate-51/VB||to-50/TO	vmod||model-49/NN||investigate-51/VB	amod||interactions-53/NNS||food-gene-52/JJ	nsubj||relevant-54/JJ||interactions-53/NNS	xcomp||investigate-51/VB||relevant-54/JJ	amod||cd-57/NN||human-56/JJ	prep_to||relevant-54/JJ||cd-57/NN	ibd-30||cd-57||no_rel||our results suggest that colonic inflammation in il10 -/- mice inoculated with solutions containing enterococcus strains is associated with gene expression changes similar to those of human ibd, specifically cd, and that with the efâ·cif inoculum in particular this is an appropriate model to investigate food-gene interactions relevant to human cd.
det||pathophysiology-2/NN||the-1/DT	nsubj||multifactorial-6/JJ||pathophysiology-2/NN	nsubj||related-8/VBN||pathophysiology-2/NN	prep_of||pathophysiology-2/NN||anemia-4/NN	cop||multifactorial-6/JJ||is-5/VBZ	root||ROOT-0/null||multifactorial-6/JJ	conj_and||multifactorial-6/JJ||related-8/VBN	amod||factors-11/NNS||various-10/JJ	prep_to||related-8/VBN||factors-11/NNS	prep_including||factors-11/NNS||hemodilution-14/NN	nn||losses-17/NNS||iron-16/NN	appos||hemodilution-14/NN||losses-17/NNS	amod||drugs-20/NNS||anti-platelet-19/JJ	prep_from||losses-17/NNS||drugs-20/NNS	appos||hemodilution-14/NN||activation-22/NN	det||cascade-26/NN||the-24/DT	amod||cascade-26/NN||inflammatory-25/JJ	prep_of||activation-22/NN||cascade-26/NN	amod||losses-29/NNS||urinary-28/JJ	appos||hemodilution-14/NN||losses-29/NNS	prep_of||losses-29/NNS||erythropoietin-31/NN	conj_and||multifactorial-6/JJ||associated-33/VBN	conj_and||related-8/VBN||associated-33/VBN	advmod||associated-33/VBN||renalinsufficiency-34/RB	anemia-4||iron-16||no_rel||the pathophysiology of anemia is multifactorial and related to various factors including; hemodilution, iron losses from anti-platelet drugs, activation of the inflammatory cascade, urinary losses of erythropoietin and associated renalinsufficiency.
det||aim-2/NN||the-1/DT	nsubj||was-6/VBD||aim-2/NN	nsubj||characterize-8/VB||aim-2/NN	det||work-5/NN||this-4/DT	prep_of||aim-2/NN||work-5/NN	root||ROOT-0/null||was-6/VBD	aux||characterize-8/VB||to-7/TO	xcomp||was-6/VBD||characterize-8/VB	xcomp||characterize-8/VB||using-10/VBG	prep_in||using-10/VBG||vitro-12/NN	prep_in||using-10/VBG||in-14/IN	conj_and||vitro-12/NN||in-14/IN	nn||strategies-16/NNS||vivo-15/NN	pobj||in-14/IN||strategies-16/NNS	det||anti-inflammatory-19/NN||the-18/DT	pobj||in-14/IN||anti-inflammatory-19/NN	conj_and||strategies-16/NNS||anti-inflammatory-19/NN	amod||anti-angiogenic-23/JJ||anti-coagulant-21/JJ	pobj||in-14/IN||anti-angiogenic-23/JJ	amod||strategies-16/NNS||anti-angiogenic-23/JJ	conj_and||strategies-16/NNS||anti-angiogenic-23/JJ	amod||activities-27/NNS||anti-tumor-26/JJ	pobj||in-14/IN||activities-27/NNS	conj_and||strategies-16/NNS||activities-27/NNS	num||fractions-33/NNS||two-29/CD	amod||fractions-33/NNS||main-30/JJ	amod||fractions-33/NNS||sulfated-31/JJ	nn||fractions-33/NNS||polysaccharide-32/NN	prep_of||activities-27/NNS||fractions-33/NNS	vmod||fractions-33/NNS||obtained-34/VBN	nn||saccharina-37/NN||l.-36/NN	prep_from||obtained-34/VBN||saccharina-37/NN	det||fraction-42/NN||a-38/DT	amod||fraction-42/NN||-rrb--39/JJ	amod||fraction-42/NN||l.s.-1-40/JJ	dep||l.s.-1-40/JJ||.0-41/CD	dobj||using-10/VBG||fraction-42/NN	advmod||consisting-44/VBG||mainly-43/RB	vmod||fraction-42/NN||consisting-44/VBG	amod||mannoglucuronofucans-47/NNS||o-sulfated-46/JJ	prep_of||consisting-44/VBG||mannoglucuronofucans-47/NNS	prep_of||consisting-44/VBG||b-49/SYM	conj_and||mannoglucuronofucans-47/NNS||b-49/SYM	amod||fraction-53/NN||-rrb--50/JJ	amod||fraction-53/NN||l.s.-1-51/JJ	num||fraction-53/NN||.25-52/CD	dobj||consisting-44/VBG||fraction-53/NN	advmod||composed-55/VBN||mainly-54/RB	vmod||fraction-53/NN||composed-55/VBN	amod||fucans-58/NNS||sulfated-57/JJ	prep_of||composed-55/VBN||fucans-58/NNS	coagulant--1||tumor--1||no_rel||the aim of this work was to characterize , using in vitro and in vivo strategies , the anti-inflammatory , anti-coagulant , anti-angiogenic , and anti-tumor activities of two main sulfated polysaccharide fractions obtained from l. saccharina a -rrb- l.s.-1 .0 fraction mainly consisting of o-sulfated mannoglucuronofucans and b -rrb- l.s.-1 .25 fraction mainly composed of sulfated fucans .
nsubj||ion-5/NN||formate-1/NN	cop||ion-5/NN||was-2/VBD	det||ion-5/NN||the-3/DT	amod||ion-5/NN||principal-4/JJ	root||ROOT-0/null||ion-5/NN	nsubj||displayed-7/VBD||ion-5/NN	rcmod||ion-5/NN||displayed-7/VBD	det||difference-10/NN||a-8/DT	amod||difference-10/NN||significant-9/JJ	dobj||displayed-7/VBD||difference-10/NN	nn||classifications-14/NNS||asthma-12/NN	nn||classifications-14/NNS||status-13/NN	prep_between||difference-10/NN||classifications-14/NNS	asthma-12||ion-5||no_rel||formate was the principal ion that displayed a significant difference between asthma status classifications.
amod||climates-3/NNS||temperate-2/JJ	prep_in||tends-11/VBZ||climates-3/NNS	nn||incidence-10/NN||invasive-5/NNP	amod||incidence-10/NN||meningococcaldisease-6/JJ	nn||incidence-10/NN||imd-8/NN	nsubj||tends-11/VBZ||incidence-10/NN	nsubj||coincide-13/VB||incidence-10/NN	nsubj||follow-17/VB||incidence-10/NN	root||ROOT-0/null||tends-11/VBZ	aux||coincide-13/VB||to-12/TO	xcomp||tends-11/VBZ||coincide-13/VB	prep||coincide-13/VB||with-14/IN	advmod||follow-17/VB||closely-16/RB	xcomp||tends-11/VBZ||follow-17/VB	conj_or||coincide-13/VB||follow-17/VB	amod||incidence-19/NN||peak-18/JJ	dobj||follow-17/VB||incidence-19/NN	prep_of||incidence-19/NN||influenzavirusinfection-21/NN	det||level-26/NN||a-24/DT	amod||level-26/NN||seasonal-25/JJ	prep_at||correlates-32/VBZ||level-26/NN	amod||activity-30/NN||increased-28/VBN	nn||activity-30/NN||influenza-29/NN	nsubj||correlates-32/VBZ||activity-30/NN	advmod||correlates-32/VBZ||frequently-31/RB	parataxis||tends-11/VBZ||correlates-32/VBZ	amod||risk-36/NN||increased-34/VBN	amod||risk-36/NN||seasonal-35/JJ	prep_with||correlates-32/VBZ||risk-36/NN	prep_of||risk-36/NN||imd-38/NN	influenza-29||influenzavirus--1||no||in temperate climates, invasive meningococcaldisease (imd) incidence tends to coincide with or closely follow peak incidence of influenzavirusinfection; at a seasonal level, increased influenza activity frequently correlates with increased seasonal risk of imd.
det||potential-7/NN||an-1/DT	advmod||high-3/JJ||unexpectedly-2/RB	amod||potential-7/NN||high-3/JJ	amod||potential-7/NN||seroprevalence-4/JJ	conj_and||seroprevalence-4/JJ||pathogenic-6/JJ	amod||potential-7/NN||pathogenic-6/JJ	nsubjpass||observed-16/VBN||potential-7/NN	amod||parvovirusb19-10/NNS||human-9/JJ	prep_of||potential-7/NN||parvovirusb19-10/NNS	appos||potential-7/NN||b19v-12/NNP	aux||observed-16/VBN||have-14/VBP	auxpass||observed-16/VBN||been-15/VBN	root||ROOT-0/null||observed-16/VBN	amod||countries-20/NNS||certain-18/JJ	amod||countries-20/NNS||malaria-endemic-19/JJ	prep_in||observed-16/VBN||countries-20/NNS	prep_in||countries-20/NNS||parallel-22/NN	amod||use-25/NN||local-24/JJ	prep_with||observed-16/VBN||use-25/NN	prep_of||use-25/NN||chloroquine-27/NN	appos||chloroquine-27/NN||cq-29/NN	amod||treatment-33/NN||first-line-32/JJ	prep_as||observed-16/VBN||treatment-33/NN	prep_for||treatment-33/NN||malaria-35/NN	malaria-35||chloroquine-27||yes||an unexpectedly high seroprevalence and pathogenic potential of human parvovirusb19 (b19v) have been observed in certain malaria-endemic countries in parallel with local use of chloroquine (cq) as first-line treatment for malaria.
det||effects-2/NNS||the-1/DT	nsubjpass||evaluated-10/VBN||effects-2/NNS	nn||severity-5/NN||disease-4/NN	prep_of||effects-2/NNS||severity-5/NN	prep_on||severity-5/NN||outcomes-7/NNS	aux||evaluated-10/VBN||will-8/MD	auxpass||evaluated-10/VBN||be-9/VB	root||ROOT-0/null||evaluated-10/VBN	xcomp||evaluated-10/VBN||using-11/VBG	amod||markers-13/NNS||important-12/JJ	dobj||using-11/VBG||markers-13/NNS	nn||severity-16/NN||disease-15/NN	prep_of||markers-13/NNS||severity-16/NN	prep_of||markers-13/NNS||survival-18/NN	conj_and||severity-16/NN||survival-18/NN	amod||capacity-24/NN||forced-22/VBN	amod||capacity-24/NN||vital-23/JJ	prep_such_as||markers-13/NNS||capacity-24/NN	amod||factor-28/NN||carbonmonoxide-26/JJ	nn||factor-28/NN||transfer-27/NN	prep_such_as||markers-13/NNS||factor-28/NN	conj_and||capacity-24/NN||factor-28/NN	prep_such_as||markers-13/NNS||pulmonaryhypertension-30/NN	conj_and||capacity-24/NN||pulmonaryhypertension-30/NN	carbonmonoxide-26||pulmonaryhypertension-30||no_rel||the effects of disease severity on outcomes will be evaluated using important markers of disease severity and survival, such as forced vital capacity, carbonmonoxide transfer factor and pulmonaryhypertension.
nsubjpass||excluded-8/VBN||patients-1/NNS	dep||patients-1/NNS||taking-2/VBG	dobj||taking-2/VBG||antihypertensiveagents-3/NNS	dep||patients-1/NNS||with-5/IN	conj_or||taking-2/VBG||with-5/IN	pobj||with-5/IN||renalinsufficiency-6/NN	auxpass||excluded-8/VBN||were-7/VBD	root||ROOT-0/null||excluded-8/VBN	antihypertensiveagents-3||renalinsufficiency-6||no_rel||patients taking antihypertensiveagents or with renalinsufficiency were excluded.
det||reason-3/NN||this-2/DT	prep_for||underwent-11/VBD||reason-3/NN	num||male-5/NN||41-4/CD	nsubj||underwent-11/VBD||male-5/NN	num||patients-10/NNS||15-7/CD	amod||patients-10/NNS||female-8/JJ	nn||patients-10/NNS||alcohol-9/NN	conj_and||male-5/NN||patients-10/NNS	nsubj||underwent-11/VBD||patients-10/NNS	root||ROOT-0/null||underwent-11/VBD	dobj||underwent-11/VBD||mri-scanning-12/NN	amod||detoxification-15/NN||in-patient-14/JJ	nsubj||entering-19/VBG||detoxification-15/NN	appos||detoxification-15/NN||baseline-17/NN	prepc_after||underwent-11/VBD||entering-19/VBG	nn||programs-22/NNS||alcoholism-20/NN	nn||programs-22/NNS||treatment-21/NN	dobj||entering-19/VBG||programs-22/NNS	amod||6-26/CD||between-25/IN	num||months-29/NNS||6-26/CD	conj_and||6-26/CD||9â-28/CD	num||months-29/NNS||9â-28/CD	npadvmod||later-30/RB||months-29/NNS	dobj||entering-19/VBG||later-30/RB	advmod||programs-22/NNS||later-30/RB	conj_and||programs-22/NNS||later-30/RB	dep||underwent-11/VBD||follow-up-32/VB	det||phase-37/NN||a-36/DT	prep_in||underwent-11/VBD||phase-37/NN	prep_of||phase-37/NN||convalescence-39/NN	alcoholism-20||alcohol-9||no||for this reason 41 male and 15 female alcohol patients underwent mri-scanning after in-patient detoxification (baseline) entering alcoholism treatment programs, and between 6 and 9â months later (follow-up), in a phase of convalescence.
det||aim-2/NN||the-1/DT	nsubj||is-6/VBZ||aim-2/NN	nsubj||evaluate-8/VB||aim-2/NN	det||paper-5/NN||this-4/DT	prep_of||aim-2/NN||paper-5/NN	root||ROOT-0/null||is-6/VBZ	aux||evaluate-8/VB||to-7/TO	xcomp||is-6/VBZ||evaluate-8/VB	det||effect-10/NN||the-9/DT	dobj||evaluate-8/VB||effect-10/NN	prep_of||effect-10/NN||antipsychotics-12/NNS	det||treatment-15/NN||the-14/DT	prep_for||antipsychotics-12/NNS||treatment-15/NN	prep_of||treatment-15/NN||schizophrenia-17/NN	det||community-20/NN||a-19/DT	prep_in||evaluate-8/VB||community-20/NN	vmod||community-20/NN||based-21/VBN	dobj||based-21/VBN||study-22/NN	amod||function-25/NN||sexual-24/JJ	prep_on||based-21/VBN||function-25/NN	nn||levels-28/NNS||prolactin-27/NN	prep_on||based-21/VBN||levels-28/NNS	conj_and||function-25/NN||levels-28/NNS	vmod||function-25/NN||comparing-29/VBG	det||use-31/NN||the-30/DT	dobj||comparing-29/VBG||use-31/NN	prep_of||use-31/NN||aripiprazole-33/NN	prep_of||use-31/NN||standard-35/NN	conj_and||aripiprazole-33/NN||standard-35/NN	prep_of||use-31/NN||care-37/NN	nsubj||choice-46/NN||care-37/NN	appos||care-37/NN||soc-39/NN	cop||choice-46/NN||was-43/VBD	det||choice-46/NN||a-44/DT	amod||choice-46/NN||limited-45/JJ	rcmod||care-37/NN||choice-46/NN	num||antipsychotics-53/NNS||three-48/CD	advmod||used-50/JJ||widely-49/RB	amod||antipsychotics-53/NNS||used-50/JJ	conj_and||used-50/JJ||available-52/JJ	amod||antipsychotics-53/NNS||available-52/JJ	prep_of||choice-46/NN||antipsychotics-53/NNS	dep||antipsychotics-53/NNS||olanzapine-55/NN	dep||olanzapine-55/NN||quetiapine-57/JJ	dep||olanzapine-55/NN||risperidone-59/JJ	conj_or||quetiapine-57/JJ||risperidone-59/JJ	det||trial-64/NN||the-62/DT	nn||trial-64/NN||schizophrenia-63/NN	dep||antipsychotics-53/NNS||trial-64/NN	amod||-RSB--73/NNS||aripiprazole-66/JJ	nn||-RSB--73/NNS||-LSB--67/NNP	nn||-RSB--73/NNS||star-68/NN	nn||-RSB--73/NNS||-RSB--69/NN	nn||-RSB--73/NNS||study-70/NN	nn||-RSB--73/NNS||-LSB--71/NN	amod||-RSB--73/NNS||nct00237913-72/JJ	prep_of||trial-64/NN||-RSB--73/NNS	schizophrenia-63||aripiprazole-66||yes||the aim of this paper is to evaluate the effect of antipsychotics for the treatment of schizophrenia in a community based study on sexual function and prolactin levels comparing the use of aripiprazole and standard of care (soc), which was a limited choice of three widely used and available antipsychotics (olanzapine, quetiapine or risperidone) (the schizophrenia trial of aripiprazole [star] study [nct00237913]).
mark||known-4/VBN||although-1/IN	nsubjpass||known-4/VBN||little-2/RB	auxpass||known-4/VBN||is-3/VBZ	advcl||some-30/DT||known-4/VBN	det||factors-8/NNS||the-6/DT	nn||factors-8/NNS||host-7/NN	prep_about||known-4/VBN||factors-8/NNS	mark||mycobacteriumtuberculosis-13/VBZ||that-9/IN	csubj||mycobacteriumtuberculosis-13/VBZ||induce-10/VB	conj_and||induce-10/VB||maintain-12/VB	csubj||mycobacteriumtuberculosis-13/VBZ||maintain-12/VB	ccomp||known-4/VBN||mycobacteriumtuberculosis-13/VBZ	amod||-rrb--17/NNS||-lrb--14/JJ	nn||-rrb--17/NNS||m.-15/NN	nn||-rrb--17/NNS||tb-16/NN	dobj||mycobacteriumtuberculosis-13/VBZ||-rrb--17/NNS	nn||lesions-20/NNS||latent-19/NN	prep_within||mycobacteriumtuberculosis-13/VBZ||lesions-20/NNS	amod||limitation-26/NN||o2-22/JJ	nn||limitation-26/NN||depletion-23/NN	conj_and||limitation-26/NN||nutrient-25/NN	nsubj||some-30/DT||nutrient-25/NN	nsubj||some-30/DT||limitation-26/NN	conj_and||limitation-26/NN||acidification-28/NN	nsubj||some-30/DT||acidification-28/NN	cop||some-30/DT||are-29/VBP	root||ROOT-0/null||some-30/DT	det||stresses-33/NN||the-32/DT	prep_of||some-30/DT||stresses-33/NN	vmod||stresses-33/NN||implicated-34/VBN	amod||arrest-39/NN||bacterial-36/JJ	nn||arrest-39/NN||dormancy-37/NN	nn||arrest-39/NN||development/growth-38/NN	prep_in||implicated-34/VBN||arrest-39/NN	tb-16||mycobacteriumtuberculosis-13||no||although little is known about the host factors that induce and maintain mycobacteriumtuberculosis -lrb- m. tb -rrb- within latent lesions , o2 depletion , nutrient limitation and acidification are some of the stresses implicated in bacterial dormancy development/growth arrest .
nsubj||propose-2/VBP||we-1/PRP	root||ROOT-0/null||propose-2/VBP	mark||provide-17/VBP||that-3/IN	det||stratifications-6/NNS||these-4/DT	nn||stratifications-6/NNS||risk-5/NN	nsubj||provide-17/VBP||stratifications-6/NNS	mark||adapted-9/VBD||as-8/IN	dep||stratifications-6/NNS||adapted-9/VBD	det||conditions-12/NNS||the-11/DT	prep_to||adapted-9/VBD||conditions-12/NNS	amod||hospitals-15/NNS||specific-14/JJ	prep_in||adapted-9/VBD||hospitals-15/NNS	ccomp||propose-2/VBP||provide-17/VBP	det||approach-21/NN||the-18/DT	advmod||rational-20/JJ||most-19/RBS	amod||approach-21/NN||rational-20/JJ	dobj||provide-17/VBP||approach-21/NN	aux||lidocaine-23/VB||to-22/TO	vmod||provide-17/VBP||lidocaine-23/VB	dobj||lidocaine-23/VB||prophylaxis-24/NNS	amod||ventricularfibrillation-27/NN||primary-26/JJ	prep_of||prophylaxis-24/NNS||ventricularfibrillation-27/NN	ventricularfibrillation-27||lidocaine-23||yes||we propose that these risk stratifications, as adapted to the conditions in specific hospitals, provide the most rational approach to lidocaine prophylaxis of primary ventricularfibrillation.
nsubj||result-6/VBP||mutations-1/NNS	nsubj||produce-11/VB||mutations-1/NNS	det||gene-5/NN||the-3/DT	nn||gene-5/NN||hfe-4/NN	prep_in||mutations-1/NNS||gene-5/NN	ccomp||characterized-22/VBD||result-6/VBP	prep_in||result-6/VBP||ironoverload-8/NN	aux||produce-11/VB||can-10/MD	conj_and||result-6/VBP||produce-11/VB	ccomp||characterized-22/VBD||produce-11/VB	dobj||produce-11/VB||hereditaryhemochromatosis-12/NNS	appos||hereditaryhemochromatosis-12/NNS||hh-14/NN	det||disorder-18/NN||a-17/DT	nsubj||characterized-22/VBD||disorder-18/NN	nn||metabolism-21/NN||iron-20/NN	prep_of||disorder-18/NN||metabolism-21/NN	root||ROOT-0/null||characterized-22/VBD	amod||absorption-27/NN||increased-24/VBN	amod||absorption-27/NN||intestinal-25/JJ	nn||absorption-27/NN||iron-26/NN	prep_by||characterized-22/VBD||absorption-27/NN	hereditaryhemochromatosis-12||iron-26||no||mutations in the hfe gene result in ironoverload and can produce hereditaryhemochromatosis (hh), a disorder of iron metabolism characterized by increased intestinal iron absorption.
amod||asthma-2/NN||aspirin-intolerant-1/JJ	nsubjpass||caused-9/VBN||asthma-2/NN	nsubj||causes-20/VBZ||asthma-2/NN	appos||asthma-2/NN||aia-4/NN	auxpass||caused-9/VBN||is-8/VBZ	rcmod||asthma-2/NN||caused-9/VBN	amod||anti-inflammatorydrugs-12/NNS||non-steroidal-11/JJ	agent||caused-9/VBN||anti-inflammatorydrugs-12/NNS	appos||anti-inflammatorydrugs-12/NNS||nsaids-14/NNS	prep_such_as||anti-inflammatorydrugs-12/NNS||aspirin-18/NN	root||ROOT-0/null||causes-20/VBZ	nn||inflammation-22/NN||lung-21/NN	dobj||causes-20/VBZ||inflammation-22/NN	nn||reduction-26/NN||reversal-24/NN	nn||reduction-26/NN||bronchi-25/NNS	dobj||causes-20/VBZ||reduction-26/NN	conj_and||inflammation-22/NN||reduction-26/NN	appos||inflammation-22/NN||leading-28/VBG	prep_to||leading-28/VBG||difficulty-30/NN	prep_in||leading-28/VBG||breathing-32/NN	asthma-2||aspirin-18||no||aspirin-intolerant asthma (aia), which is caused by non-steroidal anti-inflammatorydrugs (nsaids) such as aspirin, causes lung inflammation and reversal bronchi reduction, leading to difficulty in breathing.
det||effects-4/NNS||the-1/DT	amod||effects-4/NNS||possible-2/JJ	nn||effects-4/NNS||neuroprotector-3/NN	nsubjpass||studied-11/VBN||effects-4/NNS	prep_of||effects-4/NNS||ptx-6/NN	amod||deficit-9/NN||behavioral-8/JJ	prep_on||ptx-6/NN||deficit-9/NN	auxpass||studied-11/VBN||were-10/VBD	root||ROOT-0/null||studied-11/VBN	amod||rats-15/NNS||male-13/JJ	nn||rats-15/NNS||wistar-14/NN	prep_in||studied-11/VBN||rats-15/NNS	vmod||rats-15/NNS||subjected-16/VBN	det||model-19/NN||a-18/DT	prep_to||subjected-16/VBN||model-19/NN	amod||brainischemia-23/NN||transient-21/JJ	amod||brainischemia-23/NN||global-22/JJ	prep_of||model-19/NN||brainischemia-23/NN	brainischemia-23||ptx-6||yes||the possible neuroprotector effects of ptx on behavioral deficit were studied in male wistar rats subjected to a model of transient global brainischemia.
det||dose-3/NN||the-1/DT	amod||dose-3/NN||same-2/JJ	nsubj||produced-8/VBD||dose-3/NN	nsubj||reduced-43/VBD||dose-3/NN	amod||cepa-7/NN||crude-5/JJ	nn||cepa-7/NN||allium-6/NN	prep_of||dose-3/NN||cepa-7/NN	root||ROOT-0/null||produced-8/VBD	det||reduction-11/NN||a-9/DT	amod||reduction-11/NN||significant-10/JJ	dobj||produced-8/VBD||reduction-11/NN	det||hyperglycemia-15/NN||the-13/DT	amod||hyperglycemia-15/NN||induced-14/JJ	prep_in||reduction-11/NN||hyperglycemia-15/NN	appos||reduction-11/NN||gtt-17/NN	quantmod||120-21/CD||about-20/RB	num||mg/dl-22/NN||120-21/CD	prep_by||produced-8/VBD||mg/dl-22/NN	prepc_compared_to||produced-8/VBD||to-24/TO	pobj||produced-8/VBD||water-25/NN	num||mg/dl-28/NN||77-27/CD	appos||water-25/NN||mg/dl-28/NN	pobj||produced-8/VBD||insulin-31/NN	conj_and||water-25/NN||insulin-31/NN	num||mg/dl-34/NN||153-33/CD	appos||water-25/NN||mg/dl-34/NN	nn||patients-40/NNS||type-37/NN	num||patients-40/NNS||1-38/CD	nn||patients-40/NNS||diabetic-39/NN	prep_in||produced-8/VBD||patients-40/NNS	advmod||reduced-43/VBD||considerably-42/RB	conj_and||produced-8/VBD||reduced-43/VBD	dobj||reduced-43/VBD||gtt-44/NN	amod||mg/dl-47/NN||159-46/JJ	prep_by||reduced-43/VBD||mg/dl-47/NN	prep_in||mg/dl-47/NN||relation-49/NN	prep_to||reduced-43/VBD||water-51/NN	num||mg/dl-54/NN||55-53/CD	appos||water-51/NN||mg/dl-54/NN	prep_to||reduced-43/VBD||glibenclamide-57/NN	conj_and||water-51/NN||glibenclamide-57/NN	number||mg/dl-60/CD||114-59/CD	dep||glibenclamide-57/NN||mg/dl-60/CD	amod||patients-66/NNS||type-63/NN	number||type-63/NN||2-64/CD	amod||patients-66/NNS||diabetic-65/JJ	prep_in||glibenclamide-57/NN||patients-66/NNS	num||hours-70/NNS||4-69/CD	prep_after||reduced-43/VBD||hours-70/NNS	hyperglycemia-15||insulin-31||yes||the same dose of crude allium cepa produced a significant reduction in the induced hyperglycemia (gtt) by about 120 mg/dl compared to water (77 mg/dl) and insulin (153 mg/dl) in type 1 diabetic patients and considerably reduced gtt by 159 mg/dl in relation to water (55 mg/dl) and glibenclamide (114 mg/dl) in type 2 diabetic patients, after 4 hours.
det||study-2/NN||this-1/DT	nsubj||aimed-3/VBD||study-2/NN	nsubj||examine-5/VB||study-2/NN	root||ROOT-0/null||aimed-3/VBD	aux||examine-5/VB||to-4/TO	xcomp||aimed-3/VBD||examine-5/VB	det||effect-7/NN||the-6/DT	dobj||examine-5/VB||effect-7/NN	prep_of||effect-7/NN||chemerin-9/NN	nn||metabolism-16/NNS||weight-11/NN	conj_and||weight-11/NN||glucose-13/NN	nn||metabolism-16/NNS||glucose-13/NN	conj_and||weight-11/NN||lipid-15/NN	nn||metabolism-16/NNS||lipid-15/NN	prep_on||chemerin-9/NN||metabolism-16/NNS	prep_of||effect-7/NN||atherosclerosis-21/NNS	conj_and||chemerin-9/NN||atherosclerosis-21/NNS	prep_in||atherosclerosis-21/NNS||vivo-23/NN	atherosclerosis-21||glucose-13||no_rel||this study aimed to examine the effect of chemerin on weight, glucose and lipid metabolism, as well as atherosclerosis in vivo.
det||diagnosis-2/NN||the-1/DT	nsubj||challenging-15/VBG||diagnosis-2/NN	nsubj||changing-27/VBG||diagnosis-2/NN	conj_and||diagnosis-2/NN||management-4/NN	nsubj||challenging-15/VBG||management-4/NN	prep_of||diagnosis-2/NN||patients-6/NNS	nsubj||have-8/VBP||patients-6/NNS	rcmod||patients-6/NNS||have-8/VBP	amod||vasculitis-12/NNS||anti-neutrophil-9/JJ	amod||vasculitis-12/NNS||cytoplasmic-10/JJ	amod||vasculitis-12/NNS||antibody-associated-11/JJ	dobj||have-8/VBP||vasculitis-12/NNS	aux||challenging-15/VBG||may-13/MD	aux||challenging-15/VBG||be-14/VB	root||ROOT-0/null||challenging-15/VBG	poss||infrequency-20/NN||its-18/PRP$	amod||infrequency-20/NN||relative-19/JJ	prep_because_of||challenging-15/VBG||infrequency-20/NN	appos||infrequency-20/NN||variability-22/NN	amod||expression-25/NN||clinical-24/JJ	prep_of||variability-22/NN||expression-25/NN	conj_and||challenging-15/VBG||changing-27/VBG	dobj||changing-27/VBG||nomenclature-28/NN	antibody--1||vasculitis-12||no_rel||the diagnosis and management of patients who have anti-neutrophil cytoplasmic antibody-associated vasculitis may be challenging because of its relative infrequency, variability of clinical expression and changing nomenclature.
amod||2â-4/NNS||neuacî-2/JJ	amod||2â-4/NNS||±-3/JJ	prep_as||has-28/VBZ||2â-4/NNS	nsubj||has-28/VBZ||$-5/$	num||play-10/NN||6-7/CD	amod||play-10/NN||polylactosamine-8/JJ	nn||play-10/NN||glycans-9/NNS	npadvmod||in-23/RB||play-10/NN	amod||roles-12/NNS||major-11/JJ	advmod||play-10/NN||roles-12/NNS	amod||virusinfection-15/NN||human-14/JJ	prep_in||roles-12/NNS||virusinfection-15/NN	det||importance-18/NN||the-17/DT	appos||virusinfection-15/NN||importance-18/NN	det||components-22/NNS||these-20/DT	nn||components-22/NNS||receptor-21/NN	prep_of||importance-18/NN||components-22/NNS	dep||virusinfection-24/CD||in-23/RB	num||$-5/$||virusinfection-24/CD	amod||cells-27/NNS||swine-26/JJ	prep_of||$-5/$||cells-27/NNS	root||ROOT-0/null||has-28/VBZ	dobj||has-28/VBZ||implications-29/NNS	prep_for||implications-29/NNS||transmission-31/NN	prep_of||transmission-31/NN||viruses-33/NNS	prep_between||viruses-33/NNS||humans-35/NNS	prep_between||viruses-33/NNS||pigs-37/NNS	conj_and||humans-35/NNS||pigs-37/NNS	prep_for||implications-29/NNS||pigs-40/NNS	conj_and||transmission-31/NN||pigs-40/NNS	amod||hosts-44/NNS||possible-42/JJ	nn||hosts-44/NNS||adaptation-43/NN	prep_as||pigs-40/NNS||hosts-44/NNS	nn||humaninfluenzaviruses-47/NNS||novel-46/NN	prep_of||hosts-44/NNS||humaninfluenzaviruses-47/NNS	virusinfection-24||viruses-33||no||as neuacî±2â6 polylactosamine glycans play major roles in human virusinfection, the importance of these receptor components in virusinfection of swine cells has implications for transmission of viruses between humans and pigs and for pigs as possible adaptation hosts of novel humaninfluenzaviruses.
nsubjpass||caused-3/VBN||type2diabetes-1/NNS	auxpass||caused-3/VBN||is-2/VBZ	root||ROOT-0/null||caused-3/VBN	agent||caused-3/VBN||defects-5/NNS	preconj||signaling-9/NN||both-7/DT	nn||signaling-9/NN||insulin-8/NN	prep_in||defects-5/NNS||signaling-9/NN	nn||secretion-12/NN||insulin-11/NN	prep_in||defects-5/NNS||secretion-12/NN	conj_and||signaling-9/NN||secretion-12/NN	insulin-11||type2diabetes-1||no_rel||type2diabetes is caused by defects in both insulin signaling and insulin secretion.
amod||5-fluorouracil-2/NN||adjuvant-1/JJ	root||ROOT-0/null||5-fluorouracil-2/NN	appos||5-fluorouracil-2/NN||5fu-4/NNP	vmod||5-fluorouracil-2/NN||based-7/VBN	nsubjpass||considered-11/VBN||chemo-radiotherapy-8/NN	auxpass||considered-11/VBN||is-9/VBZ	advmod||considered-11/VBN||currently-10/RB	ccomp||based-7/VBN||considered-11/VBN	det||standard-13/NN||a-12/DT	dobj||considered-11/VBN||standard-13/NN	prep_of||standard-13/NN||care-15/NN	det||treatment-18/NN||the-17/DT	prep_for||5-fluorouracil-2/NN||treatment-18/NN	amod||cancer-21/NN||gastric-20/JJ	prep_of||treatment-18/NN||cancer-21/NN	cancer-21||5fu-4||no_rel||adjuvant 5-fluorouracil (5fu)-based chemo-radiotherapy is currently considered a standard of care for the treatment of gastric cancer.
nsubj||predisposes-2/VBZ||osteoarthritis-1/NNS	root||ROOT-0/null||predisposes-2/VBZ	amod||deposition-6/NN||local-4/JJ	nn||deposition-6/NN||crystal-5/NN	prep_to||predisposes-2/VBZ||deposition-6/NN	crystal-5||osteoarthritis-1||no_rel||osteoarthritis predisposes to local crystal deposition.
det||step-3/NN||a-1/DT	amod||step-3/NN||key-2/JJ	nsubj||dysfunction-11/NN||step-3/NN	det||development-6/NN||the-5/DT	prep_in||step-3/NN||development-6/NN	prep_of||development-6/NN||atherosclerosis-8/NNS	cop||dysfunction-11/NN||is-9/VBZ	amod||dysfunction-11/NN||endothelial-10/JJ	root||ROOT-0/null||dysfunction-11/NN	amod||dysfunction-11/NN||manifest-13/JJ	det||reduction-16/NN||a-15/DT	prep_by||manifest-13/JJ||reduction-16/NN	prep_in||reduction-16/NN||bioactivity-18/NN	prep_of||bioactivity-18/NN||nitricoxide-20/NN	discourse||nitricoxide-20/NN||no-22/UH	nitricoxide-20||atherosclerosis-8||no_rel||a key step in the development of atherosclerosis is endothelial dysfunction, manifest by a reduction in bioactivity of nitricoxide (no).
nsubjpass||associated-35/VBN||diarrhoea-1/NN	dep||diarrhoea-1/NN||p-3/VBN	dep||0.0740-5/CD||=-4/SYM	ccomp||p-3/VBN||0.0740-5/CD	appos||diarrhoea-1/NN||neutropenia-8/NN	dep||neutropenia-8/NN||p-10/VBN	dep||0.396-12/CD||=-11/SYM	ccomp||p-10/VBN||0.396-12/CD	amod||efficacy-17/NN||clinical-16/JJ	conj_and||diarrhoea-1/NN||efficacy-17/NN	nsubjpass||associated-35/VBN||efficacy-17/NN	nn||rate-20/NN||response-19/NN	dep||efficacy-17/NN||rate-20/NN	appos||rate-20/NN||p-22/NN	dep||0.583-24/CD||=-23/SYM	rcmod||p-22/NN||0.583-24/CD	dep||p-22/NN||pfs-26/NN	vmod||pfs-26/NN||p-28/VBN	dep||0.916-30/CD||=-29/SYM	ccomp||p-28/VBN||0.916-30/CD	auxpass||associated-35/VBN||were-32/VBD	neg||associated-35/VBN||not-33/RB	advmod||associated-35/VBN||significantly-34/RB	root||ROOT-0/null||associated-35/VBN	amod||genotype-38/NN||cyp2a6-37/JJ	prep_with||associated-35/VBN||genotype-38/NN	prep_despite||associated-35/VBN||differences-41/NNS	amod||exposure-44/NN||5-fu-43/JJ	prep_in||differences-41/NNS||exposure-44/NN	neutropenia-8||5-fu-43||no||diarrhoea ( p =0.0740), neutropenia ( p =0.396), and clinical efficacy (response rate, p =0.583; pfs, p =0.916) were not significantly associated with cyp2a6 genotype, despite differences in 5-fu exposure.
poss||study-3/NN||our-1/PRP$	amod||study-3/NN||previous-2/JJ	nsubj||showed-4/VBD||study-3/NN	root||ROOT-0/null||showed-4/VBD	mark||increased-14/VBN||that-5/IN	nsubjpass||increased-14/VBN||expression-6/NN	prep_of||expression-6/NN||c-met-8/NN	nn||cells-12/NNS||prostate-10/NN	nn||cells-12/NNS||cancer-11/NN	prep_in||c-met-8/NN||cells-12/NNS	auxpass||increased-14/VBN||was-13/VBD	ccomp||showed-4/VBD||increased-14/VBN	prep_after||increased-14/VBN||attenuation-16/NN	nn||receptor-19/NN||androgen-18/NN	prep_of||attenuation-16/NN||receptor-19/NN	appos||receptor-19/NN||ar-21/NN	vmod||receptor-19/NN||signalling-23/VBG	androgen-18||cancer-11||no_rel||our previous study showed that expression of c-met in prostate cancer cells was increased after attenuation of androgen receptor (ar) signalling.
amod||components-4/NNS||hiv/aids-1/JJ	nn||components-4/NNS||prevention-2/NN	nn||components-4/NNS||program-3/NN	nsubj||include-6/VB||components-4/NNS	nsubj||promoting-17/VBG||components-4/NNS	aux||include-6/VB||could-5/MD	root||ROOT-0/null||include-6/VB	nn||campaigns-8/NNS||media-7/NNS	dobj||include-6/VB||campaigns-8/NNS	amod||improvement-12/NN||educational-10/JJ	nn||improvement-12/NN||intervention-11/NN	appos||campaigns-8/NNS||improvement-12/NN	conj_and||include-6/VB||promoting-17/VBG	dobj||promoting-17/VBG||policies-18/NNS	nsubj||shape-20/VBP||policies-18/NNS	rcmod||policies-18/NNS||shape-20/VBP	amod||livelihoods-23/NNS||female-21/JJ	nn||livelihoods-23/NNS||youth-22/NN	dobj||shape-20/VBP||livelihoods-23/NNS	aids--1||hiv--1||no||hiv/aids prevention program components could include media campaigns, educational intervention improvement, as well as promoting policies that shape female youth livelihoods.
advmod||emphasized-7/VBD||recently-1/RB	det||organization-6/NN||the-3/DT	nn||organization-6/NN||world-4/NN	nn||organization-6/NN||health-5/NN	nsubj||emphasized-7/VBD||organization-6/NN	nsubj||recommended-25/VBD||organization-6/NN	root||ROOT-0/null||emphasized-7/VBD	det||benefit-10/NN||the-8/DT	amod||benefit-10/NN||potential-9/JJ	dobj||emphasized-7/VBD||benefit-10/NN	amod||treatment-14/NN||intermittent-12/JJ	nn||treatment-14/NN||preventive-13/NN	prep_of||benefit-10/NN||treatment-14/NN	prep_in||treatment-14/NN||infants-16/NNS	appos||infants-16/NNS||ipti-18/NNP	nn||malaria-22/NN||control-21/NN	prep_to||emphasized-7/VBD||malaria-22/NN	advmod||recommended-25/VBD||officially-24/RB	conj_and||emphasized-7/VBD||recommended-25/VBD	dobj||recommended-25/VBD||implementation-26/NN	prep_of||implementation-26/NN||ipti-28/NNS	amod||sp-32/NN||sulfadoxine-pyrimethamine-30/JJ	prep_with||ipti-28/NNS||sp-32/NN	prep_in||sp-32/NN||areas-35/NNS	amod||transmission-40/NN||moderate-37/JJ	conj_and||moderate-37/JJ||high-39/JJ	amod||transmission-40/NN||high-39/JJ	prep_with||areas-35/NNS||transmission-40/NN	advmod||high-47/JJ||where-42/WRB	nn||resistance-44/NN||sp-43/NN	nsubj||high-47/JJ||resistance-44/NN	cop||high-47/JJ||is-45/VBZ	neg||high-47/JJ||not-46/RB	rcmod||transmission-40/NN||high-47/JJ	malaria-22||pyrimethamine--1||yes||recently, the world health organization emphasized the potential benefit of intermittent preventive treatment in infants (ipti) to control malaria and officially recommended implementation of ipti with sulfadoxine-pyrimethamine (sp) in areas with moderate and high transmission, where sp resistance is not high.
advmod||reduction-3/NN||moreover-1/RB	det||reduction-3/NN||the-2/DT	nsubj||lead-18/VB||reduction-3/NN	prep_of||reduction-3/NN||campylobacter-5/NN	quantmod||2-8/CD||approximately-7/RB	num||log10cfu/g-9/NNS||2-8/CD	prep_by||campylobacter-5/NN||log10cfu/g-9/NNS	mark||occurred-12/VBD||as-11/IN	dep||reduction-3/NN||occurred-12/VBD	poss||study-15/NN||our-14/PRP$	prep_in||occurred-12/VBD||study-15/NN	aux||lead-18/VB||could-17/MD	root||ROOT-0/null||lead-18/VB	det||reduction-22/NN||a-20/DT	amod||reduction-22/NN||30-fold-21/JJ	prep_to||lead-18/VB||reduction-22/NN	det||incidence-25/NN||the-24/DT	prep_in||reduction-22/NN||incidence-25/NN	prep_of||incidence-25/NN||campylobacteriosis-27/NNS	vmod||campylobacteriosis-27/NNS||associated-28/VBN	prep_with||associated-28/VBN||consumption-30/NN	nn||meals-33/NNS||chicken-32/NN	prep_of||consumption-30/NN||meals-33/NNS	prepc_according_to||consumption-30/NN||to-36/TO	amod||models-38/NNS||mathematical-37/JJ	pobj||consumption-30/NN||models-38/NNS	campylobacteriosis-27||campylobacter-5||no||moreover the reduction of campylobacter by approximately 2 log10cfu/g, as occurred in our study, could lead to a 30-fold reduction in the incidence of campylobacteriosis associated with consumption of chicken meals (according to mathematical models).
nsubj||predictive-10/JJ||presence-1/NN	det||value-5/NN||a-3/DT	amod||value-5/NN||positive-4/JJ	prep_of||presence-1/NN||value-5/NN	prep_for||value-5/NN||hbsag-7/NN	cop||predictive-10/JJ||was-8/VBD	neg||predictive-10/JJ||not-9/RB	root||ROOT-0/null||predictive-10/JJ	det||dna-15/NN||a-12/DT	amod||dna-15/NN||positive-13/JJ	nn||dna-15/NN||hbv-14/NN	prep_of||predictive-10/JJ||dna-15/NN	poss||level-18/NN||its-17/PRP$	conj_or||predictive-10/JJ||level-18/NN	prep_in||level-18/NN||blood-20/NN	nn||0.05-24/NNS||p-22/NN	nn||0.05-24/NNS||ë-23/NN	appos||blood-20/NN||0.05-24/NNS	hbv-14||hbsag-7||yes||presence of a positive value for hbsag was not predictive of a positive hbv dna or its level in blood (p ë 0.05).
vmod||has-26/VBZ||conclusionsâ-1/VBG	dobj||conclusionsâ-1/VBG||$-2/$	prep_in||$-2/$||contrast-5/NN	prep_to||conclusionsâ-1/VBG||animals-7/NNS	prep_in||conclusionsâ-1/VBG||humans-10/NNS	nsubj||has-26/VBZ||prevention-12/NN	amod||hypoglycemia-15/NN||portal-14/JJ	prep_of||prevention-12/NN||hypoglycemia-15/NN	amod||glucose-18/NN||oral-17/JJ	prep_with||hypoglycemia-15/NN||glucose-18/NN	det||beginning-21/NN||the-20/DT	prep_from||glucose-18/NN||beginning-21/NN	amod||hypoglycemia-25/NN||insulin-induced-23/JJ	amod||hypoglycemia-25/NN||slow-fall-24/JJ	prep_of||beginning-21/NN||hypoglycemia-25/NN	root||ROOT-0/null||has-26/VBZ	neg||effect-28/NN||no-27/DT	dobj||has-26/VBZ||effect-28/NN	amod||responses-33/NNS||sympathoadrenal-30/JJ	conj_and||sympathoadrenal-30/JJ||symptomatic-32/JJ	amod||responses-33/NNS||symptomatic-32/JJ	prep_on||effect-28/NN||responses-33/NNS	prep_to||has-26/VBZ||hypoglycemia-35/NN	hypoglycemia-35||glucose-18||yes||conclusionsâ in contrast to animals, in humans, prevention of portal hypoglycemia with oral glucose from the beginning of insulin-induced slow-fall hypoglycemia has no effect on sympathoadrenal and symptomatic responses to hypoglycemia.
det||strategy-5/NN||a-1/DT	amod||strategy-5/NN||pubmed-2/JJ	nn||strategy-5/NN||literature-3/NN	nn||strategy-5/NN||search-4/NN	nsubjpass||used-12/VBN||strategy-5/NN	det||terms-10/NNS||the-7/DT	amod||terms-10/NNS||following-8/JJ	nn||terms-10/NNS||mesh-9/NN	prep_including||strategy-5/NN||terms-10/NNS	auxpass||used-12/VBN||were-11/VBD	root||ROOT-0/null||used-12/VBN	mark||follows-14/VBZ||as-13/IN	advcl||used-12/VBN||follows-14/VBZ	dep||follows-14/VBZ||â-15/VB	dobj||â-15/VB||$-16/$	num||$-16/$||dentin-17/CD	vmod||$-16/$||sensitivityâ-18/VBG	dobj||sensitivityâ-18/VBG||$-19/$	num||$-19/$||-LSB--20/CD	vmod||$-19/$||mesh-21/VBN	iobj||mesh-21/VBN||terms-22/NNS	iobj||mesh-21/VBN||-RSB--23/NN	iobj||mesh-21/VBN||â-25/NN	conj_or||-RSB--23/NN||â-25/NN	dep||mesh-21/VBN||$-26/$	num||$-26/$||dentinâ-27/CD	dep||mesh-21/VBN||$-28/$	num||$-28/$||-LSB--29/CD	det||fields-31/NNS||all-30/DT	iobj||mesh-21/VBN||fields-31/NNS	iobj||mesh-21/VBN||-RSB--32/NN	iobj||mesh-21/VBN||â-34/NN	conj_and||-RSB--32/NN||â-34/NN	dep||mesh-21/VBN||$-35/$	num||$-35/$||sensitivityâ-36/CD	dep||mesh-21/VBN||$-37/$	num||$-37/$||-LSB--38/CD	det||fields-40/NNS||all-39/DT	iobj||mesh-21/VBN||fields-40/NNS	iobj||mesh-21/VBN||-RSB--41/NN	iobj||mesh-21/VBN||â-43/NN	conj_or||-RSB--41/NN||â-43/NN	dep||mesh-21/VBN||$-44/$	num||$-44/$||dentin-45/CD	num||$-44/$||sensitivityâ-46/CD	dep||mesh-21/VBN||$-47/$	num||$-47/$||-LSB--48/CD	det||fields-50/NNS||all-49/DT	iobj||mesh-21/VBN||fields-50/NNS	iobj||mesh-21/VBN||-RSB--51/NN	iobj||mesh-21/VBN||â-53/NN	conj_or||-RSB--51/NN||â-53/NN	dep||mesh-21/VBN||$-54/$	num||$-54/$||dentinâ-55/CD	dep||mesh-21/VBN||$-56/$	num||$-56/$||-LSB--57/CD	det||fields-59/NNS||all-58/DT	iobj||mesh-21/VBN||fields-59/NNS	iobj||mesh-21/VBN||-RSB--60/NN	iobj||mesh-21/VBN||â-62/NN	conj_and||-RSB--60/NN||â-62/NN	dep||mesh-21/VBN||$-63/$	num||$-63/$||hypersensitivityâ-64/CD	dep||mesh-21/VBN||$-65/$	num||$-65/$||-LSB--66/CD	det||fields-68/NNS||all-67/DT	iobj||mesh-21/VBN||fields-68/NNS	iobj||mesh-21/VBN||-RSB--69/NN	iobj||mesh-21/VBN||â-71/NN	conj_or||-RSB--69/NN||â-71/NN	dep||mesh-21/VBN||$-72/$	num||$-72/$||dentin-73/CD	num||$-72/$||hypersensitivityâ-74/CD	dep||mesh-21/VBN||$-75/$	num||$-75/$||-LSB--76/CD	det||fields-78/NNS||all-77/DT	iobj||mesh-21/VBN||fields-78/NNS	iobj||mesh-21/VBN||-RSB--79/NN	iobj||mesh-21/VBN||â-81/NN	conj_and||-RSB--79/NN||â-81/NN	dep||mesh-21/VBN||$-82/$	num||$-82/$||diagnosisâ-83/CD	dep||mesh-21/VBN||$-84/$	num||$-84/$||-LSB--85/CD	amod||-RSB--87/NN||subheading-86/JJ	iobj||mesh-21/VBN||-RSB--87/NN	iobj||mesh-21/VBN||â-89/NN	conj_or||-RSB--87/NN||â-89/NN	dep||mesh-21/VBN||$-90/$	num||$-90/$||diagnosisâ-91/CD	dep||mesh-21/VBN||$-92/$	num||$-92/$||-LSB--93/CD	det||fields-95/NNS||all-94/DT	iobj||mesh-21/VBN||fields-95/NNS	iobj||mesh-21/VBN||-RSB--96/NN	iobj||mesh-21/VBN||â-98/NN	conj_or||-RSB--96/NN||â-98/NN	dep||mesh-21/VBN||$-99/$	num||$-99/$||diagnosisâ-100/CD	dep||mesh-21/VBN||$-101/$	num||$-101/$||-LSB--102/CD	nn||terms-104/NNS||mesh-103/NN	iobj||mesh-21/VBN||terms-104/NNS	iobj||mesh-21/VBN||-RSB--105/NN	iobj||mesh-21/VBN||â-107/NN	conj_and||-RSB--105/NN||â-107/NN	dobj||mesh-21/VBN||$-108/$	num||$-108/$||assessmentâ-109/CD	prep||mesh-21/VBN||$-110/$	num||$-110/$||-LSB--111/CD	det||-RSB--114/NN||all-112/DT	nn||-RSB--114/NN||fields-113/NNS	dep||$-110/$||-RSB--114/NN	dep||-RSB--114/NN||â-117/NN	dep||â-117/NN||$-118/$	num||$-118/$||methodsâ-119/CD	num||-RSB--123/NNS||$-120/$	number||subheading-122/CD||-LSB--121/CD	num||$-120/$||subheading-122/CD	dep||$-118/$||-RSB--123/NNS	advmod||$-126/$||â-125/RB	dep||-RSB--114/NN||$-126/$	conj_or||â-117/NN||$-126/$	rcmod||â-117/NN||$-126/$	num||$-126/$||methodsâ-127/CD	dep||$-126/$||$-128/$	num||$-128/$||-LSB--129/CD	det||-RSB--132/NN||all-130/DT	nn||-RSB--132/NN||fields-131/NNS	dep||$-110/$||-RSB--132/NN	conj_and||-RSB--114/NN||-RSB--132/NN	dep||follows-14/VBZ||â-134/VB	conj_or||â-15/VB||â-134/VB	dobj||â-134/VB||$-135/$	num||$-135/$||methodsâ-136/CD	num||terms-140/NNS||$-137/$	number||mesh-139/CD||-LSB--138/CD	num||$-137/$||mesh-139/CD	npadvmod||-RSB--141/JJ||terms-140/NNS	amod||$-135/$||-RSB--141/JJ	hypersensitivity--1||hypersensitivity--1||no||a pubmed literature search strategy including the following mesh terms were used as follows âdentin sensitivityâ?[mesh terms] or âdentinâ?[all fields] and âsensitivityâ?[all fields] or âdentin sensitivityâ?[all fields] or âdentinâ?[all fields] and âhypersensitivityâ?[all fields] or âdentin hypersensitivityâ?[all fields] and âdiagnosisâ?[subheading] or âdiagnosisâ?[all fields] or âdiagnosisâ?[mesh terms] and âassessmentâ?[all fields] and (âmethodsâ?[subheading] or âmethodsâ?[all fields] or âmethodsâ?[mesh terms].
nsubj||led-9/VBD||over-expression-1/NN	amod||proteins-4/NNS||socs-3/JJ	prep_of||over-expression-1/NN||proteins-4/NNS	nn||lines-8/NNS||melanoma-6/NN	nn||lines-8/NNS||cell-7/NN	prep_in||proteins-4/NNS||lines-8/NNS	root||ROOT-0/null||led-9/VBD	amod||inhibition-12/NN||significant-11/JJ	prep_to||led-9/VBD||inhibition-12/NN	amod||stat1-15/NNS||tyr701-phosphorylated-14/JJ	prep_of||inhibition-12/NN||stat1-15/NNS	dep||stat1-15/NNS||p-stat1-17/JJ	nn||expression-21/NN||gene-20/NN	prep_to||led-9/VBD||expression-21/NN	conj_and||inhibition-12/NN||expression-21/NN	prep_following||expression-21/NN||stimulation-23/NN	nn||±-26/NNP||ifn-î-25/NNP	prep_with||stimulation-23/NN||±-26/NNP	dep||±-26/NNP||ifit2-28/NNP	dep||ifit2-28/NNP||oas-1-30/JJ	dep||ifit2-28/NNP||isg-15-32/JJ	nn||³-36/NNP||ifn-î-35/NNP	prep_with||stimulation-23/NN||³-36/NNP	conj_or||±-26/NNP||³-36/NNP	appos||±-26/NNP||irf1-38/NNP	ifn--1||oas--1||no_rel||over-expression of socs proteins in melanoma cell lines led to significant inhibition of tyr701-phosphorylated stat1 (p-stat1) and gene expression following stimulation with ifn-î± (ifit2, oas-1, isg-15) or ifn-î³ (irf1).
det||study-4/NN||a-1/DT	amod||cohort-3/JJ||retrospective-2/JJ	amod||study-4/NN||cohort-3/JJ	nsubjpass||conducted-6/VBN||study-4/NN	auxpass||conducted-6/VBN||was-5/VBD	root||ROOT-0/null||conducted-6/VBN	xcomp||conducted-6/VBN||using-7/VBG	det||center-11/NN||an-8/DT	amod||center-11/NN||academic-9/JJ	nn||center-11/NN||health-10/NN	dobj||using-7/VBG||center-11/NN	amod||record-15/NN||enterprise-wide-12/JJ	amod||record-15/NN||electronic-13/JJ	nn||record-15/NN||health-14/NN	prep||center-11/NN||record-15/NN	appos||record-15/NN||ehr-17/NN	dep||record-15/NN||system-19/NN	aux||identify-21/VB||to-20/TO	vmod||system-19/NN||identify-21/VB	num||patients-23/NNS||11,141-22/CD	dobj||identify-21/VB||patients-23/NNS	prep_with||identify-21/VB||type2diabetes-25/NNS	num||initiators-28/NNS||4,279-27/CD	dep||type2diabetes-25/NNS||initiators-28/NNS	prep_of||initiators-28/NNS||monotherapy-30/NN	prep_with||monotherapy-30/NN||glyburide-32/NN	num||initiators-35/NNS||4,325-34/CD	dep||type2diabetes-25/NNS||initiators-35/NNS	conj_and||initiators-28/NNS||initiators-35/NNS	prep_of||initiators-35/NNS||monotherapy-37/NN	prep_with||monotherapy-37/NN||glipizide-39/NN	num||initiators-43/NNS||2,537-42/CD	dep||type2diabetes-25/NNS||initiators-43/NNS	conj_and||initiators-28/NNS||initiators-43/NNS	prep_of||initiators-43/NNS||monotherapy-45/NN	prep_with||monotherapy-45/NN||glimepiride-47/NN	vmod||system-19/NN||â-50/VB	conj_and||identify-21/VB||â-50/VB	conj_and||identify-21/VB||â-50/VB	conj_and||â-50/VB||â-50/VB	nn||¥-52/NNP||-51/NNP	dobj||â-50/VB||¥-52/NNP	num||years-54/NNS||18-53/CD	npadvmod||¥-52/NNP||years-54/NNS	prep_of||¥-52/NNP||age-56/NN	det||history-61/NN||a-60/DT	prep_with||â-50/VB||history-61/NN	prep_without||â-50/VB||history-61/NN	amod||disease-65/NN||coronary-63/JJ	nn||disease-65/NN||artery-64/NN	prep_of||history-61/NN||disease-65/NN	appos||history-61/NN||cad-67/NN	vmod||system-19/NN||not-70/RB	conj_and||identify-21/VB||not-70/RB	neg||identify-21/VB||not-70/RB	prep_on||not-70/RB||insulin-72/NN	det||noninsulin-75/NN||a-74/DT	prep_on||not-70/RB||noninsulin-75/NN	conj_or||insulin-72/NN||noninsulin-75/NN	vmod||system-19/NN||injectable-76/VB	conj_and||identify-21/VB||injectable-76/VB	prep_at||injectable-76/VB||baseline-78/NN	type2diabetes-25||insulin-72||yes||a retrospective cohort study was conducted using an academic health center enterprise-wide electronic health record (ehr) system to identify 11,141 patients with type2diabetes (4,279 initiators of monotherapy with glyburide, 4,325 initiators of monotherapy with glipizide, and 2,537 initiators of monotherapy with glimepiride), â¥18 years of age with and without a history of coronary artery disease (cad) and not on insulin or a noninsulin injectable at baseline.
nsubj||likely-3/JJ||it-1/PRP	cop||likely-3/JJ||is-2/VBZ	root||ROOT-0/null||likely-3/JJ	mark||decreases-13/VBZ||that-4/IN	det||expression-7/NN||the-5/DT	amod||expression-7/NN||augmented-6/JJ	nsubj||decreases-13/VBZ||expression-7/NN	nsubj||reduces-18/VBZ||expression-7/NN	prep_of||expression-7/NN||c-jun-9/NN	amod||islets-12/NNS||diabetic-11/JJ	prep_in||c-jun-9/NN||islets-12/NNS	ccomp||likely-3/JJ||decreases-13/VBZ	nn||expression-15/NN||mafa-14/NN	dobj||decreases-13/VBZ||expression-15/NN	advmod||reduces-18/VBZ||thereby-17/RB	ccomp||likely-3/JJ||reduces-18/VBZ	conj_and||decreases-13/VBZ||reduces-18/VBZ	nn||biosynthesis-20/NNS||insulin-19/NN	dobj||reduces-18/VBZ||biosynthesis-20/NNS	nsubjpass||observed-25/VBN||biosynthesis-20/NNS	auxpass||observed-25/VBN||is-23/VBZ	advmod||observed-25/VBN||often-24/RB	rcmod||biosynthesis-20/NNS||observed-25/VBN	prep_in||observed-25/VBN||type2diabetes-27/CD	type2diabetes-27||insulin-19||yes||it is likely that the augmented expression of c-jun in diabetic islets decreases mafa expression and thereby reduces insulin biosynthesis, which is often observed in type2diabetes.
advmod||suggest-7/VBP||importantly-1/RB	det||analyses-6/NNS||the-3/DT	amod||analyses-6/NNS||warfarin-polymer-4/JJ	amod||analyses-6/NNS||rebinding-5/VBG	nsubj||suggest-7/VBP||analyses-6/NNS	root||ROOT-0/null||suggest-7/VBP	dobj||suggest-7/VBP||strategies-8/NNS	prepc_for||suggest-7/VBP||regulating-10/VBG	amod||binding-12/JJ||ligand-11/JJ	amod||capacity-13/NN||binding-12/JJ	dobj||regulating-10/VBG||capacity-13/NN	dobj||regulating-10/VBG||specificity-15/NN	conj_and||capacity-13/NN||specificity-15/NN	prep_through||regulating-10/VBG||variation-17/NN	det||degree-20/NN||the-19/DT	prep_of||variation-17/NN||degree-20/NN	prep_of||degree-20/NN||cross-linking-22/NN	advmod||afford-33/VB||where-24/WRB	nsubj||afford-33/VB||polymers-25/NNS	vmod||polymers-25/NNS||prepared-26/VBN	det||degree-30/NN||a-28/DT	amod||degree-30/NN||lower-29/JJR	prep_with||prepared-26/VBN||degree-30/NN	prep_of||degree-30/NN||cross-linking-32/NN	advcl||suggest-7/VBP||afford-33/VB	amod||capacity-35/NN||higher-34/JJR	dobj||afford-33/VB||capacity-35/NN	dep||non-specific-37/JJ||though-36/IN	acomp||afford-33/VB||non-specific-37/JJ	prep_in||non-specific-37/JJ||character-39/NN	cross--1||warfarin--1||no_rel||importantly, the warfarin-polymer rebinding analyses suggest strategies for regulating ligand binding capacity and specificity through variation of the degree of cross-linking, where polymers prepared with a lower degree of cross-linking afford higher capacity though non-specific in character.
mark||expected-2/VBN||as-1/IN	advcl||produced-6/VBD||expected-2/VBN	amod||hypoglycemia-5/NN||insulin-induced-4/JJ	nsubj||produced-6/VBD||hypoglycemia-5/NN	root||ROOT-0/null||produced-6/VBD	det||increase-9/NN||a-7/DT	amod||increase-9/NN||threefold-8/JJ	dobj||produced-6/VBD||increase-9/NN	nn||glucagon-12/NN||plasma-11/NN	prep_in||produced-6/VBD||glucagon-12/NN	hypoglycemia-5||glucagon-12||yes||as expected, insulin-induced hypoglycemia produced a threefold increase in plasma glucagon.
nsubjpass||documented-34/VBN||viruses-1/NNS	nsubj||develop-36/VB||viruses-1/NNS	dep||viruses-1/NNS||other-2/JJ	det||viruses-6/NNS||the-4/DT	nn||viruses-6/NNS||hepatitis-5/NN	prep_than||viruses-1/NNS||viruses-6/NNS	amod||virus-15/NN||parvovirusb19-9/JJ	amod||epstein-13/JJ||cytomegalovirus-11/JJ	amod||virus-15/NN||epstein-13/JJ	nn||virus-15/NN||bar-14/NN	prep_such_as||viruses-6/NNS||virus-15/NN	nn||virus-19/NN||transfusion-17/NN	amod||virus-19/NN||transmitted-18/JJ	prep_such_as||viruses-6/NNS||virus-19/NN	conj_and||virus-15/NN||virus-19/NN	appos||virus-19/NN||ttv-21/NN	amod||virus-26/NN||non-a-e-24/JJ	nn||virus-26/NN||hepatitis-25/NN	prep_such_as||viruses-6/NNS||virus-26/NN	conj_and||virus-15/NN||virus-26/NN	amod||viruses-29/NNS||unknown-28/JJ	appos||virus-26/NN||viruses-29/NNS	aux||documented-34/VBN||has-31/VBZ	advmod||documented-34/VBN||also-32/RB	auxpass||documented-34/VBN||been-33/VBN	root||ROOT-0/null||documented-34/VBN	aux||develop-36/VB||to-35/TO	xcomp||documented-34/VBN||develop-36/VB	det||syndrome-38/NN||the-37/DT	dobj||develop-36/VB||syndrome-38/NN	virus-26||viruses-29||no||viruses other than the hepatitis viruses such as parvovirusb19, cytomegalovirus, epstein bar virus, transfusion transmitted virus (ttv) and non-a-e hepatitis virus (unknown viruses) has also been documented to develop the syndrome.
det||transmission-3/NN||the-1/DT	nn||transmission-3/NN||household-2/NN	nsubj||problem-13/NN||transmission-3/NN	prep_of||transmission-3/NN||hepatitisbvirus-5/NNS	appos||hepatitisbvirus-5/NNS||hbv-7/NN	cop||problem-13/NN||is-9/VBZ	det||problem-13/NN||a-10/DT	amod||problem-13/NN||major-11/JJ	nn||problem-13/NN||health-12/NN	root||ROOT-0/null||problem-13/NN	hbv-7||hepatitisbvirus-5||no||the household transmission of hepatitisbvirus (hbv) is a major health problem.
nsubjpass||genotyped-14/VBN||participants-1/NNS	nn||â-4/NN||n-3/NN	dep||participants-1/NNS||â-4/NN	nsubj||â-8/VBP||$-5/$	number||=-7/CD||-6/CD	num||$-5/$||=-7/CD	rcmod||â-4/NN||â-8/VBP	dobj||â-8/VBP||$-9/$	number||2,751-11/CD||-10/CD	num||$-9/$||2,751-11/CD	auxpass||genotyped-14/VBN||were-13/VBD	root||ROOT-0/null||genotyped-14/VBN	num||snps-17/NNS||73-16/CD	prep_for||genotyped-14/VBN||snps-17/NNS	prep_from||computed-53/VBN||snps-17/NNS	advmod||associated-19/VBN||previously-18/RB	vmod||snps-17/NNS||associated-19/VBN	amod||levels-30/NNS||type2diabetes-21/JJ	amod||levels-30/NNS||fasting-23/JJ	nn||levels-30/NNS||glucose/insulin-24/NN	nn||levels-30/NNS||concentrations-25/NNS	conj_or||concentrations-25/NNS||obesity-27/NN	nn||levels-30/NNS||obesity-27/NN	conj_or||concentrations-25/NNS||lipid-29/NN	nn||levels-30/NNS||lipid-29/NN	prep_with||associated-19/VBN||levels-30/NNS	num||scores-37/NNS||five-34/CD	amod||scores-37/NNS||genetic-35/JJ	nn||scores-37/NNS||risk-36/NN	nsubjpass||computed-53/VBN||scores-37/NNS	dep||scores-37/NNS||one-39/CD	prep_for||one-39/CD||each-41/DT	det||traits-45/NNS||the-43/DT	num||traits-45/NNS||four-44/CD	prep_of||each-41/DT||traits-45/NNS	prep_for||one-39/CD||one-47/CD	conj_and||each-41/DT||one-47/CD	vmod||one-47/CD||combining-48/VBG	det||snps-50/NNS||all-49/DT	dobj||combining-48/VBG||snps-50/NNS	auxpass||computed-53/VBN||were-52/VBD	rcmod||snps-17/NNS||computed-53/VBN	type2diabetes-21||insulin--1||yes||participants ( n â=â2,751) were genotyped for 73 snps previously associated with type2diabetes, fasting glucose/insulin concentrations, obesity or lipid levels, from which five genetic risk scores (one for each of the four traits and one combining all snps) were computed.
nsubjpass||stimulated-17/VBN||ams-1/NN	nsubjpass||stimulated-17/VBN||ams-1/NN	vmod||ams-1/NN||obtained-2/VBN	amod||bronchoscopy-5/NN||fiberoptic-4/JJ	agent||obtained-2/VBN||bronchoscopy-5/NN	num||non-asthmatics-8/NNS||14-7/CD	prep_from||obtained-2/VBN||non-asthmatics-8/NNS	num||non-severe-11/NN||12-10/CD	prep_from||obtained-2/VBN||non-severe-11/NN	conj_and||non-asthmatics-8/NNS||non-severe-11/NN	num||asthmatics-15/NNS||11-13/CD	amod||asthmatics-15/NNS||severe-14/JJ	prep_from||obtained-2/VBN||asthmatics-15/NNS	conj_and||non-asthmatics-8/NNS||asthmatics-15/NNS	auxpass||stimulated-17/VBN||were-16/VBD	root||ROOT-0/null||stimulated-17/VBN	conj_or||stimulated-17/VBN||stimulated-17/VBN	prep_with||stimulated-17/VBN||lipopolysaccharide-19/NN	number||,10-22/CD||lps-21/CD	num||1/4-24/CD||,10-22/CD	number||1/4-24/CD||î-23/CD	npadvmod||g/ml-25/JJ||1/4-24/CD	dep||lipopolysaccharide-19/NN||g/ml-25/JJ	prep_with||stimulated-17/VBN||dexamethasone-30/NN	prep_without||stimulated-17/VBN||dexamethasone-30/NN	dep||dexamethasone-30/NN||10-6m-32/JJ	asthmatics-15||dexamethasone-30||yes||ams obtained by fiberoptic bronchoscopy from 14 non-asthmatics, 12 non-severe and 11 severe asthmatics were stimulated with lipopolysaccharide (lps,10 î¼g/ml) with or without dexamethasone (10-6m).
det||incidence-3/NN||the-1/DT	amod||incidence-3/NN||reported-2/JJ	nsubj||growing-10/VBG||incidence-3/NN	amod||isolates-6/NNS||drug-resistant-5/JJ	prep_of||incidence-3/NN||isolates-6/NNS	prep_of||isolates-6/NNS||m.tuberculosis-8/NNS	aux||growing-10/VBG||is-9/VBZ	root||ROOT-0/null||growing-10/VBG	advmod||growing-10/VBG||steadily-11/RB	advmod||reported-52/VBN||however-13/RB	nsubjpass||reported-52/VBN||data-15/NNS	det||variation-19/NN||the-17/DT	amod||variation-19/NN||genetic-18/JJ	prep_on||data-15/NNS||variation-19/NN	prep_of||variation-19/NN||isolates-21/NNP	prep_of||isolates-21/NNP||m.tuberculosis-23/NNS	vmod||m.tuberculosis-23/NNS||circulating-24/VBG	vmod||m.tuberculosis-23/NNS||circulating-24/VBG	conj_and||circulating-24/VBG||circulating-24/VBG	amod||ukraine-27/NN||northern-26/JJ	prep_in||circulating-24/VBG||ukraine-27/NN	det||spectrum-31/NN||the-30/DT	prep_on||circulating-24/VBG||spectrum-31/NN	prep_on||circulating-24/VBG||frequency-33/NN	conj_and||spectrum-31/NN||frequency-33/NN	prep_of||spectrum-31/NN||occurrence-35/NN	prep_of||occurrence-35/NN||mutations-37/NNS	vmod||mutations-37/NNS||determining-38/VBG	dobj||determining-38/VBG||resistance-39/NN	det||drugs-44/NNS||the-41/DT	amod||drugs-44/NNS||principal-42/JJ	amod||drugs-44/NNS||anti-tuberculosis-43/JJ	prep_to||determining-38/VBG||drugs-44/NNS	amod||drugs-44/NNS||isoniazid-45/JJ	amod||drugs-44/NNS||rifampicin-47/JJ	conj_and||isoniazid-45/JJ||rifampicin-47/JJ	aux||reported-52/VBN||have-48/VBP	neg||reported-52/VBN||not-49/RB	advmod||reported-52/VBN||yet-50/RB	auxpass||reported-52/VBN||been-51/VBN	parataxis||growing-10/VBG||reported-52/VBN	tuberculosis--1||m.tuberculosis-23||no||the reported incidence of drug-resistant isolates of m.tuberculosis is growing steadily ; however , data on the genetic variation of isolates of m.tuberculosis circulating in northern ukraine and on the spectrum and frequency of occurrence of mutations determining resistance to the principal anti-tuberculosis drugs isoniazid and rifampicin have not yet been reported .
mark||encouraging-4/VBG||though-1/IN	nsubj||encouraging-4/VBG||results-2/NNS	cop||encouraging-4/VBG||were-3/VBD	advcl||revealed-23/VBD||encouraging-4/VBG	nsubj||revealed-23/VBD||efforts-6/NNS	aux||examine-8/VB||to-7/TO	vmod||efforts-6/NNS||examine-8/VB	amod||use-10/NN||surfactant-9/JJ	dobj||examine-8/VB||use-10/NN	prep_in||examine-8/VB||infants-12/NNS	prep_with||infants-12/NNS||rds-14/NN	det||measure-18/NN||a-16/DT	nn||measure-18/NN||process-17/NN	prep_as||examine-8/VB||measure-18/NN	vmod||measure-18/NN||reflecting-19/VBG	dobj||reflecting-19/VBG||quality-20/NN	prep_of||quality-20/NN||care-22/NN	root||ROOT-0/null||revealed-23/VBD	amod||challenges-25/NNS||significant-24/JJ	dobj||revealed-23/VBD||challenges-25/NNS	surfactant-9||rds-14||no_rel||though results were encouraging, efforts to examine surfactant use in infants with rds as a process measure reflecting quality of care revealed significant challenges.
det||inhibition-4/NN||the-2/DT	amod||inhibition-4/NN||platelet-3/JJ	prep_in||reduced-14/VBD||inhibition-4/NN	amod||outcomes-7/NNS||patient-6/JJ	conj_and||inhibition-4/NN||outcomes-7/NNS	prep_in||reduced-14/VBD||outcomes-7/NNS	appos||outcomes-7/NNS||plato-9/NNP	dep||outcomes-7/NNS||trial-11/NN	nsubj||reduced-14/VBD||ticagrelor-13/NN	root||ROOT-0/null||reduced-14/VBD	det||endpoint-18/NN||the-15/DT	amod||endpoint-18/NN||primary-16/JJ	amod||endpoint-18/NN||composite-17/JJ	dobj||reduced-14/VBD||endpoint-18/NN	amod||death-21/NN||cardiovascular-20/JJ	prep_of||endpoint-18/NN||death-21/NN	prep_of||endpoint-18/NN||myocardialinfarction-23/NN	conj_or||death-21/NN||myocardialinfarction-23/NN	prep_of||endpoint-18/NN||stroke-26/NN	conj_or||death-21/NN||stroke-26/NN	conj_but||reduced-14/VBD||with-29/IN	amod||rates-31/NNS||similar-30/JJ	pobj||with-29/IN||rates-31/NNS	amod||bleeding-34/NN||major-33/JJ	prep_of||rates-31/NNS||bleeding-34/NN	prepc_compared_with||reduced-14/VBD||with-36/IN	pobj||reduced-14/VBD||clopidogrel-37/NN	bleeding-34||clopidogrel-37||no||in the platelet inhibition and patient outcomes (plato) trial, ticagrelor reduced the primary composite endpoint of cardiovascular death, myocardialinfarction, or stroke, but with similar rates of major bleeding compared with clopidogrel.
det||proteins-3/NNS||the-1/DT	amod||proteins-3/NNS||dihalogenated-2/JJ	nsubjpass||separated-5/VBN||proteins-3/NNS	auxpass||separated-5/VBN||were-4/VBD	root||ROOT-0/null||separated-5/VBN	amod||electrophoresis-10/NNS||two-dimensional-7/JJ	amod||electrophoresis-10/NNS||polyacrylamide-8/JJ	nn||electrophoresis-10/NNS||gel-9/NN	nsubj||using-14/VBG||electrophoresis-10/NNS	dep||electrophoresis-10/NNS||2d-page-12/JJ	agent||separated-5/VBN||using-14/VBG	amod||antibodies-17/NNS||novel-15/JJ	amod||antibodies-17/NNS||monoclonal-16/JJ	dobj||using-14/VBG||antibodies-17/NNS	prep_against||using-14/VBG||dibromotyrosine-19/NN	dep||using-14/VBG||dibry-21/RB	nsubjpass||identified-27/VBN||they-25/PRP	auxpass||identified-27/VBN||were-26/VBD	conj_and||separated-5/VBN||identified-27/VBN	amod||time-of-flight-32/NN||matrix-assisted-29/JJ	nn||time-of-flight-32/NN||laser-30/NN	nn||time-of-flight-32/NN||desorption/ionization-31/NN	agent||identified-27/VBN||time-of-flight-32/NN	dep||time-of-flight-32/NN||maldi-tof-34/JJ	amod||fingerprinting-38/NN||peptide-36/JJ	amod||fingerprinting-38/NN||mass-37/JJ	dep||time-of-flight-32/NN||fingerprinting-38/NN	det||search-43/NN||a-40/DT	nn||search-43/NN||mascot-41/NN	nn||search-43/NN||database-42/NN	agent||identified-27/VBN||search-43/NN	conj_and||time-of-flight-32/NN||search-43/NN	tof--1||antibodies-17||no_rel||the dihalogenated proteins were separated by two-dimensional polyacrylamide gel electrophoresis (2d-page) using novel monoclonal antibodies against dibromotyrosine (dibry), and they were identified by matrix-assisted laser desorption/ionization time-of-flight (maldi-tof) peptide mass fingerprinting and a mascot database search.
csubj||misses-7/VBZ||testing-1/VBG	amod||clients-3/NNS||only-2/JJ	dobj||testing-1/VBG||clients-3/NNS	nn||risk-6/NN||hiv-5/NN	prep_with||testing-1/VBG||risk-6/NN	root||ROOT-0/null||misses-7/VBZ	amod||number-9/NN||large-8/JJ	dobj||misses-7/VBZ||number-9/NN	amod||patients-12/NNS||hivpositive-11/JJ	prep_of||number-9/NN||patients-12/NNS	hivpositive-11||hiv-5||no||testing only clients with hiv risk misses large number of hivpositive patients.
vmod||evaluated-19/VBN||considering-1/VBG	mark||considered-7/VBN||that-2/IN	amod||control-5/NN||poor-3/JJ	amod||control-5/NN||metabolic-4/JJ	nsubjpass||considered-7/VBN||control-5/NN	auxpass||considered-7/VBN||is-6/VBZ	ccomp||considering-1/VBG||considered-7/VBN	det||factor-10/NN||a-8/DT	amod||factor-10/NN||deranging-9/VBG	dobj||considered-7/VBN||factor-10/NN	amod||performance-13/NN||cognitive-12/JJ	prep_for||factor-10/NN||performance-13/NN	amod||patients-16/NNS||diabetic-15/JJ	prep_in||performance-13/NN||patients-16/NNS	nsubj||evaluated-19/VBN||we-18/PRP	root||ROOT-0/null||evaluated-19/VBN	mark||independent-34/JJ||whether-20/IN	det||contributions-22/NNS||the-21/DT	nsubj||independent-34/JJ||contributions-22/NNS	prep_of||contributions-22/NNS||mage-24/NN	aux||cognitive-26/VB||to-25/TO	vmod||mage-24/NN||cognitive-26/VB	dobj||cognitive-26/VB||status-27/NN	amod||patients-30/NNS||older-29/JJR	prep_in||cognitive-26/VB||patients-30/NNS	prep_with||patients-30/NNS||type2diabetes-32/CD	cop||independent-34/JJ||were-33/VBD	ccomp||evaluated-19/VBN||independent-34/JJ	det||markers-38/NNS||the-36/DT	amod||markers-38/NNS||main-37/JJ	prep_from||independent-34/JJ||markers-38/NNS	amod||control-41/NN||glycemic-40/JJ	prep_of||markers-38/NNS||control-41/NN	amod||hyperglycemia-47/NN||sustained-45/VBN	amod||hyperglycemia-47/NN||chronic-46/JJ	prep_such_as||markers-38/NNS||hyperglycemia-47/NN	appos||hyperglycemia-47/NN||a1c-49/NNP	amod||glycemia-53/NN||postprandial-52/JJ	prep_such_as||markers-38/NNS||glycemia-53/NN	conj_and||hyperglycemia-47/NN||glycemia-53/NN	dep||glycemia-53/NN||ppg-55/VBN	amod||glucose-61/NN||fasting-59/VBG	nn||glucose-61/NN||plasma-60/NN	prep_such_as||markers-38/NNS||glucose-61/NN	conj_and||hyperglycemia-47/NN||glucose-61/NN	appos||glucose-61/NN||fpg-63/NN	hyperglycemia-47||glucose-61||no||considering that poor metabolic control is considered a deranging factor for cognitive performance in diabetic patients, we evaluated whether the contributions of mage to cognitive status in older patients with type2diabetes were independent from the main markers of glycemic control, such as sustained chronic hyperglycemia (a1c), postprandial glycemia (ppg), and fasting plasma glucose (fpg).
det||burden-3/NN||the-1/DT	nn||burden-3/NN||disease-2/NN	nsubj||highest-15/JJS||burden-3/NN	prep_of||burden-3/NN||humanimmunodeficiencyvirus-5/NNS	appos||humanimmunodeficiencyvirus-5/NNS||hiv-7/NN	amod||aids-12/NNS||acquiredimmunodeficiencysyndrome-10/JJ	dep||humanimmunodeficiencyvirus-5/NNS||aids-12/NNS	cop||highest-15/JJS||is-14/VBZ	root||ROOT-0/null||highest-15/JJS	amod||africa-18/NN||sub-saharan-17/JJ	prep_in||highest-15/JJS||africa-18/NN	expl||are-21/VBP||there-20/EX	conj_but||highest-15/JJS||are-21/VBP	amod||studies-23/NNS||few-22/JJ	nsubj||are-21/VBP||studies-23/NNS	det||disorders-28/NNS||the-25/DT	amod||disorders-28/NNS||associated-26/VBN	amod||disorders-28/NNS||neurocognitive-27/JJ	prep_on||studies-23/NNS||disorders-28/NNS	det||region-31/NN||this-30/DT	prep_in||disorders-28/NNS||region-31/NN	hiv)--1||humanimmunodeficiencyvirus-5||no||the disease burden of humanimmunodeficiencyvirus (hiv) - acquiredimmunodeficiencysyndrome (aids) is highest in sub-saharan africa but there are few studies on the associated neurocognitive disorders in this region.
nsubj||tool-8/NN||genotyping-1/NN	prep_of||genotyping-1/NN||mycobacteriumtuberculosis-3/NNS	dep||mycobacteriumtuberculosis-3/NNS||isolates-4/VBZ	cop||tool-8/NN||is-5/VBZ	det||tool-8/NN||a-6/DT	amod||tool-8/NN||powerful-7/JJ	root||ROOT-0/null||tool-8/NN	amod||control-11/NN||epidemiological-10/JJ	prep_for||tool-8/NN||control-11/NN	prep_of||control-11/NN||tuberculosis-13/NNP	appos||tuberculosis-13/NNP||tb-15/NN	amod||exploration-19/NN||phylogenetic-18/JJ	prep_for||tool-8/NN||exploration-19/NN	conj_and||control-11/NN||exploration-19/NN	det||pathogen-22/NN||the-21/DT	prep_of||exploration-19/NN||pathogen-22/NN	tb-15||mycobacteriumtuberculosis-3||no||genotyping of mycobacteriumtuberculosis isolates is a powerful tool for epidemiological control of tuberculosis (tb) and phylogenetic exploration of the pathogen.
det||area-3/NN||an-2/DT	prep_in||increased-14/VBN||area-3/NN	advmod||prevalent-8/JJ||where-4/WRB	amod||mrsa-6/NN||pvl-containing-5/JJ	nsubj||prevalent-8/JJ||mrsa-6/NN	cop||prevalent-8/JJ||is-7/VBZ	rcmod||area-3/NN||prevalent-8/JJ	nn||risk-12/NN||skin-10/NN	nn||risk-12/NN||infection-11/NN	nsubjpass||increased-14/VBN||risk-12/NN	auxpass||increased-14/VBN||was-13/VBD	root||ROOT-0/null||increased-14/VBN	amod||carriers-18/NNS||mrsa-16/JJ	amod||carriers-18/NNS||nasal-17/JJ	prep_among||increased-14/VBN||carriers-18/NNS	prepc_compared_with||increased-14/VBN||with-20/IN	amod||carriers-23/NNS||methicillin-susceptible-21/JJ	nn||carriers-23/NNS||s.aureus-22/NN	pobj||increased-14/VBN||carriers-23/NNS	pobj||increased-14/VBN||noncarriers-25/NNS	conj_and||carriers-23/NNS||noncarriers-25/NNS	nn||differential-29/NN||risk-28/NN	nsubj||diminished-30/VBN||differential-29/NN	conj_but||increased-14/VBN||diminished-30/VBN	prep_over||diminished-30/VBN||time-32/NN	mrsa-16||s.aureus-22||no||in an area where pvl-containing mrsa is prevalent , skin infection risk was increased among mrsa nasal carriers compared with methicillin-susceptible s.aureus carriers and noncarriers , but risk differential diminished over time .
nn||intake-3/NN||urticaria-1/NN	amod||intake-3/NN||following-2/VBG	nsubjpass||observed-7/VBN||intake-3/NN	nsubjpass||observed-7/VBN||intake-3/NN	prep_of||intake-3/NN||nsaids-5/NNS	auxpass||observed-7/VBN||was-6/VBD	root||ROOT-0/null||observed-7/VBN	conj_and||observed-7/VBN||observed-7/VBN	num||patients-10/NNS||four-9/CD	prep_in||observed-7/VBN||patients-10/NNS	amod||pills-14/NNS||oralcontraceptive-13/JJ	prep_with||observed-7/VBN||pills-14/NNS	num||patient-17/NN||one-16/CD	prep_in||pills-14/NNS||patient-17/NN	urticaria-1||nsaids-5||no_rel||urticaria following intake of nsaids was observed in four patients and with oralcontraceptive pills in one patient.
det||value-2/NN||the-1/DT	nsubj||vs-22/VBP||value-2/NN	amod||³-6/NNS||standard-4/JJ	nn||³-6/NNS||î-5/NN	prep_of||value-2/NN||³-6/NNS	dep||value-2/NN||globulin-8/NN	det||titer-12/NN||a-10/DT	amod||titer-12/NN||low-11/JJ	prep_with||globulin-8/NN||titer-12/NN	prep_of||titer-12/NN||antibody-14/NN	amod||antigen-18/NN||hepatitisb-16/JJ	nn||antigen-18/NN||surface-17/NN	prep_to||antibody-14/NN||antigen-18/NN	appos||value-2/NN||anti-hbs-20/NNS	root||ROOT-0/null||vs-22/VBP	amod||immuneglobulin-24/NN||hepatitisb-23/JJ	nsubj||unclear-37/JJ||immuneglobulin-24/NN	appos||immuneglobulin-24/NN||hbig-26/NN	prep_in||immuneglobulin-24/NN||prevention-29/NN	amod||hepatitisb-32/NN||icteric-31/JJ	prep_of||prevention-29/NN||hepatitisb-32/NN	det||military-35/NN||the-34/DT	prep_in||hepatitisb-32/NN||military-35/NN	cop||unclear-37/JJ||is-36/VBZ	ccomp||vs-22/VBP||unclear-37/JJ	hepatitisb-32||hbig-26||yes||the value of standard î³-globulin with a low titer of antibody to hepatitisb surface antigen (anti-hbs) vs hepatitisb immuneglobulin (hbig) in prevention of icteric hepatitisb in the military is unclear.
nsubj||evident-3/JJ||this-1/DT	cop||evident-3/JJ||was-2/VBD	root||ROOT-0/null||evident-3/JJ	prep_from||evident-3/JJ||inhibition-5/NN	amod||formation-9/NN||estrogen-induced-7/JJ	nn||formation-9/NN||breasttumor-8/NN	prep_of||inhibition-5/NN||formation-9/NN	det||model-13/NN||the-11/DT	amod||model-13/NN||xenograft-12/JJ	prep_in||formation-9/NN||model-13/NN	det||overexpression-16/NN||both-15/DT	prep_by||evident-3/JJ||overexpression-16/NN	prep_of||overexpression-16/NN||catalase-18/NN	prep_by||evident-3/JJ||co-treatment-23/NN	conj_and||overexpression-16/NN||co-treatment-23/NN	prep_with||co-treatment-23/NN||ebselen-25/NN	breasttumor-8||estrogen--1||yes||this was evident from inhibition of estrogen-induced breasttumor formation in the xenograft model by both overexpression of catalase as well as by co-treatment with ebselen.
amod||responses-2/NNS||inappropriate-1/JJ	nsubjpass||involved-9/VBN||responses-2/NNS	amod||bacteria-6/NNS||normal-4/JJ	amod||bacteria-6/NNS||intestinal-5/JJ	prep_to||responses-2/NNS||bacteria-6/NNS	aux||involved-9/VBN||may-7/MD	auxpass||involved-9/VBN||be-8/VB	root||ROOT-0/null||involved-9/VBN	det||development-12/NN||the-11/DT	prep_in||involved-9/VBN||development-12/NN	prep_of||development-12/NN||inflammatoryboweldiseases-14/NNS	amod||ibd-16/NN||-lrb--15/JJ	nsubj||ulcerativecolitis-26/VBZ||ibd-16/NN	nn||crohn-19/NNP||e.g.-18/NNP	poss||-rrb--24/NN||crohn-19/NNP	nn||-rrb--24/NN||disease-21/NN	amod||-rrb--24/NN||-lrb--22/JJ	nn||-rrb--24/NN||cd-23/NN	appos||ibd-16/NN||-rrb--24/NN	rcmod||inflammatoryboweldiseases-14/NNS||ulcerativecolitis-26/VBZ	amod||-rrb--30/NNS||-lrb--27/JJ	nn||-rrb--30/NNS||uc-28/NN	amod||-rrb--30/NNS||-rrb--29/JJ	nsubj||mediate-38/VB||-rrb--30/NNS	conj_and||-rrb--30/NNS||variations-32/NNS	nsubj||mediate-38/VB||variations-32/NNS	det||genome-36/NN||the-34/DT	nn||genome-36/NN||host-35/NN	prep_in||-rrb--30/NNS||genome-36/NN	aux||mediate-38/VB||may-37/MD	ccomp||ulcerativecolitis-26/VBZ||mediate-38/VB	det||process-40/NN||this-39/DT	dobj||mediate-38/VB||process-40/NN	uc-28||cd-23||no_rel||inappropriate responses to normal intestinal bacteria may be involved in the development of inflammatoryboweldiseases -lrb- ibd , e.g. crohn 's disease -lrb- cd -rrb- , ulcerativecolitis -lrb- uc -rrb- -rrb- and variations in the host genome may mediate this process .
nsubjpass||reported-7/VBN||cases-1/NNS	amod||pancreatitis-4/NNS||acute-3/JJ	prep_of||cases-1/NNS||pancreatitis-4/NNS	aux||reported-7/VBN||have-5/VBP	auxpass||reported-7/VBN||been-6/VBN	root||ROOT-0/null||reported-7/VBN	prep_in||reported-7/VBN||association-9/NN	prep_with||reported-7/VBN||exenatide-11/NN	prep_with||reported-7/VBN||sitagliptin-13/NN	conj_and||exenatide-11/NN||sitagliptin-13/NN	prep_with||reported-7/VBN||type2diabetes-16/NNS	conj_and||exenatide-11/NN||type2diabetes-16/NNS	prep_without||reported-7/VBN||use-18/NN	det||medications-21/NNS||these-20/DT	prep_of||use-18/NN||medications-21/NNS	exenatide-11||type2diabetes-16||no_rel||cases of acute pancreatitis have been reported in association with exenatide, sitagliptin, and type2diabetes without use of these medications.
nsubj||dependent-4/JJ||women-1/NNS	nsubj||unlikely-33/JJ||women-1/NNS	nsubj||come-35/VB||women-1/NNS	cop||dependent-4/JJ||are-3/VBP	rcmod||women-1/NNS||dependent-4/JJ	amod||drugs-7/NNS||non-injecting-6/JJ	prep_on||dependent-4/JJ||drugs-7/NNS	prep_on||dependent-4/JJ||alcohol-9/NN	conj_and||drugs-7/NNS||alcohol-9/NN	cop||likely-12/JJ||are-10/VBP	advmod||likely-12/JJ||also-11/RB	advcl||dependent-4/JJ||likely-12/JJ	aux||increased-15/VBN||to-13/TO	aux||increased-15/VBN||have-14/VB	xcomp||likely-12/JJ||increased-15/VBN	dobj||increased-15/VBN||vulnerability-16/NN	prep_to||increased-15/VBN||hivinfection-18/NN	mark||inject-24/VB||until-21/IN	nsubj||inject-24/VB||they-22/PRP	nsubj||engage-27/VB||they-22/PRP	advmod||inject-24/VB||actually-23/RB	advcl||dependent-4/JJ||inject-24/VB	conj_but||likely-12/JJ||inject-24/VB	dobj||inject-24/VB||drugs-25/NNS	conj_but||likely-12/JJ||engage-27/VB	conj_or||inject-24/VB||engage-27/VB	nn||work-30/NN||sex-29/NN	prep_in||engage-27/VB||work-30/NN	cop||unlikely-33/JJ||are-32/VBP	root||ROOT-0/null||unlikely-33/JJ	aux||come-35/VB||to-34/TO	xcomp||unlikely-33/JJ||come-35/VB	det||attention-38/NN||the-37/DT	prep_to||come-35/VB||attention-38/NN	nn||programs-42/NNS||hiv-40/NN	nn||programs-42/NNS||prevention-41/NN	prep_of||attention-38/NN||programs-42/NNS	hivinfection-18||hiv-40||no||women who are dependent on non-injecting drugs and alcohol are also likely to have increased vulnerability to hivinfection, but until they actually inject drugs or engage in sex work, are unlikely to come to the attention of hiv prevention programs.
advmod||lower-2/JJR||significantly-1/RB	amod||performance-3/NN||lower-2/JJR	nsubjpass||seen-5/VBN||performance-3/NN	auxpass||seen-5/VBN||was-4/VBD	root||ROOT-0/null||seen-5/VBN	det||sample-10/NN||the-7/DT	nn||sample-10/NN||hiv-8/NN	nn||sample-10/NN||+-9/NN	prep_in||seen-5/VBN||sample-10/NN	prep_on||seen-5/VBN||tests-12/NNS	amod||function-15/NN||executive-14/JJ	prep_of||tests-12/NNS||function-15/NN	prep_of||tests-12/NNS||speed-17/NN	conj_and||function-15/NN||speed-17/NN	nn||processing-20/NN||information-19/NN	prep_of||speed-17/NN||processing-20/NN	amod||memory-23/NN||working-22/JJ	prep_of||tests-12/NNS||memory-23/NN	conj_and||function-15/NN||memory-23/NN	nn||speed-27/NN||psychomotor-26/NN	prep_of||tests-12/NNS||speed-27/NN	conj_and||function-15/NN||speed-27/NN	hiv+--1||speed-27||no_rel||significantly lower performance was seen in the hiv+ sample on tests of executive function, speed of information processing, working memory, and psychomotor speed.
det||patients-2/NNS||all-1/DT	nsubj||hbsag-4/JJ||patients-2/NNS	nsubj||positive-7/JJ||patients-2/NNS	cop||hbsag-4/JJ||were-3/VBD	root||ROOT-0/null||hbsag-4/JJ	advmod||positive-7/JJ||hbv-dna-6/RB	conj_and||hbsag-4/JJ||positive-7/JJ	mark||hbeag-16/VBG||while-9/IN	nsubj||hbeag-16/VBG||27-10/CD	num||%-13/NN||77-12/CD	appos||27-10/CD||%-13/NN	aux||hbeag-16/VBG||were-15/VBD	advcl||hbsag-4/JJ||hbeag-16/VBG	acomp||hbeag-16/VBG||positive-17/JJ	hbv--1||hbsag-4||yes||all patients were hbsag and hbv-dna positive, while 27 (77%) were hbeag positive.
csubj||reduced-18/VBD||adding-1/VBG	det||dose-4/NN||a-2/DT	amod||dose-4/NN||low-3/JJ	dobj||adding-1/VBG||dose-4/NN	amod||ketamine-7/NN||oral-6/JJ	prep_of||dose-4/NN||ketamine-7/NN	amod||premedication-11/NN||midazolam-based-9/JJ	amod||premedication-11/NN||oral-10/JJ	prep_to||adding-1/VBG||premedication-11/NN	amod||children-14/NNS||preschool-13/JJ	prep_in||adding-1/VBG||children-14/NNS	vmod||children-14/NNS||undergoing-15/VBG	amod||surgery-17/NN||dental-16/JJ	dobj||undergoing-15/VBG||surgery-17/NN	root||ROOT-0/null||reduced-18/VBD	amod||agitation-21/NN||sevoflurane-related-19/JJ	nn||agitation-21/NN||emergence-20/NN	dobj||reduced-18/VBD||agitation-21/NN	prepc_without||reduced-18/VBD||delaying-23/VBG	dobj||delaying-23/VBG||discharge-24/NN	agitation-21||midazolam--1||yes||adding a low dose of oral ketamine to midazolam-based oral premedication in preschool children undergoing dental surgery reduced sevoflurane-related emergence agitation without delaying discharge.
nsubj||active-5/JJ||cmx001-1/NNS	conj_and||cmx001-1/NNS||cdv-3/NN	nsubj||active-5/JJ||cdv-3/NN	cop||active-5/JJ||are-4/VBP	root||ROOT-0/null||active-5/JJ	det||families-9/NNS||all-7/DT	num||families-9/NNS||five-8/CD	prep_against||active-5/JJ||families-9/NNS	nsubj||cause-18/VBP||families-9/NNS	amod||viruses-16/NNS||double-stranded-11/JJ	nn||viruses-16/NNS||dna-12/NN	nn||viruses-16/NNS||dsdna-14/NN	prep_of||families-9/NNS||viruses-16/NNS	rcmod||families-9/NNS||cause-18/VBP	amod||morbidity-20/NN||human-19/JJ	dobj||cause-18/VBP||morbidity-20/NN	dobj||cause-18/VBP||mortality-22/NN	conj_and||morbidity-20/NN||mortality-22/NN	prep_including||cause-18/VBP||orthopoxviruses-25/NNS	prep_such_as||orthopoxviruses-25/NNS||variolavirus-28/NNS	det||cause-31/NN||the-30/DT	appos||variolavirus-28/NNS||cause-31/NN	amod||smallpox-34/NN||human-33/JJ	prep_of||cause-31/NN||smallpox-34/NN	smallpox-34||variolavirus-28||no||cmx001 and cdv are active against all five families of double-stranded dna (dsdna) viruses that cause human morbidity and mortality, including orthopoxviruses such as variolavirus, the cause of human smallpox.
num||kinds-2/NNS||two-1/CD	nsubj||viruses-7/NNS||kinds-2/NNS	prep_of||kinds-2/NNS||them-4/PRP	cop||viruses-7/NNS||are-5/VBP	amod||viruses-7/NNS||mosquito-borne-6/JJ	root||ROOT-0/null||viruses-7/NNS	nsubj||lead-16/VBP||viruses-7/NNS	nsubj||denguefever/denguehemorrhagicfever-21/VBP||viruses-7/NNS	advmod||virus-11/NN||namely-9/RB	amod||virus-11/NN||japaneseencephalitis-10/JJ	appos||viruses-7/NNS||virus-11/NN	appos||viruses-7/NNS||denguevirus-13/NNS	conj_and||virus-11/NN||denguevirus-13/NNS	rcmod||viruses-7/NNS||lead-16/VBP	prep_to||lead-16/VBP||japaneseencephalitis-18/NNS	rcmod||viruses-7/NNS||denguefever/denguehemorrhagicfever-21/VBP	conj_and||lead-16/VBP||denguefever/denguehemorrhagicfever-21/VBP	advmod||denguefever/denguehemorrhagicfever-21/VBP||respectively-22/RB	det||two-26/CD||the-24/DT	amod||two-26/CD||other-25/JJ	nsubj||viruses-29/NNS||two-26/CD	cop||viruses-29/NNS||are-27/VBP	amod||viruses-29/NNS||tick-borne-28/JJ	parataxis||viruses-7/NNS||viruses-29/NNS	nsubj||contribute-47/VBP||viruses-29/NNS	advmod||virus-33/NN||namely-31/RB	amod||virus-33/NN||tick-borneencephalitis-32/JJ	parataxis||viruses-7/NNS||virus-33/NN	conj_and||viruses-29/NNS||virus-33/NN	nsubj||contribute-47/VBP||virus-33/NN	amod||virus-36/NN||crimean-congohemorrhagicfever-35/JJ	parataxis||viruses-7/NNS||virus-36/NN	conj_and||viruses-29/NNS||virus-36/NN	nsubj||contribute-47/VBP||virus-36/NN	advmod||known-39/VBN||also-38/RB	dep||viruses-29/NNS||known-39/VBN	prepc_as||known-39/VBN||xinjiang-41/VBG	nn||virus-43/NN||hemorrhagicfever-42/NN	dobj||xinjiang-41/VBG||virus-43/NN	rcmod||viruses-29/NNS||contribute-47/VBP	prep_to||contribute-47/VBP||tick-borneencephalitis-49/NNS	nn||hemorrhagicfever-52/NN||xinjiang-51/NN	prep_to||contribute-47/VBP||hemorrhagicfever-52/NN	conj_and||tick-borneencephalitis-49/NNS||hemorrhagicfever-52/NN	advmod||contribute-47/VBP||respectively-53/RB	denguefever--1||denguevirus-13||no||two kinds of them are mosquito-borne viruses, namely japaneseencephalitis virus and denguevirus, which lead to japaneseencephalitis, and denguefever/denguehemorrhagicfever respectively; the other two are tick-borne viruses, namely tick-borneencephalitis virus and crimean-congohemorrhagicfever virus (also known as xinjiang hemorrhagicfever virus), which contribute to tick-borneencephalitis and xinjiang hemorrhagicfever respectively.
advmod||show-4/VBP||here-1/RB	nsubj||show-4/VBP||we-3/PRP	root||ROOT-0/null||show-4/VBP	mark||promotes-32/VBZ||that-5/IN	amod||expression-7/NN||ectopic-6/JJ	nsubj||promotes-32/VBZ||expression-7/NN	det||isoform-13/NN||a-9/DT	advmod||important-11/JJ||clinically-10/RB	amod||isoform-13/NN||important-11/JJ	amod||isoform-13/NN||oncogenic-12/JJ	prep_of||expression-7/NN||isoform-13/NN	prep_of||isoform-13/NN||her2-15/NNS	appos||her2-15/NNS||her2î-17/NNS	dep||expression-7/NN||16-19/CD	nsubjpass||expressed-23/VBN||16-19/CD	auxpass||expressed-23/VBN||is-22/VBZ	rcmod||16-19/CD||expressed-23/VBN	num||%-27/NN||>-25/CD	num||%-27/NN||30-26/CD	prep_in||expressed-23/VBN||%-27/NN	amod||breasttumors-30/NNS||er-positive-29/JJ	prep_of||%-27/NN||breasttumors-30/NNS	ccomp||show-4/VBP||promotes-32/VBZ	nn||resistance-34/NN||tamoxifen-33/NN	dobj||promotes-32/VBZ||resistance-34/NN	nn||independence-37/NN||estrogen-36/NN	dobj||promotes-32/VBZ||independence-37/NN	conj_and||resistance-34/NN||independence-37/NN	amod||xenografts-40/NNS||mcf-7-39/JJ	prep_of||resistance-34/NN||xenografts-40/NNS	breasttumors-30||estrogen-36||yes||here, we show that ectopic expression of a clinically important oncogenic isoform of her2, her2î16, which is expressed in >30% of er-positive breasttumors, promotes tamoxifen resistance and estrogen independence of mcf-7 xenografts.
det||analysis-3/NN||the-1/DT	amod||analysis-3/NN||multivariate-2/JJ	nsubj||showed-4/VBD||analysis-3/NN	root||ROOT-0/null||showed-4/VBD	mark||tended-9/VBD||that-5/IN	nsubj||tended-9/VBD||patients-6/NNS	nsubj||have-11/VB||patients-6/NNS	prep_at||patients-6/NNS||risk-8/NN	ccomp||showed-4/VBD||tended-9/VBD	aux||have-11/VB||to-10/TO	xcomp||tended-9/VBD||have-11/VB	det||characteristics-14/NNS||the-12/DT	amod||characteristics-14/NNS||following-13/JJ	dobj||have-11/VB||characteristics-14/NNS	vmod||characteristics-14/NNS||recruited-15/VBN	det||clinic-20/NN||the-17/DT	nn||clinic-20/NN||hiv-18/NN	nn||clinic-20/NN||testing-19/NN	prep_from||recruited-15/VBN||clinic-20/NN	dep||tended-9/VBD||lived-22/VBD	advmod||lived-22/VBD||alone-23/RB	dep||tended-9/VBD||declared-25/VBD	neg||religion-27/NN||no-26/DT	dobj||declared-25/VBD||religion-27/NN	dep||tended-9/VBD||had-29/VBD	det||level-32/NN||a-30/DT	amod||level-32/NN||low-31/JJ	dobj||had-29/VBD||level-32/NN	prep_of||level-32/NN||education-34/NN	dep||tended-9/VBD||felt-36/VBD	acomp||felt-36/VBD||uninformed-37/JJ	prep_about||felt-36/VBD||hiv/aids-39/NNS	cop||younger-42/JJR||were-41/VBD	dep||tended-9/VBD||younger-42/JJR	aux||had-45/VBN||had-44/VBD	dep||tended-9/VBD||had-45/VBN	amod||partners-48/NNS||concurrent-46/JJ	amod||partners-48/NNS||sexual-47/JJ	dobj||had-45/VBN||partners-48/NNS	det||months-53/NNS||the-50/DT	amod||months-53/NNS||last-51/JJ	num||months-53/NNS||12-52/CD	prep_in||partners-48/NNS||months-53/NNS	aids--1||hiv-18||no||the multivariate analysis showed that patients at risk tended to have the following characteristics recruited from the hiv testing clinic, lived alone, declared no religion, had a low level of education, felt uninformed about hiv/aids, were younger, had had concurrent sexual partners in the last 12 months.
det||result-2/NN||the-1/DT	nsubj||showed-3/VBD||result-2/NN	root||ROOT-0/null||showed-3/VBD	mark||had-17/VBD||that-4/IN	nsubj||had-17/VBD||c-5/SYM	num||mg/l-8/NN||128-7/CD	appos||c-5/SYM||mg/l-8/NN	prep||c-5/SYM||combined-10/VBN	pcomp||combined-10/VBN||with-11/IN	pobj||with-11/IN||ecg-12/NN	num||mg/l-15/NN||16-14/CD	appos||ecg-12/NN||mg/l-15/NN	ccomp||showed-3/VBD||had-17/VBD	det||effect-20/NN||the-18/DT	amod||effect-20/NN||greatest-19/JJS	dobj||had-17/VBD||effect-20/NN	det||combination-23/NN||the-22/DT	nsubj||reduced-25/VBD||combination-23/NN	advmod||reduced-25/VBD||also-24/RB	conj_and||showed-3/VBD||reduced-25/VBD	det||load-28/NN||the-26/DT	amod||load-28/NN||bacterial-27/JJ	dobj||reduced-25/VBD||load-28/NN	prep_in||reduced-25/VBD||blood-30/NN	amod||mice-33/NNS||septic-32/JJ	prep_of||blood-30/NN||mice-33/NNS	dep||mice-33/NNS||challenged-34/VBN	det||dose-38/NN||a-36/DT	amod||dose-38/NN||sublethal-37/JJ	prep_with||challenged-34/VBN||dose-38/NN	prep_of||dose-38/NN||mrsa-40/NN	dep||mice-33/NNS||increased-42/VBN	conj_and||challenged-34/VBN||increased-42/VBN	nn||accumulation-44/NN||daunomycin-43/NN	dobj||increased-42/VBN||accumulation-44/NN	prep_within||increased-42/VBN||mrsa-46/NN	dep||mice-33/NNS||down-regulated-48/VBN	conj_and||challenged-34/VBN||down-regulated-48/VBN	det||expression-51/NN||the-49/DT	nn||expression-51/NN||mrna-50/NN	dobj||down-regulated-48/VBN||expression-51/NN	prep_of||expression-51/NN||nora-53/NN	prep_of||expression-51/NN||norc-55/NN	conj_and||nora-53/NN||norc-55/NN	prep_of||expression-51/NN||abca-57/NN	conj_and||nora-53/NN||abca-57/NN	num||pumps-62/NNS||three-59/CD	amod||pumps-62/NNS||important-60/JJ	nn||pumps-62/NNS||efflux-61/NN	dobj||reduced-25/VBD||pumps-62/NNS	prep_of||pumps-62/NNS||mrsa-64/NN	daunomycin-43||mrsa-64||no_rel||the result showed that c (128 mg/l) combined with ecg (16 mg/l) had the greatest effect and the combination also reduced the bacterial load in blood of septic mice challenged with a sublethal dose of mrsa, increased daunomycin accumulation within mrsa and down-regulated the mrna expression of nora , norc and abca , three important efflux pumps of mrsa.
det||aim-2/NN||the-1/DT	nsubj||was-6/VBD||aim-2/NN	nsubj||identify-8/VB||aim-2/NN	det||study-5/NN||this-4/DT	prep_of||aim-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||identify-8/VB||to-7/TO	xcomp||was-6/VBD||identify-8/VB	det||presence-10/NN||the-9/DT	dobj||identify-8/VB||presence-10/NN	iobj||identify-8/VB||presence-10/NN	amod||inh-14/NN||isoniazid-12/JJ	prep_of||presence-10/NN||inh-14/NN	prep_of||presence-10/NN||rifampicin-17/NN	conj_and||inh-14/NN||rifampicin-17/NN	appos||presence-10/NN||rif-19/NN	nn||resistance-22/NN||drug-21/NN	dep||presence-10/NN||resistance-22/NN	amod||cases-32/NNS||new-24/JJ	advmod||treated-27/JJ||previously-26/RB	conj_and||new-24/JJ||treated-27/JJ	amod||cases-32/NNS||treated-27/JJ	nn||cases-32/NNS||tuberculosis-28/NNP	appos||cases-32/NNS||tb-30/NN	prep_in||resistance-22/NN||cases-32/NNS	vmod||cases-32/NNS||using-33/VBG	nn||sequencing-35/NN||dna-34/NN	dobj||using-33/VBG||sequencing-35/NN	tuberculosis-28||rifampicin-17||yes||the aim of this study was to identify the presence of isoniazid (inh) and rifampicin(rif) drug resistance in new and previously treated tuberculosis (tb) cases using dna sequencing.
mark||finding-10/NN||while-1/IN	det||presence-3/NN||the-2/DT	nsubj||finding-10/NN||presence-3/NN	amod||stroma-6/NN||lymphoid-5/JJ	prep_of||presence-3/NN||stroma-6/NN	cop||finding-10/NN||is-7/VBZ	det||finding-10/NN||a-8/DT	amod||finding-10/NN||characteristic-9/JJ	advcl||associated-21/VBN||finding-10/NN	amod||carcinoma-14/NN||ebv-associated-12/JJ	amod||carcinoma-14/NN||lymphoepithelioma-like-13/JJ	prep_in||finding-10/NN||carcinoma-14/NN	amod||granulomas-18/NNS||sarcoid-like-16/JJ	amod||granulomas-18/NNS||epithelioid-17/JJ	nsubjpass||associated-21/VBN||granulomas-18/NNS	aux||associated-21/VBN||might-19/MD	auxpass||associated-21/VBN||be-20/VB	root||ROOT-0/null||associated-21/VBN	nn||ebvinfection-24/NN||latent-23/NN	prep_with||associated-21/VBN||ebvinfection-24/NN	ebvinfection-24||ebv--1||no||while the presence of lymphoid stroma is a characteristic finding in ebv-associated lymphoepithelioma-like carcinoma, sarcoid-like epithelioid granulomas might be associated with latent ebvinfection.
vmod||showed-9/VBD||using-1/VBG	det||model-4/NN||an-2/DT	amod||model-4/NN||orthotopic-3/JJ	dobj||using-1/VBG||model-4/NN	prep_of||model-4/NN||renalcellcarcinoma-6/NN	nsubj||showed-9/VBD||we-8/PRP	root||ROOT-0/null||showed-9/VBD	advmod||showed-9/VBD||previously-10/RB	mark||resulted-16/VBD||that-11/IN	amod||immunotherapy-15/NN||il-2-12/JJ	amod||immunotherapy-15/NN||/-13/JJ	amod||immunotherapy-15/NN||anti-cd40-14/JJ	nsubj||resulted-16/VBD||immunotherapy-15/NN	ccomp||showed-9/VBD||resulted-16/VBD	amod||responses-20/NNS||synergistic-18/JJ	amod||responses-20/NNS||anti-tumor-19/JJ	prep_in||resulted-16/VBD||responses-20/NNS	mark||mediated-30/VBD||whereas-22/IN	amod||cd40-28/NNS||il-2-23/JJ	advmod||±-26/JJ||î-25/RB	conj_or||il-2-23/JJ||±-26/JJ	amod||cd40-28/NNS||±-26/JJ	nsubj||mediated-30/VBD||cd40-28/NNS	advmod||mediated-30/VBD||alone-29/RB	advcl||resulted-16/VBD||mediated-30/VBD	amod||effects-34/NNS||partial-31/JJ	amod||effects-34/NNS||transient-32/JJ	nn||effects-34/NNS||anti-tumor-33/NN	dobj||mediated-30/VBD||effects-34/NNS	tumor--1||il-2-23||no_rel||using an orthotopic model of renalcellcarcinoma, we showed previously that il-2/anti-cd40 immunotherapy resulted in synergistic anti-tumor responses, whereas il-2 or î±-cd40 alone mediated partial transient anti-tumor effects.
nsubjpass||approved-14/VBN||levofloxacin-1/NN	det||fluoroquinolone-4/NN||a-3/DT	appos||levofloxacin-1/NN||fluoroquinolone-4/NN	appos||levofloxacin-1/NN||l-isomer-6/NN	conj_and||fluoroquinolone-4/NN||l-isomer-6/NN	det||ofloxacin-10/NN||the-8/DT	amod||ofloxacin-10/NN||racemate-9/JJ	prep_of||fluoroquinolone-4/NN||ofloxacin-10/NN	aux||approved-14/VBN||has-12/VBZ	auxpass||approved-14/VBN||been-13/VBN	root||ROOT-0/null||approved-14/VBN	det||treatment-17/NN||the-16/DT	prep_for||approved-14/VBN||treatment-17/NN	amod||bacterialinfections-22/NNS||acute-19/JJ	conj_and||acute-19/JJ||chronic-21/JJ	amod||bacterialinfections-22/NNS||chronic-21/JJ	prep_of||treatment-17/NN||bacterialinfections-22/NNS	bacterialinfections-22||ofloxacin-10||yes||levofloxacin, a fluoroquinolone and l-isomer of the racemate ofloxacin, has been approved for the treatment of acute and chronic bacterialinfections.
nsubj||-LSB--21/VBD||proliferation-1/NN	nn||receptors-4/NNS||nmda-3/NN	prep_of||proliferation-1/NN||receptors-4/NNS	prep_of||proliferation-1/NN||role-6/NN	conj_and||receptors-4/NNS||role-6/NN	amod||phenomena-18/NNS||glutamate-8/JJ	prepc_in||glutamate-8/JJ||producing-10/VBG	amod||sensitization-12/NN||central-11/JJ	dobj||producing-10/VBG||sensitization-12/NN	prepc_in||glutamate-8/JJ||wind-15/VBP	conj_and||producing-10/VBG||wind-15/VBP	prt||wind-15/VBP||up-16/RP	prep_of||receptors-4/NNS||phenomena-18/NNS	prep_in||phenomena-18/NNS||crps-20/NNS	root||ROOT-0/null||-LSB--21/VBD	amod||-RSB--26/NNS||complex-22/JJ	amod||-RSB--26/NNS||regional-23/JJ	nn||-RSB--26/NNS||pain-24/NN	nn||-RSB--26/NNS||syndrome-25/NN	nsubj||forms-27/VBZ||-RSB--26/NNS	ccomp||-LSB--21/VBD||forms-27/VBZ	det||basis-30/NN||a-28/DT	amod||basis-30/NN||strong-29/JJ	dobj||forms-27/VBZ||basis-30/NN	det||use-33/NN||the-32/DT	prep_for||forms-27/VBZ||use-33/NN	prep_of||use-33/NN||ketamine-35/NN	aux||block-37/VB||to-36/TO	vmod||forms-27/VBZ||block-37/VB	det||mechanisms-40/NNS||the-38/DT	amod||mechanisms-40/NNS||cellular-39/JJ	dobj||block-37/VB||mechanisms-40/NNS	nsubj||initiate-42/VBP||mechanisms-40/NNS	nsubj||maintain-44/VBP||mechanisms-40/NNS	rcmod||mechanisms-40/NNS||initiate-42/VBP	rcmod||mechanisms-40/NNS||maintain-44/VBP	conj_and||initiate-42/VBP||maintain-44/VBP	det||changes-46/NNS||these-45/DT	dobj||initiate-42/VBP||changes-46/NNS	ketamine-35||wind-15||no_rel||proliferation of nmda receptors and role of glutamate in producing central sensitization and 'wind up' phenomena in crps [complex regional pain syndrome] forms a strong basis for the use of ketamine to block the cellular mechanisms that initiate and maintain these changes.
prepc_compared_with||had-11/VBD||with-2/IN	nn||subjects-4/NNS||control-3/NN	pobj||had-11/VBD||subjects-4/NNS	amod||patients-7/NNS||type2diabetes-low-6/JJ	conj_and||subjects-4/NNS||patients-7/NNS	pobj||had-11/VBD||patients-7/NNS	amod||patients-10/NNS||type2diabetes-high-9/JJ	nsubj||had-11/VBD||patients-10/NNS	root||ROOT-0/null||had-11/VBD	det||perfusion-16/NN||the-12/DT	amod||perfusion-16/NN||lowest-13/JJS	amod||perfusion-16/NN||hepatic-14/JJ	amod||perfusion-16/NN||parenchymal-15/JJ	dobj||had-11/VBD||perfusion-16/NN	dep||perfusion-16/NN||p-18/VBN	dep||0.004-20/CD||=-19/SYM	ccomp||p-18/VBN||0.004-20/CD	amod||uptake-26/NN||insulin-stimulated-23/JJ	amod||uptake-26/NN||hepatic-24/JJ	nn||uptake-26/NN||glucose-25/NN	dobj||had-11/VBD||uptake-26/NN	conj_and||perfusion-16/NN||uptake-26/NN	dep||uptake-26/NN||p-28/VBN	dep||0.013-30/CD||=-29/SYM	ccomp||p-28/VBN||0.013-30/CD	type2diabetes--1||glucose-25||no_rel||compared with control subjects and type2diabetes-low patients, type2diabetes-high patients had the lowest hepatic parenchymal perfusion ( p = 0.004) and insulin-stimulated hepatic glucose uptake ( p = 0.013).
nsubj||suspected-11/VBD||patients-1/NNS	nsubj||observed-13/VBD||patients-1/NNS	nsubj||investigated-23/VBD||patients-1/NNS	vmod||patients-1/NNS||seeking-2/VBG	amod||care-4/NN||medical-3/JJ	dobj||seeking-2/VBG||care-4/NN	prep_with||seeking-2/VBG||erythemamigrans-6/NNS	amod||symptoms-9/NNS||flu-like-8/JJ	prep_with||seeking-2/VBG||symptoms-9/NNS	conj_or||erythemamigrans-6/NNS||symptoms-9/NNS	prep||seeking-2/VBG||after-10/IN	root||ROOT-0/null||suspected-11/VBD	conj_or||suspected-11/VBD||observed-13/VBD	nn||bite-15/NN||tick-14/NN	dobj||suspected-11/VBD||bite-15/NN	det||southeast-18/NN||the-17/DT	prep_in||suspected-11/VBD||southeast-18/NN	prep_of||southeast-18/NN||sweden-20/NN	advmod||investigated-23/VBD||previously-22/RB	conj_and||suspected-11/VBD||investigated-23/VBD	nn||spp-26/NN||borrelia-25/NN	prep_for||investigated-23/VBD||spp-26/NN	erythemamigrans-6||borrelia-25||no||patients seeking medical care with erythemamigrans or flu-like symptoms after suspected or observed tick bite in the southeast of sweden and previously investigated for borrelia spp.
aux||evaluate-2/VB||to-1/TO	root||ROOT-0/null||evaluate-2/VB	det||frequency-4/NN||the-3/DT	dobj||evaluate-2/VB||frequency-4/NN	nn||abnormalities-7/NNS||glucose-6/NN	prep_of||frequency-4/NN||abnormalities-7/NNS	poss||correlation-10/NN||their-9/PRP$	dobj||evaluate-2/VB||correlation-10/NN	conj_and||frequency-4/NN||correlation-10/NN	amod||inflammation-15/NN||systemic-12/JJ	conj_and||systemic-12/JJ||intestinal-14/JJ	amod||inflammation-15/NN||intestinal-14/JJ	prep_with||correlation-10/NN||inflammation-15/NN	advmod||obese-18/JJ||severely-17/RB	amod||children-19/NNS||obese-18/JJ	prep_in||evaluate-2/VB||children-19/NNS	glucose-6||inflammation-15||no_rel||to evaluate the frequency of glucose abnormalities and their correlation with systemic and intestinal inflammation in severely obese children.
nsubj||becoming-4/VBG||it-1/PRP	aux||becoming-4/VBG||is-2/VBZ	advmod||becoming-4/VBG||also-3/RB	root||ROOT-0/null||becoming-4/VBG	acomp||becoming-4/VBG||clear-5/JJ	mark||is-8/VBZ||that-6/IN	expl||is-8/VBZ||there-7/EX	ccomp||becoming-4/VBG||is-8/VBZ	det||correlation-11/NN||a-9/DT	amod||correlation-11/NN||positive-10/JJ	nsubj||is-8/VBZ||correlation-11/NN	amod||status-15/NN||maternal-13/JJ	amod||status-15/NN||vitamind-14/JJ	prep_between||correlation-11/NN||status-15/NN	prep_during||status-15/NN||pregnancy-17/NN	prep_during||status-15/NN||lactation-19/NN	conj_and||pregnancy-17/NN||lactation-19/NN	det||development-22/NN||the-21/DT	prep_between||correlation-11/NN||development-22/NN	conj_and||status-15/NN||development-22/NN	prep_of||development-22/NN||rickets-24/NNS	dep||is-8/VBZ||both-25/DT	prep_in||is-8/VBZ||infancy-27/NN	prep_in||is-8/VBZ||childhood-29/NN	conj_and||infancy-27/NN||childhood-29/NN	rickets-24||vitamind-14||yes||it is also becoming clear that there is a positive correlation between maternal vitamind status during pregnancy and lactation and the development of rickets both in infancy and childhood.
det||data-2/NNS||these-1/DT	nsubj||indicate-3/VBP||data-2/NNS	root||ROOT-0/null||indicate-3/VBP	det||reduction-6/NN||a-4/DT	amod||reduction-6/NN||significant-5/JJ	dobj||indicate-3/VBP||reduction-6/NN	nn||volume-9/NN||bladdertumor-8/NN	prep_of||reduction-6/NN||volume-9/NN	det||group-13/NN||the-11/DT	amod||group-13/NN||rbcg-12/JJ	prep_for||volume-9/NN||group-13/NN	prepc_compared_to||indicate-3/VBP||to-16/TO	det||groups-21/NNS||the-17/DT	nn||groups-21/NNS||bcg-18/NN	conj_and||bcg-18/NN||pbs-20/NN	nn||groups-21/NNS||pbs-20/NN	pobj||indicate-3/VBP||groups-21/NNS	bladdertumor-8||bcg-18||yes||these data indicate a significant reduction of bladdertumor volume for the rbcg group, compared to the bcg and pbs groups.
nsubj||analyzed-2/VBD||we-1/PRP	root||ROOT-0/null||analyzed-2/VBD	amod||isolates-5/NNS||consecutive-3/JJ	nn||isolates-5/NNS||falciparummalaria-4/NN	dobj||analyzed-2/VBD||isolates-5/NNS	nn||travelers-8/NNS||canadian-7/NN	prep_from||analyzed-2/VBD||travelers-8/NNS	num||2000-12/CD||1994-10/CD	dep||2000-12/CD||to-11/TO	prep_from||analyzed-2/VBD||2000-12/CD	prep_for||analyzed-2/VBD||polymorphisms-15/NNS	prep_in||polymorphisms-15/NNS||pfcrt-17/NN	prep_in||polymorphisms-15/NNS||dhfr-19/NN	conj_and||pfcrt-17/NN||dhfr-19/NN	prep_in||polymorphisms-15/NNS||dhps-22/NN	conj_and||pfcrt-17/NN||dhps-22/NN	vmod||pfcrt-17/NN||linked-23/VBN	aux||chloroquine-25/VB||to-24/TO	xcomp||linked-23/VBN||chloroquine-25/VB	xcomp||linked-23/VBN||pyrimethamine/sulfadoxine-27/VB	conj_and||chloroquine-25/VB||pyrimethamine/sulfadoxine-27/VB	dobj||chloroquine-25/VB||resistance-28/NN	falciparummalaria-4||sulfadoxine--1||yes||we analyzed consecutive falciparummalaria isolates from canadian travelers from 1994 to 2000, for polymorphisms in pfcrt, dhfr, and dhps linked to chloroquine and pyrimethamine/sulfadoxine resistance.
amod||analysis-2/NN||multivariate-1/JJ	nsubj||identified-3/VBD||analysis-2/NN	root||ROOT-0/null||identified-3/VBD	det||factors-8/NNS||the-4/DT	amod||factors-8/NNS||following-5/JJ	amod||factors-8/NNS||independent-6/JJ	nn||factors-8/NNS||risk-7/NN	dobj||identified-3/VBD||factors-8/NNS	amod||catheterization-13/NN||candidemia-10/JJ	amod||catheterization-13/NN||central-11/JJ	nn||catheterization-13/NN||venous-12/NNS	prep_for||factors-8/NNS||catheterization-13/NN	dep||catheterization-13/NN||odds-15/NNS	nn||-LSB--17/NNS||ratio-16/NN	dep||odds-15/NNS||-LSB--17/NNS	nn||-RSB--29/NNS||-RSB--19/NNP	nn||-RSB--29/NNS||=-20/NNP	num||-RSB--29/NNS||3.2-21/CD	num||-RSB--29/NNS||95-23/CD	nn||-RSB--29/NNS||%-24/NN	nn||-RSB--29/NNS||confidence-25/NN	amod||-RSB--29/NNS||interval-26/JJ	amod||-RSB--29/NNS||-LSB--27/JJ	nn||-RSB--29/NNS||ci-28/NN	dep||odds-15/NNS||-RSB--29/NNS	conj_or||-LSB--17/NNS||-RSB--29/NNS	dep||.0-32/CD||=-30/SYM	num||.0-32/CD||1.2-9-31/CD	rcmod||-LSB--17/NNS||.0-32/CD	amod||therapy-37/NN||previous-35/JJ	amod||therapy-37/NN||steroid-36/JJ	dobj||identified-3/VBD||therapy-37/NN	conj_and||factors-8/NNS||therapy-37/NN	cc||ci-45/VBP||or-39/CC	nsubj||ci-45/VBP||=-40/NNP	num||=-40/NNP||4.7-41/CD	number||%-44/NN||95-43/CD	amod||=-40/NNP||%-44/NN	dep||therapy-37/NN||ci-45/VBP	dep||.1-48/CD||=-46/SYM	num||.1-48/CD||1.8-12-47/CD	ccomp||ci-45/VBP||.1-48/CD	nn||transfusion-52/NN||blood-51/NN	dobj||identified-3/VBD||transfusion-52/NN	conj_and||factors-8/NNS||transfusion-52/NN	det||period-57/NN||the-54/DT	amod||period-57/NN||same-55/JJ	nn||period-57/NN||admission-56/NN	prep_during||transfusion-52/NN||period-57/NN	cc||ci-65/VBP||or-59/CC	nsubj||ci-65/VBP||=-60/NNP	num||=-60/NNP||6.3-61/CD	number||%-64/NN||95-63/CD	amod||=-60/NNP||%-64/NN	dep||factors-8/NNS||ci-65/VBP	dep||.7-68/CD||=-66/SYM	num||.7-68/CD||2.4-16-67/CD	ccomp||ci-65/VBP||.7-68/CD	amod||failure-73/NN||hepatic-72/JJ	dobj||identified-3/VBD||failure-73/NN	conj_and||factors-8/NNS||failure-73/NN	amod||admission-76/NN||micu-75/JJ	prep_upon||failure-73/NN||admission-76/NN	cc||=-79/VBG||or-78/CC	dep||failure-73/NN||=-79/VBG	nn||ci-84/NN||6.9-80/CD	number||%-83/NN||95-82/CD	amod||ci-84/NN||%-83/NN	dobj||=-79/VBG||ci-84/NN	dep||.4-87/CD||=-85/SYM	num||.4-87/CD||1.7-28-86/CD	dep||=-79/VBG||.4-87/CD	candidemia-10||steroid-36||no_rel||multivariate analysis identified the following independent risk factors for candidemia central venous catheterization (odds ratio [or] = 3.2, 95% confidence interval [ci]=1.2-9.0), previous steroid therapy (or=4.7, 95% ci=1.8-12.1), blood transfusion during the same admission period (or=6.3, 95% ci=2.4-16.7), and hepatic failure upon micu admission (or=6.9, 95% ci=1.7-28.4).
det||risk-2/NN||the-1/DT	nsubj||increased-8/VBN||risk-2/NN	amod||emergence-6/NN||adefovirdipivoxil-4/JJ	nn||emergence-6/NN||resistance-5/NN	prep_of||risk-2/NN||emergence-6/NN	aux||increased-8/VBN||has-7/VBZ	root||ROOT-0/null||increased-8/VBN	amod||patients-13/NNS||lamivudine-resistant-10/JJ	amod||patients-13/NNS||hepatitisb-11/JJ	amod||patients-13/NNS||infected-12/JJ	prep_in||increased-8/VBN||patients-13/NNS	hepatitisb-11||adefovirdipivoxil-4||yes||the risk of adefovirdipivoxil resistance emergence has increased in lamivudine-resistant hepatitisb infected patients.
nsubj||identified-2/VBD||we-1/PRP	root||ROOT-0/null||identified-2/VBD	num||patients-4/NNS||50-3/CD	dobj||identified-2/VBD||patients-4/NNS	amod||influenzapneumonia-7/NN||suspected-6/VBN	prep_with||patients-4/NNS||influenzapneumonia-7/NN	det||presence-10/NN||the-9/DT	nsubjpass||confirmed-14/VBN||presence-10/NN	prep_of||presence-10/NN||influenzavirus-12/NNS	auxpass||confirmed-14/VBN||was-13/VBD	parataxis||identified-2/VBD||confirmed-14/VBN	num||11-17/CD||18-16/CD	prep_in||confirmed-14/VBN||11-17/CD	amod||h1n1-21/NNS||pandemic-19/JJ	prep_with||confirmed-14/VBN||h1n1-21/NNS	num||virus-24/NN||2009-23/CD	dep||h1n1-21/NNS||virus-24/NN	prep_with||confirmed-14/VBN||5-26/CD	conj_and||h1n1-21/NNS||5-26/CD	amod||influenza-29/NN||unsubtypeable-28/JJ	prep_with||5-26/CD||influenza-29/NN	det||virus-31/NN||a-30/DT	dep||5-26/CD||virus-31/NN	prep_with||confirmed-14/VBN||1-33/CD	conj_and||h1n1-21/NNS||1-33/CD	amod||influenza-36/NN||seasonal-35/JJ	prep_with||1-33/CD||influenza-36/NN	det||virus-38/NN||a-37/DT	dep||influenza-36/NN||virus-38/NN	appos||influenza-36/NN||h3n2-40/NNP	prep_with||confirmed-14/VBN||1-44/CD	conj_and||h1n1-21/NNS||1-44/CD	prep_in||positive-59/JJ||1-44/CD	amod||results-48/NNS||assay-47/JJ	nsubj||positive-59/JJ||results-48/NNS	prep_for||results-48/NNS||seasonal-50/JJ	amod||h1n1-54/NNS||pandemic-52/JJ	prep_for||results-48/NNS||h1n1-54/NNS	conj_and||seasonal-50/JJ||h1n1-54/NNS	num||viruses-57/NNS||2009-56/CD	dep||h1n1-54/NNS||viruses-57/NNS	cop||positive-59/JJ||were-58/VBD	rcmod||1-44/CD||positive-59/JJ	virus-38||viruses-57||no||we identified 50 patients with suspected influenzapneumonia; the presence of influenzavirus was confirmed in 18 11 with pandemic (h1n1) 2009 virus, 5 with unsubtypeable influenza a virus, 1 with seasonal influenza a virus (h3n2), and 1 in whom assay results for seasonal and pandemic (h1n1) 2009 viruses were positive.
nsubj||show-3/VBP||we-1/PRP	advmod||show-3/VBP||now-2/RB	root||ROOT-0/null||show-3/VBP	det||treatment-5/NN||that-4/DT	dobj||show-3/VBP||treatment-5/NN	amod||mice-8/NNS||tumor-bearing-7/JJ	prep_of||treatment-5/NN||mice-8/NNS	amod||cd40-24/NNS||il-2-10/JJ	punct||±-13/NNP||/-11/:	nn||±-13/NNP||î-12/NNP	dep||cd40-24/NNS||±-13/NNP	amod||cd40-24/NNS||cd40-15/JJ	neg||il-2-19/JJ||not-18/RB	dep||cd40-24/NNS||il-2-19/JJ	advmod||±-22/JJ||î-21/RB	conj_or||il-2-19/JJ||±-22/JJ	dep||cd40-24/NNS||±-22/JJ	prep_with||treatment-5/NN||cd40-24/NNS	vmod||treatment-5/NN||induced-26/VBN	amod||synthase-29/NN||significant-27/JJ	nn||synthase-29/NN||nitricoxide-28/NN	nsubj||expression-34/NN||synthase-29/NN	appos||synthase-29/NN||nos-31/NN	num||expression-34/NN||2-33/CD	xcomp||induced-26/VBN||expression-34/NN	amod||macrophages-37/NNS||tumor-associated-36/JJ	prep_in||expression-34/NN||macrophages-37/NNS	il-2-19||tumor--1||no_rel||we now show that treatment of tumor-bearing mice with il-2/î±-cd40, but not il-2 or î±-cd40, induced significant nitricoxide synthase (nos) 2 expression in tumor-associated macrophages.
advmod||predisposed-11/VBN||thereby-1/RB	nn||carriers-4/NNS||risk-2/NN	nn||carriers-4/NNS||allele-3/NN	nsubjpass||predisposed-11/VBN||carriers-4/NNS	amod||levels-8/NNS||low-6/JJ	nn||levels-8/NNS||cholesterol-7/NN	prep_with||carriers-4/NNS||levels-8/NNS	aux||predisposed-11/VBN||may-9/MD	auxpass||predisposed-11/VBN||be-10/VB	root||ROOT-0/null||predisposed-11/VBN	det||risk-15/NN||an-13/DT	amod||risk-15/NN||increased-14/VBN	prep_to||predisposed-11/VBN||risk-15/NN	amod||cvd-18/NN||developing-17/VBG	prep_of||risk-15/NN||cvd-18/NN	nsubj||seems-21/VBZ||cvd-18/NN	nsubjpass||abolished-24/VBN||cvd-18/NN	rcmod||cvd-18/NN||seems-21/VBZ	aux||abolished-24/VBN||to-22/TO	auxpass||abolished-24/VBN||be-23/VB	xcomp||seems-21/VBZ||abolished-24/VBN	nn||carriers-28/NNS||risk-26/NN	nn||carriers-28/NNS||allele-27/NN	prep_among||abolished-24/VBN||carriers-28/NNS	amod||levels-32/NNS||high-30/JJ	nn||levels-32/NNS||cholesterol-31/NN	prep_with||abolished-24/VBN||levels-32/NNS	cholesterol-31||cvd-18||no_rel||thereby risk allele carriers with low cholesterol levels may be predisposed to an increased risk of developing cvd, which seems to be abolished among risk allele carriers with high cholesterol levels.
nsubj||used-6/VBD||methods-1/NNS	det||analysis-5/NN||this-2/DT	nn||analysis-5/NN||post-3/NN	nn||analysis-5/NN||hoc-4/NN	dep||methods-1/NNS||analysis-5/NN	root||ROOT-0/null||used-6/VBD	dobj||used-6/VBD||data-7/NNS	det||study-15/NN||a-9/DT	amod||study-15/NN||1-year-10/JJ	amod||study-15/NN||randomized-12/JJ	amod||study-15/NN||open-label-14/JJ	prep_from||used-6/VBD||study-15/NN	prep_of||study-15/NN||olanzapine-17/NN	prep_of||study-15/NN||risperidone-19/NN	conj_and||olanzapine-17/NN||risperidone-19/NN	prep_of||study-15/NN||typicalantipsychotics-22/NNS	conj_and||olanzapine-17/NN||typicalantipsychotics-22/NNS	det||treatment-25/NN||the-24/DT	prep_in||used-6/VBD||treatment-25/NN	prep_of||treatment-25/NN||schizophrenia-27/NN	schizophrenia-27||olanzapine-17||yes||methods this post hoc analysis used data from a 1-year, randomized, open-label study of olanzapine, risperidone, and typicalantipsychotics in the treatment of schizophrenia.
poss||aim-2/NN||our-1/PRP$	nsubj||is-3/VBZ||aim-2/NN	nsubj||define-5/VB||aim-2/NN	root||ROOT-0/null||is-3/VBZ	aux||define-5/VB||to-4/TO	xcomp||is-3/VBZ||define-5/VB	det||targets-8/NNS||the-6/DT	amod||targets-8/NNS||potential-7/JJ	dobj||define-5/VB||targets-8/NNS	nsubj||makes-11/VBZ||targets-8/NNS	rcmod||targets-8/NNS||makes-11/VBZ	amod||cells-16/NNS||drug-sensitive-12/JJ	amod||cells-16/NNS||mcf-7-13/JJ	nn||cells-16/NNS||breast-14/NN	nn||cells-16/NNS||cancer-15/NN	nsubj||turn-17/VBP||cells-16/NNS	nsubj||drug-resistant-19/VB||cells-16/NNS	ccomp||makes-11/VBZ||turn-17/VBP	aux||drug-resistant-19/VB||to-18/TO	xcomp||turn-17/VBP||drug-resistant-19/VB	det||development-24/NN||the-22/DT	amod||development-24/NN||anti-cancerdrug-23/JJ	prep_for||define-5/VB||development-24/NN	nn||cells-30/NNS||drug-26/NN	amod||breast-28/JJ||resistant-27/JJ	amod||cells-30/NNS||breast-28/JJ	nn||cells-30/NNS||cancer-29/NN	prep_against||development-24/NN||cells-30/NNS	cancer-29||cancerdrug--1||no_rel||our aim is to define the potential targets, that makes drug-sensitive mcf-7 breast cancer cells turn to drug-resistant, for the anti-cancerdrug development against drug resistant breast cancer cells.
root||ROOT-0/null||waldenstrom-1/VB	nsubj||b-celllymphoma-7/NN||smacroglobulinemia-3/NN	cop||b-celllymphoma-7/NN||is-4/VBZ	det||b-celllymphoma-7/NN||a-5/DT	amod||b-celllymphoma-7/NN||low-grade-6/JJ	ccomp||waldenstrom-1/VB||b-celllymphoma-7/NN	vmod||b-celllymphoma-7/NN||characterized-8/VBN	det||presence-11/NN||the-10/DT	agent||characterized-8/VBN||presence-11/NN	amod||cells-14/NNS||lymphoplasmacytic-13/JJ	prep_of||presence-11/NN||cells-14/NNS	det||marrow-18/NN||the-16/DT	nn||marrow-18/NN||bone-17/NN	prep_in||cells-14/NNS||marrow-18/NN	det||m-23/NN||a-20/DT	amod||m-23/NN||monoclonal-21/JJ	nn||m-23/NN||immunoglobulin-22/NN	prep_of||presence-11/NN||m-23/NN	conj_and||cells-14/NNS||m-23/NN	det||circulation-26/NN||the-25/DT	prep_in||m-23/NN||circulation-26/NN	immunoglobulin-22||waldenstrom'smacroglobulinemia--1||no_rel||waldenstrom'smacroglobulinemia is a low-grade b-celllymphoma characterized by the presence of lymphoplasmacytic cells in the bone marrow and a monoclonal immunoglobulin m in the circulation.
nn||studies-3/NNS||lipid-1/NN	nn||studies-3/NNS||metabolism-2/NN	nsubjpass||started-8/VBN||studies-3/NNS	nsubjpass||concentrated-18/VBN||studies-3/NNS	prep_in||studies-3/NNS||psoriasis-5/NNS	aux||started-8/VBN||have-6/VBP	auxpass||started-8/VBN||been-7/VBN	root||ROOT-0/null||started-8/VBN	det||beginning-11/NN||the-10/DT	prep_at||started-8/VBN||beginning-11/NN	det||century-15/NN||the-13/DT	amod||century-15/NN||20th-14/JJ	prep_of||beginning-11/NN||century-15/NN	auxpass||concentrated-18/VBN||are-17/VBP	conj_and||started-8/VBN||concentrated-18/VBN	nn||lipids-22/NNS||skin-20/NN	nn||lipids-22/NNS||surface-21/NN	prep_on||concentrated-18/VBN||lipids-22/NNS	nn||lipids-26/NNS||stratum-24/NN	nn||lipids-26/NNS||corneum-25/NN	appos||lipids-22/NNS||lipids-26/NNS	nn||phospholipids-29/NNS||epidermal-28/NN	appos||lipids-22/NNS||phospholipids-29/NNS	conj_and||lipids-26/NNS||phospholipids-29/NNS	nn||lipids-32/NNS||serum-31/NN	appos||lipids-22/NNS||lipids-32/NNS	amod||lipoproteins-36/NNS||dermal-34/JJ	nn||lipoproteins-36/NNS||low-density-35/NN	appos||lipids-22/NNS||lipoproteins-36/NNS	det||skin-40/NN||the-38/DT	amod||skin-40/NN||psoriatic-39/JJ	prep_in||lipoproteins-36/NNS||skin-40/NN	nn||metabolism-43/NN||lipid-42/NN	prep_in||lipoproteins-36/NNS||metabolism-43/NN	conj_and||skin-40/NN||metabolism-43/NN	amod||stress-46/NN||oxidative-45/JJ	prep_in||lipoproteins-36/NNS||stress-46/NN	conj_and||skin-40/NN||stress-46/NN	prep_in||lipoproteins-36/NNS||correlations-48/NNS	conj_and||skin-40/NN||correlations-48/NNS	amod||parameters-51/NNS||inflammatory-50/JJ	prep_between||lipoproteins-36/NNS||parameters-51/NNS	nn||parameters-54/NNS||lipid-53/NN	appos||lipids-22/NNS||parameters-54/NNS	amod||symptoms-57/NNS||clinical-56/JJ	prep_on||concentrated-18/VBN||symptoms-57/NNS	conj_and||lipids-22/NNS||symptoms-57/NNS	det||disease-60/NN||the-59/DT	prep_of||symptoms-57/NNS||disease-60/NN	psoriasis-5||lipid-53||no_rel||lipid metabolism studies in psoriasis have been started at the beginning of the 20th century and are concentrated on skin surface lipids, stratum corneum lipids and epidermal phospholipids, serum lipids, dermal low-density lipoproteins in the psoriatic skin, lipid metabolism, oxidative stress and correlations between inflammatory parameters, lipid parameters and clinical symptoms of the disease.
advmod||achieved-25/VBN||moreover-1/RB	advmod||added-6/VBN||when-3/WRB	nsubjpass||added-6/VBN||thioridazine-4/NN	auxpass||added-6/VBN||was-5/VBD	advcl||achieved-25/VBN||added-6/VBN	det||regimen-9/NN||a-8/DT	prep_to||added-6/VBN||regimen-9/NN	vmod||regimen-9/NN||containing-10/VBG	dobj||containing-10/VBG||rifampicin-11/NN	dobj||containing-10/VBG||isoniazid-13/NN	conj_and||rifampicin-11/NN||isoniazid-13/NN	dobj||containing-10/VBG||pyrazinamide-15/NN	conj_and||rifampicin-11/NN||pyrazinamide-15/NN	nn||tuberculosis-18/NNP||susceptible-17/NNP	prep_for||containing-10/VBG||tuberculosis-18/NNP	det||effect-23/NN||a-20/DT	amod||effect-23/NN||significant-21/JJ	amod||effect-23/NN||synergistic-22/JJ	nsubjpass||achieved-25/VBN||effect-23/NN	auxpass||achieved-25/VBN||was-24/VBD	root||ROOT-0/null||achieved-25/VBN	poss||â-31/NNP||â-27/NNP	nn||â-31/NNP||6.2-29/NNP	nn||â-31/NNP||vs-30/NNP	poss||cfu-35/NN||â-31/NNP	number||log-34/CD||5.9-33/CD	num||cfu-35/NN||log-34/CD	dep||achieved-25/VBN||cfu-35/NN	nn||0.01-39/NNP||p-37/NNP	nn||0.01-39/NNP||<-38/NNP	appos||cfu-35/NN||0.01-39/NNP	tuberculosis-18||rifampicin-11||yes||moreover, when thioridazine was added to a regimen containing rifampicin, isoniazid and pyrazinamide for susceptible tuberculosis, a significant synergistic effect was achieved (â6.2 vs â5.9 log cfu, p<0.01).
amod||levels-3/NNS||bcar4-1/JJ	nn||levels-3/NNS||mrna-2/NN	nsubjpass||measured-5/VBN||levels-3/NNS	nsubjpass||evaluated-11/VBN||levels-3/NNS	auxpass||measured-5/VBN||were-4/VBD	root||ROOT-0/null||measured-5/VBN	amod||breasttumours-8/NNS||primary-7/JJ	prep_in||measured-5/VBN||breasttumours-8/NNS	conj_and||measured-5/VBN||evaluated-11/VBN	prep_for||evaluated-11/VBN||association-13/NN	amod||survival-16/NN||progression-free-15/JJ	prep_with||evaluated-11/VBN||survival-16/NN	appos||survival-16/NN||pfs-18/NN	amod||benefit-22/NN||clinical-21/JJ	prep_with||evaluated-11/VBN||benefit-22/NN	conj_and||survival-16/NN||benefit-22/NN	prep_in||benefit-22/NN||patients-24/NNS	nn||receptor-27/NN||oestrogen-26/NN	prep_with||patients-24/NNS||receptor-27/NN	nn||±-31/NNS||er-29/NN	nn||±-31/NNS||î-30/NN	appos||receptor-27/NN||±-31/NNS	amod||tumours-35/NNS||positive-34/JJ	dep||benefit-22/NN||tumours-35/NNS	vmod||tumours-35/NNS||receiving-36/VBG	dobj||receiving-36/VBG||tamoxifen-37/NN	amod||monotherapy-40/NN||first-line-39/JJ	prep_as||receiving-36/VBG||monotherapy-40/NN	amod||disease-43/NN||advanced-42/JJ	prep_for||monotherapy-40/NN||disease-43/NN	breasttumours-8||oestrogen-26||no||bcar4 mrna levels were measured in primary breasttumours, and evaluated for association with progression-free survival (pfs) and clinical benefit in patients with oestrogen receptor (er î± )-positive tumours receiving tamoxifen as first-line monotherapy for advanced disease.
aux||determine-2/VB||to-1/TO	csubj||improves-12/VBZ||determine-2/VB	mark||template-7/VBP||whether-3/IN	det||order-6/NN||an-4/DT	amod||order-6/NN||electronic-5/JJ	nsubj||template-7/VBP||order-6/NN	ccomp||determine-2/VB||template-7/VBP	amod||insulin-10/NN||basal-bolus-9/JJ	prep_for||template-7/VBP||insulin-10/NN	vmod||insulin-10/NN||ordering-11/VBG	root||ROOT-0/null||improves-12/VBZ	xcomp||improves-12/VBZ||mean-13/VB	nn||glucose-15/NN||blood-14/NN	dobj||mean-13/VB||glucose-15/NN	amod||patients-20/NNS||hospitalized-17/JJ	amod||patients-20/NNS||general-18/JJ	amod||patients-20/NNS||medical-19/JJ	prep_in||mean-13/VB||patients-20/NNS	prep_with||patients-20/NNS||hyperglycemia-22/NN	prep_with||patients-20/NNS||type2diabetes-24/NNS	conj_and||hyperglycemia-22/NN||type2diabetes-24/NNS	hyperglycemia-22||glucose-15||no||to determine whether an electronic order template for basal-bolus insulin ordering improves mean blood glucose in hospitalized general medical patients with hyperglycemia and type2diabetes.
amod||production-3/NN||endogenous-1/JJ	nn||production-3/NN||glucose-2/NN	nsubj||excessive-5/JJ||production-3/NN	nsubj||fails-9/VBZ||production-3/NN	nsubj||suppress-12/VB||production-3/NN	cop||excessive-5/JJ||is-4/VBZ	root||ROOT-0/null||excessive-5/JJ	prepc_before||excessive-5/JJ||eating-7/VBG	conj_and||excessive-5/JJ||fails-9/VBZ	aux||suppress-12/VB||to-10/TO	advmod||suppress-12/VB||appropriately-11/RB	xcomp||fails-9/VBZ||suppress-12/VB	prepc_after||suppress-12/VB||eating-14/VBG	prep_in||eating-14/VBG||people-16/NNS	prep_with||people-16/NNS||type2diabetes-18/CD	glucose-2||type2diabetes-18||no_rel||endogenous glucose production is excessive before eating and fails to appropriately suppress after eating in people with type2diabetes.
amod||n-3pufa-2/NN||fishoil-1/JJ	nsubjpass||consumed-8/VBN||n-3pufa-2/NN	amod||daily-5/NN||3g-4/JJ	appos||n-3pufa-2/NN||daily-5/NN	auxpass||consumed-8/VBN||were-7/VBD	root||ROOT-0/null||consumed-8/VBN	prep_during||consumed-8/VBN||5weeks-10/NNS	vmod||5weeks-10/NNS||separated-11/VBN	det||period-17/NN||a-13/DT	num||period-17/NN||5-14/CD	nn||period-17/NN||week-15/NN	nn||period-17/NN||washout-16/NN	agent||separated-11/VBN||period-17/NN	det||placebo-21/NN||a-19/DT	amod||placebo-21/NN||cross-over-20/JJ	prep_in||separated-11/VBN||placebo-21/NN	vmod||placebo-21/NN||controlled-22/VBN	dobj||controlled-22/VBN||study-23/NN	num||middle-28/NN||40-26/CD	amod||middle-28/NN||healthy-27/JJ	prep_including||controlled-22/VBN||middle-28/NN	vmod||middle-28/NN||aged-29/VBN	amod||subjects-32/NNS||elderly-31/JJ	prep_to||aged-29/VBN||subjects-32/NNS	cross--1||n-3pufa-2||no_rel||fishoil n-3pufa (3g daily) were consumed during 5weeks separated by a 5 week washout period in a cross-over placebo controlled study, including 40 healthy middle aged to elderly subjects.
amod||activities-2/NNS||enzyme-1/JJ	nsubjpass||determined-8/VBN||activities-2/NNS	amod||levels-6/NNS||total-4/JJ	nn||levels-6/NNS||glutathione-5/NN	conj_and||activities-2/NNS||levels-6/NNS	nsubjpass||determined-8/VBN||levels-6/NNS	auxpass||determined-8/VBN||were-7/VBD	root||ROOT-0/null||determined-8/VBN	prep_in||determined-8/VBN||erythrocytes-10/NNS	num||children-13/NNS||102-12/CD	prep_in||erythrocytes-10/NNS||children-13/NNS	prep_in||erythrocytes-10/NNS||adolescents-15/NNS	conj_and||children-13/NNS||adolescents-15/NNS	det||episode-20/NN||a-17/DT	amod||episode-20/NN||first-18/JJ	amod||episode-20/NN||psychotic-19/JJ	prep_with||determined-8/VBN||episode-20/NN	num||controls-24/NNS||98-22/CD	amod||controls-24/NNS||healthy-23/JJ	prep_with||determined-8/VBN||controls-24/NNS	conj_and||episode-20/NN||controls-24/NNS	enzyme-1||psychotic-19||no_rel||enzyme activities and total glutathione levels were determined in erythrocytes in 102 children and adolescents with a first psychotic episode and 98 healthy controls.
nsubj||one-3/CD||irondeficiency-1/NN	cop||one-3/CD||is-2/VBZ	root||ROOT-0/null||one-3/CD	det||disorders-9/NNS||the-5/DT	advmod||nutritional-8/JJ||most-6/RBS	amod||nutritional-8/JJ||common-7/JJ	amod||disorders-9/NNS||nutritional-8/JJ	prep_of||one-3/CD||disorders-9/NNS	advmod||one-3/CD||worldwide-10/RB	nn||donation-13/NN||blood-12/NN	nsubj||cause-15/VB||donation-13/NN	aux||cause-15/VB||may-14/MD	conj_and||one-3/CD||cause-15/VB	nn||depletion-17/NN||iron-16/NN	dobj||cause-15/VB||depletion-17/NN	irondeficiency-1||iron-16||yes||irondeficiency is one of the most common nutritional disorders worldwide and blood donation may cause iron depletion.
nsubj||introduced-2/VBD||we-1/PRP	root||ROOT-0/null||introduced-2/VBD	amod||opioids-4/NNS||strong-3/JJ	nsubj||tolerable-26/JJ||opioids-4/NNS	amod||patches-8/NNS||transdermal-6/JJ	amod||patches-8/NNS||fentanyl-7/JJ	dep||opioids-4/NNS||patches-8/NNS	det||pain-12/NN||the-10/DT	nn||pain-12/NN||background-11/NN	prep_for||patches-8/NNS||pain-12/NN	det||opioid-16/NN||a-14/DT	amod||opioid-16/NN||short-acting-15/JJ	dep||opioids-4/NNS||opioid-16/NN	conj_and||patches-8/NNS||opioid-16/NN	det||pain-20/NN||the-18/DT	nn||pain-20/NN||breakthrough-19/NN	prep_for||opioid-16/NN||pain-20/NN	poss||pain-24/NN||his-23/PRP$	conj_and||opioids-4/NNS||pain-24/NN	nsubj||tolerable-26/JJ||pain-24/NN	cop||tolerable-26/JJ||was-25/VBD	ccomp||introduced-2/VBD||tolerable-26/JJ	num||hr-31/NN||250-28/CD	nn||hr-31/NN||âµg-29/NN	nn||hr-31/NN||/-30/NN	prep_on||tolerable-26/JJ||hr-31/NN	amod||patches-34/NNS||fentanyl-33/JJ	prep_of||hr-31/NN||patches-34/NNS	num||months-37/NNS||3-36/CD	prep_for||tolerable-26/JJ||months-37/NNS	pain-24||fentanyl-33||yes||we introduced strong opioids (transdermal fentanyl patches for the background pain and a short-acting opioid for the breakthrough pain) and his pain was tolerable on 250 âµg/hr of fentanyl patches for 3 months.
det||fact-3/NN||the-2/DT	prep_despite||apparent-18/JJ||fact-3/NN	mark||suffer-10/VBP||that-4/IN	nsubj||suffer-10/VBP||men-5/NNS	conj_and||men-5/NNS||women-7/NNS	nsubj||suffer-10/VBP||women-7/NNS	prep_with||men-5/NNS||hiv/aids-9/NNS	dep||fact-3/NN||suffer-10/VBP	det||illness-13/NN||the-11/DT	amod||illness-13/NN||same-12/JJ	dobj||suffer-10/VBP||illness-13/NN	amod||disparities-16/NNS||clear-15/JJ	nsubj||apparent-18/JJ||disparities-16/NNS	cop||apparent-18/JJ||are-17/VBP	root||ROOT-0/null||apparent-18/JJ	det||women-23/NNS||the-20/DT	amod||women-23/NNS||negative-21/JJ	nn||women-23/NNS||reaction-22/NN	prep_in||apparent-18/JJ||women-23/NNS	nn||living-26/NN||men-25/NNS	prep_in||apparent-18/JJ||living-26/NN	conj_and||women-23/NNS||living-26/NN	amod||experience-29/NN||hiv/aids-28/JJ	prep_with||apparent-18/JJ||experience-29/NN	prep_in||experience-29/NN||society-31/NN	aids--1||hiv--1||no||despite the fact that men and women with hiv/aids suffer the same illness, clear disparities are apparent in the negative reaction women and men living with hiv/aids experience in society.
nsubj||aimed-2/VBD||we-1/PRP	nsubj||evaluate-4/VB||we-1/PRP	root||ROOT-0/null||aimed-2/VBD	aux||evaluate-4/VB||to-3/TO	xcomp||aimed-2/VBD||evaluate-4/VB	det||safety-6/NN||the-5/DT	dobj||evaluate-4/VB||safety-6/NN	amod||responses-9/NNS||clinical-8/JJ	dobj||evaluate-4/VB||responses-9/NNS	conj_and||safety-6/NN||responses-9/NNS	amod||ankylosingspondylitis-12/JJ||korean-11/JJ	amod||patients-16/NNS||ankylosingspondylitis-12/JJ	prep||patients-16/NNS||as-14/IN	prep_in||responses-9/NNS||patients-16/NNS	num||months-19/NNS||three-18/CD	prep_after||evaluate-4/VB||months-19/NNS	amod||therapy-22/NN||etanercept-21/JJ	prep_of||months-19/NNS||therapy-22/NN	etanercept-21||ankylosingspondylitis-12||no_rel||we aimed to evaluate the safety and clinical responses in korean ankylosingspondylitis (as) patients after three months of etanercept therapy.
amod||-lrb--2/NNS||epstein-barrvirus-1/JJ	nsubj||ebv-3/VBP||-lrb--2/NNS	root||ROOT-0/null||ebv-3/VBP	amod||infection-5/NN||-rrb--4/JJ	nsubj||finding-10/NN||infection-5/NN	cop||finding-10/NN||is-6/VBZ	det||finding-10/NN||an-7/DT	advmod||finding-10/NN||almost-8/RB	amod||finding-10/NN||universal-9/JJ	ccomp||ebv-3/VBP||finding-10/NN	prep_among||finding-10/NN||individuals-12/NNS	amod||ebvinfection-16/NN||ms.-14/JJ	amod||ebvinfection-16/NN||symptomatic-15/JJ	prep_with||individuals-12/NNS||ebvinfection-16/NN	mark||shown-26/VBN||as-17/IN	amod||-rrb--23/NNS||manifested-18/JJ	prep_by||manifested-18/JJ||infectiousmononucleosis-20/NNS	amod||-rrb--23/NNS||-lrb--21/JJ	nn||-rrb--23/NNS||im-22/NN	nsubjpass||shown-26/VBN||-rrb--23/NNS	nsubjpass||associated-33/VBN||-rrb--23/NNS	aux||shown-26/VBN||has-24/VBZ	auxpass||shown-26/VBN||been-25/VBN	advcl||finding-10/NN||shown-26/VBN	det||meta-analysis-30/NNS||a-28/DT	amod||meta-analysis-30/NNS||previous-29/JJ	prep_in||shown-26/VBN||meta-analysis-30/NNS	aux||associated-33/VBN||to-31/TO	auxpass||associated-33/VBN||be-32/VB	xcomp||shown-26/VBN||associated-33/VBN	det||risk-36/NN||the-35/DT	prep_with||associated-33/VBN||risk-36/NN	prep_of||risk-36/NN||ms-38/NN	advmod||published-50/VBN||however-40/RB	det||number-42/NN||a-41/DT	nsubjpass||published-50/VBN||number-42/NN	advmod||larger-45/JJR||much-44/RB	amod||studies-46/NNS||larger-45/JJR	prep_of||number-42/NN||studies-46/NNS	aux||published-50/VBN||have-47/VBP	advmod||published-50/VBN||since-48/IN	auxpass||published-50/VBN||been-49/VBN	parataxis||ebv-3/VBP||published-50/VBN	ebvinfection-16||ebv-3||no||epstein-barrvirus -lrb- ebv -rrb- infection is an almost universal finding among individuals with ms. symptomatic ebvinfection as manifested by infectiousmononucleosis -lrb- im -rrb- has been shown in a previous meta-analysis to be associated with the risk of ms , however a number of much larger studies have since been published .
det||course-3/NN||the-1/DT	amod||course-3/NN||clinical-2/JJ	nsubj||unknown-19/JJ||course-3/NN	prep_of||course-3/NN||humanpapillomavirus-5/NNS	appos||humanpapillomavirus-5/NNS||hpv-7/NN	vmod||humanpapillomavirus-5/NNS||associated-9/VBN	prep_with||associated-9/VBN||bowenoidpapulosis-11/NNS	prep_with||associated-9/VBN||condylomaacuminatum-13/NN	conj_and||bowenoidpapulosis-11/NNS||condylomaacuminatum-13/NN	amod||tumors-16/NNS||anogenital-15/JJ	prep_of||bowenoidpapulosis-11/NNS||tumors-16/NNS	cop||unknown-19/JJ||are-17/VBP	advmod||unknown-19/JJ||still-18/RB	root||ROOT-0/null||unknown-19/JJ	bowenoidpapulosis-11||hpv-7||no||the clinical course of humanpapillomavirus (hpv) associated with bowenoidpapulosis and condylomaacuminatum of anogenital tumors are still unknown.
det||combination-2/NN||the-1/DT	nsubj||reduced-12/VBD||combination-2/NN	amod||propofol-5/NN||cold-4/JJ	prep_of||combination-2/NN||propofol-5/NN	prep_of||combination-2/NN||pretreatment-7/NN	conj_and||propofol-5/NN||pretreatment-7/NN	prep_with||propofol-5/NN||remifentanil-9/NN	advmod||effectively-11/RB||more-10/RBR	advmod||reduced-12/VBD||effectively-11/RB	root||ROOT-0/null||reduced-12/VBD	det||incidence-14/NN||the-13/DT	dobj||reduced-12/VBD||incidence-14/NN	prep_of||incidence-14/NN||pain-16/NN	det||injection-19/NN||the-18/DT	prep_upon||reduced-12/VBD||injection-19/NN	prep_of||injection-19/NN||propofol-21/NN	det||treatment-24/NN||either-23/DT	prep_than||reduced-12/VBD||treatment-24/NN	advmod||reduced-12/VBD||alone-25/RB	pain-16||remifentanil-9||yes||the combination of cold propofol and pretreatment with remifentanil more effectively reduced the incidence of pain upon the injection of propofol than either treatment alone.
poss||findings-2/NNS||our-1/PRP$	nsubj||emphasize-3/VB||findings-2/NNS	root||ROOT-0/null||emphasize-3/VB	det||importance-5/NN||the-4/DT	dobj||emphasize-3/VB||importance-5/NN	amod||characterization-9/NN||detailed-7/VBN	amod||characterization-9/NN||physiological-8/JJ	prep_of||importance-5/NN||characterization-9/NN	amod||loci-12/NNS||such-11/JJ	prep_of||characterization-9/NN||loci-12/NNS	amod||understanding-15/NN||improved-14/VBN	prep_for||loci-12/NNS||understanding-15/NN	prep_of||understanding-15/NN||pathways-17/NNS	vmod||pathways-17/NNS||associated-18/VBN	amod||type2diabetes-26/NNS||alterations-20/JJ	prep||type2diabetes-26/NNS||in-21/IN	nn||homeostasis-23/NNS||glucose-22/NN	pobj||in-21/IN||homeostasis-23/NNS	conj_and||in-21/IN||eventually-25/RB	prep||type2diabetes-26/NNS||eventually-25/RB	prep_with||associated-18/VBN||type2diabetes-26/NNS	type2diabetes-26||glucose-22||no_rel||our findings emphasize the importance of detailed physiological characterization of such loci for improved understanding of pathways associated with alterations in glucose homeostasis and eventually type2diabetes.
amod||prionprotein-2/NN||cellular-1/JJ	nsubj||glycoprotein-8/NN||prionprotein-2/NN	appos||prionprotein-2/NN||prnp-4/NN	cop||glycoprotein-8/NN||is-6/VBZ	det||glycoprotein-8/NN||a-7/DT	root||ROOT-0/null||glycoprotein-8/NN	vmod||glycoprotein-8/NN||involved-9/VBN	det||pathogenesis-12/NNS||the-11/DT	prep_in||involved-9/VBN||pathogenesis-12/NNS	prep_of||pathogenesis-12/NNS||transmissiblespongiformencephalopathies-14/NNS	appos||transmissiblespongiformencephalopathies-14/NNS||tses-16/NNS	transmissiblespongiformencephalopathies-14||prionprotein-2||no||cellular prionprotein (prnp) is a glycoprotein involved in the pathogenesis of transmissiblespongiformencephalopathies (tses).
nsubjpass||associated-8/VBN||antibodies-1/NNS	prep_against||antibodies-1/NNS||adalimumab-3/NN	appos||antibodies-1/NNS||aaa-5/NN	auxpass||associated-8/VBN||are-7/VBP	root||ROOT-0/null||associated-8/VBN	prep_with||associated-8/VBN||non-response-10/NN	prep_to||associated-8/VBN||treatment-12/NN	aaa-5||adalimumab-3||no_rel||antibodies against adalimumab (aaa) are associated with non-response to treatment.
det||study-5/NN||a-2/DT	amod||study-5/NN||randomized-3/JJ	amod||study-5/NN||prospective-4/JJ	prep_in||enrolled-19/VBN||study-5/NN	num||patients-8/NNS||60-7/CD	nsubjpass||enrolled-19/VBN||patients-8/NNS	nsubj||determine-21/VB||patients-8/NNS	nn||i-ii-11/NN||asa-10/NN	dep||patients-8/NNS||i-ii-11/NN	appos||i-ii-11/NN||elder-13/JJR	num||years-16/NNS||65-15/CD	prep_than||elder-13/JJR||years-16/NNS	auxpass||enrolled-19/VBN||were-18/VBD	root||ROOT-0/null||enrolled-19/VBN	aux||determine-21/VB||to-20/TO	xcomp||enrolled-19/VBN||determine-21/VB	dobj||required-37/VBN||which-22/WDT	num||target-25/NN||two-24/CD	prep_of||required-37/VBN||target-25/NN	amod||concentrations-28/NNS||remifentanil-26/JJ	nn||concentrations-28/NNS||blood-27/NN	nsubjpass||required-37/VBN||concentrations-28/NNS	num||ng/ml-31/NN||3-30/CD	dep||concentrations-28/NNS||ng/ml-31/NN	num||ng/ml-34/NN||5-33/CD	appos||ng/ml-31/NN||ng/ml-34/NN	auxpass||required-37/VBN||was-36/VBD	ccomp||determine-21/VB||required-37/VBN	aux||blunt-39/VB||to-38/TO	ccomp||required-37/VBN||blunt-39/VB	amod||changes-41/NNS||hemodynamic-40/JJ	dobj||blunt-39/VB||changes-41/NNS	prep_during||blunt-39/VB||intubation-43/NN	aux||reduce-46/VB||to-45/TO	ccomp||required-37/VBN||reduce-46/VB	conj_and||blunt-39/VB||reduce-46/VB	amod||pain-48/NN||propofol-induced-47/JJ	dobj||reduce-46/VB||pain-48/NN	pain-48||propofol--1||yes||in a randomized prospective study, 60 patients (asa i-ii, elder than 65 years) were enrolled to determine which of two target remifentanil blood concentrations (3 ng/ml, 5 ng/ml) was required to blunt hemodynamic changes during intubation and to reduce propofol-induced pain.
nsubj||investigated-2/VBD||we-1/PRP	root||ROOT-0/null||investigated-2/VBD	det||significance-5/NN||the-3/DT	amod||significance-5/NN||clinical-4/JJ	dobj||investigated-2/VBD||significance-5/NN	amod||immunoglobulin-9/NN||serum-7/JJ	amod||immunoglobulin-9/NN||specific-8/JJ	prep_of||significance-5/NN||immunoglobulin-9/NN	dep||significance-5/NN||e-10/SYM	appos||significance-5/NN||lge-12/NN	det||enterotoxin-19/NN||the-15/DT	amod||enterotoxin-19/NN||staphylococcal-16/JJ	nn||enterotoxin-19/NN||superantigens-17/NNS	nn||enterotoxin-19/NN||staphylococcal-18/NN	prep_to||investigated-2/VBD||enterotoxin-19/NN	det||sea-22/NN||a-20/DT	dep||enterotoxin-19/NN||sea-22/NN	amod||enterotoxin-26/NN||staphylococcal-25/JJ	prep_to||investigated-2/VBD||enterotoxin-26/NN	conj_and||enterotoxin-19/NN||enterotoxin-26/NN	dep||enterotoxin-26/NN||b-27/SYM	appos||b-27/SYM||seb-29/NN	amod||toxin-34/NN||toxicshocksyndrome-33/JJ	prep_to||investigated-2/VBD||toxin-34/NN	conj_and||enterotoxin-19/NN||toxin-34/NN	appos||toxin-34/NN||tsst-36/NN	dep||toxin-34/NN||-1-38/CD	prep_in||investigated-2/VBD||patients-40/NNS	amod||urticaria-43/NN||chronic-42/JJ	prep_with||patients-40/NNS||urticaria-43/NN	appos||urticaria-43/NN||cu-45/NN	vmod||investigated-2/VBD||focusing-48/VBG	det||differences-51/NNS||the-50/DT	prep_on||focusing-48/VBG||differences-51/NNS	det||prevalences-54/NNS||these-53/DT	prep_in||differences-51/NNS||prevalences-54/NNS	amod||cu-57/NN||aspirin-intolerant-56/JJ	prep_between||prevalences-54/NNS||cu-57/NN	appos||cu-57/NN||aicu-59/NNP	amod||patients-67/NNS||aspirin-tolerant-62/JJ	nn||patients-67/NNS||cu-63/NN	appos||patients-67/NNS||atcu-65/NNP	prep_between||prevalences-54/NNS||patients-67/NNS	conj_and||cu-57/NN||patients-67/NNS	aspirin--1||toxicshocksyndrome-33||no_rel||we investigated the clinical significance of serum specific immunoglobulin e (lge) to the staphylococcal superantigens staphylococcal enterotoxin a (sea), staphylococcal enterotoxin b (seb), and toxicshocksyndrome toxin (tsst)-1 in patients with chronic urticaria (cu), focusing on the differences in these prevalences between aspirin-intolerant cu (aicu) and aspirin-tolerant cu (atcu) patients.
prep_in||isolates-14/VBZ||177-2/CD	num||%-5/NN||4-4/CD	appos||177-2/CD||%-5/NN	num||cases-11/NNS||4,557-8/CD	amod||cases-11/NNS||culture-positive-9/JJ	nn||cases-11/NNS||tb-10/NN	prep_of||177-2/CD||cases-11/NNS	nsubj||isolates-14/VBZ||mycobacteriumtuberculosis-13/NNS	root||ROOT-0/null||isolates-14/VBZ	auxpass||identified-16/VBN||were-15/VBD	ccomp||isolates-14/VBZ||identified-16/VBN	nn||tb-19/NN||mdr-18/NN	prep_as||identified-16/VBN||tb-19/NN	det||7-23/CD||an-21/DT	amod||7-23/CD||additional-22/JJ	nsubj||met-28/VBD||7-23/CD	num||%-26/NN||0.15-25/CD	appos||7-23/CD||%-26/NN	parataxis||isolates-14/VBZ||met-28/VBD	dobj||met-28/VBD||criteria-29/NNS	nn||tb-32/NN||xdr-31/NN	prep_for||met-28/VBD||tb-32/NN	tb-32||mycobacteriumtuberculosis-13||no||in 177 (4%) of 4,557 culture-positive tb cases, mycobacteriumtuberculosis isolates were identified as mdr tb; an additional 7 (0.15%) met criteria for xdr tb.
det||study-2/NN||this-1/DT	nsubjpass||designed-4/VBN||study-2/NN	nsubj||investigate-6/VB||study-2/NN	auxpass||designed-4/VBN||was-3/VBD	root||ROOT-0/null||designed-4/VBN	aux||investigate-6/VB||to-5/TO	xcomp||designed-4/VBN||investigate-6/VB	det||role-8/NN||the-7/DT	dobj||investigate-6/VB||role-8/NN	nn||gp73-11/NNS||serum-10/NN	prep_of||role-8/NN||gp73-11/NNS	prepc_for||investigate-6/VB||diagnosing-13/VBG	amod||fibrosis-15/NN||significant-14/JJ	dobj||diagnosing-13/VBG||fibrosis-15/NN	prep_in||diagnosing-13/VBG||patients-17/NNS	amod||infections-23/NNS||chronichepatitisbvirus-19/JJ	appos||infections-23/NNS||hbv-21/NN	prep_with||patients-17/NNS||infections-23/NNS	hbv-21||hepatitisbvirus--1||no||this study was designed to investigate the role of serum gp73 for diagnosing significant fibrosis in patients with chronichepatitisbvirus (hbv) infections.
num||kinds-2/NNS||two-1/CD	nsubj||viruses-7/NNS||kinds-2/NNS	prep_of||kinds-2/NNS||them-4/PRP	cop||viruses-7/NNS||are-5/VBP	amod||viruses-7/NNS||mosquito-borne-6/JJ	root||ROOT-0/null||viruses-7/NNS	nsubj||lead-16/VB||viruses-7/NNS	nsubj||denguefever/dengue-21/VB||viruses-7/NNS	advmod||virus-11/NN||namely-9/RB	amod||virus-11/NN||japaneseencephalitis-10/JJ	appos||viruses-7/NNS||virus-11/NN	appos||viruses-7/NNS||denguevirus-13/NNS	conj_and||virus-11/NN||denguevirus-13/NNS	rcmod||viruses-7/NNS||lead-16/VB	prep_to||lead-16/VB||japaneseencephalitis-18/NNS	rcmod||viruses-7/NNS||denguefever/dengue-21/VB	conj_and||lead-16/VB||denguefever/dengue-21/VB	dobj||denguefever/dengue-21/VB||hemorrhagicfever-22/NN	advmod||denguefever/dengue-21/VB||respectively-23/RB	det||two-27/CD||the-25/DT	amod||two-27/CD||other-26/JJ	nsubj||viruses-30/NNS||two-27/CD	cop||viruses-30/NNS||are-28/VBP	amod||viruses-30/NNS||tick-borne-29/JJ	parataxis||viruses-7/NNS||viruses-30/NNS	nsubj||contribute-49/VBP||viruses-30/NNS	advmod||virus-34/NN||namely-32/RB	amod||virus-34/NN||tick-borneencephalitis-33/JJ	parataxis||viruses-7/NNS||virus-34/NN	conj_and||viruses-30/NNS||virus-34/NN	nsubj||contribute-49/VBP||virus-34/NN	amod||virus-38/NN||crimean-congo-36/JJ	nn||virus-38/NN||hemorrhagicfever-37/NN	parataxis||viruses-7/NNS||virus-38/NN	conj_and||viruses-30/NNS||virus-38/NN	nsubj||contribute-49/VBP||virus-38/NN	advmod||known-41/VBN||also-40/RB	dep||viruses-30/NNS||known-41/VBN	prepc_as||known-41/VBN||xinjiang-43/VBG	nn||virus-45/NN||hemorrhagicfever-44/NN	dobj||xinjiang-43/VBG||virus-45/NN	rcmod||viruses-30/NNS||contribute-49/VBP	prep_to||contribute-49/VBP||tick-borneencephalitis-51/NNS	nn||hemorrhagicfever-54/NN||xinjiang-53/NN	prep_to||contribute-49/VBP||hemorrhagicfever-54/NN	conj_and||tick-borneencephalitis-51/NNS||hemorrhagicfever-54/NN	advmod||contribute-49/VBP||respectively-55/RB	hemorrhagicfever-54||viruses-30||no||two kinds of them are mosquito-borne viruses, namely japaneseencephalitis virus and denguevirus, which lead to japaneseencephalitis, and denguefever/dengue hemorrhagicfever respectively; the other two are tick-borne viruses, namely tick-borneencephalitis virus and crimean-congo hemorrhagicfever virus (also known as xinjiang hemorrhagicfever virus), which contribute to tick-borneencephalitis and xinjiang hemorrhagicfever respectively.
amod||â-2/NN||objective-1/JJ	nsubj||$-3/VBD||â-2/NN	nsubj||compare-6/VB||â-2/NN	root||ROOT-0/null||$-3/VBD	aux||compare-6/VB||to-5/TO	xcomp||$-3/VBD||compare-6/VB	det||glucose-8/NN||the-7/DT	dobj||compare-6/VB||glucose-8/NN	advmod||associated-10/VBN||variability-9/RB	vmod||glucose-8/NN||associated-10/VBN	amod||insulin-15/NN||insulinglargine-12/JJ	conj_and||insulinglargine-12/JJ||nph/lente-14/JJ	amod||insulin-15/NN||nph/lente-14/JJ	prep_with||associated-10/VBN||insulin-15/NN	vmod||insulin-15/NN||used-16/VBN	det||component-21/NN||the-18/DT	amod||component-21/NN||basal-19/JJ	nn||component-21/NN||insulin-20/NN	prep_as||used-16/VBN||component-21/NN	det||regimen-30/NN||a-23/DT	amod||regimen-30/NN||multiple-24/JJ	amod||regimen-30/NN||daily-25/JJ	nn||regimen-30/NN||injection-26/NN	discourse||regimen-30/NN||mdi-28/UH	prep_of||component-21/NN||regimen-30/NN	amod||patients-33/NNS||pediatric-32/JJ	prep_in||regimen-30/NN||patients-33/NNS	prep_with||$-3/VBD||type1diabetes-35/CD	type1diabetes-35||insulin-20||yes||objective âto compare the glucose variability associated with insulinglargine and nph/lente insulin used as the basal insulin component of a multiple daily injection (mdi) regimen in pediatric patients with type1diabetes.
vmod||analyzed-9/VBD||using-1/VBG	det||framework-5/NN||a-2/DT	amod||framework-5/NN||social-3/JJ	nn||framework-5/NN||exclusion-4/NN	dobj||using-1/VBG||framework-5/NN	det||paper-8/NN||this-7/DT	nsubj||analyzed-9/VBD||paper-8/NN	root||ROOT-0/null||analyzed-9/VBD	amod||literature-11/NN||existing-10/JJ	dobj||analyzed-9/VBD||literature-11/NN	prep_on||analyzed-9/VBD||hiv-13/NN	prep_in||hiv-13/NN||bangladesh-15/NN	aux||identify-17/VB||to-16/TO	vmod||analyzed-9/VBD||identify-17/VB	amod||forces-23/NNS||social-18/JJ	conj_and||social-18/JJ||economic-20/JJ	amod||forces-23/NNS||economic-20/JJ	conj_and||social-18/JJ||legal-22/JJ	amod||forces-23/NNS||legal-22/JJ	dobj||identify-17/VB||forces-23/NNS	nsubj||heighten-25/VB||forces-23/NNS	rcmod||forces-23/NNS||heighten-25/VB	det||vulnerability-27/NN||the-26/DT	dobj||heighten-25/VB||vulnerability-27/NN	amod||groups-31/NNS||such-29/JJ	amod||groups-31/NNS||excluded-30/VBN	prep_of||vulnerability-27/NN||groups-31/NNS	prep_to||identify-17/VB||hiv/aids-33/NNS	aids--1||hiv-13||no||using a social exclusion framework, this paper analyzed existing literature on hiv in bangladesh to identify social, economic and legal forces that heighten the vulnerability of such excluded groups to hiv/aids.
nn||studies-2/NNS||animal-1/NN	nsubj||revealed-5/VBN||studies-2/NNS	aux||revealed-5/VBN||have-3/VBP	advmod||revealed-5/VBN||further-4/RBR	root||ROOT-0/null||revealed-5/VBN	mark||induces-10/VBZ||that-6/IN	amod||treatment-9/NN||chronic-7/JJ	nn||treatment-9/NN||antidepressant-8/NN	nsubj||induces-10/VBZ||treatment-9/NN	nsubj||contributes-19/VBZ||treatment-9/NN	ccomp||revealed-5/VBN||induces-10/VBZ	amod||changes-12/NNS||robust-11/JJ	dobj||induces-10/VBZ||changes-12/NNS	nn||metabolism-16/NN||brain-14/NN	nn||metabolism-16/NN||fa-15/NN	prep_in||induces-10/VBZ||metabolism-16/NN	ccomp||revealed-5/VBN||contributes-19/VBZ	conj_but||induces-10/VBZ||contributes-19/VBZ	amod||part-21/NN||only-20/JJ	dobj||contributes-19/VBZ||part-21/NN	det||abnormalities-24/NNS||the-23/DT	prep_of||part-21/NN||abnormalities-24/NNS	vmod||abnormalities-24/NNS||found-25/VBN	det||brains-30/NNS||the-27/DT	amod||brains-30/NNS||affective-28/JJ	nn||brains-30/NNS||disorder-29/NN	prep_in||found-25/VBN||brains-30/NNS	antidepressant-8||fa-15||no_rel||animal studies have further revealed that chronic antidepressant treatment induces robust changes in brain fa metabolism, but contributes only part of the abnormalities found in the affective disorder brains.
nsubjpass||known-4/VBN||it-1/PRP	auxpass||known-4/VBN||is-2/VBZ	neg||known-4/VBN||not-3/RB	root||ROOT-0/null||known-4/VBN	mark||prescribe-11/VBP||whether-5/IN	amod||practitioners-7/NNS||general-6/JJ	nsubj||prescribe-11/VBP||practitioners-7/NNS	appos||practitioners-7/NNS||gps-9/NN	ccomp||known-4/VBN||prescribe-11/VBP	amod||medication-13/NN||analgesic-12/JJ	dobj||prescribe-11/VBP||medication-13/NN	prepc_according_to||prescribe-11/VBP||to-15/TO	pobj||prescribe-11/VBP||intensity-16/NN	prep_of||intensity-16/NN||pain-18/NN	det||regimen-23/NN||a-20/DT	amod||regimen-23/NN||hierarchical-21/JJ	nn||regimen-23/NN||prescribing-22/NN	prep_of||intensity-16/NN||regimen-23/NN	conj_or||pain-18/NN||regimen-23/NN	pain-18||analgesic-12||no_rel||it is not known whether general practitioners (gps) prescribe analgesic medication according to intensity of pain or a hierarchical prescribing regimen.
det||aim-2/NN||the-1/DT	nsubj||was-6/VBD||aim-2/NN	nsubj||examine-8/VB||aim-2/NN	det||study-5/NN||this-4/DT	prep_of||aim-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||examine-8/VB||to-7/TO	xcomp||was-6/VBD||examine-8/VB	det||potential-11/NN||the-9/DT	amod||potential-11/NN||therapeutic-10/JJ	dobj||examine-8/VB||potential-11/NN	amod||fattyacids-15/NNS||n-3-13/JJ	amod||fattyacids-15/NNS||polyunsaturated-14/JJ	prep_of||potential-11/NN||fattyacids-15/NNS	appos||fattyacids-15/NNS||pufas-17/NNS	det||model-23/NN||an-20/DT	dep||vitro-22/NN||in-21/IN	amod||model-23/NN||vitro-22/NN	prep_in||examine-8/VB||model-23/NN	nn||inflammation-26/NN||cartilage-25/NN	prep_of||model-23/NN||inflammation-26/NN	inflammation-26||fattyacids-15||no_rel||the aim of this study was to examine the therapeutic potential of n-3 polyunsaturated fattyacids (pufas) in an in vitro model of cartilage inflammation.
nsubj||remains-2/VBZ||it-1/PRP	root||ROOT-0/null||remains-2/VBZ	acomp||remains-2/VBZ||uncertain-3/JJ	mark||increases-8/VBZ||whether-4/IN	nsubj||increases-8/VBZ||use-5/NN	nsubj||decreases-21/VBZ||use-5/NN	prep_of||use-5/NN||insulin-7/NN	ccomp||remains-2/VBZ||increases-8/VBZ	nn||risk-10/NN||cancer-9/NN	dobj||increases-8/VBZ||risk-10/NN	poss||effect-14/NN||its-13/PRP$	prep_because_of||risk-10/NN||effect-14/NN	nn||growth-17/NN||cell-16/NN	prep_on||increases-8/VBZ||growth-17/NN	prep_on||increases-8/VBZ||proliferation-19/NN	conj_and||growth-17/NN||proliferation-19/NN	ccomp||remains-2/VBZ||decreases-21/VBZ	conj_or||increases-8/VBZ||decreases-21/VBZ	nn||risk-23/NN||cancer-22/NN	dobj||decreases-21/VBZ||risk-23/NN	poss||effect-28/NN||its-26/PRP$	amod||effect-28/NN||glucose-lowering-27/JJ	prep_because_of||risk-23/NN||effect-28/NN	cancer-22||glucose--1||no_rel||it remains uncertain whether use of insulin increases cancer risk because of its effect on cell growth and proliferation or decreases cancer risk because of its glucose-lowering effect.
agent||identified-20/VBN||employing-2/VBG	amod||analyses-5/NNS||two-dimensional-3/JJ	nn||analyses-5/NNS||gel-4/NN	dobj||employing-2/VBG||analyses-5/NNS	prepc_followed_by||employing-2/VBG||by-7/IN	nn||spectrometry-11/NN||immunoblotting-8/NN	conj_and||immunoblotting-8/NN||mass-10/NN	nn||spectrometry-11/NN||mass-10/NN	pobj||employing-2/VBG||spectrometry-11/NN	nn||proteins-14/NNS||lens-13/NN	nsubjpass||identified-20/VBN||proteins-14/NNS	nsubj||±-24/JJ||proteins-14/NNS	nsubj||b-27/JJ||proteins-14/NNS	nsubj||vimentin-29/JJ||proteins-14/NNS	vmod||proteins-14/NNS||cross-reacting-15/VBG	nn||antiserum-18/NN||lrua-17/NN	prep_with||cross-reacting-15/VBG||antiserum-18/NN	auxpass||identified-20/VBN||were-19/VBD	root||ROOT-0/null||identified-20/VBN	aux||±-24/JJ||to-21/TO	cop||±-24/JJ||be-22/VB	advmod||±-24/JJ||î-23/RB	xcomp||identified-20/VBN||±-24/JJ	amod||b-27/JJ||crystallin-26/JJ	xcomp||identified-20/VBN||b-27/JJ	conj_and||±-24/JJ||b-27/JJ	xcomp||identified-20/VBN||vimentin-29/JJ	conj_and||±-24/JJ||vimentin-29/JJ	cross--1||antiserum-18||no_rel||by employing two-dimensional gel analyses followed by immunoblotting and mass spectrometry, lens proteins cross-reacting with lrua antiserum were identified to be î±-crystallin b and vimentin.
aux||prevent-2/VB||to-1/TO	advcl||added-23/VBN||prevent-2/VB	dobj||prevent-2/VB||hyperinsulinemia-3/NN	nsubj||cause-7/VB||hyperinsulinemia-3/NN	aux||cause-7/VB||may-6/MD	rcmod||hyperinsulinemia-3/NN||cause-7/VB	dobj||cause-7/VB||atherosclerosis-8/NNS	nsubjpass||added-23/VBN||thiazolidinediones-10/NNS	appos||thiazolidinediones-10/NNS||tzds-12/NNS	advmod||known-16/VBN||also-15/RB	vmod||thiazolidinediones-10/NNS||known-16/VBN	nn||sensitizers-19/NNS||insulin-18/NN	prep_as||known-16/VBN||sensitizers-19/NNS	auxpass||added-23/VBN||are-21/VBP	advmod||added-23/VBN||often-22/RB	root||ROOT-0/null||added-23/VBN	det||regimen-27/NN||the-25/DT	amod||regimen-27/NN||therapeutic-26/JJ	prep_to||added-23/VBN||regimen-27/NN	prep_of||regimen-27/NN||patients-29/NNS	prep_with||added-23/VBN||type2diabetes-31/NNS	nsubj||receiving-34/VBG||type2diabetes-31/NNS	aux||receiving-34/VBG||are-33/VBP	rcmod||type2diabetes-31/NNS||receiving-34/VBG	dobj||receiving-34/VBG||insulin-35/NN	insulin-35||atherosclerosis-8||no_rel||to prevent hyperinsulinemia, which may cause atherosclerosis, thiazolidinediones (tzds), also known as insulin sensitizers, are often added to the therapeutic regimen of patients with type2diabetes who are receiving insulin.
nsubj||found-2/VBD||we-1/PRP	root||ROOT-0/null||found-2/VBD	mark||suggesting-25/VBG||that-3/IN	amod||cells-5/NNS||phototrophic-4/JJ	nsubj||suggesting-25/VBG||cells-5/NNS	cop||suggesting-25/VBG||are-6/VBP	advmod||impacted-8/JJ||less-7/RBR	acomp||suggesting-25/VBG||impacted-8/JJ	prep_by||impacted-8/JJ||irondeficiency-10/NN	det||correlates-13/NNS||this-12/DT	prep_by||impacted-8/JJ||correlates-13/NNS	conj_and||irondeficiency-10/NN||correlates-13/NNS	poss||content-18/NN||their-15/PRP$	amod||content-18/NN||higher-16/JJR	nn||content-18/NN||iron-17/NN	prep_with||suggesting-25/VBG||content-18/NN	det||basis-23/NN||a-20/DT	amod||basis-23/NN||per-21/IN	nn||basis-23/NN||cell-22/NN	prep_on||content-18/NN||basis-23/NN	ccomp||found-2/VBD||suggesting-25/VBG	det||capacity/ability-28/NN||a-26/DT	amod||capacity/ability-28/NN||greater-27/JJR	dobj||suggesting-25/VBG||capacity/ability-28/NN	nn||assimilation-31/NN||iron-30/NN	prep_for||suggesting-25/VBG||assimilation-31/NN	det||state-35/NN||this-33/DT	amod||state-35/NN||metabolic-34/JJ	prep_in||assimilation-31/NN||state-35/NN	irondeficiency-10||iron-30||yes||we found that phototrophic cells are less impacted by irondeficiency and this correlates with their higher iron content on a per cell basis, suggesting a greater capacity/ability for iron assimilation in this metabolic state.
prep_at||increased-13/VBD||center-2/NN	dep||center-2/NN||a-3/DT	det||proportion-6/NN||the-5/DT	nsubj||increased-13/VBD||proportion-6/NN	amod||infections-9/NNS||s.aureus-8/JJ	prep_of||proportion-6/NN||infections-9/NNS	vmod||infections-9/NNS||caused-10/VBN	agent||caused-10/VBN||ca-mrsa-12/NN	root||ROOT-0/null||increased-13/VBD	number||%-19/NN||4-15/CD	dep||%-19/NN||%-16/NN	dep||%-19/NN||to-17/TO	number||%-19/NN||23-18/CD	prep_from||increased-13/VBD||%-19/NN	num||years-22/NNS||2-21/CD	prep_over||increased-13/VBD||years-22/NNS	det||proportion-25/NN||the-24/DT	nsubj||decreased-33/VBD||proportion-25/NN	vmod||proportion-25/NN||caused-26/VBN	amod||-rrb--32/NNS||healthcare-associated-28/JJ	nn||-rrb--32/NNS||mrsa-29/NN	nn||-rrb--32/NNS||-lrb--30/NN	amod||-rrb--32/NNS||ha-mrsa-31/JJ	agent||caused-26/VBN||-rrb--32/NNS	parataxis||increased-13/VBD||decreased-33/VBD	number||%-39/NN||25-35/CD	dep||%-39/NN||%-36/NN	dep||%-39/NN||to-37/TO	number||%-39/NN||5-38/CD	prep_from||decreased-33/VBD||%-39/NN	mrsa-29||s.aureus-8||no||at center a , the proportion of s.aureus infections caused by ca-mrsa increased from 4 % to 23 % over 2 years ; the proportion caused by healthcare-associated mrsa -lrb- ha-mrsa -rrb- decreased from 25 % to 5 % .
nsubj||used-2/VBD||we-1/PRP	root||ROOT-0/null||used-2/VBD	nn||rip-chip-4/NN||hur-3/NN	dobj||used-2/VBD||rip-chip-4/NN	det||method-10/NN||a-6/DT	amod||method-10/NN||comprehensive-7/JJ	conj_and||comprehensive-7/JJ||systematic-9/JJ	amod||method-10/NN||systematic-9/JJ	prep_as||used-2/VBD||method-10/NN	aux||survey-12/VB||to-11/TO	vmod||used-2/VBD||survey-12/VB	nn||genes-16/NNS||breast-13/NN	nn||genes-16/NNS||cancer-14/NN	nn||genes-16/NNS||target-15/NN	dobj||survey-12/VB||genes-16/NNS	det||lines-41/NNS||both-18/DT	amod||lines-41/NNS||mcf-7-19/JJ	nn||positive-23/NN||estrogen-21/NN	nn||positive-23/NN||receptor-22/NN	dep||mcf-7-19/JJ||positive-23/NN	nn||+-26/NNS||er-25/NN	appos||positive-23/NN||+-26/NNS	conj_and||mcf-7-19/JJ||mda-mb-231-29/JJ	amod||lines-41/NNS||mda-mb-231-29/JJ	num||receptor-32/NN||estrogen-31/CD	npadvmod||negative-33/JJ||receptor-32/NN	dep||er-35/NN||negative-33/JJ	dep||mda-mb-231-29/JJ||er-35/NN	nn||lines-41/NNS||breast-38/NN	nn||lines-41/NNS||cancer-39/NN	nn||lines-41/NNS||cell-40/NN	prep_in||genes-16/NNS||lines-41/NNS	cancer-39||estrogen-31||no_rel||we used hur rip-chip as a comprehensive and systematic method to survey breast cancer target genes in both mcf-7 (estrogen receptor positive, er+) and mda-mb-231 (estrogen receptor negative, er-) breast cancer cell lines.
number||confirmed-3/CD||119-2/CD	num||cases-4/NNS||confirmed-3/CD	prep_with||ranks-13/VBZ||cases-4/NNS	prep_between||cases-4/NNS||march-6/NN	num||march-6/NN||2006-7/CD	prep_between||cases-4/NNS||december-9/NNP	conj_and||march-6/NN||december-9/NNP	num||december-9/NNP||2010-10/CD	nsubj||ranks-13/VBZ||egypt-12/NN	root||ROOT-0/null||ranks-13/VBZ	acomp||ranks-13/VBZ||second-14/JJ	prep_among||second-14/JJ||countries-16/NNS	vmod||countries-16/NNS||reporting-17/VBG	amod||influenzavirusinfections-20/NNS||human-18/JJ	amod||influenzavirusinfections-20/NNS||h5n1-19/JJ	dobj||reporting-17/VBG||influenzavirusinfections-20/NNS	h5n1-19||influenzavirus--1||no||with 119 confirmed cases between march 2006 and december 2010, egypt ranks second among countries reporting human h5n1 influenzavirusinfections.
amod||regimens-2/NNS||efavirenz-based-1/JJ	nsubjpass||associated-11/VBN||regimens-2/NNS	neg||aids-6/NNS||no-4/DT	amod||aids-6/NNS||clinical-5/JJ	conj_and||regimens-2/NNS||aids-6/NNS	nsubjpass||associated-11/VBN||aids-6/NNS	amod||initiation-9/NN||haart-8/JJ	prep_at||aids-6/NNS||initiation-9/NN	auxpass||associated-11/VBN||were-10/VBD	root||ROOT-0/null||associated-11/VBN	amod||risk-14/NN||lower-13/JJR	prep_with||associated-11/VBN||risk-14/NN	prep_of||risk-14/NN||change-16/NN	nn||ratio-19/NN||hazard-18/NN	dep||risk-14/NN||ratio-19/NN	discourse||ratio-19/NN||hr-21/UH	rcmod||ratio-19/NN||â-23/VBP	num||â-27/NN||$-24/$	number||=-26/CD||-25/CD	num||$-24/$||=-26/CD	dobj||â-23/VBP||â-27/NN	amod||â-27/NN||$-28/$	number||.7-30/CD||1-29/CD	num||$-28/$||.7-30/CD	num||%-33/NN||95-32/CD	dep||$-28/$||%-33/NN	nn||â-36/FW||ci-34/FW	nn||â-36/FW||1.1-35/FW	dep||%-33/NN||â-36/FW	dep||â-36/FW||$-37/$	num||$-37/$||2.6-39/CD	dobj||â-23/VBP||2.1-42/CD	conj_and||â-27/NN||2.1-42/CD	num||%-45/NN||95-44/CD	dep||2.1-42/CD||%-45/NN	vmod||%-45/NN||ci-46/VBN	num||â-48/NNS||1.7-47/CD	dobj||ci-46/VBN||â-48/NNS	num||â-48/NNS||$-49/$	num||$-49/$||2.5-51/CD	vmod||2.1-42/CD||comparing-53/VBG	amod||regimens-55/NNS||neverapine-based-54/JJ	dobj||comparing-53/VBG||regimens-55/NNS	amod||regimens-58/NNS||other-57/JJ	dobj||comparing-53/VBG||regimens-58/NNS	conj_and||regimens-55/NNS||regimens-58/NNS	prep_to||comparing-53/VBG||efavirenz-60/NN	advmod||comparing-53/VBG||respectively-62/RB	nn||â-68/FW||hrâ-64/FW	nn||â-68/FW||$-65/FW	nn||â-68/FW||-66/FW	nn||â-68/FW||=-67/FW	dobj||â-23/VBP||â-68/FW	conj_and||â-27/NN||â-68/FW	dep||â-68/FW||$-69/$	number||.3-71/CD||1-70/CD	num||$-69/$||.3-71/CD	num||%-74/NN||95-73/CD	dep||â-27/NN||%-74/NN	vmod||%-74/NN||ci-75/VBN	num||â-77/NNS||1.1-76/CD	dobj||ci-75/VBN||â-77/NNS	num||â-77/NNS||$-78/$	num||$-78/$||1.5-80/CD	amod||aids-84/NNS||clinical-83/JJ	prep_for||ratio-19/NN||aids-84/NNS	amod||initiation-87/NN||haart-86/JJ	prep_at||aids-84/NNS||initiation-87/NN	aids-84||efavirenz-60||yes||efavirenz-based regimens and no clinical aids at haart initiation were associated with lower risk of change (hazard ratio (hr)â=â1.7 (95% ci 1.1â2.6) and 2.1 (95% ci 1.7â2.5) comparing neverapine-based regimens and other regimens to efavirenz, respectively; hrâ=â1.3 (95% ci 1.1â1.5) for clinical aids at haart initiation).
poss||profiling-3/NN||our-1/PRP$	amod||profiling-3/NN||systematic-2/JJ	nsubj||advanced-14/VBD||profiling-3/NN	nsubj||identified-29/VBD||profiling-3/NN	nn||changes-6/NNS||phosphorylation-5/NN	prep_of||profiling-3/NN||changes-6/NNS	prep_in||changes-6/NNS||response-8/NN	amod||treatment-11/NN||bortezomib-10/JJ	prep_to||response-8/NN||treatment-11/NN	neg||only-13/JJ||not-12/RB	preconj||advanced-14/VBD||only-13/JJ	root||ROOT-0/null||advanced-14/VBD	det||understanding-18/NN||the-15/DT	amod||understanding-18/NN||global-16/JJ	amod||understanding-18/NN||mechanistic-17/JJ	dobj||advanced-14/VBD||understanding-18/NN	det||action-21/NN||the-20/DT	prep_of||understanding-18/NN||action-21/NN	prep_of||action-21/NN||bortezomib-23/NN	nn||cells-26/NNS||myeloma-25/NN	prep_on||advanced-14/VBD||cells-26/NNS	advmod||identified-29/VBD||also-28/RB	conj_but||advanced-14/VBD||identified-29/VBD	advmod||uncharacterized-31/JJ||previously-30/RB	acomp||signaling-32/VBG||uncharacterized-31/JJ	ccomp||identified-29/VBD||signaling-32/VBG	xcomp||identified-29/VBD||signaling-32/VBG	dobj||signaling-32/VBG||proteins-33/NNS	nn||cells-36/NNS||myeloma-35/NN	prep_in||signaling-32/VBG||cells-36/NNS	myeloma-35||bortezomib-23||yes||our systematic profiling of phosphorylation changes in response to bortezomib treatment not only advanced the global mechanistic understanding of the action of bortezomib on myeloma cells but also identified previously uncharacterized signaling proteins in myeloma cells.
nsubjpass||divided-3/VBN||patients-1/NNS	auxpass||divided-3/VBN||were-2/VBD	root||ROOT-0/null||divided-3/VBN	num||groups-6/NNS||two-5/CD	prep_into||divided-3/VBN||groups-6/NNS	prepc_according_to||divided-3/VBN||to-8/TO	det||centre-10/NN||the-9/DT	pobj||divided-3/VBN||centre-10/NN	nn||control-13/NN||disease-12/NN	prep_for||centre-10/NN||control-13/NN	nn||criteria-19/NNS||prevention-15/NN	nn||criteria-19/NNS||cdc-17/NN	prep_for||centre-10/NN||criteria-19/NNS	conj_and||control-13/NN||criteria-19/NNS	amod||patients-24/NNS||aids-related-21/JJ	nn||patients-24/NNS||te-22/NN	nn||patients-24/NNS||aids-23/NNS	prep_for||divided-3/VBN||patients-24/NNS	amod||neurotoxoplasmosis-27/NNS||suspected-26/VBN	prep_with||divided-3/VBN||neurotoxoplasmosis-27/NNS	prep_with||divided-3/VBN||aids-29/NNS	conj_and||neurotoxoplasmosis-27/NNS||aids-29/NNS	amod||patients-32/NNS||hiv-negative-31/JJ	nsubj||confirmed-35/VBD||patients-32/NNS	prep_with||patients-32/NNS||other-34/JJ	conj_and||divided-3/VBN||confirmed-35/VBD	amod||diseases-37/NNS||neurological-36/JJ	dobj||confirmed-35/VBD||diseases-37/NNS	prep||diseases-37/NNS||but-38/CC	neg||suspicions-40/NNS||no-39/DT	pobj||but-38/CC||suspicions-40/NNS	prep_of||suspicions-40/NNS||te-42/NN	aids-29||hiv--1||no||patients were divided into two groups according to the centre for disease control and prevention (cdc) criteria for aids-related te aids patients with suspected neurotoxoplasmosis and aids and hiv-negative patients with other confirmed neurological diseases but no suspicions of te.
amod||formulations-3/NNS||fixed-dose-1/JJ	nn||formulations-3/NNS||combination-2/NN	nsubjpass||approved-15/VBN||formulations-3/NNS	prep_of||formulations-3/NNS||olmesartanmedoxomil-5/NN	det||arb-8/NN||an-7/DT	prep_of||formulations-3/NNS||arb-8/NN	conj_and||olmesartanmedoxomil-5/NN||arb-8/NN	det||amlodipine-13/NN||the-11/DT	nn||amlodipine-13/NN||ccb-12/NN	prep_of||formulations-3/NNS||amlodipine-13/NN	conj_and||olmesartanmedoxomil-5/NN||amlodipine-13/NN	auxpass||approved-15/VBN||are-14/VBP	root||ROOT-0/null||approved-15/VBN	amod||countries-19/NNS||several-17/JJ	nn||countries-19/NNS||european-18/NN	prep_in||approved-15/VBN||countries-19/NNS	prep_for||countries-19/NNS||patients-21/NNS	amod||hypertension-24/NN||essential-23/JJ	prep_with||patients-21/NNS||hypertension-24/NN	hypertension-24||olmesartanmedoxomil-5||yes||fixed-dose combination formulations of olmesartanmedoxomil, an arb, and the ccb amlodipine are approved in several european countries for patients with essential hypertension.
prepc_in_addition_to||represent-17/VBP||facilitating-4/VBG	det||understanding-7/NN||an-5/DT	amod||understanding-7/NN||improved-6/VBN	dobj||facilitating-4/VBG||understanding-7/NN	det||mechanisms-11/NNS||the-9/DT	amod||mechanisms-11/NNS||basic-10/JJ	prep_of||understanding-7/NN||mechanisms-11/NNS	prep_of||mechanisms-11/NNS||aging-13/VBG	amod||genes-16/NNS||such-15/JJ	nsubj||represent-17/VBP||genes-16/NNS	root||ROOT-0/null||represent-17/VBP	amod||targets-19/NNS||potential-18/JJ	dobj||represent-17/VBP||targets-19/NNS	amod||intervention-22/NN||therapeutic-21/JJ	prep_for||targets-19/NNS||intervention-22/NN	amod||diseases-26/NNS||multiple-24/JJ	amod||diseases-26/NNS||age-associated-25/JJ	prep_in||intervention-22/NN||diseases-26/NNS	nn||diabetes-33/NN||cancer-29/NN	dep||diabetes-33/NN||heartdisease-31/NN	prep_including||targets-19/NNS||diabetes-33/NN	nn||disorders-37/NNS||neurodegenerative-36/NN	prep_including||targets-19/NNS||disorders-37/NNS	conj_and||diabetes-33/NN||disorders-37/NNS	heartdisease-31||basic-10||no_rel||in addition to facilitating an improved understanding of the basic mechanisms of aging, such genes represent potential targets for therapeutic intervention in multiple age-associated diseases, including cancer, heartdisease, diabetes, and neurodegenerative disorders.
amod||causes-2/NNS||leading-1/VBG	nsubj||remained-6/VBN||causes-2/NNS	prep_of||causes-2/NNS||death-4/NN	aux||remained-6/VBN||have-5/VBP	root||ROOT-0/null||remained-6/VBN	acomp||remained-6/VBN||stable-7/JJ	prep_since||remained-6/VBN||1999-9/CD	det||exception-13/NN||the-12/DT	prep_with||remained-6/VBN||exception-13/NN	det||decline-17/NN||a-15/DT	amod||decline-17/NN||large-16/JJ	prep_of||exception-13/NN||decline-17/NN	amod||mortality-20/NN||hiv/aids-19/JJ	prep_in||decline-17/NN||mortality-20/NN	aids--1||hiv--1||no||leading causes of death have remained stable since 1999, with the exception of a large decline in hiv/aids mortality.
advmod||reversed-15/VBD||however-1/RB	prep_during||reversed-15/VBD||immunotherapy-4/NN	advmod||no-7/RB||high-6/RB	dep||immunotherapy-4/NN||no-7/RB	amod||inhibition-11/NN||nos2-10/JJ	nsubj||reversed-15/VBD||inhibition-11/NN	nsubj||had-31/VBD||inhibition-11/NN	amod||depletion-14/NN||macrophage-13/JJ	conj_or||inhibition-11/NN||depletion-14/NN	nsubj||reversed-15/VBD||depletion-14/NN	root||ROOT-0/null||reversed-15/VBD	det||ability-17/NN||the-16/DT	dobj||reversed-15/VBD||ability-17/NN	amod||±-22/NNS||il-2-19/JJ	amod||±-22/NNS||/-20/JJ	nn||±-22/NNS||î-21/NN	prep_of||ability-17/NN||±-22/NNS	amod||treatment-25/NN||cd40-24/JJ	dobj||reversed-15/VBD||treatment-25/NN	aux||reduce-27/VB||to-26/TO	parataxis||reversed-15/VBD||reduce-27/VB	vmod||reversed-15/VBD||reduce-27/VB	nn||metastases-29/NNS||lung-28/NN	dobj||reduce-27/VB||metastases-29/NNS	conj_but||reversed-15/VBD||had-31/VBD	neg||effect-33/NN||no-32/DT	dobj||had-31/VBD||effect-33/NN	amod||burden-37/NN||primary-35/JJ	nn||burden-37/NN||tumor-36/NN	prep_on||effect-33/NN||burden-37/NN	il-2-19||tumor-36||no_rel||however, during immunotherapy (high no), nos2 inhibition or macrophage depletion reversed the ability of il-2/î±-cd40 treatment to reduce lung metastases but had no effect on primary tumor burden.
amod||studies-2/NNS||recent-1/JJ	nsubj||reported-4/VBN||studies-2/NNS	aux||reported-4/VBN||have-3/VBP	root||ROOT-0/null||reported-4/VBN	mark||involves-13/VBZ||that-5/IN	det||mechanism-7/NN||the-6/DT	nsubj||involves-13/VBZ||mechanism-7/NN	vmod||mechanism-7/NN||underlying-8/VBG	det||priming-10/NN||the-9/DT	dobj||underlying-8/VBG||priming-10/NN	prep_of||priming-10/NN||pulmonaryinflammation-12/NN	ccomp||reported-4/VBN||involves-13/VBZ	det||cross-talk-16/NN||the-14/DT	amod||cross-talk-16/NN||complicated-15/VBN	dobj||involves-13/VBZ||cross-talk-16/NN	amod||receptors-19/NNS||toll-like-18/JJ	prep_between||cross-talk-16/NN||receptors-19/NNS	dep||cross-talk-16/NN||tlrs-21/VBZ	dobj||involves-13/VBZ||interactions-24/NNS	conj_and||cross-talk-16/NN||interactions-24/NNS	prep_between||interactions-24/NNS||neutrophils-26/NNS	appos||neutrophils-26/NNS||pmns-28/NNS	nn||macrophages-32/NNS||alveolar-31/NN	prep_between||interactions-24/NNS||macrophages-32/NNS	conj_and||neutrophils-26/NNS||macrophages-32/NNS	advmod||-36/NN||am-34/RB	amod||-36/NN||ï-35/JJ	appos||neutrophils-26/NNS||-36/NN	amod||cells-42/NNS||endothelial-41/JJ	conj_and||cross-talk-16/NN||cells-42/NNS	conj_and||interactions-24/NNS||cells-42/NNS	prep_in||mediator-58/NN||cells-42/NNS	appos||cells-42/NNS||ecs-44/NN	amod||species-51/NNS||reactive-49/JJ	nn||species-51/NNS||oxygen-50/NN	nsubj||mediator-58/NN||species-51/NNS	appos||species-51/NNS||ros-53/NN	cop||mediator-58/NN||are-55/VBP	det||mediator-58/NN||the-56/DT	amod||mediator-58/NN||key-57/JJ	rcmod||cells-42/NNS||mediator-58/NN	pulmonaryinflammation-12||oxygen-50||yes||recent studies have reported that the mechanism underlying the priming of pulmonaryinflammation involves the complicated cross-talk between toll-like receptors (tlrs) and interactions between neutrophils (pmns) and alveolar macrophages (am ï ) as well as endothelial cells (ecs), in which reactive oxygen species (ros) are the key mediator.
nsubj||piloting-3/VBG||zambia-1/NN	aux||piloting-3/VBG||is-2/VBZ	root||ROOT-0/null||piloting-3/VBG	det||use-5/NN||the-4/DT	dobj||piloting-3/VBG||use-5/NN	prep_of||use-5/NN||artemether-lumefantrine-7/NN	appos||artemether-lumefantrine-7/NN||al-9/NNP	nn||workers-14/NNS||community-12/NN	nn||workers-14/NNS||health-13/NN	prep_by||piloting-3/VBG||workers-14/NNS	appos||workers-14/NNS||chws-16/NNS	aux||treat-19/VB||to-18/TO	vmod||piloting-3/VBG||treat-19/VB	amod||malaria-21/NN||uncomplicated-20/JJ	dobj||treat-19/VB||malaria-21/NN	malaria-21||artemether--1||yes||zambia is piloting the use of artemether-lumefantrine (al) by community health workers (chws) to treat uncomplicated malaria.
advmod||lesion-12/NN||early-1/RB	det||epidemic-5/NN||the-3/DT	nn||epidemic-5/NN||aids-4/NNS	prep_in||early-1/RB||epidemic-5/NN	nsubj||lesion-12/NN||hivan-7/NN	cop||lesion-12/NN||was-8/VBD	det||lesion-12/NN||the-9/DT	amod||lesion-12/NN||predominant-10/JJ	nn||lesion-12/NN||glomerular-11/NN	root||ROOT-0/null||lesion-12/NN	vmod||lesion-12/NN||observed-13/VBN	amod||patients-16/NNS||hiv-infected-15/JJ	prep_in||observed-13/VBN||patients-16/NNS	hivan-7||hiv--1||no||early in the aids epidemic, hivan was the predominant glomerular lesion observed in hiv-infected patients.
nsubj||revealed-2/VBD||studies-1/NNS	root||ROOT-0/null||revealed-2/VBD	mark||appeared-31/VBD||that-3/IN	det||dose-6/NN||a-5/DT	nsubj||mg/kg-11/VBG||dose-6/NN	prep_of||dose-6/NN||25-8/CD	prep_of||dose-6/NN||75-10/CD	conj_and||25-8/CD||75-10/CD	prepc_at||appeared-31/VBD||mg/kg-11/VBG	det||reduction-14/NN||a-12/DT	amod||reduction-14/NN||considerable-13/JJ	nsubjpass||observed-21/VBN||reduction-14/NN	det||extent-17/NN||the-16/DT	prep_in||reduction-14/NN||extent-17/NN	prep_of||extent-17/NN||diarrhoea-19/NN	auxpass||observed-21/VBN||was-20/VBD	ccomp||mg/kg-11/VBG||observed-21/VBN	cc||observed-21/VBN||but-22/CC	det||dose-25/NN||a-24/DT	prep_at||observed-21/VBN||dose-25/NN	num||mg/kg-28/NN||100-27/CD	prep_of||dose-25/NN||mg/kg-28/NN	det||animals-30/NNS||the-29/DT	nsubj||appeared-31/VBD||animals-30/NNS	ccomp||revealed-2/VBD||appeared-31/VBD	advmod||constipated-33/JJ||completely-32/RB	acomp||appeared-31/VBD||constipated-33/JJ	advmod||subjected-35/VBN||when-34/WRB	advcl||appeared-31/VBD||subjected-35/VBN	amod||diarrhoea-39/NN||castoroil-37/JJ	amod||diarrhoea-39/NN||induced-38/JJ	prep_to||subjected-35/VBN||diarrhoea-39/NN	amod||model-43/NN||intestinal-41/JJ	nn||model-43/NN||motility-42/NN	prep_to||subjected-35/VBN||model-43/NN	conj_and||diarrhoea-39/NN||model-43/NN	diarrhoea-39||castoroil-37||no||studies revealed that at a dose of 25 and 75 mg/kg a considerable reduction in the extent of diarrhoea was observed but at a dose of 100 mg/kg the animals appeared completely constipated when subjected to castoroil induced diarrhoea and intestinal motility model.
advmod||suggest-5/VBP||moreover-1/RB	det||findings-4/NNS||the-3/DT	nsubj||suggest-5/VBP||findings-4/NNS	root||ROOT-0/null||suggest-5/VBP	mark||barrier-14/NN||that-6/IN	csubj||barrier-14/NN||possessing-7/VBG	amod||hiv/aids-9/JJ||inaccurate-8/JJ	amod||knowledge-10/NN||hiv/aids-9/JJ	dobj||possessing-7/VBG||knowledge-10/NN	aux||barrier-14/NN||may-11/MD	cop||barrier-14/NN||be-12/VB	det||barrier-14/NN||a-13/DT	ccomp||suggest-5/VBP||barrier-14/NN	amod||testing-18/NN||timely-16/JJ	nn||testing-18/NN||hiv-17/NN	prep_to||barrier-14/NN||testing-18/NN	aids--1||hiv-17||no||moreover, the findings suggest that possessing inaccurate hiv/aids knowledge may be a barrier to timely hiv testing.
poss||article-3/NN||their-2/PRP$	prep_in||conclude-22/VBP||article-3/NN	det||use-6/NN||the-5/DT	prep_on||article-3/NN||use-6/NN	prep_of||use-6/NN||barbiturates-8/NNS	det||treatment-11/NN||the-10/DT	prep_for||barbiturates-8/NNS||treatment-11/NN	prep_of||treatment-11/NN||intracranialhypertension-13/NN	amod||injury-17/NN||traumatic-15/JJ	nn||injury-17/NN||brain-16/NN	prep_after||intracranialhypertension-13/NN||injury-17/NN	nsubj||conclude-22/VBP||perez-barcena-19/NN	conj_and||perez-barcena-19/NN||colleagues-21/NNS	nsubj||conclude-22/VBP||colleagues-21/NNS	root||ROOT-0/null||conclude-22/VBP	mark||effective-27/JJ||that-23/IN	nsubj||effective-27/JJ||thiopental-24/NN	cop||effective-27/JJ||was-25/VBD	advmod||effective-27/JJ||more-26/RBR	ccomp||conclude-22/VBP||effective-27/JJ	prep_than||effective-27/JJ||pentobarbital-29/NN	amod||pressure-33/NN||decreasing-31/VBG	amod||pressure-33/NN||intracranial-32/JJ	prep_in||pentobarbital-29/NN||pressure-33/NN	intracranialhypertension-13||thiopental-24||yes||in their article on the use of barbiturates for the treatment of intracranialhypertension after traumatic brain injury, perez-barcena and colleagues conclude that thiopental was more effective than pentobarbital in decreasing intracranial pressure.
nsubj||atypicalantipsychotic-4/NN||olanzapine-1/NN	cop||atypicalantipsychotic-4/NN||is-2/VBZ	det||atypicalantipsychotic-4/NN||an-3/DT	root||ROOT-0/null||atypicalantipsychotic-4/NN	advmod||atypicalantipsychotic-4/NN||currently-5/RB	prep_with||atypicalantipsychotic-4/NN||indications-7/NNS	det||treatment-10/NN||the-9/DT	prep_for||indications-7/NNS||treatment-10/NN	prep_of||treatment-10/NN||schizophrenia-12/NN	amod||mania-15/NN||acute-14/JJ	prep_of||treatment-10/NN||mania-15/NN	conj_and||schizophrenia-12/NN||mania-15/NN	det||prevention-18/NN||the-17/DT	prep_of||treatment-10/NN||prevention-18/NN	conj_and||schizophrenia-12/NN||prevention-18/NN	prep_of||atypicalantipsychotic-4/NN||relapse-20/NN	prep_in||relapse-20/NN||bipolardisorder-22/NN	bipolardisorder-22||olanzapine-1||yes||olanzapine is an atypicalantipsychotic currently with indications for the treatment of schizophrenia, acute mania and the prevention of relapse in bipolardisorder.
det||beginning-4/NN||the-3/DT	prep_as_of||includes-16/VBZ||beginning-4/NN	prep_of||beginning-4/NN||2013-6/CD	poss||â-9/NN||our-8/PRP$	appos||2013-6/CD||â-9/NN	amod||â-9/NN||$-10/$	dep||$-10/$||antibodies-11/JJ	aux||watchâ-13/VB||to-12/TO	vmod||beginning-4/NN||watchâ-13/VB	dobj||watchâ-13/VB||$-14/$	num||$-14/$||list-15/CD	root||ROOT-0/null||includes-16/VBZ	num||mabs-19/NNS||28-17/CD	amod||mabs-19/NNS||single-18/JJ	dobj||includes-16/VBZ||mabs-19/NNS	num||mixture-23/NN||one-21/CD	nn||mixture-23/NN||mab-22/NN	dobj||includes-16/VBZ||mixture-23/NN	conj_and||mabs-19/NNS||mixture-23/NN	nsubj||undergoing-26/VBG||mixture-23/NN	aux||undergoing-26/VBG||are-25/VBP	rcmod||mixture-23/NN||undergoing-26/VBG	dobj||undergoing-26/VBG||evaluation-27/NN	prep_in||evaluation-27/NN||phase-29/NN	num||studies-31/NNS||3-30/CD	nsubj||includes-16/VBZ||studies-31/NNS	amod||disorders-36/NNS||inflammatory-33/JJ	conj_or||inflammatory-33/JJ||immunological-35/JJ	amod||disorders-36/NNS||immunological-35/JJ	prep_for||studies-31/NNS||disorders-36/NNS	prep_for||studies-31/NNS||cancers-38/NNS	conj_and||disorders-36/NNS||cancers-38/NNS	amod||cholesterol-41/NN||high-40/JJ	prep_for||studies-31/NNS||cholesterol-41/NN	conj_and||disorders-36/NNS||cholesterol-41/NN	prep_for||studies-31/NNS||osteoporosis-43/NNS	conj_and||disorders-36/NNS||osteoporosis-43/NNS	nn||disease-46/NN||alzheimer-45/NN	prep_for||studies-31/NNS||disease-46/NN	conj_and||disorders-36/NNS||disease-46/NN	amod||disease-49/NN||infectious-48/JJ	prep_for||studies-31/NNS||disease-49/NN	conj_and||disorders-36/NNS||disease-49/NN	cholesterol-41||osteoporosis-43||no_rel||as of the beginning of 2013, our âantibodies to watchâ? list includes 28 single mabs and one mab mixture that are undergoing evaluation in phase 3 studies for inflammatory or immunological disorders, cancers, high cholesterol, osteoporosis, alzheimer disease and infectious disease.
det||risk-2/NN||the-1/DT	nsubj||increased-7/JJ||risk-2/NN	prep_of||risk-2/NN||peanutallergy-4/NN	cop||increased-7/JJ||was-5/VBD	advmod||increased-7/JJ||markedly-6/RB	root||ROOT-0/null||increased-7/JJ	prep_in||increased-7/JJ||siblings-9/NNS	det||child-13/NN||a-11/DT	amod||child-13/NN||peanut-allergic-12/JJ	prep_of||siblings-9/NNS||child-13/NN	dep||siblings-9/NNS||odds-15/NNS	nsubj||interval-22/VBP||ratio-16/NN	num||ratio-16/NN||6.72-17/CD	number||%-20/NN||95-19/CD	amod||confidence-21/NN||%-20/NN	appos||ratio-16/NN||confidence-21/NN	rcmod||odds-15/NNS||interval-22/VBP	num||.12-24/CD||2.04-22-23/CD	dobj||interval-22/VBP||.12-24/CD	peanutallergy-4||peanut--1||no||the risk of peanutallergy was markedly increased in siblings of a peanut-allergic child (odds ratio 6.72, 95% confidence interval 2.04-22.12).
prep_by||affects-5/VBZ||mechanisms-1/NNS	nsubj||understood-26/VBD||mechanisms-1/NNS	nsubj||affects-5/VBZ||hiv-4/NN	rcmod||mechanisms-1/NNS||affects-5/VBZ	det||thymus-7/NNS||the-6/DT	nsubjpass||multiple-9/JJ||thymus-7/NNS	auxpass||multiple-9/JJ||are-8/VBP	cop||multiple-9/JJ||are-8/VBP	dep||affects-5/VBZ||multiple-9/JJ	dep||affects-5/VBZ||only-11/RB	advmod||multiple-9/JJ||only-11/RB	conj_and||multiple-9/JJ||only-11/RB	advmod||known-13/VBN||partially-12/RB	dep||multiple-9/JJ||known-13/VBN	det||role-17/NN||the-16/DT	nsubj||remains-24/VBZ||role-17/NN	amod||dysfunction-20/NN||thymic-19/JJ	prep_of||role-17/NN||dysfunction-20/NN	amod||immunopathogenesis-23/NNS||hiv/aids-22/JJ	prep_in||dysfunction-20/NN||immunopathogenesis-23/NNS	dep||affects-5/VBZ||remains-24/VBZ	conj_and||multiple-9/JJ||remains-24/VBZ	advmod||understood-26/VBD||poorly-25/RB	root||ROOT-0/null||understood-26/VBD	aids--1||hiv-4||no||mechanisms by which hiv affects the thymus are multiple and only partially known, and the role of thymic dysfunction in hiv/aids immunopathogenesis remains poorly understood.
nsubj||report-2/VBP||we-1/PRP	root||ROOT-0/null||report-2/VBP	det||case-4/NN||a-3/DT	dobj||report-2/VBP||case-4/NN	nsubj||relieve-31/VB||case-4/NN	det||female-11/NN||a-6/DT	number||old-9/JJ||15-7/CD	npadvmod||old-9/JJ||year-8/NN	amod||female-11/NN||old-9/JJ	amod||female-11/NN||young-10/JJ	prep_of||case-4/NN||female-11/NN	nsubj||suffered-13/VBD||female-11/NN	rcmod||female-11/NN||suffered-13/VBD	dobj||suffered-13/VBD||autoamputation-14/NN	amod||foot-18/NN||left-16/JJ	amod||foot-18/NN||mid-17/JJ	prep_of||autoamputation-14/NN||foot-18/NN	num||digits-21/NNS||four-20/CD	dobj||suffered-13/VBD||digits-21/NNS	conj_and||autoamputation-14/NN||digits-21/NNS	amod||foot-24/NN||right-23/JJ	prep_of||digits-21/NNS||foot-24/NN	amod||application-27/NN||repeated-26/VBN	prep_following||suffered-13/VBD||application-27/NN	prep_of||application-27/NN||snow-29/NN	aux||relieve-31/VB||to-30/TO	xcomp||report-2/VBP||relieve-31/VB	det||pain-33/NN||the-32/DT	dobj||relieve-31/VB||pain-33/NN	poss||feet-38/NNS||her-35/PRP$	amod||feet-38/NNS||frost-36/JJ	nn||feet-38/NNS||bitten-37/NN	prep_in||pain-33/NN||feet-38/NNS	pain-33||snow-29||yes||we report a case of a 15 year old young female who suffered autoamputation of left mid foot and four digits of right foot following repeated application of snow to relieve the pain in her frost bitten feet.
nsubjpass||randomized-8/VBN||patients-1/NNS	nsubj||receive-10/VB||patients-1/NNS	nsubj||enalapril-17/VB||patients-1/NNS	amod||moderate-5/JJ||mild-3/JJ	dep||moderate-5/JJ||to-4/TO	amod||hypertension-6/NN||moderate-5/JJ	prep_of||patients-1/NNS||hypertension-6/NN	auxpass||randomized-8/VBN||were-7/VBD	root||ROOT-0/null||randomized-8/VBN	aux||receive-10/VB||to-9/TO	xcomp||randomized-8/VBN||receive-10/VB	det||mg-13/NN||either-11/DT	num||mg-13/NN||40-12/CD	dobj||receive-10/VB||mg-13/NN	prep_of||mg-13/NN||telmisartan-15/NN	xcomp||randomized-8/VBN||enalapril-17/VB	conj_or||receive-10/VB||enalapril-17/VB	num||mg-19/NN||10-18/CD	npadvmod||once-20/RB||mg-19/NN	advmod||enalapril-17/VB||once-20/RB	det||orally-23/NN||a-21/DT	nn||orally-23/NN||day-22/NN	dobj||enalapril-17/VB||orally-23/NN	num||weeks-26/NNS||12-25/CD	prep_for||orally-23/NN||weeks-26/NNS	hypertension-6||telmisartan-15||yes||patients of mild to moderate hypertension were randomized to receive either 40 mg of telmisartan or enalapril 10 mg once a day orally for 12 weeks.
nsubj||compared-2/VBD||we-1/PRP	nsubj||isolates-47/VBZ||we-1/PRP	root||ROOT-0/null||compared-2/VBD	det||performance-4/NN||the-3/DT	dobj||compared-2/VBD||performance-4/NN	det||mtbdr-9/NN||the-6/DT	nn||mtbdr-9/NN||genotypeâ-7/NNP	nn||mtbdr-9/NN||®-8/NNP	prep_of||performance-4/NN||mtbdr-9/NN	amod||specimens-45/NNS||assay-11/JJ	amod||tube-16/NN||mycobacterial-13/JJ	nn||tube-16/NN||growth-14/NN	nn||tube-16/NN||indicator-15/NN	prep_to||assay-11/JJ||tube-16/NN	amod||testing-20/NN||antimycobacterial-18/JJ	nn||testing-20/NN||susceptibility-19/NN	prep_for||tube-16/NN||testing-20/NN	amod||ast-23/NN||mgit-22/JJ	appos||testing-20/NN||ast-23/NN	nn||resistance-28/NN||detection-26/NN	nn||resistance-28/NN||inh-27/NN	prep_for||testing-20/NN||resistance-28/NN	nn||resistance-31/NN||rif-30/NN	appos||resistance-28/NN||resistance-31/NN	conj_and||assay-11/JJ||mdr-tb-34/JJ	amod||specimens-45/NNS||mdr-tb-34/JJ	amod||bacilli-38/NNS||stored-36/JJ	amod||bacilli-38/NNS||acid-fast-37/JJ	prep_in||mdr-tb-34/JJ||bacilli-38/NNS	appos||bacilli-38/NNS||afb-40/NN	amod||specimens-45/NNS||positive-43/JJ	nn||specimens-45/NNS||sputum-44/NN	dobj||compared-2/VBD||specimens-45/NNS	conj_plus||performance-4/NN||specimens-45/NNS	conj_and||compared-2/VBD||isolates-47/VBZ	det||laboratory-52/NN||a-49/DT	amod||laboratory-52/NN||public-50/JJ	nn||laboratory-52/NN||tb-51/NN	prep_at||isolates-47/VBZ||laboratory-52/NN	prep_in||laboratory-52/NN||bangkok-54/NN	dep||compared-2/VBD||thailand-56/VBD	tb-51||rif-30||yes||we compared the performance of the genotypeâ® mtbdr plus assay to mycobacterial growth indicator tube for antimycobacterial susceptibility testing (mgit ast) for detection inh resistance, rif resistance, and mdr-tb in stored acid-fast bacilli (afb)-positive sputum specimens and isolates at a public tb laboratory in bangkok, thailand.
amod||children-2/NNS||hivpositive-1/JJ	nsubj||had-3/VBD||children-2/NNS	root||ROOT-0/null||had-3/VBD	advmod||poorer-5/JJR||significantly-4/RB	amod||outcomes-7/NNS||poorer-5/JJR	amod||outcomes-7/NNS||nutritional-6/JJ	dobj||had-3/VBD||outcomes-7/NNS	poss||counterparts-12/NNS||their-9/PRP$	amod||counterparts-12/NNS||hiv-10/JJ	amod||counterparts-12/NNS||negative-11/JJ	prep_than||had-3/VBD||counterparts-12/NNS	hivpositive-1||hiv-10||no||hivpositive children had significantly poorer nutritional outcomes than their hiv negative counterparts.
det||study-3/NN||a-1/DT	amod||study-3/NN||cross-sectional-2/JJ	nsubj||conducted-4/VBD||study-3/NN	root||ROOT-0/null||conducted-4/VBD	prep_in||conducted-4/VBD||2006/7-6/CD	det||sample-10/NN||a-8/DT	nn||sample-10/NN||convenience-9/NN	prep_with||conducted-4/VBD||sample-10/NN	amod||users-15/NNS||295-12/JJ	amod||users-15/NNS||illicit-13/JJ	nn||users-15/NNS||drug-14/NN	prep_of||sample-10/NN||users-15/NNS	nn||janeiro-19/NNP||rio-17/NNP	nn||janeiro-19/NNP||de-18/FW	prep_in||users-15/NNS||janeiro-19/NNP	xcomp||conducted-4/VBD||assessing-21/VBG	dobj||assessing-21/VBG||knowledge-22/NN	amod||transmission-25/NN||aids/hiv-24/JJ	prep_on||assessing-21/VBG||transmission-25/NN	poss||relationship-28/NN||its-27/PRP$	prep_on||assessing-21/VBG||relationship-28/NN	conj_and||transmission-25/NN||relationship-28/NN	nn||testing-31/NN||hiv-30/NN	prep_with||assessing-21/VBG||testing-31/NN	aids--1||hiv-30||no||a cross-sectional study conducted in 2006/7 with a convenience sample of 295 illicit drug users in rio de janeiro, assessing knowledge on aids/hiv transmission and its relationship with hiv testing.
det||study-9/NN||this-1/DT	amod||study-9/NN||prospective-2/JJ	amod||study-9/NN||6-week-4/JJ	amod||study-9/NN||multicenter-6/JJ	amod||study-9/NN||double-blind-8/JJ	nsubj||compared-22/VBD||study-9/NN	vmod||study-9/NN||examined-10/VBN	det||benefits-12/NNS||the-11/DT	dobj||examined-10/VBN||benefits-12/NNS	prepc_of||benefits-12/NNS||initiating-14/VBG	dobj||initiating-14/VBG||treatment-15/NN	nn||valsartan/hydrochlorothiazide-18/NN||combination-17/NN	prep_with||initiating-14/VBG||valsartan/hydrochlorothiazide-18/NN	appos||study-9/NN||hctz-20/NNP	root||ROOT-0/null||compared-22/VBD	amod||monotherapy-26/NN||initial-24/JJ	nn||monotherapy-26/NN||valsartan-25/NN	prep_with||compared-22/VBD||monotherapy-26/NN	num||patients-29/NNS||648-28/CD	prep_for||monotherapy-26/NN||patients-29/NNS	amod||hypertension-34/NN||stage-1-31/JJ	conj_or||stage-1-31/JJ||stage-2-33/JJ	amod||hypertension-34/NN||stage-2-33/JJ	prep_with||compared-22/VBD||hypertension-34/NN	dep||hypertension-34/NN||age-36/NN	dep||years-42/NNS||=-37/SYM	num||years-42/NNS||52.6-38/CD	nn||years-42/NNS||â-39/NNP	nn||years-42/NNS||±-40/NNP	num||years-42/NNS||10-41/CD	rcmod||age-36/NN||years-42/NNS	num||%-45/NN||54-44/CD	dep||age-36/NN||%-45/NN	dep||%-45/NN||male-46/NN	nn||blood-49/NN||baseline-48/NN	dep||age-36/NN||blood-49/NN	rcmod||blood-49/NN||pressure-50/NN	dep||pressure-50/NN||bp-52/NN	amod||stage-66/NN||=-54/JJ	dep||=-54/JJ||161/98-55/CD	amod||stage-66/NN||â-56/JJ	amod||stage-66/NN||$-57/$	dep||$-57/$||-58/JJ	amod||stage-66/NN||mmâ-59/JJ	amod||stage-66/NN||$-60/$	number||hg-62/CD||-61/CD	num||$-60/$||hg-62/CD	number||%-65/NN||32-64/CD	amod||stage-66/NN||%-65/NN	dobj||pressure-50/NN||stage-66/NN	dep||age-36/NN||1-67/CD	hypertension-34||valsartan-25||yes||this prospective, 6-week, multicenter, double-blind study examined the benefits of initiating treatment with combination valsartan/hydrochlorothiazide (hctz) compared with initial valsartan monotherapy for 648 patients with stage-1 or stage-2 hypertension (age=52.6â±10 years; 54% male; baseline blood pressure (bp)=161/98âmmâhg, 32% stage 1).
aux||examine-2/VB||to-1/TO	ccomp||examined-39/VBD||examine-2/VB	det||diversity-5/NN||the-3/DT	amod||diversity-5/NN||global-4/JJ	dobj||examine-2/VB||diversity-5/NN	prep_of||diversity-5/NN||streptococcusagalactiae-7/NN	amod||-RSB--13/NNP||groupb-9/JJ	nn||-RSB--13/NNP||streptococci-10/NNP	nn||-RSB--13/NNP||-LSB--11/NNP	nn||-RSB--13/NNP||gbs-12/NN	appos||streptococcusagalactiae-7/NN||-RSB--13/NNP	aux||elucidate-17/VB||to-16/TO	conj_and||examine-2/VB||elucidate-17/VB	ccomp||examined-39/VBD||elucidate-17/VB	det||processes-20/NNS||the-18/DT	amod||processes-20/NNS||evolutionary-19/JJ	dobj||elucidate-17/VB||processes-20/NNS	nsubj||determine-22/VBP||processes-20/NNS	rcmod||processes-20/NNS||determine-22/VBP	poss||structure-26/NN||its-23/PRP$	nn||structure-26/NN||population-24/NN	nn||structure-26/NN||genetics-25/NNS	dobj||determine-22/VBP||structure-26/NN	det||changes-30/NNS||the-28/DT	amod||changes-30/NNS||reported-29/VBN	dobj||elucidate-17/VB||changes-30/NNS	conj_and||processes-20/NNS||changes-30/NNS	nsubj||determine-22/VBP||changes-30/NNS	nn||tropism-33/NN||host-32/NN	prep_in||changes-30/NNS||tropism-33/NN	nn||epidemiology-36/NN||infection-35/NN	prep_in||changes-30/NNS||epidemiology-36/NN	conj_and||tropism-33/NN||epidemiology-36/NN	nsubj||examined-39/VBD||we-38/PRP	root||ROOT-0/null||examined-39/VBD	det||collection-41/NN||a-40/DT	nsubj||isolates-47/VBZ||collection-41/NN	prep_of||collection-41/NN||238-43/CD	amod||238-43/CD||bovine-44/JJ	amod||238-43/CD||human-46/JJ	conj_and||bovine-44/JJ||human-46/JJ	ccomp||examined-39/VBD||isolates-47/VBZ	num||countries-50/NNS||nine-49/CD	prep_from||isolates-47/VBZ||countries-50/NNS	num||continents-53/NNS||five-52/CD	prep_on||countries-50/NNS||continents-53/NNS	groupb-9||streptococcusagalactiae-7||no||to examine the global diversity of streptococcusagalactiae (groupb streptococci [gbs]) and to elucidate the evolutionary processes that determine its population genetics structure and the reported changes in host tropism and infection epidemiology, we examined a collection of 238 bovine and human isolates from nine countries on five continents.
nsubj||hiv/aids-2/VBZ||results-1/NNS	root||ROOT-0/null||hiv/aids-2/VBZ	nn||knowledge-4/NN||prevention-3/NN	nsubj||cares-11/VBZ||knowledge-4/NN	conj_and||knowledge-4/NN||awareness-6/NN	nsubj||cares-11/VBZ||awareness-6/NN	vmod||knowledge-4/NN||improved-7/VBN	advmod||improved-7/VBN||significantly-8/RB	prep_in||improved-7/VBN||china-10/NN	ccomp||hiv/aids-2/VBZ||cares-11/VBZ	dobj||cares-11/VBZ||sites-12/NNS	prepc_from||cares-11/VBZ||<-14/VBG	num||%-16/NN||30-15/CD	dobj||<-14/VBG||%-16/NN	prep_in||<-14/VBG||2004-18/CD	num||%-21/NN||86-20/CD	prep_to||<-14/VBG||%-21/NN	prep_in||%-21/NN||2008-23/CD	aids--1||hiv--1||no||results hiv/aids prevention knowledge and awareness improved significantly in china cares sites from <30% in 2004 to 86% in 2008.
num||weeks-3/NNS||16-2/CD	prep_at||â-9/NN||weeks-3/NNS	nn||hbp-6/NN||morning-5/NN	nsubj||â-9/NN||hbp-6/NN	cop||â-9/NN||was-7/VBD	num||â-9/NN||135.0-8/CD	root||ROOT-0/null||â-9/NN	num||13.7-11/CD||±-10/CD	dep||â-9/NN||13.7-11/CD	punct||13.7-11/CD||/-12/:	number||â-14/CD||78.8-13/CD	num||hg-23/NN||â-14/CD	nn||hg-23/NN||±-15/NNP	num||hg-23/NN||9.9-16/CD	amod||hg-23/NN||â-17/JJ	prep||â-17/JJ||$-18/$	number||mmâ-20/CD||-19/CD	num||$-18/$||mmâ-20/CD	dep||$-18/$||$-21/$	num||$-21/$||-22/CD	nsubj||â-29/NN||hg-23/NN	amod||hbp-26/NN||bedtime-25/JJ	conj_and||hg-23/NN||hbp-26/NN	nsubj||â-29/NN||hbp-26/NN	cop||â-29/NN||was-27/VBD	num||â-29/NN||129.7-28/CD	dep||13.7-11/CD||â-29/NN	number||13.8-31/CD||±-30/CD	dep||â-29/NN||13.8-31/CD	punct||â-34/NN||/-32/:	num||â-34/NN||74.7-33/CD	dep||â-29/NN||â-34/NN	vmod||â-34/NN||±-35/VBN	num||â-37/NNS||10.1-36/CD	iobj||±-35/VBN||â-37/NNS	num||â-37/NNS||$-38/$	number||mmâ-40/CD||-39/CD	num||$-38/$||mmâ-40/CD	dobj||±-35/VBN||$-41/$	num||$-41/$||-42/CD	advmod||$-41/$||hg-43/RB	mark||±-50/NNP||whereas-45/IN	nsubj||±-50/NNP||cbp-46/NN	cop||±-50/NNP||was-47/VBD	number||â-49/CD||135.6-48/CD	num||±-50/NNP||â-49/CD	advcl||±-35/VBN||±-50/NNP	num||±-50/NNP||15.4-51/CD	punct||â-34/NN||/-52/:	number||â-54/CD||77.6-53/CD	num||â-57/NN||â-54/CD	nn||â-57/NN||±-55/NNP	num||â-57/NN||10.9-56/CD	dep||â-29/NN||â-57/NN	num||$-61/$||$-58/$	number||mmâ-60/CD||-59/CD	num||$-58/$||mmâ-60/CD	dep||â-57/NN||$-61/$	number||hg-63/CD||-62/CD	num||$-61/$||hg-63/CD	hg-63||hbp-26||no_rel||at 16 weeks, morning hbp was 135.0â±13.7/78.8â±9.9âmmâhg and bedtime hbp was 129.7â±13.8/74.7â±10.1âmmâhg, whereas cbp was 135.6â±15.4/77.6â±10.9âmmâhg.
advmod||is-4/VBZ||conversely-1/RB	expl||is-4/VBZ||there-3/EX	root||ROOT-0/null||is-4/VBZ	amod||evidence-6/NN||ample-5/JJ	nsubj||is-4/VBZ||evidence-6/NN	vmod||evidence-6/NN||demonstrating-7/VBG	amod||benefit-9/NN||remarkable-8/JJ	dobj||demonstrating-7/VBG||benefit-9/NN	prep_of||benefit-9/NN||etanercept-11/NN	prepc_in||demonstrating-7/VBG||treating-13/VBG	dobj||treating-13/VBG||juvenileidiopathicarthritis-14/NNS	juvenileidiopathicarthritis-14||etanercept-11||yes||conversely, there is ample evidence demonstrating remarkable benefit of etanercept in treating juvenileidiopathicarthritis.
amod||factors-3/NNS||numerous-1/JJ	nn||factors-3/NNS||risk-2/NN	nsubjpass||established-11/VBN||factors-3/NNS	det||development-6/NN||the-5/DT	prep_for||factors-3/NNS||development-6/NN	prep_of||development-6/NN||gout-8/NN	aux||established-11/VBN||have-9/VBP	auxpass||established-11/VBN||been-10/VBN	root||ROOT-0/null||established-11/VBN	prep_including||established-11/VBN||hyperuricaemia-14/NN	amod||factors-17/NNS||genetic-16/JJ	prep_including||established-11/VBN||factors-17/NNS	conj_and||hyperuricaemia-14/NN||factors-17/NNS	amod||factors-20/NNS||dietary-19/JJ	prep_including||established-11/VBN||factors-20/NNS	conj_and||hyperuricaemia-14/NN||factors-20/NNS	nn||consumption-23/NN||alcohol-22/NN	prep_including||established-11/VBN||consumption-23/NN	conj_and||hyperuricaemia-14/NN||consumption-23/NN	amod||syndrome-26/NN||metabolic-25/JJ	prep_including||established-11/VBN||syndrome-26/NN	conj_and||hyperuricaemia-14/NN||syndrome-26/NN	prep_including||established-11/VBN||hypertension-28/NN	conj_and||hyperuricaemia-14/NN||hypertension-28/NN	prep_including||established-11/VBN||obesity-30/NN	conj_and||hyperuricaemia-14/NN||obesity-30/NN	amod||use-33/NN||diuretic-32/JJ	prep_including||established-11/VBN||use-33/NN	conj_and||hyperuricaemia-14/NN||use-33/NN	amod||renaldisease-36/NN||chronic-35/JJ	prep_including||established-11/VBN||renaldisease-36/NN	conj_and||hyperuricaemia-14/NN||renaldisease-36/NN	diuretic-32||gout-8||no_rel||numerous risk factors for the development of gout have been established, including hyperuricaemia, genetic factors, dietary factors, alcohol consumption, metabolic syndrome, hypertension, obesity, diuretic use and chronic renaldisease.
det||study-3/NN||the-1/DT	amod||study-3/NN||present-2/JJ	nsubj||looks-4/VBZ||study-3/NN	root||ROOT-0/null||looks-4/VBZ	det||aspects-7/NNS||some-6/DT	prep_at||looks-4/VBZ||aspects-7/NNS	prep_of||aspects-7/NNS||disability-9/NN	vmod||disability-9/NN||associated-10/VBN	num||disorders-14/NNS||7-12/CD	amod||disorders-14/NNS||psychiatric-13/JJ	prep_with||associated-10/VBN||disorders-14/NNS	nn||depression-21/NN||schizophrenia-15/NN	dep||depression-21/NN||bipolaraffectivedisorder-17/NN	dep||depression-21/NN||anxietydisorders-19/NNS	dep||disorders-14/NNS||depression-21/NN	vmod||disorders-14/NNS||obsessiveâ-23/VBG	dobj||obsessiveâ-23/VBG||$-24/$	advmod||alcohol-41/CD||compulsive-26/RB	dep||mental-32/JJ||disorder-27/JJ	conj_and||mental-32/JJ||dementia-29/JJ	amod||disorders-35/NNS||dementia-29/JJ	amod||disorders-35/NNS||mental-32/JJ	conj_and||mental-32/JJ||behavioural-34/JJ	amod||disorders-35/NNS||behavioural-34/JJ	npadvmod||alcohol-41/CD||disorders-35/NNS	det||use-39/NN||the-38/DT	prep_due_to||alcohol-41/CD||use-39/NN	prep||use-39/NN||of-40/IN	num||$-24/$||alcohol-41/CD	alcohol-41||bipolaraffectivedisorder-17||no_rel||the present study looks at some aspects of disability associated with 7 psychiatric disorders schizophrenia, bipolaraffectivedisorder, anxietydisorders, depression, obsessiveâcompulsive disorder, dementia, and mental and behavioural disorders due to the use of alcohol.
amod||combinations-4/NNS||docetaxel-1/JJ	conj_and||docetaxel-1/JJ||gemcitabine-3/JJ	amod||combinations-4/NNS||gemcitabine-3/JJ	nsubj||proven-6/VBN||combinations-4/NNS	aux||proven-6/VBN||have-5/VBP	root||ROOT-0/null||proven-6/VBN	acomp||proven-6/VBN||active-7/JJ	det||treatment-10/NN||the-9/DT	prep_for||proven-6/VBN||treatment-10/NN	prep_of||treatment-10/NN||non-smallcelllungcancer-12/NN	dep||non-smallcelllungcancer-12/NN||nsclc-14/JJ	docetaxel-1||non-smallcelllungcancer-12||no_rel||docetaxel and gemcitabine combinations have proven active for the treatment of non-smallcelllungcancer (nsclc).
preconj||insulin-2/NN||both-1/DT	nsubj||reversed-5/VBD||insulin-2/NN	conj_and||insulin-2/NN||phloridzin-4/NN	nsubj||reversed-5/VBD||phloridzin-4/NN	root||ROOT-0/null||reversed-5/VBD	det||levels-10/NNS||the-6/DT	amod||levels-10/NNS||lower-7/JJR	nn||levels-10/NNS||klotho-8/NN	nn||levels-10/NNS||expression-9/NN	dobj||reversed-5/VBD||levels-10/NNS	prep_in||levels-10/NNS||kidneys-12/NNS	nn||rats-15/NNS||stz-14/NN	prep_of||kidneys-12/NNS||rats-15/NNS	det||correction-18/NN||the-17/DT	prep_by||reversed-5/VBD||correction-18/NN	prep_of||correction-18/NN||hyperglycemia-20/NN	hyperglycemia-20||insulin-2||yes||both insulin and phloridzin reversed the lower klotho expression levels in kidneys of stz rats by the correction of hyperglycemia.
amod||treatment-3/NN||titrated-1/JJ	nn||treatment-3/NN||oxygen-2/NN	nsubj||reduced-4/VBD||treatment-3/NN	root||ROOT-0/null||reduced-4/VBD	dobj||reduced-4/VBD||mortality-5/NN	prepc_compared_with||reduced-4/VBD||with-7/IN	amod||oxygen-10/NN||high-8/JJ	nn||oxygen-10/NN||flow-9/NN	pobj||reduced-4/VBD||oxygen-10/NN	num||%-13/NN||58-12/CD	prep_by||oxygen-10/NN||%-13/NN	det||patients-16/NNS||all-15/DT	prep_for||%-13/NN||patients-16/NNS	amod||risk-19/NN||relative-18/JJ	dep||patients-16/NNS||risk-19/NN	num||0.20-26/NNS||0.42-20/CD	num||0.20-26/NNS||95-22/CD	nn||0.20-26/NNS||%-23/NN	nn||0.20-26/NNS||confidence-24/NN	amod||0.20-26/NNS||interval-25/JJ	dep||risk-19/NN||0.20-26/NNS	prep_to||0.20-26/NNS||0.89-28/NNP	dep||0.20-26/NNS||p-30/NN	dep||0.02-32/CD||=-31/SYM	rcmod||p-30/NN||0.02-32/CD	num||%-37/NN||78-36/CD	prep_by||oxygen-10/NN||%-37/NN	conj_and||%-13/NN||%-37/NN	det||patients-40/NNS||the-39/DT	prep_for||%-37/NN||patients-40/NNS	amod||obstructivepulmonarydisease-44/NN||confirmed-42/JJ	amod||obstructivepulmonarydisease-44/NN||chronic-43/JJ	prep_with||patients-40/NNS||obstructivepulmonarydisease-44/NN	dep||obstructivepulmonarydisease-44/NN||0.22-46/CD	appos||0.22-46/CD||0.05-48/CD	prep_to||0.05-48/CD||0.91-50/CD	dep||0.05-48/CD||p-52/NN	dep||0.04-54/CD||=-53/SYM	rcmod||p-52/NN||0.04-54/CD	obstructivepulmonarydisease-44||oxygen-10||yes||titrated oxygen treatment reduced mortality compared with high flow oxygen by 58% for all patients (relative risk 0.42, 95% confidence interval 0.20 to 0.89; p=0.02) and by 78% for the patients with confirmed chronic obstructivepulmonarydisease (0.22, 0.05 to 0.91; p=0.04).
nn||use-3/NN||injection-1/NN	nn||use-3/NN||drug-2/NN	nsubj||contribute-12/VBP||use-3/NN	appos||use-3/NN||idu-5/NN	amod||transmission-10/NN||heterosexual-8/JJ	nn||transmission-10/NN||virus-9/NN	conj_and||use-3/NN||transmission-10/NN	nsubj||contribute-12/VBP||transmission-10/NN	dep||contribute-12/VBP||both-11/DT	root||ROOT-0/null||contribute-12/VBP	det||epidemics-18/NN||the-14/DT	amod||epidemics-18/NN||growing-15/VBG	amod||epidemics-18/NN||mixed-16/JJ	nn||epidemics-18/NN||hiv-17/NN	prep_to||contribute-12/VBP||epidemics-18/NN	amod||europe-21/NN||eastern-20/JJ	prep_in||epidemics-18/NN||europe-21/NN	amod||asia-24/NN||central-23/JJ	prep_in||epidemics-18/NN||asia-24/NN	conj_and||europe-21/NN||asia-24/NN	virus-9||idu-5||yes||injection drug use (idu) and heterosexual virus transmission both contribute to the growing mixed hiv epidemics in eastern europe and central asia.
dep||increased-11/VBD||î-1/NN	num||î-1/NN||±-2/CD	prep||î-1/NN||cp-4/RB	advmod||cp-4/RB||significantly-5/RB	amod||<-8/NNS||-lrb--6/JJ	nn||<-8/NNS||p-7/NN	pobj||cp-4/RB||<-8/NNS	num||-rrb--10/NNS||0.05-9/CD	nsubj||increased-11/VBD||-rrb--10/NNS	advcl||±-38/VBZ||increased-11/VBD	det||activities-13/NNS||the-12/DT	nn||â-19/NN||activities-13/NNS	nn||ast-16/NN||testicular-15/NN	prep_of||activities-13/NNS||ast-16/NN	amod||â-19/NN||-lrb--17/JJ	dep||-lrb--17/JJ||1.36-18/CD	iobj||increased-11/VBD||â-19/NN	num||0.12-21/CD||±-20/CD	dobj||increased-11/VBD||0.12-21/CD	prep||increased-11/VBD||vs.-22/CC	num||â-24/NN||1.19-23/CD	pobj||vs.-22/CC||â-24/NN	vmod||â-24/NN||±-25/VBG	num||-rrb--27/NNS||0.10-26/CD	dobj||±-25/VBG||-rrb--27/NNS	nn||0.11-34/NNP||alt-29/NNP	nn||0.11-34/NNP||-lrb--30/NNP	nn||0.11-34/NNP||1.78-31/NNP	nn||0.11-34/NNP||â-32/NNP	nn||0.11-34/NNP||±-33/NNP	nsubj||±-38/VBZ||0.11-34/NNP	num||â-37/NN||1.36-36/CD	prep_vs.||0.11-34/NNP||â-37/NN	dep||decreased-49/VBD||±-38/VBZ	number||-rrb--40/CD||0.09-39/CD	dobj||±-38/VBZ||-rrb--40/CD	advmod||-lrb--44/JJ||significantly-43/RB	amod||<-46/NNS||-lrb--44/JJ	nn||<-46/NNS||p-45/NN	dobj||±-38/VBZ||<-46/NNS	conj_and||-rrb--40/CD||<-46/NNS	num||-rrb--48/NNS||0.05-47/CD	dep||<-46/NNS||-rrb--48/NNS	root||ROOT-0/null||decreased-49/VBD	det||-lrb--53/NN||the-50/DT	amod||-lrb--53/NN||testosterone-51/JJ	nn||-lrb--53/NN||levels-52/NNS	dobj||decreased-49/VBD||-lrb--53/NN	num||±-56/NN||0.86-54/CD	amod||±-56/NN||â-55/JJ	nsubj||decreased-49/VBD||±-56/NN	num||±-56/NN||0.24-57/CD	prep||decreased-49/VBD||vs.-58/FW	num||-rrb--63/NNP||1.72-59/CD	nn||-rrb--63/NNP||â-60/NN	nn||-rrb--63/NNP||±-61/NNP	nn||-rrb--63/NNP||0.18-62/NNP	pobj||vs.-58/FW||-rrb--63/NNP	testosterone-51||cp-4||no_rel||î ± - cp significantly -lrb- p < 0.05 -rrb- increased the activities of testicular ast -lrb- 1.36 â ± 0.12 vs. 1.19 â ± 0.10 -rrb- , alt -lrb- 1.78 â ± 0.11 vs. 1.36 â ± 0.09 -rrb- , and significantly -lrb- p < 0.05 -rrb- decreased the testosterone levels -lrb- 0.86 â ± 0.24 vs. 1.72 â ± 0.18 -rrb- .
det||findings-2/NNS||these-1/DT	nsubj||suggest-3/VBP||findings-2/NNS	root||ROOT-0/null||suggest-3/VBP	det||role-6/NN||a-4/DT	amod||role-6/NN||potential-5/JJ	dobj||suggest-3/VBP||role-6/NN	amod||snps-11/NNS||mrp1-8/JJ	conj_and||mrp1-8/JJ||mdr1-10/JJ	amod||snps-11/NNS||mdr1-10/JJ	prep_for||role-6/NN||snps-11/NNS	prepc_in||suggest-3/VBP||modulating-13/VBG	det||outcome-16/NN||the-14/DT	amod||outcome-16/NN||long-term-15/JJ	dobj||modulating-13/VBG||outcome-16/NN	amod||patients-22/NNS||relapsed-18/JJ	amod||patients-22/NNS||and/or-19/JJ	amod||patients-22/NNS||refractory-20/JJ	nn||patients-22/NNS||myeloma-21/NN	prep_of||outcome-16/NN||patients-22/NNS	vmod||patients-22/NNS||treated-23/VBN	prepc_with||treated-23/VBN||pldâ-25/VBG	num||â-29/NN||$-26/$	number||+-28/CD||-27/CD	num||$-26/$||+-28/CD	dobj||pldâ-25/VBG||â-29/NN	npadvmod||bortezomib-32/JJ||$-30/$	num||$-30/$||-31/CD	amod||â-29/NN||bortezomib-32/JJ	myeloma-21||bortezomib-32||yes||these findings suggest a potential role for mrp1 and mdr1 snps in modulating the long-term outcome of relapsed and/or refractory myeloma patients treated with pldâ+âbortezomib.
amod||adherence-2/NN||sub-optimal-1/JJ	nsubj||places-5/VBZ||adherence-2/NN	prep_to||adherence-2/NN||warfarin-4/NN	root||ROOT-0/null||places-5/VBZ	dobj||places-5/VBZ||millions-6/NNS	prep_of||millions-6/NNS||patients-8/NNS	prep_at||patients-8/NNS||risk-10/NN	nn||complications-15/NNS||stroke-12/NN	conj_and||stroke-12/NN||bleeding-14/NN	nn||complications-15/NNS||bleeding-14/NN	prep_for||risk-10/NN||complications-15/NNS	det||year-17/NN||each-16/DT	tmod||places-5/VBZ||year-17/NN	stroke-12||warfarin-4||yes||sub-optimal adherence to warfarin places millions of patients at risk for stroke and bleeding complications each year.
amod||avianinfluenzavirus-2/NNS||pathogenic-1/JJ	nsubj||has-6/VBZ||avianinfluenzavirus-2/NNS	appos||avianinfluenzavirus-2/NNS||h5n1-4/NNP	root||ROOT-0/null||has-6/VBZ	det||potential-8/NN||the-7/DT	dobj||has-6/VBZ||potential-8/NN	aux||cause-10/VB||to-9/TO	vmod||potential-8/NN||cause-10/VB	det||pandemic-14/NN||a-11/DT	amod||pandemic-14/NN||major-12/JJ	amod||pandemic-14/NN||global-13/JJ	dobj||cause-10/VB||pandemic-14/NN	prep_in||cause-10/VB||humans-16/NNS	h5n1-4||avianinfluenzavirus-2||no||pathogenic avianinfluenzavirus (h5n1) has the potential to cause a major global pandemic in humans.
det||study-2/NN||this-1/DT	nsubj||examined-3/VBD||study-2/NN	root||ROOT-0/null||examined-3/VBD	det||prevention-5/NN||the-4/DT	dobj||examined-3/VBD||prevention-5/NN	prep_of||prevention-5/NN||pain-7/NN	amod||injection-11/NN||microemulsion-9/JJ	amod||injection-11/NN||propofol-10/JJ	prep_during||examined-3/VBD||injection-11/NN	prep_by||examined-3/VBD||pretreatment-13/NN	amod||doses-16/NNS||different-15/JJ	prep_with||examined-3/VBD||doses-16/NNS	prep_of||doses-16/NNS||remifentanil-18/JJ	prep_of||doses-16/NNS||saline-20/JJ	conj_or||remifentanil-18/JJ||saline-20/JJ	prep_of||doses-16/NNS||premixing-23/NN	conj_and||remifentanil-18/JJ||premixing-23/NN	prep_of||premixing-23/NN||lidocaine-25/NN	pain-7||remifentanil-18||yes||this study examined the prevention of pain during microemulsion propofol injection by pretreatment with different doses of remifentanil or saline, and premixing of lidocaine.
amod||seroprevalence-2/NN||overall-1/JJ	nsubjpass||found-29/VBN||seroprevalence-2/NN	nsubj||%-33/NN||seroprevalence-2/NN	vmod||seroprevalence-2/NN||evaluated-3/VBN	agent||evaluated-3/VBN||immunofluorescence-5/NN	vmod||immunofluorescence-5/NN||using-6/VBG	num||antigens-9/NNS||six-7/CD	amod||antigens-9/NNS||rickettsial-8/JJ	dobj||using-6/VBG||antigens-9/NNS	nn||group-14/NN||spottedfever-11/NN	conj_and||spottedfever-11/NN||typhus-13/NN	nn||group-14/NN||typhus-13/NN	appos||antigens-9/NNS||group-14/NN	amod||populations-18/NNS||rural-17/JJ	prep_in||antigens-9/NNS||populations-18/NNS	num||villages-21/NNS||two-20/CD	prep_of||populations-18/NNS||villages-21/NNS	det||region-25/NN||the-23/DT	amod||region-25/NN||sine-saloum-24/JJ	prep_of||villages-21/NNS||region-25/NN	prep_of||region-25/NN||senegal-27/NN	auxpass||found-29/VBN||was-28/VBD	root||ROOT-0/null||found-29/VBN	aux||%-33/NN||to-30/TO	cop||%-33/NN||be-31/VB	num||%-33/NN||21.4-32/CD	xcomp||found-29/VBN||%-33/NN	num||%-36/NN||51-35/CD	xcomp||found-29/VBN||%-36/NN	conj_and||%-33/NN||%-36/NN	nn||rickettsiae-40/NN||spottedfever-38/NN	nn||rickettsiae-40/NN||group-39/NN	prep_for||%-33/NN||rickettsiae-40/NN	nn||villages-45/NNS||dielmo-42/NN	conj_and||dielmo-42/NN||ndiop-44/NN	nn||villages-45/NNS||ndiop-44/NN	prep_for||rickettsiae-40/NN||villages-45/NNS	advmod||%-33/NN||respectively-47/RB	spottedfever-38||rickettsiae-40||no||overall seroprevalence evaluated by immunofluorescence using six rickettsial antigens (spottedfever and typhus group) in rural populations of two villages of the sine-saloum region of senegal was found to be 21.4% and 51% for spottedfever group rickettsiae for dielmo and ndiop villages, respectively.
det||study-3/NN||this-2/DT	prep_in||determined-6/VBD||study-3/NN	nsubj||determined-6/VBD||we-5/PRP	nsubj||assessed-36/VBD||we-5/PRP	root||ROOT-0/null||determined-6/VBD	det||percentage-8/NN||the-7/DT	nsubj||isolates-19/VBZ||percentage-8/NN	prep_of||percentage-8/NN||strains-10/NNS	vmod||strains-10/NNS||possessing-11/VBG	amod||resistance-13/NN||pyrazinamide-12/JJ	dobj||possessing-11/VBG||resistance-13/NN	amod||m.tuberculosis-16/NNS||pan-susceptible-15/JJ	prep_among||possessing-11/VBG||m.tuberculosis-16/NNS	prep_among||possessing-11/VBG||mdr-tb-18/NN	conj_and||m.tuberculosis-16/NNS||mdr-tb-18/NN	ccomp||determined-6/VBD||isolates-19/VBZ	prepc_by||isolates-19/VBZ||using-21/VBG	det||method-30/NN||the-22/DT	amod||method-30/NN||pyrazinamidase-23/JJ	amod||method-30/NN||assay-24/JJ	amod||method-30/NN||bactec-26/JJ	nn||method-30/NN||mgit-27/NN	num||method-30/NN||960-28/CD	nn||method-30/NN||pza-29/NNP	dobj||using-21/VBG||method-30/NN	nn||sequencing-33/NN||pnca-32/NN	dobj||using-21/VBG||sequencing-33/NN	conj_and||method-30/NN||sequencing-33/NN	conj_and||determined-6/VBD||assessed-36/VBD	det||correlation-38/NN||the-37/DT	dobj||assessed-36/VBD||correlation-38/NN	det||data-41/NNS||the-40/DT	prep_in||assessed-36/VBD||data-41/NNS	vmod||data-41/NNS||generated-42/VBN	xcomp||generated-42/VBN||using-43/VBG	det||methods-45/NNS||these-44/DT	dobj||using-43/VBG||methods-45/NNS	tb--1||pyrazinamide-12||yes||in this study , we determined the percentage of strains possessing pyrazinamide resistance among pan-susceptible m.tuberculosis and mdr-tb isolates by using the pyrazinamidase assay , bactec mgit 960 pza method and pnca sequencing , and assessed the correlation in the data generated using these methods .
nsubj||inhibitor-12/NN||sitagliptin-1/NN	cop||inhibitor-12/NN||is-2/VBZ	det||inhibitor-12/NN||a-3/DT	amod||peptidase-4-5/JJ||dipeptidyl-4/JJ	amod||inhibitor-12/NN||peptidase-4-5/JJ	nn||iv-8/NN||dpp-7/NN	dep||inhibitor-12/NN||iv-8/NN	appos||iv-8/NN||cd26-10/NNS	root||ROOT-0/null||inhibitor-12/NN	vmod||inhibitor-12/NN||indicated-13/VBN	prep_for||indicated-13/VBN||treatment-15/NN	prep_of||treatment-15/NN||typeiidiabetes-17/NNS	det||therapy-22/NN||a-19/DT	amod||therapy-22/NN||second-20/JJ	nn||therapy-22/NN||line-21/NN	prep_as||typeiidiabetes-17/NNS||therapy-22/NN	prep_after||indicated-13/VBN||metformin-24/NN	typeiidiabetes-17||metformin-24||yes||sitagliptin is a dipeptidyl peptidase-4 (dpp iv, cd26) inhibitor indicated for treatment of typeiidiabetes as a second line therapy after metformin.
mark||offered-6/VBN||since-1/IN	amod||cross-protection-3/NN||limited-2/JJ	nsubjpass||offered-6/VBN||cross-protection-3/NN	aux||offered-6/VBN||would-4/MD	auxpass||offered-6/VBN||be-5/VB	advcl||taken-18/VBN||offered-6/VBN	nn||types-9/NNS||hpv-8/NN	prep_between||offered-6/VBN||types-9/NNS	nsubjpass||taken-18/VBN||heterogeneity-11/NN	amod||distribution-15/NN||hpv-13/JJ	amod||distribution-15/NN||type-specific-14/JJ	prep_in||heterogeneity-11/NN||distribution-15/NN	aux||taken-18/VBN||should-16/MD	auxpass||taken-18/VBN||be-17/VB	root||ROOT-0/null||taken-18/VBN	prep_into||taken-18/VBN||account-20/NN	advmod||predicting-22/VBG||when-21/WRB	advcl||taken-18/VBN||predicting-22/VBG	det||effect-24/NN||the-23/DT	dobj||predicting-22/VBG||effect-24/NN	amod||vaccines-28/NNS||current-26/JJ	amod||vaccines-28/NNS||prophylactic-27/JJ	prep_of||effect-24/NN||vaccines-28/NNS	advcl||taken-18/VBN||forming-30/VBG	conj_and||predicting-22/VBG||forming-30/VBG	det||basic-32/JJ||the-31/DT	dobj||forming-30/VBG||basic-32/JJ	det||vaccines-36/NNS||the-34/DT	amod||vaccines-36/NNS||second-generation-35/JJ	prep_for||forming-30/VBG||vaccines-36/NNS	vmod||vaccines-36/NNS||targeted-37/VBN	amod||regions-40/NNS||specific-39/JJ	prep_to||targeted-37/VBN||regions-40/NNS	vaccines-36||cross--1||no_rel||since limited cross-protection would be offered between hpv types, heterogeneity in hpv type-specific distribution should be taken into account when predicting the effect of current prophylactic vaccines and forming the basic for the second-generation vaccines targeted to specific regions.
det||case-2/NN||this-1/DT	nsubj||suggests-3/VBZ||case-2/NN	root||ROOT-0/null||suggests-3/VBZ	mark||offer-7/VB||that-4/IN	nsubj||offer-7/VB||bivalirudin-5/NN	aux||offer-7/VB||could-6/MD	ccomp||suggests-3/VBZ||offer-7/VB	dobj||offer-7/VB||promise-8/NN	prep_for||promise-8/NN||use-10/NN	prep_in||offer-7/VB||patients-12/NNS	amod||thrombocytopaenia-15/NN||heparin-induced-14/JJ	prep_with||offer-7/VB||thrombocytopaenia-15/NN	dep||offer-7/VB||hit-17/VBN	prep_after||offer-7/VB||thrombolysis-20/NNS	amod||pulmonaryembolism-23/NN||massive-22/JJ	prep_for||thrombolysis-20/NNS||pulmonaryembolism-23/NN	pulmonaryembolism-23||heparin--1||yes||this case suggests that bivalirudin could offer promise for use in patients with heparin-induced thrombocytopaenia (hit) after thrombolysis for massive pulmonaryembolism.
vmod||undertook-23/VBD||theorizing-1/VBG	mark||related-8/VBN||that-2/IN	det||phenomenon-4/NN||this-3/DT	nsubjpass||related-8/VBN||phenomenon-4/NN	aux||related-8/VBN||may-5/MD	auxpass||related-8/VBN||be-6/VB	advmod||related-8/VBN||somehow-7/RB	ccomp||theorizing-1/VBG||related-8/VBN	det||eradication-11/NN||the-10/DT	prep_to||related-8/VBN||eradication-11/NN	prep_of||eradication-11/NN||smallpox-13/NN	vmod||smallpox-13/NN||followed-14/VBN	det||cessation-17/NN||the-16/DT	agent||followed-14/VBN||cessation-17/NN	nn||immunization-20/NN||vaccinia-19/NN	prep_of||cessation-17/NN||immunization-20/NN	nsubj||undertook-23/VBD||we-22/PRP	root||ROOT-0/null||undertook-23/VBD	det||comparison-25/NN||a-24/DT	dobj||undertook-23/VBD||comparison-25/NN	amod||cells-34/NNS||hiv-1-27/JJ	amod||cells-34/NNS||susceptibility-28/JJ	det||mononuclear-33/NN||the-30/DT	amod||mononuclear-33/NN||peripheral-31/JJ	nn||mononuclear-33/NN||blood-32/NN	prep_in||susceptibility-28/JJ||mononuclear-33/NN	prep_of||comparison-25/NN||cells-34/NNS	prep_from||undertook-23/VBD||subjects-36/NNS	vmod||subjects-36/NNS||immunized-37/VBN	det||vacciniavirus-40/NNS||the-39/DT	prep_with||immunized-37/VBN||vacciniavirus-40/NNS	prep_to||immunized-37/VBN||those-42/DT	amod||naive-45/JJ||vaccinia-44/JJ	amod||donors-46/NNS||naive-45/JJ	prep_from||those-42/DT||donors-46/NNS	vaccinia-44||vacciniavirus-40||no||theorizing that this phenomenon may be somehow related to the eradication of smallpox followed by the cessation of vaccinia immunization, we undertook a comparison of hiv-1 susceptibility in the peripheral blood mononuclear cells from subjects immunized with the vacciniavirus to those from vaccinia naive donors.
amod||arthroplasty-4/NN||metal-on-metal-1/JJ	nn||arthroplasty-4/NN||hip-2/NN	amod||arthroplasty-4/NN||resurfacing-3/VBG	nsubj||offer-10/VB||arthroplasty-4/NN	nn||hra-7/NN||mom-6/NN	appos||arthroplasty-4/NN||hra-7/NN	aux||offer-10/VB||may-9/MD	root||ROOT-0/null||offer-10/VB	amod||advantages-12/NNS||potential-11/JJ	dobj||offer-10/VB||advantages-12/NNS	amod||arthroplasty-16/NN||total-14/JJ	nn||arthroplasty-16/NN||hip-15/NN	prep_over||offer-10/VB||arthroplasty-16/NN	appos||arthroplasty-16/NN||tha-18/NN	amod||patients-22/NNS||certain-21/JJ	prep_for||arthroplasty-16/NN||patients-22/NNS	amod||osteoarthritis-25/NNS||advanced-24/VBN	prep_with||offer-10/VB||osteoarthritis-25/NNS	det||hip-28/NN||the-27/DT	prep_of||osteoarthritis-25/NNS||hip-28/NN	metal--1||osteoarthritis-25||no_rel||metal-on-metal hip resurfacing arthroplasty (mom hra) may offer potential advantages over total hip arthroplasty (tha) for certain patients with advanced osteoarthritis of the hip.
nn||prevention-3/NN||stroke-2/NN	prep_for||associated-21/VBN||prevention-3/NN	prep_in||prevention-3/NN||patients-5/NNS	vmod||patients-5/NNS||suffering-6/VBG	prep_from||suffering-6/VBG||atrialfibrillation-8/NN	nsubjpass||associated-21/VBN||dabigatran-10/NN	vmod||dabigatran-10/NN||administered-11/VBN	det||dose-14/NN||a-13/DT	prep_at||administered-11/VBN||dose-14/NN	number||mg-17/CD||110-16/CD	prep_of||dose-14/NN||mg-17/CD	advmod||daily-19/JJ||twice-18/RB	advmod||mg-17/CD||daily-19/JJ	auxpass||associated-21/VBN||was-20/VBD	root||ROOT-0/null||associated-21/VBN	prep_with||associated-21/VBN||rates-23/NNS	prep_of||rates-23/NNS||stroke-25/NN	amod||embolism-28/NN||systemic-27/JJ	prep_with||associated-21/VBN||embolism-28/NN	conj_and||rates-23/NNS||embolism-28/NN	nsubj||similar-31/JJ||embolism-28/NN	cop||similar-31/JJ||were-30/VBD	rcmod||embolism-28/NN||similar-31/JJ	prep_to||similar-31/JJ||those-33/DT	vmod||those-33/DT||associated-34/VBN	prep_with||associated-34/VBN||warfarin-36/NN	amod||rates-42/NNS||lower-41/JJR	prep_with||associated-34/VBN||rates-42/NNS	conj_and||warfarin-36/NN||rates-42/NNS	prep_of||rates-42/NNS||hemorrhage-44/NN	stroke-25||warfarin-36||yes||for stroke prevention in patients suffering from atrialfibrillation, dabigatran administered at a dose of 110 mg twice daily was associated with rates of stroke and systemic embolism that were similar to those associated with warfarin, as well as lower rates of hemorrhage.
mark||indicated-2/VBD||while-1/IN	advcl||extends-20/VBZ||indicated-2/VBD	prep_for||indicated-2/VBD||schizophrenia-4/NN	amod||mania-7/NN||acute-6/JJ	prep_for||indicated-2/VBD||mania-7/NN	conj_and||schizophrenia-4/NN||mania-7/NN	amod||base-14/NN||ziprasidoneâ-9/JJ	amod||base-14/NN||$-10/$	dep||$-10/$||-11/JJ	nn||base-14/NN||s-12/NN	nn||base-14/NN||evidence-13/NN	nsubj||extends-20/VBZ||base-14/NN	conj_and||base-14/NN||use-16/NN	nsubj||extends-20/VBZ||use-16/NN	amod||practice-19/NN||clinical-18/JJ	prep_in||base-14/NN||practice-19/NN	root||ROOT-0/null||extends-20/VBZ	det||approvals-24/NNS||these-22/DT	amod||approvals-24/NNS||regulatory-23/JJ	prep_beyond||extends-20/VBZ||approvals-24/NNS	schizophrenia-4||ziprasidone--1||yes||while indicated for schizophrenia and acute mania, ziprasidoneâs evidence base and use in clinical practice extends beyond these regulatory approvals.
nsubjpass||used-5/VBN||arsenictrioxide-1/NN	aux||used-5/VBN||has-2/VBZ	auxpass||used-5/VBN||been-3/VBN	advmod||used-5/VBN||successfully-4/RB	root||ROOT-0/null||used-5/VBN	det||therapeutic-8/JJ||a-7/DT	prep_as||used-5/VBN||therapeutic-8/JJ	det||treatment-11/NN||the-10/DT	prep_in||therapeutic-8/JJ||treatment-11/NN	prep_of||treatment-11/NN||acutepromyelocyticleukemia-13/NN	appos||acutepromyelocyticleukemia-13/NN||apl-15/NN	acutepromyelocyticleukemia-13||arsenictrioxide-1||yes||arsenictrioxide has been successfully used as a therapeutic in the treatment of acutepromyelocyticleukemia (apl).
det||mechanism-2/NN||this-1/DT	nsubj||has-9/VBZ||mechanism-2/NN	mark||finds-6/VBZ||if-4/IN	nsubj||finds-6/VBZ||it-5/PRP	dep||mechanism-2/NN||finds-6/VBZ	dobj||finds-6/VBZ||support-7/NN	root||ROOT-0/null||has-9/VBZ	amod||implications-11/NNS||important-10/JJ	dobj||has-9/VBZ||implications-11/NNS	amod||research-14/NN||future-13/JJ	prep_for||implications-11/NNS||research-14/NN	det||hazard-18/NN||the-16/DT	nn||hazard-18/NN||mesothelioma-17/NN	prep_into||has-9/VBZ||hazard-18/NN	prep_into||has-9/VBZ||hazard-18/NN	conj_and||hazard-18/NN||hazard-18/NN	prep_from||hazard-18/NN||harn-20/NN	advmod||hazard-18/NN||also-22/RB	poss||view-26/NN||our-24/PRP$	amod||view-26/NN||current-25/JJ	prep_for||hazard-18/NN||view-26/NN	det||origins-29/NNS||the-28/DT	prep_of||view-26/NN||origins-29/NNS	amod||mesothelioma-33/NN||asbestos-initiated-31/JJ	amod||mesothelioma-33/NN||pleural-32/JJ	prep_of||origins-29/NNS||mesothelioma-33/NN	det||use-37/NN||the-35/DT	amod||use-37/NN||common-36/JJ	prep_of||view-26/NN||use-37/NN	conj_and||origins-29/NNS||use-37/NN	prep_of||use-37/NN||lung-39/NN	amod||burden-43/NN||parenchymal-40/JJ	nn||burden-43/NN||asbestos-41/NN	nn||burden-43/NN||fibre-42/NN	pobj||hazard-18/NN||burden-43/NN	det||correlate-46/NN||a-45/DT	prep_as||has-9/VBZ||correlate-46/NN	det||tumour-49/NN||this-48/DT	prep_of||correlate-46/NN||tumour-49/NN	nsubj||arises-53/VBZ||tumour-49/NN	advmod||arises-53/VBZ||actually-52/RB	rcmod||tumour-49/NN||arises-53/VBZ	det||pleura-57/NN||the-55/DT	amod||pleura-57/NN||parietal-56/JJ	prep_in||arises-53/VBZ||pleura-57/NN	mesothelioma-33||fibre-42||no_rel||this mechanism, if it finds support, has important implications for future research into the mesothelioma hazard from harn and also for our current view of the origins of asbestos-initiated pleural mesothelioma and the common use of lung parenchymal asbestos fibre burden as a correlate of this tumour, which actually arises in the parietal pleura.
nsubj||one-3/CD||gonorrhoea-1/NN	cop||one-3/CD||is-2/VBZ	root||ROOT-0/null||one-3/CD	det||sexuallytransmittedinfections-8/NNS||the-5/DT	advmod||common-7/JJ||most-6/RBS	amod||sexuallytransmittedinfections-8/NNS||common-7/JJ	prep_of||one-3/CD||sexuallytransmittedinfections-8/NNS	appos||sexuallytransmittedinfections-8/NNS||stis-10/NNS	amod||countries-14/NNS||developing-13/VBG	prep_in||one-3/CD||countries-14/NNS	det||emergence-18/NN||the-17/DT	nsubj||obstacle-29/NN||emergence-18/NN	prep_of||emergence-18/NN||resistance-20/NN	amod||agents-23/NNS||antimicrobial-22/JJ	prep_to||resistance-20/NN||agents-23/NNS	prep_in||agents-23/NNS||neisseriagonorrhoeae-25/NN	cop||obstacle-29/NN||is-26/VBZ	det||obstacle-29/NN||a-27/DT	amod||obstacle-29/NN||major-28/JJ	conj_and||one-3/CD||obstacle-29/NN	det||control-32/NN||the-31/DT	prep_in||obstacle-29/NN||control-32/NN	prep_of||control-32/NN||gonorrhoea-34/NN	gonorrhoea-34||neisseriagonorrhoeae-25||no||gonorrhoea is one of the most common sexuallytransmittedinfections (stis) in developing countries, and the emergence of resistance to antimicrobial agents in neisseriagonorrhoeae is a major obstacle in the control of gonorrhoea.
det||gene-3/NN||the-1/DT	amod||gene-3/NN||p32-2/JJ	nsubj||identical-11/JJ||gene-3/NN	det||strain-9/NN||the-5/DT	num||strain-9/NN||2008-6/CD	nn||strain-9/NN||mongolian-7/NN	nn||strain-9/NN||goatpoxvirus-8/NNS	prep_of||gene-3/NN||strain-9/NN	cop||identical-11/JJ||was-10/VBD	root||ROOT-0/null||identical-11/JJ	det||gene-14/NN||the-13/DT	prep_to||identical-11/JJ||gene-14/NN	prep_from||identical-11/JJ||virus-16/NN	vmod||virus-16/NN||isolated-17/VBN	amod||outbreaks-21/NNS||recent-19/JJ	nn||outbreaks-21/NNS||goatpox-20/NN	prep_from||isolated-17/VBN||outbreaks-21/NNS	prep_in||outbreaks-21/NNS||china-23/NN	prep_in||outbreaks-21/NNS||vietnam-25/NN	conj_and||china-23/NN||vietnam-25/NN	goatpox-20||goatpoxvirus-8||no||the p32 gene of the 2008 mongolian goatpoxvirus strain was identical to the gene from virus isolated from recent goatpox outbreaks in china and vietnam.
nn||guidelines-2/NNS||hypertension-1/NN	nsubj||recommend-3/VBP||guidelines-2/NNS	root||ROOT-0/null||recommend-3/VBP	det||use-5/NN||the-4/DT	dobj||recommend-3/VBP||use-5/NN	prep_of||use-5/NN||thiazidediuretics-7/NNS	amod||therapy-10/NN||first-line-9/JJ	prep_as||thiazidediuretics-7/NNS||therapy-10/NN	amod||hypertension-13/NN||uncomplicated-12/JJ	prep_for||therapy-10/NN||hypertension-13/NN	nsubj||under-prescribed-18/JJ||diuretics-16/NNS	cop||under-prescribed-18/JJ||are-17/VBP	conj_yet||recommend-3/VBP||under-prescribed-18/JJ	nsubj||treated-25/JJ||hypertension-21/NN	cop||treated-25/JJ||is-22/VBZ	advmod||treated-25/JJ||frequently-23/RB	advmod||treated-25/JJ||inadequately-24/RB	conj_yet||recommend-3/VBP||treated-25/JJ	conj_and||under-prescribed-18/JJ||treated-25/JJ	hypertension-21||diuretics-16||no_rel||hypertension guidelines recommend the use of thiazidediuretics as first-line therapy for uncomplicated hypertension, yet diuretics are under-prescribed, and hypertension is frequently inadequately treated.
prepc_depending_on||achieved-52/VBD||on-2/IN	det||moiety-5/NN||the-3/DT	amod||moiety-5/NN||linking-4/JJ	pobj||achieved-52/VBD||moiety-5/NN	amod||conjugates-8/NNS||multivalent-7/JJ	nsubj||achieved-52/VBD||conjugates-8/NNS	det||adac-16/NN||the-10/DT	advmod||6-chain-12/JJ||n-11/RB	amod||adac-16/NN||6-chain-12/JJ	amod||adac-16/NN||elongated-13/JJ	nn||adac-16/NN||functionalized-14/NN	nn||adac-16/NN||congener-15/NN	prep_of||conjugates-8/NNS||adac-16/NN	dep||adac-16/NN||n-18/NN	num||n-18/NN||6-19/CD	dep||n-18/NN||-LSB--21/NNP	num||-LSB--21/NNP||4-22/CD	nn||-LSB--25/NNP||-LSB--24/NNP	dep||-LSB--21/NNP||-LSB--25/NNP	number||4-27/CD||-LSB--26/CD	amod||adenosine-50/NN||4-27/CD	nn||-LSB--31/NNP||-LSB--29/NNP	nn||-LSB--31/NNP||-LSB--30/NNP	dep||-RSB--48/NNP||-LSB--31/NNP	dep||-LSB--31/NNP||2-aminoethyl-33/JJ	amod||-RSB--48/NNP||amino-35/JJ	nn||-RSB--48/NNP||-RSB--36/NN	amod||-RSB--48/NNP||carbonyl-37/JJ	amod||-RSB--48/NNP||-RSB--38/JJ	nn||-RSB--48/NNP||methyl-39/NN	amod||-RSB--48/NNP||-RSB--40/JJ	amod||-RSB--48/NNP||anilino-41/JJ	nn||-RSB--48/NNP||-RSB--42/NN	amod||-RSB--48/NNP||carbonyl-43/JJ	amod||-RSB--48/NNP||-RSB--44/JJ	nn||-RSB--48/NNP||methyl-45/NN	nn||-RSB--48/NNP||-RSB--46/NNP	nn||-RSB--48/NNP||phenyl-47/NNP	dep||4-27/CD||-RSB--48/NNP	dep||-LSB--25/NNP||adenosine-50/NN	root||ROOT-0/null||achieved-52/VBD	amod||selectivity-55/NN||unanticipated-53/JJ	amod||selectivity-55/NN||high-54/JJ	dobj||achieved-52/VBD||selectivity-55/NN	amod||gpcr-68/NN||binding-57/JJ	det||ar-63/NN||the-59/DT	amod||ar-63/NN||cytoprotective-60/JJ	amod||ar-63/NN||human-61/JJ	amod||ar-63/NN||a3-62/JJ	prep_to||binding-57/JJ||ar-63/NN	det||class-66/NN||a-65/DT	appos||ar-63/NN||class-66/NN	det||gpcr-68/NN||a-67/DT	prep_in||achieved-52/VBD||gpcr-68/NN	adenosine-50||ar-63||no_rel||depending on the linking moiety, multivalent conjugates of the n 6-chain elongated functionalized congener adac ( n 6-[4-[[[4-[[[(2-aminoethyl)amino]carbonyl]methyl]anilino]carbonyl]methyl]phenyl]-adenosine) achieved unanticipated high selectivity in binding to the cytoprotective human a3 ar, a class a gpcr.
det||etiology-3/NN||the-1/DT	amod||etiology-3/NN||exact-2/JJ	nsubj||unknown-8/JJ||etiology-3/NN	nsubj||pneumocephalus-13/JJ||etiology-3/NN	nsubj||subsequent-16/JJ||etiology-3/NN	nsubj||cerebrospinalfluidleakage-18/VB||etiology-3/NN	det||event-6/NN||the-5/DT	prep_of||etiology-3/NN||event-6/NN	cop||unknown-8/JJ||is-7/VBZ	root||ROOT-0/null||unknown-8/JJ	dep||material-11/NN||anesthetic-10/JJ	conj_but||unknown-8/JJ||material-11/NN	conj_but||unknown-8/JJ||pneumocephalus-13/JJ	amod||subsequent-16/JJ||intracranialhypotension-15/JJ	conj_but||unknown-8/JJ||subsequent-16/JJ	aux||cerebrospinalfluidleakage-18/VB||to-17/TO	xcomp||unknown-8/JJ||cerebrospinalfluidleakage-18/VB	mark||considered-35/VBN||after-19/IN	amod||procedures-21/NNS||spinal-20/JJ	nsubjpass||considered-35/VBN||procedures-21/NNS	amod||seizure-24/NN||spinal-induced-23/JJ	conj_and||procedures-21/NNS||seizure-24/NN	nsubjpass||considered-35/VBN||seizure-24/NN	det||effect-29/NN||the-26/DT	amod||effect-29/NN||potential-27/JJ	amod||effect-29/NN||toxic-28/JJ	conj_and||procedures-21/NNS||effect-29/NN	nsubjpass||considered-35/VBN||effect-29/NN	amod||molecules-32/NNS||fat-31/JJ	prep_of||effect-29/NN||molecules-32/NNS	aux||considered-35/VBN||could-33/MD	auxpass||considered-35/VBN||be-34/VB	advcl||cerebrospinalfluidleakage-18/VB||considered-35/VBN	intracranialhypotension-15||cerebrospinalfluidleakage-18||no||the exact etiology of the event is unknown but anesthetic material, pneumocephalus, intracranialhypotension subsequent to cerebrospinalfluidleakage after spinal procedures, spinal-induced seizure and the potential toxic effect of fat molecules could be considered.
nsubj||includes-13/VBZ||hypersensitivity-1/NN	nsubjpass||known-25/VBN||hypersensitivity-1/NN	nsubj||play-27/VB||hypersensitivity-1/NN	det||esophagus-4/NNS||the-3/DT	prep_of||hypersensitivity-1/NN||esophagus-4/NNS	prep_like||includes-13/VBZ||that-7/DT	amod||organs-11/NNS||other-9/JJ	amod||organs-11/NNS||visceral-10/JJ	prep_of||that-7/DT||organs-11/NNS	root||ROOT-0/null||includes-13/VBZ	dobj||includes-13/VBZ||peripheral-14/JJ	dobj||includes-13/VBZ||central-16/JJ	conj_and||peripheral-14/JJ||central-16/JJ	advmod||hypersensitivity-21/NN||probably-18/RB	amod||hypersensitivity-21/NN||psychosocial-19/JJ	amod||hypersensitivity-21/NN||factor-mediated-20/JJ	dobj||includes-13/VBZ||hypersensitivity-21/NN	conj_and||peripheral-14/JJ||hypersensitivity-21/NN	auxpass||known-25/VBN||is-24/VBZ	conj_and||includes-13/VBZ||known-25/VBN	aux||play-27/VB||to-26/TO	xcomp||known-25/VBN||play-27/VB	amod||roles-29/NNS||crucial-28/JJ	dobj||play-27/VB||roles-29/NNS	det||pathoegenesis-32/NNS||the-31/DT	prep_in||play-27/VB||pathoegenesis-32/NNS	amod||disease-36/NN||nonerosive-34/JJ	nn||disease-36/NN||reflux-35/NN	prep_of||pathoegenesis-32/NNS||disease-36/NN	amod||heartburn-39/NN||functional-38/JJ	prep_of||pathoegenesis-32/NNS||heartburn-39/NN	conj_and||disease-36/NN||heartburn-39/NN	amod||pain-43/NN||non-cardiac-41/JJ	nn||pain-43/NN||chest-42/NN	prep_of||pathoegenesis-32/NNS||pain-43/NN	conj_and||disease-36/NN||pain-43/NN	hypersensitivity-21||hypersensitivity-21||no||hypersensitivity of the esophagus, like that of other visceral organs, includes peripheral, central and probably psychosocial factor-mediated hypersensitivity, and is known to play crucial roles in the pathoegenesis of nonerosive reflux disease, functional heartburn and non-cardiac chest pain.
nsubj||disease-9/NN||celiacdisease-1/NN	appos||celiacdisease-1/NN||cd-3/NN	cop||disease-9/NN||is-5/VBZ	det||disease-9/NN||a-6/DT	amod||disease-9/NN||common-7/JJ	amod||disease-9/NN||systemic-8/JJ	root||ROOT-0/null||disease-9/NN	dep||disease-9/NN||related-10/VBN	det||intolerance-14/NN||a-12/DT	amod||intolerance-14/NN||permanent-13/JJ	prep_to||related-10/VBN||intolerance-14/NN	prep_to||related-10/VBN||gluten-16/NN	auxpass||associated-20/VBN||is-18/VBZ	advmod||associated-20/VBN||often-19/RB	dep||disease-9/NN||associated-20/VBN	conj_and||related-10/VBN||associated-20/VBN	amod||autoimmune-23/JJ||different-22/JJ	prep_with||associated-20/VBN||autoimmune-23/JJ	amod||diseases-26/NNS||neurological-25/JJ	prep_with||associated-20/VBN||diseases-26/NNS	conj_and||autoimmune-23/JJ||diseases-26/NNS	celiacdisease-1||gluten-16||no||celiacdisease (cd) is a common systemic disease related to a permanent intolerance to gluten and is often associated with different autoimmune and neurological diseases.
det||study-3/NN||the-1/DT	nn||study-3/NN||action-2/NN	nsubj||trial-23/NN||study-3/NN	nn||hyperactivitydisorder-7/NN||attention-5/NN	nn||hyperactivitydisorder-7/NN||deficit-6/NN	dep||study-3/NN||hyperactivitydisorder-7/NN	vmod||hyperactivitydisorder-7/NN||controlled-8/VBN	nn||investigation-10/NN||trial-9/NN	dobj||controlled-8/VBN||investigation-10/NN	det||non-stimulant-13/NN||a-12/DT	prep_of||investigation-10/NN||non-stimulant-13/NN	cop||trial-23/NN||is-15/VBZ	det||trial-23/NN||a-16/DT	amod||trial-23/NN||multi-center-17/JJ	amod||trial-23/NN||double-blind-19/JJ	amod||trial-23/NN||randomized-21/JJ	amod||trial-23/NN||cross-over-22/JJ	root||ROOT-0/null||trial-23/NN	det||medication-27/NN||the-25/DT	amod||medication-27/NN||non-stimulant-26/JJ	prep_of||trial-23/NN||medication-27/NN	appos||medication-27/NN||atomoxetine-29/NN	prep_in||medication-27/NN||children-32/NNS	prep_in||medication-27/NN||adolescents-34/NNS	conj_and||children-32/NNS||adolescents-34/NNS	nn||hyperactivitydisorder-38/NN||attention-36/NN	nn||hyperactivitydisorder-38/NN||deficit-37/NN	prep_with||children-32/NNS||hyperactivitydisorder-38/NN	dep||medication-27/NN||adhd-40/VBN	adhd-40||atomoxetine-29||yes||the action study ( attention deficit hyperactivitydisorder controlled trial investigation of a non-stimulant) is a multi-center, double-blind, randomized cross-over trial of the non-stimulant medication, atomoxetine, in children and adolescents with attention deficit hyperactivitydisorder (adhd).
det||group-3/NN||the-1/DT	nn||group-3/NN||ds-2/NN	nsubj||had-4/VBD||group-3/NN	nsubj||had-35/VBD||group-3/NN	nsubj||required-67/VBD||group-3/NN	root||ROOT-0/null||had-4/VBD	det||rate-8/NN||a-5/DT	advmod||higher-7/JJR||significantly-6/RB	amod||rate-8/NN||higher-7/JJR	dobj||had-4/VBD||rate-8/NN	amod||remission-11/NN||complete-10/JJ	prep_of||rate-8/NN||remission-11/NN	prep_of||remission-11/NN||ponv-13/NNP	det||groups-19/NNS||the-15/DT	nn||groups-19/NNS||d-16/SYM	conj_and||d-16/SYM||dr-18/JJ	nn||groups-19/NNS||dr-18/JJ	prep_than||had-4/VBD||groups-19/NNS	num||%-22/NN||82.5-21/CD	dep||groups-19/NNS||%-22/NN	number||47.5-24/CD||vs-23/CD	num||%-25/NN||47.5-24/CD	dep||%-22/NN||%-25/NN	num||%-29/NN||50.0-28/CD	dep||groups-19/NNS||%-29/NN	conj_and||%-22/NN||%-29/NN	advmod||%-22/NN||respectively-31/RB	conj_and||had-4/VBD||had-35/VBD	amod||rates-37/NNS||lower-36/JJR	dobj||had-35/VBD||rates-37/NNS	prep_of||rates-37/NNS||nausea-39/NN	num||%-42/NN||17.5-41/CD	dep||rates-37/NNS||%-42/NN	vmod||%-42/NN||vs-43/VBN	num||%-45/NN||55.0-44/CD	dobj||vs-43/VBN||%-45/NN	num||%-49/NN||50.0-48/CD	dobj||vs-43/VBN||%-49/NN	conj_and||%-45/NN||%-49/NN	dobj||had-35/VBD||vomiting-53/VBG	conj_and||rates-37/NNS||vomiting-53/VBG	num||vs-57/NN||10.0-55/CD	nn||vs-57/NN||%-56/NN	dep||vomiting-53/VBG||vs-57/NN	num||%-59/NN||50.0-58/CD	dep||vs-57/NN||%-59/NN	num||%-63/NN||25.0-62/CD	dep||vomiting-53/VBG||%-63/NN	conj_and||vs-57/NN||%-63/NN	conj_and||had-4/VBD||required-67/VBD	amod||antiemetics-69/NNS||less-68/JJR	dobj||required-67/VBD||antiemetics-69/NNS	num||%-72/NN||5.0-71/CD	dep||antiemetics-69/NNS||%-72/NN	num||%-75/NN||vs-73/CD	num||%-75/NN||35.0-74/CD	dep||%-72/NN||%-75/NN	num||%-78/NN||22.5-77/CD	appos||%-75/NN||%-78/NN	nn||d-82/NN||group-81/NN	prep_than||required-67/VBD||d-82/NN	nn||dr-85/NN||group-84/NN	prep_than||required-67/VBD||dr-85/NN	conj_and||d-82/NN||dr-85/NN	det||hours-90/NNS||the-87/DT	amod||hours-90/NNS||first-88/JJ	num||hours-90/NNS||24-89/CD	prep_during||d-82/NN||hours-90/NNS	prep_after||required-67/VBD||surgery-92/NN	nausea-39||ds-2||no||the ds group had a significantly higher rate of complete remission of ponv than the d and dr groups (82.5% vs 47.5%, and 50.0%, respectively), and had lower rates of nausea (17.5% vs 55.0%, and 50.0%), and vomiting (10.0% vs 50.0%, and 25.0%), and required less antiemetics (5.0% vs 35.0%, 22.5%) than group d and group dr during the first 24 hours after surgery.
poss||study-2/NN||our-1/PRP$	nsubj||uncovers-4/VBZ||study-2/NN	advmod||uncovers-4/VBZ||thus-3/RB	root||ROOT-0/null||uncovers-4/VBZ	det||mechanism-6/NN||a-5/DT	dobj||uncovers-4/VBZ||mechanism-6/NN	prep_by||affect-12/VBP||mechanism-6/NN	det||pufas-11/NNS||these-9/DT	amod||pufas-11/NNS||18-carbon-10/JJ	nsubj||affect-12/VBP||pufas-11/NNS	rcmod||mechanism-6/NN||affect-12/VBP	amod||function-16/NN||basal-13/JJ	amod||function-16/NN||innate-14/JJ	amod||function-16/NN||immune-15/JJ	dobj||affect-12/VBP||function-16/NN	dep||function-16/NN||consequently-19/RB	det||ability-22/NN||the-21/DT	dobj||affect-12/VBP||ability-22/NN	conj_and||function-16/NN||ability-22/NN	det||organism-25/NN||an-24/DT	prep_of||ability-22/NN||organism-25/NN	aux||defend-27/VB||to-26/TO	vmod||organism-25/NN||defend-27/VB	dobj||defend-27/VB||itself-28/PRP	prep_against||defend-27/VB||bacterialinfections-30/NNS	carbon--1||bacterialinfections-30||no_rel||our study thus uncovers a mechanism by which these 18-carbon pufas affect basal innate immune function and, consequently, the ability of an organism to defend itself against bacterialinfections.
nsubj||serious-5/JJ||diabeticnephropathy-1/NN	cop||serious-5/JJ||is-2/VBZ	det||serious-5/JJ||the-3/DT	advmod||serious-5/JJ||most-4/RBS	root||ROOT-0/null||serious-5/JJ	prep_of||serious-5/JJ||complications-7/NNS	prep_in||complications-7/NNS||diabetesmellitus-9/NNS	diabeticnephropathy-1||diabetesmellitus-9||no||diabeticnephropathy is the most serious of complications in diabetesmellitus.
advmod||poses-26/VBZ||yet-1/RB	det||persistence-4/NN||the-3/DT	nsubj||poses-26/VBZ||persistence-4/NN	amod||poliovirus-7/NNS||wild-6/JJ	prep_of||persistence-4/NN||poliovirus-7/NNS	det||countriesâ-13/NNS||the-9/DT	num||countriesâ-13/NNS||4-10/CD	amod||countriesâ-13/NNS||remaining-11/VBG	amod||countriesâ-13/NNS||polio-endemic-12/JJ	nsubj||$-14/VBG||countriesâ-13/NNS	prepc_in||poliovirus-7/NNS||$-14/VBG	dobj||$-14/VBG||afghanistan-16/NN	dobj||$-14/VBG||india-18/NN	conj_and||afghanistan-16/NN||india-18/NN	dobj||$-14/VBG||nigeria-20/NN	conj_and||afghanistan-16/NN||nigeria-20/NN	nn||$-24/NNP||pakistanâ-23/NNP	dobj||$-14/VBG||$-24/NNP	conj_and||afghanistan-16/NN||$-24/NNP	root||ROOT-0/null||poses-26/VBZ	det||risk-28/NN||a-27/DT	dobj||poses-26/VBZ||risk-28/NN	poss||importation-31/NN||its-30/PRP$	prep_for||risk-28/NN||importation-31/NN	det||countries-34/NNS||all-33/DT	prep_into||poses-26/VBZ||countries-34/NNS	vmod||countries-34/NNS||declared-35/VBN	nsubj||free-37/JJ||polio-36/NNP	xcomp||declared-35/VBN||free-37/JJ	polio-36||poliovirus-7||no||yet, the persistence of wild poliovirus in the 4 remaining polio-endemic countriesâafghanistan, india, nigeria, and pakistanâposes a risk for its importation into all countries declared polio free.
poss||nanoparticles-5/NNS||ironâ-1/NNP	nn||nanoparticles-5/NNS||platinum-3/NN	nn||nanoparticles-5/NNS||alloy-4/NN	nsubj||candidates-13/NNS||nanoparticles-5/NNS	amod||nps-8/NN||fept-7/JJ	appos||nanoparticles-5/NNS||nps-8/NN	cop||candidates-13/NNS||are-10/VBP	advmod||promising-12/JJ||extremely-11/RB	amod||candidates-13/NNS||promising-12/JJ	root||ROOT-0/null||candidates-13/NNS	det||generation-17/NN||the-15/DT	amod||generation-17/NN||next-16/JJ	prep_for||candidates-13/NNS||generation-17/NN	nn||agents-20/NNS||contrast-19/NN	prep_of||generation-17/NN||agents-20/NNS	amod||imaging-28/NN||magnetic-22/JJ	nn||imaging-28/NN||resonance-23/NN	nn||imaging-28/NN||mr-25/NN	amod||imaging-28/NN||diagnostic-27/JJ	prep_for||candidates-13/NNS||imaging-28/NN	amod||interventions-31/NNS||mr-guided-30/JJ	prep_for||candidates-13/NNS||interventions-31/NNS	conj_and||imaging-28/NN||interventions-31/NNS	amod||ablation-35/NN||hyperthermic-34/JJ	prep_including||candidates-13/NNS||ablation-35/NN	amod||cancers-38/NNS||solid-37/JJ	prep_of||ablation-35/NN||cancers-38/NNS	iron--1||cancers-38||no_rel||ironâplatinum alloy nanoparticles (fept nps) are extremely promising candidates for the next generation of contrast agents for magnetic resonance (mr) diagnostic imaging and mr-guided interventions, including hyperthermic ablation of solid cancers.
root||ROOT-0/null||delayed-1/VBN	nn||results-4/NNS||insulin-2/NN	nn||results-4/NNS||secretion-3/NN	dobj||delayed-1/VBN||results-4/NNS	amod||concentrations-9/NNS||higher-6/JJR	nn||concentrations-9/NNS||peak-7/NN	nn||concentrations-9/NNS||glucose-8/NN	prep_in||results-4/NNS||concentrations-9/NNS	advmod||delayed-1/VBN||particularly-10/RB	advmod||impaired-16/JJ||when-11/WRB	nsubj||impaired-16/JJ||suppression-12/NN	prep_of||suppression-12/NN||glucagon-14/NN	cop||impaired-16/JJ||is-15/VBZ	advcl||delayed-1/VBN||impaired-16/JJ	mark||insulinresistance-19/JJ||whereas-18/IN	advcl||impaired-16/JJ||insulinresistance-19/JJ	dep||delayed-1/VBN||prolongs-20/VBZ	det||duration-22/NN||the-21/DT	nsubj||delayed-1/VBN||duration-22/NN	nsubjpass||marked-29/VBN||duration-22/NN	prep_of||duration-22/NN||hyperglycemia-24/NN	aux||marked-29/VBN||can-27/MD	auxpass||marked-29/VBN||be-28/VB	rcmod||duration-22/NN||marked-29/VBN	advmod||present-37/JJ||when-30/WRB	det||insulinresistance-35/NN||both-31/DT	amod||insulinresistance-35/NN||hepatic-32/JJ	conj_and||hepatic-32/JJ||extra-hepatic-34/JJ	amod||insulinresistance-35/NN||extra-hepatic-34/JJ	nsubj||present-37/JJ||insulinresistance-35/NN	cop||present-37/JJ||are-36/VBP	advcl||marked-29/VBN||present-37/JJ	glucose-8||insulinresistance-35||no_rel||delayed insulin secretion results in higher peak glucose concentrations particularly when suppression of glucagon is impaired, whereas insulinresistance prolongs the duration of hyperglycemia, which can be marked when both hepatic and extra-hepatic insulinresistance are present.
nsubj||applied-2/VBD||we-1/PRP	root||ROOT-0/null||applied-2/VBD	amod||principles-5/NNS||fuzzy-3/JJ	nn||principles-5/NNS||logic-4/NN	dobj||applied-2/VBD||principles-5/NNS	aux||modify-7/VB||to-6/TO	vmod||applied-2/VBD||modify-7/VB	amod||rates-14/NNS||intravenous-8/JJ	amod||rates-14/NNS||norepinephrine-9/JJ	appos||rates-14/NNS||noradrenaline-11/NN	nn||rates-14/NNS||infusion-13/NN	dobj||modify-7/VB||rates-14/NNS	amod||infusion-17/NN||norepinephrine-16/JJ	prep_during||rates-14/NNS||infusion-17/NN	amod||patients-20/NNS||septic-19/JJ	prep_in||modify-7/VB||patients-20/NNS	mark||reduce-24/VB||in-21/IN	dep||reduce-24/VB||order-22/NN	aux||reduce-24/VB||to-23/TO	advcl||modify-7/VB||reduce-24/VB	det||duration-26/NN||the-25/DT	dobj||reduce-24/VB||duration-26/NN	prep_of||duration-26/NN||shock-28/NN	shock-28||norepinephrine-16||yes||we applied fuzzy logic principles to modify intravenous norepinephrine (noradrenaline) infusion rates during norepinephrine infusion in septic patients in order to reduce the duration of shock.
det||island-2/NN||the-1/DT	nsubj||site-12/NN||island-2/NN	poss||vineyard-6/NN||martha-4/NNP	prep_of||island-2/NN||vineyard-6/NN	appos||island-2/NN||massachusetts-8/NNS	cop||site-12/NN||is-10/VBZ	det||site-12/NN||the-11/DT	root||ROOT-0/null||site-12/NN	det||outbreak-16/NN||a-14/DT	amod||outbreak-16/NN||sustained-15/VBN	prep_of||site-12/NN||outbreak-16/NN	amod||tularensis-22/NNS||tularemia-18/JJ	prep_due_to||tularensis-22/NNS||francisellatularensis-21/NNS	prep_of||outbreak-16/NN||tularensis-22/NNS	tularemia-18||francisellatularensis-21||no||the island of martha's vineyard, massachusetts, is the site of a sustained outbreak of tularemia due to francisellatularensis tularensis .
det||setting-3/NN||the-2/DT	prep_in||contribute-43/VB||setting-3/NN	nn||injury-6/NN||tissue-5/NN	prep_of||setting-3/NN||injury-6/NN	advmod||damaged-13/JJ||whereby-8/WRB	det||liver-10/NN||the-9/DT	nsubj||damaged-13/JJ||liver-10/NN	cop||damaged-13/JJ||is-11/VBZ	advmod||damaged-13/JJ||otherwise-12/RB	advcl||contribute-43/VB||damaged-13/JJ	dep||damaged-13/JJ||e.g.-15/NNP	appos||e.g.-15/NNP||viralinfection-17/NN	nn||exposure-20/NN||toxin-19/NN	appos||e.g.-15/NNP||exposure-20/NN	amod||damage-24/NN||ischemic-22/JJ	nn||damage-24/NN||tissue-23/NN	appos||e.g.-15/NNP||damage-24/NN	dep||e.g.-15/NNP||etc.-26/FW	det||populations-33/NNS||these-29/DT	amod||populations-33/NNS||same-30/JJ	amod||populations-33/NNS||immune-31/JJ	nn||populations-33/NNS||cell-32/NN	nsubj||contribute-43/VB||populations-33/NNS	nsubj||promote-46/VB||populations-33/NNS	poss||interactions-36/NNS||their-35/PRP$	conj_and||populations-33/NNS||interactions-36/NNS	nsubj||contribute-43/VB||interactions-36/NNS	det||bacteria-41/NNS||the-38/DT	amod||bacteria-41/NNS||infiltrating-39/JJ	nn||bacteria-41/NNS||gut-40/NN	prep_with||interactions-36/NNS||bacteria-41/NNS	advmod||contribute-43/VB||likely-42/RB	root||ROOT-0/null||contribute-43/VB	prep||contribute-43/VB||to-44/TO	conj_and||contribute-43/VB||promote-46/VB	det||pathologies-48/NNS||these-47/DT	dobj||promote-46/VB||pathologies-48/NNS	toxin-19||viralinfection-17||no_rel||in the setting of tissue injury, whereby the liver is otherwise damaged (e.g., viralinfection, toxin exposure, ischemic tissue damage, etc.), these same immune cell populations and their interactions with the infiltrating gut bacteria likely contribute to and promote these pathologies.
amod||patients-3/NNS||chinese-2/JJ	prep_in||predicts-8/VBZ||patients-3/NNS	prep_with||patients-3/NNS||type2diabetes-5/CD	nsubj||predicts-8/VBZ||hyperglycemia-7/NN	root||ROOT-0/null||predicts-8/VBZ	dobj||predicts-8/VBZ||cancer-9/NN	mark||associated-15/VBN||whereas-11/IN	nn||usage-13/NN||insulin-12/NN	nsubjpass||associated-15/VBN||usage-13/NN	auxpass||associated-15/VBN||was-14/VBD	advcl||predicts-8/VBZ||associated-15/VBN	det||risk-20/NN||a-17/DT	amod||risk-20/NN||reduced-18/VBN	nn||risk-20/NN||cancer-19/NN	prep_with||associated-15/VBN||risk-20/NN	cancer-19||insulin-12||no_rel||in chinese patients with type2diabetes, hyperglycemia predicts cancer, whereas insulin usage was associated with a reduced cancer risk.
nsubjpass||cured-9/VBN||patients-1/NNS	amod||tumors-6/NNS||advanced-3/JJ	nn||tumors-6/NNS||germ-4/NN	nn||tumors-6/NNS||cell-5/NN	prep_with||patients-1/NNS||tumors-6/NNS	aux||cured-9/VBN||can-7/MD	auxpass||cured-9/VBN||be-8/VB	root||ROOT-0/null||cured-9/VBN	amod||chemotherapy-12/NN||cisplatin-based-11/JJ	prep_with||cured-9/VBN||chemotherapy-12/NN	det||outcome-16/NN||the-15/DT	nsubj||remains-17/VBZ||outcome-16/NN	conj_but||cured-9/VBN||remains-17/VBZ	advmod||remains-17/VBZ||unsatisfactory-18/RB	prep_for||remains-17/VBZ||patients-20/NNS	prep_with||patients-20/NNS||relapseddisease-22/NN	det||patients-26/NNS||those-25/DT	prep_including||patients-20/NNS||patients-26/NNS	amod||disease-29/NN||refractory-28/JJ	prep_with||patients-26/NNS||disease-29/NN	nn||transplantation-33/NN||bone-31/NN	nn||transplantation-33/NN||marrow-32/NN	prep_after||disease-29/NN||transplantation-33/NN	tumors-6||cisplatin--1||no_rel||patients with advanced germ cell tumors can be cured with cisplatin-based chemotherapy, but the outcome remains unsatisfactory for patients with relapseddisease, including those patients with refractory disease after bone marrow transplantation.
det||models-4/NNS||both-2/DT	nn||models-4/NNS||mouse-3/NN	nsubj||exhibiting-5/VBG||models-4/NNS	prepc_despite||are-24/VBP||exhibiting-5/VBG	amod||influx-9/NN||increased-6/VBN	amod||influx-9/NN||in-vivo-7/JJ	nn||influx-9/NN||calcium-8/NN	dobj||exhibiting-5/VBG||influx-9/NN	det||stage-13/NN||an-11/DT	amod||stage-13/NN||early-12/JJ	prep_at||exhibiting-5/VBG||stage-13/NN	det||development-16/NN||the-15/DT	prep_in||stage-13/NN||development-16/NN	det||cardiomyopathy-19/NN||the-18/DT	prep_of||development-16/NN||cardiomyopathy-19/NN	prep_before||exhibiting-5/VBG||leftventricularhypertrophy-21/NN	expl||are-24/VBP||there-23/EX	root||ROOT-0/null||are-24/VBP	amod||differences-27/NNS||distinct-25/JJ	amod||differences-27/NNS||phenotypical-26/JJ	nsubj||are-24/VBP||differences-27/NNS	det||models-31/NNS||the-29/DT	num||models-31/NNS||2-30/CD	prep_between||differences-27/NNS||models-31/NNS	prep_in||models-31/NNS||terms-33/NNS	nn||rates-36/NNS||heart-35/NN	prep_of||terms-33/NNS||rates-36/NNS	prep_of||terms-33/NNS||hemodynamics-38/NNS	conj_and||rates-36/NNS||hemodynamics-38/NNS	prep_of||terms-33/NNS||responses-40/NNS	conj_and||rates-36/NNS||responses-40/NNS	nn||inhibitors-44/NNS||calcium-42/NN	nn||inhibitors-44/NNS||channel-43/NN	prep_to||rates-36/NNS||inhibitors-44/NNS	calcium-42||leftventricularhypertrophy-21||no_rel||despite both mouse models exhibiting increased in-vivo calcium influx at an early stage in the development of the cardiomyopathy before leftventricularhypertrophy, there are distinct phenotypical differences between the 2 models in terms of heart rates, hemodynamics and responses to calcium channel inhibitors.
amod||inactivation-4/NN||tam-mediated-1/JJ	amod||inactivation-4/NN||beta-2/JJ	amod||inactivation-4/NN||cell-specific-3/JJ	nsubj||downregulates-10/VBZ||inactivation-4/NN	nsubj||enhanced-19/VBD||inactivation-4/NN	prep_of||inactivation-4/NN||glis3-6/NNS	amod||mice-9/NNS||adult-8/JJ	prep_in||glis3-6/NNS||mice-9/NNS	root||ROOT-0/null||downregulates-10/VBZ	nn||expression-12/NN||insulin-11/NN	dobj||downregulates-10/VBZ||expression-12/NN	appos||expression-12/NN||leading-14/VBG	prep_to||leading-14/VBG||hyperglycaemia-16/NN	advmod||enhanced-19/VBD||subsequently-18/RB	conj_and||downregulates-10/VBZ||enhanced-19/VBD	amod||apoptosis-22/NNS||beta-20/JJ	nn||apoptosis-22/NNS||cell-21/NN	dobj||enhanced-19/VBD||apoptosis-22/NNS	hyperglycaemia-16||insulin-11||yes||tam-mediated beta cell-specific inactivation of glis3 in adult mice downregulates insulin expression, leading to hyperglycaemia and subsequently enhanced beta cell apoptosis.
amod||analyses-5/NNS||classical-1/JJ	conj_and||classical-1/JJ||quantitative-3/JJ	amod||analyses-5/NNS||quantitative-3/JJ	nn||analyses-5/NNS||linkage-4/NN	nsubjpass||used-12/VBN||analyses-5/NNS	amod||crosses-8/NNS||genetic-7/JJ	prep_of||analyses-5/NNS||crosses-8/NNS	aux||used-12/VBN||have-9/VBP	advmod||used-12/VBN||traditionally-10/RB	auxpass||used-12/VBN||been-11/VBN	root||ROOT-0/null||used-12/VBN	nn||genes-15/NNS||map-14/NN	prep_to||used-12/VBN||genes-15/NNS	prep_of||genes-15/NNS||interest-17/NN	prep_such_as||genes-15/NNS||those-21/DT	vmod||those-21/DT||conferring-22/VBG	amod||resistance-26/NN||chloroquine-23/JJ	conj_or||chloroquine-23/JJ||quinine-25/JJ	amod||resistance-26/NN||quinine-25/JJ	dobj||conferring-22/VBG||resistance-26/NN	nn||parasites-29/NNS||malaria-28/NN	prep_in||resistance-26/NN||parasites-29/NNS	malaria-28||quinine-25||yes||classical and quantitative linkage analyses of genetic crosses have traditionally been used to map genes of interest, such as those conferring chloroquine or quinine resistance in malaria parasites.
num||subtypes-3/NNS||four-1/CD	amod||subtypes-3/NNS||different-2/JJ	nsubjpass||identified-16/VBN||subtypes-3/NNS	dep||subtypes-3/NNS||h1n1-5/NNPS	dep||subtypes-3/NNS||h1n2-7/NNPS	conj_and||h1n1-5/NNPS||h1n2-7/NNPS	dep||subtypes-3/NNS||h3n1-9/NNPS	conj_and||h1n1-5/NNPS||h3n1-9/NNPS	dep||subtypes-3/NNS||h3n2-11/NNPS	conj_and||h1n1-5/NNPS||h3n2-11/NNPS	prep_of||subtypes-3/NNS||influenzavirus-14/NNS	auxpass||identified-16/VBN||were-15/VBD	root||ROOT-0/null||identified-16/VBN	nn||fluid-20/NN||bronchoalveolar-18/NN	nn||fluid-20/NN||lavage-19/NN	prep_in||identified-16/VBN||fluid-20/NN	vmod||fluid-20/NN||collected-21/VBN	det||lungs-24/NNS||the-23/DT	prep_from||collected-21/VBN||lungs-24/NNS	det||pigs-29/NNS||the-26/DT	amod||pigs-29/NNS||experimentally-27/JJ	amod||pigs-29/NNS||infected-28/JJ	prep_of||lungs-24/NNS||pigs-29/NNS	prep_with||collected-21/VBN||most-32/JJS	det||viruses-35/NNS||the-34/DT	prep_of||most-32/JJS||viruses-35/NNS	vmod||viruses-35/NNS||containing-36/VBG	vmod||containing-36/VBG||trig-37/VBG	det||virus-41/NN||the-39/DT	amod||virus-41/NN||tx/98-40/JJ	prep_from||trig-37/VBG||virus-41/NN	virus-41||viruses-35||no||four different subtypes (h1n1, h1n2, h3n1 and h3n2) of influenzavirus were identified in bronchoalveolar lavage fluid collected from the lungs of the experimentally infected pigs, with most of the viruses containing trig from the tx/98 virus.
det||increase-2/NN||an-1/DT	nsubj||unlikely-8/JJ||increase-2/NN	nsubj||reduce-10/VB||increase-2/NN	nn||testing-5/NN||hiv-4/NN	prep_in||increase-2/NN||testing-5/NN	advmod||unlikely-8/JJ||alone-6/RB	cop||unlikely-8/JJ||is-7/VBZ	root||ROOT-0/null||unlikely-8/JJ	aux||reduce-10/VB||to-9/TO	xcomp||unlikely-8/JJ||reduce-10/VB	nn||incidence-12/NN||hiv-11/NN	dobj||reduce-10/VB||incidence-12/NN	advmod||incidence-12/NN||substantially-13/RB	det||$-18/NNS||nsw-15/DT	amod||$-18/NNS||gay-16/JJ	num||$-18/NNS||menâ-17/CD	prep_in||incidence-12/NN||$-18/NNS	advmod||need-27/VBP||however-20/RB	det||high-24/JJ||the-22/DT	advmod||high-24/JJ||relatively-23/RB	dep||need-27/VBP||high-24/JJ	nn||levels-26/NNS||testing-25/NN	nsubj||need-27/VBP||levels-26/NNS	nsubj||continue-29/VB||levels-26/NNS	nsubj||prevent-31/VB||levels-26/NNS	dep||incidence-12/NN||need-27/VBP	aux||continue-29/VB||to-28/TO	xcomp||need-27/VBP||continue-29/VB	aux||prevent-31/VB||to-30/TO	xcomp||continue-29/VB||prevent-31/VB	det||increase-33/NN||an-32/DT	dobj||prevent-31/VB||increase-33/NN	prep_in||increase-33/NN||hivinfections-35/NNS	hivinfections-35||hiv-11||no||an increase in hiv testing alone is unlikely to reduce hiv incidence substantially in nsw gay menâ however, the relatively high testing levels need to continue to prevent an increase in hivinfections.
det||study-3/NN||this-2/DT	prep_in||investigated-6/VBD||study-3/NN	nsubj||investigated-6/VBD||we-5/PRP	root||ROOT-0/null||investigated-6/VBD	det||effect-8/NN||the-7/DT	dobj||investigated-6/VBD||effect-8/NN	det||mixture-12/NN||a-10/DT	amod||mixture-12/NN||lidocaine-11/JJ	prep_of||effect-8/NN||mixture-12/NN	prep_on||investigated-6/VBD||pain-14/NN	dep||pain-14/NN||induced-15/VBN	amod||injection-19/NN||microemulsion-17/JJ	amod||injection-19/NN||propofol-18/JJ	prep_by||induced-15/VBN||injection-19/NN	dep||pain-14/NN||sought-22/VBN	conj_and||induced-15/VBN||sought-22/VBN	aux||determine-24/VB||to-23/TO	xcomp||sought-22/VBN||determine-24/VB	det||dose-27/NN||the-25/DT	amod||dose-27/NN||optimal-26/JJ	dobj||determine-24/VB||dose-27/NN	nsubj||reduce-32/VB||dose-27/NN	prep_of||dose-27/NN||lidocaine-29/NN	aux||reduce-32/VB||could-31/MD	rcmod||dose-27/NN||reduce-32/VB	dobj||reduce-32/VB||pain-33/NN	prepc_on||reduce-32/VB||injecting-35/VBG	det||mixture-38/NN||a-36/DT	amod||mixture-38/NN||propofol-lidocaine-37/JJ	dobj||injecting-35/VBG||mixture-38/NN	pain-33||lidocaine-29||yes||in this study, we investigated the effect of a lidocaine mixture on pain induced by microemulsion propofol injection, and sought to determine the optimal dose of lidocaine that could reduce pain on injecting a propofol-lidocaine mixture.
advmod||orchestrated-16/VBN||however-1/RB	det||absence-6/NN||the-4/DT	amod||absence-6/NN||apparent-5/JJ	prep_despite||orchestrated-16/VBN||absence-6/NN	det||response-11/NN||an-8/DT	amod||response-11/NN||antiviral-9/JJ	amod||response-11/NN||immune-10/JJ	prep_of||absence-6/NN||response-11/NN	det||disease-14/NN||this-13/DT	nsubjpass||orchestrated-16/VBN||disease-14/NN	auxpass||orchestrated-16/VBN||was-15/VBD	root||ROOT-0/null||orchestrated-16/VBN	amod||cells-20/NNS||virus-specific-18/JJ	nn||cells-20/NNS||t-19/NN	agent||orchestrated-16/VBN||cells-20/NNS	antiviral-9||virus--1||no_rel||however, despite the apparent absence of an antiviral immune response, this disease was orchestrated by virus-specific t cells.
amod||genes-10/NNS||polymorphisms-1/JJ	det||iron-8/NN||the-3/DT	amod||iron-8/NN||hemochromatosis-4/JJ	appos||iron-8/NN||hfe-6/NN	prep_in||polymorphisms-1/JJ||iron-8/NN	amod||genes-10/NNS||regulatory-9/JJ	nsubjpass||shown-13/VBN||genes-10/NNS	nsubj||modify-15/VB||genes-10/NNS	aux||shown-13/VBN||have-11/VBP	auxpass||shown-13/VBN||been-12/VBN	root||ROOT-0/null||shown-13/VBN	aux||modify-15/VB||to-14/TO	xcomp||shown-13/VBN||modify-15/VB	dobj||modify-15/VB||transport-16/NN	nsubjpass||known-23/VBN||transport-16/NN	nsubj||affect-25/VB||transport-16/NN	dobj||modify-15/VB||toxicity-18/NN	conj_and||transport-16/NN||toxicity-18/NN	nsubjpass||known-23/VBN||toxicity-18/NN	nsubj||affect-25/VB||toxicity-18/NN	prep_of||transport-16/NN||lead-20/NN	auxpass||known-23/VBN||is-22/VBZ	rcmod||transport-16/NN||known-23/VBN	aux||affect-25/VB||to-24/TO	xcomp||known-23/VBN||affect-25/VB	nn||weight-27/NN||birth-26/NN	dobj||affect-25/VB||weight-27/NN	hemochromatosis-4||iron-8||no||polymorphisms in the hemochromatosis ( hfe ) iron regulatory genes have been shown to modify transport and toxicity of lead which is known to affect birth weight.
amod||mg-3/NN||tegaserod-1/JJ	dep||tegaserod-1/JJ||6-2/CD	nsubj||improved-7/VBD||mg-3/NN	vmod||mg-3/NN||given-4/VBN	advmod||given-4/VBN||twice-5/RB	advmod||improved-7/VBD||daily-6/RB	root||ROOT-0/null||improved-7/VBD	det||qol-9/NN||the-8/DT	dobj||improved-7/VBD||qol-9/NN	det||symptoms-15/NNS||the-13/DT	nn||symptoms-15/NNS||bowel-14/NN	dobj||improved-7/VBD||symptoms-15/NNS	conj_and||qol-9/NN||symptoms-15/NNS	amod||patients-20/NNS||korean-17/JJ	amod||patients-20/NNS||female-18/JJ	nn||patients-20/NNS||ibs-19/NN	prep_in||improved-7/VBD||patients-20/NNS	prep_with||patients-20/NNS||constipation-22/NN	ibs-19||tegaserod-1||yes||tegaserod 6 mg given twice daily improved the qol as well as the bowel symptoms in korean female ibs patients with constipation.
det||objectives-2/NNS||the-1/DT	nsubj||were-6/VBD||objectives-2/NNS	nsubj||assess-10/VB||objectives-2/NNS	det||study-5/NN||this-4/DT	prep_of||objectives-2/NNS||study-5/NN	root||ROOT-0/null||were-6/VBD	aux||assess-10/VB||to-7/TO	dep||assess-10/VB||1-8/LS	xcomp||were-6/VBD||assess-10/VB	det||family-12/NN||the-11/DT	dobj||assess-10/VB||family-12/NN	xcomp||assess-10/VB||impact-13/NN	prep_of||impact-13/NN||rotavirusgastroenteritis-15/NNS	amod||interviews-18/NNS||qualitative-17/JJ	prep_through||rotavirusgastroenteritis-15/NNS||interviews-18/NNS	mark||compare-24/VBP||with-19/IN	nsubj||compare-24/VBP||parents-20/NNS	dep||parents-20/NNS||2-22/CD	dep||rotavirusgastroenteritis-15/NNS||compare-24/VBP	det||severity-27/NN||the-25/DT	amod||severity-27/NN||clinical-26/JJ	dobj||compare-24/VBP||severity-27/NN	amod||gastroenteritis-32/NNS||rotavirus-positive-29/JJ	conj_and||rotavirus-positive-29/JJ||negative-31/JJ	amod||gastroenteritis-32/NNS||negative-31/JJ	prep_of||severity-27/NN||gastroenteritis-32/NNS	dep||test-36/VB||3-34/LS	dep||assess-10/VB||test-36/VB	det||questionnaire-38/NN||a-37/DT	dobj||test-36/VB||questionnaire-38/NN	xcomp||test-36/VB||asking-39/VBG	dobj||asking-39/VBG||parents-40/NNS	nsubj||rank-42/VB||parents-40/NNS	aux||rank-42/VB||to-41/TO	xcomp||asking-39/VBG||rank-42/VB	det||importance-44/NN||the-43/DT	dobj||rank-42/VB||importance-44/NN	amod||factors-47/NNS||various-46/JJ	prep_of||importance-44/NN||factors-47/NNS	vmod||factors-47/NNS||associated-48/VBN	det||case-51/NN||a-50/DT	prep_with||associated-48/VBN||case-51/NN	prep_of||case-51/NN||rotavirusgastroenteritis-53/NNS	rotavirusgastroenteritis-53||rotavirus--1||no||the objectives of this study were to 1) assess the family impact of rotavirusgastroenteritis through qualitative interviews with parents; 2) compare the clinical severity of rotavirus-positive and negative gastroenteritis; 3) test a questionnaire asking parents to rank the importance of various factors associated with a case of rotavirusgastroenteritis.
det||study-2/NN||this-1/DT	nsubj||demonstrates-3/VBZ||study-2/NN	root||ROOT-0/null||demonstrates-3/VBZ	mark||lack-9/VBP||that-4/IN	det||majority-6/NN||a-5/DT	nsubj||lack-9/VBP||majority-6/NN	prep_of||majority-6/NN||tba-8/NN	ccomp||demonstrates-3/VBZ||lack-9/VBP	amod||information-11/NN||basic-10/JJ	dobj||lack-9/VBP||information-11/NN	amod||practices-17/NNS||hiv/aids-13/JJ	conj_and||hiv/aids-13/JJ||safe-15/JJ	amod||practices-17/NNS||safe-15/JJ	nn||practices-17/NNS||delivery-16/NN	prep_about||information-11/NN||practices-17/NNS	aids--1||hiv--1||no||this study demonstrates that a majority of tba lack basic information about hiv/aids and safe delivery practices.
det||diagnosis-2/NN||the-1/DT	nsubj||clear-8/JJ||diagnosis-2/NN	conj_and||diagnosis-2/NN||indications-4/NNS	nsubj||clear-8/JJ||indications-4/NNS	prep_for||diagnosis-2/NN||treatment-6/NN	cop||clear-8/JJ||are-7/VBP	root||ROOT-0/null||clear-8/JJ	prep_for||clear-8/JJ||individuals-10/NNS	amod||levels-14/NNS||low-12/JJ	nn||levels-14/NNS||plasma-13/NN	prep_with||individuals-10/NNS||levels-14/NNS	prep_of||levels-14/NNS||vitaminb12-16/NNS	det||setting-19/NN||the-18/DT	prep_in||vitaminb12-16/NNS||setting-19/NN	amod||anaemia-22/NN||megaloblastic-21/JJ	prep_of||setting-19/NN||anaemia-22/NN	prep_of||setting-19/NN||neuropathy-24/NN	conj_and||anaemia-22/NN||neuropathy-24/NN	det||relevance-28/NN||the-27/DT	nsubj||uncertain-40/JJ||relevance-28/NN	nn||ofvitaminb12deficiency-31/NNS||treatment-30/NN	prep_of||relevance-28/NN||ofvitaminb12deficiency-31/NNS	det||absence-34/NN||the-33/DT	prep_in||ofvitaminb12deficiency-31/NNS||absence-34/NN	amod||signs-38/NNS||such-36/JJ	amod||signs-38/NNS||clinical-37/JJ	prep_of||absence-34/NN||signs-38/NNS	cop||uncertain-40/JJ||is-39/VBZ	conj_but||clear-8/JJ||uncertain-40/JJ	ofvitaminb12deficiency-31||vitaminb12-16||yes||the diagnosis and indications for treatment are clear for individuals with low plasma levels of vitaminb12 in the setting of megaloblastic anaemia and neuropathy, but the relevance of treatment ofvitaminb12deficiency in the absence of such clinical signs is uncertain.
num||type-3/NN||ten-1/CD	amod||type-3/NN||obese-2/JJ	nsubj||-lrb--11/VBD||type-3/NN	num||patients-6/NNS||2-4/CD	amod||patients-6/NNS||diabetic-5/JJ	nsubjpass||infused-8/VBN||patients-6/NNS	auxpass||infused-8/VBN||were-7/VBD	rcmod||type-3/NN||infused-8/VBN	prep_with||infused-8/VBN||insulin-10/NN	root||ROOT-0/null||-lrb--11/VBD	num||units/h-13/NN||2-12/CD	nsubjpass||infused-34/VBN||units/h-13/NN	nsubjpass||served-51/VBN||units/h-13/NN	num||ml-16/NN||100-15/CD	prep_with||units/h-13/NN||ml-16/NN	number||%-19/NN||5-18/CD	amod||-rrb--21/NNS||%-19/NN	nn||-rrb--21/NNS||dextrose/h-20/NN	prep_of||ml-16/NN||-rrb--21/NNS	number||h.-24/CD||4-23/CD	num||8-26/CD||h.-24/CD	quantmod||8-26/CD||another-25/DT	prep_for||-rrb--21/NNS||8-26/CD	num||type-29/NN||6-28/CD	prep_of||ml-16/NN||type-29/NN	conj_and||-rrb--21/NNS||type-29/NN	num||patients-32/NNS||2-30/CD	amod||patients-32/NNS||diabetic-31/JJ	dep||type-29/NN||patients-32/NNS	auxpass||infused-34/VBN||were-33/VBD	ccomp||-lrb--11/VBD||infused-34/VBN	num||ml-37/NN||100-36/CD	prep_with||infused-34/VBN||ml-37/NN	number||%-40/NN||5-39/CD	amod||dextrose/h-41/NN||%-40/NN	prep_of||ml-37/NN||dextrose/h-41/NN	prep_of||ml-37/NN||saline-43/NN	conj_or||dextrose/h-41/NN||saline-43/NN	num||h-46/NN||4-45/CD	prep_for||ml-37/NN||h-46/NN	advmod||infused-34/VBN||respectively-48/RB	ccomp||-lrb--11/VBD||served-51/VBN	conj_and||infused-34/VBN||served-51/VBN	nn||subjects-54/NNS||control-53/NN	prep_as||served-51/VBN||subjects-54/NNS	dextrose--1||obese-2||no_rel||ten obese type 2 diabetic patients were infused with insulin -lrb- 2 units/h with 100 ml of 5 % dextrose/h -rrb- for 4 h. another 8 and 6 type 2 diabetic patients were infused with 100 ml of 5 % dextrose/h or saline for 4 h , respectively , and served as control subjects .
nsubjpass||used-4/VBN||sitagliptin-1/NN	aux||used-4/VBN||may-2/MD	auxpass||used-4/VBN||be-3/VB	root||ROOT-0/null||used-4/VBN	det||stages-8/NNS||the-6/DT	amod||stages-8/NNS||early-7/JJ	prep_in||used-4/VBN||stages-8/NNS	prep_of||stages-8/NNS||type2diabetes-10/NNS	prep_in||type2diabetes-10/NNS||combination-12/NN	amod||treatments-17/NNS||metformin-14/JJ	conj_or||metformin-14/JJ||other-16/JJ	amod||treatments-17/NNS||other-16/JJ	prep_with||used-4/VBN||treatments-17/NNS	prep_in||used-4/VBN||subjects-19/NNS	amod||control-23/NN||inadequate-21/JJ	amod||control-23/NN||glycemic-22/JJ	prep_with||subjects-19/NNS||control-23/NN	det||treatments-26/NNS||these-25/DT	prep_on||control-23/NN||treatments-26/NNS	advmod||treatments-26/NNS||alone-27/RB	type2diabetes-10||metformin-14||yes||sitagliptin may be used in the early stages of type2diabetes in combination with metformin or other treatments in subjects with inadequate glycemic control on these treatments alone.
nsubj||becoming-16/VBG||hypersensitivity-1/NN	prep_to||hypersensitivity-1/NN||bloodworms-3/NNS	dep||bloodworms-3/NNS||chironomid-5/VBN	acomp||chironomid-5/VBN||larvae-6/JJ	vmod||bloodworms-3/NNS||leading-8/VBG	nn||allergicdisorders-14/NNS||asthma-10/NN	conj_and||asthma-10/NN||other-12/JJ	nn||allergicdisorders-14/NNS||other-12/JJ	amod||allergicdisorders-14/NNS||related-13/JJ	prep_to||leading-8/VBG||allergicdisorders-14/NNS	aux||becoming-16/VBG||is-15/VBZ	root||ROOT-0/null||becoming-16/VBG	xcomp||becoming-16/VBG||common-17/JJ	prep_in||common-17/JJ||individuals-19/NNS	nsubj||keep-21/VBP||individuals-19/NNS	nsubj||work-23/VBP||individuals-19/NNS	rcmod||individuals-19/NNS||keep-21/VBP	rcmod||individuals-19/NNS||work-23/VBP	conj_or||keep-21/VBP||work-23/VBP	prep_with||keep-21/VBP||fish-25/NN	det||use-30/NN||the-28/DT	amod||use-30/NN||increased-29/VBN	prep_due_to||keep-21/VBP||use-30/NN	prep_of||use-30/NN||bloodworms-32/NNS	nn||food-35/NN||fish-34/NN	prep_as||bloodworms-32/NNS||food-35/NN	prep_as||bloodworms-32/NNS||bait-37/NN	conj_or||food-35/NN||bait-37/NN	hypersensitivity-1||allergicdisorders-14||no||hypersensitivity to bloodworms (chironomid larvae) leading to asthma and other related allergicdisorders is becoming common in individuals who keep or work with fish due to the increased use of bloodworms as fish food or bait.
nsubj||cause-6/NN||trachoma-1/NN	cop||cause-6/NN||is-2/VBZ	det||cause-6/NN||the-3/DT	amod||cause-6/NN||leading-4/VBG	amod||cause-6/NN||infectious-5/JJ	root||ROOT-0/null||cause-6/NN	prep_of||cause-6/NN||blindness-8/NN	amod||infection-12/NN||conjunctival-11/JJ	prep_due_to||blindness-8/NN||infection-12/NN	prep_with||infection-12/NN||chlamydiatrachomatis-14/NNS	trachoma-1||chlamydiatrachomatis-14||no||trachoma is the leading infectious cause of blindness due to conjunctival infection with chlamydiatrachomatis .
num||cases-2/NNS||seven-1/CD	nsubjpass||caused-6/VBN||cases-2/NNS	prep_of||cases-2/NNS||candidaemia-4/NN	auxpass||caused-6/VBN||were-5/VBD	root||ROOT-0/null||caused-6/VBN	nn||dubliniensis-9/NNS||candida-8/NN	agent||caused-6/VBN||dubliniensis-9/NNS	nsubj||prevalent-14/JJ||dubliniensis-9/NNS	cop||prevalent-14/JJ||was-12/VBD	advmod||prevalent-14/JJ||more-13/RBR	rcmod||dubliniensis-9/NNS||prevalent-14/JJ	advmod||prevalent-14/JJ||even-15/RB	amod||lusitaniae-18/NN||candida-17/JJ	prep_than||prevalent-14/JJ||lusitaniae-18/NN	nn||tropicalis-21/NNS||candida-20/NN	prep_than||prevalent-14/JJ||tropicalis-21/NNS	conj_and||lusitaniae-18/NN||tropicalis-21/NNS	num||cases-24/NNS||six-23/CD	dep||lusitaniae-18/NN||cases-24/NNS	dep||cases-24/NNS||each-25/DT	candidaemia-4||candida-20||no||seven cases of candidaemia were caused by candida dubliniensis , which was more prevalent even than candida lusitaniae and candida tropicalis (six cases each).
nsubj||drug-8/NN||ablc-1/NN	cop||drug-8/NN||is-2/VBZ	det||drug-8/NN||a-3/DT	amod||drug-8/NN||safe-4/JJ	conj_and||safe-4/JJ||effective-6/JJ	amod||drug-8/NN||effective-6/JJ	amod||drug-8/NN||broad-spectrum-7/JJ	root||ROOT-0/null||drug-8/NN	det||treatment-11/NN||the-10/DT	prep_in||drug-8/NN||treatment-11/NN	amod||fungalinfections-14/NNS||invasive-13/JJ	prep_of||treatment-11/NN||fungalinfections-14/NNS	prep_in||fungalinfections-14/NNS||patients-16/NNS	nn||refractory-19/NNS||infection-18/NN	prep_with||patients-16/NNS||refractory-19/NNS	prep_with||patients-16/NNS||refractory-19/NNS	conj_or||refractory-19/NNS||refractory-19/NNS	nn||deoxycholate-22/NN||amb-21/NN	prep_to||refractory-19/NNS||deoxycholate-22/NN	nn||intolerant-26/NN||patients-25/NNS	prep_in||refractory-19/NNS||intolerant-26/NN	det||formulation-30/NN||the-28/DT	amod||formulation-30/NN||same-29/JJ	prep_of||intolerant-26/NN||formulation-30/NN	fungalinfections-14||amb-21||yes||ablc is a safe and effective broad-spectrum drug in the treatment of invasive fungalinfections in patients with infection refractory to amb deoxycholate or in patients intolerant of the same formulation.
det||discovery-3/NN||the-1/DT	amod||discovery-3/NN||western-2/JJ	nsubj||explained-13/VBD||discovery-3/NN	nsubj||explain-20/VB||discovery-3/NN	mark||due-10/JJ||that-4/IN	nsubj||due-10/JJ||endemicgoiter-5/NN	nsubj||iodinedeficiency-12/VB||endemicgoiter-5/NN	det||himalayas-8/NNS||the-7/DT	prep_in||endemicgoiter-5/NN||himalayas-8/NNS	cop||due-10/JJ||was-9/VBD	dep||discovery-3/NN||due-10/JJ	aux||iodinedeficiency-12/VB||to-11/TO	xcomp||due-10/JJ||iodinedeficiency-12/VB	root||ROOT-0/null||explained-13/VBD	det||cause-16/NN||the-14/DT	amod||cause-16/NN||proximate-15/JJ	dobj||explained-13/VBD||cause-16/NN	aux||explain-20/VB||did-18/VBD	neg||explain-20/VB||not-19/RB	conj_but||explained-13/VBD||explain-20/VB	advmod||have-24/VBP||why-21/WRB	det||individuals-23/NNS||some-22/DT	nsubj||have-24/VBP||individuals-23/NNS	advcl||explain-20/VB||have-24/VBP	dobj||have-24/VBP||goiter-25/NN	nsubj||do-28/VBP||others-27/NNS	advcl||explain-20/VB||do-28/VBP	conj_and||have-24/VBP||do-28/VBP	neg||do-28/VBP||not-29/RB	det||village-35/NN||the-31/DT	amod||village-35/NN||same-32/JJ	amod||village-35/NN||iodine-33/JJ	nn||village-35/NN||deficient-34/NN	prep_in||do-28/VBP||village-35/NN	endemicgoiter-5||iodinedeficiency-12||no||the western discovery that endemicgoiter in the himalayas was due to iodinedeficiency explained the proximate cause but did not explain why some individuals have goiter and others do not in the same iodine deficient village.
det||study-3/NN||this-2/DT	prep_in||used-5/VBD||study-3/NN	nsubj||used-5/VBD||we-4/PRP	root||ROOT-0/null||used-5/VBD	num||assays-8/NNS||two-6/CD	nn||assays-8/NNS||pcr-7/NN	dobj||used-5/VBD||assays-8/NNS	nsubj||screen-14/VB||assays-8/NNS	num||assay-12/NN||one-10/CD	nn||assay-12/NN||antibody-11/NN	dobj||used-5/VBD||assay-12/NN	conj_and||assays-8/NNS||assay-12/NN	nsubj||screen-14/VB||assay-12/NN	aux||screen-14/VB||to-13/TO	xcomp||used-5/VBD||screen-14/VB	num||samples-17/NNS||25-15/CD	nn||samples-17/NNS||blood-16/NN	dobj||screen-14/VB||samples-17/NNS	amod||children-20/NNS||autistic-19/JJ	prep_from||screen-14/VB||children-20/NNS	vmod||children-20/NNS||born-21/VBN	vmod||children-20/NNS||born-21/VBN	conj_and||born-21/VBN||born-21/VBN	prep_to||born-21/VBN||mothers-23/NNS	prep_with||mothers-23/NNS||cfs-25/NN	num||controls-30/NNS||20-28/CD	amod||controls-30/NNS||mixed-29/VBN	prep_from||born-21/VBN||controls-30/NNS	nn||members-33/NNS||family-32/NN	prep_including||controls-30/NNS||members-33/NNS	det||assayed-37/NN||the-35/DT	nn||assayed-37/NN||children-36/NNS	prep_of||members-33/NNS||assayed-37/NN	prep_including||controls-30/NNS||people-39/NNS	conj_and||members-33/NNS||people-39/NNS	prep_with||people-39/NNS||fibromyalgia-41/NNP	prep_including||controls-30/NNS||people-43/NNS	conj_and||members-33/NNS||people-43/NNS	amod||lymedisease-46/NN||chronic-45/JJ	prep_with||people-43/NNS||lymedisease-46/NN	cfs-25||antibody-11||no_rel||in this study we used two pcr assays and one antibody assay to screen 25 blood samples from autistic children born to mothers with cfs and from 20 mixed controls including family members of the children assayed, people with fibromyalgia and people with chronic lymedisease.
advmod||result-5/VBP||however-1/RB	nn||complications-4/NNS||vascular-3/NN	nsubj||result-5/VBP||complications-4/NNS	root||ROOT-0/null||result-5/VBP	prep_from||result-5/VBP||imbalances-7/NNS	vmod||imbalances-7/NNS||caused-8/VBN	agent||caused-8/VBN||increases-10/NNS	amod||metabolites-14/NNS||systemic-12/JJ	amod||metabolites-14/NNS||toxic-13/JJ	prep_in||increases-10/NNS||metabolites-14/NNS	prep_such_as||imbalances-7/NNS||those-18/DT	nsubj||occur-20/VBP||those-18/DT	nsubj||occur-20/VBP||those-18/DT	rcmod||those-18/DT||occur-20/VBP	rcmod||those-18/DT||occur-20/VBP	conj_and||occur-20/VBP||occur-20/VBP	prep_under||occur-20/VBP||conditions-22/NNS	prep_of||conditions-22/NNS||hyperglycemia-24/NN	prep_of||conditions-22/NNS||dyslipidemia-26/NN	conj_and||hyperglycemia-24/NN||dyslipidemia-26/NN	prep_by||occur-20/VBP||reductions-30/NNS	amod||factors-34/NNS||endogenous-32/JJ	amod||factors-34/NNS||protective-33/JJ	prep_in||reductions-30/NNS||factors-34/NNS	nn||factor-42/NN||insulin-37/NN	nn||factor-42/NN||vascular-39/NN	amod||factor-42/NN||endothelial-40/JJ	nn||factor-42/NN||growth-41/NN	prep_such_as||factors-34/NNS||factor-42/NN	nsubj||derived-46/VBD||platelet-45/NN	conj_and||result-5/VBP||derived-46/VBD	nn||factor-48/NN||growth-47/NN	dobj||derived-46/VBD||factor-48/NN	hyperglycemia-24||insulin-37||yes||however, vascular complications result from imbalances caused by increases in systemic toxic metabolites, such as those that occur under conditions of hyperglycemia and dyslipidemia, and by reductions in endogenous protective factors such as insulin, vascular endothelial growth factor, and platelet derived growth factor.
det||results-2/NNS||the-1/DT	nsubj||indicate-3/VBP||results-2/NNS	nsubj||interesting-29/JJ||results-2/NNS	root||ROOT-0/null||indicate-3/VBP	mark||playing-14/VBG||that-4/IN	amod||30979-11/NNS||rv0679c-5/JJ	amod||30979-11/NNS||habps-6/JJ	conj_and||habps-6/JJ||in-8/IN	amod||30979-11/NNS||in-8/IN	amod||habp-10/NN||particular-9/JJ	pobj||in-8/IN||habp-10/NN	nsubj||playing-14/VBG||30979-11/NNS	aux||playing-14/VBG||could-12/MD	aux||playing-14/VBG||be-13/VB	ccomp||indicate-3/VBP||playing-14/VBG	det||role-17/NN||an-15/DT	amod||role-17/NN||important-16/JJ	dobj||playing-14/VBG||role-17/NN	amod||invasion-20/NN||m.tuberculosis-19/JJ	prep_during||playing-14/VBG||invasion-20/NN	nn||cells-23/NNS||host-22/NN	prep_of||invasion-20/NN||cells-23/NNS	advmod||interesting-29/JJ||therefore-26/RB	aux||interesting-29/JJ||could-27/MD	cop||interesting-29/JJ||be-28/VB	conj_and||indicate-3/VBP||interesting-29/JJ	nn||targets-31/NNS||research-30/NN	dep||interesting-29/JJ||targets-31/NNS	prep_for||targets-31/NNS||studies-33/NNS	vmod||studies-33/NNS||aimed-34/VBN	prepc_at||aimed-34/VBN||developing-36/VBG	dobj||developing-36/VBG||strategies-37/NNS	aux||control-39/VB||to-38/TO	vmod||developing-36/VBG||control-39/VB	dobj||control-39/VB||tuberculosis-40/NNP	tuberculosis-40||m.tuberculosis-19||no||the results indicate that rv0679c habps and in particular habp 30979 could be playing an important role during m.tuberculosis invasion of host cells , and therefore could be interesting research targets for studies aimed at developing strategies to control tuberculosis .
advmod||suggesting-19/VBG||notably-1/RB	det||histories-5/NNS||the-3/DT	amod||histories-5/NNS||phylogenetic-4/JJ	nsubj||suggesting-19/VBG||histories-5/NNS	det||viruses-8/NNS||the-7/DT	prep_of||histories-5/NNS||viruses-8/NNS	cop||suggesting-19/VBG||are-9/VBP	neg||suggesting-19/VBG||not-10/RB	advmod||congruent-12/JJ||always-11/RB	acomp||suggesting-19/VBG||congruent-12/JJ	prep_with||suggesting-19/VBG||those-14/DT	poss||hosts-17/NNS||their-16/PRP$	prep_of||those-14/DT||hosts-17/NNS	root||ROOT-0/null||suggesting-19/VBG	mark||played-24/VBN||that-20/IN	amod||transmission-22/NN||cross-species-21/JJ	nsubj||played-24/VBN||transmission-22/NN	nsubj||played-24/VBN||transmission-22/NN	aux||played-24/VBN||has-23/VBZ	ccomp||suggesting-19/VBG||played-24/VBN	ccomp||suggesting-19/VBG||played-24/VBN	conj_and||played-24/VBN||played-24/VBN	det||role-27/NN||a-25/DT	amod||role-27/NN||major-26/JJ	dobj||played-24/VBN||role-27/NN	amod||evolution-30/NN||hantavirus-29/JJ	prep_during||played-24/VBN||evolution-30/NN	det||levels-35/NNS||all-33/DT	amod||levels-35/NNS||taxonomic-34/JJ	prep_at||played-24/VBN||levels-35/NNS	mark||noted-40/VBD||although-37/IN	nsubj||noted-40/VBD||we-38/PRP	advmod||noted-40/VBD||also-39/RB	advcl||played-24/VBN||noted-40/VBD	det||evidence-42/NN||some-41/DT	dobj||noted-40/VBD||evidence-42/NN	amod||co-divergence-45/NN||virus-host-44/JJ	prep_for||noted-40/VBD||co-divergence-45/NN	virus--1||viruses-8||no||notably, the phylogenetic histories of the viruses are not always congruent with those of their hosts, suggesting that cross-species transmission has played a major role during hantavirus evolution and at all taxonomic levels, although we also noted some evidence for virus-host co-divergence.
det||variola-4/NN||the-1/DT	advmod||virulent-3/JJ||highly-2/RB	amod||variola-4/NN||virulent-3/JJ	nsubj||express-8/VBP||variola-4/NN	nn||viruses-7/NNS||monkeypox-6/NN	conj_and||variola-4/NN||viruses-7/NNS	nsubj||express-8/VBP||viruses-7/NNS	root||ROOT-0/null||express-8/VBP	amod||inhibitors-10/NNS||secreted-9/JJ	dobj||express-8/VBP||inhibitors-10/NNS	nn||interferon-14/NN||type-12/NN	nn||interferon-14/NN||i-13/NN	prep_of||inhibitors-10/NNS||interferon-14/NN	interferon-14||variola-4||no_rel||the highly virulent variola and monkeypox viruses express secreted inhibitors of type i interferon.
mark||trigger-9/NN||since-1/IN	nsubj||trigger-9/NN||inflammation-2/NN	amod||fat-5/NN||visceral-4/JJ	prep_of||inflammation-2/NN||fat-5/NN	cop||trigger-9/NN||is-6/VBZ	det||trigger-9/NN||a-7/DT	amod||trigger-9/NN||crucial-8/JJ	advcl||explain-23/VB||trigger-9/NN	prep_of||trigger-9/NN||atherogenesis-11/NNS	amod||fat-15/NN||decreased-13/VBN	amod||fat-15/NN||visceral-14/JJ	appos||atherogenesis-11/NNS||fat-15/NN	amod||±-18/NNS||pgc-1î-17/JJ	prep_in||fat-15/NN||±-18/NNS	nn||mice-21/NNS||deficient-20/NN	nsubj||explain-23/VB||mice-21/NNS	aux||explain-23/VB||may-22/MD	root||ROOT-0/null||explain-23/VB	advmod||develop-29/VB||why-24/WRB	det||mice-26/NNS||these-25/DT	nsubj||develop-29/VB||mice-26/NNS	aux||develop-29/VB||do-27/VBP	neg||develop-29/VB||not-28/RB	advcl||explain-23/VB||develop-29/VB	amod||atherosclerosis-31/NNS||enhanced-30/JJ	dobj||develop-29/VB||atherosclerosis-31/NNS	inflammation-2||fat-15||no_rel||since inflammation of visceral fat is a crucial trigger of atherogenesis, decreased visceral fat in pgc-1î± -deficient mice may explain why these mice do not develop enhanced atherosclerosis.
amod||reservoirs-2/NNS||long-lived-1/JJ	nsubj||infected-9/VBD||reservoirs-2/NNS	prep_of||reservoirs-2/NNS||humanimmunodeficiencyvirus-4/NNS	appos||humanimmunodeficiencyvirus-4/NNS||hiv-6/NN	advmod||infected-9/VBD||latently-8/RB	root||ROOT-0/null||infected-9/VBD	nsubj||present-11/VB||cells-10/NNS	ccomp||infected-9/VBD||present-11/VB	det||barrier-14/NN||the-12/DT	amod||barrier-14/NN||main-13/JJ	dobj||present-11/VB||barrier-14/NN	det||cure-17/NN||a-16/DT	prep_to||present-11/VB||cure-17/NN	prep_for||cure-17/NN||hivinfection-19/NN	hivinfection-19||humanimmunodeficiencyvirus-4||no||long-lived reservoirs of humanimmunodeficiencyvirus (hiv) latently infected cells present the main barrier to a cure for hivinfection.
prep_after||observed-17/VBD||adjustment-2/NN	nn||sex-6/NN||age-4/NN	prep_for||adjustment-2/NN||sex-6/NN	nn||circumference-10/NN||waist-9/NN	prep_for||adjustment-2/NN||circumference-10/NN	conj_and||sex-6/NN||circumference-10/NN	det||ors-14/NN||the-12/DT	amod||ors-14/NN||standardized-13/JJ	nsubj||observed-17/VBD||ors-14/NN	prep_for||ors-14/NN||incident-16/NN	root||ROOT-0/null||observed-17/VBD	nsubj||identical-20/JJ||apnea-18/NN	cop||identical-20/JJ||were-19/VBD	ccomp||observed-17/VBD||identical-20/JJ	prepc_for||identical-20/JJ||fasting-22/VBG	dobj||fasting-22/VBG||insulin-23/NN	det||assessment-28/NN||the-25/DT	amod||assessment-28/NN||homeostasis-26/JJ	nn||assessment-28/NN||model-27/NN	dobj||fasting-22/VBG||assessment-28/NN	conj_and||insulin-23/NN||assessment-28/NN	prep_of||assessment-28/NN||insulinresistance-30/NN	num||insulinresistance-30/NN||1.31-31/CD	npadvmod||â-34/RB||1.13-33/CD	dep||$-35/$||â-34/RB	dep||insulinresistance-30/NN||$-35/$	num||$-35/$||1.51-37/CD	prep_of||assessment-28/NN||1.24-40/CD	conj_and||insulinresistance-30/NN||1.24-40/CD	npadvmod||â-43/RB||1.09-42/CD	dep||$-44/$||â-43/RB	dep||insulinresistance-30/NN||$-44/$	num||$-44/$||1.41-46/CD	prep_for||fasting-22/VBG||triglycerides-49/CD	prep_for||fasting-22/VBG||1.52-51/CD	conj_and||triglycerides-49/CD||1.52-51/CD	dep||triglycerides-49/CD||1.12-53/CD	dep||triglycerides-49/CD||$-55/$	conj_â||1.12-53/CD||$-55/$	num||$-55/$||2.05-57/CD	prep_for||fasting-22/VBG||smoking-60/NN	insulinresistance-30||insulin-23||no_rel||after adjustment for age, sex, and waist circumference, the standardized ors for incident observed apnea were identical for fasting insulin and the homeostasis model assessment of insulinresistance 1.31 (1.13â1.51) and 1.24 (1.09â1.41) for triglycerides and 1.52 (1.12â2.05) for smoking.
prep_in||changed-11/VBN||2002-2/CD	det||treatment-6/NN||the-4/DT	amod||treatment-6/NN||first-line-5/JJ	nsubjpass||changed-11/VBN||treatment-6/NN	amod||malaria-9/NN||uncomplicated-8/JJ	prep_for||treatment-6/NN||malaria-9/NN	auxpass||changed-11/VBN||was-10/VBD	root||ROOT-0/null||changed-11/VBN	prep_to||changed-11/VBN||artemether-lumefantrine-13/NN	nsubj||proved-19/VBN||artemether-lumefantrine-13/NN	nsubj||efficacious-23/JJ||artemether-lumefantrine-13/NN	appos||artemether-lumefantrine-13/NN||al-15/NNP	aux||proved-19/VBN||has-18/VBZ	rcmod||artemether-lumefantrine-13/NN||proved-19/VBN	aux||efficacious-23/JJ||to-20/TO	cop||efficacious-23/JJ||be-21/VB	advmod||efficacious-23/JJ||highly-22/RB	xcomp||proved-19/VBN||efficacious-23/JJ	prepc_against||efficacious-23/JJ||multidrug-25/VBG	amod||falciparum-28/NN||resistant-26/JJ	nn||falciparum-28/NN||plasmodium-27/NN	dobj||multidrug-25/VBG||falciparum-28/NN	malaria-9||artemether--1||yes||in 2002, the first-line treatment for uncomplicated malaria was changed to artemether-lumefantrine (al) that has proved to be highly efficacious against multidrug resistant plasmodium falciparum .
prep_in||started-10/VBD||response-2/NN	det||cancer-7/NN||the-4/DT	amod||cancer-7/NN||exacerbated-5/JJ	nn||cancer-7/NN||prostate-6/NN	prep_to||response-2/NN||cancer-7/NN	nsubj||started-10/VBD||we-9/PRP	root||ROOT-0/null||started-10/VBD	det||therapy-12/NN||a-11/DT	dobj||started-10/VBD||therapy-12/NN	det||administration-15/NN||the-14/DT	prep_involving||therapy-12/NN||administration-15/NN	num||weight-20/NN||8-17/CD	amod||weight-20/NN||mg/kg-18/JJ	nn||weight-20/NN||body-19/NN	prep_of||administration-15/NN||weight-20/NN	prep_of||weight-20/NN||dexamethasone-22/NN	num||mg/m2-25/NNS||55-24/CD	prep_of||administration-15/NN||mg/m2-25/NNS	conj_and||weight-20/NN||mg/m2-25/NNS	prep_of||mg/m2-25/NNS||docetaxel-27/NN	det||weeks-30/NNS||every-28/DT	num||weeks-30/NNS||3-29/CD	tmod||started-10/VBD||weeks-30/NNS	docetaxel-27||cancer-7||no_rel||in response to the exacerbated prostate cancer, we started a therapy involving the administration of 8 mg/kg body weight of dexamethasone and 55 mg/m2 of docetaxel every 3 weeks.
nsubj||tested-2/VBD||we-1/PRP	root||ROOT-0/null||tested-2/VBD	det||hypothesis-4/NNS||the-3/DT	dobj||tested-2/VBD||hypothesis-4/NNS	mark||suppresses-21/VBZ||that-5/IN	det||increase-7/NN||an-6/DT	nsubj||suppresses-21/VBZ||increase-7/NN	prep_in||increase-7/NN||insulin-9/NN	nn||se-11/FW||per-10/FW	advmod||insulin-9/NN||se-11/FW	dep||se-11/FW||i.e.-13/CD	det||absence-17/NN||the-16/DT	prep_in||se-11/FW||absence-17/NN	prep_of||absence-17/NN||zinc-19/NN	ccomp||tested-2/VBD||suppresses-21/VBZ	nn||secretion-23/NN||glucagon-22/NN	dobj||suppresses-21/VBZ||secretion-23/NN	prep_during||suppresses-21/VBZ||euglycemia-25/NN	mark||stimulates-34/VBZ||that-27/IN	det||decrease-29/NN||a-28/DT	nsubj||stimulates-34/VBZ||decrease-29/NN	prep_in||decrease-29/NN||insulin-31/NN	nn||se-33/FW||per-32/FW	advmod||stimulates-34/VBZ||se-33/FW	ccomp||tested-2/VBD||stimulates-34/VBZ	conj_and||suppresses-21/VBZ||stimulates-34/VBZ	nn||secretion-36/NN||glucagon-35/NN	dobj||stimulates-34/VBZ||secretion-36/NN	prep_during||stimulates-34/VBZ||hypoglycemia-38/NN	prep_in||hypoglycemia-38/NN||humans-40/NNS	hypoglycemia-38||insulin-31||no_rel||we tested the hypothesis that an increase in insulin per se, i.e., in the absence of zinc, suppresses glucagon secretion during euglycemia and that a decrease in insulin per se stimulates glucagon secretion during hypoglycemia in humans.
det||mechanism-4/NN||the-1/DT	amod||mechanism-4/NN||possible-2/JJ	amod||mechanism-4/NN||molecular-3/JJ	nsubjpass||explored-12/VBN||mechanism-4/NN	nsubj||indoleamine-18/VB||mechanism-4/NN	vmod||mechanism-4/NN||mediating-5/VBG	det||effect-8/NN||this-6/DT	amod||effect-8/NN||immunosuppressive-7/JJ	dobj||mediating-5/VBG||effect-8/NN	prep_of||effect-8/NN||uc-mscs-10/NNS	auxpass||explored-12/VBN||was-11/VBD	root||ROOT-0/null||explored-12/VBN	agent||explored-12/VBN||addition-14/NN	prep_of||addition-14/NN||inhibitors-16/NNS	aux||indoleamine-18/VB||to-17/TO	xcomp||explored-12/VBN||indoleamine-18/VB	amod||ido-21/NN||2,3-dioxygenase-19/JJ	dobj||indoleamine-18/VB||ido-21/NN	appos||ido-21/NN||nitricoxide-24/NN	discourse||nitricoxide-24/NN||no-26/UH	appos||ido-21/NN||prostaglandine2-29/NNS	conj_and||nitricoxide-24/NN||prostaglandine2-29/NNS	appos||prostaglandine2-29/NNS||pge2-31/NNP	amod||î-37/NN||transforming-34/JJ	nn||î-37/NN||growth-35/NN	nn||î-37/NN||factor-36/NN	appos||ido-21/NN||î-37/NN	conj_and||nitricoxide-24/NN||î-37/NN	number||1-39/CD||²-38/CD	amod||î-37/NN||1-39/CD	dep||1-39/CD||tgf-î-41/NNP	number||1-43/CD||²-42/CD	num||tgf-î-41/NNP||1-43/CD	appos||ido-21/NN||interleukin-46/NN	conj_and||nitricoxide-24/NN||interleukin-46/NN	num||interleukin-46/NN||10-47/CD	dep||interleukin-46/NN||il-10-49/JJ	uc--1||prostaglandine2-29||no_rel||the possible molecular mechanism mediating this immunosuppressive effect of uc-mscs was explored by addition of inhibitors to indoleamine 2,3-dioxygenase (ido), nitricoxide (no), prostaglandine2 (pge2), transforming growth factor î²1 (tgf-î²1) and interleukin 10 (il-10).
det||review-3/NN||this-2/DT	prep_in||present-6/VB||review-3/NN	nsubj||present-6/VB||we-5/PRP	nsubj||activation-14/VB||we-5/PRP	nsubj||discuss-32/VB||we-5/PRP	root||ROOT-0/null||present-6/VB	amod||knowledge-8/NN||current-7/JJ	dobj||present-6/VB||knowledge-8/NN	amod||recognition-12/NN||innate-10/JJ	amod||recognition-12/NN||immune-11/JJ	prep_on||present-6/VB||recognition-12/NN	conj_and||present-6/VB||activation-14/VB	prep_during||activation-14/VB||hivinfection-16/NN	prepc_based_on||activation-14/VB||on-18/IN	pobj||activation-14/VB||studies-19/NNS	nn||culture-22/NN||cell-21/NN	prep_in||studies-19/NNS||culture-22/NN	amod||primates-25/NNS||non-human-24/JJ	prep_in||studies-19/NNS||primates-25/NNS	conj_and||culture-22/NN||primates-25/NNS	amod||individuals-29/NNS||hiv-infected-28/JJ	prep_in||studies-19/NNS||individuals-29/NNS	conj_and||culture-22/NN||individuals-29/NNS	conj_and||present-6/VB||discuss-32/VB	det||implications-34/NNS||the-33/DT	dobj||discuss-32/VB||implications-34/NNS	det||understanding-37/NN||the-36/DT	prep_for||discuss-32/VB||understanding-37/NN	nn||immunopathogenesis-40/NNS||hiv-39/NN	prep_of||understanding-37/NN||immunopathogenesis-40/NNS	hivinfection-16||hiv-39||no||in this review, we present current knowledge on innate immune recognition and activation during hivinfection based on studies in cell culture, non-human primates, and hiv-infected individuals, and discuss the implications for the understanding of hiv immunopathogenesis.
nsubj||underway-11/JJ||scaling-1/NN	advmod||scaling-1/NN||up-2/RB	amod||therapy-5/NN||antiretroviral-4/JJ	prep_of||scaling-1/NN||therapy-5/NN	appos||scaling-1/NN||art-7/NN	cop||underway-11/JJ||is-9/VBZ	advmod||underway-11/JJ||currently-10/RB	root||ROOT-0/null||underway-11/JJ	amod||africa-14/NN||sub-saharan-13/JJ	prep_in||underway-11/JJ||africa-14/NN	dep||africa-14/NN||tanzania-17/NNP	amod||survival-20/NN||increasing-19/JJ	prep_including||africa-14/NN||survival-20/NN	nn||living-23/NN||people-22/NNS	prep_of||survival-20/NN||living-23/NN	prep_with||living-23/NN||hiv/aids-25/NNS	appos||hiv/aids-25/NNS||plwha-27/NNP	aids--1||hiv--1||no||scaling up of antiretroviral therapy (art) is currently underway in sub-saharan africa including, tanzania, increasing survival of people living with hiv/aids (plwha).
amod||studies-2/NNS||gene-profiling-1/JJ	nsubj||demonstrate-10/VBP||studies-2/NNS	amod||carcinomas-6/NNS||human-4/JJ	nn||carcinomas-6/NNS||hepatocellular-5/NN	prep_of||studies-2/NNS||carcinomas-6/NNS	appos||studies-2/NNS||hcc-8/NN	root||ROOT-0/null||demonstrate-10/VBP	nn||activation-13/NN||hh-11/NN	nn||activation-13/NN||pathway-12/NN	dobj||demonstrate-10/VBP||activation-13/NN	prep_in||activation-13/NN||hccs-15/NNS	vmod||hccs-15/NNS||related-16/VBN	amod||infection-19/NN||chronic-18/JJ	prep_to||related-16/VBN||infection-19/NN	prep_with||related-16/VBN||hepatitisbvirus-21/NNS	appos||hepatitisbvirus-21/NNS||hbv-23/NN	amod||virus-27/NN||hepatitisc-26/JJ	prep_with||related-16/VBN||virus-27/NN	conj_or||hepatitisbvirus-21/NNS||virus-27/NN	appos||hepatitisbvirus-21/NNS||hcv-29/NN	hbv-23||hepatitisbvirus-21||no||gene-profiling studies of human hepatocellular carcinomas (hcc) demonstrate hh pathway activation in hccs related to chronic infection with hepatitisbvirus (hbv) or hepatitisc virus (hcv).
amod||minimus-3/NNS||purified-1/JJ	nn||minimus-3/NNS||a.-2/NN	nsubj||cypor-4/VBP||minimus-3/NNS	root||ROOT-0/null||cypor-4/VBP	amod||-rrb--8/NNS||enzyme-5/JJ	amod||-rrb--8/NNS||-lrb--6/JJ	nn||-rrb--8/NNS||ancypor-7/NN	nsubj||partner-14/NN||-rrb--8/NNS	nsubj||loses-19/VBZ||-rrb--8/NNS	cop||partner-14/NN||is-11/VBZ	det||partner-14/NN||the-12/DT	nn||partner-14/NN||redox-13/NN	rcmod||-rrb--8/NNS||partner-14/NN	amod||p450s-17/NNS||cytochrome-16/JJ	prep_of||partner-14/NN||p450s-17/NNS	ccomp||cypor-4/VBP||loses-19/VBZ	amod||-rrb--24/NNS||flavin-adenosine-20/JJ	amod||-rrb--24/NNS||di-nucleotide-21/JJ	amod||-rrb--24/NNS||-lrb--22/JJ	nn||-rrb--24/NNS||fad-23/NN	dobj||loses-19/VBZ||-rrb--24/NNS	amod||cofactors-31/NNS||flavin-26/JJ	amod||cofactors-31/NNS||mono-nucleotide-27/JJ	amod||cofactors-31/NNS||-lrb--28/JJ	nn||cofactors-31/NNS||fmn-29/NN	nn||cofactors-31/NNS||-rrb--30/NN	dobj||loses-19/VBZ||cofactors-31/NNS	conj_and||-rrb--24/NNS||cofactors-31/NNS	nsubj||affect-33/VBP||cofactors-31/NNS	rcmod||cofactors-31/NNS||affect-33/VBP	poss||activity-36/NN||its-34/PRP$	amod||activity-36/NN||enzyme-35/JJ	dobj||affect-33/VBP||activity-36/NN	enzyme-35||di--1||no_rel||purified a. minimus cypor enzyme -lrb- ancypor -rrb- , which is the redox partner of cytochrome p450s , loses flavin-adenosine di-nucleotide -lrb- fad -rrb- and flavin mono-nucleotide -lrb- fmn -rrb- cofactors that affect its enzyme activity .
nsubj||investigated-3/VBN||we-1/PRP	aux||investigated-3/VBN||have-2/VBP	root||ROOT-0/null||investigated-3/VBN	det||effect-5/NN||the-4/DT	dobj||investigated-3/VBN||effect-5/NN	amod||treatment-9/NN||intermittent-7/JJ	nn||treatment-9/NN||preventive-8/NN	prep_of||effect-5/NN||treatment-9/NN	prep_with||treatment-9/NN||sulphadoxine-pyrimethamine-11/NN	prep_with||treatment-9/NN||artesunate-13/NN	conj_or||sulphadoxine-pyrimethamine-11/NN||artesunate-13/NN	dobj||investigated-3/VBN||amodiaquine-15/NN	conj_plus||effect-5/NN||amodiaquine-15/NN	prep_on||amodiaquine-15/NN||anaemia-17/NN	prep_on||amodiaquine-15/NN||malaria-19/NN	conj_and||anaemia-17/NN||malaria-19/NN	prep_in||investigated-3/VBN||children-21/NNS	det||area-24/NN||an-23/DT	prep_in||children-21/NNS||area-24/NN	amod||transmission-32/NN||intense-26/JJ	amod||transmission-32/NN||prolonged-28/JJ	amod||transmission-32/NN||seasonal-30/JJ	nn||transmission-32/NN||malaria-31/NN	prep_of||area-24/NN||transmission-32/NN	prep_in||investigated-3/VBN||ghana-34/NN	malaria-31||pyrimethamine--1||no||we have investigated the effect of intermittent preventive treatment with sulphadoxine-pyrimethamine or artesunate plus amodiaquine on anaemia and malaria in children in an area of intense, prolonged, seasonal malaria transmission in ghana.
nsubj||seems-14/VBZ||conclusions-1/NNS	nsubj||be-16/VB||conclusions-1/NNS	det||risk-3/NN||the-2/DT	nsubj||thromboembolism-7/VBP||risk-3/NN	amod||venous-6/NNS||non-fatal-5/JJ	prep_of||risk-3/NN||venous-6/NNS	rcmod||conclusions-1/NNS||thromboembolism-7/VBP	prep_among||thromboembolism-7/VBP||users-9/NNS	prep_of||users-9/NNS||oralcontraceptives-11/NNS	vmod||oralcontraceptives-11/NNS||containing-12/VBG	dobj||containing-12/VBG||drospirenone-13/NN	root||ROOT-0/null||seems-14/VBZ	aux||be-16/VB||to-15/TO	xcomp||seems-14/VBZ||be-16/VB	advmod||that-19/DT||twice-18/RB	prep_around||be-16/VB||that-19/DT	prep_of||that-19/DT||users-21/NNS	prep_of||users-21/NNS||oralcontraceptives-23/NNS	vmod||oralcontraceptives-23/NNS||containing-24/VBG	acomp||containing-24/VBG||levonorgestrel-25/JJ	mark||taken-38/VBN||after-27/IN	det||effects-29/NNS||the-28/DT	nsubjpass||taken-38/VBN||effects-29/NNS	amod||confounders-32/NNS||potential-31/JJ	prep_of||effects-29/NNS||confounders-32/NNS	amod||biases-35/NNS||prescribing-34/VBG	prep_of||effects-29/NNS||biases-35/NNS	conj_and||confounders-32/NNS||biases-35/NNS	aux||taken-38/VBN||have-36/VBP	auxpass||taken-38/VBN||been-37/VBN	advcl||seems-14/VBZ||taken-38/VBN	prep_into||taken-38/VBN||account-40/NN	thromboembolism-7||levonorgestrel-25||no||conclusions the risk of non-fatal venous thromboembolism among users of oralcontraceptives containing drospirenone seems to be around twice that of users of oralcontraceptives containing levonorgestrel, after the effects of potential confounders and prescribing biases have been taken into account.
advmod||achieved-25/VBN||moreover-1/RB	advmod||added-6/VBN||when-3/WRB	nsubjpass||added-6/VBN||thioridazine-4/NN	auxpass||added-6/VBN||was-5/VBD	advcl||achieved-25/VBN||added-6/VBN	det||regimen-9/NN||a-8/DT	prep_to||added-6/VBN||regimen-9/NN	vmod||regimen-9/NN||containing-10/VBG	dobj||containing-10/VBG||rifampicin-11/NN	dobj||containing-10/VBG||isoniazid-13/NN	conj_and||rifampicin-11/NN||isoniazid-13/NN	dobj||containing-10/VBG||pyrazinamide-15/NN	conj_and||rifampicin-11/NN||pyrazinamide-15/NN	nn||tuberculosis-18/NNP||susceptible-17/NNP	prep_for||containing-10/VBG||tuberculosis-18/NNP	det||effect-23/NN||a-20/DT	amod||effect-23/NN||significant-21/JJ	amod||effect-23/NN||synergistic-22/JJ	nsubjpass||achieved-25/VBN||effect-23/NN	auxpass||achieved-25/VBN||was-24/VBD	root||ROOT-0/null||achieved-25/VBN	poss||â-31/NNP||â-27/NNP	nn||â-31/NNP||6.2-29/NNP	nn||â-31/NNP||vs-30/NNP	poss||cfu-35/NN||â-31/NNP	number||log-34/CD||5.9-33/CD	num||cfu-35/NN||log-34/CD	dep||achieved-25/VBN||cfu-35/NN	nn||0.01-39/NNP||p-37/NNP	nn||0.01-39/NNP||<-38/NNP	appos||cfu-35/NN||0.01-39/NNP	tuberculosis-18||isoniazid-13||yes||moreover, when thioridazine was added to a regimen containing rifampicin, isoniazid and pyrazinamide for susceptible tuberculosis, a significant synergistic effect was achieved (â6.2 vs â5.9 log cfu, p<0.01).
nsubj||agent-6/NN||mycobacteriumtuberculosis-1/NNS	cop||agent-6/NN||is-2/VBZ	det||agent-6/NN||the-3/DT	amod||agent-6/NN||principal-4/JJ	amod||agent-6/NN||etiologic-5/JJ	root||ROOT-0/null||agent-6/NN	amod||-rrb--12/NNP||human-8/JJ	nn||-rrb--12/NNP||tuberculosis-9/NNP	nn||-rrb--12/NNP||-lrb--10/NNP	nn||-rrb--12/NNP||tb-11/NNP	prep_of||agent-6/NN||-rrb--12/NNP	det||member-15/NN||a-14/DT	conj_and||agent-6/NN||member-15/NN	det||-rrb--22/NNS||the-17/DT	amod||complex-19/JJ||m.tuberculosis-18/JJ	amod||-rrb--22/NNS||complex-19/JJ	amod||-rrb--22/NNS||-lrb--20/JJ	nn||-rrb--22/NNS||mtc-21/NN	prep_of||member-15/NN||-rrb--22/NNS	tb-11||mycobacteriumtuberculosis-1||no||mycobacteriumtuberculosis is the principal etiologic agent of human tuberculosis -lrb- tb -rrb- and a member of the m.tuberculosis complex -lrb- mtc -rrb- .
amod||diarrhea-2/NN||mucohaemorrhagic-1/JJ	nsubj||production-12/NN||diarrhea-2/NN	vmod||diarrhea-2/NN||caused-3/VBN	agent||caused-3/VBN||brachyspirahyodysenteriae-5/NN	advmod||production-12/NN||swinedysentery-7/RB	cop||production-12/NN||is-9/VBZ	det||production-12/NN||a-10/DT	amod||production-12/NN||severe-11/JJ	root||ROOT-0/null||production-12/NN	vmod||production-12/NN||limiting-13/VBG	dobj||limiting-13/VBG||disease-14/NN	prep_of||disease-14/NN||swine-16/NNS	swinedysentery-7||brachyspirahyodysenteriae-5||no||mucohaemorrhagic diarrhea caused by brachyspirahyodysenteriae, swinedysentery, is a severe production limiting disease of swine.
det||analysis-4/NN||the-2/DT	amod||analysis-4/NN||case-control-3/JJ	prep_in||2.3-26/CD||analysis-4/NN	det||ratio-9/NN||the-6/DT	amod||ratio-9/NN||conditional-7/JJ	nn||ratio-9/NN||odds-8/NNS	nsubj||2.3-26/CD||ratio-9/NN	amod||thromboembolism-12/NN||venous-11/JJ	prep_for||ratio-9/NN||thromboembolism-12/NN	vmod||thromboembolism-12/NN||comparing-13/VBG	dobj||comparing-13/VBG||use-14/NN	prep_of||use-14/NN||oralcontraceptives-16/NNS	vmod||oralcontraceptives-16/NNS||containing-17/VBG	dobj||containing-17/VBG||drospirenone-18/NN	prep_with||containing-17/VBG||use-20/NN	prep_of||use-20/NN||those-22/DT	vmod||those-22/DT||containing-23/VBG	acomp||containing-23/VBG||levonorgestrel-24/JJ	cop||2.3-26/CD||was-25/VBD	root||ROOT-0/null||2.3-26/CD	num||%-29/NN||95-28/CD	dep||2.3-26/CD||%-29/NN	nn||interval-31/NN||confidence-30/NN	dep||%-29/NN||interval-31/NN	number||3.2-34/CD||1.6-32/CD	dep||3.2-34/CD||to-33/TO	dep||interval-31/NN||3.2-34/CD	thromboembolism-12||drospirenone-18||no||in the case-control analysis, the conditional odds ratio for venous thromboembolism comparing use of oralcontraceptives containing drospirenone with use of those containing levonorgestrel was 2.3 (95% confidence interval 1.6 to 3.2).
nn||onset-3/NN||schizophrenia-2/NN	prep_after||treated-7/VBN||onset-3/NN	nsubjpass||treated-7/VBN||he-5/PRP	auxpass||treated-7/VBN||was-6/VBD	root||ROOT-0/null||treated-7/VBN	prep_in||treated-7/VBN||sequence-10/NN	prep_with||treated-7/VBN||olanzapine-13/NN	prep_with||treated-7/VBN||amisulpride-15/NN	conj_and||olanzapine-13/NN||amisulpride-15/NN	prep_with||treated-7/VBN||aripiprazole-17/NN	conj_and||olanzapine-13/NN||aripiprazole-17/NN	schizophrenia-2||aripiprazole-17||yes||after schizophrenia onset, he was treated, in sequence, with olanzapine, amisulpride and aripiprazole.
nsubj||adopt-9/VB||subjects-1/NNS	vmod||subjects-1/NNS||suffering-2/VBG	amod||allergy/intolerance-7/NN||coeliacdisease-4/JJ	amod||allergy/intolerance-7/NN||gluten-6/JJ	prep_from||suffering-2/VBG||allergy/intolerance-7/NN	aux||adopt-9/VB||must-8/MD	root||ROOT-0/null||adopt-9/VB	det||avoidance-12/NN||a-10/DT	amod||avoidance-12/NN||lifelong-11/JJ	dobj||adopt-9/VB||avoidance-12/NN	prep_of||avoidance-12/NN||gluten-14/NN	coeliacdisease-4||gluten-14||no||subjects suffering from coeliacdisease, gluten allergy/intolerance must adopt a lifelong avoidance of gluten.
advmod||confers-7/VBZ||finally-1/RB	det||lack-4/NN||the-3/DT	nsubj||confers-7/VBZ||lack-4/NN	prep_of||lack-4/NN||ptp1b-6/CD	root||ROOT-0/null||confers-7/VBZ	dobj||confers-7/VBZ||protection-8/NN	amod||tests-40/NNS||il-6â-10/JJ	dep||il-6â-10/JJ||$-11/$	advmod||insulinresistance-14/RB||induced-13/RB	dep||observed-34/CD||insulinresistance-14/RB	amod||muscle-17/NN||skeletal-16/JJ	prep_in||insulinresistance-14/RB||muscle-17/NN	prep_in||muscle-17/NN||vitro-19/NN	prep_in||muscle-17/NN||in-21/IN	conj_and||vitro-19/NN||in-21/IN	pobj||in-21/IN||vivo-22/NN	prep_in||insulinresistance-14/RB||agreement-25/NN	det||protection-28/NN||the-27/DT	prep_with||agreement-25/NN||protection-28/NN	det||effect-33/NN||the-30/DT	amod||effect-33/NN||il-6-31/JJ	amod||effect-33/NN||hyperglycemic-32/JJ	prep_against||protection-28/NN||effect-33/NN	num||$-11/$||observed-34/CD	prep_on||$-11/$||glucose-36/NN	prep_on||$-11/$||insulin-38/NN	conj_and||glucose-36/NN||insulin-38/NN	nn||tests-40/NNS||tolerance-39/NN	prep_against||protection-8/NN||tests-40/NNS	amod||mice-44/NNS||adult-42/JJ	amod||mice-44/NNS||male-43/JJ	prep_in||tests-40/NNS||mice-44/NNS	glucose-36||insulinresistance-14||no_rel||finally, the lack of ptp1b confers protection against il-6âinduced insulinresistance in skeletal muscle in vitro and in vivo, in agreement with the protection against the il-6 hyperglycemic effect observed on glucose and insulin tolerance tests in adult male mice.
nsubj||herpesvirus-17/NNS||varicella-zostervirus-1/NNS	nsubj||first-24/JJ||varicella-zostervirus-1/NNS	appos||varicella-zostervirus-1/NNS||vzv-3/NN	det||cause-7/NN||the-6/DT	appos||varicella-zostervirus-1/NNS||cause-7/NN	prep_of||cause-7/NN||chickenpox-9/NN	prep_of||cause-7/NN||zoster-11/NN	conj_and||chickenpox-9/NN||zoster-11/NN	cop||herpesvirus-17/NNS||was-13/VBD	det||herpesvirus-17/NNS||the-14/DT	amod||herpesvirus-17/NNS||first-15/JJ	amod||herpesvirus-17/NNS||human-16/JJ	root||ROOT-0/null||herpesvirus-17/NNS	aux||sequenced-20/VBN||to-18/TO	auxpass||sequenced-20/VBN||be-19/VB	vmod||herpesvirus-17/NNS||sequenced-20/VBN	advmod||sequenced-20/VBN||fully-21/RB	det||first-24/JJ||the-23/DT	conj_and||herpesvirus-17/NNS||first-24/JJ	prep_for||licensed-30/VBN||first-24/JJ	nsubjpass||licensed-30/VBN||vaccines-27/NNS	nsubjpass||used-33/VBN||vaccines-27/NNS	aux||licensed-30/VBN||have-28/VBP	auxpass||licensed-30/VBN||been-29/VBN	rcmod||first-24/JJ||licensed-30/VBN	advmod||used-33/VBN||widely-32/RB	rcmod||first-24/JJ||used-33/VBN	conj_and||licensed-30/VBN||used-33/VBN	chickenpox-9||varicella-zostervirus-1||no||varicella-zostervirus (vzv), the cause of chickenpox and zoster, was the first human herpesvirus to be sequenced fully and the first for which vaccines have been licensed and widely used.
amod||studies-2/NNS||more-1/JJR	nsubjpass||suggested-4/VBN||studies-2/NNS	auxpass||suggested-4/VBN||are-3/VBP	root||ROOT-0/null||suggested-4/VBN	aux||evaluate-6/VB||to-5/TO	ccomp||suggested-4/VBN||evaluate-6/VB	det||efficacy-8/NN||the-7/DT	dobj||evaluate-6/VB||efficacy-8/NN	prep_of||efficacy-8/NN||clozapine-10/NN	conj_and||in-11/IN||in-11/IN	prep_in||evaluate-6/VB||patients-12/NNS	prep_with||patients-12/NNS||bpd-14/NN	preconj||in-11/IN||both-16/DT	amod||features-21/NNS||psychotic-20/JJ	prep_with||in-11/IN||features-21/NNS	prep_without||in-11/IN||features-21/NNS	aux||find-24/VB||to-23/TO	ccomp||suggested-4/VBN||find-24/VB	conj_and||evaluate-6/VB||find-24/VB	prt||find-24/VB||out-25/RP	det||dose-28/NN||the-26/DT	amod||dose-28/NN||optimum-27/JJ	dobj||find-24/VB||dose-28/NN	aux||weigh-31/VB||to-30/TO	ccomp||suggested-4/VBN||weigh-31/VB	conj_and||evaluate-6/VB||weigh-31/VB	det||risk-33/NN||the-32/DT	dobj||weigh-31/VB||risk-33/NN	dobj||weigh-31/VB||benefits-35/NNS	conj_and||risk-33/NN||benefits-35/NNS	prep_of||risk-33/NN||clozapine-37/NN	psychotic-20||clozapine-37||yes||more studies are suggested to evaluate the efficacy of clozapine in patients with bpd, both with and without psychotic features, to find out the optimum dose and to weigh the risk and benefits of clozapine.
root||ROOT-0/null||mal/hok/24-1/CD	punct||mal/hok/24-1/CD||/-2/:	nsubj||avianinfluenzavirus-10/NNS||09-3/CD	nsubj||quails-18/VBZ||09-3/CD	nsubj||antigenically-22/JJ||09-3/CD	appos||09-3/CD||h5n1-5/NNP	cop||avianinfluenzavirus-10/NNS||is-7/VBZ	det||avianinfluenzavirus-10/NNS||a-8/DT	amod||avianinfluenzavirus-10/NNS||non-pathogenic-9/JJ	dep||mal/hok/24-1/CD||avianinfluenzavirus-10/NNS	prep_for||avianinfluenzavirus-10/NNS||chickens-12/NNS	amod||ducks-15/NNS||domestic-14/JJ	appos||chickens-12/NNS||ducks-15/NNS	dep||mal/hok/24-1/CD||quails-18/VBZ	conj_and||avianinfluenzavirus-10/NNS||quails-18/VBZ	cop||antigenically-22/JJ||is-21/VBZ	dep||mal/hok/24-1/CD||antigenically-22/JJ	conj_and||avianinfluenzavirus-10/NNS||antigenically-22/JJ	advmod||distinct-25/JJ||genetically-24/RB	conj_and||avianinfluenzavirus-10/NNS||distinct-25/JJ	conj_and||antigenically-22/JJ||distinct-25/JJ	det||hpaivs-29/NNS||the-27/DT	amod||hpaivs-29/NNS||h5n1-28/JJ	prep_from||distinct-25/JJ||hpaivs-29/NNS	vmod||hpaivs-29/NNS||prevailing-30/VBG	prep_in||prevailing-30/VBG||birds-32/NNS	prep_in||birds-32/NNS||eurasia-34/NN	prep_in||birds-32/NNS||africa-36/NN	conj_and||eurasia-34/NN||africa-36/NN	h5n1-28||avianinfluenzavirus-10||no||mal/hok/24/09 (h5n1) is a non-pathogenic avianinfluenzavirus for chickens, domestic ducks, and quails, and is antigenically and genetically distinct from the h5n1 hpaivs prevailing in birds in eurasia and africa.
nsubj||ligand-5/VBD||alterations-1/NNS	nn||cxcr3-4/NNS||serum-3/NN	prep_in||alterations-1/NNS||cxcr3-4/NNS	root||ROOT-0/null||ligand-5/VBD	nsubjpass||examined-8/VBN||levels-6/NNS	auxpass||examined-8/VBN||were-7/VBD	ccomp||ligand-5/VBD||examined-8/VBN	amod||cystitis-11/NNS||interstitial-10/JJ	prep_in||examined-8/VBN||cystitis-11/NNS	appos||cystitis-11/NNS||ic-13/NN	dep||cystitis-11/NNS||patients-15/NNS	amod||patterns-19/NNS||similar-17/JJ	nn||patterns-19/NNS||expression-18/NN	dep||cystitis-11/NNS||patterns-19/NNS	prep_in||patterns-19/NNS||serum-21/NN	amod||ligands-28/NNS||cxcr3-25/JJ	amod||ligands-28/NNS||cxcr3-27/JJ	prep_in||examined-8/VBN||ligands-28/NNS	conj_and||cystitis-11/NNS||ligands-28/NNS	nsubjpass||characterized-40/VBN||cytokines-31/NNS	vmod||cytokines-31/NNS||expressed-32/VBN	amod||subpopulations-38/NNS||peripheral-34/JJ	conj_and||peripheral-34/JJ||local-36/JJ	amod||subpopulations-38/NNS||local-36/JJ	nn||subpopulations-38/NNS||leukocyte-37/NN	agent||expressed-32/VBN||subpopulations-38/NNS	auxpass||characterized-40/VBN||were-39/VBD	conj_and||ligand-5/VBD||characterized-40/VBN	prep_during||characterized-40/VBN||cyclophosphamide-42/NN	appos||cyclophosphamide-42/NN||cyp-44/NN	amod||cystitis-49/NNS||induced-47/JJ	amod||cystitis-49/NNS||acute-48/JJ	dep||cyclophosphamide-42/NN||cystitis-49/NNS	prep_in||cystitis-49/NNS||mice-51/NNS	cyclophosphamide-42||cystitis-49||no_rel||alterations in serum cxcr3 ligand levels were examined in interstitial cystitis (ic) patients; similar expression patterns in serum as well as cxcr3, cxcr3 ligands, and cytokines expressed by peripheral and local leukocyte subpopulations were characterized during cyclophosphamide (cyp)-induced acute cystitis in mice.
det||therapy-3/NN||a-1/DT	nn||therapy-3/NN||salvage-2/NN	nsubjpass||performed-15/VBN||therapy-3/NN	prep_including||therapy-3/NN||osmotherapy-6/NN	prep_including||therapy-3/NN||corticosteroids-8/NN	conj_and||osmotherapy-6/NN||corticosteroids-8/NN	prep_including||therapy-3/NN||treatment-10/NN	conj_and||osmotherapy-6/NN||treatment-10/NN	prep_of||osmotherapy-6/NN||epilepticseizures-12/NNS	auxpass||performed-15/VBN||was-14/VBD	root||ROOT-0/null||performed-15/VBN	det||patient-19/NN||the-18/DT	nsubj||died-20/VBD||patient-19/NN	conj_but||performed-15/VBN||died-20/VBD	nn||herniation-23/NN||brainstem-22/NN	prep_from||died-20/VBD||herniation-23/NN	num||hours-25/NNS||48-24/CD	dobj||died-20/VBD||hours-25/NNS	prep_after||died-20/VBD||admission-27/NN	corticosteroids-8||herniation-23||no_rel||a salvage therapy, including osmotherapy, corticosteroids and treatment of epilepticseizures, was performed, but the patient died from brainstem herniation 48 hours after admission.
dep||important-27/JJ||given-1/VBN	mark||suffer-9/VBP||that-2/IN	mwe||than-4/IN||more-3/JJR	quantmod||billion-6/CD||than-4/IN	number||billion-6/CD||2-5/CD	num||people-7/NNS||billion-6/CD	nsubj||suffer-9/VBP||people-7/NNS	advmod||suffer-9/VBP||worldwide-8/RB	pcomp||given-1/VBN||suffer-9/VBP	prep_from||suffer-9/VBP||irondeficiency-11/NN	mark||one-16/CD||that-13/IN	nsubj||one-16/CD||ironoverload-14/NN	cop||one-16/CD||is-15/VBZ	pcomp||given-1/VBN||one-16/CD	conj_and||suffer-9/VBP||one-16/CD	det||diseases-23/NNS||the-18/DT	advmod||common-20/JJ||most-19/RBS	amod||diseases-23/NNS||common-20/JJ	amod||diseases-23/NNS||single-gene-21/JJ	amod||diseases-23/NNS||inherited-22/VBN	prep_of||one-16/CD||diseases-23/NNS	nsubj||important-27/JJ||it-25/PRP	nsubj||understand-29/VB||it-25/PRP	cop||important-27/JJ||is-26/VBZ	root||ROOT-0/null||important-27/JJ	aux||understand-29/VB||to-28/TO	xcomp||important-27/JJ||understand-29/VB	mark||influence-35/VB||whether-30/IN	nn||status-33/NN||host-31/NN	nn||status-33/NN||iron-32/NN	nsubj||influence-35/VB||status-33/NN	aux||influence-35/VB||may-34/MD	ccomp||understand-29/VB||influence-35/VB	advmod||glabrata-37/JJ||c.-36/RB	amod||progression-40/NN||glabrata-37/JJ	amod||progression-40/NN||infectious-38/JJ	nn||progression-40/NN||disease-39/NN	dobj||influence-35/VB||progression-40/NN	ironoverload-14||iron-32||no||given that more than 2 billion people worldwide suffer from irondeficiency and that ironoverload is one of the most common single-gene inherited diseases , it is important to understand whether host iron status may influence c. glabrata infectious disease progression .
det||report-3/NN||this-2/DT	prep_in||present-6/VBP||report-3/NN	nsubj||present-6/VBP||we-5/PRP	root||ROOT-0/null||present-6/VBP	amod||data-8/NNS||additional-7/JJ	nsubj||had-59/VBD||data-8/NNS	det||relationship-11/NN||the-10/DT	prep_concerning||data-8/NNS||relationship-11/NN	prep_of||relationship-11/NN||pruritus-13/NNS	aux||bile-15/VB||to-14/TO	vmod||pruritus-13/NNS||bile-15/VB	amod||retention-17/NN||acid-16/JJ	iobj||bile-15/VB||retention-17/NN	dep||excretion-23/NN||1-19/LS	det||excretion-23/NN||the-21/DT	amod||excretion-23/NN||urinary-22/JJ	dobj||bile-15/VB||excretion-23/NN	amod||acids-29/NNS||sulfated-25/JJ	conj_and||sulfated-25/JJ||nonsulfated-27/JJ	amod||acids-29/NNS||nonsulfated-27/JJ	nn||acids-29/NNS||bile-28/NN	prep_of||excretion-23/NN||acids-29/NNS	cop||different-33/JJ||was-30/VBD	neg||different-33/JJ||not-31/RB	advmod||different-33/JJ||significantly-32/RB	rcmod||acids-29/NNS||different-33/JJ	prep_in||different-33/JJ||patients-35/NNS	prep_with||patients-35/NNS||cholestasis-37/NNS	nsubj||itched-39/VBN||cholestasis-37/NNS	rcmod||cholestasis-37/NNS||itched-39/VBN	prepc_compared_to||itched-39/VBN||to-41/TO	pobj||itched-39/VBN||those-42/DT	nsubj||did-44/VBD||those-42/DT	rcmod||those-42/DT||did-44/VBD	neg||did-44/VBD||not-45/RB	dep||patient-51/NN||2-48/LS	num||patient-51/NN||one-50/CD	dep||excretion-23/NN||patient-51/NN	prep_with||patient-51/NN||itch-53/NN	vmod||itch-53/NN||associated-54/VBN	det||abscess-58/NNS||a-56/DT	nn||abscess-58/NNS||liver-57/NN	prep_with||associated-54/VBN||abscess-58/NNS	ccomp||present-6/VBP||had-59/VBD	amod||levels-61/NNS||normal-60/JJ	dobj||had-59/VBD||levels-61/NNS	nn||acids-64/NNS||bile-63/NN	prep_of||levels-61/NNS||acids-64/NNS	prep_in||had-59/VBD||serum-66/NN	prep_in||had-59/VBD||skin-68/NN	conj_and||serum-66/NN||skin-68/NN	prep_in||had-59/VBD||urine-71/NN	conj_and||serum-66/NN||urine-71/NN	dep||patients-76/NNS||3-74/LS	dep||serum-66/NN||patients-76/NNS	prep_with||patients-76/NNS||primarybiliarycirrhosis-78/NNS	nsubj||had-81/VBD||primarybiliarycirrhosis-78/NNS	advmod||had-81/VBD||itched-80/RB	rcmod||primarybiliarycirrhosis-78/NNS||had-81/VBD	amod||levels-86/NNS||lower-82/JJR	amod||levels-86/NNS||serum-83/JJ	nn||levels-86/NNS||bile-84/NN	nn||levels-86/NNS||acid-85/NN	dobj||had-81/VBD||levels-86/NNS	prep_than||levels-86/NNS||patients-88/NNS	amod||obstruction-92/NN||mechanical-90/JJ	nn||obstruction-92/NN||biliary-91/NN	prep_with||had-81/VBD||obstruction-92/NN	nsubj||itch-96/VB||obstruction-92/NN	aux||itch-96/VB||did-94/VBD	neg||itch-96/VB||not-95/RB	rcmod||obstruction-92/NN||itch-96/VB	primarybiliarycirrhosis-78||cholestasis-37||no||in this report, we present additional data concerning the relationship of pruritus to bile acid retention (1) the urinary excretion of sulfated and nonsulfated bile acids was not significantly different in patients with cholestasis who itched compared to those who did not; (2) one patient with itch associated with a liver abscess had normal levels of bile acids in serum, skin, and urine; (3) patients with primarybiliarycirrhosis who itched had lower serum bile acid levels than patients with mechanical biliary obstruction who did not itch.
det||effects-3/NNS||the-1/DT	amod||effects-3/NNS||therapeutic-2/JJ	nsubjpass||explored-21/VBN||effects-3/NNS	amod||infusion-6/NN||systemic-5/JJ	prep_of||effects-3/NNS||infusion-6/NN	amod||uc-mscs-9/NNS||human-8/JJ	prep_of||infusion-6/NN||uc-mscs-9/NNS	amod||arthritis-12/NN||collagen-induced-11/JJ	prep_on||uc-mscs-9/NNS||arthritis-12/NN	appos||arthritis-12/NN||cia-14/NN	det||model-19/NN||a-17/DT	nn||model-19/NN||mouse-18/NN	prep_in||arthritis-12/NN||model-19/NN	auxpass||explored-21/VBN||were-20/VBD	root||ROOT-0/null||explored-21/VBN	uc--1||collagen--1||no_rel||the therapeutic effects of systemic infusion of human uc-mscs on collagen-induced arthritis (cia) in a mouse model were explored.
mark||suggested-6/VBN||although-1/IN	det||studies-4/NNS||some-2/DT	amod||studies-4/NNS||previous-3/JJ	nsubj||suggested-6/VBN||studies-4/NNS	aux||suggested-6/VBN||have-5/VBP	advcl||examined-24/VBN||suggested-6/VBN	mark||comprised-14/VBN||that-7/IN	amod||growth-9/NN||posttraumatic-8/JJ	nsubjpass||comprised-14/VBN||growth-9/NN	appos||growth-9/NN||ptg-11/NN	auxpass||comprised-14/VBN||is-13/VBZ	ccomp||suggested-6/VBN||comprised-14/VBN	amod||factors-17/NNS||several-16/JJ	prep_of||comprised-14/VBN||factors-17/NNS	amod||properties-20/NNS||different-19/JJ	prep_with||comprised-14/VBN||properties-20/NNS	nsubj||examined-24/VBN||few-22/JJ	aux||examined-24/VBN||have-23/VBP	root||ROOT-0/null||examined-24/VBN	predet||association-27/NN||both-25/PDT	det||association-27/NN||the-26/DT	dobj||examined-24/VBN||association-27/NN	prep_between||examined-24/VBN||ptg-29/NN	prep_between||examined-24/VBN||posttraumaticstressdisorder-31/NN	conj_and||ptg-29/NN||posttraumaticstressdisorder-31/NN	dep||examined-24/VBN||ptsd-33/VBN	prep_between||examined-24/VBN||ptg-37/NN	conj_and||ptg-29/NN||ptg-37/NN	conj_and||ptg-29/NN||resilience-39/NN	conj_and||ptg-37/NN||resilience-39/NN	vmod||ptg-37/NN||focusing-41/VBG	prep_on||focusing-41/VBG||each-43/DT	det||factors-46/NNS||the-45/DT	prep_of||each-43/DT||factors-46/NNS	prep_of||factors-46/NNS||ptg-48/NN	ptg-48||posttraumaticstressdisorder-31||no_rel||although some previous studies have suggested that posttraumatic growth (ptg) is comprised of several factors with different properties, few have examined both the association between ptg and posttraumaticstressdisorder (ptsd) and between ptg and resilience, focusing on each of the factors of ptg.
nsubj||trial-9/NN||this-1/DT	cop||trial-9/NN||is-2/VBZ	det||trial-9/NN||a-3/DT	amod||trial-9/NN||randomized-4/JJ	amod||trial-9/NN||double-blind-6/JJ	amod||trial-9/NN||clinical-8/JJ	root||ROOT-0/null||trial-9/NN	vmod||trial-9/NN||comparing-11/VBG	det||association-13/NN||the-12/DT	dobj||comparing-11/VBG||association-13/NN	prep_of||association-13/NN||chlorthalidone-15/NN	prep_of||association-13/NN||amiloride-17/NN	conj_and||chlorthalidone-15/NN||amiloride-17/NN	prep_with||comparing-11/VBG||losartan-19/NN	amod||option-23/NN||first-21/JJ	nn||option-23/NN||drug-22/NN	prep_as||comparing-11/VBG||option-23/NN	prep_in||option-23/NN||patients-25/NNS	vmod||patients-25/NNS||aged-26/VBN	number||70-29/CD||30-27/CD	dep||70-29/CD||to-28/TO	num||years-30/NNS||70-29/CD	tmod||aged-26/VBN||years-30/NNS	nn||hypertension-35/NN||stage-33/NN	nn||hypertension-35/NN||i-34/NN	prep_with||aged-26/VBN||hypertension-35/NN	hypertension-35||losartan-19||yes||this is a randomized, double-blind, clinical trial, comparing the association of chlorthalidone and amiloride with losartan as first drug option in patients aged 30 to 70 years, with stage i hypertension.
amod||advances-2/NNS||newer-1/JJR	nsubj||include-3/VBP||advances-2/NNS	ccomp||revolutionized-63/VBD||include-3/VBP	dobj||include-3/VBP||introduction-4/NN	amod||techniques-7/NNS||newer-6/JJR	prep_of||introduction-4/NN||techniques-7/NNS	amod||epidurals-11/NNS||combined-9/VBN	amod||epidurals-11/NNS||spinal-10/JJ	prep_like||techniques-7/NNS||epidurals-11/NNS	amod||epidurals-14/NNS||low-dose-13/JJ	dobj||include-3/VBP||epidurals-14/NNS	conj_and||introduction-4/NN||epidurals-14/NNS	vmod||epidurals-14/NNS||facilitating-15/VBG	dobj||facilitating-15/VBG||ambulation-16/NN	amod||advances-19/NNS||pharmacological-18/JJ	dobj||include-3/VBP||advances-19/NNS	conj_and||introduction-4/NN||advances-19/NNS	prep_like||advances-19/NNS||introduction-21/NN	prep_of||introduction-21/NN||remifentanil-23/NN	amod||analgesia-27/NN||patient-controlled-25/JJ	amod||analgesia-27/NN||intravenous-26/JJ	prep_for||remifentanil-23/NN||analgesia-27/NN	dobj||include-3/VBP||introduction-29/NN	conj_and||introduction-4/NN||introduction-29/NN	amod||anaesthetics-33/NNS||newer-31/JJR	amod||anaesthetics-33/NNS||local-32/JJ	prep_of||introduction-29/NN||anaesthetics-33/NNS	dobj||include-3/VBP||adjuvants-35/NNS	conj_and||introduction-4/NN||adjuvants-35/NNS	prep_like||adjuvants-35/NNS||ropivacaine-37/JJ	prep_like||adjuvants-35/NNS||levobupivacaine-39/JJ	conj_and||ropivacaine-37/JJ||levobupivacaine-39/JJ	prep_like||adjuvants-35/NNS||sufentanil-41/JJ	conj_and||ropivacaine-37/JJ||sufentanil-41/JJ	prep_like||adjuvants-35/NNS||clonidine-43/JJ	conj_and||ropivacaine-37/JJ||clonidine-43/JJ	prep_like||adjuvants-35/NNS||neostigmine-45/JJ	conj_and||ropivacaine-37/JJ||neostigmine-45/JJ	appos||introduction-4/NN||use-47/NN	amod||agents-50/NNS||inhalational-49/JJ	prep_of||use-47/NN||agents-50/NNS	prep_like||agents-50/NNS||sevoflourane-52/NN	amod||analgesia-56/NN||patient-controlled-54/JJ	amod||analgesia-56/NN||inhalational-55/JJ	prep_for||sevoflourane-52/NN||analgesia-56/NN	vmod||analgesia-56/NN||using-57/VBG	amod||vaporizers-59/NNS||special-58/JJ	dobj||using-57/VBG||vaporizers-59/NNS	nsubj||revolutionized-63/VBD||all-61/DT	aux||revolutionized-63/VBD||have-62/VBP	root||ROOT-0/null||revolutionized-63/VBD	det||practice-65/NN||the-64/DT	dobj||revolutionized-63/VBD||practice-65/NN	nn||management-68/NN||pain-67/NN	prep_of||practice-65/NN||management-68/NN	prepc_in||revolutionized-63/VBD||labouring-70/VBG	dobj||labouring-70/VBG||parturients-71/NNS	pain-67||levobupivacaine-39||yes||newer advances include introduction of newer techniques like combined spinal epidurals, low-dose epidurals facilitating ambulation, pharmacological advances like introduction of remifentanil for patient-controlled intravenous analgesia, introduction of newer local anaesthetics and adjuvants like ropivacaine, levobupivacaine, sufentanil, clonidine and neostigmine, use of inhalational agents like sevoflourane for patient-controlled inhalational analgesia using special vaporizers, all have revolutionized the practice of pain management in labouring parturients.
nsubj||revealed-6/VBD||studies-1/NNS	vmod||studies-1/NNS||conducted-2/VBN	poss||laboratory-5/NN||our-4/PRP$	prep_in||conducted-2/VBN||laboratory-5/NN	root||ROOT-0/null||revealed-6/VBD	mark||affected-22/VBN||that-7/IN	det||bm-hscs-12/NNS||the-8/DT	amod||bm-hscs-12/NNS||primitive-9/JJ	amod||bm-hscs-12/NNS||sca-1-10/JJ	nn||bm-hscs-12/NNS||+-11/NN	nsubjpass||affected-22/VBN||bm-hscs-12/NNS	nn||marrow-15/NN||bone-14/NN	dep||bm-hscs-12/NNS||marrow-15/NN	amod||cell-18/NN||hematopoietic-16/JJ	nn||cell-18/NN||stem-17/NN	dep||marrow-15/NN||cell-18/NN	auxpass||affected-22/VBN||are-20/VBP	advmod||affected-22/VBN||significantly-21/RB	ccomp||revealed-6/VBD||affected-22/VBN	amod||animals-26/NNS||experimental-24/JJ	amod||animals-26/NNS||aplastic-25/JJ	prep_in||affected-22/VBN||animals-26/NNS	vmod||animals-26/NNS||pretreated-27/VBN	amod||drugs-30/NNS||chemotherapeutic-29/JJ	prep_with||pretreated-27/VBN||drugs-30/NNS	dep||drugs-30/NNS||busulfan-32/JJ	dep||drugs-30/NNS||cyclophosphamide-34/JJ	conj_and||busulfan-32/JJ||cyclophosphamide-34/JJ	expl||is-38/VBZ||there-37/EX	ccomp||revealed-6/VBD||is-38/VBZ	conj_and||affected-22/VBN||is-38/VBZ	amod||activity-41/NN||increased-39/VBN	amod||activity-41/NN||caspase-3-40/JJ	nsubj||is-38/VBZ||activity-41/NN	amod||high-44/JJ||consecutive-43/JJ	amod||population-58/NN||high-44/JJ	amod||population-58/NN||annexin-v-45/JJ	advmod||leading-47/JJ||positivity-46/RB	amod||population-58/NN||leading-47/JJ	amod||apoptosis-50/NNS||premature-49/JJ	prep_to||leading-47/JJ||apoptosis-50/NNS	det||marrow-54/NN||the-52/DT	nn||marrow-54/NN||bone-53/NN	prep_in||apoptosis-50/NNS||marrow-54/NN	amod||population-58/NN||hematopoietic-55/JJ	nn||population-58/NN||stem-56/NN	nn||population-58/NN||cell-57/NN	prep_with||activity-41/NN||population-58/NN	amod||condition-61/NN||aplastic-60/JJ	prep_in||activity-41/NN||condition-61/NN	cyclophosphamide-34||sca--1||no_rel||studies conducted in our laboratory revealed that the primitive sca-1+ bm-hscs (bone marrow hematopoietic stem cell) are significantly affected in experimental aplastic animals pretreated with chemotherapeutic drugs (busulfan and cyclophosphamide) and there is increased caspase-3 activity with consecutive high annexin-v positivity leading to premature apoptosis in the bone marrow hematopoietic stem cell population in aplastic condition.
nn||prevention-3/NN||stroke-2/NN	prep_for||associated-21/VBN||prevention-3/NN	prep_in||prevention-3/NN||patients-5/NNS	vmod||patients-5/NNS||suffering-6/VBG	prep_from||suffering-6/VBG||atrialfibrillation-8/NN	nsubjpass||associated-21/VBN||dabigatran-10/NN	vmod||dabigatran-10/NN||administered-11/VBN	det||dose-14/NN||a-13/DT	prep_at||administered-11/VBN||dose-14/NN	number||mg-17/CD||110-16/CD	prep_of||dose-14/NN||mg-17/CD	advmod||daily-19/JJ||twice-18/RB	advmod||mg-17/CD||daily-19/JJ	auxpass||associated-21/VBN||was-20/VBD	root||ROOT-0/null||associated-21/VBN	prep_with||associated-21/VBN||rates-23/NNS	prep_of||rates-23/NNS||stroke-25/NN	amod||embolism-28/NN||systemic-27/JJ	prep_with||associated-21/VBN||embolism-28/NN	conj_and||rates-23/NNS||embolism-28/NN	nsubj||similar-31/JJ||embolism-28/NN	cop||similar-31/JJ||were-30/VBD	rcmod||embolism-28/NN||similar-31/JJ	prep_to||similar-31/JJ||those-33/DT	vmod||those-33/DT||associated-34/VBN	prep_with||associated-34/VBN||warfarin-36/NN	amod||rates-42/NNS||lower-41/JJR	prep_with||associated-34/VBN||rates-42/NNS	conj_and||warfarin-36/NN||rates-42/NNS	prep_of||rates-42/NNS||hemorrhage-44/NN	stroke-25||warfarin-36||yes||for stroke prevention in patients suffering from atrialfibrillation, dabigatran administered at a dose of 110 mg twice daily was associated with rates of stroke and systemic embolism that were similar to those associated with warfarin, as well as lower rates of hemorrhage.
nsubj||±-9/VBZ||mice-1/NNS	det||deletion-5/NN||a-3/DT	amod||deletion-5/NN||whole-body-4/JJ	prep_with||mice-1/NNS||deletion-5/NN	det||î-8/NN||the-7/DT	prep_of||deletion-5/NN||î-8/NN	root||ROOT-0/null||±-9/VBZ	num||subunit-12/NN||2-10/CD	amod||subunit-12/NN||catalytic-11/JJ	dobj||±-9/VBZ||subunit-12/NN	prep_of||subunit-12/NN||ampk-14/NN	dep||±-9/VBZ||ampkî-16/VBG	nn||2â-18/NNP||±-17/NNP	poss||â-21/NNP||2â-18/NNP	nn||â-21/NNP||/-20/NNP	dobj||ampkî-16/VBG||â-21/NNP	poss||littermates-27/NNS||their-25/PRP$	amod||littermates-27/NNS||wild-type-26/JJ	nsubjpass||fed-29/VBN||littermates-27/NNS	auxpass||fed-29/VBN||were-28/VBD	conj_and||±-9/VBZ||fed-29/VBN	advmod||chow-34/NN||either-31/RB	det||chow-34/NN||a-32/DT	amod||chow-34/NN||low-fat-33/JJ	prep_on||fed-29/VBN||chow-34/NN	det||corn-38/NN||a-37/DT	prep_on||fed-29/VBN||corn-38/NN	conj_or||chow-34/NN||corn-38/NN	amod||diet-41/NN||oil-based-39/JJ	amod||diet-41/NN||high-fat-40/JJ	dep||corn-38/NN||diet-41/NN	appos||diet-41/NN||chf-43/NN	det||diet-49/NN||a-47/DT	nn||diet-49/NN||chf-48/NN	prep_on||fed-29/VBN||diet-49/NN	conj_or||chow-34/NN||diet-49/NN	number||%-52/NN||15-51/CD	amod||lipids-53/NNS||%-52/NN	prep_with||diet-49/NN||lipids-53/NNS	vmod||lipids-53/NNS||replaced-54/VBN	amod||concentrate-58/NN||n-3-56/JJ	amod||concentrate-58/NN||lc-pufa-57/JJ	agent||replaced-54/VBN||concentrate-58/NN	nn||f-62/NNP||chf-60/NNP	nn||f-62/NNP||+-61/NNP	appos||concentrate-58/NN||f-62/NNP	fat--1||chf-60||no_rel||mice with a whole-body deletion of the î±2 catalytic subunit of ampk (ampkî±2â/â) and their wild-type littermates were fed on either a low-fat chow, or a corn oil-based high-fat diet (chf), or a chf diet with 15% lipids replaced by n-3 lc-pufa concentrate (chf+f).
advmod||reversed-10/VBD||moreover-1/RB	amod||hc-030031-4/NN||oral-3/JJ	nsubj||reversed-10/VBD||hc-030031-4/NN	num||mg/kg-7/NN||100-6/CD	appos||hc-030031-4/NN||mg/kg-7/NN	advmod||reversed-10/VBD||significantly-9/RB	root||ROOT-0/null||reversed-10/VBD	amod||hypersensitivity-12/NN||mechanical-11/JJ	dobj||reversed-10/VBD||hypersensitivity-12/NN	det||models-17/NNS||the-14/DT	amod||models-17/NNS||more-15/JJR	amod||models-17/NNS||chronic-16/JJ	prep_in||reversed-10/VBD||models-17/NNS	amod||adjuvant-21/NN||complete-19/JJ	nn||adjuvant-21/NN||freunds-20/NNS	prep_of||models-17/NNS||adjuvant-21/NN	appos||adjuvant-21/NN||cfa-23/NN	advmod||inflammatory-27/JJ||induced-26/RB	amod||pain-28/NN||inflammatory-27/JJ	prep_of||models-17/NNS||pain-28/NN	conj_and||adjuvant-21/NN||pain-28/NN	det||model-34/NN||the-30/DT	amod||model-34/NN||spinal-31/JJ	nn||model-34/NN||nerve-32/NN	nn||model-34/NN||ligation-33/NN	prep_of||models-17/NNS||model-34/NN	conj_and||adjuvant-21/NN||model-34/NN	prep_of||model-34/NN||neuropathicpain-36/NN	pain-28||adjuvant-21||no_rel||moreover, oral hc-030031 (100 mg/kg) significantly reversed mechanical hypersensitivity in the more chronic models of complete freunds adjuvant (cfa)-induced inflammatory pain and the spinal nerve ligation model of neuropathicpain.
prepc_compared_with||lower-10/JJR||with-2/IN	pobj||lower-10/JJR||adolescents-3/NNS	prep_with||adolescents-3/NNS||ngt-5/NN	amod||insulin-8/NN||first-phase-7/JJ	nsubj||lower-10/JJR||insulin-8/NN	cop||lower-10/JJR||was-9/VBD	root||ROOT-0/null||lower-10/JJR	det||function-38/NN||those-12/DT	prep_with||igt-16/JJ||ifg-14/NN	amod||function-38/NN||igt-16/JJ	conj_and||igt-16/JJ||ifg/igt-19/JJ	amod||function-38/NN||ifg/igt-19/JJ	amod||deterioration-22/NN||further-21/JJ	prep_with||ifg/igt-19/JJ||deterioration-22/NN	prep_in||deterioration-22/NN||those-24/DT	prep_with||those-24/DT||type2diabetes-26/CD	dep||ifg/igt-19/JJ||p-28/NNP	number||0.001-30/CD||<-29/CD	num||p-28/NNP||0.001-30/CD	advmod||²-35/JJ||î-34/RB	conj_and||igt-16/JJ||²-35/JJ	amod||function-38/NN||²-35/JJ	nn||function-38/NN||cell-37/NN	prep_in||lower-10/JJR||function-38/NN	advmod||function-38/NN||relative-39/JJ	nn||sensitivity-42/NN||insulin-41/NN	prep_to||relative-39/JJ||sensitivity-42/NN	nn||-RSB--49/NNP||glucose-44/NN	nn||-RSB--49/NNP||disposition-45/NN	nn||-RSB--49/NNP||index-46/NN	nn||-RSB--49/NNP||-LSB--47/NNP	nn||-RSB--49/NNP||gdi-48/NNP	nsubj||lower-53/JJR||-RSB--49/NNP	cop||lower-53/JJR||was-51/VBD	advmod||lower-53/JJR||also-52/RB	rcmod||sensitivity-42/NN||lower-53/JJR	prep_in||lower-53/JJR||those-55/DT	prep_with||those-55/DT||ifg-57/NN	prep_with||those-55/DT||igt-59/NN	conj_and||ifg-57/NN||igt-59/NN	prep_with||those-55/DT||ifg/igt-62/NN	conj_and||ifg-57/NN||ifg/igt-62/NN	dep||ifg-57/NN||40-64/CD	dep||ifg-57/NN||47-66/CD	conj_and||40-64/CD||47-66/CD	num||%-70/NN||47-69/CD	dep||ifg-57/NN||%-70/NN	conj_and||40-64/CD||%-70/NN	advmod||%-70/NN||respectively-72/RB	det||decrease-78/NN||a-76/DT	amod||decrease-78/NN||further-77/JJ	prep_with||lower-10/JJR||decrease-78/NN	num||%-81/NN||80-80/CD	appos||decrease-78/NN||%-81/NN	prep_in||decrease-78/NN||those-84/DT	prep_with||those-84/DT||type2diabetes-86/NNS	appos||type2diabetes-86/NNS||p-88/NNP	number||0.001-90/CD||<-89/CD	num||p-88/NNP||0.001-90/CD	type2diabetes-86||insulin-41||yes||compared with adolescents with ngt, first-phase insulin was lower in those with ifg, igt, and ifg/igt with further deterioration in those with type2diabetes ( p < 0.001), and î²-cell function relative to insulin sensitivity (glucose disposition index [gdi]) was also lower in those with ifg, igt, and ifg/igt (40, 47, and 47%, respectively), with a further decrease (80%) in those with type2diabetes ( p < 0.001).
nsubj||allows-2/VBZ||it-1/PRP	root||ROOT-0/null||allows-2/VBZ	dobj||allows-2/VBZ||us-3/PRP	nsubj||show-5/VB||us-3/PRP	aux||show-5/VB||to-4/TO	xcomp||allows-2/VBZ||show-5/VB	mark||related-12/VBN||that-6/IN	det||sars-cov-8/NN||the-7/DT	nsubj||related-12/VBN||sars-cov-8/NN	cop||related-12/VBN||is-9/VBZ	advmod||closely-11/RB||most-10/RBS	advmod||related-12/VBN||closely-11/RB	ccomp||show-5/VB||related-12/VBN	det||coronavirus-15/NNS||a-14/DT	prep_to||related-12/VBN||coronavirus-15/NNS	det||civet-19/NN||the-17/DT	nn||civet-19/NN||palm-18/NN	prep_from||coronavirus-15/NNS||civet-19/NN	neg||related-12/VBN||not-20/RB	det||bird-23/NN||a-22/DT	prep_from||related-12/VBN||bird-23/NN	mark||suspected-26/VBD||as-24/IN	advmod||suspected-26/VBD||initially-25/RB	dep||related-12/VBN||suspected-26/VBD	det||hcov-hku1-34/NN||the-29/DT	advmod||discovered-31/VBN||newly-30/RB	amod||hcov-hku1-34/NN||discovered-31/VBN	amod||hcov-hku1-34/NN||human-32/JJ	nn||hcov-hku1-34/NN||coronavirus-33/NNS	nsubj||related-38/VBN||hcov-hku1-34/NN	cop||related-38/VBN||is-35/VBZ	advmod||related-38/VBN||more-36/RBR	advmod||related-38/VBN||closely-37/RB	conj_and||allows-2/VBZ||related-38/VBN	prep_to||related-38/VBN||sars-40/NNS	advmod||related-38/VBN||than-41/IN	det||member-46/NN||any-43/DT	amod||member-46/NN||other-44/JJ	amod||member-46/NN||known-45/VBN	prep_to||than-41/IN||member-46/NN	nn||coronavirus-50/NNS||group-48/NN	num||coronavirus-50/NNS||2-49/CD	prep_of||member-46/NN||coronavirus-50/NNS	sars-40||sars-cov-8||no||it allows us to show that the sars-cov is most closely related to a coronavirus from the palm civet not from a bird as initially suspected, and the newly discovered human coronavirus hcov-hku1 is more closely related to sars than to any other known member of group 2 coronavirus.
advmod||administrated-13/VBN||even-1/RB	mark||administrated-13/VBN||though-2/IN	nsubjpass||administrated-13/VBN||immunoprophylaxis-3/NNS	amod||immunoglobulin-6/NN||hepatitisb-5/JJ	prep_with||immunoprophylaxis-3/NNS||immunoglobulin-6/NN	appos||immunoglobulin-6/NN||hbig-8/NN	prep_with||immunoprophylaxis-3/NNS||hepatitisbvaccine-11/NN	conj_and||immunoglobulin-6/NN||hepatitisbvaccine-11/NN	auxpass||administrated-13/VBN||is-12/VBZ	advcl||suffer-31/VBP||administrated-13/VBN	prep_to||administrated-13/VBN||neonates-15/NNS	poss||mothers-17/NNS||neonates-15/NNS	nsubjpass||hepatitisbsurfaceantigen-19/VBN||mothers-17/NNS	auxpass||hepatitisbsurfaceantigen-19/VBN||are-18/VBP	rcmod||neonates-15/NNS||hepatitisbsurfaceantigen-19/VBN	dep||positive-23/JJ||hbsag-21/JJ	acomp||hepatitisbsurfaceantigen-19/VBN||positive-23/JJ	quantmod||10-26/CD||about-25/RB	num||%-27/NN||10-26/CD	nsubj||suffer-31/VBP||%-27/NN	det||neonates-30/NNS||the-29/DT	prep_of||%-27/NN||neonates-30/NNS	root||ROOT-0/null||suffer-31/VBP	nn||infection-34/NN||hbv-33/NN	prep_from||suffer-31/VBP||infection-34/NN	poss||life-38/NN||their-36/PRP$	amod||life-38/NN||early-37/JJ	prep_in||infection-34/NN||life-38/NN	hbv-33||hepatitisbsurfaceantigen-19||yes||even though immunoprophylaxis with hepatitisb immunoglobulin (hbig) and hepatitisbvaccine is administrated to neonates whose mothers are hepatitisbsurfaceantigen (hbsag) positive, about 10% of the neonates suffer from hbv infection in their early life.
nn||±-2/NNP||pparî-1/NNP	nsubj||serves-3/VBZ||±-2/NNP	nsubj||regulate-11/VB||±-2/NNP	root||ROOT-0/null||serves-3/VBZ	det||sensor-9/NN||a-5/DT	nn||sensor-9/NN||xenobiotic-6/NN	conj_and||xenobiotic-6/NN||lipid-8/NN	nn||sensor-9/NN||lipid-8/NN	prep_as||serves-3/VBZ||sensor-9/NN	aux||regulate-11/VB||to-10/TO	xcomp||serves-3/VBZ||regulate-11/VB	nn||combustion-13/NN||energy-12/NN	dobj||regulate-11/VB||combustion-13/NN	amod||steatosis-16/NNS||hepatic-15/JJ	dobj||regulate-11/VB||steatosis-16/NNS	conj_and||combustion-13/NN||steatosis-16/NNS	nn||synthesis-19/NN||lipoprotein-18/NN	dobj||regulate-11/VB||synthesis-19/NN	conj_and||combustion-13/NN||synthesis-19/NN	dobj||regulate-11/VB||inflammation-21/NN	conj_and||combustion-13/NN||inflammation-21/NN	nn||cancer-24/NN||liver-23/NN	dobj||regulate-11/VB||cancer-24/NN	conj_and||combustion-13/NN||cancer-24/NN	lipid-8||inflammation-21||no_rel||pparî± serves as a xenobiotic and lipid sensor to regulate energy combustion, hepatic steatosis, lipoprotein synthesis, inflammation and liver cancer.
det||factors-7/NNS||the-1/DT	nn||factors-7/NNS||frequency-2/NN	conj_and||frequency-2/NN||severity-4/NN	nn||factors-7/NNS||severity-4/NN	conj_and||frequency-2/NN||risk-6/NN	nn||factors-7/NNS||risk-6/NN	nsubjpass||determined-11/VBN||factors-7/NNS	nsubjpass||compared-13/VBN||factors-7/NNS	prep_for||factors-7/NNS||rop-9/NN	auxpass||determined-11/VBN||were-10/VBD	root||ROOT-0/null||determined-11/VBN	conj_and||determined-11/VBN||compared-13/VBN	det||group-16/NN||a-15/DT	prep_to||determined-11/VBN||group-16/NN	prep_of||group-16/NN||singletons-18/NNS	nsubjpass||matched-21/VBN||singletons-18/NNS	auxpass||matched-21/VBN||were-20/VBD	rcmod||singletons-18/NNS||matched-21/VBN	prep_in||matched-21/VBN||terms-23/NNS	prep_of||terms-23/NNS||gender-25/NN	nn||weight-28/NN||birth-27/NN	prep_of||terms-23/NNS||weight-28/NN	conj_and||gender-25/NN||weight-28/NN	appos||gender-25/NN||bw-30/NN	amod||ga-36/NN||gestational-33/JJ	nn||ga-36/NN||age-34/NN	prep_of||terms-23/NNS||ga-36/NN	conj_and||gender-25/NN||ga-36/NN	nn||therapy-40/NN||oxygen-39/NN	prep_of||terms-23/NNS||therapy-40/NN	conj_and||gender-25/NN||therapy-40/NN	prep_of||terms-23/NNS||respiratorydistresssyndrome-42/NN	conj_and||gender-25/NN||respiratorydistresssyndrome-42/NN	nn||transfusion-45/NN||blood-44/NN	prep_of||terms-23/NNS||transfusion-45/NN	conj_and||gender-25/NN||transfusion-45/NN	prep_of||terms-23/NNS||sepsis-47/NN	conj_and||gender-25/NN||sepsis-47/NN	prep_of||terms-23/NNS||phototherapy-49/NN	conj_and||gender-25/NN||phototherapy-49/NN	rop-9||oxygen-39||no||the frequency, severity and risk factors for rop were determined and compared to a group of singletons who were matched in terms of gender, birth weight (bw), gestational age (ga), oxygen therapy, respiratorydistresssyndrome, blood transfusion, sepsis and phototherapy.
nn||gain-3/NN||body-1/NN	nn||gain-3/NN||weight-2/NN	nsubjpass||suppressed-20/VBN||gain-3/NN	amod||accumulation-7/NN||fat-5/JJ	nn||accumulation-7/NN||pad-6/NN	conj_and||gain-3/NN||accumulation-7/NN	nsubjpass||suppressed-20/VBN||accumulation-7/NN	det||development-10/NN||the-9/DT	conj_and||gain-3/NN||development-10/NN	nsubjpass||suppressed-20/VBN||development-10/NN	prep_of||development-10/NN||hyperlipidemia-12/NN	conj_and||gain-3/NN||hyperglycemia-14/NN	nsubjpass||suppressed-20/VBN||hyperglycemia-14/NN	conj_and||gain-3/NN||insulinresistance-17/NN	nsubjpass||suppressed-20/VBN||insulinresistance-17/NN	auxpass||suppressed-20/VBN||were-18/VBD	advmod||suppressed-20/VBN||significantly-19/RB	root||ROOT-0/null||suppressed-20/VBN	amod||polyphenols-23/NNS||lemon-22/JJ	agent||suppressed-20/VBN||polyphenols-23/NNS	fat-5||hyperglycemia-14||no_rel||body weight gain, fat pad accumulation, the development of hyperlipidemia, hyperglycemia, and insulinresistance were significantly suppressed by lemon polyphenols.
det||vulnerability-3/NN||this-1/DT	amod||vulnerability-3/NN||increased-2/VBN	nsubj||due-6/JJ||vulnerability-3/NN	aux||due-6/JJ||may-4/MD	cop||due-6/JJ||be-5/VB	root||ROOT-0/null||due-6/JJ	amod||symptom-9/NN||more-8/JJR	prep_to||due-6/JJ||symptom-9/NN	vmod||symptom-9/NN||â-10/VBN	dobj||â-10/VBN||$-11/$	num||$-11/$||noiseâ-12/CD	dep||$-11/$||$-13/$	quantmod||euglycemia-18/CD||more-15/JJR	quantmod||euglycemia-18/CD||symptoms-16/IN	quantmod||euglycemia-18/CD||during-17/IN	npadvmod||more-37/JJR||euglycemia-18/CD	appos||euglycemia-18/CD||making-21/NN	npadvmod||harder-23/JJR||it-22/PRP	amod||making-21/NN||harder-23/JJR	amod||driving-28/NN||detect-25/JJ	nn||driving-28/NN||hypoglycemia-26/NN	nn||driving-28/NN||while-27/NN	prep_to||harder-23/JJR||driving-28/NN	advmod||driving-28/NN||possibly-30/RB	amod||utilization-33/NN||greater-31/JJR	nn||utilization-33/NN||carbohydrate-32/NN	dep||driving-28/NN||utilization-33/NN	prep_rendering||euglycemia-18/CD||them-36/PRP	dep||hypoglycemia-41/CD||more-37/JJR	dep||more-37/JJR||vulnerable-38/CD	prep_to||more-37/JJR||experiencing-40/NNP	num||$-13/$||hypoglycemia-41/CD	amod||counterregulation-45/NN||less-43/JJR	amod||counterregulation-45/NN||hormonal-44/JJ	dobj||â-10/VBN||counterregulation-45/NN	conj_and||$-11/$||counterregulation-45/NN	appos||counterregulation-45/NN||leading-47/VBG	amod||hypoglycemia-51/NN||more-49/JJR	amod||hypoglycemia-51/NN||profound-50/JJ	prep_to||leading-47/VBG||hypoglycemia-51/NN	amod||neuroglycopenia-55/NN||more-54/JJR	dobj||â-10/VBN||neuroglycopenia-55/NN	conj_and||$-11/$||neuroglycopenia-55/NN	vmod||â-10/VBN||rendering-57/VBG	nsubj||driving-63/VBG||them-58/PRP	advmod||vulnerable-60/JJ||more-59/RBR	dep||driving-63/VBG||vulnerable-60/JJ	prep_to||vulnerable-60/JJ||impaired-62/JJ	xcomp||rendering-57/VBG||driving-63/VBG	hypoglycemia-51||carbohydrate-32||no_rel||this increased vulnerability may be due to more symptom ânoiseâ? (more symptoms during euglycemia), making it harder to detect hypoglycemia while driving; possibly greater carbohydrate utilization, rendering them more vulnerable to experiencing hypoglycemia; less hormonal counterregulation, leading to more profound hypoglycemia; and more neuroglycopenia, rendering them more vulnerable to impaired driving.
amod||melioidosis-2/NNS||endemic-1/JJ	nsubjpass||caused-4/VBN||melioidosis-2/NNS	auxpass||caused-4/VBN||is-3/VBZ	root||ROOT-0/null||caused-4/VBN	advmod||diverse-7/JJ||genetically-6/RB	amod||strains-9/NNS||diverse-7/JJ	nn||strains-9/NNS||burkholderiapseudomallei-8/NN	agent||caused-4/VBN||strains-9/NNS	melioidosis-2||burkholderiapseudomallei-8||no||endemic melioidosis is caused by genetically diverse burkholderiapseudomallei strains.
nn||transfers-2/NNS||cash-1/NN	nsubjpass||implemented-5/VBN||transfers-2/NNS	aux||implemented-5/VBN||can-3/MD	auxpass||implemented-5/VBN||be-4/VB	root||ROOT-0/null||implemented-5/VBN	prep_in||implemented-5/VBN||conjunction-7/NN	amod||services-10/NNS||other-9/JJ	prep_with||implemented-5/VBN||services-10/NNS	xcomp||implemented-5/VBN||involving-11/VBG	nn||welfare-19/NN||education-12/NN	dobj||involving-11/VBG||health-14/NN	conj_and||welfare-19/NN||health-14/NN	dobj||involving-11/VBG||nutrition-16/NN	conj_and||welfare-19/NN||nutrition-16/NN	dobj||involving-11/VBG||social-18/JJ	amod||welfare-19/NN||social-18/JJ	conj_and||welfare-19/NN||social-18/JJ	dobj||involving-11/VBG||welfare-19/NN	dobj||involving-11/VBG||others-21/NNS	conj_and||welfare-19/NN||others-21/NNS	prep_including||implemented-5/VBN||those-24/DT	vmod||those-24/DT||related-25/VBN	prep_to||related-25/VBN||hiv-27/NN	prep_to||related-25/VBN||aids-29/NNS	conj_and||hiv-27/NN||aids-29/NNS	aids-29||hiv-27||no||cash transfers can be implemented in conjunction with other services involving education, health, nutrition, social welfare and others, including those related to hiv and aids.
nn||dal-1-3/NNS||treponemapallidum-1/NN	nn||dal-1-3/NNS||strain-2/NN	nsubj||pathogen-8/NN||dal-1-3/NNS	cop||pathogen-8/NN||is-4/VBZ	det||pathogen-8/NN||a-5/DT	amod||pathogen-8/NN||human-6/JJ	nn||pathogen-8/NN||uncultivable-7/NN	root||ROOT-0/null||pathogen-8/NN	vmod||pathogen-8/NN||causing-9/VBG	det||disease-13/NN||the-10/DT	advmod||disease-13/NN||sexually-11/RB	amod||disease-13/NN||transmitted-12/JJ	dobj||causing-9/VBG||disease-13/NN	advmod||causing-9/VBG||syphilis-14/RB	syphilis-14||treponemapallidum-1||no||treponemapallidum strain dal-1 is a human uncultivable pathogen causing the sexually transmitted disease syphilis.
amod||offspring-2/NN||sedentary-1/JJ	nsubj||insulin-resistant-10/JJ||offspring-2/NN	prep_of||offspring-2/NN||patients-4/NNS	prep_with||patients-4/NNS||type2diabetes-6/CD	cop||insulin-resistant-10/JJ||are-7/VBP	advmod||insulin-resistant-10/JJ||often-8/RB	advmod||insulin-resistant-10/JJ||more-9/RBR	root||ROOT-0/null||insulin-resistant-10/JJ	prep_than||insulin-resistant-10/JJ||persons-12/NNS	neg||history-16/NN||no-14/DT	nn||history-16/NN||family-15/NN	prep_with||persons-12/NNS||history-16/NN	prep_of||history-16/NN||diabetes-18/NN	advmod||are-31/VBP||when-21/WRB	amod||offspring-25/NN||active-22/JJ	conj_or||active-22/JJ||fit-24/JJ	amod||offspring-25/NN||fit-24/JJ	nsubj||are-31/VBP||offspring-25/NN	amod||patients-30/NNS||type-27/NN	number||type-27/NN||2-28/CD	amod||patients-30/NNS||diabetic-29/JJ	prep_of||offspring-25/NN||patients-30/NNS	advcl||evident-42/JJ||are-31/VBP	prepc_compared_with||are-31/VBP||with-33/IN	amod||persons-35/NNS||non-diabetic-34/JJ	pobj||are-31/VBP||persons-35/NNS	nsubj||evident-42/JJ||differences-37/NNS	prep_in||differences-37/NNS||insulinresistance-39/NN	cop||evident-42/JJ||are-40/VBP	advmod||evident-42/JJ||less-41/RBR	conj_but||insulin-resistant-10/JJ||evident-42/JJ	insulin--1||type2diabetes-6||no_rel||sedentary offspring of patients with type2diabetes are often more insulin-resistant than persons with no family history of diabetes, but when active or fit offspring of type 2 diabetic patients are compared with non-diabetic persons, differences in insulinresistance are less evident.
nsubj||evident-24/JJ||protection-1/NN	vmod||protection-1/NN||indicated-3/VBN	amod||parameters-6/NNS||reduced-5/VBN	agent||indicated-3/VBN||parameters-6/NNS	prep_of||parameters-6/NNS||disease-8/NN	amod||ige-11/NN||allergen-specific-10/JJ	dep||disease-8/NN||ige-11/NN	prep_in||ige-11/NN||serum-13/NN	amod||inflammation-16/NN||eosinophilic-15/JJ	dep||disease-8/NN||inflammation-16/NN	conj_and||ige-11/NN||inflammation-16/NN	det||airways-19/NNS||the-18/DT	prep_in||inflammation-16/NN||airways-19/NNS	dep||disease-8/NN||lung-21/NN	conj_and||ige-11/NN||lung-21/NN	cop||evident-24/JJ||were-23/VBD	root||ROOT-0/null||evident-24/JJ	amod||mice-27/NNS||fcrn-sufficient-26/JJ	prep_in||evident-24/JJ||mice-27/NNS	vmod||mice-27/NNS||nursed-28/VBD	prep_as||nursed-28/VBD||neonates-30/NNS	amod||mothers-33/NNS||allergic-32/JJ	agent||nursed-28/VBD||mothers-33/NNS	allergen--1||inflammation-16||no_rel||protection, indicated by reduced parameters of disease (allergen-specific ige in serum, eosinophilic inflammation in the airways and lung) were evident in fcrn-sufficient mice nursed as neonates by allergic mothers.
nsubj||repeated-2/VBD||conclusion-1/NN	root||ROOT-0/null||repeated-2/VBD	nsubj||have-4/VBP||estimates-3/NNS	ccomp||repeated-2/VBD||have-4/VBP	amod||understanding-6/NN||improved-5/VBN	dobj||have-4/VBP||understanding-6/NN	det||epidemic-10/NN||the-8/DT	amod||epidemic-10/NN||hiv/aids-9/JJ	prep_of||understanding-6/NN||epidemic-10/NN	prep_in||epidemic-10/NN||china-12/NN	aids--1||hiv--1||no||conclusion repeated estimates have improved understanding of the hiv/aids epidemic in china.
nsubj||examined-2/VBD||we-1/PRP	root||ROOT-0/null||examined-2/VBD	det||mechanisms-6/NNS||the-3/DT	amod||mechanisms-6/NNS||possible-4/JJ	amod||mechanisms-6/NNS||anti-inflammatory-5/JJ	dobj||examined-2/VBD||mechanisms-6/NNS	prep_of||mechanisms-6/NNS||gabapentin-8/NN	det||attenuation-11/NN||the-10/DT	prep_in||examined-2/VBD||attenuation-11/NN	prep_of||attenuation-11/NN||neuropathicpain-13/NN	det||interaction-16/NN||the-15/DT	prep_in||examined-2/VBD||interaction-16/NN	conj_and||attenuation-11/NN||interaction-16/NN	det||effects-20/NNS||the-18/DT	amod||effects-20/NNS||anti-allodynic-19/JJ	prep_between||interaction-16/NN||effects-20/NNS	prep_of||effects-20/NNS||gabapentin-22/NN	amod||expression-28/NN||interleukin-10-24/JJ	dep||expression-28/NN||il-10-26/JJ	prep_between||interaction-16/NN||expression-28/NN	conj_and||effects-20/NNS||expression-28/NN	det||model-32/NN||a-30/DT	nn||model-32/NN||rat-31/NN	prep_in||expression-28/NN||model-32/NN	prep_of||model-32/NN||neuropathicpain-34/NN	anti-inflammatory-5||neuropathicpain-34||no_rel||we examined the possible anti-inflammatory mechanisms of gabapentin in the attenuation of neuropathicpain and the interaction between the anti-allodynic effects of gabapentin and interleukin-10 (il-10) expression in a rat model of neuropathicpain.
amod||differentiation-5/NN||neuroendocrine-1/JJ	appos||differentiation-5/NN||ne-3/NN	nsubjpass||correlated-11/VBN||differentiation-5/NN	nn||cancer-8/NN||prostate-7/NN	prep_in||differentiation-5/NN||cancer-8/NN	aux||correlated-11/VBN||has-9/VBZ	auxpass||correlated-11/VBN||been-10/VBN	root||ROOT-0/null||correlated-11/VBN	det||prognosis-15/NN||a-13/DT	amod||prognosis-15/NN||poor-14/JJ	prep_with||correlated-11/VBN||prognosis-15/NN	nn||disease-19/NN||hormone-17/NN	amod||disease-19/NN||refractory-18/JJ	prep_with||correlated-11/VBN||disease-19/NN	conj_and||prognosis-15/NN||disease-19/NN	cancer-8||hormone-17||no_rel||neuroendocrine (ne) differentiation in prostate cancer has been correlated with a poor prognosis and hormone refractory disease.
det||results-2/NNS||these-1/DT	nsubj||support-3/VBP||results-2/NNS	root||ROOT-0/null||support-3/VBP	det||use-6/NN||the-4/DT	amod||use-6/NN||therapeutic-5/JJ	dobj||support-3/VBP||use-6/NN	prep_of||use-6/NN||anti-igf-1r-8/JJ	punct||bortezomib-10/NN||/-9/:	dep||anti-igf-1r-8/JJ||bortezomib-10/NN	amod||patients-14/NNS||cd45neg-12/JJ	nn||patients-14/NNS||myeloma-13/NN	prep_in||bortezomib-10/NN||patients-14/NNS	advmod||those-17/DT||particularly-16/RB	appos||bortezomib-10/NN||those-17/DT	det||form-22/NN||the-19/DT	advmod||aggressive-21/JJ||most-20/RBS	amod||form-22/NN||aggressive-21/JJ	prep_with||those-17/DT||form-22/NN	dep||bortezomib-10/NN||t-24/JJ	appos||anti-igf-1r-8/JJ||4,14-26/CD	myeloma-13||bortezomib-10||yes||these results support the therapeutic use of anti-igf-1r/bortezomib in cd45neg myeloma patients, particularly those with the most aggressive form, t (4,14).
det||corynebacteriumdiphtheriae-6/NN||the-1/DT	amod||corynebacteriumdiphtheriae-6/NN||aerobic-2/JJ	amod||corynebacteriumdiphtheriae-6/NN||gram-3/JJ	amod||corynebacteriumdiphtheriae-6/NN||positive-4/JJ	nn||corynebacteriumdiphtheriae-6/NN||bacterium-5/NN	nsubj||causes-7/VBZ||corynebacteriumdiphtheriae-6/NN	ccomp||characterized-14/VBD||causes-7/VBZ	dobj||causes-7/VBZ||diphtheria-8/NN	det||illness-13/NN||a-10/DT	amod||illness-13/NN||respiratory-11/JJ	nn||illness-13/NN||tract-12/NN	nsubj||characterized-14/VBD||illness-13/NN	nsubj||nasal-36/VBP||illness-13/NN	root||ROOT-0/null||characterized-14/VBD	prep_by||characterized-14/VBD||symptoms-16/NNS	amod||throat-20/NN||sore-19/JJ	prep_such_as||symptoms-16/NNS||throat-20/NN	amod||fever-23/NN||low-22/JJ	prep_such_as||symptoms-16/NNS||fever-23/NN	conj_and||throat-20/NN||fever-23/NN	det||membrane-28/NN||an-26/DT	amod||membrane-28/NN||adherent-27/JJ	prep_such_as||symptoms-16/NNS||membrane-28/NN	conj_and||throat-20/NN||membrane-28/NN	det||tonsils-31/NNS||the-30/DT	prep_on||characterized-14/VBD||tonsils-31/NNS	appos||tonsils-31/NNS||pharynx-33/NN	conj_and/or||characterized-14/VBD||nasal-36/VBP	advmod||nasal-36/VBP||cavity-37/RB	diphtheria-8||corynebacteriumdiphtheriae-6||no||the aerobic gram positive bacterium corynebacteriumdiphtheriae causes diphtheria, a respiratory tract illness characterized by symptoms such as sore throat, low fever, and an adherent membrane on the tonsils, pharynx, and/or nasal cavity.
amod||outcome-2/NN||main-1/JJ	nsubj||measures-3/VBZ||outcome-2/NN	root||ROOT-0/null||measures-3/VBZ	amod||number-5/NN||monthly-4/JJ	dobj||measures-3/VBZ||number-5/NN	prep_of||number-5/NN||prescriptions-7/NNS	amod||prophylaxis-10/NNS||antibiotic-9/JJ	prep_for||prescriptions-7/NNS||prophylaxis-10/NNS	vmod||prophylaxis-10/NNS||consisting-11/VBG	det||dose-18/NN||a-13/DT	amod||dose-18/NN||single-14/JJ	number||g-16/CD||3-15/CD	num||dose-18/NN||g-16/CD	amod||dose-18/NN||oral-17/JJ	prep_of||consisting-11/VBG||dose-18/NN	prep_of||dose-18/NN||amoxicillin-20/NNP	det||dose-27/NN||a-22/DT	amod||dose-27/NN||single-23/JJ	number||mg-25/CD||600-24/CD	num||dose-27/NN||mg-25/CD	amod||dose-27/NN||oral-26/JJ	dobj||measures-3/VBZ||dose-27/NN	conj_or||number-5/NN||dose-27/NN	prep_of||dose-27/NN||clindamycin-29/NN	amod||number-33/NN||monthly-32/JJ	dobj||measures-3/VBZ||number-33/NN	conj_and||number-5/NN||number-33/NN	prep_of||number-33/NN||cases-35/NNS	prep_of||cases-35/NNS||infectiveendocarditis-37/NNS	amod||deaths-41/NNS||infectiveendocarditis-39/JJ	amod||deaths-41/NNS||related-40/JJ	prep_of||number-33/NN||deaths-41/NNS	conj_or||cases-35/NNS||deaths-41/NNS	prep_in||deaths-41/NNS||hospital-43/NN	prep_of||number-33/NN||cases-46/NNS	conj_or||cases-35/NNS||cases-46/NNS	prep_of||cases-46/NNS||infectiveendocarditis-48/NNS	det||origin-53/NN||a-50/DT	amod||origin-53/NN||possible-51/JJ	amod||origin-53/NN||oral-52/JJ	prep_with||infectiveendocarditis-48/NNS||origin-53/NN	prep_for||origin-53/NN||streptococci-55/NNS	infectiveendocarditis-48||clindamycin-29||yes||main outcome measures monthly number of prescriptions for antibiotic prophylaxis consisting of a single 3 g oral dose of amoxicillin or a single 600 mg oral dose of clindamycin, and monthly number of cases of infectiveendocarditis, infectiveendocarditis related deaths in hospital, or cases of infectiveendocarditis with a possible oral origin for streptococci.
nsubj||found-2/VBD||we-1/PRP	root||ROOT-0/null||found-2/VBD	neg||evidence-4/NN||no-3/DT	dobj||found-2/VBD||evidence-4/NN	prep_of||evidence-4/NN||associations-6/NNS	prep_with||found-2/VBD||type2diabetes-8/NNS	cc||-LSB--12/NNS||or-10/CC	num||-LSB--12/NNS||1.05-11/CD	dep||type2diabetes-8/NNS||-LSB--12/NNS	num||-RSB--15/NNS||0.90-1-13/CD	num||-RSB--15/NNS||.23-14/CD	nsubj||0.54-19/CD||-RSB--15/NNS	vmod||-RSB--15/NNS||p-17/VBN	dep||0.54-19/CD||=-18/SYM	rcmod||-LSB--12/NNS||0.54-19/CD	amod||assessment-24/NN||homeostasis-22/JJ	nn||assessment-24/NN||model-23/NN	prep_with||found-2/VBD||assessment-24/NN	conj_or||type2diabetes-8/NNS||assessment-24/NN	nn||sensitivity-27/NN||insulin-26/NN	prep_of||assessment-24/NN||sensitivity-27/NN	appos||sensitivity-27/NN||homa-s-29/NNS	dep||assessment-24/NN||p-32/VBN	dep||0.86-34/CD||=-33/SYM	ccomp||p-32/VBN||0.86-34/CD	nn||status-38/NN||sleep-37/NN	prep_with||found-2/VBD||status-38/NN	conj_or||type2diabetes-8/NNS||status-38/NN	nn||-42/NNS||p-40/NN	nn||-42/NNS||â-41/NN	nsubj||¥-43/VBZ||-42/NNS	dep||status-38/NN||¥-43/VBZ	dobj||¥-43/VBZ||0.44-44/CD	type2diabetes-8||insulin-26||yes||we found no evidence of associations with type2diabetes (or 1.05 [0.90-1.23], p = 0.54), homeostasis model assessment of insulin sensitivity (homa-s) ( p = 0.86) or sleep status ( p â¥ 0.44).
det||aim-2/NN||the-1/DT	nsubj||was-6/VBD||aim-2/NN	nsubj||elucidate-8/VB||aim-2/NN	det||study-5/NN||this-4/DT	prep_of||aim-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||elucidate-8/VB||to-7/TO	xcomp||was-6/VBD||elucidate-8/VB	det||mechanisms-10/NNS||the-9/DT	nsubj||underlying-11/VBG||mechanisms-10/NNS	dep||elucidate-8/VB||underlying-11/VBG	det||elimination-14/NN||the-12/DT	amod||elimination-14/NN||renal-13/JJ	dobj||underlying-11/VBG||elimination-14/NN	amod||creatinine-18/NN||uremic-16/JJ	nn||creatinine-18/NN||toxin-17/NN	prep_of||elimination-14/NN||creatinine-18/NN	nsubj||accumulate-20/VBP||creatinine-18/NN	rcmod||creatinine-18/NN||accumulate-20/VBP	prep_in||accumulate-20/VBP||chronicrenalfailure-22/NN	chronicrenalfailure-22||toxin-17||no_rel||the aim of this study was to elucidate the mechanisms underlying the renal elimination of uremic toxin creatinine that accumulate in chronicrenalfailure.
advmod||increasing-14/VBG||however-1/RB	det||perception-5/NN||the-3/DT	amod||perception-5/NN||official-4/JJ	nsubj||increasing-14/VBG||perception-5/NN	poss||risk-8/NN||their-7/PRP$	prep_for||perception-5/NN||risk-8/NN	amod||infection-11/NN||hiv/aids-10/JJ	prep_of||risk-8/NN||infection-11/NN	aux||increasing-14/VBG||has-12/VBZ	aux||increasing-14/VBG||been-13/VBN	root||ROOT-0/null||increasing-14/VBG	det||province-17/NN||the-16/DT	prep_in||increasing-14/VBG||province-17/NN	det||years-20/NNS||the-19/DT	prep_over||province-17/NN||years-20/NNS	aids--1||hiv--1||no||however, the official perception for their risk of hiv/aids infection has been increasing in the province over the years.
aux||investigate-2/VB||to-1/TO	root||ROOT-0/null||investigate-2/VB	mark||produce-18/VB||whether-3/IN	ccomp||investigate-2/VB||not-5/RB	conj_or||produce-18/VB||not-5/RB	nsubj||produce-18/VB||coadministration-6/NN	prep_of||coadministration-6/NN||tacrolimus-8/NNS	appos||tacrolimus-8/NNS||tac-10/NN	prep_with||tacrolimus-8/NNS||prednisolone-13/NN	appos||prednisolone-13/NN||psl-15/NN	aux||produce-18/VB||can-17/MD	ccomp||investigate-2/VB||produce-18/VB	det||effect-21/NN||a-19/DT	amod||effect-21/NN||beneficial-20/JJ	dobj||produce-18/VB||effect-21/NN	det||treatment-24/NN||the-23/DT	prep_in||produce-18/VB||treatment-24/NN	amod||dermatomyositis-28/NNS||polymyositis-26/JJ	amod||dermatomyositis-28/NNS||/-27/JJ	prep_of||treatment-24/NN||dermatomyositis-28/NNS	appos||dermatomyositis-28/NNS||pm/dm-30/NNP	prednisolone-13||dermatomyositis-28||no_rel||to investigate whether or not coadministration of tacrolimus (tac) with prednisolone (psl) can produce a beneficial effect in the treatment of polymyositis/ dermatomyositis (pm/dm).
nsubj||mediated-11/JJ||damage-1/NN	amod||mucosa-4/NN||intestinal-3/JJ	prep_to||damage-1/NN||mucosa-4/NN	prep_in||mucosa-4/NN||celiacdisease-6/NN	appos||damage-1/NN||cd-8/NN	cop||mediated-11/JJ||is-10/VBZ	root||ROOT-0/null||mediated-11/JJ	preconj||mediated-11/JJ||both-12/DT	prep_by||mediated-11/JJ||inflammation-14/NN	amod||inflammation-14/NN||due-15/JJ	aux||adaptive-17/VB||to-16/TO	xcomp||due-15/JJ||adaptive-17/VB	xcomp||due-15/JJ||innate-19/VB	conj_and||adaptive-17/VB||innate-19/VB	amod||responses-21/NNS||immune-20/JJ	dobj||adaptive-17/VB||responses-21/NNS	prep_with||responses-21/NNS||il-15-24/CD	det||mediator-28/NN||a-26/DT	amod||mediator-28/NN||major-27/JJ	prep_as||adaptive-17/VB||mediator-28/NN	det||response-33/NN||the-30/DT	amod||response-33/NN||innate-31/JJ	amod||response-33/NN||immune-32/JJ	prep_of||mediator-28/NN||response-33/NN	nsubj||causing-48/VBG||proliferation-37/NN	amod||enterocytes-40/NNS||crypt-39/JJ	prep_of||proliferation-37/NN||enterocytes-40/NNS	det||alteration-44/NN||an-42/DT	amod||alteration-44/NN||early-43/JJ	prep_as||enterocytes-40/NNS||alteration-44/NN	nn||mucosa-47/NN||cd-46/NN	prep_of||alteration-44/NN||mucosa-47/NN	prep_by||mediated-11/JJ||causing-48/VBG	conj_and||inflammation-14/NN||causing-48/VBG	amod||hyperplasia-50/NN||crypts-49/JJ	dobj||causing-48/VBG||hyperplasia-50/NN	cd-46||celiacdisease-6||no_rel||damage to intestinal mucosa in celiacdisease (cd) is mediated both by inflammation due to adaptive and innate immune responses, with il-15 as a major mediator of the innate immune response, and by proliferation of crypt enterocytes as an early alteration of cd mucosa causing crypts hyperplasia.
amod||glucose-3/NN||fasting-1/JJ	nn||glucose-3/NN||blood-2/NN	nn||levels-7/NNS||glucose-3/NN	appos||levels-7/NNS||fbg-5/NN	nsubjpass||correlated-11/VBN||levels-7/NNS	auxpass||correlated-11/VBN||were-8/VBD	advmod||moderately-10/RB||only-9/RB	advmod||correlated-11/VBN||moderately-10/RB	root||ROOT-0/null||correlated-11/VBN	prep_with||correlated-11/VBN||indexes-13/NNS	prep_of||indexes-13/NNS||hyperglycemia-15/NN	prep_of||indexes-13/NNS||average-17/NN	conj_and||hyperglycemia-15/NN||average-17/NN	amod||levels-21/NNS||postprandial-19/JJ	nn||levels-21/NNS||glucose-20/NN	prep_of||indexes-13/NNS||levels-21/NNS	conj_or||hyperglycemia-15/NN||levels-21/NNS	hyperglycemia-15||glucose-20||no||fasting blood glucose (fbg) levels were only moderately correlated with indexes of hyperglycemia and average or postprandial glucose levels.
amod||diagnosis-3/NN||early-1/JJ	nn||diagnosis-3/NN||infant-2/NN	nsubj||service-12/NN||diagnosis-3/NN	appos||diagnosis-3/NN||eid-5/NN	prep_of||diagnosis-3/NN||hivinfection-8/NN	cop||service-12/NN||is-9/VBZ	det||service-12/NN||an-10/DT	amod||service-12/NN||important-11/JJ	root||ROOT-0/null||service-12/NN	aux||reduce-14/VB||to-13/TO	vmod||service-12/NN||reduce-14/VB	amod||morbidity-16/NN||paediatric-15/JJ	dobj||reduce-14/VB||morbidity-16/NN	dobj||reduce-14/VB||mortality-18/NN	conj_and||morbidity-16/NN||mortality-18/NN	advmod||reduce-14/VB||related-19/VBN	prep_to||related-19/VBN||hiv/aids-21/NNS	aids--1||hiv--1||no||early infant diagnosis (eid) of hivinfection is an important service to reduce paediatric morbidity and mortality related to hiv/aids.
vmod||discusses-22/VBZ||drawing-1/VBG	amod||international-4/JJ||intrahealth-3/JJ	poss||lessons-6/NNS||international-4/JJ	prep_on||drawing-1/VBG||lessons-6/NNS	vmod||lessons-6/NNS||learned-7/VBN	prepc_in||learned-7/VBN||designing-9/VBG	amod||health-11/NN||reproductive-10/JJ	dobj||designing-9/VBG||health-11/NN	nn||training-14/NN||hiv/aids-13/NN	dobj||designing-9/VBG||training-14/NN	conj_and||health-11/NN||training-14/NN	nn||programmes-18/NNS||performance-16/NN	nn||programmes-18/NNS||improvement-17/NN	dobj||designing-9/VBG||programmes-18/NNS	conj_and||health-11/NN||programmes-18/NNS	det||commentary-21/NN||this-20/DT	nsubj||discusses-22/VBZ||commentary-21/NN	root||ROOT-0/null||discusses-22/VBZ	amod||practices-24/NNS||promising-23/JJ	dobj||discusses-22/VBZ||practices-24/NNS	prepc_for||discusses-22/VBZ||strengthening-26/VBG	amod||resources-28/NNS||human-27/JJ	dobj||strengthening-26/VBG||resources-28/NNS	prep_for||resources-28/NNS||health-30/NN	advmod||efficient-33/JJ||more-32/RBR	amod||training-36/NN||efficient-33/JJ	conj_and||efficient-33/JJ||effective-35/JJ	amod||training-36/NN||effective-35/JJ	prep_through||strengthening-26/VBG||training-36/NN	prepc_for||discusses-22/VBZ||learning-38/VBG	conj_and||strengthening-26/VBG||learning-38/VBG	dobj||learning-38/VBG||programmes-39/NNS	nsubj||avoid-41/VBP||programmes-39/NNS	rcmod||programmes-39/NNS||avoid-41/VBP	det||traps-45/NNS||the-42/DT	amod||traps-45/NNS||same-43/JJ	amod||traps-45/NNS||old-44/JJ	dobj||avoid-41/VBP||traps-45/NNS	aids--1||hiv--1||no||drawing on intrahealth international's lessons learned in designing reproductive health and hiv/aids training and performance improvement programmes, this commentary discusses promising practices for strengthening human resources for health through more efficient and effective training and learning programmes that avoid the same old traps.
neg||differences-3/NNS||no-1/DT	amod||differences-3/NNS||significant-2/JJ	nsubjpass||found-5/VBN||differences-3/NNS	auxpass||found-5/VBN||were-4/VBD	root||ROOT-0/null||found-5/VBN	nn||subjects-10/NNS||smoking-7/NN	conj_and||smoking-7/NN||non-smoking-9/NN	nn||subjects-10/NNS||non-smoking-9/NN	prep_between||found-5/VBN||subjects-10/NNS	amod||asthma-13/NN||mild-12/JJ	prep_with||subjects-10/NNS||asthma-13/NN	prep_in||asthma-13/NN||regard-15/NN	amod||changes-18/NNS||clinical-17/JJ	prep_to||found-5/VBN||changes-18/NNS	nn||control-21/NN||asthma-20/NN	prep_in||changes-18/NNS||control-21/NN	amod||function-24/NN||pulmonary-23/JJ	appos||control-21/NN||function-24/NN	nn||inflammation-27/NN||airway-26/NN	appos||control-21/NN||inflammation-27/NN	conj_and||function-24/NN||inflammation-27/NN	det||period-32/NN||a-29/DT	amod||period-32/NN||2-month-30/JJ	nn||period-32/NN||treatment-31/NN	prep_following||function-24/NN||period-32/NN	prep_with||period-32/NN||budesonide-34/NN	det||association-37/NN||the-36/DT	prep_following||function-24/NN||association-37/NN	conj_or||period-32/NN||association-37/NN	prep_of||association-37/NN||budesonide-39/NN	prep_of||association-37/NN||formoterol-41/NN	conj_and||budesonide-39/NN||formoterol-41/NN	det||period-44/NN||a-43/DT	prep_for||association-37/NN||period-44/NN	num||months-47/NNS||2-46/CD	prep_of||period-44/NN||months-47/NNS	asthma-20||formoterol-41||yes||no significant differences were found between smoking and non-smoking subjects with mild asthma in regard to clinical changes in asthma control, pulmonary function and airway inflammation following a 2-month treatment period with budesonide or the association of budesonide and formoterol for a period of 2 months.
nsubj||leads-10/VBZ||inability-1/NN	nsubj||deposition-12/VB||inability-1/NN	amod||development-5/NN||adipose-3/JJ	nn||development-5/NN||tissue-4/NN	prep_of||inability-1/NN||development-5/NN	aux||engulf-7/VB||to-6/TO	vmod||development-5/NN||engulf-7/VB	amod||fat-9/NN||incoming-8/JJ	dobj||engulf-7/VB||fat-9/NN	root||ROOT-0/null||leads-10/VBZ	aux||deposition-12/VB||to-11/TO	xcomp||leads-10/VBZ||deposition-12/VB	amod||organs-15/NNS||other-14/JJ	prep_in||deposition-12/VB||organs-15/NNS	advmod||deposition-12/VB||mainly-17/RB	det||liver-20/NN||the-19/DT	prep_in||mainly-17/RB||liver-20/NN	prep_with||deposition-12/VB||consequences-23/NNS	prep_on||consequences-23/NNS||insulinresistance-25/NN	fat-9||insulinresistance-25||no_rel||inability of adipose tissue development to engulf incoming fat leads to deposition in other organs, mainly in the liver, with consequences on insulinresistance.
nsubj||examined-2/VBD||we-1/PRP	root||ROOT-0/null||examined-2/VBD	det||risks-5/NNS||the-3/DT	amod||risks-5/NNS||potential-4/JJ	dobj||examined-2/VBD||risks-5/NNS	dobj||examined-2/VBD||benefits-7/NNS	conj_and||risks-5/NNS||benefits-7/NNS	prepc_of||risks-5/NNS||switching-9/VBG	prep_from||switching-9/VBG||olanzapine-11/NN	aux||quetiapine-13/VB||to-12/TO	xcomp||switching-9/VBG||quetiapine-13/VB	advmod||obese-18/JJ||mentally-15/RB	amod||obese-18/JJ||stable-16/JJ	prep_in||quetiapine-13/VB||obese-18/JJ	amod||patients-22/NNS||overweight-21/JJ	prep_in||quetiapine-13/VB||patients-22/NNS	conj_or||obese-18/JJ||patients-22/NNS	nn||disorder-27/NN||schizophrenia-24/NN	conj_or||schizophrenia-24/NN||schizoaffective-26/NN	nn||disorder-27/NN||schizoaffective-26/NN	prep_with||patients-22/NNS||disorder-27/NN	schizophrenia-24||olanzapine-11||yes||we examined the potential risks and benefits of switching from olanzapine to quetiapine in mentally stable, obese, or overweight patients with schizophrenia or schizoaffective disorder.
prep_by||low-11/JJ||contrast-2/NN	nn||levels-9/NNS||rag1-4/CD	conj_and||rag1-4/CD||pretî-6/JJ	nn||levels-9/NNS||pretî-6/JJ	amod||levels-9/NNS||±-7/JJ	nn||levels-9/NNS||mrna-8/NN	nsubj||low-11/JJ||levels-9/NNS	cop||low-11/JJ||were-10/VBD	root||ROOT-0/null||low-11/JJ	prep_in||low-11/JJ||patients-13/NNS	prep_with||patients-13/NNS||coeliacdisease-15/NN	prepc_compared_to||low-11/JJ||to-17/TO	pobj||low-11/JJ||controls-18/NNS	preconj||controls-18/NNS||both-20/DT	amod||disease-23/NN||active-22/JJ	prep_with||controls-18/NNS||disease-23/NN	amod||symptom-free-28/JJ||inactive-26/JJ	amod||disease-29/NN||symptom-free-28/JJ	prep_with||controls-18/NNS||disease-29/NN	conj_and||disease-23/NN||disease-29/NN	det||diet-33/NN||a-31/DT	amod||diet-33/NN||gluten-free-32/JJ	prep_on||disease-29/NN||diet-33/NN	nn||values-36/NNS||p-35/NN	dep||disease-29/NN||values-36/NNS	vmod||values-36/NNS||<-37/VBG	dobj||<-37/VBG||0.01-38/CD	prep_for||<-37/VBG||mature-40/JJ	dep||disease-29/NN||<-42/NNP	conj_and||values-36/NNS||<-42/NNP	num||<-42/NNP||0.05-43/CD	amod||iels-46/NNS||immature-45/JJ	prep_for||<-42/NNP||iels-46/NNS	coeliacdisease-15||gluten--1||no||by contrast, rag1 and pretî± mrna levels were low in patients with coeliacdisease compared to controls, both with active disease and with inactive, symptom-free disease on a gluten-free diet (p values <0.01 for mature and <0.05 for immature iels).
mark||increased-2/VBD||while-1/IN	advcl||suggests-21/VBZ||increased-2/VBD	amod||expression-7/NN||urokinase-typeplasminogenactivator-3/JJ	appos||expression-7/NN||upa-5/NN	nsubjpass||associated-14/VBN||expression-7/NN	nn||tissue-11/NN||breast-9/NN	nn||tissue-11/NN||cancer-10/NN	prep_in||expression-7/NN||tissue-11/NN	auxpass||associated-14/VBN||is-12/VBZ	advmod||associated-14/VBN||directly-13/RB	ccomp||increased-2/VBD||associated-14/VBN	amod||prognosis-17/NN||poor-16/JJ	prep_with||associated-14/VBN||prognosis-17/NN	amod||evidence-20/NN||recent-19/JJ	nsubj||suggests-21/VBZ||evidence-20/NN	root||ROOT-0/null||suggests-21/VBZ	mark||suppress-26/VB||that-22/IN	nn||overexpression-24/NN||upa-23/NN	nsubj||suppress-26/VB||overexpression-24/NN	nsubj||prolong-30/VB||overexpression-24/NN	aux||suppress-26/VB||may-25/MD	ccomp||suggests-21/VBZ||suppress-26/VB	nn||growth-28/NN||tumor-27/NN	dobj||suppress-26/VB||growth-28/NN	ccomp||suggests-21/VBZ||prolong-30/VB	conj_and||suppress-26/VB||prolong-30/VB	dobj||prolong-30/VB||survival-31/NN	cancer-10||urokinase-typeplasminogenactivator-3||no_rel||while increased urokinase-typeplasminogenactivator (upa) expression in breast cancer tissue is directly associated with poor prognosis, recent evidence suggests that upa overexpression may suppress tumor growth and prolong survival.
nn||vaccination-2/NN||bcg-1/NN	nsubj||represents-9/VBZ||vaccination-2/NN	vmod||vaccination-2/NN||combined-4/VBN	amod||boosts-7/NNS||adenoviral-delivered-6/JJ	prep_with||combined-4/VBN||boosts-7/NNS	root||ROOT-0/null||represents-9/VBZ	det||strategy-12/NN||a-10/DT	amod||strategy-12/NN||reasonable-11/JJ	dobj||represents-9/VBZ||strategy-12/NN	aux||augment-14/VB||to-13/TO	vmod||strategy-12/NN||augment-14/VB	vmod||strategy-12/NN||broaden-16/VB	conj_and||augment-14/VB||broaden-16/VB	vmod||strategy-12/NN||prolong-18/VB	conj_and||augment-14/VB||prolong-18/VB	amod||protection-20/NN||immune-19/JJ	dobj||augment-14/VB||protection-20/NN	prep_against||augment-14/VB||tuberculosis-22/NNP	appos||tuberculosis-22/NNP||tb-24/NN	bcg-1||tb-24||no_rel||bcg vaccination, combined with adenoviral-delivered boosts, represents a reasonable strategy to augment, broaden and prolong immune protection against tuberculosis (tb).
det||msm-2/NN||the-1/DT	nsubj||likely-32/JJ||msm-2/NN	nsubj||receive-34/VB||msm-2/NN	vmod||msm-2/NN||sampled-3/VBN	amod||pride-6/NN||gay-5/JJ	prep_at||sampled-3/VBN||pride-6/NN	nsubj||reported-8/VBD||pride-6/NN	rcmod||pride-6/NN||reported-8/VBD	ccomp||reported-8/VBD||engaging-9/VBG	prep_in||engaging-9/VBG||uai-11/NN	aux||used-14/VBN||having-13/VBG	ccomp||reported-8/VBD||used-14/VBN	conj_or||engaging-9/VBG||used-14/VBN	det||stimulant-16/NN||any-15/DT	dobj||used-14/VBN||stimulant-16/NN	dep||stimulant-16/NN||cocaine-18/NN	dep||stimulant-16/NN||crack-cocaine-20/NN	conj_or||cocaine-18/NN||crack-cocaine-20/NN	dep||stimulant-16/NN||methamphetamine-23/NN	conj_or||cocaine-18/NN||methamphetamine-23/NN	det||months-29/NNS||the-26/DT	amod||months-29/NNS||last-27/JJ	num||months-29/NNS||12â-28/CD	prep_in||used-14/VBN||months-29/NNS	cop||likely-32/JJ||were-30/VBD	advmod||likely-32/JJ||more-31/RBR	root||ROOT-0/null||likely-32/JJ	aux||receive-34/VB||to-33/TO	xcomp||likely-32/JJ||receive-34/VB	nn||vaccination-36/NN||hepatitis-35/NN	dobj||receive-34/VB||vaccination-36/NN	advmod||receive-34/VB||on-site-37/JJ	hepatitis-35||cocaine-18||no_rel||the msm sampled at gay pride who reported engaging in uai or having used any stimulant (cocaine, crack-cocaine, or methamphetamine) in the last 12â months were more likely to receive hepatitis vaccination on-site.
advmod||assessed-3/VBN||adiposity-1/RB	auxpass||assessed-3/VBN||was-2/VBD	root||ROOT-0/null||assessed-3/VBN	prep_in||assessed-3/VBN||terms-5/NNS	prep_of||terms-5/NNS||bmi-7/NN	appos||bmi-7/NN||body-9/NN	num||%-11/NN||fat-10/CD	nsubjpass||assessed-3/VBN||%-11/NN	amod||mass-14/NN||fat-13/JJ	appos||%-11/NN||mass-14/NN	amod||index-18/NN||fat-16/JJ	amod||index-18/NN||mass-17/JJ	appos||%-11/NN||index-18/NN	conj_and||mass-14/NN||index-18/NN	amod||circumference-21/NN||waist-20/JJ	appos||%-11/NN||circumference-21/NN	conj_and||mass-14/NN||circumference-21/NN	adiposity-1||fat-16||no_rel||adiposity was assessed in terms of bmi, body fat %, fat mass, fat mass index and waist circumference.
amod||analysis-3/NN||comparative-1/JJ	nn||analysis-3/NN||genome-2/NN	nsubj||revealed-4/VBD||analysis-3/NN	root||ROOT-0/null||revealed-4/VBD	mark||resembles-8/VBZ||that-5/IN	det||chromosome-7/NN||the-6/DT	nsubj||resembles-8/VBZ||chromosome-7/NN	ccomp||revealed-4/VBD||resembles-8/VBZ	xcomp||resembles-8/VBZ||those-9/DT	prep_of||those-9/DT||non-11/NN	amod||members-14/NNS||b.anthracis-13/JJ	nsubj||plasmids-30/VBZ||members-14/NNS	det||group-19/NN||the-16/DT	amod||group-19/NN||bacillus-17/JJ	nn||group-19/NN||cereus-18/NNS	prep_of||members-14/NNS||group-19/NN	mark||identical-25/JJ||whereas-21/IN	num||plasmids-23/NNS||two-22/CD	nsubj||identical-25/JJ||plasmids-23/NNS	cop||identical-25/JJ||were-24/VBD	dep||group-19/NN||identical-25/JJ	det||virulence-29/NN||the-27/DT	nn||virulence-29/NN||anthrax-28/NN	prep_to||identical-25/JJ||virulence-29/NN	parataxis||revealed-4/VBD||plasmids-30/VBZ	dobj||plasmids-30/VBZ||pxo1-31/NNS	dobj||plasmids-30/VBZ||pxo2-33/NNS	conj_and||pxo1-31/NNS||pxo2-33/NNS	anthrax-28||b.anthracis-13||no||comparative genome analysis revealed that the chromosome resembles those of non - b.anthracis members of the bacillus cereus group , whereas two plasmids were identical to the anthrax virulence plasmids pxo1 and pxo2 .
nsubj||knowledge-4/NN||it-1/PRP	cop||knowledge-4/NN||is-2/VBZ	amod||knowledge-4/NN||common-3/JJ	root||ROOT-0/null||knowledge-4/NN	mark||causes-8/VBZ||that-5/IN	nn||exposure-7/NN||asbestos-6/NN	nsubj||causes-8/VBZ||exposure-7/NN	dep||knowledge-4/NN||causes-8/VBZ	amod||diseases-10/NNS||asbestos-related-9/JJ	dobj||causes-8/VBZ||diseases-10/NNS	prep_such_as||diseases-10/NNS||asbestosis-13/NNS	nn||cancer-16/NN||lung-15/NN	prep_such_as||diseases-10/NNS||cancer-16/NN	conj_and||asbestosis-13/NNS||cancer-16/NN	amod||mesothelioma-19/NN||malignant-18/JJ	prep_such_as||diseases-10/NNS||mesothelioma-19/NN	conj_and||asbestosis-13/NNS||mesothelioma-19/NN	appos||knowledge-4/NN||mm-21/NN	neg||only-24/RB||not-23/RB	dep||knowledge-4/NN||only-24/RB	dep||only-24/RB||in-25/IN	conj||knowledge-4/NN||people-26/NNS	nsubj||handled-29/VBN||people-26/NNS	aux||handled-29/VBN||have-28/VBP	rcmod||people-26/NNS||handled-29/VBN	dobj||handled-29/VBN||asbestos-30/NN	det||environment-34/NN||the-32/DT	nn||environment-34/NN||work-33/NN	prep_in||handled-29/VBN||environment-34/NN	cc||in-38/IN||but-36/CC	dep||in-38/IN||also-37/RB	dep||handled-29/VBN||in-38/IN	nsubj||living-40/VBG||residents-39/NNS	pcomp||in-38/IN||living-40/VBG	amod||factories-42/NNS||near-41/JJ	dobj||living-40/VBG||factories-42/NNS	mark||handle-44/VBP||that-43/IN	ccomp||handled-29/VBN||handle-44/VBP	dobj||handle-44/VBP||asbestos-45/NN	asbestosis-13||asbestos-45||no||it is common knowledge that asbestos exposure causes asbestos-related diseases such as asbestosis, lung cancer and malignant mesothelioma (mm) not only in people who have handled asbestos in the work environment, but also in residents living near factories that handle asbestos.
advmod||expressed-10/VBN||therefore-1/RB	det||number-4/NN||a-3/DT	nsubjpass||expressed-10/VBN||number-4/NN	nsubj||cp-17/VBP||number-4/NN	amod||proteins-8/NNS||specific-6/JJ	nn||proteins-8/NNS||transport-7/NN	prep_of||number-4/NN||proteins-8/NNS	auxpass||expressed-10/VBN||are-9/VBP	root||ROOT-0/null||expressed-10/VBN	nn||cells-15/NNS||brain-12/NN	nn||cells-15/NNS||capillary-13/NN	nn||cells-15/NNS||endothelial-14/NN	prep_in||expressed-10/VBN||cells-15/NNS	conj_and||expressed-10/VBN||cp-17/VBP	amod||cells-19/NNS||epithelial-18/JJ	dobj||cp-17/VBP||cells-19/NNS	nsubj||provide-21/VBP||cells-19/NNS	rcmod||cells-19/NNS||provide-21/VBP	dobj||provide-21/VBP||transport-22/NN	prep_of||transport-22/NN||nutrients-24/NNS	prep_of||transport-22/NN||ions-26/NNS	conj_and||nutrients-24/NNS||ions-26/NNS	det||cns-29/NN||the-28/DT	prep_into||cp-17/VBP||cns-29/NN	prep_into||cp-17/VBP||removal-31/NN	conj_and||cns-29/NN||removal-31/NN	nn||products-34/NNS||waste-33/NN	prep_of||cns-29/NN||products-34/NNS	prep_of||cns-29/NN||ions-36/NNS	conj_and||products-34/NNS||ions-36/NNS	det||csf-39/NN||the-38/DT	prep_from||cp-17/VBP||csf-39/NN	ions-36||cp-17||no_rel||therefore, a number of specific transport proteins are expressed in brain capillary endothelial cells and cp epithelial cells that provide transport of nutrients and ions into the cns and removal of waste products and ions from the csf.
det||diagnosis-2/NN||the-1/DT	nsubjpass||confirmed-6/VBN||diagnosis-2/NN	prep_of||diagnosis-2/NN||typhoidfever-4/NN	auxpass||confirmed-6/VBN||is-5/VBZ	root||ROOT-0/null||confirmed-6/VBN	agent||confirmed-6/VBN||culture-8/NN	nn||-rrb--16/NNP||salmonella-10/NN	nn||-rrb--16/NNP||enterica-11/NN	nn||-rrb--16/NNP||serotype-12/NN	nn||-rrb--16/NNP||typhi-13/NNP	nn||-rrb--16/NNP||-lrb--14/NNP	nn||-rrb--16/NNP||s.typhi-15/NNP	prep_of||culture-8/NN||-rrb--16/NNP	typhoidfever-4||s.typhi-15||no||the diagnosis of typhoidfever is confirmed by culture of salmonella enterica serotype typhi -lrb- s.typhi -rrb- .
amod||mice-3/NNS||stz-induced-1/JJ	amod||mice-3/NNS||fat-1-2/JJ	nsubj||develop-6/VB||mice-3/NNS	nsubj||î-14/VB||mice-3/NNS	aux||develop-6/VB||did-4/VBD	neg||develop-6/VB||not-5/RB	root||ROOT-0/null||develop-6/VB	dobj||develop-6/VB||hyperglycemia-7/NN	prepc_compared_with||develop-6/VB||with-9/IN	amod||mice-11/NNS||wild-type-10/JJ	pobj||develop-6/VB||mice-11/NNS	conj_and||develop-6/VB||î-14/VB	dobj||î-14/VB||²-15/NNS	nn||destruction-18/NN||cell-17/NN	nsubjpass||prevented-20/VBN||destruction-18/NN	auxpass||prevented-20/VBN||was-19/VBD	parataxis||develop-6/VB||prevented-20/VBN	mark||evidenced-22/VBN||as-21/IN	advcl||prevented-20/VBN||evidenced-22/VBN	prep_by||evidenced-22/VBN||lack-24/NN	amod||damage-28/NN||histological-26/JJ	amod||damage-28/NN||pancreatic-27/JJ	prep_of||lack-24/NN||damage-28/NN	amod||level-32/NN||reduced-30/VBN	nn||level-32/NN||insulin-31/NN	prep_of||lack-24/NN||level-32/NN	conj_or||damage-28/NN||level-32/NN	hyperglycemia-7||insulin-31||yes||stz-induced fat-1 mice did not develop hyperglycemia compared with wild-type mice, and î²-cell destruction was prevented as evidenced by lack of histological pancreatic damage or reduced insulin level.
nsubj||reported-3/VBD||we-1/PRP	advmod||reported-3/VBD||recently-2/RB	root||ROOT-0/null||reported-3/VBD	det||association-6/NN||a-4/DT	amod||association-6/NN||negative-5/JJ	dobj||reported-3/VBD||association-6/NN	amod||igm-antibodies-9/NNS||natural-8/JJ	prep_between||association-6/NN||igm-antibodies-9/NNS	prep_against||igm-antibodies-9/NNS||phosphorylcholine-11/NN	dep||phosphorylcholine-11/NN||anti-pc-13/JJ	det||population-18/NN||the-16/DT	amod||population-18/NN||general-17/JJ	prep_in||reported-3/VBD||population-18/NN	amod||levels-22/NNS||high-20/JJ	amod||levels-22/NNS||anti-pc-21/JJ	prep_in||reported-3/VBD||levels-22/NNS	conj_and||population-18/NN||levels-22/NNS	vmod||levels-22/NNS||leading-23/VBG	amod||development-27/NN||decreased-25/VBN	nn||development-27/NN||atherosclerosis-26/NNS	prep_to||leading-23/VBG||development-27/NN	amod||levels-30/NNS||low-29/JJ	prep_in||reported-3/VBD||levels-30/NNS	conj_and||population-18/NN||levels-30/NNS	amod||risk-33/NN||increased-32/VBN	prep_to||levels-30/NNS||risk-33/NN	prep_of||risk-33/NN||cvd-35/NN	atherosclerosis-26||antibodies--1||no_rel||we recently reported a negative association between natural igm-antibodies against phosphorylcholine (anti-pc) in the general population, high anti-pc levels leading to decreased atherosclerosis development and low levels to increased risk of cvd.
nsubj||receiving-12/VBG||resistance-1/NN	amod||insecticides-4/NNS||pyrethroid-3/JJ	prep_to||resistance-1/NN||insecticides-4/NNS	det||gambiae-10/NN||the-6/DT	nn||gambiae-10/NN||malaria-7/NN	nn||gambiae-10/NN||vector-8/NN	nn||gambiae-10/NN||anopheles-9/NNS	prep_in||insecticides-4/NNS||gambiae-10/NN	aux||receiving-12/VBG||is-11/VBZ	root||ROOT-0/null||receiving-12/VBG	vmod||receiving-12/VBG||increasing-13/VBG	dobj||increasing-13/VBG||attention-14/NN	mark||threatens-17/VBZ||because-15/IN	nsubj||threatens-17/VBZ||it-16/PRP	advcl||increasing-13/VBG||threatens-17/VBZ	det||sustainability-19/NN||the-18/DT	dobj||threatens-17/VBZ||sustainability-19/NN	nn||programs-24/NNS||malaria-21/NN	nn||programs-24/NNS||vector-22/NN	nn||programs-24/NNS||control-23/NN	prep_of||sustainability-19/NN||programs-24/NNS	amod||africa-27/NN||sub-saharan-26/JJ	prep_in||threatens-17/VBZ||africa-27/NN	malaria-21||pyrethroid-3||no_rel||resistance to pyrethroid insecticides in the malaria vector anopheles gambiae is receiving increasing attention because it threatens the sustainability of malaria vector control programs in sub-saharan africa.
vmod||present-17/VBP||using-1/VBG	det||$-11/FW||the-2/DT	nn||$-11/FW||caenorhabditis-3/FW	nn||$-11/FW||elegans-4/FW	nn||$-11/FW||â-5/FW	nn||$-11/FW||$-6/FW	nn||$-11/FW||pseudomonas-8/FW	nn||$-11/FW||aeruginosa-9/FW	nn||$-11/FW||hostâ-10/FW	dobj||using-1/VBG||$-11/FW	iobj||using-1/VBG||$-11/FW	nn||system-14/NN||pathogen-13/NN	dep||$-11/FW||system-14/NN	nsubj||present-17/VBP||we-16/PRP	root||ROOT-0/null||present-17/VBP	amod||evidence-19/NN||genetic-18/JJ	dobj||present-17/VBP||evidence-19/NN	mark||required-74/VBN||that-20/IN	det||fat-3-25/NNS||a-21/DT	nn||fat-3-25/NNS||î-22/NN	amod||fat-3-25/NNS||6-desaturase-24/JJ	nsubjpass||required-74/VBN||fat-3-25/NNS	advmod||$-32/NNS||through-27/RB	poss||$-32/NNS||its-28/PRP$	num||$-32/NNS||two-29/CD	amod||$-32/NNS||18-carbon-30/JJ	amod||$-32/NNS||productsâ-31/JJ	appos||fat-3-25/NNS||$-32/NNS	amod||acid-35/NN||gamma-linolenic-34/JJ	dep||fat-3-25/NNS||acid-35/NN	dep||acid-35/NN||gla-37/NN	appos||gla-37/NN||183n6-39/NNS	amod||acid-43/NN||stearidonic-42/JJ	dep||fat-3-25/NNS||acid-43/NN	conj_and||acid-35/NN||acid-43/NN	dep||acid-43/NN||sda-45/NN	appos||sda-45/NN||184n3-47/NNS	det||acid-56/NN||the-52/DT	num||pufas-54/NNS||20-carbon-53/CD	npadvmod||arachidonic-55/JJ||pufas-54/NNS	amod||acid-56/NN||arachidonic-55/JJ	dep||fat-3-25/NNS||acid-56/NN	conj_negcc||acid-35/NN||acid-56/NN	dep||acid-56/NN||aa-58/NN	appos||aa-58/NN||204n6-60/NNS	amod||$-71/NNS||eicosapentaenoic-63/JJ	amod||$-71/NNS||acid-64/JJ	dep||$-71/NNS||epa-66/NN	appos||epa-66/NN||205n3-68/NNS	nn||$-71/NNS||â-70/NN	conj_negcc||acid-35/NN||$-71/NNS	conj_and||acid-56/NN||$-71/NNS	auxpass||required-74/VBN||is-73/VBZ	ccomp||present-17/VBP||required-74/VBN	amod||immunity-78/NN||basal-76/JJ	nn||immunity-78/NN||innate-77/NN	prep_for||required-74/VBN||immunity-78/NN	prep_in||immunity-78/NN||vivo-80/NN	carbon--1||gla-37||no_rel||using the caenorhabditis elegans â pseudomonas aeruginosa hostâpathogen system, we present genetic evidence that a î6-desaturase fat-3, through its two 18-carbon productsâgamma-linolenic acid (gla, 183n6) and stearidonic acid (sda, 184n3), but not the 20-carbon pufas arachidonic acid (aa, 204n6) and eicosapentaenoic acid (epa, 205n3)âis required for basal innate immunity in vivo.
advmod||found-11/VBN||furthermore-1/RB	nn||expression-4/NN||differential-3/NN	nsubjpass||found-11/VBN||expression-4/NN	prep_in||expression-4/NN||one-6/CD	det||dnmts-9/NNS||the-8/DT	prep_of||one-6/CD||dnmts-9/NNS	auxpass||found-11/VBN||was-10/VBD	root||ROOT-0/null||found-11/VBN	det||subset-14/NN||a-13/DT	prep_in||found-11/VBN||subset-14/NN	amod||patients-17/NNS||lupus-16/JJ	prep_of||subset-14/NN||patients-17/NNS	nn||therapy-23/NN||dehydroepiandrosterone-19/NNP	appos||therapy-23/NN||dhea-21/NNP	prep_on||found-11/VBN||therapy-23/NN	lupus-16||dhea-21||yes||furthermore, differential expression in one of the dnmts was found in a subset of lupus patients on dehydroepiandrosterone (dhea) therapy.
amod||disease-2/NN||mycobacteriumulcerans-1/JJ	nsubj||mycobacterialdisease-10/NN||disease-2/NN	appos||disease-2/NN||buruliulcer-4/NN	cop||mycobacterialdisease-10/NN||is-6/VBZ	det||mycobacterialdisease-10/NN||the-7/DT	advmod||widespread-9/JJ||most-8/RBS	amod||mycobacterialdisease-10/NN||widespread-9/JJ	root||ROOT-0/null||mycobacterialdisease-10/NN	det||world-13/NN||the-12/DT	prep_in||mycobacterialdisease-10/NN||world-13/NN	prep_after||world-13/NN||leprosy-15/NNP	prep_after||world-13/NN||tuberculosis-17/NNP	conj_and||leprosy-15/NNP||tuberculosis-17/NNP	buruliulcer-4||mycobacteriumulcerans-1||no||mycobacteriumulcerans disease (buruliulcer) is the most widespread mycobacterialdisease in the world after leprosy and tuberculosis.
nsubjpass||understood-9/VBN||mechanisms-1/NNS	nn||action-4/NN||ethanol-3/NN	prep_of||mechanisms-1/NNS||action-4/NN	auxpass||understood-9/VBN||are-5/VBP	neg||understood-9/VBN||not-6/RB	advmod||well-8/RB||sufficiently-7/RB	advmod||understood-9/VBN||well-8/RB	root||ROOT-0/null||understood-9/VBN	det||level-13/NN||the-11/DT	amod||level-13/NN||molecular-12/JJ	prep_at||understood-9/VBN||level-13/NN	det||pharmacotherapy-16/NN||the-15/DT	nsubj||is-19/VBZ||pharmacotherapy-16/NN	prep_of||pharmacotherapy-16/NN||alcoholism-18/NN	conj_and||understood-9/VBN||is-19/VBZ	advmod||is-19/VBZ||still-20/RB	poss||infancy-23/NN||its-22/PRP$	prep_in||is-19/VBZ||infancy-23/NN	alcoholism-18||ethanol-3||no||mechanisms of ethanol action are not sufficiently well understood at the molecular level and the pharmacotherapy of alcoholism is still in its infancy.
advmod||î-7/VBP||furthermore-1/RB	nn||/-6/NNP||ppar-3/NN	nn||/-6/NNP||î-4/NN	nn||/-6/NNP||²-5/NNP	nsubj||î-7/VBP||/-6/NNP	root||ROOT-0/null||î-7/VBP	amod||ligands-9/NNS||´-8/JJ	nsubj||prevent-10/VB||ligands-9/NNS	nsubj||avoid-18/VB||ligands-9/NNS	nsubj||suppress-26/VB||ligands-9/NNS	ccomp||î-7/VBP||prevent-10/VB	amod||inflammation-12/NN||fattyacid-induced-11/JJ	dobj||prevent-10/VB||inflammation-12/NN	amod||cells-16/NNS||skeletal-14/JJ	nn||cells-16/NNS||muscle-15/NN	prep_in||prevent-10/VB||cells-16/NNS	ccomp||î-7/VBP||avoid-18/VB	conj_and||prevent-10/VB||avoid-18/VB	det||development-20/NN||the-19/DT	dobj||avoid-18/VB||development-20/NN	amod||hypertrophy-23/NN||cardiac-22/JJ	prep_of||development-20/NN||hypertrophy-23/NN	ccomp||î-7/VBP||suppress-26/VB	conj_and||prevent-10/VB||suppress-26/VB	amod||inflammation-28/NN||macrophage-derived-27/JJ	dobj||suppress-26/VB||inflammation-28/NN	prep_in||suppress-26/VB||atherosclerosis-30/NNS	inflammation-28||fattyacid--1||no_rel||furthermore, ppar î² / î´ ligands prevent fattyacid-induced inflammation in skeletal muscle cells, avoid the development of cardiac hypertrophy, and suppress macrophage-derived inflammation in atherosclerosis.
amod||studies-2/NNS||epidemiological-1/JJ	nsubj||show-3/VBP||studies-2/NNS	root||ROOT-0/null||show-3/VBP	det||link-6/NN||the-4/DT	amod||link-6/NN||apparent-5/JJ	dobj||show-3/VBP||link-6/NN	amod||consumption-10/NN||excessive-8/JJ	nn||consumption-10/NN||alcohol-9/NN	prep_between||link-6/NN||consumption-10/NN	prep_between||link-6/NN||hypertension-12/NN	conj_and||consumption-10/NN||hypertension-12/NN	alcohol-9||hypertension-12||no_rel||epidemiological studies show the apparent link between excessive alcohol consumption and hypertension.
det||findings-2/NNS||these-1/DT	nsubj||extend-3/VB||findings-2/NNS	nsubj||possess-12/VB||findings-2/NNS	nsubj||highlight-18/VB||findings-2/NNS	root||ROOT-0/null||extend-3/VB	det||range-6/NN||the-4/DT	nn||range-6/NN||host-5/NN	dobj||extend-3/VB||range-6/NN	det||influenzavirus-10/NNS||the-8/DT	amod||influenzavirus-10/NNS||h5n1-9/JJ	prep_of||range-6/NN||influenzavirus-10/NNS	conj_and||extend-3/VB||possess-12/VB	dobj||possess-12/VB||implications-13/NNS	prep_for||implications-13/NNS||influenzavirus-15/NNS	advmod||possess-12/VB||epidemiology-16/RB	conj_and||extend-3/VB||highlight-18/VB	det||need-20/NN||the-19/DT	dobj||highlight-18/VB||need-20/NN	det||surveillance-24/NN||the-22/DT	amod||surveillance-24/NN||systematic-23/JJ	prep_for||need-20/NN||surveillance-24/NN	prep_of||surveillance-24/NN||h5n1-26/CD	prep_in||highlight-18/VB||animals-28/NNS	det||vicinity-31/NN||the-30/DT	prep_in||animals-28/NNS||vicinity-31/NN	nn||units-35/NNS||backyard-33/NN	nn||units-35/NNS||poultry-34/NN	prep_of||vicinity-31/NN||units-35/NNS	advmod||highlight-18/VB||especially-36/RB	amod||areas-39/NNS||endemic-38/JJ	prep_in||highlight-18/VB||areas-39/NNS	h5n1-26||influenzavirus-15||no||these findings extend the host range of the h5n1 influenzavirus, possess implications for influenzavirus epidemiology and highlight the need for the systematic surveillance of h5n1 in animals in the vicinity of backyard poultry units especially in endemic areas.
nsubj||eligible-3/JJ||patients-1/NNS	cop||eligible-3/JJ||are-2/VBP	root||ROOT-0/null||eligible-3/JJ	det||study-6/NN||the-5/DT	prep_for||eligible-3/JJ||study-6/NN	mark||old-15/JJ||if-7/IN	nsubj||old-15/JJ||they-8/PRP	cop||old-15/JJ||are-9/VBP	amod||40-11/CD||between-10/IN	num||years-14/NNS||40-11/CD	conj_and||40-11/CD||80-13/CD	num||years-14/NNS||80-13/CD	npadvmod||old-15/JJ||years-14/NNS	advcl||treated-26/VBN||old-15/JJ	dep||treated-26/VBN||diagnosed-17/VBN	prep_with||diagnosed-17/VBN||type2diabetes-19/CD	mwe||than-21/IN||more-20/JJR	quantmod||one-22/CD||than-21/IN	num||year-23/NN||one-22/CD	npadvmod||ago-24/RB||year-23/NN	advmod||diagnosed-17/VBN||ago-24/RB	rcmod||study-6/NN||treated-26/VBN	det||practitioner-30/NN||a-28/DT	amod||practitioner-30/NN||general-29/JJ	prep_by||treated-26/VBN||practitioner-30/NN	neg||-50/VBZ||not-32/RB	nn||treatment-35/NN||insulin-34/NN	prep_on||-50/VBZ||treatment-35/NN	amod||-41/NNS||hba1c-39/JJ	nn||-41/NNS||â-40/NN	prep_with||-50/VBZ||-41/NNS	dep||%-44/NN||$-42/$	num||$-42/$||7.5-43/CD	amod||-41/NNS||%-44/NN	amod||â-49/NN||systolic-46/JJ	nn||â-49/NN||blood-47/NN	nn||â-49/NN||pressure-48/NN	nsubj||-50/VBZ||â-49/NN	nsubj||-50/VBZ||â-49/NN	parataxis||treated-26/VBN||-50/VBZ	parataxis||treated-26/VBN||-50/VBZ	conj_and||-50/VBZ||-50/VBZ	dobj||-50/VBZ||$-51/$	num||$-51/$||145-52/CD	vmod||$-51/$||mmhg-53/VBG	amod||-58/NNS||total-55/JJ	nn||-58/NNS||cholesterol-56/NN	nn||-58/NNS||â-57/NN	dep||mmol/l-61/JJ||-58/NNS	npadvmod||mmol/l-61/JJ||$-59/$	num||$-59/$||5.2-60/CD	rcmod||study-6/NN||mmol/l-61/JJ	conj_and||treated-26/VBN||mmol/l-61/JJ	type2diabetes-19||insulin-34||yes||patients are eligible for the study if they are between 40 and 80 years old, diagnosed with type2diabetes more than one year ago, treated by a general practitioner, not on insulin treatment, and with hba1c â¤7.5%, systolic blood pressure â¤145 mmhg and total cholesterol â¤5.2 mmol/l.
nsubj||efficacious-13/NNS||bosentan-1/NN	det||receptor-6/NN||a-3/DT	amod||receptor-6/NN||dual-4/JJ	nn||receptor-6/NN||et-5/NNP	appos||bosentan-1/NN||receptor-6/NN	appos||receptor-6/NN||eta/etb-8/NN	dep||receptor-6/NN||antagonist-10/NN	cop||efficacious-13/NNS||is-12/VBZ	root||ROOT-0/null||efficacious-13/NNS	prep_in||efficacious-13/NNS||treatment-15/NN	prep_of||treatment-15/NN||pulmonaryhypertension-17/NN	pulmonaryhypertension-17||bosentan-1||yes||bosentan, a dual et receptor (eta/etb) antagonist, is efficacious in treatment of pulmonaryhypertension.
det||background-3/NN||this-2/DT	prep_with||review-8/VBP||background-3/NN	prep_in||background-3/NN||mind-5/NN	nsubj||review-8/VBP||we-7/PRP	root||ROOT-0/null||review-8/VBP	amod||issues-12/NNS||diagnostic-9/JJ	conj_and||diagnostic-9/JJ||treatment-related-11/JJ	amod||issues-12/NNS||treatment-related-11/JJ	nsubj||suffering-17/VBG||issues-12/NNS	dep||suffering-17/VBG||specific-13/JJ	amod||patients-16/NNS||elderly-15/JJ	prep_to||specific-13/JJ||patients-16/NNS	xcomp||review-8/VBP||suffering-17/VBG	nn||conditions-23/NNS||schizophrenia-19/NN	conj_and||schizophrenia-19/NN||other-21/JJ	nn||conditions-23/NNS||other-21/JJ	amod||conditions-23/NNS||psychotic-22/JJ	prep_from||suffering-17/VBG||conditions-23/NNS	dep||suffering-17/VBG||focusing-25/VBG	det||role-29/NN||the-27/DT	amod||role-29/NN||potential-28/JJ	prep_on||focusing-25/VBG||role-29/NN	prep_of||role-29/NN||aripiprazole-31/NN	schizophrenia-19||aripiprazole-31||yes||with this background in mind, we review diagnostic and treatment-related issues specific to elderly patients suffering from schizophrenia and other psychotic conditions, focusing on the potential role of aripiprazole.
nn||analysis-6/NN||retrospective-1/NN	amod||analysis-6/NN||reverse-2/JJ	amod||analysis-6/NN||transcription-polymerase-3/JJ	nn||analysis-6/NN||chain-4/NN	nn||analysis-6/NN||reaction-5/NN	root||ROOT-0/null||analysis-6/NN	prep_of||analysis-6/NN||influenza-8/NN	det||viruses-11/NNS||a-9/DT	amod||viruses-11/NNS||h1-10/JJ	nsubj||isolated-12/VBD||viruses-11/NNS	dep||analysis-6/NN||isolated-12/VBD	det||u.k.-15/NN||the-14/DT	prep_in||isolated-12/VBD||u.k.-15/NN	det||winter-19/NN||the-17/DT	amod||winter-19/NN||previous-18/JJ	prep_during||isolated-12/VBD||winter-19/NN	vmod||winter-19/NN||identified-20/VBN	det||virus-24/NN||a-21/DT	amod||virus-24/NN||single-22/JJ	amod||virus-24/NN||h1n2-23/JJ	dobj||identified-20/VBN||virus-24/NN	vmod||analysis-6/NN||isolated-26/VBN	prep_in||isolated-26/VBN||march-28/NN	num||march-28/NN||2001-29/CD	vmod||analysis-6/NN||indicating-31/VBG	mark||circulate-38/VB||that-32/IN	amod||viruses-34/NNS||h1n2-33/JJ	nsubj||circulate-38/VB||viruses-34/NNS	aux||circulate-38/VB||did-35/VBD	neg||circulate-38/VB||not-36/RB	advmod||circulate-38/VB||widely-37/RB	ccomp||indicating-31/VBG||circulate-38/VB	det||u.k.-41/NN||the-40/DT	prep_in||circulate-38/VB||u.k.-41/NN	prep_before||analysis-6/NN||september-43/NNP	num||september-43/NNP||2001-44/CD	virus-24||viruses-34||no||retrospective reverse transcription-polymerase chain reaction analysis of influenza a h1 viruses isolated in the u.k. during the previous winter identified a single h1n2 virus , isolated in march 2001 , indicating that h1n2 viruses did not widely circulate in the u.k. before september 2001 .
det||male-4/NN||a-1/DT	num||male-4/NN||27-2/CD	nn||male-4/NN||yo-3/NN	nsubj||received-8/VBD||male-4/NN	nn||origin-7/NN||african-6/NN	prep_of||male-4/NN||origin-7/NN	root||ROOT-0/null||received-8/VBD	dobj||received-8/VBD||telbivudine-9/NN	prep_for||received-8/VBD||hepatitisb-11/NN	num||months-14/NNS||3-13/CD	prep_during||received-8/VBD||months-14/NNS	hepatitisb-11||telbivudine-9||yes||a 27 yo male of african origin received telbivudine for hepatitisb during 3 months.
nsubjpass||shown-4/VBN||it-1/PRP	aux||shown-4/VBN||has-2/VBZ	auxpass||shown-4/VBN||been-3/VBN	root||ROOT-0/null||shown-4/VBN	nsubj||containing-9/VBG||that-5/DT	dep||containing-9/VBG||2,4-diamino-6-arylmethylpteridines-6/JJ	conj_and||2,4-diamino-6-arylmethylpteridines-6/JJ||2,4-diamino-5-arylmethylpyrimidines-8/JJ	dep||containing-9/VBG||2,4-diamino-5-arylmethylpyrimidines-8/JJ	xcomp||shown-4/VBN||containing-9/VBG	det||o-11/NN||an-10/DT	dobj||containing-9/VBG||o-11/NN	amod||group-14/NN||carboxylalkyloxy-13/JJ	nsubj||inhibitors-23/NNS||group-14/NN	det||moiety-18/NN||the-16/DT	amod||moiety-18/NN||aryl-17/JJ	prep_in||group-14/NN||moiety-18/NN	cop||inhibitors-23/NNS||are-19/VBP	amod||inhibitors-23/NNS||potent-20/JJ	conj_and||potent-20/JJ||selective-22/JJ	amod||inhibitors-23/NNS||selective-22/JJ	parataxis||shown-4/VBN||inhibitors-23/NNS	det||reductase-27/NN||the-25/DT	amod||reductase-27/NN||dihydrofolate-26/JJ	prep_of||inhibitors-23/NNS||reductase-27/NN	appos||reductase-27/NN||dhfr-29/NN	amod||pathogens-33/NNS||opportunistic-32/JJ	prep_from||inhibitors-23/NNS||pathogens-33/NNS	amod||carinii-37/NNS||pneumocystis-36/JJ	prep_such_as||pathogens-33/NNS||carinii-37/NNS	det||agent-41/NN||the-39/DT	amod||agent-41/NN||causative-40/JJ	dep||inhibitors-23/NNS||agent-41/NN	prep_of||agent-41/NN||pneumocystispneumonia-43/NN	amod||patients-46/NNS||hiv/aids-45/JJ	prep_in||pneumocystispneumonia-43/NN||patients-46/NNS	aids--1||hiv--1||no||it has been shown that 2,4-diamino-6-arylmethylpteridines and 2,4-diamino-5-arylmethylpyrimidines containing an o -carboxylalkyloxy group in the aryl moiety are potent and selective inhibitors of the dihydrofolate reductase (dhfr) from opportunistic pathogens such as pneumocystis carinii , the causative agent of pneumocystispneumonia in hiv/aids patients.
amod||rates-2/NNS||prevalence-1/JJ	nsubj||have-34/VBP||rates-2/NNS	amod||virus-5/NN||hepatitisc-4/JJ	prep_of||rates-2/NNS||virus-5/NN	appos||virus-5/NN||hcv-7/NN	dep||virus-5/NN||co-infection-9/NN	det||distribution-12/NN||the-11/DT	prep_of||rates-2/NNS||distribution-12/NN	conj_and||virus-5/NN||distribution-12/NN	nn||genotypes-15/NNS||hcv-14/NN	prep_of||distribution-12/NN||genotypes-15/NNS	det||frequency-19/NN||the-18/DT	prep_of||rates-2/NNS||frequency-19/NN	conj_and||virus-5/NN||frequency-19/NN	amod||resolution-22/NN||spontaneous-21/JJ	prep_of||frequency-19/NN||resolution-22/NN	prep_of||resolution-22/NN||hepatitisc-24/NN	prep_in||hepatitisc-24/NN||patients-26/NNS	vmod||patients-26/NNS||infected-27/VBN	det||humanimmunodeficiencyvirus-30/NNS||the-29/DT	prep_with||infected-27/VBN||humanimmunodeficiencyvirus-30/NNS	appos||humanimmunodeficiencyvirus-30/NNS||hiv-32/NN	root||ROOT-0/null||have-34/VBP	det||disparity-37/NN||a-35/DT	amod||disparity-37/NN||worldwide-36/JJ	dobj||have-34/VBP||disparity-37/NN	hepatitisc-24||hcv-14||no||prevalence rates of hepatitisc virus (hcv) co-infection, the distribution of hcv genotypes, and the frequency of spontaneous resolution of hepatitisc in patients infected with the humanimmunodeficiencyvirus (hiv) have a worldwide disparity.
det||ability-2/NN||the-1/DT	nsubj||suggests-20/VBZ||ability-2/NN	prep_of||ability-2/NN||ride-4/NN	aux||enhance-6/VB||to-5/TO	vmod||ride-4/NN||enhance-6/VB	dobj||enhance-6/VB||infectivity-7/NN	amod||vzv-10/NN||cell-free-9/JJ	prep_of||infectivity-7/NN||vzv-10/NN	det||range-14/NN||a-12/DT	amod||range-14/NN||wide-13/JJ	prep_over||enhance-6/VB||range-14/NN	nn||times-17/NNS||incubation-16/NN	prep_of||range-14/NN||times-17/NNS	prep_of||range-14/NN||temperatures-19/NNS	conj_and||times-17/NNS||temperatures-19/NNS	root||ROOT-0/null||suggests-20/VBZ	mark||useful-25/JJ||that-21/IN	nsubj||useful-25/JJ||ride-22/NN	aux||useful-25/JJ||may-23/MD	cop||useful-25/JJ||be-24/VB	ccomp||suggests-20/VBZ||useful-25/JJ	prepc_for||useful-25/JJ||increasing-27/VBG	det||stability-29/NN||the-28/DT	dobj||increasing-27/VBG||stability-29/NN	nn||vaccines-34/NNS||varicella-31/NN	conj_or||varicella-31/NN||zoster-33/NN	nn||vaccines-34/NNS||zoster-33/NN	prep_of||stability-29/NN||vaccines-34/NNS	varicella-31||vzv-10||no||the ability of ride to enhance infectivity of cell-free vzv over a wide range of incubation times and temperatures suggests that ride may be useful for increasing the stability of varicella or zoster vaccines.
mark||applied-7/VBN||after-1/IN	number||%-3/NN||5-2/CD	amod||patches-5/NNS||%-3/NN	nn||patches-5/NNS||lidocaine-4/NN	nsubjpass||applied-7/VBN||patches-5/NNS	auxpass||applied-7/VBN||were-6/VBD	advcl||exhibited-19/VBD||applied-7/VBN	det||part-12/NN||the-9/DT	amod||part-12/NN||painful-10/JJ	nn||part-12/NN||body-11/NN	prep_to||applied-7/VBN||part-12/NN	num||weeks-15/NNS||two-14/CD	prep_for||part-12/NN||weeks-15/NNS	nn||patients-18/NNS||cbp-17/NN	nsubj||exhibited-19/VBD||patients-18/NNS	root||ROOT-0/null||exhibited-19/VBD	det||decrease-22/NN||a-20/DT	amod||decrease-22/NN||significant-21/JJ	dobj||exhibited-19/VBD||decrease-22/NN	amod||measures-26/NNS||clinical-24/JJ	nn||measures-26/NNS||pain-25/NN	prep_in||exhibited-19/VBD||measures-26/NNS	mark||showed-35/VBD||while-28/IN	nn||questionnaire-32/NN||oa-30/NN	amod||questionnaire-32/NN||clinical-31/JJ	prep_in||showed-35/VBD||questionnaire-32/NN	vmod||questionnaire-32/NN||based-33/VBN	nsubj||showed-35/VBD||outcomes-34/NNS	advcl||exhibited-19/VBD||showed-35/VBD	neg||effect-38/NN||no-36/DT	nn||effect-38/NN||treatment-37/NN	nsubj||evoked-41/VBD||effect-38/NN	prep||effect-38/NN||but-39/CC	pobj||but-39/CC||stimulus-40/NN	ccomp||showed-35/VBD||evoked-41/VBD	nsubj||showed-43/VBD||pain-42/NN	ccomp||evoked-41/VBD||showed-43/VBD	det||decrease-46/NN||a-44/DT	amod||decrease-46/NN||borderline-45/JJ	dobj||showed-43/VBD||decrease-46/NN	pain-42||lidocaine-4||yes||after 5% lidocaine patches were applied to the painful body part for two weeks, cbp patients exhibited a significant decrease in clinical pain measures, while in oa clinical questionnaire based outcomes showed no treatment effect but stimulus evoked pain showed a borderline decrease.
prep_on||developed-5/VBD||admission-2/NN	nsubj||developed-5/VBD||he-4/PRP	root||ROOT-0/null||developed-5/VBD	dobj||developed-5/VBD||pulmonaryoedema-6/NN	amod||hypertension-9/NN||systolic-8/JJ	prep_from||developed-5/VBD||hypertension-9/NN	nsubjpass||controlled-12/VBN||hypertension-9/NN	auxpass||controlled-12/VBN||was-11/VBD	rcmod||hypertension-9/NN||controlled-12/VBN	amod||support-15/NN||ventilatory-14/JJ	agent||controlled-12/VBN||support-15/NN	agent||controlled-12/VBN||nitroglycerine-17/NN	conj_and||support-15/NN||nitroglycerine-17/NN	agent||controlled-12/VBN||furosemide-19/NN	conj_and||support-15/NN||furosemide-19/NN	pulmonaryoedema-6||furosemide-19||yes||on admission, he developed pulmonaryoedema from systolic hypertension which was controlled by ventilatory support, nitroglycerine and furosemide.
det||form-3/NN||a-1/DT	amod||form-3/NN||long-acting-2/JJ	nsubj||available-12/JJ||form-3/NN	det||risperidone-8/NN||the-5/DT	amod||risperidone-8/NN||second-generation-6/JJ	nn||risperidone-8/NN||antipsychoticdrug-7/NN	prep_of||form-3/NN||risperidone-8/NN	cop||available-12/JJ||is-9/VBZ	advmod||available-12/JJ||now-10/RB	advmod||available-12/JJ||broadly-11/RB	root||ROOT-0/null||available-12/JJ	det||treatment-15/NN||the-14/DT	prep_for||available-12/JJ||treatment-15/NN	prep_of||treatment-15/NN||schizophrenia-17/NN	advmod||related-20/VBN||closely-19/RB	amod||conditions-22/NNS||related-20/VBN	amod||conditions-22/NNS||psychiatric-21/JJ	prep_for||available-12/JJ||conditions-22/NNS	conj_and||treatment-15/NN||conditions-22/NNS	schizophrenia-17||risperidone-8||yes||a long-acting form of the second-generation antipsychoticdrug risperidone is now broadly available for the treatment of schizophrenia and closely related psychiatric conditions.
nsubj||remains-2/VBZ||it-1/PRP	root||ROOT-0/null||remains-2/VBZ	acomp||remains-2/VBZ||uncertain-3/JJ	mark||increases-8/VBZ||whether-4/IN	nsubj||increases-8/VBZ||use-5/NN	nsubj||decreases-21/VBZ||use-5/NN	prep_of||use-5/NN||insulin-7/NN	ccomp||remains-2/VBZ||increases-8/VBZ	nn||risk-10/NN||cancer-9/NN	dobj||increases-8/VBZ||risk-10/NN	poss||effect-14/NN||its-13/PRP$	prep_because_of||risk-10/NN||effect-14/NN	nn||growth-17/NN||cell-16/NN	prep_on||increases-8/VBZ||growth-17/NN	prep_on||increases-8/VBZ||proliferation-19/NN	conj_and||growth-17/NN||proliferation-19/NN	ccomp||remains-2/VBZ||decreases-21/VBZ	conj_or||increases-8/VBZ||decreases-21/VBZ	nn||risk-23/NN||cancer-22/NN	dobj||decreases-21/VBZ||risk-23/NN	poss||effect-28/NN||its-26/PRP$	amod||effect-28/NN||glucose-lowering-27/JJ	prep_because_of||risk-23/NN||effect-28/NN	cancer-22||glucose--1||no_rel||it remains uncertain whether use of insulin increases cancer risk because of its effect on cell growth and proliferation or decreases cancer risk because of its glucose-lowering effect.
det||ehrlichiaruminantium-4/NN||the-1/DT	amod||ehrlichiaruminantium-4/NN||rickettsial-2/JJ	nn||ehrlichiaruminantium-4/NN||bacterium-3/NN	nsubj||agent-8/NN||ehrlichiaruminantium-4/NN	cop||agent-8/NN||is-5/VBZ	det||agent-8/NN||the-6/DT	amod||agent-8/NN||causative-7/JJ	root||ROOT-0/null||agent-8/NN	prep_of||agent-8/NN||heartwater-10/NN	det||zoonoticdisease-14/NN||a-12/DT	amod||zoonoticdisease-14/NN||potential-13/JJ	appos||heartwater-10/NN||zoonoticdisease-14/NN	prep_of||zoonoticdisease-14/NN||ruminants-16/NNS	vmod||ruminants-16/NNS||transmitted-17/VBN	agent||transmitted-17/VBN||ticks-19/NNS	det||amblyomma-23/NN||the-21/DT	amod||amblyomma-23/NN||genus-22/JJ	prep_of||ticks-19/NNS||amblyomma-23/NN	heartwater-10||ehrlichiaruminantium-4||no||the rickettsial bacterium ehrlichiaruminantium is the causative agent of heartwater, a potential zoonoticdisease of ruminants transmitted by ticks of the genus amblyomma .
nsubj||investigated-2/VBD||we-1/PRP	root||ROOT-0/null||investigated-2/VBD	det||significance-5/NN||the-3/DT	amod||significance-5/NN||clinical-4/JJ	dobj||investigated-2/VBD||significance-5/NN	amod||immunoglobulin-9/NN||serum-7/JJ	amod||immunoglobulin-9/NN||specific-8/JJ	prep_of||significance-5/NN||immunoglobulin-9/NN	dep||significance-5/NN||e-10/SYM	appos||significance-5/NN||lge-12/NN	det||enterotoxin-19/NN||the-15/DT	amod||enterotoxin-19/NN||staphylococcal-16/JJ	nn||enterotoxin-19/NN||superantigens-17/NNS	nn||enterotoxin-19/NN||staphylococcal-18/NN	prep_to||investigated-2/VBD||enterotoxin-19/NN	det||sea-22/NN||a-20/DT	dep||enterotoxin-19/NN||sea-22/NN	amod||enterotoxin-26/NN||staphylococcal-25/JJ	prep_to||investigated-2/VBD||enterotoxin-26/NN	conj_and||enterotoxin-19/NN||enterotoxin-26/NN	dep||enterotoxin-26/NN||b-27/SYM	appos||b-27/SYM||seb-29/NN	amod||toxin-34/NN||toxicshocksyndrome-33/JJ	prep_to||investigated-2/VBD||toxin-34/NN	conj_and||enterotoxin-19/NN||toxin-34/NN	appos||toxin-34/NN||tsst-36/NN	dep||toxin-34/NN||-1-38/CD	prep_in||investigated-2/VBD||patients-40/NNS	amod||urticaria-43/NN||chronic-42/JJ	prep_with||patients-40/NNS||urticaria-43/NN	appos||urticaria-43/NN||cu-45/NN	vmod||investigated-2/VBD||focusing-48/VBG	det||differences-51/NNS||the-50/DT	prep_on||focusing-48/VBG||differences-51/NNS	det||prevalences-54/NNS||these-53/DT	prep_in||differences-51/NNS||prevalences-54/NNS	amod||cu-57/NN||aspirin-intolerant-56/JJ	prep_between||prevalences-54/NNS||cu-57/NN	appos||cu-57/NN||aicu-59/NNP	amod||patients-67/NNS||aspirin-tolerant-62/JJ	nn||patients-67/NNS||cu-63/NN	appos||patients-67/NNS||atcu-65/NNP	prep_between||prevalences-54/NNS||patients-67/NNS	conj_and||cu-57/NN||patients-67/NNS	cu-63||urticaria-43||no_rel||we investigated the clinical significance of serum specific immunoglobulin e (lge) to the staphylococcal superantigens staphylococcal enterotoxin a (sea), staphylococcal enterotoxin b (seb), and toxicshocksyndrome toxin (tsst)-1 in patients with chronic urticaria (cu), focusing on the differences in these prevalences between aspirin-intolerant cu (aicu) and aspirin-tolerant cu (atcu) patients.
det||result-2/NN||this-1/DT	nsubj||suggested-3/VBD||result-2/NN	root||ROOT-0/null||suggested-3/VBD	mark||useful-12/JJ||that-4/IN	amod||chemotherapy-6/NN||preoperative-5/JJ	nsubj||useful-12/JJ||chemotherapy-6/NN	vmod||chemotherapy-6/NN||chosen-7/VBN	agent||chosen-7/VBN||atp-cra-9/NN	aux||useful-12/JJ||may-10/MD	cop||useful-12/JJ||be-11/VB	ccomp||suggested-3/VBD||useful-12/JJ	prepc_for||useful-12/JJ||treating-14/VBG	amod||cancer-17/NN||advanced-15/JJ	nn||cancer-17/NN||colon-16/NN	dobj||treating-14/VBG||cancer-17/NN	amod||liver-20/NN||unresectable-19/JJ	prep_with||treating-14/VBG||liver-20/NN	amod||metastases-23/NNS||peritoneal-22/JJ	prep_with||treating-14/VBG||metastases-23/NNS	conj_and||liver-20/NN||metastases-23/NNS	atp--1||metastases-23||no_rel||this result suggested that preoperative chemotherapy chosen by atp-cra may be useful for treating advanced colon cancer with unresectable liver and peritoneal metastases.
det||initiative-7/NN||the-1/DT	amod||initiative-7/NN||womenâ-2/JJ	amod||initiative-7/NN||$-3/$	number||s-5/CD||-4/CD	num||$-3/$||s-5/CD	nn||initiative-7/NN||health-6/NN	nsubj||found-8/VBD||initiative-7/NN	root||ROOT-0/null||found-8/VBD	mark||increases-17/VBZ||that-9/IN	nn||estrogen-11/NN||combination-10/NN	nsubj||increases-17/VBZ||estrogen-11/NN	amod||therapy-16/NN||progesterone-13/JJ	nn||therapy-16/NN||hormone-14/NN	nn||therapy-16/NN||replacement-15/NN	conj_and||estrogen-11/NN||therapy-16/NN	nsubj||increases-17/VBZ||therapy-16/NN	ccomp||found-8/VBD||increases-17/VBZ	nn||cancer-19/NN||breast-18/NN	dobj||increases-17/VBZ||cancer-19/NN	nsubj||compelled-25/VBN||cancer-19/NN	nn||risk-22/NN||cardiovasculardisease-21/NN	dobj||increases-17/VBZ||risk-22/NN	conj_and||cancer-19/NN||risk-22/NN	nsubj||compelled-25/VBN||risk-22/NN	rcmod||cancer-19/NN||compelled-25/VBN	amod||women-27/NNS||many-26/JJ	dobj||compelled-25/VBN||women-27/NNS	nsubj||seek-29/VB||women-27/NNS	aux||seek-29/VB||to-28/TO	xcomp||compelled-25/VBN||seek-29/VB	amod||alternatives-31/NNS||herbal-30/JJ	dobj||seek-29/VB||alternatives-31/NNS	prep_such_as||alternatives-31/NNS||blackcohoshextract-34/NN	appos||blackcohoshextract-34/NN||bce-36/NN	aux||relieve-39/VB||to-38/TO	vmod||blackcohoshextract-34/NN||relieve-39/VB	poss||symptoms-42/NNS||their-40/PRP$	amod||symptoms-42/NNS||menopausal-41/JJ	dobj||relieve-39/VB||symptoms-42/NNS	cardiovasculardisease-21||blackcohoshextract-34||no_rel||the womenâs health initiative found that combination estrogen and progesterone hormone replacement therapy increases breast cancer and cardiovasculardisease risk, which compelled many women to seek herbal alternatives such as blackcohoshextract (bce) to relieve their menopausal symptoms.
det||seconds-4/NNS||the-2/DT	num||seconds-4/NNS||10-3/CD	prep_during||measured-12/VBN||seconds-4/NNS	amod||injection-7/NN||propofol-6/JJ	prep_after||seconds-4/NNS||injection-7/NN	nn||intensity-10/NN||pain-9/NN	nsubjpass||measured-12/VBN||intensity-10/NN	auxpass||measured-12/VBN||was-11/VBD	root||ROOT-0/null||measured-12/VBN	det||scale-18/NN||an-14/DT	amod||scale-18/NN||11-point-15/JJ	amod||scale-18/NN||numerical-16/JJ	nn||scale-18/NN||rating-17/NN	prep_on||measured-12/VBN||scale-18/NN	dep||scale-18/NN||0-20/CD	dep||pain-23/NN||=-21/SYM	neg||pain-23/NN||no-22/DT	rcmod||0-20/CD||pain-23/NN	num||=-26/NNS||10-25/CD	dep||scale-18/NN||=-26/NNS	conj_and||0-20/CD||=-26/NNS	dep||possible-28/JJ||worst-27/JJS	amod||pain-29/NN||possible-28/JJ	dep||=-26/NNS||pain-29/NN	pain-29||propofol-6||yes||during the 10 seconds after propofol injection, pain intensity was measured on an 11-point numerical rating scale (0 = no pain and 10 = worst possible pain).
nsubjpass||detected-6/VBN||anti-thyroglobulin-1/NN	appos||anti-thyroglobulin-1/NN||atg-3/NN	auxpass||detected-6/VBN||was-5/VBD	root||ROOT-0/null||detected-6/VBN	num||%-9/NN||29-8/CD	prep_in||detected-6/VBN||%-9/NN	amod||peroxidase-12/NN||anti-thyroid-11/JJ	prep_in||detected-6/VBN||peroxidase-12/NN	conj_and||%-9/NN||peroxidase-12/NN	appos||peroxidase-12/NN||atpo-14/NNP	num||%-18/NN||21-17/CD	prep_in||peroxidase-12/NN||%-18/NN	det||patients-21/NNS||the-20/DT	prep_of||%-18/NN||patients-21/NNS	det||children-25/NNS||these-24/DT	prep_of||had-29/VBD||children-25/NNS	num||%-28/NN||14-27/CD	nsubj||had-29/VBD||%-28/NN	parataxis||detected-6/VBN||had-29/VBD	dobj||had-29/VBD||hypothyroidism-30/NN	hypothyroidism-30||thyroglobulin--1||yes||anti-thyroglobulin (atg) was detected in 29% and anti-thyroid peroxidase (atpo) in 21% of the patients; of these children, 14% had hypothyroidism.
det||agent-3/NN||the-1/DT	amod||agent-3/NN||causative-2/JJ	nsubj||forms-9/VBZ||agent-3/NN	prep_of||agent-3/NN||legionnairesdisease-5/NN	appos||agent-3/NN||legionellapneumophila-7/NN	root||ROOT-0/null||forms-9/VBZ	det||vacuole-12/NN||a-10/DT	amod||vacuole-12/NN||replicative-11/JJ	dobj||forms-9/VBZ||vacuole-12/NN	amod||system-29/NN||phagocytes-14/JJ	det||trafficking-22/NN||the-18/DT	amod||multiplication/defective-20/JJ||intracellular-19/JJ	amod||trafficking-22/NN||multiplication/defective-20/JJ	nn||trafficking-22/NN||organelle-21/NN	prep_by_means_of||phagocytes-14/JJ||trafficking-22/NN	appos||trafficking-22/NN||icm/dot-24/NN	nn||system-29/NN||type-26/NN	nn||system-29/NN||iv-27/NN	nn||system-29/NN||secretion-28/NN	prep_in||vacuole-12/NN||system-29/NN	prep_of||some-35/DT||system-29/NN	amod||proteins-33/NNS||translocated-31/JJ	nn||proteins-33/NNS||effector-32/NN	prep_in||vacuole-12/NN||proteins-33/NNS	conj_and||system-29/NN||proteins-33/NNS	prep_of||some-35/DT||proteins-33/NNS	nsubj||subvert-38/VB||some-35/DT	rcmod||system-29/NN||subvert-38/VB	nn||gtp-40/NN||host-39/NN	dobj||subvert-38/VB||gtp-40/NN	amod||metabolism-46/NN||phosphoinositide-42/JJ	appos||metabolism-46/NN||pi-44/NNP	dobj||subvert-38/VB||metabolism-46/NN	conj_and||gtp-40/NN||metabolism-46/NN	legionnairesdisease-5||legionellapneumophila-7||no||the causative agent of legionnairesdisease, legionellapneumophila , forms a replicative vacuole in phagocytes by means of the intracellular multiplication/defective organelle trafficking (icm/dot) type iv secretion system and translocated effector proteins, some of which subvert host gtp and phosphoinositide (pi) metabolism.
det||total-2/NN||a-1/DT	nsubjpass||randomized-9/VBN||total-2/NN	num||patients-5/NNS||3,095-4/CD	prep_of||total-2/NN||patients-5/NNS	prep_with||patients-5/NNS||type2diabetes-7/CD	auxpass||randomized-9/VBN||were-8/VBD	root||ROOT-0/null||randomized-9/VBN	dobj||randomized-9/VBN||21-10/CD	prep_to||randomized-9/VBN||bromocriptine-qr-12/NN	prep_to||randomized-9/VBN||placebo-14/NN	conj_or||bromocriptine-qr-12/NN||placebo-14/NN	prep_in||randomized-9/VBN||conjunction-16/NN	det||patient-19/NN||the-18/DT	poss||therapy-23/NN||patient-19/NN	amod||therapy-23/NN||usual-21/JJ	nn||therapy-23/NN||diabetes-22/NN	prep_with||randomized-9/VBN||therapy-23/NN	dep||therapy-23/NN||diet-25/NN	vmod||diet-25/NN||controlled-26/VBN	advmod||controlled-26/VBN||only-27/RB	advmod||controlled-26/VBN||up-29/RB	conj_or||only-27/RB||up-29/RB	num||medications-33/NNS||two-31/CD	amod||medications-33/NNS||antidiabetes-32/JJ	prep_to||controlled-26/VBN||medications-33/NNS	prep_including||diet-25/NN||insulin-36/NN	type2diabetes-7||insulin-36||yes||a total of 3,095 patients with type2diabetes were randomized 21 to bromocriptine-qr or placebo in conjunction with the patient's usual diabetes therapy (diet controlled only or up to two antidiabetes medications, including insulin).
nsubj||one-6/CD||valproicacid-1/NN	appos||valproicacid-1/NN||vpa-3/NN	cop||one-6/CD||is-5/VBZ	root||ROOT-0/null||one-6/CD	det||anticonvulsant-12/NN||the-8/DT	advmod||used-11/VBN||most-9/RBS	advmod||used-11/VBN||widely-10/RB	amod||anticonvulsant-12/NN||used-11/VBN	prep_of||one-6/CD||anticonvulsant-12/NN	amod||agents-15/NNS||mood-stabilizing-14/JJ	prep_of||one-6/CD||agents-15/NNS	conj_and||anticonvulsant-12/NN||agents-15/NNS	prepc_for||agents-15/NNS||treating-17/VBG	dobj||treating-17/VBG||epilepsy-18/NN	dobj||treating-17/VBG||bipolardisorder-20/NN	conj_and||epilepsy-18/NN||bipolardisorder-20/NN	epilepsy-18||valproicacid-1||yes||valproicacid (vpa) is one of the most widely used anticonvulsant and mood-stabilizing agents for treating epilepsy and bipolardisorder.
num||groups-2/NNS||three-1/CD	nsubj||hiv-5/VBP||groups-2/NNS	prep_of||groups-2/NNS||swiss-4/NNS	root||ROOT-0/null||hiv-5/VBP	amod||participants-8/NNS||cohort-6/JJ	nn||participants-8/NNS||study-7/NN	nsubjpass||analyzed-10/VBN||participants-8/NNS	auxpass||analyzed-10/VBN||were-9/VBD	ccomp||hiv-5/VBP||analyzed-10/VBN	dobj||estimated-19/VBN||whom-13/WP	det||age-15/NN||the-14/DT	nsubjpass||estimated-19/VBN||age-15/NN	prep_of||age-15/NN||infection-17/NN	auxpass||estimated-19/VBN||was-18/VBD	prepc_for||analyzed-10/VBN||estimated-19/VBN	det||basis-22/NN||the-21/DT	prep_on||estimated-19/VBN||basis-22/NN	amod||calculation-26/NN||bayesian-24/JJ	amod||calculation-26/NN||back-25/JJ	prep_of||basis-22/NN||calculation-26/NN	nn||â-29/NN||n-28/NN	dep||basis-22/NN||â-29/NN	nsubj||â-33/VBP||$-30/$	number||=-32/CD||-31/CD	num||$-30/$||=-32/CD	rcmod||â-29/NN||â-33/VBP	dobj||â-33/VBP||$-34/$	number||3,307-36/CD||-35/CD	num||$-34/$||3,307-36/CD	prep_on||estimated-19/VBN||seroconversion-39/NN	conj_or||basis-22/NN||seroconversion-39/NN	nn||â-42/NN||n-41/NN	dep||seroconversion-39/NN||â-42/NN	nsubj||â-46/VBP||$-43/$	number||=-45/CD||-44/CD	num||$-43/$||=-45/CD	rcmod||â-42/NN||â-46/VBP	dobj||â-46/VBP||$-47/$	number||366-49/CD||-48/CD	num||$-47/$||366-49/CD	prep_on||estimated-19/VBN||diagnoses-53/NNS	conj_or||basis-22/NN||diagnoses-53/NNS	amod||hivinfection-56/NN||primary-55/JJ	prep_of||diagnoses-53/NNS||hivinfection-56/NN	nn||â-59/NN||n-58/NN	dep||diagnoses-53/NNS||â-59/NN	nsubj||â-63/VBP||$-60/$	number||=-62/CD||-61/CD	num||$-60/$||=-62/CD	rcmod||â-59/NN||â-63/VBP	dobj||â-63/VBP||$-64/$	number||130-66/CD||-65/CD	num||$-64/$||130-66/CD	hivinfection-56||hiv-5||no||three groups of swiss hiv cohort study participants were analyzed, for whom the age of infection was estimated on the basis of bayesian back calculation ( n â=â3,307), seroconversion ( n â=â366), or diagnoses of primary hivinfection ( n â=â130).
amod||factors-3/NNS||modifiable-1/JJ	nn||factors-3/NNS||risk-2/NN	nsubj||determinants-16/NNS||factors-3/NNS	advmod||cholesterol-6/NN||especially-5/RB	appos||factors-3/NNS||cholesterol-6/NN	advmod||duration-10/NN||also-9/RB	appos||factors-3/NNS||duration-10/NN	conj_and||cholesterol-6/NN||duration-10/NN	prep_of||duration-10/NN||haart-12/NN	cop||determinants-16/NNS||were-14/VBD	amod||determinants-16/NNS||key-15/JJ	root||ROOT-0/null||determinants-16/NNS	nn||risk-19/NN||cvd-18/NN	prep_of||determinants-16/NNS||risk-19/NN	cholesterol-6||cvd-18||no_rel||modifiable risk factors, especially cholesterol, and also duration of haart, were key determinants of cvd risk.
amod||vasculitis-4/NNS||anti-neutrophil-1/JJ	amod||vasculitis-4/NNS||cytoplasmic-2/JJ	amod||vasculitis-4/NNS||antibody-associated-3/JJ	nsubjpass||associated-7/VBN||vasculitis-4/NNS	aux||associated-7/VBN||has-5/VBZ	auxpass||associated-7/VBN||been-6/VBN	root||ROOT-0/null||associated-7/VBN	amod||drugs-10/NNS||many-9/JJ	prep_with||associated-7/VBN||drugs-10/NNS	nsubj||effect-18/NN||it-12/PRP	cop||effect-18/NN||is-13/VBZ	det||effect-18/NN||a-14/DT	advmod||rare-16/JJ||relatively-15/RB	amod||effect-18/NN||rare-16/JJ	nn||effect-18/NN||side-17/NN	conj_and||associated-7/VBN||effect-18/NN	det||hydralazine-22/NN||the-20/DT	amod||hydralazine-22/NN||antihypertensivedrug-21/VBG	prep_of||effect-18/NN||hydralazine-22/NN	vasculitis-4||hydralazine-22||no_rel||anti-neutrophil cytoplasmic antibody-associated vasculitis has been associated with many drugs and it is a relatively rare side effect of the antihypertensivedrug hydralazine.
amod||analysis-2/NN||immunohistological-1/JJ	nsubj||confirmed-6/VBD||analysis-2/NN	det||granulomas-5/NNS||these-4/DT	prep_of||analysis-2/NN||granulomas-5/NNS	root||ROOT-0/null||confirmed-6/VBD	det||abundance-9/NN||the-7/DT	amod||abundance-9/NN||disproportionate-8/JJ	dobj||confirmed-6/VBD||abundance-9/NN	det||proteins-12/NNS||the-11/DT	prep_of||abundance-9/NN||proteins-12/NNS	vmod||proteins-12/NNS||involved-13/VBN	nn||metabolism-16/NN||lipid-15/NN	prep_in||involved-13/VBN||metabolism-16/NN	prep_in||involved-13/VBN||cells-18/NNS	vmod||cells-18/NNS||surrounding-19/VBG	det||caseum-21/NN||the-20/DT	dobj||surrounding-19/VBG||caseum-21/NN	advmod||biochemical-36/VBP||namely-23/RB	nn||member-31/NN||adipophilin-25/NN	amod||member-31/NN||acyl-coa-27/JJ	nn||member-31/NN||synthetase-28/NN	amod||member-31/NN||long-chain-29/JJ	nn||member-31/NN||family-30/NN	nsubj||biochemical-36/VBP||member-31/NN	num||member-31/NN||1-32/CD	amod||c.-35/NN||saposin-34/JJ	conj_and||member-31/NN||c.-35/NN	nsubj||biochemical-36/VBP||c.-35/NN	parataxis||confirmed-6/VBD||biochemical-36/VBP	dobj||biochemical-36/VBP||analysis-37/NN	det||species-41/NN||the-39/DT	nn||species-41/NN||lipid-40/NN	prep_of||analysis-37/NN||species-41/NN	det||caseum-44/NN||the-43/DT	prep_within||biochemical-36/VBP||caseum-44/NN	nsubj||implicated-56/VBN||caseum-44/NN	vmod||caseum-44/NN||identified-45/VBN	dobj||identified-45/VBN||cholesterol-46/NN	amod||esters-49/NNS||cholesteryl-48/JJ	dobj||identified-45/VBN||esters-49/NNS	conj_and||cholesterol-46/NN||esters-49/NNS	dobj||identified-45/VBN||triacylglycerols-51/NNS	conj_and||cholesterol-46/NN||triacylglycerols-51/NNS	dobj||identified-45/VBN||lactosylceramide-53/NN	conj_and||cholesterol-46/NN||lactosylceramide-53/NN	rcmod||caseum-44/NN||implicated-56/VBN	amod||lipids-59/NNS||low-density-57/JJ	amod||lipids-59/NNS||lipoprotein-derived-58/JJ	dobj||implicated-56/VBN||lipids-59/NNS	det||source-64/NN||the-61/DT	advmod||likely-63/JJ||most-62/RBS	amod||source-64/NN||likely-63/JJ	prep_as||implicated-56/VBN||source-64/NN	granulomas-5||lipids-59||no_rel||immunohistological analysis of these granulomas confirmed the disproportionate abundance of the proteins involved in lipid metabolism in cells surrounding the caseum ; namely , adipophilin , acyl-coa synthetase long-chain family member 1 and saposin c. biochemical analysis of the lipid species within the caseum identified cholesterol , cholesteryl esters , triacylglycerols and lactosylceramide , which implicated low-density lipoprotein-derived lipids as the most likely source .
nn||modeling-3/NN||growth-1/NN	nn||modeling-3/NN||mixture-2/NN	nsubjpass||applied-8/VBN||modeling-3/NN	appos||modeling-3/NN||gmm-5/NN	auxpass||applied-8/VBN||was-7/VBD	root||ROOT-0/null||applied-8/VBN	prep_to||applied-8/VBN||data-10/NNS	det||study-18/NN||a-12/DT	amod||study-18/NN||randomized-13/JJ	amod||study-18/NN||double-blind-15/JJ	amod||study-18/NN||12-week-17/JJ	prep_from||data-10/NNS||study-18/NN	num||patients-21/NNS||628-20/CD	prep_of||study-18/NN||patients-21/NNS	nn||disorder-26/NN||schizophrenia-23/NN	conj_or||schizophrenia-23/NN||schizo-affective-25/JJ	nn||disorder-26/NN||schizo-affective-25/JJ	prep_with||applied-8/VBN||disorder-26/NN	vmod||disorder-26/NN||treated-27/VBN	prep_with||treated-27/VBN||risperidone-29/NN	prep_with||treated-27/VBN||olanzapine-31/NN	conj_or||risperidone-29/NN||olanzapine-31/NN	schizophrenia-23||olanzapine-31||yes||growth mixture modeling (gmm) was applied to data from a randomized, double-blind, 12-week study of 628 patients with schizophrenia or schizo-affective disorder treated with risperidone or olanzapine.
amod||resonance-4/NN||manganese-enhanced-1/JJ	amod||resonance-4/NN||cardiovascular-2/JJ	amod||resonance-4/NN||magnetic-3/JJ	nsubj||assess-10/VB||resonance-4/NN	appos||resonance-4/NN||mecmr-6/NN	aux||assess-10/VB||can-8/MD	advmod||assess-10/VB||non-invasively-9/RB	root||ROOT-0/null||assess-10/VB	amod||influx-13/NN||myocardial-11/JJ	nn||influx-13/NN||calcium-12/NN	dobj||assess-10/VB||influx-13/NN	nn||levels-17/NNS||calcium-16/NN	nsubjpass||known-19/VBN||levels-17/NNS	nsubjpass||elevated-22/VBN||levels-17/NNS	auxpass||known-19/VBN||are-18/VBP	conj_and||assess-10/VB||known-19/VBN	aux||elevated-22/VBN||to-20/TO	auxpass||elevated-22/VBN||be-21/VB	xcomp||known-19/VBN||elevated-22/VBN	amod||cardiomyopathy-25/NN||musculardystrophy-24/JJ	prep_in||elevated-22/VBN||cardiomyopathy-25/NN	prepc_based_on||elevated-22/VBN||on-27/IN	amod||studies-29/NNS||cellular-28/JJ	pobj||elevated-22/VBN||studies-29/NNS	calcium-16||cardiomyopathy-25||no_rel||manganese-enhanced cardiovascular magnetic resonance (mecmr) can non-invasively assess myocardial calcium influx, and calcium levels are known to be elevated in musculardystrophy cardiomyopathy based on cellular studies.
amod||-rrb--10/NNPS||vaccination-1/JJ	amod||calmette-guã-5/NNS||mycobacteriumbovis-3/JJ	nn||calmette-guã-5/NNS||bacille-4/NN	prep_with||vaccination-1/JJ||calmette-guã-5/NNS	amod||-rrb--10/NNPS||©-6/JJ	nn||-rrb--10/NNPS||rin-7/NN	nn||-rrb--10/NNPS||-lrb--8/NNP	nn||-rrb--10/NNPS||bcg-9/NNPS	nsubjpass||used-13/VBN||-rrb--10/NNPS	nsubj||reduce-15/VB||-rrb--10/NNPS	nsubjpass||reported-24/VBN||-rrb--10/NNPS	nsubj||have-26/VB||-rrb--10/NNPS	auxpass||used-13/VBN||is-11/VBZ	advmod||used-13/VBN||widely-12/RB	root||ROOT-0/null||used-13/VBN	aux||reduce-15/VB||to-14/TO	xcomp||used-13/VBN||reduce-15/VB	det||risk-17/NN||the-16/DT	dobj||reduce-15/VB||risk-17/NN	nn||tuberculosis-20/NNP||childhood-19/NNP	prep_of||risk-17/NN||tuberculosis-20/NNP	aux||reported-24/VBN||has-22/VBZ	auxpass||reported-24/VBN||been-23/VBN	conj_and||used-13/VBN||reported-24/VBN	aux||have-26/VB||to-25/TO	xcomp||reported-24/VBN||have-26/VB	amod||-rrb--42/NNP||efficacy-27/JJ	num||mycobacterialdiseases-31/NNS||two-29/CD	amod||mycobacterialdiseases-31/NNS||other-30/JJ	prep_against||efficacy-27/JJ||mycobacterialdiseases-31/NNS	prep_against||efficacy-27/JJ||leprosy-33/NNP	conj_and||mycobacterialdiseases-31/NNS||leprosy-33/NNP	prep_against||efficacy-27/JJ||buruliulcer-35/NN	conj_and||mycobacterialdiseases-31/NNS||buruliulcer-35/NN	vmod||buruliulcer-35/NN||caused-36/VBN	nn||ulcerans-39/NNS||m.-38/NN	agent||caused-36/VBN||ulcerans-39/NNS	nn||-rrb--42/NNP||-lrb--40/NNP	nn||-rrb--42/NNP||mu-41/NNP	dobj||have-26/VB||-rrb--42/NNP	tuberculosis-20||bcg-9||yes||vaccination with mycobacteriumbovis bacille calmette-guã © rin -lrb- bcg -rrb- is widely used to reduce the risk of childhood tuberculosis and has been reported to have efficacy against two other mycobacterialdiseases , leprosy and buruliulcer caused by m. ulcerans -lrb- mu -rrb- .
nsubj||consequence-4/NN||herpeszoster-1/NN	cop||consequence-4/NN||is-2/VBZ	det||consequence-4/NN||the-3/DT	root||ROOT-0/null||consequence-4/NN	prep_of||consequence-4/NN||reactivation-6/NN	nn||varicellazostervirus-9/NNS||latent-8/NN	prep_of||reactivation-6/NN||varicellazostervirus-9/NNS	amod||ganglia-13/NN||dorsal-11/JJ	nn||ganglia-13/NN||root-12/NN	prep_from||varicellazostervirus-9/NNS||ganglia-13/NN	herpeszoster-1||varicellazostervirus-9||no||herpeszoster is the consequence of reactivation of latent varicellazostervirus from dorsal root ganglia.
det||themes-2/NNS||the-1/DT	nsubj||included-11/VBD||themes-2/NNS	vmod||themes-2/NNS||emerging-3/VBG	det||discussions-8/NNS||the-5/DT	nn||discussions-8/NNS||focus-6/NN	nn||discussions-8/NNS||group-7/NN	prep_from||emerging-3/VBG||discussions-8/NNS	prep_from||emerging-3/VBG||interviews-10/NNS	conj_and||discussions-8/NNS||interviews-10/NNS	root||ROOT-0/null||included-11/VBD	num||factors-16/NNS||four-12/CD	amod||factors-16/NNS||main-13/JJ	amod||factors-16/NNS||suggested-14/JJ	nn||factors-16/NNS||barrier-15/NN	dobj||included-11/VBD||factors-16/NNS	dep||fears-20/NNS||1-18/LS	dep||factors-16/NNS||fears-20/NNS	prep_of||fears-20/NNS||hiv/aids-22/NNS	amod||coinfection-25/NN||tb-hiv-24/JJ	prep_of||fears-20/NNS||coinfection-25/NN	conj_and||hiv/aids-22/NNS||coinfection-25/NN	prep_of||fears-20/NNS||death-27/NN	conj_and||hiv/aids-22/NNS||death-27/NN	prep_of||fears-20/NNS||stigma-30/NN	conj_and||hiv/aids-22/NNS||stigma-30/NN	dep||lack-36/NN||2-33/LS	amod||lack-36/NN||perceived-35/VBN	dobj||included-11/VBD||lack-36/NN	conj_and||factors-16/NNS||lack-36/NN	prep_of||lack-36/NN||confidentiality-38/NN	nn||results-42/NNS||hiv-40/NN	nn||results-42/NNS||test-41/NN	prep_of||confidentiality-38/NN||results-42/NNS	dep||shortages-48/NNS||3-45/LS	nn||shortages-48/NNS||staff-47/NN	dobj||included-11/VBD||shortages-48/NNS	conj_and||factors-16/NNS||shortages-48/NNS	prep||shortages-48/NNS||and-49/CC	amod||workload-51/NN||high-50/JJ	pobj||and-49/CC||workload-51/NN	dep||infrastructure-58/NN||4-55/LS	amod||infrastructure-58/NN||poor-57/VBN	dobj||included-11/VBD||infrastructure-58/NN	conj_and||factors-16/NNS||infrastructure-58/NN	aux||encourage-60/VB||to-59/TO	vmod||included-11/VBD||encourage-60/VB	vmod||included-11/VBD||monitor-62/VB	conj_and||encourage-60/VB||monitor-62/VB	vmod||included-11/VBD||deliver-65/VB	conj_and||encourage-60/VB||deliver-65/VB	dobj||encourage-60/VB||hct-66/NN	aids--1||hiv-40||no||the themes emerging from the focus group discussions and interviews included four main suggested barrier factors (1) fears of hiv/aids, tb-hiv coinfection, death, and stigma; (2) perceived lack of confidentiality of hiv test results; (3) staff shortages and high workload; and (4) poor infrastructure to encourage, monitor, and deliver hct.
nsubjpass||measured-19/VBN||markers-1/NNS	nn||control-4/NN||glucose-3/NN	prep_of||markers-1/NNS||control-4/NN	amod||test-10/NN||oral-7/JJ	nn||test-10/NN||glucose-8/NN	nn||test-10/NN||tolerance-9/NN	prep_including||markers-1/NNS||test-10/NN	amod||hemoglobin-13/NN||glycated-12/JJ	prep_including||markers-1/NNS||hemoglobin-13/NN	conj_and||test-10/NN||hemoglobin-13/NN	amod||glucose-16/NN||urinary-15/JJ	prep_including||markers-1/NNS||glucose-16/NN	conj_and||test-10/NN||glucose-16/NN	auxpass||measured-19/VBN||were-18/VBD	root||ROOT-0/null||measured-19/VBN	dobj||measured-19/VBN||adiposity-23/NN	det||accumulation-26/NN||the-25/DT	dobj||measured-19/VBN||accumulation-26/NN	conj_and||adiposity-23/NN||accumulation-26/NN	nn||lipids-29/NNS||liver-28/NN	prep_of||accumulation-26/NN||lipids-29/NNS	adiposity-23||glucose-16||no_rel||markers of glucose control, including oral glucose tolerance test, glycated hemoglobin and urinary glucose, were measured as well as adiposity and the accumulation of liver lipids.
nn||propofol-2/NN||microemulsion-1/NN	nsubj||produces-3/VBZ||propofol-2/NN	root||ROOT-0/null||produces-3/VBZ	advmod||frequent-5/JJ||more-4/RBR	amod||pain-8/NN||frequent-5/JJ	conj_and||frequent-5/JJ||severe-7/JJ	amod||pain-8/NN||severe-7/JJ	dobj||produces-3/VBZ||pain-8/NN	prep_upon||produces-3/VBZ||injection-10/NN	nn||propofol-14/NN||lipid-12/NN	nn||propofol-14/NN||emulsion-13/NN	prep_than||injection-10/NN||propofol-14/NN	pain-8||propofol-14||yes||microemulsion propofol produces more frequent and severe pain upon injection than lipid emulsion propofol.
nn||levels-3/NNS||plasma-1/NN	nn||levels-3/NNS||cholesterol-2/NN	nsubj||correlated-12/VBD||levels-3/NNS	prep_in||levels-3/NNS||female-5/NN	amod||mice-11/NNS||male-9/JJ	amod||mice-11/NNS||apoe2ki-10/JJ	conj_negcc||levels-3/NNS||mice-11/NNS	nsubj||correlated-12/VBD||mice-11/NNS	root||ROOT-0/null||correlated-12/VBD	advmod||correlated-12/VBD||significantly-13/RB	prep_with||correlated-12/VBD||inflammation-15/NN	cholesterol-2||inflammation-15||no_rel||plasma cholesterol levels in female, but not male apoe2ki mice correlated significantly with inflammation.
nsubjpass||shown-7/VBN||clozapine-1/NN	nsubj||effective-10/JJ||clozapine-1/NN	nsubj||elevate-15/VBP||clozapine-1/NN	conj_and||clozapine-1/NN||olanzapine-3/NN	nsubjpass||shown-7/VBN||olanzapine-3/NN	nsubj||effective-10/JJ||olanzapine-3/NN	nsubj||elevate-15/VBP||olanzapine-3/NN	auxpass||shown-7/VBN||were-6/VBD	rcmod||clozapine-1/NN||shown-7/VBN	aux||effective-10/JJ||to-8/TO	cop||effective-10/JJ||be-9/VB	xcomp||shown-7/VBN||effective-10/JJ	prepc_in||effective-10/JJ||stabilizing-12/VBG	dobj||stabilizing-12/VBG||bipolardisorder-13/NN	root||ROOT-0/null||elevate-15/VBP	amod||levels-17/NNS||pregnenolone-16/JJ	dobj||elevate-15/VBP||levels-17/NNS	nn||hippocampus-20/NNS||rat-19/NN	prep_in||elevate-15/VBP||hippocampus-20/NNS	amod||cortex-23/NN||cerebral-22/JJ	prep_in||elevate-15/VBP||cortex-23/NN	conj_and||hippocampus-20/NNS||cortex-23/NN	prep_in||elevate-15/VBP||serum-26/NN	conj_and||hippocampus-20/NNS||serum-26/NN	bipolardisorder-13||clozapine-1||yes||clozapine and olanzapine, which were shown to be effective in stabilizing bipolardisorder, elevate pregnenolone levels in rat hippocampus, cerebral cortex, and serum.
amod||dependent-2/JJ||vitamind-1/JJ	amod||i-5/NNS||dependent-2/JJ	amod||i-5/NNS||rickets-3/JJ	nn||i-5/NNS||type-4/NN	nsubj||disorder-29/NN||i-5/NNS	appos||i-5/NNS||vddr-i-7/NNP	advmod||referred-11/VBN||also-10/RB	vmod||i-5/NNS||referred-11/VBN	advmod||vitamind-14/JJ||as-13/RB	amod||±-16/NNS||vitamind-14/JJ	amod||±-16/NNS||1î-15/JJ	prep_to||referred-11/VBN||±-16/NNS	amod||deficiency-19/NN||hydroxylase-18/JJ	dep||±-16/NNS||deficiency-19/NN	amod||rickets-23/NNS||pseudovitamind-21/JJ	nn||rickets-23/NNS||deficiency-22/NN	dep||±-16/NNS||rickets-23/NNS	conj_or||deficiency-19/NN||rickets-23/NNS	cop||disorder-29/NN||is-25/VBZ	det||disorder-29/NN||an-26/DT	amod||disorder-29/NN||autosomal-27/JJ	nn||disorder-29/NN||recessive-28/NN	root||ROOT-0/null||disorder-29/NN	vmod||disorder-29/NN||characterized-30/VBN	dep||characterized-30/VBN||clinically-31/RB	prep_by||clinically-31/RB||hypotonia-33/NN	conj_and||disorder-29/NN||muscleweakness-35/NNS	nn||failure-38/NN||growth-37/NN	appos||muscleweakness-35/NNS||failure-38/NN	amod||seizures-41/NNS||hypocalcemic-40/JJ	conj_and||disorder-29/NN||seizures-41/NNS	amod||infancy-44/NN||early-43/JJ	prep_in||seizures-41/NNS||infancy-44/NN	amod||findings-48/NNS||radiographic-47/JJ	conj_and||disorder-29/NN||findings-48/NNS	prep_of||findings-48/NNS||rickets-50/NNS	rickets-50||vitamind-14||yes||vitamind dependent rickets type i (vddr-i), also referred to as vitamind 1î±-hydroxylase deficiency or pseudovitamind deficiency rickets, is an autosomal recessive disorder characterized clinically by hypotonia, muscleweakness, growth failure, hypocalcemic seizures in early infancy, and radiographic findings of rickets.
csubj||be-44/VB||based-1/VBN	det||study-4/NN||this-3/DT	prep_on||based-1/VBN||study-4/NN	prep_on||based-1/VBN||ceftriaxone-6/NN	conj_and||study-4/NN||ceftriaxone-6/NN	prep_on||based-1/VBN||cefixime-8/NN	conj_and||study-4/NN||cefixime-8/NN	prep_on||based-1/VBN||spectinomycin-11/NN	conj_and||study-4/NN||spectinomycin-11/NN	aux||used-14/VBN||can-12/MD	auxpass||used-14/VBN||be-13/VB	rcmod||study-4/NN||used-14/VBN	det||therapy-19/NN||an-16/DT	amod||therapy-19/NN||empirical-17/JJ	amod||therapy-19/NN||first-line-18/JJ	prep_as||used-14/VBN||therapy-19/NN	prep_for||therapy-19/NN||gonorrhoea-21/NN	prep_in||used-14/VBN||india-23/NN	prep_in||used-14/VBN||pakistan-25/NN	conj_and||india-23/NN||pakistan-25/NN	prep_in||used-14/VBN||bhutan-28/NN	conj_and||india-23/NN||bhutan-28/NN	amod||ciprofloxacin-31/NN||whereas-30/JJ	prep_in||used-14/VBN||ciprofloxacin-31/NN	conj_and||india-23/NN||ciprofloxacin-31/NN	nn||g-34/NN||penicillin-33/NN	prep_in||used-14/VBN||g-34/NN	conj_and||india-23/NN||g-34/NN	prep_in||used-14/VBN||tetracycline-36/NN	conj_and||india-23/NN||tetracycline-36/NN	prep_in||used-14/VBN||erythromycin-38/NN	conj_and||india-23/NN||erythromycin-38/NN	prep_in||used-14/VBN||azithromycin-41/NN	conj_and||india-23/NN||azithromycin-41/NN	aux||be-44/VB||should-42/MD	neg||be-44/VB||not-43/RB	root||ROOT-0/null||be-44/VB	tetracycline-36||gonorrhoea-21||no_rel||based on this study, ceftriaxone, cefixime, and spectinomycin can be used as an empirical first-line therapy for gonorrhoea in india, pakistan, and bhutan, whereas ciprofloxacin, penicillin g, tetracycline, erythromycin, and azithromycin should not be.
det||aims-2/NNS||the-1/DT	nsubj||were-7/VBD||aims-2/NNS	det||study-6/NN||the-4/DT	amod||study-6/NN||present-5/JJ	prep_of||aims-2/NNS||study-6/NN	root||ROOT-0/null||were-7/VBD	aux||assess-9/VB||to-8/TO	ccomp||were-7/VBD||assess-9/VB	det||association-12/NN||a-10/DT	amod||association-12/NN||potential-11/JJ	dobj||assess-9/VB||association-12/NN	prepc_between||association-12/NN||circulating-14/VBG	dobj||circulating-14/VBG||levels-15/NNS	amod||markers-18/NNS||inflammatory-17/JJ	prep_of||levels-15/NNS||markers-18/NNS	dobj||circulating-14/VBG||hyperglycaemia-20/NN	conj_and||levels-15/NNS||hyperglycaemia-20/NN	vmod||hyperglycaemia-20/NN||measured-21/VBN	det||myocardialinfarction-26/NN||an-23/DT	amod||st-elevation-25/JJ||acute-24/JJ	amod||myocardialinfarction-26/NN||st-elevation-25/JJ	prep_during||measured-21/VBN||myocardialinfarction-26/NN	appos||myocardialinfarction-26/NN||stemi-28/NNP	prep_in||measured-21/VBN||patients-31/NNS	amod||diabetes-34/NN||known-33/JJ	prep_without||measured-21/VBN||diabetes-34/NN	aux||determine-38/VB||to-37/TO	ccomp||were-7/VBD||determine-38/VB	conj_and||assess-9/VB||determine-38/VB	mark||associated-53/VBN||whether-39/IN	dep||associated-53/VBN||circulating-40/VBG	dobj||circulating-40/VBG||levels-41/NNS	amod||markers-44/NNS||inflammatory-43/JJ	prep_of||levels-41/NNS||markers-44/NNS	vmod||markers-44/NNS||measured-45/VBN	advmod||measured-45/VBN||early-46/RB	det||stemi-50/NN||an-48/DT	amod||stemi-50/NN||acute-49/JJ	prep_after||measured-45/VBN||stemi-50/NN	auxpass||associated-53/VBN||were-52/VBD	ccomp||determine-38/VB||associated-53/VBN	det||presence-56/NN||the-55/DT	prep_with||associated-53/VBN||presence-56/NN	amod||regulation-60/NN||abnormal-58/JJ	nn||regulation-60/NN||glucose-59/NN	prep_of||presence-56/NN||regulation-60/NN	vmod||regulation-60/NN||classified-61/VBN	det||test-67/NN||an-63/DT	amod||test-67/NN||oral-64/JJ	nn||test-67/NN||glucose-65/NN	nn||test-67/NN||tolerance-66/NN	agent||classified-61/VBN||test-67/NN	appos||test-67/NN||ogtt-69/NN	amod||follow-up-73/NN||three-month-72/JJ	prep_at||classified-61/VBN||follow-up-73/NN	det||cohort-77/NN||the-75/DT	amod||cohort-77/NN||same-76/JJ	prep_in||follow-up-73/NN||cohort-77/NN	hyperglycaemia-20||glucose-65||no||the aims of the present study were to assess a potential association between circulating levels of inflammatory markers and hyperglycaemia measured during an acute st-elevation myocardialinfarction (stemi) in patients without known diabetes, and to determine whether circulating levels of inflammatory markers measured early after an acute stemi, were associated with the presence of abnormal glucose regulation classified by an oral glucose tolerance test (ogtt) at three-month follow-up in the same cohort.
aux||compare-2/VB||to-1/TO	csubj||adjuncts-16/VBZ||compare-2/VB	conj_and||compare-2/VB||evaluate-4/VB	csubj||adjuncts-16/VBZ||evaluate-4/VB	det||effect-6/NN||the-5/DT	dobj||compare-2/VB||effect-6/NN	prepc_of||effect-6/NN||adding-8/VBG	npadvmod||as-15/RB||ketamine-9/NN	conj_or||ketamine-9/NN||nitroglycerin-11/NN	npadvmod||as-15/RB||nitroglycerin-11/NN	appos||ketamine-9/NN||ntg-13/NN	advmod||adding-8/VBG||as-15/RB	root||ROOT-0/null||adjuncts-16/VBZ	aux||lidocaine-18/VB||to-17/TO	xcomp||adjuncts-16/VBZ||lidocaine-18/VB	amod||anesthesia-22/NN||intravenous-20/JJ	amod||anesthesia-22/NN||regional-21/JJ	prep_for||lidocaine-18/VB||anesthesia-22/NN	appos||anesthesia-22/NN||ivra-24/NNP	prep_on||anesthesia-22/NN||intraoperative-27/NN	xcomp||adjuncts-16/VBZ||postoperative-29/VB	conj_and||lidocaine-18/VB||postoperative-29/VB	nn||times-37/NNS||analgesia-30/NN	conj_and||analgesia-30/NN||sensorial-32/NN	nn||times-37/NNS||sensorial-32/NN	conj_and||analgesia-30/NN||motor-34/NN	nn||times-37/NNS||motor-34/NN	nn||times-37/NNS||block-35/NN	nn||times-37/NNS||onset-36/NN	dobj||postoperative-29/VB||times-37/NNS	xcomp||adjuncts-16/VBZ||tourniquet-40/VB	conj_and||lidocaine-18/VB||tourniquet-40/VB	dobj||tourniquet-40/VB||pain-41/NN	pain-41||lidocaine-18||yes||to compare and evaluate the effect of adding ketamine or nitroglycerin (ntg) as adjuncts to lidocaine for intravenous regional anesthesia (ivra) on intraoperative and postoperative analgesia, sensorial and motor block onset times, and tourniquet pain.
prep_in||found-9/VBN||contrast-2/NN	nsubjpass||found-9/VBN||mutations-4/NNS	prep_in||mutations-4/NNS||pfcyt-b-6/NN	auxpass||found-9/VBN||were-7/VBD	neg||found-9/VBN||not-8/RB	root||ROOT-0/null||found-9/VBN	num||patients-12/NNS||three-11/CD	prep_in||found-9/VBN||patients-12/NNS	vmod||patients-12/NNS||treated-13/VBN	prep_with||treated-13/VBN||atovaquone-proguanil-15/NN	nsubj||exhibited-17/VBD||atovaquone-proguanil-15/NN	rcmod||atovaquone-proguanil-15/NN||exhibited-17/VBD	amod||clearance-19/NN||delayed-18/JJ	dobj||exhibited-17/VBD||clearance-19/NN	det||infection-23/NN||the-21/DT	amod||infection-23/NN||primary-22/JJ	prep_of||clearance-19/NN||infection-23/NN	dobj||exhibited-17/VBD||in-26/IN	conj_nor||clearance-19/NN||in-26/IN	pobj||in-26/IN||two-27/CD	xcomp||exhibited-17/VBD||returning-28/VBG	dobj||returning-28/VBG||travellers-29/NNS	prep_with||returning-28/VBG||malaria-31/NN	nsubj||used-34/VBN||malaria-31/NN	aux||used-34/VBN||had-33/VBD	rcmod||malaria-31/NN||used-34/VBN	det||combination-36/NN||the-35/DT	dobj||used-34/VBN||combination-36/NN	prep_for||combination-36/NN||prophylaxis-38/NNS	malaria-31||proguanil--1||yes||in contrast, mutations in pfcyt-b were not found in three patients treated with atovaquone-proguanil who exhibited delayed clearance of the primary infection, nor in two returning travellers with malaria who had used the combination for prophylaxis.
prep_in||causes-5/VBZ||humans-2/NNS	nsubj||causes-5/VBZ||c.neoformans-4/NNS	root||ROOT-0/null||causes-5/VBZ	num||types-7/NNS||three-6/CD	dobj||causes-5/VBZ||types-7/NNS	amod||cryptococcalmeningitis-12/NNS||infections-9/JJ	nn||cryptococcalmeningitis-12/NNS||pulmonarycryptococcosis-10/NNS	prep_of||types-7/NNS||cryptococcalmeningitis-12/NNS	prep_of||types-7/NNS||wound-14/NN	conj_and||cryptococcalmeningitis-12/NNS||wound-14/NN	nn||cryptococcosis-17/NNS||cutaneous-16/NN	prep_of||types-7/NNS||cryptococcosis-17/NNS	conj_or||cryptococcalmeningitis-12/NNS||cryptococcosis-17/NNS	pulmonarycryptococcosis-10||c.neoformans-4||no||in humans , c.neoformans causes three types of infections pulmonarycryptococcosis , cryptococcalmeningitis and wound or cutaneous cryptococcosis .
det||individuals-2/NNS||the-1/DT	nsubj||have-16/VBP||individuals-2/NNS	nsubj||identified-4/VBD||we-3/PRP	rcmod||individuals-2/NNS||identified-4/VBD	prepc_as||identified-4/VBD||having-6/VBG	amod||influence-10/NN||regional-7/JJ	conj_or||regional-7/JJ||international-9/JJ	amod||influence-10/NN||international-9/JJ	dobj||having-6/VBG||influence-10/NN	det||field-13/NN||the-12/DT	prep_in||influence-10/NN||field-13/NN	prep_of||field-13/NN||hiv/aids-15/NNS	root||ROOT-0/null||have-16/VBP	det||ability-18/NN||the-17/DT	dobj||have-16/VBP||ability-18/NN	prep_to||ability-18/NN||leverage-20/NN	det||environment-25/NN||an-21/DT	advmod||conducive-23/JJ||increasingly-22/RB	amod||environment-25/NN||conducive-23/JJ	nn||environment-25/NN||funding-24/NN	dep||leverage-20/NN||environment-25/NN	det||base-30/NN||a-27/DT	amod||base-30/NN||growing-28/VBG	nn||base-30/NN||evidence-29/NN	prep_to||ability-18/NN||base-30/NN	conj_and||leverage-20/NN||base-30/NN	aux||address-32/VB||to-31/TO	vmod||have-16/VBP||address-32/VB	det||challenges-39/NNS||the-33/DT	amod||challenges-39/NNS||policy-34/NN	conj_and||policy-34/NN||programmatic-36/JJ	amod||challenges-39/NNS||programmatic-36/JJ	conj_and||policy-34/NN||operational-38/JJ	amod||challenges-39/NNS||operational-38/JJ	dobj||address-32/VB||challenges-39/NNS	prepc_to||address-32/VB||integrating-41/VBG	nn||planning-43/NN||family-42/NN	dobj||integrating-41/VBG||planning-43/NN	prep_with||integrating-41/VBG||hiv/aids-45/NNS	aids--1||hiv--1||no||the individuals we identified as having regional or international influence in the field of hiv/aids have the ability to leverage an increasingly conducive funding environment and a growing evidence base to address the policy, programmatic and operational challenges to integrating family planning with hiv/aids.
amod||women-2/NNS||young-1/JJ	nsubj||bear-6/VBP||women-2/NNS	nsubj||limited-17/VBN||women-2/NNS	amod||africa-5/NN||sub-saharan-4/JJ	prep_in||women-2/NNS||africa-5/NN	root||ROOT-0/null||bear-6/VBP	det||burden-9/NN||a-7/DT	amod||burden-9/NN||disproportionate-8/JJ	dobj||bear-6/VBP||burden-9/NN	prep_of||burden-9/NN||hivinfection-11/NN	prepc_compared_to||hivinfection-11/NN||to-13/TO	pobj||hivinfection-11/NN||men-14/NNS	aux||limited-17/VBN||have-16/VBP	conj_but||bear-6/VBP||limited-17/VBN	dobj||limited-17/VBN||options-18/NNS	aux||reduce-20/VB||to-19/TO	vmod||limited-17/VBN||reduce-20/VB	poss||risk-23/NN||their-21/PRP$	nn||risk-23/NN||hiv-22/NN	dobj||reduce-20/VB||risk-23/NN	hivinfection-11||hiv-22||no||young women in sub-saharan africa bear a disproportionate burden of hivinfection compared to men but have limited options to reduce their hiv risk.
mark||demonstrated-5/VBN||since-1/IN	neg||studies-3/NNS||no-2/DT	nsubj||demonstrated-5/VBN||studies-3/NNS	aux||demonstrated-5/VBN||have-4/VBP	advcl||observed-28/VBD||demonstrated-5/VBN	dobj||demonstrated-5/VBN||efficacy-6/NN	amod||³-10/NNS||standard-8/JJ	nn||³-10/NNS||î-9/NN	prep_of||efficacy-6/NN||³-10/NNS	dep||efficacy-6/NN||globulin-12/NN	dep||efficacy-6/NN||hbig-14/NN	conj_or||globulin-12/NN||hbig-14/NN	det||population-18/NN||a-16/DT	amod||population-18/NN||drug-using-17/JJ	prep_in||globulin-12/NN||population-18/NN	advmod||likely-24/JJ||where-19/WRB	amod||exposures-22/NNS||multiple-20/JJ	nn||exposures-22/NNS||hbv-21/NN	nsubj||likely-24/JJ||exposures-22/NNS	cop||likely-24/JJ||are-23/VBP	advcl||demonstrated-5/VBN||likely-24/JJ	det||results-27/NNS||the-26/DT	nsubj||observed-28/VBD||results-27/NNS	root||ROOT-0/null||observed-28/VBD	mark||comparable-34/JJ||in-29/IN	amod||trials-31/NNS||most-30/JJS	nsubj||comparable-34/JJ||trials-31/NNS	nsubj||hepatitisb-36/VB||trials-31/NNS	cop||comparable-34/JJ||are-32/VBP	neg||comparable-34/JJ||not-33/RB	advcl||observed-28/VBD||comparable-34/JJ	aux||hepatitisb-36/VB||to-35/TO	xcomp||comparable-34/JJ||hepatitisb-36/VB	dep||hepatitisb-36/VB||associated-37/VBN	prep_with||associated-37/VBN||drugabuse-39/NN	det||military-42/NN||the-41/DT	prep_in||drugabuse-39/NN||military-42/NN	hbv-21||hbig-14||yes||since no studies have demonstrated efficacy of standard î³-globulin or hbig in a drug-using population where multiple hbv exposures are likely, the results observed in most trials are not comparable to hepatitisb associated with drugabuse in the military.
advmod||tested-4/VBD||here-1/RB	nsubj||tested-4/VBD||we-3/PRP	root||ROOT-0/null||tested-4/VBD	det||hypothesis-6/NNS||the-5/DT	dobj||tested-4/VBD||hypothesis-6/NNS	mark||give-15/VB||that-7/IN	amod||overactivity-9/NN||pharmacological-induced-8/JJ	nsubj||give-15/VB||overactivity-9/NN	det||thalamus-13/NNS||the-11/DT	amod||thalamus-13/NNS||medial-12/JJ	prep_of||overactivity-9/NN||thalamus-13/NNS	aux||give-15/VB||could-14/MD	ccomp||tested-4/VBD||give-15/VB	dobj||give-15/VB||rise-16/NN	amod||behaviors-19/NNS||abnormal-18/JJ	prep_to||give-15/VB||behaviors-19/NNS	nsubj||observed-23/VBD||that-22/WDT	prepc_close_to||give-15/VB||observed-23/VBD	prep_in||observed-23/VBD||ocd-25/NN	rise-16||ocd-25||no_rel||here, we tested the hypothesis that pharmacological-induced overactivity of the medial thalamus could give rise to abnormal behaviors close to that observed in ocd.
vmod||showed-9/VBD||using-1/VBG	det||model-4/NN||an-2/DT	amod||model-4/NN||orthotopic-3/JJ	dobj||using-1/VBG||model-4/NN	prep_of||model-4/NN||renalcellcarcinoma-6/NN	nsubj||showed-9/VBD||we-8/PRP	root||ROOT-0/null||showed-9/VBD	advmod||showed-9/VBD||previously-10/RB	mark||resulted-16/VBD||that-11/IN	amod||immunotherapy-15/NN||il-2-12/JJ	amod||immunotherapy-15/NN||/-13/JJ	amod||immunotherapy-15/NN||anti-cd40-14/JJ	nsubj||resulted-16/VBD||immunotherapy-15/NN	ccomp||showed-9/VBD||resulted-16/VBD	amod||responses-20/NNS||synergistic-18/JJ	amod||responses-20/NNS||anti-tumor-19/JJ	prep_in||resulted-16/VBD||responses-20/NNS	mark||mediated-30/VBD||whereas-22/IN	amod||cd40-28/NNS||il-2-23/JJ	advmod||±-26/JJ||î-25/RB	conj_or||il-2-23/JJ||±-26/JJ	amod||cd40-28/NNS||±-26/JJ	nsubj||mediated-30/VBD||cd40-28/NNS	advmod||mediated-30/VBD||alone-29/RB	advcl||resulted-16/VBD||mediated-30/VBD	amod||effects-34/NNS||partial-31/JJ	amod||effects-34/NNS||transient-32/JJ	nn||effects-34/NNS||anti-tumor-33/NN	dobj||mediated-30/VBD||effects-34/NNS	il-2-23||tumor--1||no_rel||using an orthotopic model of renalcellcarcinoma, we showed previously that il-2/anti-cd40 immunotherapy resulted in synergistic anti-tumor responses, whereas il-2 or î±-cd40 alone mediated partial transient anti-tumor effects.
prep_regardless_of||similar-10/JJ||aetiology-3/NN	prep_of||aetiology-3/NN||heartdisease-5/NN	nn||benefit-8/NN||icd-7/NN	nsubj||similar-10/JJ||benefit-8/NN	cop||similar-10/JJ||was-9/VBD	root||ROOT-0/null||similar-10/JJ	nn||rr-14/FW||cad-12/FW	nn||rr-14/FW||-lrb--13/FW	prep_for||similar-10/JJ||rr-14/FW	dep||rr-14/FW||0.67-15/CD	num||%-18/NN||95-17/CD	dep||rr-14/FW||%-18/NN	nn||0.74-30/FW||ci-19/FW	nn||0.74-30/FW||0.51-20/FW	nn||0.74-30/FW||â-21/FW	nn||0.74-30/FW||$-22/FW	nn||0.74-30/FW||0.88-24/FW	nn||0.74-30/FW||-rrb--25/FW	nn||0.74-30/FW||vs.-26/FW	nn||0.74-30/FW||dcm-27/FW	nn||0.74-30/FW||-lrb--28/FW	nn||0.74-30/FW||rr-29/FW	dep||%-18/NN||0.74-30/FW	num||%-33/NN||95-32/CD	dep||rr-14/FW||%-33/NN	nn||â-36/FW||ci-34/FW	nn||â-36/FW||0.59-35/FW	dep||%-33/NN||â-36/FW	dep||-rrb--40/NN||$-37/$	num||$-37/$||0.93-39/CD	amod||rr-14/FW||-rrb--40/NN	dcm-27||cad-12||no_rel||regardless of aetiology of heartdisease , icd benefit was similar for cad -lrb- rr 0.67 ; 95 % ci 0.51 â $ `` 0.88 -rrb- vs. dcm -lrb- rr 0.74 ; 95 % ci 0.59 â $ `` 0.93 -rrb- .
amod||analysis-3/NN||logistic-1/JJ	nn||analysis-3/NN||regression-2/NN	nsubj||yielded-4/VBD||analysis-3/NN	nsubj||had-17/VBD||analysis-3/NN	nsubj||unprotected-28/VBN||analysis-3/NN	nsubj||had-40/VBD||analysis-3/NN	nsubj||used-64/VBD||analysis-3/NN	nsubj||used-76/VBD||analysis-3/NN	root||ROOT-0/null||yielded-4/VBD	num||factors-6/NNS||eight-5/CD	dobj||yielded-4/VBD||factors-6/NNS	nsubjpass||associated-9/VBN||factors-6/NNS	auxpass||associated-9/VBN||were-8/VBD	rcmod||factors-6/NNS||associated-9/VBN	prep_with||associated-9/VBN||non-attendance-11/NN	amod||age-15/NN||gay-13/JJ	nn||age-15/NN||pride-14/NN	prep_of||non-attendance-11/NN||age-15/NN	conj_and||yielded-4/VBD||had-17/VBD	nn||high-20/NN||sex-18/NN	nn||high-20/NN||while-19/NN	dobj||had-17/VBD||high-20/NN	det||months-25/NNS||the-22/DT	amod||months-25/NNS||last-23/JJ	num||months-25/NNS||12â-24/CD	prep_in||high-20/NN||months-25/NNS	aux||unprotected-28/VBN||had-27/VBD	conj_and||yielded-4/VBD||unprotected-28/VBN	amod||intercourse-30/NN||anal-29/JJ	dobj||unprotected-28/VBN||intercourse-30/NN	appos||intercourse-30/NN||uai-32/NN	det||months-38/NNS||the-35/DT	amod||months-38/NNS||last-36/JJ	num||months-38/NNS||12â-37/CD	prep_in||unprotected-28/VBN||months-38/NNS	conj_and||yielded-4/VBD||had-40/VBD	dobj||had-40/VBD||sex-41/NN	prep_for||had-40/VBD||drugs/money-43/NN	det||months-48/NNS||the-45/DT	amod||months-48/NNS||last-46/JJ	num||months-48/NNS||12â-47/CD	prep_in||drugs/money-43/NN||months-48/NNS	auxpass||diagnosed-51/VBN||been-50/VBN	vmod||drugs/money-43/NN||diagnosed-51/VBN	det||sexuallytransmittedinfection-54/NN||a-53/DT	prep_with||diagnosed-51/VBN||sexuallytransmittedinfection-54/NN	appos||sexuallytransmittedinfection-54/NN||sti-56/NN	det||months-62/NNS||the-59/DT	amod||months-62/NNS||last-60/JJ	num||months-62/NNS||12â-61/CD	prep_in||had-40/VBD||months-62/NNS	conj_and||yielded-4/VBD||used-64/VBD	dobj||used-64/VBD||nitrites-65/NNS	appos||nitrites-65/NNS||poppers-67/NNS	det||months-73/NNS||the-70/DT	amod||months-73/NNS||last-71/JJ	num||months-73/NNS||12â-72/CD	prep_in||used-64/VBD||months-73/NNS	conj_and||yielded-4/VBD||used-76/VBD	dobj||used-76/VBD||methamphetamine-77/NN	det||months-82/NNS||the-79/DT	amod||months-82/NNS||last-80/JJ	num||months-82/NNS||12â-81/CD	prep_in||used-76/VBD||months-82/NNS	sexuallytransmittedinfection-54||nitrites-65||no_rel||logistic regression analysis yielded eight factors that were associated with non-attendance of gay pride age, had sex while high in the last 12â months, had unprotected anal intercourse (uai) in the last 12â months, had sex for drugs/money in the last 12â months, been diagnosed with a sexuallytransmittedinfection (sti) in the last 12â months, used nitrites (poppers) in the last 12â months, and used methamphetamine in the last 12â months.
det||face-3/NN||the-2/DT	prep_in||attributes-36/NNS||face-3/NN	det||epidemic-7/NN||the-5/DT	amod||epidemic-7/NN||hiv/aids-6/JJ	prep_of||face-3/NN||epidemic-7/NN	nsubj||contributed-10/VBN||epidemic-7/NN	aux||contributed-10/VBN||has-9/VBZ	rcmod||epidemic-7/NN||contributed-10/VBN	det||increase-14/NN||the-12/DT	amod||increase-14/NN||dramatic-13/JJ	prep_to||contributed-10/VBN||increase-14/NN	prep_in||increase-14/NN||orphans-16/NNS	amod||children-19/NNS||abandoned-18/VBN	prep_of||face-3/NN||children-19/NNS	conj_and||epidemic-7/NN||children-19/NNS	nsubj||contributed-10/VBN||children-19/NNS	appos||children-19/NNS||oac-21/NN	advmod||children-19/NNS||worldwide-23/RB	nn||attitudes-26/NNS||caregiver-25/NN	nsubj||attributes-36/NNS||attitudes-26/NNS	prep_about||attitudes-26/NNS||hiv-28/NN	amod||stigma-32/NN||hiv-related-31/JJ	prep_about||attitudes-26/NNS||stigma-32/NN	conj_and||hiv-28/NN||stigma-32/NN	cop||attributes-36/NNS||are-34/VBP	num||attributes-36/NNS||two-35/CD	root||ROOT-0/null||attributes-36/NNS	nsubj||affect-39/VB||attributes-36/NNS	aux||affect-39/VB||may-38/MD	rcmod||attributes-36/NNS||affect-39/VB	dobj||affect-39/VB||caregiving-40/NN	aids--1||hiv-28||no||in the face of the hiv/aids epidemic that has contributed to the dramatic increase in orphans and abandoned children (oac) worldwide, caregiver attitudes about hiv, and hiv-related stigma, are two attributes that may affect caregiving.
nn||levels-2/NNS||glucagon-1/NN	nsubj||remained-3/VBD||levels-2/NNS	root||ROOT-0/null||remained-3/VBD	acomp||remained-3/VBD||suppressed-4/VBN	det||decrease-7/NN||a-6/DT	prep_following||suppressed-4/VBN||decrease-7/NN	amod||insulin-10/NN||zinc-free-9/JJ	prep_in||decrease-7/NN||insulin-10/NN	prep_in||decrease-7/NN||insulin-10/NN	conj_and||insulin-10/NN||insulin-10/NN	prep_with||insulin-10/NN||euglycemia-12/NN	dep||insulin-10/NN||â-14/VB	num||±-17/NN||14-15/CD	nn||±-17/NN||â-16/NN	nsubj||-LSB--20/VBG||±-17/NN	number||pg/ml-19/JJ||3-18/CD	dep||-LSB--20/VBG||pg/ml-19/JJ	xcomp||â-14/VB||-LSB--20/VBG	poss||-RSB--28/NN||â-21/NNP	number||â-24/CD||4.0-23/CD	num||-RSB--28/NN||â-24/CD	nn||-RSB--28/NN||±-25/NN	num||-RSB--28/NN||0.9-26/CD	nn||-RSB--28/NN||pmol/l-27/NN	dobj||-LSB--20/VBG||-RSB--28/NN	amod||hyperinsulinemia-33/NN||sustained-32/VBN	prep_during||insulin-10/NN||hyperinsulinemia-33/NN	prep_with||hyperinsulinemia-33/NN||hypoglycemia-35/NN	nn||±-40/NN||â-37/NN	num||±-40/NN||14-38/CD	nn||±-40/NN||â-39/NN	dep||hypoglycemia-35/NN||±-40/NN	num||-LSB--43/NNS||2-41/CD	amod||-LSB--43/NNS||pg/ml-42/JJ	dep||±-40/NN||-LSB--43/NNS	poss||-RSB--51/NN||â-44/NNP	amod||-RSB--51/NN||4.0-46/JJ	nn||-RSB--51/NN||â-47/NN	nn||-RSB--51/NN||±-48/NN	num||-RSB--51/NN||0.6-49/CD	amod||-RSB--51/NN||pmol/l-50/JJ	dep||-LSB--43/NNS||-RSB--51/NN	acomp||remained-3/VBD||increased-54/VBN	conj_but||suppressed-4/VBN||increased-54/VBN	poss||pg/ml-62/NN||â-56/NNP	number||â-59/CD||3-58/CD	num||pg/ml-62/NN||â-59/CD	amod||pg/ml-62/NN||±-60/JJ	num||pg/ml-62/NN||3-61/CD	prep_to||increased-54/VBN||pg/ml-62/NN	poss||â-67/NN||â-64/NNP	num||â-67/NN||0.9-66/CD	npadvmod||pmol/l-70/JJ||â-67/NN	number||0.9-69/CD||±-68/CD	num||â-67/NN||0.9-69/CD	dep||pg/ml-62/NN||pmol/l-70/JJ	parataxis||increased-54/VBN||p-73/VB	num||0.01-75/CD||<-74/CD	dobj||p-73/VB||0.01-75/CD	det||decrease-79/NN||a-78/DT	prep_following||increased-54/VBN||decrease-79/NN	amod||insulin-82/NN||zinc-free-81/JJ	prep_in||decrease-79/NN||insulin-82/NN	prep_with||insulin-82/NN||hypoglycemia-84/NN	det||min-89/NNS||the-86/DT	amod||min-89/NNS||next-87/JJ	num||min-89/NNS||120-88/CD	prep_over||hypoglycemia-84/NN||min-89/NNS	zinc--1||hypoglycemia-84||no_rel||glucagon levels remained suppressed following a decrease in zinc-free insulin with euglycemia (â14 â± 3 pg/ml [â4.0 â± 0.9 pmol/l]) and during sustained hyperinsulinemia with hypoglycemia (â14 â± 2 pg/ml [â4.0 â± 0.6 pmol/l]) but increased to â3 â± 3 pg/ml (â0.9 â± 0.9 pmol/l) ( p < 0.01) following a decrease in zinc-free insulin with hypoglycemia over the next 120 min.
det||reduction-3/NN||a-1/DT	amod||reduction-3/NN||significant-2/JJ	nsubjpass||observed-11/VBN||reduction-3/NN	amod||cholesterol-6/NN||total-5/JJ	prep_in||reduction-3/NN||cholesterol-6/NN	nn||concentrations-9/NNS||ldl-cholesterol-8/NN	prep_in||reduction-3/NN||concentrations-9/NNS	conj_and||cholesterol-6/NN||concentrations-9/NNS	auxpass||observed-11/VBN||was-10/VBD	root||ROOT-0/null||observed-11/VBN	det||month-15/NN||the-13/DT	amod||month-15/NN||first-14/JJ	prep_during||observed-11/VBN||month-15/NN	prep_of||month-15/NN||treatment-17/NN	xcomp||observed-11/VBN||suggesting-19/VBG	mark||used-29/VBN||that-20/IN	det||administration-22/NN||the-21/DT	nsubjpass||used-29/VBN||administration-22/NN	nn||lecithin-25/NN||soy-24/NN	prep_of||administration-22/NN||lecithin-25/NN	advmod||used-29/VBN||daily-26/RB	aux||used-29/VBN||may-27/MD	auxpass||used-29/VBN||be-28/VB	ccomp||suggesting-19/VBG||used-29/VBN	det||treatment-33/NN||a-31/DT	amod||treatment-33/NN||supplemental-32/JJ	prep_as||used-29/VBN||treatment-33/NN	prep_in||treatment-33/NN||hypercholesterolemia-35/NN	hypercholesterolemia-35||cholesterol-6||no||a significant reduction in total cholesterol and ldl-cholesterol concentrations was observed during the first month of treatment, suggesting that the administration of soy lecithin daily may be used as a supplemental treatment in hypercholesterolemia.
det||study-3/NN||this-1/DT	amod||study-3/NN||open-label-2/JJ	nsubj||compared-4/VBD||study-3/NN	ccomp||used-17/VBD||compared-4/VBD	det||efficacy-6/NN||the-5/DT	dobj||compared-4/VBD||efficacy-6/NN	dobj||compared-4/VBD||tolerability-8/NN	conj_and||efficacy-6/NN||tolerability-8/NN	prep_of||efficacy-6/NN||aripiprazole-10/NN	prep_with||compared-4/VBD||haloperidol-12/NN	det||typicalantipsychotic-15/NN||a-14/DT	nsubj||used-17/VBD||typicalantipsychotic-15/NN	nsubj||treat-19/VB||typicalantipsychotic-15/NN	advmod||used-17/VBD||widely-16/RB	root||ROOT-0/null||used-17/VBD	aux||treat-19/VB||to-18/TO	xcomp||used-17/VBD||treat-19/VB	dobj||treat-19/VB||patients-20/NNS	prep_with||treat-19/VB||ticdisorders-22/NNS	aripiprazole-10||ticdisorders-22||no_rel||this open-label study compared the efficacy and tolerability of aripiprazole with haloperidol, a typicalantipsychotic widely used to treat patients with ticdisorders.
nsubjpass||found-12/VBN||four-1/CD	dep||four-1/CD||b245-3/NNP	dep||b245-3/NNP||b376-5/NNP	dep||b245-3/NNP||b1581-7/JJ	dep||b245-3/NNP||b1789-9/JJ	conj_and||b1581-7/JJ||b1789-9/JJ	auxpass||found-12/VBN||were-11/VBD	root||ROOT-0/null||found-12/VBN	det||ability-15/NN||the-14/DT	prep_with||found-12/VBN||ability-15/NN	aux||inhibit-18/VB||to-16/TO	advmod||inhibit-18/VB||potently-17/RB	vmod||ability-15/NN||inhibit-18/VB	nn||rna-20/NN||hbv-19/NN	dobj||inhibit-18/VB||rna-20/NN	iobj||inhibit-18/VB||rna-20/NN	dobj||inhibit-18/VB||dna-22/NN	iobj||inhibit-18/VB||dna-22/NN	conj_and||rna-20/NN||dna-22/NN	nn||antigen-25/NN||surface-24/NN	dobj||inhibit-18/VB||antigen-25/NN	iobj||inhibit-18/VB||antigen-25/NN	conj_and||rna-20/NN||antigen-25/NN	appos||antigen-25/NN||hbsag-27/NN	amod||antigen-31/NN||e-30/JJ	appos||antigen-25/NN||antigen-31/NN	appos||antigen-31/NN||hbeag-33/NN	nn||antigen-37/NN||core-36/NN	dobj||inhibit-18/VB||antigen-37/NN	iobj||inhibit-18/VB||antigen-37/NN	conj_and||rna-20/NN||antigen-37/NN	dep||rna-20/NN||hbcag-39/VBG	dep||rna-20/NN||expression-41/NN	nn||genotypes-44/NNS||hbv-43/NN	prep_in||expression-41/NN||genotypes-44/NNS	dep||genotypes-44/NNS||a-45/SYM	dep||genotypes-44/NNS||b-47/SYM	conj_and||a-45/SYM||b-47/SYM	dep||genotypes-44/NNS||c-49/SYM	conj_and||a-45/SYM||c-49/SYM	dep||genotypes-44/NNS||d-51/SYM	conj_and||a-45/SYM||d-51/SYM	dep||genotypes-44/NNS||i-53/JJ	conj_and||a-45/SYM||i-53/JJ	det||genotype-58/NN||a-55/DT	advmod||identified-57/JJ||newly-56/RB	amod||genotype-58/NN||identified-57/JJ	appos||ability-15/NN||genotype-58/NN	amod||cells-62/NNS||huh7-61/JJ	prep_in||ability-15/NN||cells-62/NNS	prep_in||ability-15/NN||mice-65/NNS	conj_and||cells-62/NNS||mice-65/NNS	hbv-43||hbsag-27||yes||four (b245, b376, b1581 and b1789) were found with the ability to potently inhibit hbv rna, dna, surface antigen (hbsag), e antigen (hbeag) and core antigen (hbcag) expression in hbv genotypes a, b, c, d and i (a newly identified genotype) in huh7 cells and in mice.
nsubj||followed-3/VBD||we-1/PRP	advmod||followed-3/VBD||prospectively-2/RB	root||ROOT-0/null||followed-3/VBD	prt||followed-3/VBD||up-4/RP	advmod||ill-6/JJ||critically-5/RB	amod||patients-8/NNS||ill-6/JJ	nn||patients-8/NNS||hiv/aids-7/NNS	dobj||followed-3/VBD||patients-8/NNS	aux||evaluate-10/VB||to-9/TO	vmod||followed-3/VBD||evaluate-10/VB	det||factors-14/NNS||the-11/DT	amod||factors-14/NNS||main-12/JJ	nn||factors-14/NNS||risk-13/NN	dobj||evaluate-10/VB||factors-14/NNS	nn||mortality-17/NN||hospital-16/NN	prep_for||factors-14/NNS||mortality-17/NN	det||impact-20/NN||the-19/DT	dobj||evaluate-10/VB||impact-20/NN	conj_and||factors-14/NNS||impact-20/NN	amod||sepsis-23/NN||severe-22/JJ	prep_of||impact-20/NN||sepsis-23/NN	det||survival-30/NN||the-25/DT	amod||survival-30/NN||short-26/JJ	conj_and||short-26/JJ||long-term-29/JJ	amod||survival-30/NN||long-term-29/JJ	prep_on||evaluate-10/VB||survival-30/NN	aids--1||hiv--1||no||we prospectively followed up critically ill hiv/aids patients to evaluate the main risk factors for hospital mortality and the impact of severe sepsis on the short- and long-term survival.
nsubj||disease-5/NN||type1diabetesmellitus-1/NNS	cop||disease-5/NN||is-2/VBZ	det||disease-5/NN||an-3/DT	amod||disease-5/NN||autoimmune-4/JJ	root||ROOT-0/null||disease-5/NN	dep||disease-5/NN||caused-6/VBN	prep_by||caused-6/VBN||destruction-8/NN	amod||cells-12/NNS||pancreatic-10/JJ	nn||cells-12/NNS||beta-11/NN	prep_of||destruction-8/NN||cells-12/NNS	dep||disease-5/NN||characterized-14/VBN	conj_and||caused-6/VBN||characterized-14/VBN	prep_by||characterized-14/VBN||defect-16/NN	nn||secretion-19/NN||insulin-18/NN	prep_in||defect-16/NN||secretion-19/NN	mark||and/or-28/VBZ||while-20/IN	amod||results-22/NNS||type2diabetesmellitus-21/JJ	nsubj||and/or-28/VBZ||results-22/NNS	prep_from||results-22/NNS||abnormalities-24/NNS	nn||secretion-27/NN||insulin-26/NN	prep_in||abnormalities-24/NNS||secretion-27/NN	advcl||characterized-14/VBN||and/or-28/VBZ	nn||action-30/NN||insulin-29/NN	dobj||and/or-28/VBZ||action-30/NN	dobj||and/or-28/VBZ||both-32/DT	conj_or||action-30/NN||both-32/DT	type1diabetesmellitus-1||insulin-29||yes||type1diabetesmellitus is an autoimmune disease caused by destruction of pancreatic beta cells and characterized by defect in insulin secretion while type2diabetesmellitus results from abnormalities in insulin secretion and/or insulin action or both.
aux||review-2/VB||to-1/TO	root||ROOT-0/null||review-2/VB	det||literature-4/NN||the-3/DT	dobj||review-2/VB||literature-4/NN	det||treatment-7/NN||the-6/DT	prep_on||literature-4/NN||treatment-7/NN	amod||disease-11/NN||gastroesophageal-9/JJ	nn||disease-11/NN||reflux-10/NN	prep_of||treatment-7/NN||disease-11/NN	dep||treatment-7/NN||gerd-13/VBN	prep_with||review-2/VB||emphasis-16/NN	prep_on||emphasis-16/NN||protonpumpinhibitors-18/NNS	appos||protonpumpinhibitors-18/NNS||ppis-20/NNS	advmod||review-2/VB||particularly-23/RB	amod||esomeprazole-26/NN||delayed-release-25/JJ	prep_on||review-2/VB||esomeprazole-26/NN	aux||identify-30/VB||to-29/TO	conj_and||review-2/VB||identify-30/VB	dobj||identify-30/VB||properties-31/NNS	amod||effects-34/NNS||adverse-33/JJ	nsubj||observed-37/VBD||effects-34/NNS	prep_of||effects-34/NNS||ppis-36/NNS	conj_and||review-2/VB||observed-37/VBD	det||treatment-40/NN||the-39/DT	prep_in||observed-37/VBD||treatment-40/NN	prep_of||treatment-40/NN||gerd-42/NN	prep_in||observed-37/VBD||children-44/NNS	prep_in||observed-37/VBD||adolescents-46/NNS	conj_and||children-44/NNS||adolescents-46/NNS	gerd-42||protonpumpinhibitors-18||no_rel||to review the literature on the treatment of gastroesophageal reflux disease (gerd) with emphasis on protonpumpinhibitors (ppis), particularly on delayed-release esomeprazole, and to identify properties and adverse effects of ppis observed in the treatment of gerd in children and adolescents.
amod||prevalence-2/NN||increasing-1/VBG	nsubj||worsening-17/VBG||prevalence-2/NN	nn||resistance-5/NN||inh-4/NN	prep_of||prevalence-2/NN||resistance-5/NN	advmod||resistance-5/NN||especially-7/RB	amod||tb-12/NN||high-9/JJ	nn||tb-12/NN||tuberculosis-10/NNP	nn||tb-12/NN||-lrb--11/NNP	prep_in||especially-7/RB||tb-12/NN	advmod||prevalent-14/JJ||-rrb--13/RB	amod||countries-15/NNS||prevalent-14/JJ	dep||resistance-5/NN||countries-15/NNS	aux||worsening-17/VBG||is-16/VBZ	root||ROOT-0/null||worsening-17/VBG	det||burden-19/NN||the-18/DT	dobj||worsening-17/VBG||burden-19/NN	nn||programs-23/NNS||tb-21/NN	nn||programs-23/NNS||control-22/NN	prep_of||burden-19/NN||programs-23/NNS	mark||noted-30/VBN||since-25/IN	amod||rates-28/NNS||similar-26/JJ	nn||rates-28/NNS||transmission-27/NN	nsubjpass||noted-30/VBN||rates-28/NNS	auxpass||noted-30/VBN||are-29/VBP	advcl||worsening-17/VBG||noted-30/VBN	nn||strains-37/NNS||inh-32/NN	amod||strains-37/NNS||susceptible-33/JJ	conj_and||susceptible-33/JJ||resistant-35/JJ	amod||strains-37/NNS||resistant-35/JJ	nn||strains-37/NNS||m.tuberculosis-36/NN	prep_for||noted-30/VBN||strains-37/NNS	tuberculosis-10||inh-32||yes||increasing prevalence of inh resistance , especially in high tuberculosis -lrb- tb -rrb- prevalent countries is worsening the burden of tb control programs , since similar transmission rates are noted for inh susceptible and resistant m.tuberculosis strains .
det||report-2/NN||this-1/DT	nsubj||describes-3/VBZ||report-2/NN	root||ROOT-0/null||describes-3/VBZ	det||case-5/NN||the-4/DT	dobj||describes-3/VBZ||case-5/NN	nsubj||became-13/VBD||case-5/NN	det||woman-8/NN||a-7/DT	prep_of||case-5/NN||woman-8/NN	amod||schizophrenia-11/NN||treatment-resistant-10/JJ	prep_with||woman-8/NN||schizophrenia-11/NN	rcmod||case-5/NN||became-13/VBD	acomp||became-13/VBD||pregnant-14/JJ	auxpass||treated-17/VBN||being-16/VBG	prepc_while||pregnant-14/JJ||treated-17/VBN	advmod||treated-17/VBN||successfully-18/RB	prep_with||treated-17/VBN||clozapine-20/NN	schizophrenia-11||clozapine-20||yes||this report describes the case of a woman with treatment-resistant schizophrenia who became pregnant while being treated successfully with clozapine.
mark||clear-4/JJ||although-1/IN	nsubj||clear-4/JJ||it-2/PRP	cop||clear-4/JJ||is-3/VBZ	advcl||cause-47/VB||clear-4/JJ	mark||have-16/VBP||that-5/IN	det||patients-7/NNS||some-6/DT	nsubj||have-16/VBP||patients-7/NNS	prep_with||patients-7/NNS||acetylsalicylicacid-9/NN	appos||acetylsalicylicacid-9/NN||asa-11/NN	amod||asthma-15/NN||sensitive-14/JJ	dep||acetylsalicylicacid-9/NN||asthma-15/NN	ccomp||clear-4/JJ||have-16/VBP	poss||onset-19/NN||their-17/PRP$	amod||onset-19/NN||clinical-18/JJ	dobj||have-16/VBP||onset-19/NN	prep_of||onset-19/NN||disease-21/NN	prep_in||disease-21/NN||childhood-23/NN	prep_in||disease-21/NN||bronchoconstriction-25/NN	conj_and||childhood-23/NN||bronchoconstriction-25/NN	mark||seen-30/VBN||after-26/IN	nn||challenge-28/NN||asa-27/NN	nsubjpass||seen-30/VBN||challenge-28/NN	auxpass||seen-30/VBN||is-29/VBZ	advcl||have-16/VBP||seen-30/VBN	prep_in||seen-30/VBN||0-32/CD	num||%-35/NN||22-34/CD	prep_to||seen-30/VBN||%-35/NN	amod||children-38/NNS||asthmatic-37/JJ	prep_of||%-35/NN||children-38/NNS	advmod||challenged-40/VBN||so-39/RB	vmod||children-38/NNS||challenged-40/VBN	nsubj||cause-47/VB||ibuprofen-42/NN	amod||doses-45/NNS||antipyretic-44/JJ	prep_at||ibuprofen-42/NN||doses-45/NNS	aux||cause-47/VB||may-46/MD	root||ROOT-0/null||cause-47/VB	amod||problems-50/NNS||acute-48/JJ	nn||problems-50/NNS||respiratory-49/NN	dobj||cause-47/VB||problems-50/NNS	advmod||cause-47/VB||only-51/RB	det||number-56/NN||a-53/DT	advmod||small-55/JJ||very-54/RB	amod||number-56/NN||small-55/JJ	prep_in||cause-47/VB||number-56/NN	amod||moderate-60/JJ||mild-58/JJ	dep||moderate-60/JJ||to-59/TO	amod||asthmatics-61/NNS||moderate-60/JJ	prep_of||number-56/NN||asthmatics-61/NNS	asthma-15||asa-27||no||although it is clear that some patients with acetylsalicylicacid (asa)-sensitive asthma have their clinical onset of disease in childhood and bronchoconstriction after asa challenge is seen in 0 to 22% of asthmatic children so challenged, ibuprofen at antipyretic doses may cause acute respiratory problems only in a very small number of mild to moderate asthmatics.
prep_in||secondary-23/VBZ||countries-2/NNS	advmod||employed-8/VBN||where-3/WRB	amod||rehydration-5/NN||intravenous-4/JJ	nsubjpass||employed-8/VBN||rehydration-5/NN	auxpass||employed-8/VBN||is-6/VBZ	advmod||employed-8/VBN||often-7/RB	rcmod||countries-2/NNS||employed-8/VBN	det||administration-13/NN||the-10/DT	nn||administration-13/NN||emergency-11/NN	nn||administration-13/NN||department-12/NN	nsubj||secondary-23/VBZ||administration-13/NN	nsubj||gastroenteritis-25/VB||administration-13/NN	amod||ondansetron-16/NN||oral-15/JJ	prep_of||administration-13/NN||ondansetron-16/NN	prep_to||ondansetron-16/NN||children-18/NNS	prep_with||children-18/NNS||dehydration-20/NN	prep_with||children-18/NNS||vomiting-22/NN	conj_and||dehydration-20/NN||vomiting-22/NN	root||ROOT-0/null||secondary-23/VBZ	aux||gastroenteritis-25/VB||to-24/TO	xcomp||secondary-23/VBZ||gastroenteritis-25/VB	dobj||gastroenteritis-25/VB||results-26/NNS	amod||savings-30/NNS||significant-28/JJ	amod||savings-30/NNS||monetary-29/JJ	prep_in||results-26/NNS||savings-30/NNS	prepc_compared_to||gastroenteritis-25/VB||to-32/TO	det||policy-35/NN||a-33/DT	amod||policy-35/NN||no-ondansetron-34/JJ	pobj||gastroenteritis-25/VB||policy-35/NN	vomiting-22||ondansetron-16||yes||in countries where intravenous rehydration is often employed, the emergency department administration of oral ondansetron to children with dehydration and vomiting secondary to gastroenteritis results in significant monetary savings compared to a no-ondansetron policy.
det||combination-2/NN||the-1/DT	nsubj||option-12/NN||combination-2/NN	amod||docetaxel-7/NN||s-1-4/JJ	conj_and||s-1-4/JJ||biweekly-6/JJ	amod||docetaxel-7/NN||biweekly-6/JJ	prep_of||combination-2/NN||docetaxel-7/NN	cop||option-12/NN||is-8/VBZ	det||option-12/NN||an-9/DT	amod||option-12/NN||acceptable-10/JJ	amod||option-12/NN||therapeutic-11/JJ	root||ROOT-0/null||option-12/NN	prep_in||option-12/NN||patients-14/NNS	advmod||treated-17/JJ||previously-16/RB	amod||regardless-20/NNS||treated-17/JJ	amod||regardless-20/NNS||advanced-18/JJ	amod||regardless-20/NNS||nsclc-19/JJ	prep_with||patients-14/NNS||regardless-20/NNS	det||type-24/NN||the-22/DT	amod||type-24/NN||histological-23/JJ	prep_of||regardless-20/NNS||type-24/NN	nsclc-19||docetaxel-7||yes||the combination of s-1 and biweekly docetaxel is an acceptable therapeutic option in patients with previously treated advanced nsclc regardless of the histological type.
det||knowledge-7/NN||the-2/DT	amod||knowledge-7/NN||authorâ-3/VBG	num||knowledge-7/NN||$-4/$	number||s-6/CD||-5/CD	num||$-4/$||s-6/CD	prep_to||case-14/NN||knowledge-7/NN	nsubj||case-14/NN||this-9/DT	cop||case-14/NN||is-10/VBZ	det||case-14/NN||the-11/DT	amod||case-14/NN||first-12/JJ	amod||case-14/NN||reported-13/JJ	root||ROOT-0/null||case-14/NN	prep_in||injected-20/VBN||case-14/NN	nsubjpass||injected-20/VBN||r-tpa-17/NN	nsubj||liquefy-26/VB||r-tpa-17/NN	nsubj||drain-28/VB||r-tpa-17/NN	auxpass||injected-20/VBN||was-18/VBD	advmod||injected-20/VBN||successfully-19/RB	rcmod||case-14/NN||injected-20/VBN	det||space-24/NN||the-22/DT	amod||space-24/NN||suprachoroidal-23/JJ	prep_in||injected-20/VBN||space-24/NN	aux||liquefy-26/VB||to-25/TO	xcomp||injected-20/VBN||liquefy-26/VB	xcomp||injected-20/VBN||drain-28/VB	conj_and||liquefy-26/VB||drain-28/VB	det||hemorrhage-31/NN||a-29/DT	amod||hemorrhage-31/NN||suprachoroidal-30/JJ	dobj||liquefy-26/VB||hemorrhage-31/NN	amod||dissolution-35/NN||natural-34/JJ	prep_prior_to||liquefy-26/VB||dissolution-35/NN	hemorrhage-31||r-tpa-17||no_rel||to the authorâs knowledge, this is the first reported case in which r-tpa was successfully injected in the suprachoroidal space to liquefy and drain a suprachoroidal hemorrhage prior to natural dissolution.
nsubjpass||documented-34/VBN||viruses-1/NNS	nsubj||develop-36/VB||viruses-1/NNS	dep||viruses-1/NNS||other-2/JJ	det||viruses-6/NNS||the-4/DT	nn||viruses-6/NNS||hepatitis-5/NN	prep_than||viruses-1/NNS||viruses-6/NNS	amod||virus-15/NN||parvovirusb19-9/JJ	amod||epstein-13/JJ||cytomegalovirus-11/JJ	amod||virus-15/NN||epstein-13/JJ	nn||virus-15/NN||bar-14/NN	prep_such_as||viruses-6/NNS||virus-15/NN	nn||virus-19/NN||transfusion-17/NN	amod||virus-19/NN||transmitted-18/JJ	prep_such_as||viruses-6/NNS||virus-19/NN	conj_and||virus-15/NN||virus-19/NN	appos||virus-19/NN||ttv-21/NN	amod||virus-26/NN||non-a-e-24/JJ	nn||virus-26/NN||hepatitis-25/NN	prep_such_as||viruses-6/NNS||virus-26/NN	conj_and||virus-15/NN||virus-26/NN	amod||viruses-29/NNS||unknown-28/JJ	appos||virus-26/NN||viruses-29/NNS	aux||documented-34/VBN||has-31/VBZ	advmod||documented-34/VBN||also-32/RB	auxpass||documented-34/VBN||been-33/VBN	root||ROOT-0/null||documented-34/VBN	aux||develop-36/VB||to-35/TO	xcomp||documented-34/VBN||develop-36/VB	det||syndrome-38/NN||the-37/DT	dobj||develop-36/VB||syndrome-38/NN	virus-26||viruses-29||no||viruses other than the hepatitis viruses such as parvovirusb19, cytomegalovirus, epstein bar virus, transfusion transmitted virus (ttv) and non-a-e hepatitis virus (unknown viruses) has also been documented to develop the syndrome.
root||ROOT-0/null||achieving-1/VBG	det||goals-5/NNS||the-2/DT	amod||goals-5/NNS||millennium-3/JJ	nn||goals-5/NNS||development-4/NN	dobj||achieving-1/VBG||goals-5/NNS	nsubj||aim-7/VBP||goals-5/NNS	nsubj||reduce-9/VB||goals-5/NNS	rcmod||goals-5/NNS||aim-7/VBP	aux||reduce-9/VB||to-8/TO	xcomp||aim-7/VBP||reduce-9/VB	nn||mortality-13/NN||malnutrition-10/NN	conj_and||malnutrition-10/NN||child-12/NN	nn||mortality-13/NN||child-12/NN	dobj||reduce-9/VB||mortality-13/NN	dep||achieving-1/VBG||depends-14/VBZ	prep_in||depends-14/VBZ||part-16/NN	det||ability-19/NN||the-18/DT	prep_on||part-16/NN||ability-19/NN	prep_of||ability-19/NN||governments/policymakers-21/NNS	aux||address-23/VB||to-22/TO	xcomp||depends-14/VBZ||address-23/VB	acomp||address-23/VB||nutritional-24/JJ	nsubj||achieving-1/VBG||status-25/NN	prep_of||status-25/NN||children-27/NNS	prep_in||children-27/NNS||general-29/NN	prep_of||status-25/NN||those-31/DT	conj_and||children-27/NNS||those-31/DT	vmod||those-31/DT||infected-32/VBN	vmod||those-31/DT||affected-34/VBN	conj_or||infected-32/VBN||affected-34/VBN	agent||infected-32/VBN||hiv/aids-36/NNS	prep_in||hiv/aids-36/NNS||particular-38/NN	aids--1||hiv--1||no||achieving the millennium development goals that aim to reduce malnutrition and child mortality depends in part on the ability of governments/policymakers to address nutritional status of children in general and those infected or affected by hiv/aids in particular.
prep_in||resulted-29/VBD||contrast-2/NN	nsubj||comprises-9/VBZ||treatment-4/NN	nsubj||resulted-29/VBD||treatment-4/NN	prep_with||treatment-4/NN||rehydrate-6/NN	rcmod||treatment-4/NN||comprises-9/VBZ	dobj||comprises-9/VBZ||fructose-10/NN	nn||polymer-13/NNP||glucose-12/NNP	dobj||comprises-9/VBZ||polymer-13/NNP	conj_and||fructose-10/NN||polymer-13/NNP	dobj||comprises-9/VBZ||calcium-15/NN	conj_and||fructose-10/NN||calcium-15/NN	dobj||comprises-9/VBZ||magnesium-17/NN	conj_and||fructose-10/NN||magnesium-17/NN	dobj||comprises-9/VBZ||sodium-19/NN	conj_and||fructose-10/NN||sodium-19/NN	dobj||comprises-9/VBZ||potassium-21/NN	conj_and||fructose-10/NN||potassium-21/NN	dobj||comprises-9/VBZ||aminoacids-23/NNS	conj_and||fructose-10/NN||aminoacids-23/NNS	dobj||comprises-9/VBZ||thiols-25/NNS	conj_and||fructose-10/NN||thiols-25/NNS	dobj||comprises-9/VBZ||vitamins-27/NNS	conj_and||fructose-10/NN||vitamins-27/NNS	root||ROOT-0/null||resulted-29/VBD	det||increase-34/NN||a-31/DT	number||%-33/NN||7.3-32/CD	amod||increase-34/NN||%-33/NN	prep_in||resulted-29/VBD||increase-34/NN	amod||relative-38/NN||treadmill-36/JJ	nn||relative-38/NN||time-37/NN	prep_in||increase-34/NN||relative-38/NN	prep_to||resulted-29/VBD||that-40/DT	det||state-44/NN||the-42/DT	amod||state-44/NN||dehydrated-43/JJ	prep_of||that-40/DT||state-44/NN	dehydrated-43||glucose-12||no||in contrast, treatment with rehydrate, which comprises fructose, glucose polymer, calcium, magnesium, sodium, potassium, aminoacids, thiols and vitamins, resulted in a 7.3% increase in treadmill time relative to that of the dehydrated state.
det||aim-2/NN||the-1/DT	nsubj||is-6/VBZ||aim-2/NN	det||review-5/NN||this-4/DT	prep_of||aim-2/NN||review-5/NN	root||ROOT-0/null||is-6/VBZ	aux||analyze-8/VB||to-7/TO	ccomp||is-6/VBZ||analyze-8/VB	det||results-10/NNS||the-9/DT	dobj||analyze-8/VB||results-10/NNS	dobj||analyze-8/VB||experiences-12/NNS	conj_and||results-10/NNS||experiences-12/NNS	amod||treatments-18/NNS||old-14/JJ	conj_and||old-14/JJ||new-16/JJ	amod||treatments-18/NNS||new-16/JJ	amod||treatments-18/NNS||medical-17/JJ	prep_with||analyze-8/VB||treatments-18/NNS	prep_of||treatments-18/NNS||cd-20/NN	aux||reevaluate-23/VB||to-22/TO	ccomp||is-6/VBZ||reevaluate-23/VB	conj_and||analyze-8/VB||reevaluate-23/VB	amod||therapies-25/NNS||medical-24/JJ	dobj||reevaluate-23/VB||therapies-25/NNS	prep_for||reevaluate-23/VB||complications-27/NNS	prep_of||complications-27/NNS||cd-29/NN	prep_of||complications-27/NNS||hypopituitarism-31/NN	conj_and||cd-29/NN||hypopituitarism-31/NN	prep_in||reevaluate-23/VB||patients-33/NNS	amod||cd-36/NN||cured-35/JJ	prep_with||patients-33/NNS||cd-36/NN	hypopituitarism-31||cd-36||no_rel||the aim of this review is to analyze the results and experiences with old and new medical treatments of cd and to reevaluate medical therapies for complications of cd and hypopituitarism in patients with cured cd.
det||combination-2/NN||the-1/DT	nsubj||led-20/VBN||combination-2/NN	prep_of||combination-2/NN||hiv/aids-4/NNS	nn||insecurity-7/NN||food-6/NN	prep_of||combination-2/NN||insecurity-7/NN	conj_and||hiv/aids-4/NNS||insecurity-7/NN	det||capacity-11/NN||a-9/DT	amod||capacity-11/NN||weakened-10/VBN	prep_of||combination-2/NN||capacity-11/NN	conj_and||hiv/aids-4/NNS||capacity-11/NN	prep_for||capacity-11/NN||governments-13/NNS	aux||deliver-15/VB||to-14/TO	vmod||governments-13/NNS||deliver-15/VB	amod||services-18/NNS||basic-16/JJ	amod||services-18/NNS||social-17/JJ	dobj||deliver-15/VB||services-18/NNS	aux||led-20/VBN||has-19/VBZ	root||ROOT-0/null||led-20/VBN	det||region-23/NN||the-22/DT	prep_to||led-20/VBN||region-23/NN	vmod||region-23/NN||experiencing-24/VBG	det||phase-27/NN||an-25/DT	amod||phase-27/NN||acute-26/JJ	dobj||experiencing-24/VBG||phase-27/NN	det||emergency-31/NN||a-29/DT	amod||emergency-31/NN||long-term-30/JJ	prep_of||phase-27/NN||emergency-31/NN	aids--1||hiv--1||no||the combination of hiv/aids, food insecurity and a weakened capacity for governments to deliver basic social services has led to the region experiencing an acute phase of a long-term emergency.
nsubj||consisted-2/VBD||treatment-1/NN	root||ROOT-0/null||consisted-2/VBD	amod||treatment-11/NN||antibiotics-4/JJ	conj_and||antibiotics-4/JJ||corticosteroids-6/JJ	amod||treatment-11/NN||corticosteroids-6/JJ	conj_and||antibiotics-4/JJ||immunoglobulin-8/JJ	amod||treatment-11/NN||immunoglobulin-8/JJ	conj_and||antibiotics-4/JJ||supportive-10/JJ	amod||treatment-11/NN||supportive-10/JJ	prep_of||consisted-2/VBD||treatment-11/NN	prep_for||consisted-2/VBD||haemodynamic-13/JJ	prep_for||consisted-2/VBD||respiratory-15/JJ	conj_and||haemodynamic-13/JJ||respiratory-15/JJ	prep_for||consisted-2/VBD||renalfailure-17/JJ	conj_and||haemodynamic-13/JJ||renalfailure-17/JJ	antibiotics-4||renalfailure-17||no_rel||treatment consisted of antibiotics, corticosteroids, immunoglobulin and supportive treatment for haemodynamic, respiratory and renalfailure.
nsubj||investigated-2/VBD||we-1/PRP	root||ROOT-0/null||investigated-2/VBD	mark||²-7/VBZ||whether-3/IN	nsubj||²-7/VBZ||improvements-4/NNS	prep_in||improvements-4/NNS||î-6/NN	ccomp||investigated-2/VBD||²-7/VBZ	nsubj||function-10/VBP||cell-9/NN	parataxis||investigated-2/VBD||function-10/VBP	amod||sensitivity-13/NN||and/or-11/JJ	nn||sensitivity-13/NN||insulin-12/NN	nsubj||underlie-14/VB||sensitivity-13/NN	ccomp||function-10/VBP||underlie-14/VB	det||effects-17/NNS||these-15/DT	amod||effects-17/NNS||preventive-16/JJ	dobj||underlie-14/VB||effects-17/NNS	det||valsartan-21/NN||the-19/DT	nn||valsartan-21/NN||arb-20/NN	prep_of||effects-17/NNS||valsartan-21/NN	det||onset-24/NN||the-23/DT	prep_in||valsartan-21/NN||onset-24/NN	prep_of||onset-24/NN||type2diabetes-26/CD	type2diabetes-26||insulin-12||yes||we investigated whether improvements in î²-cell function and/or insulin sensitivity underlie these preventive effects of the arb valsartan in the onset of type2diabetes.
det||goal-2/NN||the-1/DT	nsubj||was-6/VBD||goal-2/NN	nsubj||describe-8/VB||goal-2/NN	det||study-5/NN||this-4/DT	prep_of||goal-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||describe-8/VB||to-7/TO	xcomp||was-6/VBD||describe-8/VB	advmod||reflected-32/VBD||how-9/WRB	nsubj||reflected-32/VBD||activists-10/NNS	vmod||activists-10/NNS||engaged-11/VBN	prep_in||engaged-11/VBN||campaigns-13/NNS	aux||change-15/VB||to-14/TO	xcomp||engaged-11/VBN||change-15/VB	nn||policies-17/NNS||alcohol-16/NN	dobj||change-15/VB||policies-17/NNS	dep||change-15/VB||in-18/IN	amod||areas-21/NNS||inner-19/JJ	nn||areas-21/NNS||city-20/NN	pobj||in-18/IN||areas-21/NNS	vmod||areas-21/NNS||framed-22/VBN	nn||problems-24/NNS||alcohol-23/NN	dobj||framed-22/VBN||problems-24/NNS	mark||not-29/RB||whether-27/IN	cc||not-29/RB||or-28/CC	dep||change-15/VB||not-29/RB	conj_and||in-18/IN||not-29/RB	poss||frameworks-31/NN||their-30/PRP$	dep||not-29/RB||frameworks-31/NN	ccomp||describe-8/VB||reflected-32/VBD	amod||models-34/NNS||major-33/JJ	dobj||reflected-32/VBD||models-34/NNS	vmod||models-34/NNS||used-35/VBN	det||field-38/NN||the-37/DT	prep_in||used-35/VBN||field-38/NN	det||alcoholism-43/NN||the-42/DT	prep_such_as||field-38/NN||alcoholism-43/NN	det||model-47/NN||a-45/DT	nn||model-47/NN||disease-46/NN	prep_as||alcoholism-43/NN||model-47/NN	det||perspective-52/NN||an-49/DT	nn||perspective-52/NN||alcohol-50/NN	nn||perspective-52/NN||problems-51/NNS	prep_as||alcoholism-43/NN||perspective-52/NN	conj_or||model-47/NN||perspective-52/NN	det||approach-58/NN||a-55/DT	amod||approach-58/NN||public-56/JJ	nn||approach-58/NN||health-57/NN	prep_as||alcoholism-43/NN||approach-58/NN	conj_or||model-47/NN||approach-58/NN	nn||problems-61/NNS||alcohol-60/NN	prep_to||used-35/VBN||problems-61/NNS	alcoholism-43||alcohol-60||no||the goal of this study was to describe how activists engaged in campaigns to change alcohol policies in inner city areas framed alcohol problems, and whether or not their frameworks reflected major models used in the field, such as the alcoholism as a disease model, an alcohol problems perspective, or a public health approach to alcohol problems.
poss||terbutaline-5/NN||conclusions-1/NNS	amod||terbutaline-5/NN||$-3/JJ	nsubjpass||shown-8/VBN||terbutaline-5/NN	nsubj||effective-11/JJ||terbutaline-5/NN	nsubj||safe-13/JJ||terbutaline-5/NN	aux||shown-8/VBN||may-6/MD	auxpass||shown-8/VBN||be-7/VB	root||ROOT-0/null||shown-8/VBN	aux||effective-11/JJ||to-9/TO	cop||effective-11/JJ||be-10/VB	xcomp||shown-8/VBN||effective-11/JJ	xcomp||shown-8/VBN||safe-13/JJ	conj_and||effective-11/JJ||safe-13/JJ	det||prevention-16/NN||the-15/DT	prep_in||effective-11/JJ||prevention-16/NN	amod||hypoglycemia-19/NN||nocturnal-18/JJ	prep_of||prevention-16/NN||hypoglycemia-19/NN	prep_in||hypoglycemia-19/NN||type1diabetes-21/NNS	det||trial-28/NN||a-23/DT	advmod||powered-25/VBN||suitably-24/RB	amod||trial-28/NN||powered-25/VBN	amod||trial-28/NN||randomized-26/JJ	amod||trial-28/NN||controlled-27/VBN	prep_in||type1diabetes-21/NNS||trial-28/NN	terbutaline-5||type1diabetes-21||no_rel||conclusions âterbutaline may be shown to be effective and safe in the prevention of nocturnal hypoglycemia in type1diabetes in a suitably powered randomized controlled trial.
amod||denguevirus-2/NNS||mosquito-borne-1/JJ	nsubj||emerged-10/VBN||denguevirus-2/NNS	appos||denguevirus-2/NNS||denv-4/NNP	amod||flavivirus-7/NNS||genus-6/JJ	dep||denv-4/NNP||flavivirus-7/NNS	aux||emerged-10/VBN||has-9/VBZ	root||ROOT-0/null||emerged-10/VBN	det||threat-14/NN||a-12/DT	amod||threat-14/NN||major-13/JJ	prep_as||emerged-10/VBN||threat-14/NN	amod||health-18/NN||global-16/JJ	amod||health-18/NN||human-17/JJ	prep_to||emerged-10/VBN||health-18/NN	amod||decades-21/NNS||recent-20/JJ	prep_in||health-18/NN||decades-21/NNS	amod||strategies-25/NNS||novel-24/JJ	nsubjpass||needed-34/VBN||strategies-25/NNS	aux||contain-27/VB||to-26/TO	vmod||strategies-25/NNS||contain-27/VB	det||pandemic-31/NN||the-28/DT	amod||pandemic-31/NN||escalating-29/JJ	nn||pandemic-31/NN||denguefever-30/NN	dobj||contain-27/VB||pandemic-31/NN	auxpass||needed-34/VBN||are-32/VBP	advmod||needed-34/VBN||urgently-33/RB	conj_and||emerged-10/VBN||needed-34/VBN	denguefever-30||denguevirus-2||no||mosquito-borne denguevirus (denv, genus flavivirus ) has emerged as a major threat to global human health in recent decades, and novel strategies to contain the escalating denguefever pandemic are urgently needed.
nn||injection-2/NN||lps-1/NN	root||ROOT-0/null||injection-2/NN	vmod||injection-2/NN||induced-3/VBN	det||increase-6/NN||a-4/DT	amod||increase-6/NN||rapid-5/JJ	dobj||induced-3/VBN||increase-6/NN	nn||concentrations-9/NNS||plasma-8/NN	prep_in||increase-6/NN||concentrations-9/NNS	amod||metabolites-12/NNS||nitricoxide-11/JJ	prep_of||concentrations-9/NNS||metabolites-12/NNS	amod||concentrations-9/NNS||nitrite-14/JJ	amod||concentrations-9/NNS||nitrate-16/JJ	conj_and||nitrite-14/JJ||nitrate-16/JJ	appos||concentrations-9/NNS||nom-18/NN	amod||acidâ-23/NNS||thiobarbituric-22/JJ	dobj||induced-3/VBN||acidâ-23/NNS	conj_and||increase-6/NN||acidâ-23/NNS	dep||acidâ-23/NNS||$-24/$	advmod||substances-27/RB||reacting-26/RB	dep||generation-41/CD||substances-27/RB	pobj||substances-27/RB||tbars-29/NN	det||increase-33/NN||an-32/DT	appos||tbars-29/NN||increase-33/NN	amod||species-37/NNS||reactive-35/JJ	nn||species-37/NNS||oxygen-36/NN	prep_in||increase-33/NN||species-37/NNS	appos||species-37/NNS||ros-39/NN	num||$-24/$||generation-41/CD	nn||leukocytes-44/NNS||polymorphonuclear-43/NN	agent||induced-3/VBN||leukocytes-44/NNS	dep||injection-2/NN||pmnls-46/NNS	amod||increases-51/NNS||marked-50/VBN	conj_and||injection-2/NN||increases-51/NNS	amod||fattyacids-55/NNS||plasma-53/JJ	amod||fattyacids-55/NNS||free-54/JJ	prep_in||increases-51/NNS||fattyacids-55/NNS	nn||necrosis-58/NNS||tumor-57/NN	appos||fattyacids-55/NNS||necrosis-58/NNS	nn||±-60/NNP||factor-î-59/NNP	dep||injection-2/NN||±-60/NNP	nn||±-63/NNP||tnf-î-62/NNP	appos||±-60/NNP||±-63/NNP	dep||injection-2/NN||interleukin-6-66/JJ	conj_and||±-60/NNP||interleukin-6-66/JJ	dep||interleukin-6-66/JJ||il-6-68/JJ	amod||protein-1-73/NN||monocyte-71/JJ	nn||protein-1-73/NN||chemoattractant-72/NN	dep||injection-2/NN||protein-1-73/NN	conj_and||±-60/NNP||protein-1-73/NN	dep||protein-1-73/NN||mcp-1-75/JJ	amod||factor-81/NN||macrophage-78/JJ	nn||factor-81/NN||migration-79/NN	nn||factor-81/NN||inhibition-80/NN	appos||protein-1-73/NN||factor-81/NN	appos||factor-81/NN||mif-83/NN	amod||protein-87/NN||c-reactive-86/JJ	appos||protein-1-73/NN||protein-87/NN	appos||protein-87/NN||resistin-89/NN	vmod||protein-1-73/NN||visfatin-91/VBN	nn||protein-95/NN||lipopolysaccharide-93/NN	amod||protein-95/NN||binding-94/VBG	appos||protein-1-73/NN||protein-95/NN	appos||protein-95/NN||lbp-97/NN	advmod||group-b1-102/JJ||high-100/RB	advmod||group-b1-102/JJ||mobility-101/RB	dep||injection-2/NN||group-b1-102/JJ	amod||±-60/NNP||group-b1-102/JJ	conj_and||±-60/NNP||group-b1-102/JJ	dep||group-b1-102/JJ||hmg-b1-104/JJ	nn||concentrations-109/NNS||myoglobin-108/NN	dep||injection-2/NN||concentrations-109/NNS	conj_and||±-60/NNP||concentrations-109/NNS	tumor-57||myoglobin-108||no_rel||lps injection induced a rapid increase in plasma concentrations of nitricoxide metabolites, nitrite and nitrate (nom), and thiobarbituric acidâreacting substances (tbars), an increase in reactive oxygen species (ros) generation by polymorphonuclear leukocytes (pmnls), and marked increases in plasma free fattyacids, tumor necrosis factor-î± (tnf-î±), interleukin-6 (il-6), monocyte chemoattractant protein-1 (mcp-1), macrophage migration inhibition factor (mif), c-reactive protein, resistin, visfatin, lipopolysaccharide binding protein (lbp), high mobility group-b1 (hmg-b1), and myoglobin concentrations.
nsubj||introduced-2/VBD||we-1/PRP	root||ROOT-0/null||introduced-2/VBD	amod||opioids-4/NNS||strong-3/JJ	nsubj||tolerable-26/JJ||opioids-4/NNS	amod||patches-8/NNS||transdermal-6/JJ	amod||patches-8/NNS||fentanyl-7/JJ	dep||opioids-4/NNS||patches-8/NNS	det||pain-12/NN||the-10/DT	nn||pain-12/NN||background-11/NN	prep_for||patches-8/NNS||pain-12/NN	det||opioid-16/NN||a-14/DT	amod||opioid-16/NN||short-acting-15/JJ	dep||opioids-4/NNS||opioid-16/NN	conj_and||patches-8/NNS||opioid-16/NN	det||pain-20/NN||the-18/DT	nn||pain-20/NN||breakthrough-19/NN	prep_for||opioid-16/NN||pain-20/NN	poss||pain-24/NN||his-23/PRP$	conj_and||opioids-4/NNS||pain-24/NN	nsubj||tolerable-26/JJ||pain-24/NN	cop||tolerable-26/JJ||was-25/VBD	ccomp||introduced-2/VBD||tolerable-26/JJ	num||hr-31/NN||250-28/CD	nn||hr-31/NN||âµg-29/NN	nn||hr-31/NN||/-30/NN	prep_on||tolerable-26/JJ||hr-31/NN	amod||patches-34/NNS||fentanyl-33/JJ	prep_of||hr-31/NN||patches-34/NNS	num||months-37/NNS||3-36/CD	prep_for||tolerable-26/JJ||months-37/NNS	pain-24||fentanyl-33||yes||we introduced strong opioids (transdermal fentanyl patches for the background pain and a short-acting opioid for the breakthrough pain) and his pain was tolerable on 250 âµg/hr of fentanyl patches for 3 months.
prep_in||contribute-6/VB||owat-2/NN	nsubj||contribute-6/VB||fibrosis-4/NN	nsubj||limit-8/VB||fibrosis-4/NN	nsubjpass||associated-13/VBN||fibrosis-4/NN	aux||contribute-6/VB||could-5/MD	root||ROOT-0/null||contribute-6/VB	aux||limit-8/VB||to-7/TO	xcomp||contribute-6/VB||limit-8/VB	amod||hypertrophy-10/NN||adipocyte-9/JJ	dobj||limit-8/VB||hypertrophy-10/NN	auxpass||associated-13/VBN||is-12/VBZ	conj_and||contribute-6/VB||associated-13/VBN	det||profile-18/NN||a-15/DT	amod||profile-18/NN||better-16/JJR	nn||profile-18/NN||lipid-17/NN	prep_with||associated-13/VBN||profile-18/NN	mark||hamper-24/VB||whereas-20/IN	nn||fibrosis-22/NN||scwat-21/NN	nsubj||hamper-24/VB||fibrosis-22/NN	aux||hamper-24/VB||may-23/MD	dep||profile-18/NN||hamper-24/VB	amod||loss-27/NN||fat-25/JJ	amod||loss-27/NN||mass-26/JJ	dobj||hamper-24/VB||loss-27/NN	vmod||loss-27/NN||induced-28/VBN	agent||induced-28/VBN||surgery-30/NN	fat-25||fibrosis-22||no_rel||in owat, fibrosis could contribute to limit adipocyte hypertrophy and is associated with a better lipid profile, whereas scwat fibrosis may hamper fat mass loss induced by surgery.
aux||identify-2/VB||to-1/TO	advcl||undertaken-29/VBN||identify-2/VB	det||variations-5/NNS||the-3/DT	amod||variations-5/NNS||genetic-4/JJ	dobj||identify-2/VB||variations-5/NNS	vmod||variations-5/NNS||associated-6/VBN	nn||intolerance-9/NN||aspirin-8/NN	prep_with||associated-6/VBN||intolerance-9/NN	prep_in||intolerance-9/NN||asthmatics-11/NNS	det||stage-15/NN||the-13/DT	amod||stage-15/NN||first-14/JJ	nsubjpass||undertaken-29/VBN||stage-15/NN	amod||study-19/NN||genome-wide-17/JJ	nn||study-19/NN||association-18/NN	prep_of||stage-15/NN||study-19/NN	num||polymorphisms-24/NNS||109,365-21/CD	amod||polymorphisms-24/NNS||single-22/JJ	nn||polymorphisms-24/NNS||nucleotide-23/NN	prep_with||study-19/NN||polymorphisms-24/NNS	appos||polymorphisms-24/NNS||snps-26/NNS	auxpass||undertaken-29/VBN||was-28/VBD	root||ROOT-0/null||undertaken-29/VBN	det||cohort-43/NN||a-31/DT	amod||cohort-43/NN||korean-32/JJ	amod||cohort-43/NN||aia-33/JJ	dep||cohort-43/NN||nâ-35/NN	num||â-39/NN||$-36/$	number||=-38/CD||-37/CD	num||$-36/$||=-38/CD	dep||nâ-35/NN||â-39/NN	dep||â-39/NN||$-40/$	num||$-40/$||80-41/CD	prep_in||undertaken-29/VBN||cohort-43/NN	nn||subjects-58/NNS||aspirin-tolerant-45/NN	nn||subjects-58/NNS||asthma-46/NN	dep||subjects-58/NNS||ata-48/NN	appos||ata-48/NN||nâ-50/NN	num||â-54/NN||$-51/$	number||=-53/CD||-52/CD	num||$-51/$||=-53/CD	dep||nâ-50/NN||â-54/NN	dep||ata-48/NN||$-55/$	num||$-55/$||100-56/CD	prep_in||undertaken-29/VBN||subjects-58/NNS	conj_and||cohort-43/NN||subjects-58/NNS	prep_as||cohort-43/NN||controls-60/NNS	asthma-46||aspirin-8||no||to identify the genetic variations associated with aspirin intolerance in asthmatics, the first stage of genome-wide association study with 109,365 single nucleotide polymorphisms (snps) was undertaken in a korean aia (nâ=â80) cohort and aspirin-tolerant asthma (ata, nâ=â100) subjects as controls.
nn||reviews-2/NNS||retrospective-1/NN	nsubj||suggest-3/VBP||reviews-2/NNS	root||ROOT-0/null||suggest-3/VBP	mark||differ-30/VB||that-4/IN	det||receptor-7/NN||the-5/DT	nn||receptor-7/NN||estrogen-6/NN	nsubj||differ-30/VB||receptor-7/NN	appos||receptor-7/NN||er-9/NN	amod||receptor-13/NN||progesterone-12/JJ	appos||receptor-7/NN||receptor-13/NN	appos||receptor-13/NN||pr-15/NN	amod||receptor-28/NN||human-18/JJ	nn||receptor-28/NN||epidermal-19/NN	nn||receptor-28/NN||growth-20/NN	nn||receptor-28/NN||factor-21/NN	nn||receptor-28/NN||receptor-22/NN	nn||receptor-28/NN||type-23/NN	num||receptor-28/NN||2-24/CD	nn||receptor-28/NN||her2-26/NN	conj_and||receptor-7/NN||receptor-28/NN	nsubj||differ-30/VB||receptor-28/NN	aux||differ-30/VB||may-29/MD	ccomp||suggest-3/VBP||differ-30/VB	det||recurrence-36/NN||the-32/DT	amod||recurrence-36/NN||primary-33/JJ	conj_and||primary-33/JJ||loco-regional-35/JJ	amod||recurrence-36/NN||loco-regional-35/JJ	prep_between||differ-30/VB||recurrence-36/NN	amod||metastases-39/NNS||distant-38/JJ	prep_between||differ-30/VB||metastases-39/NNS	conj_or||recurrence-36/NN||metastases-39/NNS	progesterone-12||metastases-39||no_rel||retrospective reviews suggest that the estrogen receptor (er), progesterone receptor (pr) and human epidermal growth factor receptor type 2 (her2) receptor may differ between the primary and loco-regional recurrence or distant metastases.
det||study-2/NN||this-1/DT	nsubj||aimed-3/VBN||study-2/NN	nsubj||investigate-5/VB||study-2/NN	nsubj||determine-21/VB||study-2/NN	nsubj||spreading-32/VBG||study-2/NN	root||ROOT-0/null||aimed-3/VBN	aux||investigate-5/VB||to-4/TO	xcomp||aimed-3/VBN||investigate-5/VB	det||relationship-9/NN||the-6/DT	amod||relationship-9/NN||molecular-7/JJ	amod||relationship-9/NN||structural-8/JJ	dobj||investigate-5/VB||relationship-9/NN	nn||cd44-14/NNS||cell-11/NN	nn||cd44-14/NNS||adhesive-12/NN	nn||cd44-14/NNS||molecule-13/NN	prep_between||relationship-9/NN||cd44-14/NNS	amod||antigen-18/NN||lewis-16/JJ	nn||antigen-18/NN||y-17/NN	prep_between||relationship-9/NN||antigen-18/NN	conj_and||cd44-14/NNS||antigen-18/NN	xcomp||aimed-3/VBN||determine-21/VB	conj_and||investigate-5/VB||determine-21/VB	det||effects-23/NNS||the-22/DT	dobj||determine-21/VB||effects-23/NNS	amod||antigen-27/NN||lewis-25/JJ	nn||antigen-27/NN||y-26/NN	prep_of||effects-23/NNS||antigen-27/NN	amod||adhesion-30/NN||cd44-mediated-29/JJ	prep_on||determine-21/VB||adhesion-30/NN	conj_and||aimed-3/VBN||spreading-32/VBG	amod||rmg-i-38/NNS||ovarian-34/JJ	nn||rmg-i-38/NNS||cancer-35/NN	nn||rmg-i-38/NNS||cell-36/NN	nn||rmg-i-38/NNS||line-37/NN	prep_of||spreading-32/VBG||rmg-i-38/NNS	det||rmg-i-h-46/NN||the-40/DT	amod||rmg-i-h-46/NN||lewis-41/JJ	amod||rmg-i-h-46/NN||y-42/JJ	amod||rmg-i-h-46/NN||antigen-overexpressed-43/JJ	nn||rmg-i-h-46/NN||cell-44/NN	nn||rmg-i-h-46/NN||line-45/NN	prep_of||spreading-32/VBG||rmg-i-h-46/NN	conj_and||rmg-i-38/NNS||rmg-i-h-46/NN	cancer-35||i---1||no_rel||this study aimed to investigate the molecular structural relationship between cell adhesive molecule cd44 and lewis y antigen, and determine the effects of lewis y antigen on cd44-mediated adhesion and spreading of ovarian cancer cell line rmg-i and the lewis y antigen-overexpressed cell line rmg-i-h.
nn||xenografts-2/NNS||tumor-1/NN	nsubjpass||established-4/VBN||xenografts-2/NNS	auxpass||established-4/VBN||were-3/VBD	root||ROOT-0/null||established-4/VBN	det||pad-9/NN||the-6/DT	advmod||fat-8/JJ||mammary-7/RB	amod||pad-9/NN||fat-8/JJ	prep_in||established-4/VBN||pad-9/NN	amod||mice-12/NNS||nu/nu-11/JJ	prep_of||pad-9/NN||mice-12/NNS	xcomp||established-4/VBN||using-13/VBG	amod||cells-17/NNS||human-14/JJ	nn||cells-17/NNS||breast-15/NN	nn||cells-17/NNS||cancer-16/NN	dobj||using-13/VBG||cells-17/NNS	nsubjpass||pre-exposed-20/VBN||cells-17/NNS	auxpass||pre-exposed-20/VBN||were-19/VBD	rcmod||cells-17/NNS||pre-exposed-20/VBN	preconj||hypoxic-23/JJ||either-22/DT	amod||conditions-26/NNS||hypoxic-23/JJ	conj_or||hypoxic-23/JJ||normoxic-25/JJ	amod||conditions-26/NNS||normoxic-25/JJ	prep_to||pre-exposed-20/VBN||conditions-26/NNS	cancer-16||fat-8||no_rel||tumor xenografts were established in the mammary fat pad of nu/nu mice using human breast cancer cells that were pre-exposed to either hypoxic or normoxic conditions.
vmod||produced-10/VBD||resultsâ-1/VBG	dobj||resultsâ-1/VBG||$-2/$	prep_with||resultsâ-1/VBG||hyperinsulinemia-5/FW	prep_with||resultsâ-1/VBG||hyperglycemia-7/FW	conj_and||hyperinsulinemia-5/FW||hyperglycemia-7/FW	nsubj||produced-10/VBD||exenatide-9/NN	root||ROOT-0/null||produced-10/VBD	det||increase-13/NN||a-11/DT	amod||increase-13/NN||significant-12/JJ	dobj||produced-10/VBD||increase-13/NN	amod||turnover-17/NN||total-15/JJ	nn||turnover-17/NN||glucose-16/NN	prep_in||produced-10/VBD||turnover-17/NN	quantmod||30-21/CD||â-19/RB	number||30-21/CD||1/4-20/CD	num||%-22/NN||30-21/CD	prep_by||produced-10/VBD||%-22/NN	mark||indicated-25/VBD||as-24/IN	advcl||produced-10/VBD||indicated-25/VBD	amod||infusion-29/NN||portal-27/JJ	nn||infusion-29/NN||glucose-28/NN	prep_by||indicated-25/VBD||infusion-29/NN	dobj||indicated-25/VBD||rate-30/NN	nn||rate-30/NN||-lrb--31/FW	nn||rate-30/NN||saline-32/FW	nn||rate-30/NN||15.9-33/FW	nn||rate-30/NN||â-34/FW	nn||rate-30/NN||±-35/FW	nn||rate-30/NN||1.6-36/FW	nn||rate-30/NN||vs.-37/FW	nn||rate-30/NN||exenatide-38/FW	nn||rate-30/NN||20.4-39/FW	nn||rate-30/NN||â-40/FW	nn||rate-30/NN||±-41/FW	nn||rate-30/NN||2.1-42/FW	nn||rate-30/NN||mg-43/FW	nn||rate-30/NN||â-44/FW	nn||rate-30/NN||·-45/FW	nn||rate-30/NN||kgâ-46/FW	nn||rate-30/NN||1-48/FW	nn||rate-30/NN||â-49/FW	nn||rate-30/NN||·-50/FW	dep||rate-30/NN||minâ-51/FW	nsubj||â-70/VBP||1-53/CD	nsubj||increased-76/VBD||1-53/CD	vmod||1-53/CD||p-55/VBN	dep||-rrb--58/NNS||<-56/SYM	num||-rrb--58/NNS||0.001-57/CD	ccomp||p-55/VBN||-rrb--58/NNS	xcomp||p-55/VBN||resulting-60/VBG	amod||d-68/NNP||increased-62/VBN	amod||d-68/NNP||whole-body-63/JJ	nn||d-68/NNP||glucose-64/NN	nn||d-68/NNP||disposal-65/NN	nn||d-68/NNP||-lrb--66/NN	nn||d-68/NNP||r-67/NNP	prep_from||resulting-60/VBG||d-68/NNP	rcmod||rate-30/NN||â-70/VBP	number||20-72/CD||1/4-71/CD	num||%-73/NN||20-72/CD	nsubj||-rrb--74/NN||%-73/NN	xcomp||â-70/VBP||-rrb--74/NN	rcmod||rate-30/NN||increased-76/VBD	conj_and||â-70/VBP||increased-76/VBD	amod||uptake-79/NN||net-77/JJ	amod||uptake-79/NN||hepatic-78/JJ	nsubj||-rrb--88/NN||uptake-79/NN	nn||â-84/FW||exogenous-81/FW	nn||â-84/FW||glucose-82/FW	nn||â-84/FW||-lrb--83/FW	prep_of||uptake-79/NN||â-84/FW	number||%-87/NN||1/4-85/CD	number||%-87/NN||80-86/CD	amod||â-84/FW||%-87/NN	xcomp||increased-76/VBD||-rrb--88/NN	hyperglycemia-7||glucose-82||no||resultsâ $ '' with hyperinsulinemia and hyperglycemia , exenatide produced a significant increase in total glucose turnover by â 1/4 30 % , as indicated by portal glucose infusion rate -lrb- saline 15.9 â ± 1.6 vs. exenatide 20.4 â ± 2.1 mg â · kgâ ' 1 â · minâ ' 1 , p < 0.001 -rrb- , resulting from increased whole-body glucose disposal -lrb- r d , â 1/4 20 % -rrb- and increased net hepatic uptake of exogenous glucose -lrb- â 1/4 80 % -rrb- .
quantmod||75-3/CD||up-1/IN	dep||75-3/CD||to-2/TO	num||%-4/NN||75-3/CD	nsubj||relate-9/VBP||%-4/NN	det||concerns-8/NNS||the-6/DT	nn||concerns-8/NNS||safety-7/NN	prep_of||%-4/NN||concerns-8/NNS	root||ROOT-0/null||relate-9/VBP	nn||reactions-12/NNS||skin-11/NN	prep_to||relate-9/VBP||reactions-12/NNS	det||increases-15/NNS||this-14/DT	prep_to||relate-9/VBP||increases-15/NNS	conj_and||reactions-12/NNS||increases-15/NNS	amod||patients-18/NNS||hiv/aids-17/JJ	prep_in||relate-9/VBP||patients-18/NNS	aids--1||hiv--1||no||up to 75% of the safety concerns relate to skin reactions and this increases in hiv/aids patients.
nsubj||±-9/VBZ||mice-1/NNS	det||deletion-5/NN||a-3/DT	amod||deletion-5/NN||whole-body-4/JJ	prep_with||mice-1/NNS||deletion-5/NN	det||î-8/NN||the-7/DT	prep_of||deletion-5/NN||î-8/NN	root||ROOT-0/null||±-9/VBZ	num||subunit-12/NN||2-10/CD	amod||subunit-12/NN||catalytic-11/JJ	dobj||±-9/VBZ||subunit-12/NN	prep_of||subunit-12/NN||ampk-14/NN	dep||±-9/VBZ||ampkî-16/VBG	nn||2â-18/NNP||±-17/NNP	poss||â-21/NNP||2â-18/NNP	nn||â-21/NNP||/-20/NNP	dobj||ampkî-16/VBG||â-21/NNP	poss||littermates-27/NNS||their-25/PRP$	amod||littermates-27/NNS||wild-type-26/JJ	nsubjpass||fed-29/VBN||littermates-27/NNS	auxpass||fed-29/VBN||were-28/VBD	conj_and||±-9/VBZ||fed-29/VBN	advmod||chow-34/NN||either-31/RB	det||chow-34/NN||a-32/DT	amod||chow-34/NN||low-fat-33/JJ	prep_on||fed-29/VBN||chow-34/NN	det||corn-38/NN||a-37/DT	prep_on||fed-29/VBN||corn-38/NN	conj_or||chow-34/NN||corn-38/NN	amod||diet-41/NN||oil-based-39/JJ	amod||diet-41/NN||high-fat-40/JJ	dep||corn-38/NN||diet-41/NN	appos||diet-41/NN||chf-43/NN	det||diet-49/NN||a-47/DT	nn||diet-49/NN||chf-48/NN	prep_on||fed-29/VBN||diet-49/NN	conj_or||chow-34/NN||diet-49/NN	number||%-52/NN||15-51/CD	amod||lipids-53/NNS||%-52/NN	prep_with||diet-49/NN||lipids-53/NNS	vmod||lipids-53/NNS||replaced-54/VBN	amod||concentrate-58/NN||n-3-56/JJ	amod||concentrate-58/NN||lc-pufa-57/JJ	agent||replaced-54/VBN||concentrate-58/NN	nn||f-62/NNP||chf-60/NNP	nn||f-62/NNP||+-61/NNP	appos||concentrate-58/NN||f-62/NNP	chf-60||fat--1||no_rel||mice with a whole-body deletion of the î±2 catalytic subunit of ampk (ampkî±2â/â) and their wild-type littermates were fed on either a low-fat chow, or a corn oil-based high-fat diet (chf), or a chf diet with 15% lipids replaced by n-3 lc-pufa concentrate (chf+f).
nsubj||correlated-2/VBD||ebvinfection-1/NN	nsubj||affected-14/VBD||ebvinfection-1/NN	root||ROOT-0/null||correlated-2/VBD	det||blockage-5/NN||a-4/DT	prep_with||correlated-2/VBD||blockage-5/NN	det||activation-8/NN||the-7/DT	prep_in||correlated-2/VBD||activation-8/NN	amod||members-12/NNS||jak/stat-10/JJ	nn||members-12/NNS||pathway-11/NN	prep_of||activation-8/NN||members-12/NNS	conj_and||correlated-2/VBD||affected-14/VBD	det||level-16/NN||the-15/DT	dobj||affected-14/VBD||level-16/NN	amod||ifn-19/NN||phosphorylated-18/JJ	prep_of||level-16/NN||ifn-19/NN	amod||factor-21/NN||regulatory-20/JJ	dobj||correlated-2/VBD||factor-21/NN	num||factor-21/NN||7-22/CD	appos||factor-21/NN||irf7-24/NNP	ifn-19||ebvinfection-1||no_rel||ebvinfection correlated with a blockage in the activation of jak/stat pathway members and affected the level of phosphorylated ifn regulatory factor 7 (irf7).
aux||compare-2/VB||to-1/TO	csubj||doublet-12/VBP||compare-2/VB	det||activity-4/NN||the-3/DT	dobj||compare-2/VB||activity-4/NN	dobj||compare-2/VB||toxicity-6/NN	conj_and||activity-4/NN||toxicity-6/NN	prep_of||activity-4/NN||docetaxel/carboplatin-8/NN	appos||docetaxel/carboplatin-8/NN||dc-10/NN	root||ROOT-0/null||doublet-12/VBP	amod||agent-15/NN||vs-13/JJ	amod||agent-15/NN||single-14/JJ	nsubj||docetaxel-16/VB||agent-15/NN	ccomp||doublet-12/VBP||docetaxel-16/VB	dep||treatment-22/NN||d-18/LS	amod||treatment-22/NN||as-20/IN	amod||treatment-22/NN||second-line-21/JJ	dobj||docetaxel-16/VB||treatment-22/NN	prep_in||treatment-22/NN||patients-24/NNS	amod||non-smallcelllungcancer-27/NN||advanced-26/VBN	prep_with||patients-24/NNS||non-smallcelllungcancer-27/NN	dep||treatment-22/NN||nsclc-29/JJ	nsclc-29||docetaxel-16||yes||to compare the activity and toxicity of docetaxel/carboplatin (dc) doublet vs single agent docetaxel (d) as second-line treatment in patients with advanced non-smallcelllungcancer (nsclc).
nn||fluctuation-3/NN||blood-1/NN	nn||fluctuation-3/NN||glucose-2/NN	nsubjpass||shown-6/VBN||fluctuation-3/NN	nsubj||mediate-8/VB||fluctuation-3/NN	aux||shown-6/VBN||has-4/VBZ	auxpass||shown-6/VBN||been-5/VBN	root||ROOT-0/null||shown-6/VBN	aux||mediate-8/VB||to-7/TO	xcomp||shown-6/VBN||mediate-8/VB	amod||effects-11/NNS||more-9/JJR	amod||effects-11/NNS||adverse-10/JJ	dobj||mediate-8/VB||effects-11/NNS	nn||cells-15/NNS||vascular-13/NN	nn||cells-15/NNS||endothelial-14/NN	prep_on||mediate-8/VB||cells-15/NNS	nn||complications-18/NNS||diabetes-17/NN	prep_on||mediate-8/VB||complications-18/NNS	conj_and||cells-15/NNS||complications-18/NNS	amod||hyperglycemia-21/NN||chronic-20/JJ	prep_than||cells-15/NNS||hyperglycemia-21/NN	nsubjpass||explained-26/VBN||hyperglycemia-21/NN	aux||explained-26/VBN||has-24/VBZ	auxpass||explained-26/VBN||been-25/VBN	rcmod||hyperglycemia-21/NN||explained-26/VBN	amod||oxidative-30/JJ||due-28/JJ	dep||oxidative-30/JJ||to-29/TO	amod||stress-31/NN||oxidative-30/JJ	prep_as||explained-26/VBN||stress-31/NN	hyperglycemia-21||glucose-2||no||blood glucose fluctuation has been shown to mediate more adverse effects on vascular endothelial cells and diabetes complications than chronic hyperglycemia, which has been explained as due to oxidative stress.
nsubj||exploring-3/VBG||perform-1/NNP	aux||exploring-3/VBG||is-2/VBZ	root||ROOT-0/null||exploring-3/VBG	det||efficacy-5/NN||the-4/DT	dobj||exploring-3/VBG||efficacy-5/NN	prep_of||efficacy-5/NN||terutroban-7/NN	prep_versus||terutroban-7/NN||aspirin-9/NN	amod||prevention-12/NN||secondary-11/JJ	prep_for||terutroban-7/NN||prevention-12/NN	prep_in||terutroban-7/NN||patients-14/NNS	det||history-17/NN||a-16/DT	prep_with||terutroban-7/NN||history-17/NN	prep_of||terutroban-7/NN||ischemicstroke-19/NN	prep_of||terutroban-7/NN||transientischemicattacks-21/NNS	conj_or||ischemicstroke-19/NN||transientischemicattacks-21/NNS	dep||terutroban-7/NN||tias-23/VBZ	transientischemicattacks-21||aspirin-9||yes||perform is exploring the efficacy of terutroban versus aspirin for secondary prevention in patients with a history of ischemicstroke or transientischemicattacks (tias).
